// this file contains all the data needed to parsed from the datasource
// tree data
trees = [{"name": "3TR", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Biobanks", "children": [{"name": "BIOMAP"}, {"name": "CARDIATEAM"}, {"name": "CONCEPTION"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "IABC"}, {"name": "RESCEU"}]}, {"name": "Disease taxonomy", "children": [{"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Respiratory diseases", "children": [{"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Autoimmune diseases", "children": [{"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}]}, {"name": "ABDIRECT", "children": [{"name": "Conducting clinical trials", "children": [{"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "AMR Accelerator", "children": [{"name": "COMBINE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}]}]}, {"name": "ABIRISK", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Manufacturing technologies", "children": [{"name": "CHEM21"}, {"name": "EBOMAN"}, {"name": "ICONSENSUS"}]}, {"name": "Biologicals", "children": [{"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "ICONSENSUS"}, {"name": "IMMUCAN"}, {"name": "IMMUNEIMAGE"}, {"name": "RTCURE"}]}]}, {"name": "ADAPTSMART", "children": [{"name": "Clinical trial design", "children": [{"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Real-world data, evidence", "children": [{"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}]}, {"name": "ADAPTED", "children": [{"name": "Stem cells", "children": [{"name": "EBISC"}, {"name": "EBISC2"}, {"name": "EUAIMS"}, {"name": "IMPRIND"}, {"name": "PHAGO"}, {"name": "STEMBANCC"}]}, {"name": "Target identification", "children": [{"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "ADVANCE", "children": [{"name": "Methods for benefit/risk assessment", "children": [{"name": "DRIVEAB"}, {"name": "PREFER"}, {"name": "PROTECT"}, {"name": "WEBRADR_2"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Vaccines", "children": [{"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "AETIONOMY", "children": [{"name": "Big data and knowledge management", "children": [{"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "AIMS2TRIALS", "children": [{"name": "Autism", "children": [{"name": "EUAIMS"}]}]}, {"name": "AMYPAD", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Imaging", "children": [{"name": "DRAGON"}, {"name": "EQIPD"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNEIMAGE"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "QUICCONCEPT"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "APPROACH", "children": [{"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Osteoarthritis", "children": []}]}, {"name": "ARDAT", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Drug delivery", "children": [{"name": "COMPACT"}, {"name": "IABC"}, {"name": "IM2PACT"}, {"name": "ORBITO"}]}, {"name": "Rare/orphan diseases", "children": [{"name": "EUPEARL"}, {"name": "STOPFOP"}]}, {"name": "Biologicals", "children": [{"name": "ABIRISK"}, {"name": "COMPACT"}, {"name": "ICONSENSUS"}, {"name": "IMMUCAN"}, {"name": "IMMUNEIMAGE"}, {"name": "RTCURE"}]}]}, {"name": "BEATDKD", "children": [{"name": "Diabetes & metabolic disorders", "children": [{"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "BIGDATAHEART", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Cardiovascular diseases", "children": [{"name": "CARDIATEAM"}, {"name": "EBISC"}, {"name": "MOBILISED"}]}, {"name": "BD4BO", "children": [{"name": "DOIT"}, {"name": "EHDEN"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "PIONEER"}, {"name": "ROADMAP"}]}]}, {"name": "BIOMAP", "children": [{"name": "Biobanks", "children": [{"name": "3TR"}, {"name": "CARDIATEAM"}, {"name": "CONCEPTION"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "IABC"}, {"name": "RESCEU"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}, {"name": "Skin diseases", "children": [{"name": "IMMUNIVERSE"}]}]}, {"name": "BIOVACSAFE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "BTCURE", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}]}, {"name": "C4C", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Clinical networks", "children": [{"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "EUPEARL"}, {"name": "IABC"}]}, {"name": "Patient involvement in R&D", "children": [{"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Tools for pediatrics", "children": [{"name": "CONCEPTION"}, {"name": "ITCCP4"}]}]}, {"name": "CANCERID", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Cancer", "children": [{"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}]}, {"name": "CARDIATEAM", "children": [{"name": "Biobanks", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "CONCEPTION"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "IABC"}, {"name": "RESCEU"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Cardiovascular diseases", "children": [{"name": "BIGDATAHEART"}, {"name": "EBISC"}, {"name": "MOBILISED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "CARE", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "RAPIDCOVID"}]}]}, {"name": "CHEM21", "children": [{"name": "Environmental aspects", "children": [{"name": "IPIE"}, {"name": "PREMIER"}]}, {"name": "Manufacturing technologies", "children": [{"name": "ABIRISK"}, {"name": "EBOMAN"}, {"name": "ICONSENSUS"}]}]}, {"name": "COMBACTECARE", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "IABC"}, {"name": "TRANSLOCATION"}]}]}, {"name": "COMBACTECDI", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Clinical networks", "children": [{"name": "C4C"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "EUPEARL"}, {"name": "IABC"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "IABC"}, {"name": "TRANSLOCATION"}]}]}, {"name": "COMBACTEMAGNET", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Clinical networks", "children": [{"name": "C4C"}, {"name": "COMBACTECDI"}, {"name": "COMBACTENET"}, {"name": "EUPEARL"}, {"name": "IABC"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTENET"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "IABC"}, {"name": "TRANSLOCATION"}]}]}, {"name": "COMBACTENET", "children": [{"name": "Clinical networks", "children": [{"name": "C4C"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "EUPEARL"}, {"name": "IABC"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "IABC"}, {"name": "TRANSLOCATION"}]}]}, {"name": "COMBINE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "AMR Accelerator", "children": [{"name": "ABDIRECT"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}]}]}, {"name": "COMPACT", "children": [{"name": "Drug delivery", "children": [{"name": "ARDAT"}, {"name": "IABC"}, {"name": "IM2PACT"}, {"name": "ORBITO"}]}, {"name": "Biologicals", "children": [{"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "ICONSENSUS"}, {"name": "IMMUCAN"}, {"name": "IMMUNEIMAGE"}, {"name": "RTCURE"}]}]}, {"name": "CONCEPTION", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Biobanks", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "CARDIATEAM"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "IABC"}, {"name": "RESCEU"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Tools for pediatrics", "children": [{"name": "C4C"}, {"name": "ITCCP4"}]}]}, {"name": "COVIDRED", "children": [{"name": "Digital health", "children": [{"name": "EMIF"}, {"name": "GRAVITATEHEALTH"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "CARE"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "RAPIDCOVID"}]}, {"name": "Diagnostics", "children": [{"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "DDMORE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}]}, {"name": "DECISION", "children": [{"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DRAGON"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "RAPIDCOVID"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "DIRECT", "children": [{"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "DOIT", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "BD4BO", "children": [{"name": "BIGDATAHEART"}, {"name": "EHDEN"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "PIONEER"}, {"name": "ROADMAP"}]}]}, {"name": "DRAGON", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Imaging", "children": [{"name": "AMYPAD"}, {"name": "EQIPD"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNEIMAGE"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "QUICCONCEPT"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "RAPIDCOVID"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "DRIVE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "DRIVEAB", "children": [{"name": "Methods for benefit/risk assessment", "children": [{"name": "ADVANCE"}, {"name": "PREFER"}, {"name": "PROTECT"}, {"name": "WEBRADR_2"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "ENABLE"}, {"name": "IABC"}, {"name": "TRANSLOCATION"}]}]}, {"name": "EBISC", "children": [{"name": "Biobanks", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "CARDIATEAM"}, {"name": "CONCEPTION"}, {"name": "EBISC2"}, {"name": "IABC"}, {"name": "RESCEU"}]}, {"name": "Stem cells", "children": [{"name": "ADAPTED"}, {"name": "EBISC2"}, {"name": "EUAIMS"}, {"name": "IMPRIND"}, {"name": "PHAGO"}, {"name": "STEMBANCC"}]}, {"name": "Cardiovascular diseases", "children": [{"name": "BIGDATAHEART"}, {"name": "CARDIATEAM"}, {"name": "MOBILISED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "EBISC2", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Biobanks", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "CARDIATEAM"}, {"name": "CONCEPTION"}, {"name": "EBISC"}, {"name": "IABC"}, {"name": "RESCEU"}]}, {"name": "Stem cells", "children": [{"name": "ADAPTED"}, {"name": "EBISC"}, {"name": "EUAIMS"}, {"name": "IMPRIND"}, {"name": "PHAGO"}, {"name": "STEMBANCC"}]}]}, {"name": "EBODAC", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "EBOLAMODRAD", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "EBOMAN", "children": [{"name": "Manufacturing technologies", "children": [{"name": "ABIRISK"}, {"name": "CHEM21"}, {"name": "ICONSENSUS"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "EBOVAC1", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "EBOVAC2", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "EBOVAC3", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "EFOEUPATI", "children": [{"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Education and training", "children": [{"name": "EMTRAIN"}, {"name": "EQIPD"}, {"name": "EU2P"}, {"name": "EUPATI"}, {"name": "FAIRPLUS"}, {"name": "PHARMATRAIN"}, {"name": "SAFESCIMET"}]}]}, {"name": "EHDEN", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "BD4BO", "children": [{"name": "BIGDATAHEART"}, {"name": "DOIT"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "PIONEER"}, {"name": "ROADMAP"}]}]}, {"name": "EHR4CR", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}]}, {"name": "ELF", "children": [{"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}]}, {"name": "EMIF", "children": [{"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "GRAVITATEHEALTH"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "EMTRAIN", "children": [{"name": "Education and training", "children": [{"name": "EFOEUPATI"}, {"name": "EQIPD"}, {"name": "EU2P"}, {"name": "EUPATI"}, {"name": "FAIRPLUS"}, {"name": "PHARMATRAIN"}, {"name": "SAFESCIMET"}]}]}, {"name": "ENABLE", "children": [{"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "DRIVEAB"}, {"name": "IABC"}, {"name": "TRANSLOCATION"}]}]}, {"name": "EPAD", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "EQIPD", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Education and training", "children": [{"name": "EFOEUPATI"}, {"name": "EMTRAIN"}, {"name": "EU2P"}, {"name": "EUPATI"}, {"name": "FAIRPLUS"}, {"name": "PHARMATRAIN"}, {"name": "SAFESCIMET"}]}, {"name": "Imaging", "children": [{"name": "AMYPAD"}, {"name": "DRAGON"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNEIMAGE"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "QUICCONCEPT"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Psychiatric diseases", "children": [{"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "NEWMEDS"}, {"name": "PRISM"}, {"name": "RADARCNS"}, {"name": "STEMBANCC"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "ERA4TB", "children": [{"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "AMR Accelerator", "children": [{"name": "ABDIRECT"}, {"name": "COMBINE"}, {"name": "GNA_NOW"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}]}]}, {"name": "ESCULAB", "children": [{"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}]}, {"name": "ETOX", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "3Rs - animal use in research", "children": [{"name": "ETRANSAFE"}, {"name": "IMSAVAR"}, {"name": "MARCAR"}, {"name": "NEURODERISK"}, {"name": "VAC2VAC"}]}]}, {"name": "ETRANSAFE", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "3Rs - animal use in research", "children": [{"name": "ETOX"}, {"name": "IMSAVAR"}, {"name": "MARCAR"}, {"name": "NEURODERISK"}, {"name": "VAC2VAC"}]}]}, {"name": "ETRIKS", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}]}, {"name": "EUAIMS", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Stem cells", "children": [{"name": "ADAPTED"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "IMPRIND"}, {"name": "PHAGO"}, {"name": "STEMBANCC"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Psychiatric diseases", "children": [{"name": "EQIPD"}, {"name": "EUPEARL"}, {"name": "NEWMEDS"}, {"name": "PRISM"}, {"name": "RADARCNS"}, {"name": "STEMBANCC"}]}, {"name": "Autism", "children": [{"name": "AIMS2TRIALS"}]}]}, {"name": "EUPEARL", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Clinical networks", "children": [{"name": "C4C"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "IABC"}]}, {"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}, {"name": "Psychiatric diseases", "children": [{"name": "EQIPD"}, {"name": "EUAIMS"}, {"name": "NEWMEDS"}, {"name": "PRISM"}, {"name": "RADARCNS"}, {"name": "STEMBANCC"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Rare/orphan diseases", "children": [{"name": "ARDAT"}, {"name": "STOPFOP"}]}]}, {"name": "EU2P", "children": [{"name": "Education and training", "children": [{"name": "EFOEUPATI"}, {"name": "EMTRAIN"}, {"name": "EQIPD"}, {"name": "EUPATI"}, {"name": "FAIRPLUS"}, {"name": "PHARMATRAIN"}, {"name": "SAFESCIMET"}]}]}, {"name": "EUBOPEN", "children": [{"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}]}, {"name": "EUPATI", "children": [{"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Education and training", "children": [{"name": "EFOEUPATI"}, {"name": "EMTRAIN"}, {"name": "EQIPD"}, {"name": "EU2P"}, {"name": "FAIRPLUS"}, {"name": "PHARMATRAIN"}, {"name": "SAFESCIMET"}]}]}, {"name": "EUROPAIN", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Pain", "children": [{"name": "IMIPAINCARE"}, {"name": "NGNPET"}]}]}, {"name": "FAIRPLUS", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Education and training", "children": [{"name": "EFOEUPATI"}, {"name": "EMTRAIN"}, {"name": "EQIPD"}, {"name": "EU2P"}, {"name": "EUPATI"}, {"name": "PHARMATRAIN"}, {"name": "SAFESCIMET"}]}]}, {"name": "FILODIAG", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "FLUCOP", "children": [{"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "GETREAL", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}]}, {"name": "GETREAL_INITIATIVE", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}]}, {"name": "GNA_NOW", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "AMR Accelerator", "children": [{"name": "ABDIRECT"}, {"name": "COMBINE"}, {"name": "ERA4TB"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}]}]}, {"name": "GRAVITATEHEALTH", "children": [{"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "EMIF"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}]}]}, {"name": "H2O", "children": [{"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}]}, {"name": "HARMONY", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}, {"name": "BD4BO", "children": [{"name": "BIGDATAHEART"}, {"name": "DOIT"}, {"name": "EHDEN"}, {"name": "HARMONY_PLUS"}, {"name": "PIONEER"}, {"name": "ROADMAP"}]}]}, {"name": "HARMONY_PLUS", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}, {"name": "BD4BO", "children": [{"name": "BIGDATAHEART"}, {"name": "DOIT"}, {"name": "EHDEN"}, {"name": "HARMONY"}, {"name": "PIONEER"}, {"name": "ROADMAP"}]}]}, {"name": "HYPORESOLVE", "children": [{"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "IABC", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Biobanks", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "CARDIATEAM"}, {"name": "CONCEPTION"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "RESCEU"}]}, {"name": "Clinical networks", "children": [{"name": "C4C"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "EUPEARL"}]}, {"name": "Drug delivery", "children": [{"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "IM2PACT"}, {"name": "ORBITO"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "TRANSLOCATION"}]}]}, {"name": "ICONSENSUS", "children": [{"name": "Manufacturing technologies", "children": [{"name": "ABIRISK"}, {"name": "CHEM21"}, {"name": "EBOMAN"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Biologicals", "children": [{"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "IMMUCAN"}, {"name": "IMMUNEIMAGE"}, {"name": "RTCURE"}]}]}, {"name": "IDEAFAST", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "EMIF"}, {"name": "GRAVITATEHEALTH"}, {"name": "MOBILISED"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}]}, {"name": "IM2PACT", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Drug delivery", "children": [{"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "IABC"}, {"name": "ORBITO"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "IMIPAINCARE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Imaging", "children": [{"name": "AMYPAD"}, {"name": "DRAGON"}, {"name": "EQIPD"}, {"name": "IMMUNEIMAGE"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "QUICCONCEPT"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Pain", "children": [{"name": "EUROPAIN"}, {"name": "NGNPET"}]}]}, {"name": "IMIDIA", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "IMMUCAN", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}, {"name": "Biologicals", "children": [{"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "ICONSENSUS"}, {"name": "IMMUNEIMAGE"}, {"name": "RTCURE"}]}]}, {"name": "IMMUNEIMAGE", "children": [{"name": "Imaging", "children": [{"name": "AMYPAD"}, {"name": "DRAGON"}, {"name": "EQIPD"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "QUICCONCEPT"}]}, {"name": "Biologicals", "children": [{"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "ICONSENSUS"}, {"name": "IMMUCAN"}, {"name": "RTCURE"}]}]}, {"name": "IMMUNIVERSE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}, {"name": "Skin diseases", "children": [{"name": "BIOMAP"}]}]}, {"name": "IMPENTRI", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "RAPIDCOVID"}]}]}, {"name": "IMPRIND", "children": [{"name": "Stem cells", "children": [{"name": "ADAPTED"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "EUAIMS"}, {"name": "PHAGO"}, {"name": "STEMBANCC"}]}, {"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "IMSAVAR", "children": [{"name": "3Rs - animal use in research", "children": [{"name": "ETOX"}, {"name": "ETRANSAFE"}, {"name": "MARCAR"}, {"name": "NEURODERISK"}, {"name": "VAC2VAC"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}]}, {"name": "INNODIA", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "INNODIA_HARVEST", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "IPIE", "children": [{"name": "Environmental aspects", "children": [{"name": "CHEM21"}, {"name": "PREMIER"}]}]}, {"name": "ITCCP4", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Tools for pediatrics", "children": [{"name": "C4C"}, {"name": "CONCEPTION"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}]}, {"name": "K4DD", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}]}, {"name": "KRONO", "children": [{"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "IMPENTRI"}, {"name": "MADCOV_2"}, {"name": "RAPIDCOVID"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "LITMUS", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "MACUSTAR", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Imaging", "children": [{"name": "AMYPAD"}, {"name": "DRAGON"}, {"name": "EQIPD"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNEIMAGE"}, {"name": "MARCAR"}, {"name": "QUICCONCEPT"}]}, {"name": "Ageing-associated diseases", "children": [{"name": "MOBILISED"}, {"name": "SPRINTT"}, {"name": "VITAL"}]}, {"name": "Eye diseases", "children": []}]}, {"name": "MADCOV_2", "children": [{"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "RAPIDCOVID"}]}]}, {"name": "MARCAR", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "3Rs - animal use in research", "children": [{"name": "ETOX"}, {"name": "ETRANSAFE"}, {"name": "IMSAVAR"}, {"name": "NEURODERISK"}, {"name": "VAC2VAC"}]}, {"name": "Imaging", "children": [{"name": "AMYPAD"}, {"name": "DRAGON"}, {"name": "EQIPD"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNEIMAGE"}, {"name": "MACUSTAR"}, {"name": "QUICCONCEPT"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}]}, {"name": "MELLODDY", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}]}, {"name": "MIPDILI", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}]}, {"name": "MOBILISED", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "EMIF"}, {"name": "GRAVITATEHEALTH"}, {"name": "IDEAFAST"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Cardiovascular diseases", "children": [{"name": "BIGDATAHEART"}, {"name": "CARDIATEAM"}, {"name": "EBISC"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Ageing-associated diseases", "children": [{"name": "MACUSTAR"}, {"name": "SPRINTT"}, {"name": "VITAL"}]}]}, {"name": "MOFINA", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "MOPEAD", "children": [{"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "PARADIGM"}, {"name": "SOPHIA"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "NECESSITY", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}]}, {"name": "NEURODERISK", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "3Rs - animal use in research", "children": [{"name": "ETOX"}, {"name": "ETRANSAFE"}, {"name": "IMSAVAR"}, {"name": "MARCAR"}, {"name": "VAC2VAC"}]}]}, {"name": "NEURONET", "children": [{"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "NEWMEDS", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Psychiatric diseases", "children": [{"name": "EQIPD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "PRISM"}, {"name": "RADARCNS"}, {"name": "STEMBANCC"}]}]}, {"name": "NGNPET", "children": [{"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Pain", "children": [{"name": "EUROPAIN"}, {"name": "IMIPAINCARE"}]}]}, {"name": "ONCO_TRACK", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "PIONEER"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}]}, {"name": "OPEN_PHACTS", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}]}, {"name": "ORBITO", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Drug delivery", "children": [{"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "IABC"}, {"name": "IM2PACT"}]}]}, {"name": "PARADIGM", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "SOPHIA"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}]}, {"name": "PDMIND", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}]}, {"name": "PDMITOQUANT", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}]}, {"name": "PERISCOPE", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "PEVIA", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "PHAGO", "children": [{"name": "Stem cells", "children": [{"name": "ADAPTED"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "EUAIMS"}, {"name": "IMPRIND"}, {"name": "STEMBANCC"}]}, {"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "PHARMACOG", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "PHARMALEDGER", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}]}, {"name": "PHARMATRAIN", "children": [{"name": "Education and training", "children": [{"name": "EFOEUPATI"}, {"name": "EMTRAIN"}, {"name": "EQIPD"}, {"name": "EU2P"}, {"name": "EUPATI"}, {"name": "FAIRPLUS"}, {"name": "SAFESCIMET"}]}]}, {"name": "PIONEER", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PREDECT"}, {"name": "QUICCONCEPT"}]}, {"name": "BD4BO", "children": [{"name": "BIGDATAHEART"}, {"name": "DOIT"}, {"name": "EHDEN"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "ROADMAP"}]}]}, {"name": "PRECISESADS", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "RTCURE"}, {"name": "ULTRADD"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "PREDECT", "children": [{"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "QUICCONCEPT"}]}]}, {"name": "PREDICTTB", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "PREFER", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}, {"name": "Methods for benefit/risk assessment", "children": [{"name": "ADVANCE"}, {"name": "DRIVEAB"}, {"name": "PROTECT"}, {"name": "WEBRADR_2"}]}]}, {"name": "PREMIER", "children": [{"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}, {"name": "Environmental aspects", "children": [{"name": "CHEM21"}, {"name": "IPIE"}]}]}, {"name": "PRISM", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "RESOLUTE"}, {"name": "RESPIRINTM"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Psychiatric diseases", "children": [{"name": "EQIPD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "NEWMEDS"}, {"name": "RADARCNS"}, {"name": "STEMBANCC"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}]}, {"name": "PROACTIVE", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}]}, {"name": "PROTECT", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Methods for benefit/risk assessment", "children": [{"name": "ADVANCE"}, {"name": "DRIVEAB"}, {"name": "PREFER"}, {"name": "WEBRADR_2"}]}]}, {"name": "QUICCONCEPT", "children": [{"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Imaging", "children": [{"name": "AMYPAD"}, {"name": "DRAGON"}, {"name": "EQIPD"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNEIMAGE"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}]}, {"name": "Cancer", "children": [{"name": "CANCERID"}, {"name": "EBISC"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IMMUCAN"}, {"name": "IMSAVAR"}, {"name": "ITCCP4"}, {"name": "MARCAR"}, {"name": "ONCO_TRACK"}, {"name": "PIONEER"}, {"name": "PREDECT"}]}]}, {"name": "RADARAD", "children": [{"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "EMIF"}, {"name": "GRAVITATEHEALTH"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "RADARCNS"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "ROADMAP"}]}, {"name": "RADAR", "children": [{"name": "RADARCNS"}]}]}, {"name": "RADARCNS", "children": [{"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "EMIF"}, {"name": "GRAVITATEHEALTH"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "RADARAD"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "ROADMAP"}, {"name": "WEBRADR_2"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "ROADMAP"}]}, {"name": "Psychiatric diseases", "children": [{"name": "EQIPD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "NEWMEDS"}, {"name": "PRISM"}, {"name": "STEMBANCC"}]}, {"name": "RADAR", "children": [{"name": "RADARAD"}]}]}, {"name": "RAPIDCOVID", "children": [{"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Coronaviruses", "children": [{"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPPID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "RAPPID", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}]}]}, {"name": "RESCEU", "children": [{"name": "Biobanks", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "CARDIATEAM"}, {"name": "CONCEPTION"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "IABC"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "UBIOPRED"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "RESOLUTE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESPIRINTM"}]}]}, {"name": "RESPIRINTM", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Target identification", "children": [{"name": "ADAPTED"}, {"name": "APPROACH"}, {"name": "CARE"}, {"name": "ESCULAB"}, {"name": "EUBOPEN"}, {"name": "IMPRIND"}, {"name": "MADCOV_2"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PRISM"}, {"name": "RESOLUTE"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "AMR Accelerator", "children": [{"name": "ABDIRECT"}, {"name": "COMBINE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}]}]}, {"name": "RESPIRITB", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "STOPFOP"}, {"name": "TRICTB"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "AMR Accelerator", "children": [{"name": "ABDIRECT"}, {"name": "COMBINE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "RESPIRINTM"}, {"name": "TRICTB"}]}]}, {"name": "RHAPSODY", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRIALSHOME"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "ROADMAP", "children": [{"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "WEBRADR_2"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Neurodegenerative diseases", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "EUROPAIN"}, {"name": "IDEAFAST"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMPRIND"}, {"name": "MOBILISED"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PDMIND"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}, {"name": "RADARCNS"}]}, {"name": "Alzheimer's disease", "children": [{"name": "ADAPTED"}, {"name": "AETIONOMY"}, {"name": "AMYPAD"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EPAD"}, {"name": "EQIPD"}, {"name": "IM2PACT"}, {"name": "IMPRIND"}, {"name": "MOPEAD"}, {"name": "NEURONET"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "RADARAD"}]}, {"name": "BD4BO", "children": [{"name": "BIGDATAHEART"}, {"name": "DOIT"}, {"name": "EHDEN"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "PIONEER"}]}]}, {"name": "RTCURE", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "ULTRADD"}]}, {"name": "Biologicals", "children": [{"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "COMPACT"}, {"name": "ICONSENSUS"}, {"name": "IMMUCAN"}, {"name": "IMMUNEIMAGE"}]}]}, {"name": "SAFET", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}]}, {"name": "SAFESCIMET", "children": [{"name": "Education and training", "children": [{"name": "EFOEUPATI"}, {"name": "EMTRAIN"}, {"name": "EQIPD"}, {"name": "EU2P"}, {"name": "EUPATI"}, {"name": "FAIRPLUS"}, {"name": "PHARMATRAIN"}]}]}, {"name": "SOPHIA", "children": [{"name": "Patient involvement in R&D", "children": [{"name": "C4C"}, {"name": "EFOEUPATI"}, {"name": "EUPEARL"}, {"name": "EUPATI"}, {"name": "H2O"}, {"name": "IMIPAINCARE"}, {"name": "MACUSTAR"}, {"name": "MOPEAD"}, {"name": "PARADIGM"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SPRINTT"}, {"name": "UBIOPRED"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "STEMBANCC"}, {"name": "SUMMIT"}]}]}, {"name": "SPRINTT", "children": [{"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "UBIOPRED"}]}, {"name": "Ageing-associated diseases", "children": [{"name": "MACUSTAR"}, {"name": "MOBILISED"}, {"name": "VITAL"}]}]}, {"name": "STEMBANCC", "children": [{"name": "Stem cells", "children": [{"name": "ADAPTED"}, {"name": "EBISC"}, {"name": "EBISC2"}, {"name": "EUAIMS"}, {"name": "IMPRIND"}, {"name": "PHAGO"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "SUMMIT"}]}, {"name": "Psychiatric diseases", "children": [{"name": "EQIPD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "NEWMEDS"}, {"name": "PRISM"}, {"name": "RADARCNS"}]}]}, {"name": "STOPFOP", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}]}, {"name": "Rare/orphan diseases", "children": [{"name": "ARDAT"}, {"name": "EUPEARL"}]}]}, {"name": "SUMMIT", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "TRANSBIOLINE"}, {"name": "WEBRADR_2"}]}, {"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "TRIALSHOME"}]}, {"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "TRANSLOCATION"}, {"name": "ULTRADD"}]}, {"name": "Diabetes & metabolic disorders", "children": [{"name": "BEATDKD"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "EBISC"}, {"name": "EMIF"}, {"name": "EUPEARL"}, {"name": "H2O"}, {"name": "HYPORESOLVE"}, {"name": "IM2PACT"}, {"name": "IMIDIA"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "RHAPSODY"}, {"name": "SOPHIA"}, {"name": "STEMBANCC"}]}]}, {"name": "TRANSBIOLINE", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "WEBRADR_2"}]}]}, {"name": "TRANSLOCATION", "children": [{"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "ULTRADD"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "ND4BB", "children": [{"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "IABC"}]}]}, {"name": "TRANSQST", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}]}, {"name": "TRIALSHOME", "children": [{"name": "Clinical trial design", "children": [{"name": "ADAPTSMART"}, {"name": "AMYPAD"}, {"name": "C4C"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBINE"}, {"name": "EBOVAC1"}, {"name": "EHR4CR"}, {"name": "EPAD"}, {"name": "EUAIMS"}, {"name": "EUPEARL"}, {"name": "EUROPAIN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "IABC"}, {"name": "IDEAFAST"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "NECESSITY"}, {"name": "NEWMEDS"}, {"name": "PARADIGM"}, {"name": "PHARMACOG"}, {"name": "PREDICTTB"}, {"name": "PREFER"}, {"name": "PRISM"}, {"name": "RHAPSODY"}, {"name": "SUMMIT"}]}, {"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "EMIF"}, {"name": "GRAVITATEHEALTH"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "WEBRADR"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "VITAL"}, {"name": "WEBRADR_2"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}]}, {"name": "TRICTB", "children": [{"name": "Conducting clinical trials", "children": [{"name": "ABDIRECT"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTEMAGNET"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "EPAD"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "INNODIA_HARVEST"}, {"name": "PDMIND"}, {"name": "PERISCOPE"}, {"name": "PRECISESADS"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "STOPFOP"}]}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "VALUEDX"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "AMR Accelerator", "children": [{"name": "ABDIRECT"}, {"name": "COMBINE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}]}]}, {"name": "TRISTAN", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}]}, {"name": "UBIOPRED", "children": [{"name": "Disease taxonomy", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "CARDIATEAM"}, {"name": "DIRECT"}, {"name": "HYPORESOLVE"}, {"name": "IMIPAINCARE"}, {"name": "IMMUNIVERSE"}, {"name": "INNODIA"}, {"name": "INNODIA_HARVEST"}, {"name": "LITMUS"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PRISM"}, {"name": "QUICCONCEPT"}, {"name": "RESOLUTE"}, {"name": "RHAPSODY"}, {"name": "RTCURE"}, {"name": "SOPHIA"}, {"name": "SPRINTT"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "VALUEDX"}]}]}, {"name": "ULTRADD", "children": [{"name": "Drug discovery", "children": [{"name": "ADAPTED"}, {"name": "CARE"}, {"name": "ELF"}, {"name": "ENABLE"}, {"name": "ESCULAB"}, {"name": "EUAIMS"}, {"name": "EUBOPEN"}, {"name": "EUROPAIN"}, {"name": "IMPRIND"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "NEWMEDS"}, {"name": "NGNPET"}, {"name": "OPEN_PHACTS"}, {"name": "PDMITOQUANT"}, {"name": "PHAGO"}, {"name": "PHARMACOG"}, {"name": "PRISM"}, {"name": "SUMMIT"}, {"name": "TRANSLOCATION"}]}, {"name": "Autoimmune diseases", "children": [{"name": "3TR"}, {"name": "BIOMAP"}, {"name": "BTCURE"}, {"name": "H2O"}, {"name": "IDEAFAST"}, {"name": "IMMUNIVERSE"}, {"name": "IMSAVAR"}, {"name": "NECESSITY"}, {"name": "PRECISESADS"}, {"name": "RTCURE"}]}]}, {"name": "VAC2VAC", "children": [{"name": "3Rs - animal use in research", "children": [{"name": "ETOX"}, {"name": "ETRANSAFE"}, {"name": "IMSAVAR"}, {"name": "MARCAR"}, {"name": "NEURODERISK"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR"}, {"name": "WEBRADR_2"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "VALUEDX", "children": [{"name": "Economic model", "children": []}, {"name": "Antimicrobial resistance", "children": [{"name": "ABDIRECT"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "DRIVEAB"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}]}, {"name": "Respiratory diseases", "children": [{"name": "3TR"}, {"name": "CARE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "FLUCOP"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOBILISED"}, {"name": "PROACTIVE"}, {"name": "RAPIDCOVID"}, {"name": "RESCEU"}, {"name": "UBIOPRED"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VHFMODRAD"}]}]}, {"name": "VHFMODRAD", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Diagnostics", "children": [{"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "EBOLAMODRAD"}, {"name": "FILODIAG"}, {"name": "KRONO"}, {"name": "LITMUS"}, {"name": "MOFINA"}, {"name": "PRECISESADS"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "VALUEDX"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}, {"name": "VITAL", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VSVEBOPLUS"}, {"name": "WEBRADR"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "WEBRADR_2"}]}, {"name": "Ageing-associated diseases", "children": [{"name": "MACUSTAR"}, {"name": "MOBILISED"}, {"name": "SPRINTT"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}]}, {"name": "VSVEBOPLUS", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "WEBRADR"}]}, {"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOVAC"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOVAC"}]}]}, {"name": "VSVEBOVAC", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "ZAPI"}]}, {"name": "Ebola and related diseases", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "ZAPI"}]}, {"name": "Ebola+", "children": [{"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FILODIAG"}, {"name": "MOFINA"}, {"name": "PEVIA"}, {"name": "VHFMODRAD"}, {"name": "VSVEBOPLUS"}]}]}, {"name": "WEBRADR", "children": [{"name": "Tools for predicting/monitoring efficacy", "children": [{"name": "3TR"}, {"name": "ABIRISK"}, {"name": "ARDAT"}, {"name": "BIOVACSAFE"}, {"name": "CANCERID"}, {"name": "COMBINE"}, {"name": "DDMORE"}, {"name": "DRIVE"}, {"name": "EBISC2"}, {"name": "EBODAC"}, {"name": "EQIPD"}, {"name": "ETOX"}, {"name": "IM2PACT"}, {"name": "IMIPAINCARE"}, {"name": "IMMUCAN"}, {"name": "IMMUNIVERSE"}, {"name": "K4DD"}, {"name": "LITMUS"}, {"name": "MACUSTAR"}, {"name": "MARCAR"}, {"name": "MELLODDY"}, {"name": "MOBILISED"}, {"name": "NECESSITY"}, {"name": "PDMITOQUANT"}, {"name": "PROTECT"}, {"name": "RESOLUTE"}, {"name": "RTCURE"}, {"name": "SAFET"}, {"name": "TRANSQST"}, {"name": "TRISTAN"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}]}, {"name": "Digital health", "children": [{"name": "COVIDRED"}, {"name": "EMIF"}, {"name": "GRAVITATEHEALTH"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "TRIALSHOME"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR_2"}]}]}, {"name": "WEBRADR_2", "children": [{"name": "Tools for predicting/monitoring safety", "children": [{"name": "ARDAT"}, {"name": "BTCURE"}, {"name": "COMBINE"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "EBISC2"}, {"name": "EQIPD"}, {"name": "ETRANSAFE"}, {"name": "EUAIMS"}, {"name": "EUROPAIN"}, {"name": "IMIDIA"}, {"name": "IMMUCAN"}, {"name": "ITCCP4"}, {"name": "K4DD"}, {"name": "MELLODDY"}, {"name": "MIPDILI"}, {"name": "NEURODERISK"}, {"name": "NEWMEDS"}, {"name": "ONCO_TRACK"}, {"name": "ORBITO"}, {"name": "PHARMACOG"}, {"name": "PROACTIVE"}, {"name": "RTCURE"}, {"name": "SUMMIT"}, {"name": "TRANSBIOLINE"}]}, {"name": "Big data and knowledge management", "children": [{"name": "AETIONOMY"}, {"name": "BIGDATAHEART"}, {"name": "CONCEPTION"}, {"name": "DDMORE"}, {"name": "DOIT"}, {"name": "DRAGON"}, {"name": "EHDEN"}, {"name": "EHR4CR"}, {"name": "EMIF"}, {"name": "ETRANSAFE"}, {"name": "ETRIKS"}, {"name": "FAIRPLUS"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "MELLODDY"}, {"name": "OPEN_PHACTS"}, {"name": "PHARMALEDGER"}, {"name": "PIONEER"}, {"name": "RADARAD"}, {"name": "RADARCNS"}, {"name": "ROADMAP"}]}, {"name": "Real-world data, evidence", "children": [{"name": "ADAPTSMART"}, {"name": "BIGDATAHEART"}, {"name": "COMBACTECDI"}, {"name": "CONCEPTION"}, {"name": "DOIT"}, {"name": "DRIVE"}, {"name": "EHDEN"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "H2O"}, {"name": "HARMONY"}, {"name": "HARMONY_PLUS"}, {"name": "IDEAFAST"}, {"name": "MOBILISED"}, {"name": "NGNPET"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "ROADMAP"}, {"name": "SOPHIA"}, {"name": "TRIALSHOME"}, {"name": "VITAL"}]}, {"name": "Regulatory and HTA processes", "children": [{"name": "ADAPTSMART"}, {"name": "GETREAL"}, {"name": "GETREAL_INITIATIVE"}, {"name": "PARADIGM"}, {"name": "PREFER"}, {"name": "PREMIER"}, {"name": "RESCEU"}, {"name": "TRIALSHOME"}, {"name": "VAC2VAC"}, {"name": "WEBRADR"}]}, {"name": "Methods for benefit/risk assessment", "children": [{"name": "ADVANCE"}, {"name": "DRIVEAB"}, {"name": "PREFER"}, {"name": "PROTECT"}]}]}, {"name": "ZAPI", "children": [{"name": "Infectious diseases", "children": [{"name": "ABDIRECT"}, {"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "CARE"}, {"name": "COMBACTECARE"}, {"name": "COMBACTECDI"}, {"name": "COMBACTEMAGNET"}, {"name": "COMBACTENET"}, {"name": "COMBINE"}, {"name": "COVIDRED"}, {"name": "DECISION"}, {"name": "DRAGON"}, {"name": "DRIVE"}, {"name": "DRIVEAB"}, {"name": "EBODAC"}, {"name": "EBOLAMODRAD"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "ENABLE"}, {"name": "ERA4TB"}, {"name": "EUPEARL"}, {"name": "FILODIAG"}, {"name": "FLUCOP"}, {"name": "GNA_NOW"}, {"name": "IABC"}, {"name": "IMPENTRI"}, {"name": "KRONO"}, {"name": "MADCOV_2"}, {"name": "MOFINA"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "PREDICTTB"}, {"name": "RAPIDCOVID"}, {"name": "RAPPID"}, {"name": "RESCEU"}, {"name": "RESPIRINTM"}, {"name": "RESPIRITB"}, {"name": "TRANSLOCATION"}, {"name": "TRICTB"}, {"name": "VAC2VAC"}, {"name": "VALUEDX"}, {"name": "VHFMODRAD"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}, {"name": "Vaccines", "children": [{"name": "ADVANCE"}, {"name": "BIOVACSAFE"}, {"name": "DRIVE"}, {"name": "EBODAC"}, {"name": "EBOMAN"}, {"name": "EBOVAC1"}, {"name": "EBOVAC2"}, {"name": "EBOVAC3"}, {"name": "FLUCOP"}, {"name": "ICONSENSUS"}, {"name": "PERISCOPE"}, {"name": "PEVIA"}, {"name": "VAC2VAC"}, {"name": "VITAL"}, {"name": "VSVEBOPLUS"}, {"name": "VSVEBOVAC"}]}]}]



var tree_map_data = [{"name": "3TR", "children": [{"project": "RESOLUTE", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "EBISC2", "index": 29, "tags": [" Biobanks", "Tools for predicting/monitoring efficacy"]}, {"project": "IMMUNIVERSE", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "LITMUS", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "NECESSITY", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "PDMITOQUANT", "index": 25, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "RTCURE", "index": 25, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "IMIPAINCARE", "index": 22, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "SAFET", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "ABDIRECT", "children": [{"project": "GNA_NOW", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRITB", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "TRICTB", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRINTM", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "ERA4TB", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBINE", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBACTENET", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DRIVEAB", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ENABLE", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IMPENTRI", "index": 33, "tags": ["Conducting clinical trials", " Infectious diseases"]}]}, {"name": "ABIRISK", "children": [{"project": "IMMUCAN", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", "Biologicals"]}, {"project": "ARDAT", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", "Biologicals"]}, {"project": "RTCURE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", "Biologicals"]}, {"project": "SAFET", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CHEM21", "index": 25, "tags": [" Manufacturing technologies"]}, {"project": "COMPACT", "index": 25, "tags": ["Biologicals"]}, {"project": "ETOX", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "ADAPTSMART", "children": [{"project": "GETREAL", "index": 100, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL_INITIATIVE", "index": 100, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "PREFER", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "TRIALSHOME", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "PARADIGM", "index": 50, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "IDEAFAST", "index": 33, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "WEBRADR_2", "index": 33, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "COMBACTECDI", "index": 29, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "EHR4CR", "index": 25, "tags": ["Clinical trial design"]}, {"project": "PREDICTTB", "index": 25, "tags": ["Clinical trial design"]}]}, {"name": "ADAPTED", "children": [{"project": "IMPRIND", "index": 100, "tags": [" Drug discovery", "Neurodegenerative diseases", " Target identification", "Stem cells", " Alzheimer's disease"]}, {"project": "PHAGO", "index": 100, "tags": [" Drug discovery", "Neurodegenerative diseases", " Target identification", "Stem cells", " Alzheimer's disease"]}, {"project": "PRISM", "index": 50, "tags": [" Target identification", " Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PDMITOQUANT", "index": 43, "tags": [" Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "PHARMACOG", "index": 43, "tags": [" Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "ADVANCE", "children": [{"project": "ZAPI", "index": 67, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "BIOVACSAFE", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PERISCOPE", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "DRIVE", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PEVIA", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VAC2VAC", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBODAC", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOMAN", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOVAC2", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}]}, {"name": "AETIONOMY", "children": [{"project": "NEURONET", "index": 67, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ROADMAP", "index": 60, "tags": ["Big data and knowledge management", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 50, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ADAPTED", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ETRIKS", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "IMPRIND", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHARMACOG", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "AIMS2TRIALS", "children": []}, {"name": "AMYPAD", "children": [{"project": "EPAD", "index": 60, "tags": ["Clinical trial design", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 50, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EQIPD", "index": 38, "tags": [" Imaging", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PRISM", "index": 38, "tags": ["Clinical trial design", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ADAPTED", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "IDEAFAST", "index": 29, "tags": ["Clinical trial design", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "APPROACH", "children": [{"project": "ESCULAB", "index": 33, "tags": ["Target identification"]}, {"project": "EUBOPEN", "index": 33, "tags": ["Target identification"]}, {"project": "MADCOV_2", "index": 20, "tags": ["Target identification"]}]}, {"name": "ARDAT", "children": [{"project": "IMMUCAN", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety", "Biologicals"]}, {"project": "RTCURE", "index": 43, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety", "Biologicals"]}, {"project": "ABIRISK", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", "Biologicals"]}, {"project": "DDMORE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "K4DD", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "EBISC2", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "MELLODDY", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "IM2PACT", "index": 25, "tags": [" Drug delivery", "Tools for predicting/monitoring efficacy"]}, {"project": "COMBINE", "index": 22, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "EQIPD", "index": 20, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}]}, {"name": "BEATDKD", "children": [{"project": "DIRECT", "index": 50, "tags": ["Diabetes & metabolic disorders"]}, {"project": "HYPORESOLVE", "index": 50, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 50, "tags": ["Diabetes & metabolic disorders"]}, {"project": "INNODIA", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "RHAPSODY", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "STEMBANCC", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "LITMUS", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "SOPHIA", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "SUMMIT", "index": 25, "tags": ["Diabetes & metabolic disorders"]}]}, {"name": "BIGDATAHEART", "children": [{"project": "DOIT", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "EHDEN", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY_PLUS", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "ROADMAP", "index": 50, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "PIONEER", "index": 40, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "ETRIKS", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "MOBILISED", "index": 22, "tags": ["Cardiovascular diseases", " Real-world data, evidence"]}, {"project": "FAIRPLUS", "index": 20, "tags": ["Big data and knowledge management"]}]}, {"name": "BIOMAP", "children": [{"project": "IMMUNIVERSE", "index": 60, "tags": [" Disease taxonomy", " Skin diseases", "Autoimmune diseases"]}, {"project": "BTCURE", "index": 40, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "CARDIATEAM", "index": 33, "tags": [" Disease taxonomy", "Biobanks"]}, {"project": "NECESSITY", "index": 33, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "RTCURE", "index": 29, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "ULTRADD", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "IMSAVAR", "index": 17, "tags": ["Autoimmune diseases"]}, {"project": "INNODIA", "index": 17, "tags": [" Disease taxonomy"]}, {"project": "PRECISESADS", "index": 17, "tags": ["Autoimmune diseases"]}, {"project": "RESOLUTE", "index": 17, "tags": [" Disease taxonomy"]}]}, {"name": "BIOVACSAFE", "children": [{"project": "DRIVE", "index": 75, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "ZAPI", "index": 67, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBODAC", "index": 60, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "VSVEBOPLUS", "index": 60, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "ADVANCE", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PERISCOPE", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PEVIA", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VAC2VAC", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOMAN", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}]}, {"name": "BTCURE", "children": [{"project": "BIOMAP", "index": 40, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "IMMUNIVERSE", "index": 40, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "NECESSITY", "index": 40, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "MIPDILI", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "RTCURE", "index": 33, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "TRANSBIOLINE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "IMIDIA", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "C4C", "children": [{"project": "PARADIGM", "index": 40, "tags": ["Clinical trial design", " Patient involvement in R&D"]}, {"project": "EUPEARL", "index": 38, "tags": ["Clinical trial design", " Patient involvement in R&D", " Clinical networks"]}, {"project": "COMBACTECDI", "index": 25, "tags": ["Clinical trial design", " Clinical networks"]}, {"project": "COMBACTEMAGNET", "index": 25, "tags": ["Clinical trial design", " Clinical networks"]}, {"project": "EHR4CR", "index": 20, "tags": ["Clinical trial design"]}, {"project": "IABC", "index": 20, "tags": ["Clinical trial design", " Clinical networks"]}, {"project": "PREDICTTB", "index": 20, "tags": ["Clinical trial design"]}, {"project": "ADAPTSMART", "index": 17, "tags": ["Clinical trial design"]}, {"project": "GETREAL", "index": 17, "tags": ["Clinical trial design"]}, {"project": "GETREAL_INITIATIVE", "index": 17, "tags": ["Clinical trial design"]}]}, {"name": "CANCERID", "children": [{"project": "IMMUCAN", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Cancer"]}, {"project": "MARCAR", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Cancer"]}, {"project": "PREDECT", "index": 50, "tags": ["Cancer"]}, {"project": "SAFET", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ETOX", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ONCO_TRACK", "index": 33, "tags": ["Cancer"]}, {"project": "PROTECT", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ABIRISK", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "CARDIATEAM", "children": [{"project": "EBISC", "index": 43, "tags": ["Cardiovascular diseases", " Diabetes & metabolic disorders", "Biobanks"]}, {"project": "BIOMAP", "index": 33, "tags": [" Disease taxonomy", "Biobanks"]}, {"project": "BTCURE", "index": 17, "tags": [" Disease taxonomy"]}, {"project": "INNODIA", "index": 17, "tags": [" Disease taxonomy"]}, {"project": "RESOLUTE", "index": 17, "tags": [" Disease taxonomy"]}, {"project": "RHAPSODY", "index": 17, "tags": [" Disease taxonomy"]}, {"project": "BIGDATAHEART", "index": 14, "tags": ["Cardiovascular diseases"]}, {"project": "IMMUNIVERSE", "index": 14, "tags": [" Disease taxonomy"]}, {"project": "INNODIA_HARVEST", "index": 14, "tags": [" Disease taxonomy"]}, {"project": "LITMUS", "index": 14, "tags": [" Disease taxonomy"]}]}, {"name": "CARE", "children": [{"project": "IMPENTRI", "index": 67, "tags": [" Coronaviruses", "Conducting clinical trials", " Infectious diseases", "Respiratory diseases"]}, {"project": "DECISION", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "KRONO", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "RAPIDCOVID", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "COVIDRED", "index": 38, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "RESPIRINTM", "index": 38, "tags": ["Conducting clinical trials", " Target identification", " Infectious diseases"]}, {"project": "DRAGON", "index": 33, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 29, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 25, "tags": ["Conducting clinical trials", " Infectious diseases"]}]}, {"name": "CHEM21", "children": [{"project": "IPIE", "index": 50, "tags": ["Environmental aspects"]}, {"project": "ABIRISK", "index": 25, "tags": [" Manufacturing technologies"]}]}, {"name": "COMBACTECARE", "children": [{"project": "COMBACTEMAGNET", "index": 83, "tags": ["Clinical trial design", " Conducting clinical trials", "Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "IABC", "index": 62, "tags": ["Clinical trial design", " Conducting clinical trials", "Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECDI", "index": 57, "tags": ["Antimicrobial resistance", "Clinical trial design", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTENET", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "DRIVEAB", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ENABLE", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "TRANSLOCATION", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ERA4TB", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "EPAD", "index": 29, "tags": ["Clinical trial design", " Conducting clinical trials"]}]}, {"name": "COMBACTECDI", "children": [{"project": "COMBACTEMAGNET", "index": 71, "tags": ["Clinical trial design", "Antimicrobial resistance", " Infectious diseases", "ND4BB", " Clinical networks"]}, {"project": "COMBACTECARE", "index": 57, "tags": ["Antimicrobial resistance", "Clinical trial design", " Infectious diseases", "ND4BB"]}, {"project": "IABC", "index": 56, "tags": ["Clinical trial design", "Antimicrobial resistance", " Infectious diseases", "ND4BB", " Clinical networks"]}, {"project": "COMBACTENET", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "DRIVEAB", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ENABLE", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "TRANSLOCATION", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "EUPEARL", "index": 30, "tags": ["Clinical trial design", " Infectious diseases", " Clinical networks"]}, {"project": "ADAPTSMART", "index": 29, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "ERA4TB", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}]}, {"name": "COMBACTEMAGNET", "children": [{"project": "COMBACTECARE", "index": 83, "tags": ["Clinical trial design", " Conducting clinical trials", "Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "IABC", "index": 75, "tags": ["Clinical trial design", " Conducting clinical trials", "Antimicrobial resistance", " Infectious diseases", " Clinical networks", "ND4BB"]}, {"project": "COMBACTECDI", "index": 71, "tags": ["Clinical trial design", "Antimicrobial resistance", " Infectious diseases", "ND4BB", " Clinical networks"]}, {"project": "COMBACTENET", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "DRIVEAB", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ENABLE", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "TRANSLOCATION", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "EUPEARL", "index": 30, "tags": ["Clinical trial design", " Infectious diseases", " Clinical networks"]}, {"project": "ERA4TB", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 25, "tags": ["Antimicrobial resistance", " Infectious diseases"]}]}, {"name": "COMBACTENET", "children": [{"project": "DRIVEAB", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ENABLE", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "TRANSLOCATION", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECARE", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECDI", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTEMAGNET", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ERA4TB", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IABC", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}]}, {"name": "COMBINE", "children": [{"project": "ERA4TB", "index": 50, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRITB", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "TRICTB", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRINTM", "index": 38, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "DDMORE", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "K4DD", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "COMBACTENET", "index": 25, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DRIVEAB", "index": 25, "tags": ["Antimicrobial resistance", " Infectious diseases"]}]}, {"name": "COMPACT", "children": [{"project": "IMMUNEIMAGE", "index": 33, "tags": ["Biologicals"]}, {"project": "ABIRISK", "index": 25, "tags": ["Biologicals"]}, {"project": "IMMUCAN", "index": 20, "tags": ["Biologicals"]}, {"project": "ARDAT", "index": 17, "tags": ["Biologicals"]}, {"project": "RTCURE", "index": 17, "tags": ["Biologicals"]}]}, {"name": "CONCEPTION", "children": [{"project": "WEBRADR_2", "index": 43, "tags": [" Real-world data, evidence", "Tools for predicting/monitoring safety", " Big data and knowledge management"]}, {"project": "ETRANSAFE", "index": 33, "tags": [" Big data and knowledge management", "Tools for predicting/monitoring safety"]}, {"project": "ITCCP4", "index": 33, "tags": ["Tools for predicting/monitoring safety", " Tools for pediatrics"]}, {"project": "MIPDILI", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "EHR4CR", "index": 17, "tags": [" Big data and knowledge management"]}, {"project": "IMIDIA", "index": 17, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 17, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 17, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 17, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "COVIDRED", "children": [{"project": "DECISION", "index": 80, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "KRONO", "index": 80, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "RAPIDCOVID", "index": 80, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "DRAGON", "index": 57, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "IMPENTRI", "index": 50, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 50, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "CARE", "index": 38, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RESCEU", "index": 29, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "VALUEDX", "index": 25, "tags": ["Diagnostics", " Infectious diseases"]}]}, {"name": "DDMORE", "children": [{"project": "MELLODDY", "index": 75, "tags": [" Big data and knowledge management", " Tools for predicting/monitoring safety", "Tools for predicting/monitoring efficacy"]}, {"project": "K4DD", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "EBISC2", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "IMMUCAN", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "ARDAT", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "RTCURE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "SAFET", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "COMBINE", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}]}, {"name": "DECISION", "children": [{"project": "KRONO", "index": 100, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "RAPIDCOVID", "index": 100, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "COVIDRED", "index": 80, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "DRAGON", "index": 67, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "IMPENTRI", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "CARE", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RESCEU", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "VALUEDX", "index": 29, "tags": [" Infectious diseases", "Diagnostics"]}]}, {"name": "DIRECT", "children": [{"project": "HYPORESOLVE", "index": 100, "tags": ["Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "BEATDKD", "index": 50, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "SPRINTT", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "UBIOPRED", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "INNODIA", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "QUICCONCEPT", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "RHAPSODY", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "STEMBANCC", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 20, "tags": ["Diabetes & metabolic disorders"]}]}, {"name": "DOIT", "children": [{"project": "EHDEN", "index": 100, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "BIGDATAHEART", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY_PLUS", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "ROADMAP", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "PIONEER", "index": 50, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "ETRIKS", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "FAIRPLUS", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "OPEN_PHACTS", "index": 25, "tags": ["Big data and knowledge management"]}]}, {"name": "DRAGON", "children": [{"project": "DECISION", "index": 67, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "KRONO", "index": 67, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "RAPIDCOVID", "index": 67, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "COVIDRED", "index": 57, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "IMPENTRI", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "CARE", "index": 33, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 29, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RESCEU", "index": 25, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "VALUEDX", "index": 22, "tags": ["Diagnostics", " Infectious diseases"]}]}, {"name": "DRIVE", "children": [{"project": "BIOVACSAFE", "index": 75, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "EBODAC", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "VITAL", "index": 50, "tags": [" Real-world data, evidence", "Tools for predicting/monitoring efficacy", "Vaccines"]}, {"project": "VSVEBOPLUS", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "ZAPI", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "ADVANCE", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PERISCOPE", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PEVIA", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VAC2VAC", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}]}, {"name": "DRIVEAB", "children": [{"project": "COMBACTENET", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ENABLE", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "TRANSLOCATION", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECARE", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECDI", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTEMAGNET", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ERA4TB", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IABC", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}]}, {"name": "EBISC", "children": [{"project": "CARDIATEAM", "index": 43, "tags": ["Cardiovascular diseases", " Diabetes & metabolic disorders", "Biobanks"]}, {"project": "NEURONET", "index": 14, "tags": [" Alzheimer's disease"]}, {"project": "AETIONOMY", "index": 12, "tags": [" Alzheimer's disease"]}, {"project": "IMSAVAR", "index": 12, "tags": [" Cancer"]}, {"project": "MOPEAD", "index": 12, "tags": [" Alzheimer's disease"]}, {"project": "AMYPAD", "index": 11, "tags": [" Alzheimer's disease"]}, {"project": "BIGDATAHEART", "index": 11, "tags": ["Cardiovascular diseases"]}, {"project": "BIOMAP", "index": 11, "tags": ["Biobanks"]}, {"project": "EBISC2", "index": 11, "tags": [" Stem cells"]}, {"project": "EPAD", "index": 11, "tags": [" Alzheimer's disease"]}]}, {"name": "EBISC2", "children": [{"project": "DDMORE", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "K4DD", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "IMMUCAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "MELLODDY", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "3TR", "index": 29, "tags": [" Biobanks", "Tools for predicting/monitoring efficacy"]}, {"project": "ARDAT", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "RTCURE", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "COMBINE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "SAFET", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "EBODAC", "children": [{"project": "VSVEBOPLUS", "index": 100, "tags": ["Infectious diseases", "Tools for predicting/monitoring efficacy", "Vaccines", "Ebola+", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOMAN", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "BIOVACSAFE", "index": 60, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "EBOVAC1", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "DRIVE", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "EBOLAMODRAD", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "EBOLAMODRAD", "children": [{"project": "FILODIAG", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "MOFINA", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VHFMODRAD", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOVAC", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBODAC", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOMAN", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "RAPPID", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}]}, {"name": "EBOMAN", "children": [{"project": "PEVIA", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBODAC", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOPLUS", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC1", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOLAMODRAD", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "MOFINA", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "EBOVAC1", "children": [{"project": "PEVIA", "index": 67, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 67, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBODAC", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOMAN", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOPLUS", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOLAMODRAD", "index": 43, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 43, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "MOFINA", "index": 43, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "EBOVAC2", "children": [{"project": "EBOVAC3", "index": 100, "tags": ["Conducting clinical trials", "Infectious diseases", "Vaccines", "Ebola+", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBODAC", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOMAN", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOPLUS", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "PERISCOPE", "index": 60, "tags": ["Conducting clinical trials", "Vaccines", "Infectious diseases"]}, {"project": "EBOVAC1", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOLAMODRAD", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "EBOVAC3", "children": [{"project": "EBOVAC2", "index": 100, "tags": ["Conducting clinical trials", "Infectious diseases", "Vaccines", "Ebola+", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBODAC", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOMAN", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOPLUS", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "PERISCOPE", "index": 60, "tags": ["Conducting clinical trials", "Vaccines", "Infectious diseases"]}, {"project": "EBOVAC1", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOLAMODRAD", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "EFOEUPATI", "children": [{"project": "EUPATI", "index": 100, "tags": ["Patient involvement in R&D", " Education and training"]}, {"project": "FAIRPLUS", "index": 33, "tags": [" Education and training"]}, {"project": "MOPEAD", "index": 25, "tags": ["Patient involvement in R&D"]}, {"project": "SOPHIA", "index": 20, "tags": ["Patient involvement in R&D"]}, {"project": "H2O", "index": 17, "tags": ["Patient involvement in R&D"]}, {"project": "EQIPD", "index": 12, "tags": [" Education and training"]}]}, {"name": "EHDEN", "children": [{"project": "DOIT", "index": 100, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "BIGDATAHEART", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY_PLUS", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "ROADMAP", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "PIONEER", "index": 50, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "ETRIKS", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "FAIRPLUS", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "OPEN_PHACTS", "index": 25, "tags": ["Big data and knowledge management"]}]}, {"name": "EHR4CR", "children": [{"project": "PREDICTTB", "index": 33, "tags": ["Clinical trial design"]}, {"project": "ADAPTSMART", "index": 25, "tags": ["Clinical trial design"]}, {"project": "DDMORE", "index": 25, "tags": [" Big data and knowledge management"]}, {"project": "ETRANSAFE", "index": 25, "tags": [" Big data and knowledge management"]}, {"project": "GETREAL", "index": 25, "tags": ["Clinical trial design"]}, {"project": "GETREAL_INITIATIVE", "index": 25, "tags": ["Clinical trial design"]}, {"project": "INNODIA", "index": 25, "tags": ["Clinical trial design"]}, {"project": "PARADIGM", "index": 25, "tags": ["Clinical trial design"]}, {"project": "RHAPSODY", "index": 25, "tags": ["Clinical trial design"]}, {"project": "AMYPAD", "index": 20, "tags": ["Clinical trial design"]}]}, {"name": "ELF", "children": [{"project": "ULTRADD", "index": 50, "tags": ["Drug discovery"]}, {"project": "ENABLE", "index": 25, "tags": ["Drug discovery"]}, {"project": "TRANSLOCATION", "index": 25, "tags": ["Drug discovery"]}]}, {"name": "EMIF", "children": [{"project": "IM2PACT", "index": 43, "tags": [" Neurodegenerative diseases", " Alzheimer's disease", "Diabetes & metabolic disorders"]}, {"project": "RADARAD", "index": 43, "tags": ["Digital health", " Big data and knowledge management", " Alzheimer's disease"]}, {"project": "RADARCNS", "index": 25, "tags": ["Digital health", " Big data and knowledge management"]}, {"project": "BEATDKD", "index": 20, "tags": ["Diabetes & metabolic disorders"]}, {"project": "GRAVITATEHEALTH", "index": 20, "tags": ["Digital health"]}, {"project": "DIRECT", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "EHR4CR", "index": 17, "tags": [" Big data and knowledge management"]}, {"project": "HYPORESOLVE", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "NEURONET", "index": 17, "tags": [" Alzheimer's disease"]}]}, {"name": "EMTRAIN", "children": [{"project": "EU2P", "index": 100, "tags": ["Education and training"]}, {"project": "PHARMATRAIN", "index": 100, "tags": ["Education and training"]}, {"project": "SAFESCIMET", "index": 100, "tags": ["Education and training"]}]}, {"name": "ENABLE", "children": [{"project": "TRANSLOCATION", "index": 100, "tags": ["Drug discovery", "Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTENET", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "DRIVEAB", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECARE", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECDI", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTEMAGNET", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ERA4TB", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IABC", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}]}, {"name": "EPAD", "children": [{"project": "AMYPAD", "index": 60, "tags": ["Clinical trial design", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 50, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PRISM", "index": 38, "tags": ["Clinical trial design", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "INNODIA_HARVEST", "index": 33, "tags": ["Clinical trial design", " Conducting clinical trials"]}, {"project": "ADAPTED", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "COMBACTECARE", "index": 29, "tags": ["Clinical trial design", " Conducting clinical trials"]}, {"project": "IDEAFAST", "index": 29, "tags": ["Clinical trial design", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "EQIPD", "children": [{"project": "AMYPAD", "index": 38, "tags": [" Imaging", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "IMIPAINCARE", "index": 30, "tags": ["Tools for predicting/monitoring efficacy", " Imaging", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PRISM", "index": 27, "tags": [" Alzheimer's disease", " Psychiatric diseases", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 25, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "DDMORE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "K4DD", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "MOPEAD", "index": 25, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EBISC2", "index": 22, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "EPAD", "index": 22, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "ERA4TB", "children": [{"project": "ABDIRECT", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRITB", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "TRICTB", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRINTM", "index": 60, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBINE", "index": 50, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBACTENET", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DRIVEAB", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ENABLE", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "TRANSLOCATION", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}]}, {"name": "ESCULAB", "children": [{"project": "EUBOPEN", "index": 100, "tags": ["Target identification", " Drug discovery"]}, {"project": "APPROACH", "index": 33, "tags": ["Target identification"]}, {"project": "OPEN_PHACTS", "index": 33, "tags": [" Drug discovery"]}, {"project": "K4DD", "index": 25, "tags": [" Drug discovery"]}, {"project": "NGNPET", "index": 25, "tags": [" Drug discovery"]}, {"project": "MADCOV_2", "index": 20, "tags": ["Target identification"]}, {"project": "MELLODDY", "index": 20, "tags": [" Drug discovery"]}, {"project": "NEWMEDS", "index": 20, "tags": [" Drug discovery"]}, {"project": "SUMMIT", "index": 20, "tags": [" Drug discovery"]}, {"project": "ADAPTED", "index": 17, "tags": [" Drug discovery"]}]}, {"name": "ETOX", "children": [{"project": "MARCAR", "index": 50, "tags": [" 3Rs - animal use in research", "Tools for predicting/monitoring efficacy"]}, {"project": "SAFET", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "NEURODERISK", "index": 33, "tags": [" 3Rs - animal use in research"]}, {"project": "PROTECT", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ABIRISK", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "BIOVACSAFE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "DDMORE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "ETRANSAFE", "children": [{"project": "NEURODERISK", "index": 67, "tags": [" 3Rs - animal use in research", "Tools for predicting/monitoring safety"]}, {"project": "CONCEPTION", "index": 33, "tags": [" Big data and knowledge management", "Tools for predicting/monitoring safety"]}, {"project": "MIPDILI", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "WEBRADR_2", "index": 33, "tags": [" Big data and knowledge management", "Tools for predicting/monitoring safety"]}, {"project": "EHR4CR", "index": 25, "tags": [" Big data and knowledge management"]}, {"project": "ETOX", "index": 25, "tags": [" 3Rs - animal use in research"]}, {"project": "IMIDIA", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "ETRIKS", "children": [{"project": "PHARMALEDGER", "index": 100, "tags": ["Big data and knowledge management"]}, {"project": "FAIRPLUS", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "OPEN_PHACTS", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "AETIONOMY", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "DOIT", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "EHDEN", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "PIONEER", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "BIGDATAHEART", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "HARMONY", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "HARMONY_PLUS", "index": 25, "tags": ["Big data and knowledge management"]}]}, {"name": "EUAIMS", "children": [{"project": "NEWMEDS", "index": 67, "tags": ["Psychiatric diseases", "Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "SUMMIT", "index": 43, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "EUROPAIN", "index": 38, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "PHARMACOG", "index": 38, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "MIPDILI", "index": 17, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 17, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ESCULAB", "index": 14, "tags": [" Drug discovery"]}, {"project": "EUBOPEN", "index": 14, "tags": [" Drug discovery"]}, {"project": "IMIDIA", "index": 14, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 14, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "EUPEARL", "children": [{"project": "C4C", "index": 38, "tags": ["Clinical trial design", " Patient involvement in R&D", " Clinical networks"]}, {"project": "COMBACTECDI", "index": 30, "tags": ["Clinical trial design", " Infectious diseases", " Clinical networks"]}, {"project": "COMBACTEMAGNET", "index": 30, "tags": ["Clinical trial design", " Infectious diseases", " Clinical networks"]}, {"project": "IABC", "index": 25, "tags": ["Clinical trial design", " Infectious diseases", " Clinical networks"]}, {"project": "INNODIA", "index": 25, "tags": ["Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "PARADIGM", "index": 25, "tags": ["Clinical trial design", " Patient involvement in R&D"]}, {"project": "RHAPSODY", "index": 25, "tags": ["Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "STEMBANCC", "index": 25, "tags": [" Psychiatric diseases", "Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 22, "tags": ["Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "COMBACTECARE", "index": 20, "tags": ["Clinical trial design", " Infectious diseases"]}]}, {"name": "EU2P", "children": [{"project": "EMTRAIN", "index": 100, "tags": ["Education and training"]}, {"project": "PHARMATRAIN", "index": 100, "tags": ["Education and training"]}, {"project": "SAFESCIMET", "index": 100, "tags": ["Education and training"]}]}, {"name": "EUBOPEN", "children": [{"project": "ESCULAB", "index": 100, "tags": ["Target identification", " Drug discovery"]}, {"project": "APPROACH", "index": 33, "tags": ["Target identification"]}, {"project": "OPEN_PHACTS", "index": 33, "tags": [" Drug discovery"]}, {"project": "K4DD", "index": 25, "tags": [" Drug discovery"]}, {"project": "NGNPET", "index": 25, "tags": [" Drug discovery"]}, {"project": "MADCOV_2", "index": 20, "tags": ["Target identification"]}, {"project": "MELLODDY", "index": 20, "tags": [" Drug discovery"]}, {"project": "NEWMEDS", "index": 20, "tags": [" Drug discovery"]}, {"project": "SUMMIT", "index": 20, "tags": [" Drug discovery"]}, {"project": "ADAPTED", "index": 17, "tags": [" Drug discovery"]}]}, {"name": "EUPATI", "children": [{"project": "EFOEUPATI", "index": 100, "tags": ["Patient involvement in R&D", " Education and training"]}, {"project": "FAIRPLUS", "index": 33, "tags": [" Education and training"]}, {"project": "MOPEAD", "index": 25, "tags": ["Patient involvement in R&D"]}, {"project": "SOPHIA", "index": 20, "tags": ["Patient involvement in R&D"]}, {"project": "H2O", "index": 17, "tags": ["Patient involvement in R&D"]}, {"project": "EQIPD", "index": 12, "tags": [" Education and training"]}]}, {"name": "EUROPAIN", "children": [{"project": "PHARMACOG", "index": 67, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design", "Neurodegenerative diseases"]}, {"project": "NEWMEDS", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "SUMMIT", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "EUAIMS", "index": 38, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "ADAPTED", "index": 25, "tags": [" Drug discovery", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 25, "tags": [" Drug discovery", "Neurodegenerative diseases"]}, {"project": "PDMITOQUANT", "index": 25, "tags": [" Drug discovery", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 25, "tags": [" Drug discovery", "Neurodegenerative diseases"]}, {"project": "IMIPAINCARE", "index": 22, "tags": [" Pain", "Neurodegenerative diseases"]}, {"project": "MIPDILI", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "FAIRPLUS", "children": [{"project": "ETRIKS", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "EFOEUPATI", "index": 33, "tags": [" Education and training"]}, {"project": "EUPATI", "index": 33, "tags": [" Education and training"]}, {"project": "OPEN_PHACTS", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "AETIONOMY", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "DOIT", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "EHDEN", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "PIONEER", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "BIGDATAHEART", "index": 20, "tags": ["Big data and knowledge management"]}]}, {"name": "FILODIAG", "children": [{"project": "EBOLAMODRAD", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "MOFINA", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VHFMODRAD", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOVAC", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBODAC", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOMAN", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "RAPPID", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}]}, {"name": "FLUCOP", "children": [{"project": "DECISION", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "IMPENTRI", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "KRONO", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RAPIDCOVID", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RESCEU", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "COVIDRED", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "VITAL", "index": 33, "tags": [" Infectious diseases", "Vaccines"]}, {"project": "CARE", "index": 29, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "DRAGON", "index": 29, "tags": ["Respiratory diseases", " Infectious diseases"]}]}, {"name": "GETREAL", "children": [{"project": "ADAPTSMART", "index": 100, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL_INITIATIVE", "index": 100, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "PREFER", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "TRIALSHOME", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "PARADIGM", "index": 50, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "IDEAFAST", "index": 33, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "WEBRADR_2", "index": 33, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "COMBACTECDI", "index": 29, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "EHR4CR", "index": 25, "tags": ["Clinical trial design"]}, {"project": "PREDICTTB", "index": 25, "tags": ["Clinical trial design"]}]}, {"name": "GETREAL_INITIATIVE", "children": [{"project": "ADAPTSMART", "index": 100, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL", "index": 100, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "PREFER", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "TRIALSHOME", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "PARADIGM", "index": 50, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "IDEAFAST", "index": 33, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "WEBRADR_2", "index": 33, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "COMBACTECDI", "index": 29, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "EHR4CR", "index": 25, "tags": ["Clinical trial design"]}, {"project": "PREDICTTB", "index": 25, "tags": ["Clinical trial design"]}]}, {"name": "GNA_NOW", "children": [{"project": "ABDIRECT", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRITB", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "TRICTB", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRINTM", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "ERA4TB", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBINE", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBACTENET", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DRIVEAB", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ENABLE", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IMPENTRI", "index": 33, "tags": ["Conducting clinical trials", " Infectious diseases"]}]}, {"name": "GRAVITATEHEALTH", "children": [{"project": "COVIDRED", "index": 20, "tags": ["Digital health"]}, {"project": "EMIF", "index": 20, "tags": ["Digital health"]}, {"project": "RADARAD", "index": 20, "tags": ["Digital health"]}, {"project": "RADARCNS", "index": 20, "tags": ["Digital health"]}]}, {"name": "H2O", "children": [{"project": "SOPHIA", "index": 50, "tags": ["Patient involvement in R&D", " Real-world data, evidence", "Diabetes & metabolic disorders"]}, {"project": "IDEAFAST", "index": 25, "tags": [" Real-world data, evidence", " Autoimmune diseases"]}, {"project": "BEATDKD", "index": 20, "tags": ["Diabetes & metabolic disorders"]}, {"project": "DIRECT", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "EFOEUPATI", "index": 17, "tags": ["Patient involvement in R&D"]}, {"project": "EUPATI", "index": 17, "tags": ["Patient involvement in R&D"]}, {"project": "HYPORESOLVE", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "ADAPTSMART", "index": 14, "tags": [" Real-world data, evidence"]}, {"project": "DOIT", "index": 14, "tags": [" Real-world data, evidence"]}]}, {"name": "HARMONY", "children": [{"project": "HARMONY_PLUS", "index": 100, "tags": [" Real-world data, evidence", "Cancer", "Big data and knowledge management", "BD4BO"]}, {"project": "DOIT", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "EHDEN", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "PIONEER", "index": 75, "tags": ["Cancer", "Big data and knowledge management", "BD4BO"]}, {"project": "BIGDATAHEART", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "ROADMAP", "index": 50, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "ETRIKS", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "PREDECT", "index": 25, "tags": ["Cancer"]}, {"project": "CANCERID", "index": 20, "tags": ["Cancer"]}]}, {"name": "HARMONY_PLUS", "children": [{"project": "HARMONY", "index": 100, "tags": [" Real-world data, evidence", "Cancer", "Big data and knowledge management", "BD4BO"]}, {"project": "DOIT", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "EHDEN", "index": 75, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "PIONEER", "index": 75, "tags": ["Cancer", "Big data and knowledge management", "BD4BO"]}, {"project": "BIGDATAHEART", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "ROADMAP", "index": 50, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "ETRIKS", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "PREDECT", "index": 25, "tags": ["Cancer"]}, {"project": "CANCERID", "index": 20, "tags": ["Cancer"]}]}, {"name": "HYPORESOLVE", "children": [{"project": "DIRECT", "index": 100, "tags": ["Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "BEATDKD", "index": 50, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "SPRINTT", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "UBIOPRED", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "INNODIA", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "QUICCONCEPT", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "RHAPSODY", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "STEMBANCC", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 20, "tags": ["Diabetes & metabolic disorders"]}]}, {"name": "IABC", "children": [{"project": "COMBACTEMAGNET", "index": 75, "tags": ["Clinical trial design", " Conducting clinical trials", "Antimicrobial resistance", " Infectious diseases", " Clinical networks", "ND4BB"]}, {"project": "COMBACTECARE", "index": 62, "tags": ["Clinical trial design", " Conducting clinical trials", "Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECDI", "index": 56, "tags": ["Clinical trial design", "Antimicrobial resistance", " Infectious diseases", "ND4BB", " Clinical networks"]}, {"project": "COMBACTENET", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "DRIVEAB", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ENABLE", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "TRANSLOCATION", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "EUPEARL", "index": 25, "tags": ["Clinical trial design", " Infectious diseases", " Clinical networks"]}, {"project": "ERA4TB", "index": 22, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 20, "tags": ["Antimicrobial resistance", " Infectious diseases"]}]}, {"name": "ICONSENSUS", "children": [{"project": "EBOMAN", "index": 33, "tags": ["Vaccines", "Manufacturing technologies"]}, {"project": "ZAPI", "index": 25, "tags": ["Vaccines"]}, {"project": "ADVANCE", "index": 20, "tags": ["Vaccines"]}, {"project": "BIOVACSAFE", "index": 20, "tags": ["Vaccines"]}, {"project": "FLUCOP", "index": 20, "tags": ["Vaccines"]}, {"project": "PERISCOPE", "index": 20, "tags": ["Vaccines"]}, {"project": "DRIVE", "index": 17, "tags": ["Vaccines"]}, {"project": "PEVIA", "index": 17, "tags": ["Vaccines"]}, {"project": "VAC2VAC", "index": 17, "tags": ["Vaccines"]}, {"project": "VSVEBOVAC", "index": 17, "tags": ["Vaccines"]}]}, {"name": "IDEAFAST", "children": [{"project": "TRIALSHOME", "index": 50, "tags": ["Clinical trial design", " Real-world data, evidence", " Digital health"]}, {"project": "ADAPTSMART", "index": 33, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "GETREAL", "index": 33, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "GETREAL_INITIATIVE", "index": 33, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "AMYPAD", "index": 29, "tags": ["Clinical trial design", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 29, "tags": ["Clinical trial design", "Neurodegenerative diseases"]}, {"project": "PREFER", "index": 29, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "H2O", "index": 25, "tags": [" Real-world data, evidence", " Autoimmune diseases"]}, {"project": "ROADMAP", "index": 25, "tags": [" Real-world data, evidence", "Neurodegenerative diseases"]}, {"project": "COMBACTECDI", "index": 22, "tags": ["Clinical trial design", " Real-world data, evidence"]}]}, {"name": "IM2PACT", "children": [{"project": "EMIF", "index": 43, "tags": [" Neurodegenerative diseases", " Alzheimer's disease", "Diabetes & metabolic disorders"]}, {"project": "LITMUS", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", "Diabetes & metabolic disorders"]}, {"project": "ARDAT", "index": 25, "tags": [" Drug delivery", "Tools for predicting/monitoring efficacy"]}, {"project": "BEATDKD", "index": 20, "tags": ["Diabetes & metabolic disorders"]}, {"project": "EQIPD", "index": 20, "tags": ["Tools for predicting/monitoring efficacy", " Alzheimer's disease"]}, {"project": "MOBILISED", "index": 20, "tags": [" Neurodegenerative diseases", "Tools for predicting/monitoring efficacy"]}, {"project": "SAFET", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 17, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "IMIPAINCARE", "children": [{"project": "MACUSTAR", "index": 38, "tags": ["Tools for predicting/monitoring efficacy", " Imaging", " Patient involvement in R&D"]}, {"project": "PDMITOQUANT", "index": 38, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Neurodegenerative diseases"]}, {"project": "EQIPD", "index": 30, "tags": ["Tools for predicting/monitoring efficacy", " Imaging", "Neurodegenerative diseases"]}, {"project": "RESOLUTE", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "AMYPAD", "index": 25, "tags": [" Imaging", "Neurodegenerative diseases"]}, {"project": "IMMUNIVERSE", "index": 25, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "LITMUS", "index": 25, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "MARCAR", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Imaging"]}, {"project": "NECESSITY", "index": 25, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "3TR", "index": 22, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}]}, {"name": "IMIDIA", "children": [{"project": "BEATDKD", "index": 50, "tags": ["Diabetes & metabolic disorders"]}, {"project": "MIPDILI", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "SUMMIT", "index": 50, "tags": ["Tools for predicting/monitoring safety", "Diabetes & metabolic disorders"]}, {"project": "TRANSBIOLINE", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "DIRECT", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "HYPORESOLVE", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "NEURODERISK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PROACTIVE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "IMMUCAN", "children": [{"project": "ARDAT", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety", "Biologicals"]}, {"project": "CANCERID", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Cancer"]}, {"project": "RTCURE", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety", "Biologicals"]}, {"project": "ABIRISK", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", "Biologicals"]}, {"project": "DDMORE", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "K4DD", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "EBISC2", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "MARCAR", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", "Cancer"]}, {"project": "MELLODDY", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "COMBINE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}]}, {"name": "IMMUNEIMAGE", "children": [{"project": "COMPACT", "index": 33, "tags": ["Biologicals"]}, {"project": "ABIRISK", "index": 25, "tags": ["Biologicals"]}, {"project": "IMMUCAN", "index": 20, "tags": ["Biologicals"]}, {"project": "ARDAT", "index": 17, "tags": ["Biologicals"]}, {"project": "RTCURE", "index": 17, "tags": ["Biologicals"]}]}, {"name": "IMMUNIVERSE", "children": [{"project": "BIOMAP", "index": 60, "tags": [" Disease taxonomy", " Skin diseases", "Autoimmune diseases"]}, {"project": "NECESSITY", "index": 60, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Autoimmune diseases"]}, {"project": "RTCURE", "index": 50, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Autoimmune diseases"]}, {"project": "BTCURE", "index": 40, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "RESOLUTE", "index": 40, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "LITMUS", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "3TR", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "PDMITOQUANT", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "IMIPAINCARE", "index": 25, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "SAFET", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "IMPENTRI", "children": [{"project": "CARE", "index": 67, "tags": [" Coronaviruses", "Conducting clinical trials", " Infectious diseases", "Respiratory diseases"]}, {"project": "DECISION", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "KRONO", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "RAPIDCOVID", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "COVIDRED", "index": 50, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "DRAGON", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 33, "tags": ["Conducting clinical trials", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 33, "tags": ["Conducting clinical trials", " Infectious diseases"]}]}, {"name": "IMPRIND", "children": [{"project": "ADAPTED", "index": 100, "tags": [" Drug discovery", "Neurodegenerative diseases", " Target identification", "Stem cells", " Alzheimer's disease"]}, {"project": "PHAGO", "index": 100, "tags": [" Drug discovery", "Neurodegenerative diseases", " Target identification", "Stem cells", " Alzheimer's disease"]}, {"project": "PRISM", "index": 50, "tags": [" Target identification", " Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PDMITOQUANT", "index": 43, "tags": [" Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "PHARMACOG", "index": 43, "tags": [" Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "IMSAVAR", "children": [{"project": "ULTRADD", "index": 25, "tags": ["Autoimmune diseases"]}, {"project": "BTCURE", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "PRECISESADS", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "BIOMAP", "index": 17, "tags": ["Autoimmune diseases"]}, {"project": "IMMUNIVERSE", "index": 17, "tags": ["Autoimmune diseases"]}, {"project": "NECESSITY", "index": 17, "tags": ["Autoimmune diseases"]}, {"project": "VAC2VAC", "index": 17, "tags": ["3Rs - animal use in research"]}, {"project": "H2O", "index": 14, "tags": [" Cancer"]}, {"project": "RTCURE", "index": 14, "tags": ["Autoimmune diseases"]}, {"project": "EBISC", "index": 12, "tags": [" Cancer"]}]}, {"name": "INNODIA", "children": [{"project": "RHAPSODY", "index": 100, "tags": [" Disease taxonomy", "Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 75, "tags": [" Disease taxonomy", "Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "LITMUS", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "SOPHIA", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "BEATDKD", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "DIRECT", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "EHR4CR", "index": 25, "tags": ["Clinical trial design"]}, {"project": "EUPEARL", "index": 25, "tags": ["Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "HYPORESOLVE", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 25, "tags": ["Diabetes & metabolic disorders"]}]}, {"name": "INNODIA_HARVEST", "children": [{"project": "INNODIA", "index": 75, "tags": [" Disease taxonomy", "Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "RHAPSODY", "index": 75, "tags": [" Disease taxonomy", "Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "EPAD", "index": 33, "tags": ["Clinical trial design", " Conducting clinical trials"]}, {"project": "LITMUS", "index": 33, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "SOPHIA", "index": 33, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "COMBACTECARE", "index": 29, "tags": ["Clinical trial design", " Conducting clinical trials"]}, {"project": "BEATDKD", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "COMBACTEMAGNET", "index": 25, "tags": ["Clinical trial design", " Conducting clinical trials"]}, {"project": "EBOVAC1", "index": 25, "tags": ["Clinical trial design", " Conducting clinical trials"]}, {"project": "EUPEARL", "index": 22, "tags": ["Clinical trial design", "Diabetes & metabolic disorders"]}]}, {"name": "IPIE", "children": [{"project": "CHEM21", "index": 50, "tags": ["Environmental aspects"]}]}, {"name": "ITCCP4", "children": [{"project": "ONCO_TRACK", "index": 67, "tags": ["Tools for predicting/monitoring safety", "Cancer"]}, {"project": "CONCEPTION", "index": 33, "tags": ["Tools for predicting/monitoring safety", " Tools for pediatrics"]}, {"project": "MIPDILI", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PREDECT", "index": 33, "tags": ["Cancer"]}, {"project": "TRANSBIOLINE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "CANCERID", "index": 25, "tags": ["Cancer"]}, {"project": "IMIDIA", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PROACTIVE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "K4DD", "children": [{"project": "MELLODDY", "index": 75, "tags": ["Tools for predicting/monitoring efficacy", " Drug discovery", " Tools for predicting/monitoring safety"]}, {"project": "DDMORE", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "EBISC2", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "IMMUCAN", "index": 40, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "ARDAT", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "PDMITOQUANT", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Drug discovery"]}, {"project": "RTCURE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "SAFET", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "KRONO", "children": [{"project": "DECISION", "index": 100, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "RAPIDCOVID", "index": 100, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "COVIDRED", "index": 80, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "DRAGON", "index": 67, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "IMPENTRI", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "CARE", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RESCEU", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "VALUEDX", "index": 29, "tags": [" Infectious diseases", "Diagnostics"]}]}, {"name": "LITMUS", "children": [{"project": "INNODIA", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "RESOLUTE", "index": 40, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "RHAPSODY", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "IMMUNIVERSE", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "INNODIA_HARVEST", "index": 33, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "NECESSITY", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "SOPHIA", "index": 33, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "3TR", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "IM2PACT", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", "Diabetes & metabolic disorders"]}, {"project": "PDMITOQUANT", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}]}, {"name": "MACUSTAR", "children": [{"project": "IMIPAINCARE", "index": 38, "tags": ["Tools for predicting/monitoring efficacy", " Imaging", " Patient involvement in R&D"]}, {"project": "MARCAR", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Imaging"]}, {"project": "VITAL", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", "Ageing-associated diseases"]}, {"project": "EQIPD", "index": 20, "tags": ["Tools for predicting/monitoring efficacy", " Imaging"]}, {"project": "SAFET", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 17, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ETOX", "index": 17, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "PROTECT", "index": 17, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "MADCOV_2", "children": [{"project": "DECISION", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "IMPENTRI", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "KRONO", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "RAPIDCOVID", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "COVIDRED", "index": 50, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "CARE", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "DRAGON", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RESCEU", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "APPROACH", "index": 20, "tags": ["Target identification"]}]}, {"name": "MARCAR", "children": [{"project": "CANCERID", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Cancer"]}, {"project": "ETOX", "index": 50, "tags": [" 3Rs - animal use in research", "Tools for predicting/monitoring efficacy"]}, {"project": "QUICCONCEPT", "index": 40, "tags": ["Cancer", " Imaging"]}, {"project": "IMMUCAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", "Cancer"]}, {"project": "MACUSTAR", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Imaging"]}, {"project": "IMIPAINCARE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Imaging"]}, {"project": "PREDECT", "index": 25, "tags": ["Cancer"]}, {"project": "SAFET", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "MELLODDY", "children": [{"project": "DDMORE", "index": 75, "tags": [" Big data and knowledge management", " Tools for predicting/monitoring safety", "Tools for predicting/monitoring efficacy"]}, {"project": "K4DD", "index": 75, "tags": ["Tools for predicting/monitoring efficacy", " Drug discovery", " Tools for predicting/monitoring safety"]}, {"project": "EBISC2", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "IMMUCAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "ARDAT", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "PDMITOQUANT", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Drug discovery"]}, {"project": "RTCURE", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "COMBINE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "SAFET", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "MIPDILI", "children": [{"project": "TRANSBIOLINE", "index": 100, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "IMIDIA", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PROACTIVE", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "BTCURE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ETRANSAFE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ITCCP4", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEWMEDS", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "MOBILISED", "children": [{"project": "WEBRADR", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Digital health"]}, {"project": "BIGDATAHEART", "index": 22, "tags": ["Cardiovascular diseases", " Real-world data, evidence"]}, {"project": "DRIVE", "index": 22, "tags": [" Real-world data, evidence", "Tools for predicting/monitoring efficacy"]}, {"project": "TRIALSHOME", "index": 22, "tags": [" Real-world data, evidence", " Digital health"]}, {"project": "IDEAFAST", "index": 20, "tags": [" Real-world data, evidence", " Digital health"]}, {"project": "IM2PACT", "index": 20, "tags": [" Neurodegenerative diseases", "Tools for predicting/monitoring efficacy"]}, {"project": "VITAL", "index": 20, "tags": [" Real-world data, evidence", "Tools for predicting/monitoring efficacy"]}, {"project": "SAFET", "index": 14, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 14, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 14, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "MOFINA", "children": [{"project": "EBOLAMODRAD", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VHFMODRAD", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOVAC", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBODAC", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOMAN", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "RAPPID", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}]}, {"name": "MOPEAD", "children": [{"project": "NEURONET", "index": 67, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 50, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ADAPTED", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHARMACOG", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "RADARAD", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ROADMAP", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "NECESSITY", "children": [{"project": "IMMUNIVERSE", "index": 60, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Autoimmune diseases"]}, {"project": "RTCURE", "index": 50, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Autoimmune diseases"]}, {"project": "BTCURE", "index": 40, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "RESOLUTE", "index": 40, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "BIOMAP", "index": 33, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "LITMUS", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "3TR", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "PDMITOQUANT", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "COMBINE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Clinical trial design"]}, {"project": "IMIPAINCARE", "index": 25, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}]}, {"name": "NEURODERISK", "children": [{"project": "ETRANSAFE", "index": 67, "tags": [" 3Rs - animal use in research", "Tools for predicting/monitoring safety"]}, {"project": "MIPDILI", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ETOX", "index": 33, "tags": [" 3Rs - animal use in research"]}, {"project": "IMIDIA", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PROACTIVE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "BTCURE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ITCCP4", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "NEURONET", "children": [{"project": "AETIONOMY", "index": 67, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 67, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 50, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 50, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ADAPTED", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHARMACOG", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "RADARAD", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ROADMAP", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "NEWMEDS", "children": [{"project": "EUAIMS", "index": 67, "tags": ["Psychiatric diseases", "Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "SUMMIT", "index": 60, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "EUROPAIN", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "PHARMACOG", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "MIPDILI", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ESCULAB", "index": 20, "tags": [" Drug discovery"]}, {"project": "EUBOPEN", "index": 20, "tags": [" Drug discovery"]}, {"project": "IMIDIA", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "NGNPET", "children": [{"project": "ESCULAB", "index": 25, "tags": [" Drug discovery"]}, {"project": "EUBOPEN", "index": 25, "tags": [" Drug discovery"]}, {"project": "OPEN_PHACTS", "index": 25, "tags": [" Drug discovery"]}, {"project": "K4DD", "index": 20, "tags": [" Drug discovery"]}, {"project": "PREMIER", "index": 20, "tags": ["Real-world data, evidence"]}, {"project": "MELLODDY", "index": 17, "tags": [" Drug discovery"]}, {"project": "NEWMEDS", "index": 17, "tags": [" Drug discovery"]}, {"project": "SUMMIT", "index": 17, "tags": [" Drug discovery"]}, {"project": "ADAPTED", "index": 14, "tags": [" Drug discovery"]}, {"project": "EUROPAIN", "index": 14, "tags": [" Drug discovery"]}]}, {"name": "ONCO_TRACK", "children": [{"project": "ITCCP4", "index": 67, "tags": ["Tools for predicting/monitoring safety", "Cancer"]}, {"project": "MIPDILI", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PREDECT", "index": 50, "tags": ["Cancer"]}, {"project": "TRANSBIOLINE", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "CANCERID", "index": 33, "tags": ["Cancer"]}, {"project": "IMIDIA", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PROACTIVE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "BTCURE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "OPEN_PHACTS", "children": [{"project": "ETRIKS", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "ESCULAB", "index": 33, "tags": [" Drug discovery"]}, {"project": "EUBOPEN", "index": 33, "tags": [" Drug discovery"]}, {"project": "FAIRPLUS", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "AETIONOMY", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "DOIT", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "EHDEN", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "K4DD", "index": 25, "tags": [" Drug discovery"]}, {"project": "NGNPET", "index": 25, "tags": [" Drug discovery"]}]}, {"name": "ORBITO", "children": [{"project": "MIPDILI", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "IMIDIA", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PROACTIVE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "BTCURE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ETRANSAFE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ITCCP4", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEWMEDS", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "PARADIGM", "children": [{"project": "ADAPTSMART", "index": 50, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "GETREAL", "index": 50, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "GETREAL_INITIATIVE", "index": 50, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "C4C", "index": 40, "tags": ["Clinical trial design", " Patient involvement in R&D"]}, {"project": "PREFER", "index": 40, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "TRIALSHOME", "index": 40, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "EHR4CR", "index": 25, "tags": ["Clinical trial design"]}, {"project": "EUPEARL", "index": 25, "tags": ["Clinical trial design", " Patient involvement in R&D"]}, {"project": "PREDICTTB", "index": 25, "tags": ["Clinical trial design"]}, {"project": "INNODIA", "index": 20, "tags": ["Clinical trial design"]}]}, {"name": "PDMIND", "children": [{"project": "NEURONET", "index": 33, "tags": ["Neurodegenerative diseases"]}, {"project": "STOPFOP", "index": 33, "tags": ["Conducting clinical trials"]}, {"project": "AETIONOMY", "index": 25, "tags": ["Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 25, "tags": ["Neurodegenerative diseases"]}, {"project": "PERISCOPE", "index": 25, "tags": ["Conducting clinical trials"]}, {"project": "PRECISESADS", "index": 25, "tags": ["Conducting clinical trials"]}, {"project": "ABDIRECT", "index": 20, "tags": ["Conducting clinical trials"]}, {"project": "AMYPAD", "index": 20, "tags": ["Neurodegenerative diseases"]}, {"project": "EPAD", "index": 20, "tags": ["Neurodegenerative diseases"]}, {"project": "GNA_NOW", "index": 20, "tags": ["Conducting clinical trials"]}]}, {"name": "PDMITOQUANT", "children": [{"project": "RESOLUTE", "index": 60, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", " Target identification"]}, {"project": "PRISM", "index": 50, "tags": [" Disease taxonomy", " Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "ADAPTED", "index": 43, "tags": [" Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 43, "tags": [" Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 43, "tags": [" Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "IMIPAINCARE", "index": 38, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Neurodegenerative diseases"]}, {"project": "K4DD", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Drug discovery"]}, {"project": "IMMUNIVERSE", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "LITMUS", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "MELLODDY", "index": 29, "tags": ["Tools for predicting/monitoring efficacy", " Drug discovery"]}]}, {"name": "PERISCOPE", "children": [{"project": "ZAPI", "index": 67, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOVAC2", "index": 60, "tags": ["Conducting clinical trials", "Vaccines", "Infectious diseases"]}, {"project": "EBOVAC3", "index": 60, "tags": ["Conducting clinical trials", "Vaccines", "Infectious diseases"]}, {"project": "ADVANCE", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "BIOVACSAFE", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "DRIVE", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PEVIA", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VAC2VAC", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBODAC", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}]}, {"name": "PEVIA", "children": [{"project": "VSVEBOVAC", "index": 100, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBODAC", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOMAN", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOVAC2", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOVAC3", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOPLUS", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOVAC1", "index": 67, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOLAMODRAD", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "MOFINA", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "PHAGO", "children": [{"project": "ADAPTED", "index": 100, "tags": [" Drug discovery", "Neurodegenerative diseases", " Target identification", "Stem cells", " Alzheimer's disease"]}, {"project": "IMPRIND", "index": 100, "tags": [" Drug discovery", "Neurodegenerative diseases", " Target identification", "Stem cells", " Alzheimer's disease"]}, {"project": "PRISM", "index": 50, "tags": [" Target identification", " Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PDMITOQUANT", "index": 43, "tags": [" Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "PHARMACOG", "index": 43, "tags": [" Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "PHARMACOG", "children": [{"project": "EUROPAIN", "index": 67, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design", "Neurodegenerative diseases"]}, {"project": "NEWMEDS", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "SUMMIT", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "ADAPTED", "index": 43, "tags": [" Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 43, "tags": [" Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 43, "tags": [" Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EUAIMS", "index": 38, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "AETIONOMY", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "PHARMALEDGER", "children": [{"project": "ETRIKS", "index": 100, "tags": ["Big data and knowledge management"]}, {"project": "FAIRPLUS", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "OPEN_PHACTS", "index": 50, "tags": ["Big data and knowledge management"]}, {"project": "AETIONOMY", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "DOIT", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "EHDEN", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "PIONEER", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "BIGDATAHEART", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "HARMONY", "index": 25, "tags": ["Big data and knowledge management"]}, {"project": "HARMONY_PLUS", "index": 25, "tags": ["Big data and knowledge management"]}]}, {"name": "PHARMATRAIN", "children": [{"project": "EMTRAIN", "index": 100, "tags": ["Education and training"]}, {"project": "EU2P", "index": 100, "tags": ["Education and training"]}, {"project": "SAFESCIMET", "index": 100, "tags": ["Education and training"]}]}, {"name": "PIONEER", "children": [{"project": "HARMONY", "index": 75, "tags": ["Cancer", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY_PLUS", "index": 75, "tags": ["Cancer", "Big data and knowledge management", "BD4BO"]}, {"project": "DOIT", "index": 50, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "EHDEN", "index": 50, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "BIGDATAHEART", "index": 40, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "ETRIKS", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "PHARMALEDGER", "index": 33, "tags": ["Big data and knowledge management"]}, {"project": "PREDECT", "index": 33, "tags": ["Cancer"]}, {"project": "ROADMAP", "index": 33, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "CANCERID", "index": 25, "tags": ["Cancer"]}]}, {"name": "PRECISESADS", "children": [{"project": "PDMIND", "index": 25, "tags": ["Conducting clinical trials"]}, {"project": "RAPPID", "index": 25, "tags": ["Diagnostics"]}, {"project": "STOPFOP", "index": 25, "tags": ["Conducting clinical trials"]}, {"project": "ULTRADD", "index": 25, "tags": ["Autoimmune diseases"]}, {"project": "BTCURE", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "IMSAVAR", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "PERISCOPE", "index": 20, "tags": ["Conducting clinical trials"]}, {"project": "ABDIRECT", "index": 17, "tags": ["Conducting clinical trials"]}, {"project": "BIOMAP", "index": 17, "tags": ["Autoimmune diseases"]}, {"project": "DECISION", "index": 17, "tags": ["Diagnostics"]}]}, {"name": "PREDECT", "children": [{"project": "CANCERID", "index": 50, "tags": ["Cancer"]}, {"project": "ONCO_TRACK", "index": 50, "tags": ["Cancer"]}, {"project": "ITCCP4", "index": 33, "tags": ["Cancer"]}, {"project": "PIONEER", "index": 33, "tags": ["Cancer"]}, {"project": "QUICCONCEPT", "index": 33, "tags": ["Cancer"]}, {"project": "HARMONY", "index": 25, "tags": ["Cancer"]}, {"project": "HARMONY_PLUS", "index": 25, "tags": ["Cancer"]}, {"project": "IMMUCAN", "index": 25, "tags": ["Cancer"]}, {"project": "MARCAR", "index": 25, "tags": ["Cancer"]}]}, {"name": "PREDICTTB", "children": [{"project": "EBOVAC1", "index": 33, "tags": ["Clinical trial design", "Infectious diseases"]}, {"project": "EHR4CR", "index": 33, "tags": ["Clinical trial design"]}, {"project": "RAPPID", "index": 33, "tags": ["Infectious diseases"]}, {"project": "ZAPI", "index": 33, "tags": ["Infectious diseases"]}, {"project": "ADAPTSMART", "index": 25, "tags": ["Clinical trial design"]}, {"project": "ADVANCE", "index": 25, "tags": ["Infectious diseases"]}, {"project": "BIOVACSAFE", "index": 25, "tags": ["Infectious diseases"]}, {"project": "GETREAL", "index": 25, "tags": ["Clinical trial design"]}, {"project": "GETREAL_INITIATIVE", "index": 25, "tags": ["Clinical trial design"]}, {"project": "INNODIA", "index": 25, "tags": ["Clinical trial design"]}]}, {"name": "PREFER", "children": [{"project": "ADAPTSMART", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL_INITIATIVE", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "TRIALSHOME", "index": 60, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "WEBRADR_2", "index": 50, "tags": [" Real-world data, evidence", " Methods for benefit/risk assessment", " Regulatory and HTA processes"]}, {"project": "PARADIGM", "index": 40, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "IDEAFAST", "index": 29, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "COMBACTECDI", "index": 25, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "EHR4CR", "index": 20, "tags": ["Clinical trial design"]}, {"project": "PREDICTTB", "index": 20, "tags": ["Clinical trial design"]}]}, {"name": "PREMIER", "children": [{"project": "ADAPTSMART", "index": 20, "tags": [" Regulatory and HTA processes"]}, {"project": "GETREAL", "index": 20, "tags": [" Regulatory and HTA processes"]}, {"project": "GETREAL_INITIATIVE", "index": 20, "tags": [" Regulatory and HTA processes"]}, {"project": "NGNPET", "index": 20, "tags": ["Real-world data, evidence"]}, {"project": "PARADIGM", "index": 20, "tags": [" Regulatory and HTA processes"]}, {"project": "WEBRADR", "index": 20, "tags": [" Regulatory and HTA processes"]}, {"project": "PREFER", "index": 17, "tags": [" Regulatory and HTA processes"]}, {"project": "RESCEU", "index": 17, "tags": [" Regulatory and HTA processes"]}, {"project": "TRIALSHOME", "index": 17, "tags": [" Regulatory and HTA processes"]}, {"project": "VAC2VAC", "index": 17, "tags": [" Regulatory and HTA processes"]}]}, {"name": "PRISM", "children": [{"project": "ADAPTED", "index": 50, "tags": [" Target identification", " Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 50, "tags": [" Target identification", " Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PDMITOQUANT", "index": 50, "tags": [" Disease taxonomy", " Target identification", " Drug discovery", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 50, "tags": [" Target identification", " Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 38, "tags": ["Clinical trial design", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 38, "tags": ["Clinical trial design", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHARMACOG", "index": 33, "tags": [" Drug discovery", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "NEURONET", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EQIPD", "index": 27, "tags": [" Alzheimer's disease", " Psychiatric diseases", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 25, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "PROACTIVE", "children": [{"project": "MIPDILI", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "IMIDIA", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "UBIOPRED", "index": 33, "tags": ["Respiratory diseases"]}, {"project": "BTCURE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ETRANSAFE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "FLUCOP", "index": 25, "tags": ["Respiratory diseases"]}]}, {"name": "PROTECT", "children": [{"project": "SAFET", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ETOX", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ABIRISK", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "BIOVACSAFE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "DDMORE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "K4DD", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "RESOLUTE", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "QUICCONCEPT", "children": [{"project": "MARCAR", "index": 40, "tags": ["Cancer", " Imaging"]}, {"project": "PREDECT", "index": 33, "tags": ["Cancer"]}, {"project": "CANCERID", "index": 25, "tags": ["Cancer"]}, {"project": "DIRECT", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "HYPORESOLVE", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "ONCO_TRACK", "index": 25, "tags": ["Cancer"]}, {"project": "SPRINTT", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "UBIOPRED", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "ITCCP4", "index": 20, "tags": ["Cancer"]}, {"project": "PIONEER", "index": 20, "tags": ["Cancer"]}]}, {"name": "RADARAD", "children": [{"project": "RADARCNS", "index": 67, "tags": ["Digital health", " Big data and knowledge management", "RADAR", "Neurodegenerative diseases"]}, {"project": "EMIF", "index": 43, "tags": ["Digital health", " Big data and knowledge management", " Alzheimer's disease"]}, {"project": "NEURONET", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "AMYPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "EPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "ADAPTED", "index": 25, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "IMPRIND", "index": 25, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PHAGO", "index": 25, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "RADARCNS", "children": [{"project": "RADARAD", "index": 67, "tags": ["Digital health", " Big data and knowledge management", "RADAR", "Neurodegenerative diseases"]}, {"project": "EMIF", "index": 25, "tags": ["Digital health", " Big data and knowledge management"]}, {"project": "EQIPD", "index": 20, "tags": [" Psychiatric diseases", "Neurodegenerative diseases"]}, {"project": "GRAVITATEHEALTH", "index": 20, "tags": ["Digital health"]}, {"project": "PRISM", "index": 20, "tags": [" Psychiatric diseases", "Neurodegenerative diseases"]}, {"project": "EHR4CR", "index": 17, "tags": [" Big data and knowledge management"]}, {"project": "NEURONET", "index": 17, "tags": ["Neurodegenerative diseases"]}, {"project": "PDMIND", "index": 17, "tags": ["Neurodegenerative diseases"]}, {"project": "AETIONOMY", "index": 14, "tags": ["Neurodegenerative diseases"]}, {"project": "DDMORE", "index": 14, "tags": [" Big data and knowledge management"]}]}, {"name": "RAPIDCOVID", "children": [{"project": "DECISION", "index": 100, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "KRONO", "index": 100, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "COVIDRED", "index": 80, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "DRAGON", "index": 67, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases", "Diagnostics"]}, {"project": "IMPENTRI", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 60, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "CARE", "index": 43, "tags": [" Coronaviruses", "Respiratory diseases", " Infectious diseases"]}, {"project": "FLUCOP", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RESCEU", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "VALUEDX", "index": 29, "tags": [" Infectious diseases", "Diagnostics"]}]}, {"name": "RAPPID", "children": [{"project": "EBOLAMODRAD", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}, {"project": "FILODIAG", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}, {"project": "MOFINA", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}, {"project": "VHFMODRAD", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}, {"project": "PREDICTTB", "index": 33, "tags": ["Infectious diseases"]}, {"project": "ZAPI", "index": 33, "tags": ["Infectious diseases"]}, {"project": "ADVANCE", "index": 25, "tags": ["Infectious diseases"]}, {"project": "BIOVACSAFE", "index": 25, "tags": ["Infectious diseases"]}, {"project": "PERISCOPE", "index": 25, "tags": ["Infectious diseases"]}, {"project": "PRECISESADS", "index": 25, "tags": ["Diagnostics"]}]}, {"name": "RESCEU", "children": [{"project": "FLUCOP", "index": 40, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "DECISION", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "IMPENTRI", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "KRONO", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "MADCOV_2", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "RAPIDCOVID", "index": 33, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "COVIDRED", "index": 29, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "CARE", "index": 25, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "DRAGON", "index": 25, "tags": ["Respiratory diseases", " Infectious diseases"]}, {"project": "PROACTIVE", "index": 20, "tags": ["Respiratory diseases"]}]}, {"name": "RESOLUTE", "children": [{"project": "PDMITOQUANT", "index": 60, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", " Target identification"]}, {"project": "IMMUNIVERSE", "index": 40, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "LITMUS", "index": 40, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "NECESSITY", "index": 40, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "3TR", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "RTCURE", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "SAFET", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "IMIPAINCARE", "index": 29, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}]}, {"name": "RESPIRINTM", "children": [{"project": "ABDIRECT", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRITB", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "TRICTB", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "ERA4TB", "index": 60, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "CARE", "index": 38, "tags": ["Conducting clinical trials", " Target identification", " Infectious diseases"]}, {"project": "COMBINE", "index": 38, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBACTENET", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DRIVEAB", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ENABLE", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}]}, {"name": "RESPIRITB", "children": [{"project": "ABDIRECT", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "TRICTB", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRINTM", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "ERA4TB", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBINE", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBACTENET", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DRIVEAB", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ENABLE", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IMPENTRI", "index": 33, "tags": ["Conducting clinical trials", " Infectious diseases"]}]}, {"name": "RHAPSODY", "children": [{"project": "INNODIA", "index": 100, "tags": [" Disease taxonomy", "Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 75, "tags": [" Disease taxonomy", "Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "LITMUS", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "SOPHIA", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "BEATDKD", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "DIRECT", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "EHR4CR", "index": 25, "tags": ["Clinical trial design"]}, {"project": "EUPEARL", "index": 25, "tags": ["Clinical trial design", "Diabetes & metabolic disorders"]}, {"project": "HYPORESOLVE", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 25, "tags": ["Diabetes & metabolic disorders"]}]}, {"name": "ROADMAP", "children": [{"project": "AETIONOMY", "index": 60, "tags": ["Big data and knowledge management", " Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "DOIT", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "EHDEN", "index": 60, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "BIGDATAHEART", "index": 50, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY", "index": 50, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "HARMONY_PLUS", "index": 50, "tags": [" Real-world data, evidence", "Big data and knowledge management", "BD4BO"]}, {"project": "NEURONET", "index": 40, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "MOPEAD", "index": 33, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}, {"project": "PIONEER", "index": 33, "tags": ["Big data and knowledge management", "BD4BO"]}, {"project": "AMYPAD", "index": 29, "tags": [" Alzheimer's disease", "Neurodegenerative diseases"]}]}, {"name": "RTCURE", "children": [{"project": "IMMUCAN", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety", "Biologicals"]}, {"project": "IMMUNIVERSE", "index": 50, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Autoimmune diseases"]}, {"project": "NECESSITY", "index": 50, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy", "Autoimmune diseases"]}, {"project": "ARDAT", "index": 43, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety", "Biologicals"]}, {"project": "ABIRISK", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", "Biologicals"]}, {"project": "BTCURE", "index": 33, "tags": [" Disease taxonomy", "Autoimmune diseases"]}, {"project": "DDMORE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "K4DD", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", " Tools for predicting/monitoring safety"]}, {"project": "RESOLUTE", "index": 33, "tags": [" Disease taxonomy", "Tools for predicting/monitoring efficacy"]}, {"project": "BIOMAP", "index": 29, "tags": [" Disease taxonomy", "Autoimmune diseases"]}]}, {"name": "SAFET", "children": [{"project": "TRANSQST", "index": 100, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 100, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ETOX", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "PROTECT", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ABIRISK", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "BIOVACSAFE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "DDMORE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "K4DD", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "RESOLUTE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "SAFESCIMET", "children": [{"project": "EMTRAIN", "index": 100, "tags": ["Education and training"]}, {"project": "EU2P", "index": 100, "tags": ["Education and training"]}, {"project": "PHARMATRAIN", "index": 100, "tags": ["Education and training"]}]}, {"name": "SOPHIA", "children": [{"project": "H2O", "index": 50, "tags": ["Patient involvement in R&D", " Real-world data, evidence", "Diabetes & metabolic disorders"]}, {"project": "INNODIA", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "RHAPSODY", "index": 40, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 33, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "LITMUS", "index": 33, "tags": [" Disease taxonomy", "Diabetes & metabolic disorders"]}, {"project": "BEATDKD", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "DIRECT", "index": 20, "tags": ["Diabetes & metabolic disorders"]}, {"project": "EFOEUPATI", "index": 20, "tags": ["Patient involvement in R&D"]}, {"project": "EUPATI", "index": 20, "tags": ["Patient involvement in R&D"]}, {"project": "HYPORESOLVE", "index": 20, "tags": ["Diabetes & metabolic disorders"]}]}, {"name": "SPRINTT", "children": [{"project": "DIRECT", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "HYPORESOLVE", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "UBIOPRED", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "QUICCONCEPT", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "MACUSTAR", "index": 17, "tags": ["Ageing-associated diseases"]}, {"project": "VITAL", "index": 17, "tags": ["Ageing-associated diseases"]}]}, {"name": "STEMBANCC", "children": [{"project": "BEATDKD", "index": 33, "tags": ["Diabetes & metabolic disorders"]}, {"project": "DIRECT", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "EUPEARL", "index": 25, "tags": [" Psychiatric diseases", "Diabetes & metabolic disorders"]}, {"project": "HYPORESOLVE", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "IMIDIA", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "INNODIA", "index": 20, "tags": ["Diabetes & metabolic disorders"]}, {"project": "RHAPSODY", "index": 20, "tags": ["Diabetes & metabolic disorders"]}, {"project": "INNODIA_HARVEST", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "LITMUS", "index": 17, "tags": ["Diabetes & metabolic disorders"]}, {"project": "SOPHIA", "index": 17, "tags": ["Diabetes & metabolic disorders"]}]}, {"name": "STOPFOP", "children": [{"project": "PDMIND", "index": 33, "tags": ["Conducting clinical trials"]}, {"project": "PERISCOPE", "index": 25, "tags": ["Conducting clinical trials"]}, {"project": "PRECISESADS", "index": 25, "tags": ["Conducting clinical trials"]}, {"project": "ABDIRECT", "index": 20, "tags": ["Conducting clinical trials"]}, {"project": "GNA_NOW", "index": 20, "tags": ["Conducting clinical trials"]}, {"project": "IMPENTRI", "index": 20, "tags": ["Conducting clinical trials"]}, {"project": "RESPIRITB", "index": 20, "tags": ["Conducting clinical trials"]}, {"project": "TRICTB", "index": 20, "tags": ["Conducting clinical trials"]}, {"project": "ARDAT", "index": 17, "tags": ["Rare/orphan diseases"]}, {"project": "EBOVAC2", "index": 17, "tags": ["Conducting clinical trials"]}]}, {"name": "SUMMIT", "children": [{"project": "NEWMEDS", "index": 60, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "EUROPAIN", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "IMIDIA", "index": 50, "tags": ["Tools for predicting/monitoring safety", "Diabetes & metabolic disorders"]}, {"project": "PHARMACOG", "index": 50, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "EUAIMS", "index": 43, "tags": ["Tools for predicting/monitoring safety", " Drug discovery", " Clinical trial design"]}, {"project": "BEATDKD", "index": 25, "tags": ["Diabetes & metabolic disorders"]}, {"project": "MIPDILI", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "DIRECT", "index": 20, "tags": ["Diabetes & metabolic disorders"]}, {"project": "ESCULAB", "index": 20, "tags": [" Drug discovery"]}]}, {"name": "TRANSBIOLINE", "children": [{"project": "MIPDILI", "index": 100, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "IMIDIA", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEURODERISK", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ONCO_TRACK", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ORBITO", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "PROACTIVE", "index": 50, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "BTCURE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ETRANSAFE", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "ITCCP4", "index": 33, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "NEWMEDS", "index": 25, "tags": ["Tools for predicting/monitoring safety"]}]}, {"name": "TRANSLOCATION", "children": [{"project": "ENABLE", "index": 100, "tags": ["Drug discovery", "Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTENET", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "DRIVEAB", "index": 60, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECARE", "index": 50, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTECDI", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "COMBACTEMAGNET", "index": 43, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}, {"project": "ERA4TB", "index": 40, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IABC", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases", "ND4BB"]}]}, {"name": "TRANSQST", "children": [{"project": "SAFET", "index": 100, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 100, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ETOX", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "PROTECT", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ABIRISK", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "BIOVACSAFE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "DDMORE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "K4DD", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "RESOLUTE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "TRIALSHOME", "children": [{"project": "ADAPTSMART", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL_INITIATIVE", "index": 75, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "PREFER", "index": 60, "tags": ["Clinical trial design", " Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "IDEAFAST", "index": 50, "tags": ["Clinical trial design", " Real-world data, evidence", " Digital health"]}, {"project": "PARADIGM", "index": 40, "tags": ["Clinical trial design", " Regulatory and HTA processes"]}, {"project": "WEBRADR", "index": 40, "tags": [" Digital health", " Regulatory and HTA processes"]}, {"project": "WEBRADR_2", "index": 29, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "COMBACTECDI", "index": 25, "tags": ["Clinical trial design", " Real-world data, evidence"]}, {"project": "MOBILISED", "index": 22, "tags": [" Real-world data, evidence", " Digital health"]}]}, {"name": "TRICTB", "children": [{"project": "ABDIRECT", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRITB", "index": 100, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "RESPIRINTM", "index": 80, "tags": ["Antimicrobial resistance", "Conducting clinical trials", "AMR Accelerator", " Infectious diseases"]}, {"project": "ERA4TB", "index": 75, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBINE", "index": 43, "tags": ["Antimicrobial resistance", "AMR Accelerator", " Infectious diseases"]}, {"project": "COMBACTENET", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DRIVEAB", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ENABLE", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "IMPENTRI", "index": 33, "tags": ["Conducting clinical trials", " Infectious diseases"]}]}, {"name": "TRISTAN", "children": [{"project": "SAFET", "index": 100, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 100, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ETOX", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "PROTECT", "index": 50, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ABIRISK", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "BIOVACSAFE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "DDMORE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "K4DD", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "RESOLUTE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "UBIOPRED", "children": [{"project": "DIRECT", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "HYPORESOLVE", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "PROACTIVE", "index": 33, "tags": ["Respiratory diseases"]}, {"project": "SPRINTT", "index": 33, "tags": ["Disease taxonomy"]}, {"project": "FLUCOP", "index": 25, "tags": ["Respiratory diseases"]}, {"project": "QUICCONCEPT", "index": 25, "tags": ["Disease taxonomy"]}, {"project": "DECISION", "index": 20, "tags": ["Respiratory diseases"]}, {"project": "IMPENTRI", "index": 20, "tags": ["Respiratory diseases"]}, {"project": "KRONO", "index": 20, "tags": ["Respiratory diseases"]}, {"project": "MADCOV_2", "index": 20, "tags": ["Respiratory diseases"]}]}, {"name": "ULTRADD", "children": [{"project": "ELF", "index": 50, "tags": ["Drug discovery"]}, {"project": "BTCURE", "index": 25, "tags": ["Autoimmune diseases"]}, {"project": "IMSAVAR", "index": 25, "tags": ["Autoimmune diseases"]}, {"project": "PRECISESADS", "index": 25, "tags": ["Autoimmune diseases"]}, {"project": "BIOMAP", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "ENABLE", "index": 20, "tags": ["Drug discovery"]}, {"project": "IMMUNIVERSE", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "NECESSITY", "index": 20, "tags": ["Autoimmune diseases"]}, {"project": "TRANSLOCATION", "index": 20, "tags": ["Drug discovery"]}, {"project": "RTCURE", "index": 17, "tags": ["Autoimmune diseases"]}]}, {"name": "VAC2VAC", "children": [{"project": "ZAPI", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "ADVANCE", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "BIOVACSAFE", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PERISCOPE", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "DRIVE", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PEVIA", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 33, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBODAC", "index": 29, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOMAN", "index": 29, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOVAC2", "index": 29, "tags": ["Vaccines", "Infectious diseases"]}]}, {"name": "VALUEDX", "children": [{"project": "ERA4TB", "index": 33, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ABDIRECT", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "COMBACTENET", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "DECISION", "index": 29, "tags": [" Infectious diseases", "Diagnostics"]}, {"project": "DRIVEAB", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "ENABLE", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "GNA_NOW", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}, {"project": "KRONO", "index": 29, "tags": [" Infectious diseases", "Diagnostics"]}, {"project": "RAPIDCOVID", "index": 29, "tags": [" Infectious diseases", "Diagnostics"]}, {"project": "RESPIRITB", "index": 29, "tags": ["Antimicrobial resistance", " Infectious diseases"]}]}, {"name": "VHFMODRAD", "children": [{"project": "EBOLAMODRAD", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "MOFINA", "index": 100, "tags": ["Diagnostics", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "VSVEBOVAC", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBODAC", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOMAN", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "RAPPID", "index": 50, "tags": ["Diagnostics", "Infectious diseases"]}]}, {"name": "VITAL", "children": [{"project": "DRIVE", "index": 50, "tags": [" Real-world data, evidence", "Tools for predicting/monitoring efficacy", "Vaccines"]}, {"project": "BIOVACSAFE", "index": 33, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines"]}, {"project": "FLUCOP", "index": 33, "tags": [" Infectious diseases", "Vaccines"]}, {"project": "EBODAC", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines"]}, {"project": "MACUSTAR", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", "Ageing-associated diseases"]}, {"project": "VSVEBOPLUS", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines"]}, {"project": "COMBACTECDI", "index": 22, "tags": [" Real-world data, evidence", " Infectious diseases"]}, {"project": "COMBINE", "index": 22, "tags": ["Tools for predicting/monitoring efficacy", " Infectious diseases"]}, {"project": "MOBILISED", "index": 20, "tags": [" Real-world data, evidence", "Tools for predicting/monitoring efficacy"]}, {"project": "SAFET", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}]}, {"name": "VSVEBOPLUS", "children": [{"project": "EBODAC", "index": 100, "tags": ["Infectious diseases", "Tools for predicting/monitoring efficacy", "Vaccines", "Ebola+", " Ebola and related diseases"]}, {"project": "PEVIA", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOMAN", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC2", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "EBOVAC3", "index": 67, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "BIOVACSAFE", "index": 60, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "EBOVAC1", "index": 57, "tags": ["Vaccines", "Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "DRIVE", "index": 50, "tags": ["Tools for predicting/monitoring efficacy", "Vaccines", "Infectious diseases"]}, {"project": "EBOLAMODRAD", "index": 50, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "VSVEBOVAC", "children": [{"project": "PEVIA", "index": 100, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBODAC", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOMAN", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOVAC2", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOVAC3", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "VSVEBOPLUS", "index": 80, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOVAC1", "index": 67, "tags": ["Ebola+", "Vaccines", " Ebola and related diseases", "Infectious diseases"]}, {"project": "EBOLAMODRAD", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "FILODIAG", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}, {"project": "MOFINA", "index": 60, "tags": ["Ebola+", "Infectious diseases", " Ebola and related diseases"]}]}, {"name": "WEBRADR", "children": [{"project": "TRIALSHOME", "index": 40, "tags": [" Digital health", " Regulatory and HTA processes"]}, {"project": "SAFET", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRANSQST", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "TRISTAN", "index": 33, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "CANCERID", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ETOX", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "MOBILISED", "index": 25, "tags": ["Tools for predicting/monitoring efficacy", " Digital health"]}, {"project": "PROTECT", "index": 25, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ABIRISK", "index": 20, "tags": ["Tools for predicting/monitoring efficacy"]}, {"project": "ADAPTSMART", "index": 20, "tags": [" Regulatory and HTA processes"]}]}, {"name": "WEBRADR_2", "children": [{"project": "PREFER", "index": 50, "tags": [" Real-world data, evidence", " Methods for benefit/risk assessment", " Regulatory and HTA processes"]}, {"project": "CONCEPTION", "index": 43, "tags": [" Real-world data, evidence", "Tools for predicting/monitoring safety", " Big data and knowledge management"]}, {"project": "ADAPTSMART", "index": 33, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "ETRANSAFE", "index": 33, "tags": [" Big data and knowledge management", "Tools for predicting/monitoring safety"]}, {"project": "GETREAL", "index": 33, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "GETREAL_INITIATIVE", "index": 33, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "TRIALSHOME", "index": 29, "tags": [" Real-world data, evidence", " Regulatory and HTA processes"]}, {"project": "MIPDILI", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "TRANSBIOLINE", "index": 20, "tags": ["Tools for predicting/monitoring safety"]}, {"project": "EHR4CR", "index": 17, "tags": [" Big data and knowledge management"]}]}, {"name": "ZAPI", "children": [{"project": "ADVANCE", "index": 67, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "BIOVACSAFE", "index": 67, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PERISCOPE", "index": 67, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "DRIVE", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "PEVIA", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VAC2VAC", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "VSVEBOVAC", "index": 50, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBODAC", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOMAN", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}, {"project": "EBOVAC2", "index": 40, "tags": ["Vaccines", "Infectious diseases"]}]}]

var projects_list = [{"-- All":['3TR', 'ABDIRECT', 'ABIRISK', 'ADAPTED', 'ADAPTSMART', 'ADVANCE', 'AETIONOMY', 'AIMS2TRIALS', 'AMYPAD', 'APPROACH', 'ARDAT', 'BEATDKD', 'BIGDATAHEART', 'BIOMAP', 'BIOVACSAFE', 'BTCURE', 'C4C', 'CANCERID', 'CARDIATEAM', 'CARE', 'CHEM21', 'COMBACTECARE', 'COMBACTECDI', 'COMBACTEMAGNET', 'COMBACTENET', 'COMBINE', 'COMPACT', 'CONCEPTION', 'COVIDRED', 'DDMORE', 'DECISION', 'DIRECT', 'DOIT', 'DRAGON', 'DRIVE', 'DRIVEAB', 'EBISC', 'EBISC2', 'EBODAC', 'EBOLAMODRAD', 'EBOMAN', 'EBOVAC1', 'EBOVAC2', 'EBOVAC3', 'EFOEUPATI', 'EHDEN', 'EHR4CR', 'ELF', 'EMIF', 'EMTRAIN', 'ENABLE', 'EPAD', 'EQIPD', 'ERA4TB', 'ESCULAB', 'ETOX', 'ETRANSAFE', 'ETRIKS', 'EU2P', 'EUAIMS', 'EUBOPEN', 'EUPATI', 'EUPEARL', 'EUROPAIN', 'FAIRPLUS', 'FILODIAG', 'FLUCOP', 'GETREAL', 'GETREAL_INITIATIVE', 'GNA_NOW', 'GRAVITATEHEALTH', 'H2O', 'HARMONY', 'HARMONY_PLUS', 'HYPORESOLVE', 'IABC', 'ICONSENSUS', 'IDEAFAST', 'IM2PACT', 'IMIDIA', 'IMIPAINCARE', 'IMMUCAN', 'IMMUNEIMAGE', 'IMMUNIVERSE', 'IMPENTRI', 'IMPRIND', 'IMSAVAR', 'INNODIA', 'INNODIA_HARVEST', 'IPIE', 'ITCCP4', 'K4DD', 'KRONO', 'LITMUS', 'MACUSTAR', 'MADCOV_2', 'MARCAR', 'MELLODDY', 'MIPDILI', 'MOBILISED', 'MOFINA', 'MOPEAD', 'NECESSITY', 'NEURODERISK', 'NEURONET', 'NEWMEDS', 'NGNPET', 'ONCO_TRACK', 'OPEN_PHACTS', 'ORBITO', 'PARADIGM', 'PDMIND', 'PDMITOQUANT', 'PERISCOPE', 'PEVIA', 'PHAGO', 'PHARMACOG', 'PHARMALEDGER', 'PHARMATRAIN', 'PIONEER', 'PRECISESADS', 'PREDECT', 'PREDICTTB', 'PREFER', 'PREMIER', 'PRISM', 'PROACTIVE', 'PROTECT', 'QUICCONCEPT', 'RADARAD', 'RADARCNS', 'RAPIDCOVID', 'RAPPID', 'RESCEU', 'RESOLUTE', 'RESPIRINTM', 'RESPIRITB', 'RHAPSODY', 'ROADMAP', 'RTCURE', 'SAFESCIMET', 'SAFET', 'SOPHIA', 'SPRINTT', 'STEMBANCC', 'STOPFOP', 'SUMMIT', 'TRANSBIOLINE', 'TRANSLOCATION', 'TRANSQST', 'TRIALSHOME', 'TRICTB', 'TRISTAN', 'UBIOPRED', 'ULTRADD', 'VAC2VAC', 'VALUEDX', 'VHFMODRAD', 'VITAL', 'VSVEBOPLUS', 'VSVEBOVAC', 'WEBRADR', 'WEBRADR_2', 'ZAPI']},
{"A. Persidis & S.A Oe, Athina, Greece":['NEURODERISK']},
{"ANGLE Europe Ltd, Guildford, United Kingdom":['CANCERID']},
{"Aalborg Universitet, Aalborg OE, Denmark":['IMIPAINCARE']},
{"Aarhus Universitet, Aarhus C, Denmark":['ADVANCE', 'IM2PACT', 'IMIPAINCARE', 'IMMUNIVERSE', 'PROTECT', 'ROADMAP']},
{"Aarhus Universitetshospital, Aarhus, Denmark":['ADVANCE', 'EMIF', 'EUROPAIN', 'IMMUNIVERSE']},
{"Abac Therapeutics, SL, Esplugues De Llobregat, Spain":['ENABLE']},
{"AbbVie Ltd, Maidenhead, United Kingdom":['ADAPTSMART', 'IMPRIND', 'PREFER']},
{"Abbott Biologicals BV, Weesp, Netherlands":['DRIVE', 'FLUCOP']},
{"Abbott Diabetes Care, Alameda, United States":['HYPORESOLVE']},
{"Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany":['ADAPTED', 'COMPACT', 'EUROPAIN', 'IMPRIND', 'MIPDILI', 'NEWMEDS', 'ORBITO', 'PHAGO', 'STEMBANCC', 'TRANSQST', 'TRISTAN']},
{"Abbvie Inc, North Chicago, Illinois, United States":['BEATDKD', 'CARE', 'CONCEPTION', 'EFOEUPATI', 'EHDEN', 'EQIPD', 'ETRANSAFE', 'H2O', 'HARMONY', 'IDEAFAST', 'IMMUCAN', 'PHARMALEDGER', 'PREDECT', 'WEBRADR_2']},
{"Abx Cro Advanced Pharmaceutical Services Forschungsgesellschaft Mbh, Oberwil, Switzerland":['TRANSBIOLINE']},
{"Ac Immune SA, Lausanne, Switzerland":['EPAD', 'ROADMAP']},
{"Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands":['3TR', 'ABIRISK', 'BIOMAP', 'BTCURE', 'COMBACTECARE', 'COMBACTEMAGNET', 'IMMUNIVERSE', 'IMPENTRI', 'ITCCP4', 'LITMUS', 'UBIOPRED']},
{"Academisch Ziekenhuis Groningen, Groningen, Netherlands":['3TR', 'BEATDKD', 'CANCERID', 'CARDIATEAM', 'CONCEPTION', 'GETREAL', 'GETREAL_INITIATIVE', 'IMMUNEIMAGE', 'NECESSITY', 'PROACTIVE', 'PROTECT', 'RESCEU', 'RHAPSODY', 'TRISTAN', 'VAC2VAC', 'VALUEDX', 'VITAL', 'WEBRADR']},
{"Academisch Ziekenhuis Leiden, Leiden, Netherlands":['ABIRISK', 'APPROACH', 'BIOMAP', 'BTCURE', 'CARE', 'COMBACTECDI', 'DIRECT', 'ELF', 'EUBOPEN', 'IDEAFAST', 'IM2PACT', 'IMSAVAR', 'INNODIA', 'INNODIA_HARVEST', 'OPEN_PHACTS', 'PERISCOPE', 'PRISM', 'RESPIRINTM', 'RESPIRITB', 'RHAPSODY', 'ROADMAP', 'RTCURE', 'VSVEBOPLUS', 'VSVEBOVAC', 'ZAPI']},
{"Accelerate Diagnostics SL, Tucson, United States":['VALUEDX']},
{"Acib GMBH, Graz, Austria":['CHEM21']},
{"Actelion Pharmaceuticals LTD, Allschwil, Switzerland":['PREFER']},
{"Actual Analytics LTD, Edinburgh, United Kingdom":['IMIPAINCARE']},
{"Aerocrine AB, Solna, Sweden":['UBIOPRED']},
{"Agena Bioscience GmbH, Hamburg, Germany":['CANCERID']},
{"Agence nationale de sécurité du médicament et des produits de santé, Saint-Denis Cedex, France":['EU2P']},
{"Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain":['ADVANCE', 'GRAVITATEHEALTH', 'HARMONY', 'HARMONY_PLUS', 'PROTECT', 'WEBRADR_2']},
{"Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain":['3TR', 'ADAPTED', 'BTCURE', 'ENABLE', 'NEWMEDS', 'PRECISESADS', 'ZAPI']},
{"Agencia Publica Empresarial Sanitaria Costa Del Sol, Marbella Malaga, Spain":['RAPIDCOVID']},
{"Agencia Publica Empresarial Sanitaria Hospital De Poniente, El Ejido Almeria, Spain":['3TR']},
{"Agencija Za Lijekove I Medicinske Proizvode, Zagreb, Croatia":['WEBRADR', 'WEBRADR_2']},
{"Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands":['GRAVITATEHEALTH', 'RADARAD', 'ROADMAP', 'VAC2VAC']},
{"Agenzia Di Tutela Della Salute Della Val Padana, Mantova, Italy":['ADVANCE']},
{"Agenzia Italiana Del Farmaco, Rome, Italy":['ADAPTSMART', 'PARADIGM']},
{"Agenzia Regionale Di Sanita, Firenze, Italy":['ADVANCE', 'CONCEPTION', 'EMIF']},
{"Agilent Technologies Sales & Services GmbH & Co. KG, Waldbronn, Germany":['CANCERID']},
{"Ai-Biopharma, Montpellier, France":['CARE']},
{"Aibili Associacao Para Investigacao Biomedica E Innovacao Em Luz E Imagem, Coimbra, Portugal":['MACUSTAR']},
{"Aicuris Anti-Infective Cures GMBH, Wuppertal, Germany":['CARE', 'COMBACTEMAGNET']},
{"Ait Austrian Institute Of Technology GMBH, Wien, Austria":['BIOMAP', 'IM2PACT', 'IMMUNIVERSE']},
{"Aj Innuscreen GMBH, Berlin, Germany":['EBOLAMODRAD']},
{"Akershus Universitetssykehus Hf, Lorenskog, Norway":['GRAVITATEHEALTH']},
{"Alacris Theranostics GMBH, Berlin, Germany":['3TR', 'CANCERID', 'ONCO_TRACK']},
{"Alaxia":['IABC']},
{"Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany":['MIPDILI']},
{"Alcediag, Montpellier, France":['NEURODERISK']},
{"Alere International Limited, galway, Ireland":['VALUEDX']},
{"Alere Technologies GMBH, Jena, Germany":['MOFINA']},
{"Alexion Services Europe SPRL, Brussels, Belgium":['PARADIGM']},
{"Alleanza Contro Il Cancro, Roma, Italy":['ITCCP4']},
{"Allergan Limited, Marlow, United Kingdom":['EUPEARL', 'LITMUS', 'TRIALSHOME']},
{"Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy":['CONCEPTION', 'HARMONY', 'HARMONY_PLUS', 'MOBILISED', 'PRISM']},
{"Almirall SA, Barcelona, Spain":['EMTRAIN', 'EU2P', 'OPEN_PHACTS', 'PHARMATRAIN', 'PROACTIVE', 'SAFESCIMET', 'SAFET', 'UBIOPRED']},
{"Alta Ricerca E Sviluppo In Biotecnologie Srlu, Siena, Italy":['ABIRISK']},
{"Altoida AG, Luzern, Switzerland":['RADARAD']},
{"Altona Diagnostics GMBH, Hamburg, Germany":['MOFINA']},
{"Alzheimer Europe, Luxembourg, Luxembourg":['AETIONOMY', 'AMYPAD', 'EMIF', 'EPAD', 'MOPEAD', 'NEURONET', 'PARADIGM', 'PHARMACOG', 'RADARAD', 'ROADMAP']},
{"Amc Medical Research BV, Amsterdam, Netherlands":['UBIOPRED']},
{"Amgen Limited, Cambridge, United Kingdom":['GETREAL_INITIATIVE', 'MOBILISED', 'PARADIGM', 'PREFER']},
{"Amgen Research (Munich) GMBH, Munchen, Germany":['MELLODDY']},
{"Amgen, Brussels, Belgium":['ADAPTSMART', 'DOIT', 'EHR4CR', 'EMIF', 'EPAD', 'EU2P', 'EUPATI', 'GETREAL', 'HARMONY', 'PHARMATRAIN', 'PROTECT', 'QUICCONCEPT', 'SAFET', 'UBIOPRED', 'WEBRADR']},
{"Anocca AB, Karlskrona, Sweden":['RTCURE']},
{"Antaros Medical AB, Mölndal, Sweden":['IMMUNEIMAGE', 'LITMUS', 'TRISTAN']},
{"Ao Documentation And Publishing Foundation, Davos, Switzerland":['COMBACTENET']},
{"Apeiron Biologics AG, Wien, Austria":['MADCOV_2']},
{"Apitope International Nv, Diepenbeek, Belgium":['RTCURE']},
{"Apuliabiotech Societa Consortile Ar L, Bari, Italy":['BEATDKD']},
{"Araclon Biotech S.L., Zaragoza, Spain":['EPAD']},
{"Aridhia Informatics Limited, Glasgow, United Kingdom":['EPAD']},
{"Aristotelio Panepistimio Thessalonikis, Thessaloniki, Greece":['C4C']},
{"Arlenda SA, Saint-Georges, Belgium":['EQIPD']},
{"Arsenal.It - Centro Veneto Ricercae Innovazione Per La Sanita Digitale, Treviso Tv, Italy":['C4C']},
{"Arteevo Technologies LTD, Tel Aviv, Israel":['PHARMALEDGER']},
{"Artemis Bio-Support B.V., Utrecht, Netherlands":['FLUCOP', 'IM2PACT', 'ZAPI']},
{"Arthritis Research UK, Chesterfield, United Kingdom":['APPROACH']},
{"Arthrogen BV, Amsterdam, Netherlands":['BTCURE']},
{"Artialis SA, Liège (Sart-Tilman), Belgium":['APPROACH']},
{"Arttic, Paris, France":['AIMS2TRIALS', 'CANCERID', 'EBISC', 'EBISC2', 'ELF', 'EUAIMS', 'PHAGO']},
{"Asclepia Outsourcing Solutions Bvba, Destelbergen, Belgium":['COMBINE', 'ENABLE']},
{"Asdm Consulting, Bruxelles, Belgium":['MOPEAD']},
{"Asociacion Centro De Investigacion Cooperativa En Biociencias, Derio, Spain":['LITMUS']},
{"Asociacion Nacional Empresarial De La Industria Farmaceutica, Madrid, Spain":['DOIT', 'EUPATI']},
{"Asociacion Parkinson Madrid, Madrid, Spain":['IDEAFAST']},
{"Asphalion SL, Barcelona, Spain":['ARDAT']},
{"Assistance Publique Hopitaux De Paris, Paris, France":['ABIRISK', 'AIMS2TRIALS', 'APPROACH', 'CARDIATEAM', 'COMBACTEMAGNET', 'DRIVE', 'EHR4CR', 'EPAD', 'EUPEARL', 'HARMONY', 'IMIPAINCARE', 'LITMUS', 'NECESSITY', 'PEVIA', 'RAPIDCOVID', 'SAFET', 'TRANSBIOLINE', 'TRANSLOCATION']},
{"Association Eisbm, Vourles, France":['ETRIKS', 'PIONEER']},
{"Association Francaise Gougerot-Sjogren, Courbevoie, France":['NECESSITY']},
{"Association Genethon, Evry, France":['ARDAT']},
{"Association Internationale De Standardisation Biologique Pour LEurope (IABS-EU), Lyon, France":['ZAPI']},
{"Association Internationale De Standardisation Biologique Pour LEurope(Iabs-Eu), Lyon, France":['DRIVE', 'VAC2VAC']},
{"Association Pour Le Developpement De LEnseignement Et Des Recherches Aupres Des Universites, Des Centres De Recherche Et Des Entreprises DAquitaine, Pessac, France":['EU2P']},
{"Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Lisbon, Portugal":['C4C']},
{"Astellas Pharma Europe BV, Leiden, Netherlands":['ARDAT', 'BEATDKD', 'CARE', 'EUROPAIN', 'GETREAL_INITIATIVE', 'MELLODDY', 'PIONEER', 'PREFER', 'SPRINTT']},
{"Astellas Pharma Europe LTD, Chertsey, United Kingdom":['ADAPTSMART', 'DRIVEAB']},
{"Asthma Uk Lbg, London, United Kingdom":['UBIOPRED']},
{"Aston University, Birmingham, United Kingdom":['ENABLE', 'SPRINTT']},
{"Astrazeneca AB, Södertälje, Sweden":['3TR', 'ADAPTSMART', 'BTCURE', 'COMBACTEMAGNET', 'COMBACTENET', 'DDMORE', 'DRIVEAB', 'EBISC', 'EHDEN', 'EHR4CR', 'ELF', 'EMTRAIN', 'ENABLE', 'ESCULAB', 'ETOX', 'ETRANSAFE', 'ETRIKS', 'EU2P', 'EUPATI', 'EUPEARL', 'EUROPAIN', 'FAIRPLUS', 'FLUCOP', 'GETREAL', 'GETREAL_INITIATIVE', 'GRAVITATEHEALTH', 'IDEAFAST', 'IMIDIA', 'IPIE', 'K4DD', 'LITMUS', 'MELLODDY', 'MIPDILI', 'MOBILISED', 'MOPEAD', 'NEURODERISK', 'ONCO_TRACK', 'OPEN_PHACTS', 'ORBITO', 'PDMIND', 'PHAGO', 'PHARMACOG', 'PHARMALEDGER', 'PHARMATRAIN', 'PREDECT', 'PREFER', 'PREMIER', 'PROACTIVE', 'PROTECT', 'QUICCONCEPT', 'RESCEU', 'SAFESCIMET', 'SAFET', 'STEMBANCC', 'STOPFOP', 'SUMMIT', 'TRANSLOCATION', 'TRANSQST', 'TRIALSHOME', 'UBIOPRED', 'WEBRADR', 'ZAPI']},
{"Atrys Health, SA, Madrid, Spain":['3TR', 'PRECISESADS']},
{"Atturos Limited, Limerick Clare, Ireland":['SOPHIA']},
{"Autism Speaks Inc. Non Profit Corporation, Princeton, NJ, United States":['AIMS2TRIALS', 'EUAIMS']},
{"Autisme-Europe Aisbl, Bruxelles, Belgium":['AIMS2TRIALS']},
{"Autistica, London, United Kingdom":['AIMS2TRIALS']},
{"Ava AG, Zurich, Switzerland":['COVIDRED']},
{"Axxam S.A, Bresso (Milan), Italy":['NGNPET', 'PHAGO', 'RESOLUTE']},
{"Azienda Ospedale Universita Padova, Padova, Italy":['3TR']},
{"Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino, Torino, Italy":['RHAPSODY']},
{"Azienda Ospedaliero-Universitaria Anna Meyer, Firenze, Italy":['3TR', 'C4C']},
{"Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy":['C4C']},
{"Azienda Sanitaria Universitaria Integrata Di Udine, Udine, Italy":['C4C']},
{"Azienda Socia-Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy":['C4C']},
{"B G Research LTD, Kimbolton, United Kingdom":['KRONO']},
{"Bar Ilan University, Ramat Gan, Israel":['NEWMEDS']},
{"Barcelona Supercomputing Center - Centro Nacional De Supercomputacion, Barcelona, Spain":['ETRANSAFE', 'FAIRPLUS']},
{"Barts And The London Nhs Trust, London, United Kingdom":['HARMONY']},
{"Basilea Pharmaceutica International AG, Basel, Switzerland":['COMBACTECARE', 'COMBACTEMAGNET', 'ENABLE', 'TRANSLOCATION']},
{"Bavarian Nordic As, Kvistgaard, Denmark":['EBOMAN']},
{"Bayer Aktiengesellschaft, Leverkusen, Germany":['ARDAT', 'BIGDATAHEART', 'C4C', 'CANCERID', 'CARDIATEAM', 'CARE', 'DOIT', 'EBISC', 'EBISC2', 'EFOEUPATI', 'EHDEN', 'ELF', 'ESCULAB', 'ETRANSAFE', 'ETRIKS', 'EUBOPEN', 'FAIRPLUS', 'GETREAL_INITIATIVE', 'GRAVITATEHEALTH', 'HARMONY', 'HARMONY_PLUS', 'ICONSENSUS', 'IMIPAINCARE', 'IMMUCAN', 'IMMUNEIMAGE', 'IPIE', 'ITCCP4', 'K4DD', 'MACUSTAR', 'MELLODDY', 'MOBILISED', 'PARADIGM', 'PHARMALEDGER', 'PIONEER', 'PRECISESADS', 'PREMIER', 'RESOLUTE', 'TRIALSHOME', 'TRISTAN', 'ULTRADD']},
{"Bayer Pharma AG, Berlin, Germany":['ABIRISK', 'ADAPTSMART', 'BEATDKD', 'CHEM21', 'EHR4CR', 'EMTRAIN', 'ETOX', 'EU2P', 'EUPATI', 'GETREAL', 'MARCAR', 'ONCO_TRACK', 'ORBITO', 'PHARMATRAIN', 'PREDECT', 'PREFER', 'PROTECT', 'SAFESCIMET', 'SAFET', 'WEBRADR']},
{"Bd Switzerland SARL, Eysins, Switzerland":['VALUEDX']},
{"Beactica Therapeutics AB, Uppsala, Sweden":['ENABLE']},
{"Beam Alliance, Paris, France":['COMBINE']},
{"Belfast Health And Social Care Trust, Belfast, United Kingdom":['IABC']},
{"Bernhard-Nocht-Institut Fuer Tropenmedizin, Hamburg, Germany":['MOFINA', 'PEVIA']},
{"Berry Consultants Llp, London, United Kingdom":['EPAD', 'EUPEARL', 'VALUEDX']},
{"Berufsgenossenschafliches Universitaetsklinikum Bergmannsheil GMBH, Bochum, Germany":['EUROPAIN']},
{"Beth Israel Deaconess Medical Center, Inc Non Profit Corporation, Boston Ma, United States":['GRAVITATEHEALTH']},
{"Bill & Melinda Gates Foundation, Seattle, United States":['CARE', 'ERA4TB', 'PERISCOPE']},
{"Bio-Rad, Marnes-La-Coquette, France":['VALUEDX']},
{"BioSolveIT GmbH, Sankt Augustin, Germany":['OPEN_PHACTS']},
{"BioVersys SAS, Lille, France":['TRICTB']},
{"Bioascent Discovery Limited, Newhouse, United Kingdom":['ELF', 'ESCULAB']},
{"Bioaster Fondation De Cooperation Scientifique, Lyon, France":['ERA4TB', 'GNA_NOW', 'VALUEDX']},
{"Biobanks And Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric), Graz, Austria":['CONCEPTION', 'EMTRAIN']},
{"Biocom, Berlin, Germany":['COMBINE']},
{"Biocomputing Platforms LTD Oy, Espoo, Finland":['SUMMIT']},
{"Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom":['ADAPTED', 'EPAD', 'IDEAFAST', 'RADARCNS', 'ROADMAP']},
{"Biogene LTD, Kimbolton, United Kingdom":['KRONO']},
{"Biomedcode Ellas Anonimi Eteria Epistimonikis Kai Texnologikis Erevnas Kai Emborikis Ekmetallefsis Epharmogon Iatrikis, Vari, Greece":['BTCURE']},
{"Biomedical Sciences Research Center Alexander Fleming, Vari - Athens, Greece":['BTCURE']},
{"Biomedicum Genomics Ltd, Helsinki, Finland":['PREDECT']},
{"Biomerieux SA, Marcy LEtoile, France":['COMBACTECDI', 'VALUEDX', 'VITAL']},
{"Biomonitor A/S, Copenhagen, Denmark":['ABIRISK']},
{"Bioneer A/S, Horsholm, Denmark":['COMPACT', 'EBISC', 'EBISC2']},
{"Bionotus, Temse, Belgium":['CONCEPTION']},
{"Biophytis SA, Paris, France":['SPRINTT']},
{"Bioprotection Systems Corporation, Ames, United States":['VSVEBOVAC']},
{"Bioresources Technology & Engineering GmbH, Giessen, Germany":['ENABLE']},
{"Biosci Consulting Bvba, Maasmechelen, Belgium":['AIMS2TRIALS', 'DRAGON', 'ETRIKS', 'IMSAVAR', 'UBIOPRED']},
{"Biosistemika, Raziskave In Razvoj Doo, Ljubljana, Slovenia":['RAPIDCOVID']},
{"Biotech Investissement, Besancon, France":['VHFMODRAD']},
{"Biotrial, Rennes, France":['PRISM']},
{"Bioversys AG, Basel, Switzerland":['TRICTB']},
{"Bioxydyn Limited, Manchester, United Kingdom":['TRISTAN']},
{"Birkbeck College - University Of London, London, United Kingdom":['AIMS2TRIALS', 'EUAIMS']},
{"Bluebird Bio Inc., Cambridge Ma, United States":['IMSAVAR']},
{"Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany":['ADAPTSMART', 'AETIONOMY', 'BEATDKD', 'BIOMAP', 'BTCURE', 'CANCERID', 'CARE', 'COMPACT', 'DIRECT', 'DOIT', 'EMIF', 'EMTRAIN', 'EPAD', 'EQIPD', 'ETOX', 'ETRANSAFE', 'EU2P', 'EUBOPEN', 'EUPATI', 'EUROPAIN', 'FAIRPLUS', 'GETREAL', 'IMIDIA', 'IMSAVAR', 'IPIE', 'LITMUS', 'MARCAR', 'MELLODDY', 'ONCO_TRACK', 'ORBITO', 'PHARMACOG', 'PHARMALEDGER', 'PREDECT', 'PRISM', 'PROACTIVE', 'RESOLUTE', 'SAFESCIMET', 'SAFET', 'SOPHIA', 'SPRINTT', 'STEMBANCC', 'SUMMIT', 'TRANSQST', 'TRIALSHOME', 'UBIOPRED']},
{"Boehringer Ingelheim Vetmedica GMBH, Ingelheim am Rhein, Germany":['VAC2VAC', 'ZAPI']},
{"Bristol-Myers Squibb Company Corp, Princeton, NJ, United States":['BTCURE', 'CONCEPTION', 'EUPATI', 'GETREAL', 'IPIE', 'LITMUS', 'MIPDILI', 'NECESSITY', 'ORBITO', 'PREMIER', 'RTCURE']},
{"British Lung Foundation, London, United Kingdom":['PROACTIVE']},
{"British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom":['DRIVEAB']},
{"Bruker Biospin Mri GMBH, Ettlingen, Germany":['TRISTAN']},
{"Bruker Daltonik GMBH, Bremen, Germany":['TRANSLOCATION']},
{"Budapesti Muszaki Es Gazdasagtudomanyi Egyetem, Budapest, Hungary":['MELLODDY']},
{"Bundesinstitut Fur Arzneimittel Und Medizinprodukte, Bonn, Germany":['HARMONY', 'HARMONY_PLUS']},
{"Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany":['ABIRISK', 'COMBINE', 'EUPEARL', 'FLUCOP', 'IMSAVAR', 'VAC2VAC']},
{"Bundesministerium Der Verteidigung, Bonn, Germany":['DECISION']},
{"Byteflies, Antwerpen, Belgium":['IDEAFAST']},
{"CHDI Foundation, Inc., New York, United States":['IDEAFAST']},
{"CHU de Pointe-à-Pitre, Pointe-à-Pitre, France":['COMBACTENET']},
{"Caebi Bioinformatica Sociedad Limitada, Sevilla, Spain":['ADAPTED']},
{"Cambridge Cognition Limited, Cambridge, United Kingdom":['EMIF', 'IDEAFAST']},
{"Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom":['3TR']},
{"Cardiff University, Cardiff, United Kingdom":['COMBACTECARE', 'COMPACT', 'ENABLE', 'EPAD', 'IM2PACT', 'INNODIA', 'INNODIA_HARVEST', 'PHARMATRAIN', 'PREDECT', 'RAPPID']},
{"Caretek SRL, Torino, Italy":['SPRINTT']},
{"Carl Zeiss Meditec AG, Jena, Germany":['MACUSTAR']},
{"CatScI Ltd, Wentloog, Cardiff, United Kingdom":['CHEM21']},
{"Cdisc Europe Foundation Fondation, Brussels, Belgium":['BIOVACSAFE', 'DRAGON', 'EHR4CR', 'ETRIKS']},
{"Celgene Management SARL, Couvet, Switzerland":['DOIT', 'EHDEN', 'HARMONY', 'HARMONY_PLUS']},
{"Cemm - Forschungszentrum Fuer Molekulare Medizin GMBH, Vienna, Austria":['RESOLUTE']},
{"Central Manchester University Hospitals Nhs Foundation Trust, Manchester, United Kingdom":['EUPATI']},
{"Centre DEtude Et De Recherche Multimodal Et Pluridisciplinaire En Imagerie Du Vivant Gie, Bron Cedex, France":['CARDIATEAM']},
{"Centre De Lutte Contre Le Cancer Leon Berard, Lyon, France":['IMMUCAN']},
{"Centre Europeen De Recherche En Biologie Et Medecine, Illkirch, France":['EMTRAIN']},
{"Centre Federal DExpertise Des Soins De Sante, Brussels, Belgium":['PREFER']},
{"Centre Hospitalier De Luxembourg, Luxembourg, Luxembourg":['INNODIA', 'INNODIA_HARVEST']},
{"Centre Hospitalier National DOphtalmologie Des Quinze-Vingts, Paris, France":['MACUSTAR']},
{"Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux Marseille, Marseille, France":['PHARMACOG', 'UBIOPRED']},
{"Centre Hospitalier Regional Et Universitaire De Brest, Brest, France":['3TR', 'NECESSITY', 'PRECISESADS']},
{"Centre Hospitalier Regional Et Universitaire De Lille, Lille, France":['DIRECT', 'PEVIA', 'PHARMACOG', 'RHAPSODY', 'SOPHIA']},
{"Centre Hospitalier Regional Universitaire De Tours, Tours, France":['ABDIRECT', 'AIMS2TRIALS']},
{"Centre Hospitalier Regional Universitaire Nancy, Nancy Cedex, France":['3TR', 'IMMUNIVERSE']},
{"Centre Hospitalier Universitaire De Liege, Liege, Belgium":['DRAGON']},
{"Centre Hospitalier Universitaire De Poitiers, Poitiers, France":['ABDIRECT', 'COMBACTECARE']},
{"Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France":['AMYPAD', 'CONCEPTION', 'EPAD', 'SPRINTT']},
{"Centre Hospitalier Universitaire Montpellier, Montpellier, France":['BTCURE', 'HYPORESOLVE', 'MOBILISED']},
{"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland":['BIOMAP', 'CARE', 'COMBACTEMAGNET', 'CONCEPTION', 'IMMUCAN', 'PERISCOPE', 'PEVIA']},
{"Centre Muraz, Bobo Dioulasso, Burkina Faso":['EBOVAC2']},
{"Centre National De La Recherche Scientifique Cnrs, Paris, France":['ABIRISK', 'APPROACH', 'CARE', 'DIRECT', 'ENABLE', 'ETRIKS', 'IMIDIA', 'IMPRIND', 'PDMITOQUANT', 'PEVIA', 'PHARMACOG', 'RHAPSODY', 'TRANSLOCATION', 'TRISTAN', 'UBIOPRED', 'VITAL']},
{"Centre de Recherches Medicales de Lambaréné, Lambaréné, Gabon":['VSVEBOPLUS', 'VSVEBOVAC']},
{"Centre hospitalier universitaire de Limoges, Limoges, France":['COMBACTECARE', 'COMBACTEMAGNET', 'COMBACTENET', 'SPRINTT']},
{"Centro De Neurociencias E Biologiacelular Associacao, Coimbra, Portugal":['ARDAT']},
{"Centro Hospitalar Universitario Do Porto Epe, Porto, Portugal":['PRECISESADS']},
{"Centrum Voor Innovatie En Stimulatie Van Medicijnontwikkeling Leuven Vzw, Leuven, Belgium":['CARE']},
{"Cepheid Europe, Maurens Scopont, France":['VHFMODRAD']},
{"Certara Uk Limited, London, United Kingdom":['DDMORE', 'ETRANSAFE', 'ORBITO', 'TRANSQST']},
{"Chalmers Tekniska Hoegskola AB, Goeteborg, Sweden":['BIOVACSAFE', 'TRISTAN']},
{"Charite - Universitaetsmedizin Berlin, Berlin, Germany":['3TR', 'BIGDATAHEART', 'BTCURE', 'CANCERID', 'EBISC', 'EBISC2', 'EQIPD', 'EUPEARL', 'H2O', 'HARMONY', 'HARMONY_PLUS', 'IMMUCAN', 'ITCCP4', 'ONCO_TRACK', 'PHAGO', 'PRECISESADS', 'RADARCNS', 'SAFESCIMET', 'SAFET', 'STEMBANCC', 'TRANSBIOLINE']},
{"Charles River Discovery Research Services Germany GMBH, Freiburg, Germany":['ITCCP4', 'PREDECT']},
{"ChemAxon Kutató-Fejlesztő Korlátolt Felelősségű Társaság, Budapest, Hungary":['ELF']},
{"Chemotargets S.L., Barcelona, Spain":['ETOX']},
{"Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung, Frankfurt, Germany":['EUBOPEN']},
{"Chiesi Farmaceutici S.A, Parma, Italy":['EUPATI', 'PROACTIVE', 'UBIOPRED']},
{"ChildrenS Hospital Corporation, Boston, United States":['IMIPAINCARE']},
{"ChildrenS Tumor Foundation, New York, United States":['EUPEARL']},
{"Choice Healthcare solutions Ltd, Hitchin, Hertfordshire, United Kingdom":['PROACTIVE']},
{"Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany":['3TR', 'BIOMAP', 'EUROPAIN', 'IDEAFAST', 'IMIPAINCARE', 'IMMUNIVERSE', 'MOBILISED']},
{"Chu Hopitaux De Bordeaux, Talence, France":['BEATDKD', 'EBOVAC1', 'EBOVAC2', 'EBOVAC3', 'ROADMAP']},
{"City University Of London, London, United Kingdom":['MACUSTAR']},
{"Clarivate Analytics (Uk) Limited, London, United Kingdom":['ETRANSAFE']},
{"Clearbridge Biomedics Pte Ltd, Singapore, Singapore":['CANCERID']},
{"Clinical Trial Center Maastricht, Maastricht, Netherlands":['CARDIATEAM']},
{"Cliniques Universitaires Saint-Luc, Brussels, Belgium":['3TR', 'COMBACTEMAGNET', 'COMBACTENET', 'IMIPAINCARE']},
{"Clonit SRL, Milano, Italy":['EBOLAMODRAD']},
{"Cloudselling BV, Rijswijk, Netherlands":['IMMUNEIMAGE']},
{"Coalition For Epidemic Preparedness Innovation, Oslo, Norway":['EBOVAC3']},
{"Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France":['ABIRISK', 'AIMS2TRIALS', 'ARDAT', 'BIOVACSAFE', 'CARE', 'ERA4TB', 'EUAIMS', 'IMIDIA', 'IMMUNEIMAGE', 'PERISCOPE', 'PEVIA']},
{"Concentris Research Management GmbH, Fürstenfeldbruck, Germany":['EMIF', 'EQIPD', 'PRISM', 'STEMBANCC']},
{"Confederation Of Meningitis Organisations LTD, Bristol, United Kingdom":['DRIVE']},
{"Connected Discovery Ltd, Walmer, Deal, United Kingdom":['OPEN_PHACTS']},
{"Consept Consulting SARL, Friesenheim, France":['EHR4CR']},
{"Consiglio Nazionale Delle Ricerche, Roma, Italy":['CONCEPTION', 'DDMORE', 'DIRECT', 'ERA4TB', 'LITMUS', 'PDMITOQUANT', 'SOPHIA']},
{"Consorci Institut Català De Ciències Cardiovasculars, Barcelona, Spain":['SAFET']},
{"Consorci Institut DInvestigacions Biomediques August Pi I Sunyer, Barcelona, Spain":['3TR', 'AETIONOMY', 'COMBACTEMAGNET', 'COMBACTENET', 'DIRECT', 'PHARMACOG', 'PRECISESADS']},
{"Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain":['3TR', 'CARDIATEAM', 'PRISM', 'RADARCNS']},
{"Consorcio Mar Parc De Salut De Barcelona, Barcelona, Spain":['ETOX', 'OPEN_PHACTS']},
{"Consorzio Per Valutazioni Biologiche E Farmacologiche, Pavia, Italy":['C4C']},
{"Consultech Technologieberatung GMBH, Berlin, Germany":['IMIPAINCARE']},
{"Coris Bioconcept SPRL, Gembloux, Belgium":['EBOLAMODRAD', 'VHFMODRAD']},
{"Covance Clinical And Periapproval Services, Woluwe-Saint-Lambert, Belgium":['TRIALSHOME']},
{"Covance Laboratories LTD, Harrogate, United Kingdom":['CONCEPTION', 'IMSAVAR', 'PARADIGM', 'PIONEER']},
{"Critical Path Institute, Limited, Dublin, Ireland":['ERA4TB']},
{"Csl Behring GMBH, Marburg, Germany":['PREFER', 'WEBRADR_2']},
{"Custodix Nv, Sint-Martens-Latem, Belgium":['EHR4CR', 'EMIF', 'EUPEARL']},
{"Cxr Biosciences Limited, Dundee, United Kingdom":['MARCAR']},
{"Cyprotex Discovery Ltd, Macclesfield, United Kingdom":['DDMORE']},
{"DIA Europe GmbH, Basel, Switzerland":['EUPATI', 'PHARMATRAIN']},
{"Da Volterra SAS, Paris, France":['COMBACTECDI', 'COMBACTENET']},
{"Dahlem Center For Genome Research And Medical Systems Biology GMBH, Berlin, Germany":['ONCO_TRACK']},
{"Danmarks Tekniske Universitet, Kgs. Lyngby, Denmark":['DIRECT', 'ELF', 'ETOX', 'ETRANSAFE', 'OPEN_PHACTS']},
{"Datapharm Limited, Leatherhead, United Kingdom":['GRAVITATEHEALTH']},
{"Datawizard SRL, Roma, Italy":['GRAVITATEHEALTH']},
{"Dc Biosceinces  LTD, Dundee, United Kingdom":['ADAPTED']},
{"De Duve Institute Aisbl, Bruxelles, Belgium":['IMMUCAN']},
{"DefiniGEN Ltd, Cambridge, United Kingdom":['EBISC']},
{"Demcon Advanced Mechatronics Bestb.V., Best, Netherlands":['AIMS2TRIALS']},
{"Demcon Advanced Mechatronics Enschede B.V., Enschede, Netherlands":['AIMS2TRIALS']},
{"Demcon Flex Center BV, Enschede, Netherlands":['AIMS2TRIALS']},
{"Demcon Macawi Respiratory Systems BV, Enschede, Netherlands":['AIMS2TRIALS']},
{"Demcon Production BV, Enschede, Netherlands":['AIMS2TRIALS']},
{"Den Selvejende Institution Dansk Borneastma Center, Gentofte, Denmark":['BIOMAP']},
{"Department of Health, Leeds, United Kingdom":['BIOVACSAFE', 'DRAGON', 'EBISC', 'EBISC2', 'EBOLAMODRAD', 'ERA4TB', 'FLUCOP', 'MOFINA', 'PERISCOPE', 'PREDICTTB', 'PROTECT', 'VAC2VAC', 'VHFMODRAD', 'VSVEBOVAC', 'WEBRADR']},
{"Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany":['CANCERID', 'ITCCP4', 'MIPDILI']},
{"Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany":['3TR', 'BTCURE', 'RTCURE']},
{"Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev, Bonn, Germany":['IMPRIND', 'PDMITOQUANT', 'PHAGO']},
{"Diabetes Frail Limited, Droitwich, United Kingdom":['SPRINTT']},
{"Diakonhjemmet Sykehus As, Oslo, Norway":['APPROACH', 'BTCURE']},
{"Diamond Light Source Limited, Didcot, United Kingdom":['EUBOPEN']},
{"Diaxonhit SA, Paris, France":['PHARMACOG']},
{"Dimokritio Panepistimio Thrakis, Komotini, Greece":['PHARMALEDGER']},
{"DiscoveRx Corp Ltd, Birmingham, United Kingdom":['ULTRADD']},
{"Documental Ou, Tallinn, Estonia":['EUPEARL']},
{"Dreem, Paris, France":['IDEAFAST', 'TRIALSHOME']},
{"Drk-Blutspendedienst Baden-Wurttemberg-Hessen Ggmbh, Mannheim, Germany":['ABIRISK']},
{"Drug Target Id BV, Nijmegen, Netherlands":['PRISM']},
{"Dyadic Nederland BV, Wageningen, Netherlands":['ZAPI']},
{"Dynamic42 GMBH, Jena, Germany":['IMSAVAR']},
{"ECOLOGIC INSTITUT gemeinnützige GmbH, Berlin, Germany":['PREMIER']},
{"EKF Diagnostics Limited, Trinity Technology and Enterprise Centre, Ireland":['SAFET']},
{"Eatris Eric, Amsterdam, Netherlands":['EUPEARL']},
{"Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany":['COMBACTECDI', 'COMBACTEMAGNET', 'COMBACTENET', 'DIRECT', 'DRIVEAB', 'EQIPD', 'IMMUNEIMAGE', 'IMSAVAR', 'MARCAR', 'RHAPSODY', 'SOPHIA', 'VSVEBOPLUS', 'VSVEBOVAC']},
{"Echalliance Company Limited By Guarantee, Dublin, Ireland":['GRAVITATEHEALTH']},
{"Echosens, Paris, France":['LITMUS']},
{"Eclinicalhealth LTD, Stirling, United Kingdom":['TRIALSHOME']},
{"Ecole Polytechnique Federale De Lausanne, Lausanne, Switzerland":['ERA4TB', 'MOBILISED', 'PREDECT', 'PREDICTTB']},
{"Ecrin European Clinical Research Infrastructure Network, Paris, France":['C4C', 'COMBACTENET', 'EUPEARL', 'IDEAFAST', 'MACUSTAR', 'NECESSITY']},
{"Ect Oekotoxikologie GMBH, Flörsheim a.M., Germany":['IPIE', 'PREMIER']},
{"Edelris SAS, Lyon, France":['ELF', 'ESCULAB']},
{"Edelweiss Connect GMBH, Zeiningen, Switzerland":['EBISC']},
{"Edi Experimentelle Und Diagnostische Immunologie GMBH, Reutlingen, Germany":['SAFET']},
{"Eidgenoessische Anstalt Fuer Wasserversorgung Abwasserreinigung Und Gewaesserschutz, Duebendorf, Switzerland":['PREMIER']},
{"Eidgenoessische Technische Hochschule Zuerich, Zurich, Switzerland":['EUBOPEN', 'QUICCONCEPT', 'ULTRADD']},
{"Eidgenoessisches Departement Des Innern, Bern, Switzerland":['CARE']},
{"Eidgenossisches Departement Fur Verteidigung, Bevolkerungsschutz Und Sport, Bern, Switzerland":['VSVEBOPLUS', 'VSVEBOVAC']},
{"Eisai Co LTD, Bunkyo Ku Tokyo, Japan":['ETRANSAFE']},
{"Eisai Limited, Hatfield, United Kingdom":['PHAGO', 'PHARMACOG']},
{"Ekon Modeling Sofware Systems LTD*Ekon, Modiin-Maccabim-Reut, Israel":['PHARMALEDGER']},
{"Electrophoretics LTD, Cobham, United Kingdom":['EMIF']},
{"Elevate BV, Utrecht, Netherlands":['CONCEPTION']},
{"Eli Lilly and Company Limited, Basingstoke, United Kingdom":['ADAPTSMART', 'BEATDKD', 'C4C', 'CANCERID', 'CARDIATEAM', 'CONCEPTION', 'DDMORE', 'DIRECT', 'DOIT', 'EBISC', 'EBISC2', 'EHDEN', 'EHR4CR', 'EPAD', 'ETRIKS', 'EU2P', 'EUAIMS', 'EUPATI', 'EUROPAIN', 'FAIRPLUS', 'GETREAL', 'GETREAL_INITIATIVE', 'GRAVITATEHEALTH', 'H2O', 'HYPORESOLVE', 'IDEAFAST', 'IMIDIA', 'IMIPAINCARE', 'IMMUCAN', 'IMMUNIVERSE', 'IMPRIND', 'INNODIA', 'INNODIA_HARVEST', 'IPIE', 'ITCCP4', 'LITMUS', 'MIPDILI', 'MOPEAD', 'NEURONET', 'NEWMEDS', 'ONCO_TRACK', 'OPEN_PHACTS', 'PARADIGM', 'PHAGO', 'PHARMACOG', 'PRECISESADS', 'PREFER', 'PREMIER', 'PRISM', 'PROTECT', 'QUICCONCEPT', 'RADARAD', 'RHAPSODY', 'ROADMAP', 'SAFESCIMET', 'SAFET', 'SOPHIA', 'STEMBANCC', 'SUMMIT', 'TRANSBIOLINE', 'TRANSQST']},
{"Ellegaard Gottingen Minipigs As, Dalmose, Denmark":['CONCEPTION', 'LITMUS']},
{"Elliniki Etairia Nosoy Alzheimer Kai Syggenon Diatarachon Somateio, Thessaloniki, Greece":['PHARMACOG']},
{"Emergency Life Support For Civilian War Victims Ong Onlus, Milan, Italy":['EBOLAMODRAD', 'FILODIAG', 'VHFMODRAD']},
{"Emory University Non Profit Corp, Atlanta, Georgia, United States":['VSVEBOVAC']},
{"Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany":['GRAVITATEHEALTH', 'IDEAFAST']},
{"Endometriosis.Org LTD, London, United Kingdom":['IMIPAINCARE']},
{"Enyo Pharma, Lyon, France":['CARE']},
{"Epidemico LTD, Irishtown, Ireland":['WEBRADR']},
{"Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands":['ADAPTED', 'ADVANCE', 'AETIONOMY', 'COMBACTEMAGNET', 'COMBACTENET', 'EHDEN', 'EMIF', 'EPAD', 'ETOX', 'ETRANSAFE', 'EU2P', 'EUPEARL', 'FLUCOP', 'GNA_NOW', 'H2O', 'HARMONY', 'HARMONY_PLUS', 'IABC', 'IDEAFAST', 'PIONEER', 'PREDECT', 'PREDICTTB', 'PREFER', 'PRISM', 'QUICCONCEPT', 'ROADMAP', 'SOPHIA', 'TRANSQST', 'ZAPI']},
{"Erasmus Universiteit Rotterdam, Rotterdam, Netherlands":['PREFER']},
{"Eresearch Technology Inc, Philadelphia, United States":['MOBILISED']},
{"Esteve Pharmaceuticals, SA, Barcelona, Spain":['EMTRAIN', 'ETOX', 'EUPATI', 'EUROPAIN', 'IMIPAINCARE', 'NGNPET', 'OPEN_PHACTS', 'PHARMATRAIN']},
{"Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece":['CANCERID', 'COMBACTECARE', 'COMBACTENET', 'EHR4CR', 'LITMUS', 'NECESSITY', 'ORBITO']},
{"Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece":['PHARMALEDGER', 'RADARAD', 'TRIALSHOME']},
{"Eu-Open SRL, veronella (Vr), Italy":['SPRINTT']},
{"Eurice European Research And Project Office GMBH, Saarbrücken, Germany":['3TR', 'BIOMAP', 'HYPORESOLVE', 'IMMUNIVERSE', 'PERISCOPE']},
{"European Aids Treatment Group Ev, Duesseldorf, Germany":['EFOEUPATI', 'EUPATI', 'PARADIGM']},
{"European Alliance For Personalised Medicine Asbl, Brussels, Belgium":['HARMONY', 'PIONEER']},
{"European Association For The Studyof The Liver, Zürich, Switzerland":['LITMUS']},
{"European Biotechnology Network aisbl, Brussels, Belgium":['ENABLE']},
{"European Cancer Patient Coalition, Brussels, Belgium":['DOIT', 'IMMUNEIMAGE', 'PIONEER', 'PREFER']},
{"European Centre for Disease Prevention and Control, Stockholm, Sweden":['ADVANCE']},
{"European Commission - Directorate General Joint Research Centre - JRC, Brussels, Belgium":['VAC2VAC']},
{"European Cystic Fibrosis Society, Karup, Denmark":['C4C']},
{"European Federation For Pharmaceutical Sciences, Järfälla, Stockholm, Sweden":['PHARMATRAIN', 'SAFESCIMET']},
{"European Federation Of Asthma &Allergy Associations Ideell Forening, Brussels, Belgium":['3TR', 'IMMUNIVERSE', 'UBIOPRED']},
{"European Federation Of CrohnS And Ulcerative Colitis Associations, Bruxelles, Belgium":['IDEAFAST', 'IMMUNIVERSE']},
{"European Forum For Good Clinical Practice, Brussels, Belgium":['COMBACTEMAGNET', 'COMBACTENET', 'CONCEPTION', 'EFOEUPATI', 'EUPATI', 'PARADIGM', 'PHARMALEDGER', 'PHARMATRAIN']},
{"European Genetic Alliances Network, Brussels, Belgium":['EUPATI']},
{"European Heart Network Aisbl, Bruxelles, Netherlands":['BIGDATAHEART']},
{"European Hematology Association, The Hague, Netherlands":['HARMONY', 'HARMONY_PLUS']},
{"European Institute For Health Records, Lille, France":['EHR4CR', 'EMIF']},
{"European Institute Of WomenS Health Company Limited By Guarantee, Dublin, Ireland":['CONCEPTION', 'MOPEAD']},
{"European Lung Foundation, Lausanne, Switzerland":['3TR', 'DRAGON', 'UBIOPRED']},
{"European Molecular Biology Laboratory, Heidelberg, Germany":['DDMORE', 'EBISC', 'EHR4CR', 'EMIF', 'EMTRAIN', 'ETOX', 'ETRANSAFE', 'EUAIMS', 'EUBOPEN', 'FAIRPLUS', 'OPEN_PHACTS', 'TRANSQST']},
{"European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium":['CANCERID', 'EUPATI', 'GETREAL', 'HARMONY', 'IMMUCAN', 'PHARMATRAIN', 'PIONEER', 'QUICCONCEPT', 'TRISTAN']},
{"European Pain Federation Efic, Aarschot, Belgium":['IMIPAINCARE']},
{"European Patients’ Forum (EPF), Brussels, Belgium":['ADAPTSMART', 'EFOEUPATI', 'EHDEN', 'EUPATI', 'EUPEARL', 'IMMUCAN', 'IMMUNIVERSE', 'PARADIGM', 'PHARMALEDGER', 'PREFER']},
{"European Platform for Patients Oganisations, Science and Industry, Leuven, Belgium":['EHR4CR']},
{"European Research Initiative On Cll Ev, Köln, Germany":['HARMONY', 'HARMONY_PLUS']},
{"European Respiratory Society, Lausanne, Switzerland":['3TR', 'DRAGON', 'PROACTIVE', 'VALUEDX']},
{"European Society Clinical Microbiology Infectious Diseases (Europaische Gesellschaft Fur Klinische Mikrobiologie Infektionskrankheiten), Basel, Switzerland":['VALUEDX']},
{"European Society For Blood And Marrow Transplantation, Leiden, Netherlands":['HARMONY', 'HARMONY_PLUS']},
{"European Society Of Anaesthesiology And Intensive Care Aisbl, Bruxelles, Belgium":['IMIPAINCARE']},
{"European Society Of Regional Anaesthesia And Pain Therapy, Homberg, Germany":['IMIPAINCARE']},
{"European Vaccine Initiative - EEIG, Heidelberg, Germany":['FLUCOP', 'VAC2VAC']},
{"Europese Federatie Van Familieverenigingen Van Psychiatrisch Zieke Personen Ivzw, Leuven, Belgium":['PRISM']},
{"Eurordis - European Organisation For Rare Diseases Association, Paris, France":['ADAPTSMART', 'C4C', 'EUPATI', 'PARADIGM', 'WEBRADR']},
{"Euroscan International Network Ev, Koln, Germany":['EUPEARL']},
{"Eurovacc Foundation, Lausanne, Switzerland":['CARE']},
{"Evolva AG, Reinach, Switzerland":['CHEM21']},
{"Evotec International GMBH, Hamburg, Germany":['COMBINE', 'ENABLE', 'ERA4TB', 'GNA_NOW']},
{"Excellgene SA, Monthey, Switzerland":['PEVIA']},
{"Experimentelle Pharmakologie Und Onkologie Berlin-Buch GMBH, Berlin, Germany":['ITCCP4', 'ONCO_TRACK']},
{"Exscientia Limited, Dundee, United Kingdom":['CARE']},
{"Exvastat LTD, Cambridge, United Kingdom":['IMPENTRI']},
{"F. Hoffmann-La Roche AG, Basel, Switzerland":['3TR', 'ADAPTSMART', 'AIMS2TRIALS', 'C4C', 'DDMORE', 'DOIT', 'DRIVEAB', 'EHR4CR', 'EMIF', 'EMTRAIN', 'EPAD', 'EQIPD', 'ETOX', 'ETRANSAFE', 'ETRIKS', 'EU2P', 'EUAIMS', 'EUPATI', 'GETREAL', 'GRAVITATEHEALTH', 'H2O', 'IDEAFAST', 'IMIDIA', 'IMMUNEIMAGE', 'IMSAVAR', 'IPIE', 'ITCCP4', 'K4DD', 'MACUSTAR', 'NEURONET', 'NEWMEDS', 'ONCO_TRACK', 'PARADIGM', 'PHAGO', 'PHARMACOG', 'PHARMALEDGER', 'PHARMATRAIN', 'PREDECT', 'PREFER', 'PREMIER', 'PRISM', 'PROTECT', 'QUICCONCEPT', 'ROADMAP', 'SAFESCIMET', 'SAFET', 'STEMBANCC', 'SUMMIT', 'TRANSBIOLINE', 'UBIOPRED']},
{"Faculdade De Ciencias Da Universidade De Lisboa, Lisboa, Portugal":['IDEAFAST']},
{"Faculdade De Medicina Da Universidade De Lisboa, Lisbon, Portugal":['LITMUS']},
{"Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal":['LITMUS']},
{"Faculty Of Medicine, University Of Belgrade, Belgrade, Serbia":['PHARMATRAIN']},
{"Farmaceutski Fakultet Univerzitetau Beogradu, Belgrade, Serbia":['NEURODERISK']},
{"Fciencias.Id - Associacao Para A Investigacao E Desenvolvimento De Ciencias, Lisbon, Portugal":['IDEAFAST']},
{"Federation Europeenne DAssociations Et DIndustries Pharmaceutiques, Brussels, Belgium":['ADAPTSMART', 'DOIT', 'PARADIGM', 'VITAL']},
{"Federation Internationale Du Diabete Region Europe Aisbl, Brussels, Belgium":['TRIALSHOME']},
{"Federation Internationale Du Diabete, Brussels, Belgium":['HYPORESOLVE']},
{"Ffund BV, Amsterdam, Netherlands":['RESPIRINTM', 'RESPIRITB']},
{"Fh Joanneum Gesellschaft Mbh, Graz, Austria":['TRIALSHOME']},
{"Finovatis, Lyon, France":['ZAPI']},
{"Firalis, Huningue, France":['BTCURE', 'SAFET']},
{"Folkehelseinstituttet, Oslo, Norway":['DOIT', 'DRIVEAB', 'VITAL']},
{"Folkhalsomyndigheten, Solna, Sweden":['EBOLAMODRAD', 'VHFMODRAD']},
{"Fondation De Cooperation Scientifique Voir Et Entendre, Paris, France":['MACUSTAR']},
{"Fondation Health Sciences e-Training, Lausanne, Switzerland":['PHARMATRAIN']},
{"Fondation Innovative Medicines For Tuberculosis (Im4tb), Lausanne, Switzerland":['ERA4TB']},
{"Fondazione Humanitas Per La Ricerca, Rozzano, Italy":['BTCURE']},
{"Fondazione Irccs Ca Granda - Ospedale Maggiore Policlinico, Milan, Italy":['3TR', 'C4C', 'COMBACTENET', 'IABC', 'PRECISESADS']},
{"Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Italy":['ITCCP4']},
{"Fondazione Italiana Sindromi Mielodisplastiche Ets, Alessandria, Italy":['HARMONY', 'HARMONY_PLUS']},
{"Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy":['C4C', 'COMBACTEMAGNET', 'EMIF', 'RESCEU', 'VALUEDX']},
{"Fondazione Per L Istituto Di Ricerca In Biomedicina, Bellinzona, Switzerland":['ABIRISK', 'RTCURE']},
{"Fondazione Per La Ricerca Farmacologica Gianni Benzi Onlus, Valenzano Bari, Italy":['C4C']},
{"Fondazione Sdn Per La Ricerca E LAlta Formazione In Diagnostica Nucleare, Napoli, Italy":['PHARMACOG']},
{"Fondazione Stella Maris, Pisa, Italy":['AIMS2TRIALS']},
{"Forschungsgesellschaft Fur Arbeitsphysiologie Und Arbeitsschutz E.V., Dortmund, Germany":['TRANSQST']},
{"Forschungszentrum Borstel, Borstel, Germany":['ENABLE', 'ERA4TB']},
{"Forum Des Patients Europeens, 1040, Belgium":['EFOEUPATI', 'EHDEN', 'EUPEARL', 'GRAVITATEHEALTH', 'H2O', 'IMMUCAN', 'IMMUNIVERSE', 'PARADIGM', 'PHARMALEDGER', 'PREFER']},
{"Foundation For Innovative New Diagnostics, Geneva, Switzerland":['MOFINA', 'VALUEDX']},
{"Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany":['AETIONOMY', 'COMBINE', 'EBISC', 'EBISC2', 'EPAD', 'ETOX', 'ETRANSAFE', 'EUBOPEN', 'FAIRPLUS', 'GNA_NOW', 'IMSAVAR', 'K4DD', 'PHAGO', 'PIONEER', 'PREMIER', 'RADARAD', 'TRANSLOCATION', 'UBIOPRED']},
{"Fraunhofer Uk Research Limited, Glasgow, United Kingdom":['EBISC2']},
{"Freie Universitaet Berlin, Berlin, Germany":['DDMORE']},
{"Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer Tiergesundheit, Greifswald-Insel Riems, Germany":['ZAPI']},
{"Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany":['APPROACH', 'EHR4CR', 'MOBILISED', 'SPRINTT']},
{"Frisq Holding AB, Stockholm, Sweden":['GRAVITATEHEALTH']},
{"Fujifilm Cellular Dynamics Inc, Madison, United States":['EBISC2', 'IM2PACT', 'NEURODERISK']},
{"Fundacio Ace, Barcelona , Spain":['ADAPTED', 'MOPEAD']},
{"Fundacio Barcelonabeta Brain Research Center, Barcelona, Spain":['AETIONOMY', 'AMYPAD', 'EPAD']},
{"Fundacio Centre De Regulacio Genomica, Barcelona, Spain":['3TR', 'IMMUCAN']},
{"Fundacio Clinic Per A La Recerca Biomedica, Barcelona, Spain":['AIMS2TRIALS', 'IABC', 'NECESSITY']},
{"Fundacio Hospital Universitari Vall DHebron - Institut De Recerca, Barcelona, Spain":['ABIRISK', 'CARDIATEAM', 'EUPEARL', 'IABC', 'IMMUNEIMAGE', 'MOPEAD', 'RADARCNS']},
{"Fundacio Institut Català de Farmacologia, Barcelona, Spain":['EU2P', 'PROTECT']},
{"Fundacio Institut DInvestigacio Biomedica De Bellvitge, Hospitalet De Llobregat, Spain":['PRECISESADS']},
{"Fundacio Institut DInvestigacio Biomedica De Girona Doctor Josep Trueta, Salt, Spain":['SOPHIA']},
{"Fundacio Institut De Bioenginyeria De Catalunya, Barcelona, Spain":['MADCOV_2']},
{"Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Barcelona, Spain":['HARMONY', 'HARMONY_PLUS']},
{"Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain":['ETOX', 'ETRANSAFE', 'FAIRPLUS', 'IPIE', 'OPEN_PHACTS', 'TRANSQST']},
{"Fundacio Institut Universitari Pera La Recerca A LAtencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain":['ADVANCE', 'EMIF', 'ROADMAP']},
{"Fundacio Privada Centre De Medicina Regenerativa De Barcelona, Barcelona, Spain":['EBISC']},
{"Fundacio Privada Institut DInvestigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain":['HARMONY', 'IMMUNEIMAGE', 'ONCO_TRACK']},
{"Fundacio Privada Institut De Recerca De LHospital De La Santa Creu I Sant Pau, Barcelona, Spain":['CARDIATEAM', 'TRANSBIOLINE']},
{"Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain":['C4C', 'ITCCP4', 'PARADIGM', 'RADARCNS']},
{"Fundacion Centro De Excelencia En Investigacion De Medicamentos Innovadores En Andalucia, Granada, Spain":['ENABLE']},
{"Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii, Madrid, Spain":['ETOX', 'OPEN_PHACTS']},
{"Fundacion Española Para La Cooperacion Internacional Salud Y Politica Social, Madrid, Spain":['ADVANCE']},
{"Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon, Soria, Spain":['HARMONY', 'HARMONY_PLUS']},
{"Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain":['CONCEPTION', 'DRIVE', 'TRIALSHOME', 'VITAL']},
{"Fundacion Para La Investigacion Biomedica De Cordoba, Cordoba, Spain":['3TR']},
{"Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon, Madrid, Spain":['CARDIATEAM']},
{"Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La Paz, Madrid, Spain":['CARE', 'ERA4TB']},
{"Fundacion Para La Investigacion Biomedica Del Hospital Universitario Clinico San Carlos, Madrid, Spain":['3TR', 'IDEAFAST']},
{"Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal, Madrid, Spain":['CARDIATEAM']},
{"Fundacion Para La Investigacion Biosanitaria De Andalucia Oriental-Alejandro Otero, Granada, Spain":['3TR']},
{"Fundacion Para La Investigacion Del Hospital Clinico De La Comunitat Valenciana, Fundacion Incliva, Valencia, Spain":['BIGDATAHEART', 'IMIPAINCARE']},
{"Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain":['HARMONY', 'HARMONY_PLUS']},
{"Fundacion Privada Instituto De Salud Global Barcelona, Barcelona, Spain":['COMBACTECARE', 'COMBACTENET', 'MOBILISED', 'TRANSLOCATION']},
{"Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud, Malaga, Spain":['3TR']},
{"Fundacion Publica Andaluza Progreso Y Salud, Seville , Spain":['3TR', 'EBISC', 'NECESSITY', 'PRECISESADS']},
{"Fundación Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain":['PROTECT']},
{"Fundazioa Policlinica Gipuzkoa Fundacion, Donostia / San Sebastián, Spain":['AIMS2TRIALS']},
{"Gabo:Mi Gesellschaft Fur Ablauforganisation:Milliarium mbH & Co. KG, Munich, Germany":['NEWMEDS']},
{"Ge Healthcare Limited, Little Chalfont, United Kingdom":['AMYPAD', 'ROADMAP', 'TRISTAN']},
{"Genefirst Limited, Abingdon, United Kingdom":['RAPIDCOVID']},
{"Genetic Alliance Uk LTD, 436 Essex Road, London, United Kingdom":['EUPATI']},
{"Genexplain GMBH, Wolfenbuttel, Germany":['PDMITOQUANT']},
{"Genfit, Loos, France":['LITMUS']},
{"Genome Research Limited, London, United Kingdom":['EBISC', 'HARMONY', 'HARMONY_PLUS']},
{"Genomedics S.R.L., Firenze, Italy":['EMIF']},
{"Genos Doo Za Vjestacenje I Analizu, Osijek, Croatia":['3TR']},
{"Genosafe SAS, Evry, France":['ARDAT']},
{"Genzyme Europe B.V., Naarden, Netherlands":['EMTRAIN', 'PROTECT']},
{"George Washington University Corporation, Washington Dc, United States":['SOPHIA']},
{"George-Huntington-Institut GMBH, Munster, Germany":['IDEAFAST']},
{"Gesundheit Osterreich GMBH, Wien, Austria":['VALUEDX']},
{"Gilead Sciences Inc, Foster City Ca, United States":['LITMUS']},
{"Gilupi GMBH, Potsdam, Germany":['CANCERID']},
{"Glaxosmithkline Biologicals SA, Rixensart, Belgium":['ADVANCE', 'BIOVACSAFE', 'COMBACTECDI', 'DRIVE', 'FLUCOP', 'PERISCOPE', 'RESCEU', 'VAC2VAC', 'VITAL']},
{"Glaxosmithkline Investigacion Y Desarrollo SL, Tres Cantos, Spain":['ERA4TB', 'PREDICTTB', 'TRICTB']},
{"Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom":['3TR', 'ABDIRECT', 'ABIRISK', 'ADAPTSMART', 'APPROACH', 'BTCURE', 'C4C', 'CHEM21', 'COMBACTECARE', 'COMBACTEMAGNET', 'COMBACTENET', 'COMBINE', 'COMPACT', 'CONCEPTION', 'DDMORE', 'DOIT', 'DRIVEAB', 'EFOEUPATI', 'EHR4CR', 'EMIF', 'EMTRAIN', 'ENABLE', 'ETOX', 'ETRIKS', 'EU2P', 'EUPATI', 'FAIRPLUS', 'GETREAL', 'GETREAL_INITIATIVE', 'ICONSENSUS', 'IMMUCAN', 'IMMUNIVERSE', 'INNODIA', 'INNODIA_HARVEST', 'IPIE', 'K4DD', 'MELLODDY', 'MIPDILI', 'NECESSITY', 'OPEN_PHACTS', 'ORBITO', 'PARADIGM', 'PHARMACOG', 'PHARMALEDGER', 'PHARMATRAIN', 'PREMIER', 'PROACTIVE', 'PROTECT', 'QUICCONCEPT', 'RAPPID', 'RTCURE', 'SAFESCIMET', 'SAFET', 'SPRINTT', 'TRANSLOCATION', 'TRANSQST', 'TRISTAN', 'UBIOPRED', 'WEBRADR']},
{"Glaxosmithkline Vaccines SRL, Siena, Italy":['BIOVACSAFE', 'RAPPID']},
{"Global Alliance For Tb Drug Development Non Profit Organisation, New York, United States":['ERA4TB', 'EUPEARL']},
{"Global Health Drug Discovery Institute, Beijing, China (Peoples Republic of)":['CARE']},
{"Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain":['ETRANSAFE', 'HARMONY', 'HARMONY_PLUS', 'MOPEAD']},
{"Gna Biosolutions GMBH, Martinsried, Germany":['DECISION', 'FILODIAG']},
{"Goeteborgs Universitet, Gothenburg, Sweden":['BIOVACSAFE', 'EMIF', 'PHAGO', 'PHARMATRAIN', 'PIONEER', 'PREMIER', 'ROADMAP', 'SOPHIA', 'SUMMIT', 'VSVEBOPLUS', 'VSVEBOVAC']},
{"Gottfried Wilhelm Leibniz Universitaet Hannover, Hannover, Germany":['AETIONOMY', 'EBISC']},
{"Gpoh Gemeinnutzige GMBH, Hannover, Germany":['HARMONY', 'HARMONY_PLUS']},
{"Grameen Foundation Usa, Washington, District of Columbia, United States":['EBODAC']},
{"Greater Glasgow Health Board, Glasgow, United Kingdom":['3TR', 'AIMS2TRIALS', 'IDEAFAST']},
{"Gritsystems As, Dragør, Denmark":['COMBINE', 'ERA4TB', 'TRANSLOCATION']},
{"Group For Research On Adult Acute Lymphoblastic Leukemia, Pierre-Bénite, France":['HARMONY']},
{"Groupe DEtudes Therapeutiques Desaffections Inflammatoires Digestives Association, Paris, France":['ABIRISK']},
{"Groupe Francophone Des Myelodysplasies, Paris, France":['HARMONY', 'HARMONY_PLUS']},
{"Grunenthal GMBH, Aachen, Germany":['ESCULAB', 'EUROPAIN', 'GRAVITATEHEALTH', 'IMIPAINCARE', 'MOBILISED', 'NGNPET', 'PARADIGM']},
{"Guardtime Ou, Tallinn, Estonia":['GRAVITATEHEALTH']},
{"Gustave Roussy Transfert, Villejuif, France":['ITCCP4']},
{"Gyermekgyogyaszati Klinikai Vizsgaloi Halozat, Budapest, Hungary":['C4C']},
{"H. Lundbeck As, Valby, Denmark":['ADAPTSMART', 'EBISC', 'EBISC2', 'ELF', 'EMTRAIN', 'EPAD', 'ETOX', 'ETRIKS', 'EU2P', 'EUROPAIN', 'IM2PACT', 'IMPRIND', 'MARCAR', 'MIPDILI', 'NEWMEDS', 'OPEN_PHACTS', 'ORBITO', 'PARADIGM', 'PDMITOQUANT', 'PHAGO', 'PHARMACOG', 'PROTECT', 'RADARCNS', 'ROADMAP', 'SAFESCIMET']},
{"HAHN-SCHICKARD-GESELLSCHAFT FUER ANGEWANDTE FORSCHUNG E.v., Villingen, Germany":['BIOMAP']},
{"Hannoversche Kinderheilanstalt, Hannover, Germany":['INNODIA', 'INNODIA_HARVEST']},
{"Harbour Antibodies BV, Rotterdam, Netherlands":['ZAPI']},
{"Haskoli Islands, Reykjavik, Iceland":['SPRINTT']},
{"Haute Autorite De Sante, Saint-Denis la Plaine , France":['ADAPTSMART', 'GETREAL']},
{"Health Iq Limited, London, United Kingdom":['DOIT']},
{"Health Technology Assessment International Society, Edmonton, Canada":['PARADIGM']},
{"Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany":['ABIRISK', 'BIOMAP', 'CANCERID', 'EHR4CR', 'HARMONY']},
{"Heinrich-Pette Institut Leibniz Institut Fuer Experimentelle Virologie, Hamburg, Germany":['PEVIA']},
{"Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany":['CARDIATEAM', 'DIRECT', 'EMTRAIN', 'INNODIA', 'INNODIA_HARVEST', 'STEMBANCC', 'SUMMIT']},
{"Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany":['CARE', 'COMBACTENET', 'COMPACT', 'EMTRAIN', 'ENABLE', 'GNA_NOW']},
{"Helmholtz-Zentrum Fur Umweltforschung GMBH - Ufz, Leipzig, Germany":['IPIE']},
{"Helperby Therapeutics Limited, London, United Kingdom":['ENABLE']},
{"Helse Bergen Hf*Haukeland University Hospital, Bergen, Norway":['C4C']},
{"Helse Stavanger Hf, Stavanger, Norway":['IDEAFAST', 'NECESSITY', 'PDMIND']},
{"Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä, Helsinki, Finland":['C4C', 'CANCERID', 'IMIPAINCARE']},
{"Heptares Therapeutics Limited, Welwyn Garden City, United Kingdom":['K4DD']},
{"Heriot-Watt University, Edinburgh, United Kingdom":['FAIRPLUS']},
{"Hibernia College, Dublin, Ireland":['EUPATI', 'PHARMATRAIN']},
{"Himss Europe GMBH, Berlin, Germany":['GRAVITATEHEALTH']},
{"Histoindex Pte LTD, Singapore, Singapore":['LITMUS']},
{"Hits Ggmbh, Heidelberg, Germany":['K4DD']},
{"Hl7 International Fondation, Brussels, Belgium":['GRAVITATEHEALTH']},
{"Hopitaux Universitaires De Strasbourg, Strasbourg, France":['NECESSITY']},
{"Hospices Civils De Lyon, lyon, France":['CARDIATEAM', 'IABC', 'SAFESCIMET']},
{"Hospital Clinic De Barcelona, Barcelona, Spain":['3TR', 'AIMS2TRIALS', 'NECESSITY']},
{"Hospital Clinico Y Provincial De Barcelona, Barcelona, Spain":['COMBACTEMAGNET', 'COMBACTENET', 'DIRECT']},
{"Hospital Do Espirito Santo De Evora Epe, Evora, Portugal":['PHARMALEDGER']},
{"Humanitas Mirasole S.A, Rozzano (Mi), Italy":['IMMUNIVERSE']},
{"Humanitas University, Pieve Emanuele, Italy":['IMMUNIVERSE']},
{"Hvidovre Hospital, Hvidovre, Denmark":['UBIOPRED']},
{"ID Business Solutions Limited, Guildford, United Kingdom":['ETRIKS']},
{"IS GLOBAL - Barcelona Institute for Global Health, Barcelona, Spain":['PROACTIVE']},
{"Iceta Instituto De Ciencias, Tecnologias E Agroambiente Da Universidade Do Porto, Porto, Portugal":['NEURODERISK']},
{"Icon Clinical Research Limited, Dublin, Ireland":['MOBILISED']},
{"Idryma Iatroviologikon Ereunon Akademias Athinon, Athens, Greece":['BTCURE', 'IMPRIND']},
{"Ifakara Health Institute Trust, Dar es Salaam, Tanzania (United Republic of)":['PEVIA']},
{"Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden":['DOIT', 'PIONEER']},
{"Iktos, Paris, France":['MELLODDY']},
{"Imabiotech SAS, Loos, France":['ERA4TB']},
{"Imaginab, Inc, Inglewood Ca, United States":['IMMUNEIMAGE']},
{"Imcyse SA, Sart Tilman, Belgium":['INNODIA', 'INNODIA_HARVEST']},
{"ImmunArray Ltd, Rehovot, Israel":['BIOVACSAFE']},
{"Immunodiagnostic Systems Holdings PLC, Boldon, United Kingdom":['APPROACH']},
{"Imperial College Of Science Technology And Medicine, London, United Kingdom":['3TR', 'BIOVACSAFE', 'DIRECT', 'DOIT', 'DRAGON', 'EQIPD', 'ETRIKS', 'EUROPAIN', 'FAIRPLUS', 'IDEAFAST', 'IMIDIA', 'K4DD', 'MOBILISED', 'PIONEER', 'PROTECT', 'QUICCONCEPT', 'RESCEU', 'RHAPSODY', 'UBIOPRED', 'VITAL']},
{"Imprensa Nacional - Casa Da Moeda, S. A., Lisboa, Portugal":['PHARMALEDGER']},
{"Ims Information Solutions Medical Research Limited, London, United Kingdom":['PIONEER']},
{"Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg":['BIOMAP', 'IMMUNIVERSE', 'IMSAVAR', 'TRANSBIOLINE']},
{"Innovation Acta S.R.L., Roma, Italy":['NECESSITY']},
{"Innovative Concepts in Drug Development (ICDD-sas), Meyreuil, France":['PHARMACOG']},
{"Innovative Therapies For Children With Cancer Association, Villejuif, France":['ITCCP4']},
{"Inserm Transfert SA, Paris, France":['ABDIRECT', 'CARDIATEAM', 'CARE', 'EBOLAMODRAD', 'EBOVAC2', 'MADCOV_2', 'VHFMODRAD']},
{"Inspiralis Ltd, Norwich, United Kingdom":['ENABLE']},
{"Inst Cardiometabolisme Nutrition Ican, Paris, France":['COMBACTEMAGNET', 'LITMUS']},
{"Institut Catala De La Salut, Barcelona, Spain":['COMBACTEMAGNET', 'H2O', 'IABC', 'PROTECT']},
{"Institut Curie, Paris, France":['CANCERID', 'IMMUCAN', 'ITCCP4']},
{"Institut De Recerca I Tecnologia Agroalimentaries, Caldes De Montbui- Barcelona, Spain":['ZAPI']},
{"Institut De Recherche Pierre Fabresas, Toulouse, France":['IMMUCAN']},
{"Institut De Recherches Internationales Servier Iris, Suresnes, France":['ADAPTSMART', 'APPROACH', 'BIGDATAHEART', 'C4C', 'DDMORE', 'DIRECT', 'DOIT', 'EHDEN', 'EMIF', 'ETOX', 'ETRANSAFE', 'EUPEARL', 'IMMUCAN', 'MIPDILI', 'NECESSITY', 'PARADIGM', 'PRECISESADS', 'PREMIER', 'SPRINTT', 'TRANSQST']},
{"Institut De Recherches Servier, Suresnes, France":['CANCERID', 'CARE', 'EBISC2', 'EQIPD', 'ESCULAB', 'EUAIMS', 'EUBOPEN', 'IMIDIA', 'IMPRIND', 'IMSAVAR', 'MELLODDY', 'NEWMEDS', 'PHARMACOG', 'PREDECT', 'RHAPSODY']},
{"Institut Du Cerveau Et De La Moelle Epiniere, Paris, France":['AETIONOMY', 'ARDAT', 'PDMITOQUANT']},
{"Institut Fuer Molekulare Biotechnologie GMBH, Wien, Austria":['MADCOV_2']},
{"Institut Gustave Roussy, Villejuif, France":['CANCERID', 'ITCCP4']},
{"Institut Jules Bordet, Brussels, Belgium":['IMMUCAN']},
{"Institut Mines-Telecom, Paris, France":['IDEAFAST']},
{"Institut National De L Environnement Et Des Risques Ineris, Verneuil En Halatte, France":['STEMBANCC']},
{"Institut National De La Sante Et De La Recherche Medicale, Paris, France":['3TR', 'ABDIRECT', 'ABIRISK', 'AETIONOMY', 'AIMS2TRIALS', 'ARDAT', 'BTCURE', 'C4C', 'CARDIATEAM', 'CARE', 'COMBACTECARE', 'COMBACTEMAGNET', 'COMBACTENET', 'CONCEPTION', 'DDMORE', 'DOIT', 'DRIVE', 'EBOLAMODRAD', 'EBOVAC1', 'EBOVAC2', 'EBOVAC3', 'EHR4CR', 'EMIF', 'EMTRAIN', 'EPAD', 'FAIRPLUS', 'GNA_NOW', 'IABC', 'IMIDIA', 'IMIPAINCARE', 'IMMUCAN', 'IMPRIND', 'INNODIA', 'INNODIA_HARVEST', 'MARCAR', 'MIPDILI', 'NECESSITY', 'PERISCOPE', 'PEVIA', 'PHARMACOG', 'PROTECT', 'QUICCONCEPT', 'RHAPSODY', 'SPRINTT', 'STEMBANCC', 'VHFMODRAD', 'VITAL']},
{"Institut National De Recherche Eninformatique Et Automatique, LE CHESNAY Cedex, France":['DDMORE']},
{"Institut Pasteur De Dakar, Dakar, Senegal":['EBOLAMODRAD', 'VHFMODRAD']},
{"Institut Pasteur De Lille Fondation, Lille, France":['ERA4TB', 'PERISCOPE']},
{"Institut Pasteur, Paris, France":['AIMS2TRIALS', 'EBOLAMODRAD', 'ERA4TB', 'EUAIMS', 'NECESSITY', 'PREDICTTB', 'ZAPI']},
{"Institut Scientifique De Sante Publique, Brussels, Belgium":['VAC2VAC']},
{"Instituto Aragones De  Ciencias De La Salud, Zaragoza, Spain":['PARADIGM']},
{"Instituto De Biologia Experimental E Tecnologica, Oeiras, Portugal":['ARDAT', 'PREDECT']},
{"Instituto De Biologia Molecular E Celular-Ibmc, Porto, Portugal":['IMIPAINCARE']},
{"Instituto De Medicina Molecular Joao Lobo Antunes, Lisboa, Portugal":['3TR', 'IDEAFAST']},
{"Instituto De Salud Carlos Iii, Madrid, Spain":['EBISC']},
{"Instituto Nacional De Saude Dr. Ricardo Jorge, Lisbon, Portugal":['COMBACTENET']},
{"Instituto Tumori Giovanni Paolo Ii, Bari, Italy":['PREFER']},
{"Instytut Pomnik Centrum Zdrowia Dziecka, Warszawa, Poland":['C4C']},
{"Instytut Psychiatrii I Neurologii, Warszawa, Poland":['IDEAFAST']},
{"Inte:Ligand Software-Entwicklungs-Und Consulting GMBH, Vienna, Austria":['ETOX', 'NEURODERISK']},
{"Intercept Pharma Europe LTD, Bristol, United Kingdom":['LITMUS']},
{"Interface Europe, Bruxelles, Belgium":['MIPDILI', 'SAFET']},
{"International Alliance Of PatientOrganizations, London, United Kingdom":['GETREAL', 'GETREAL_INITIATIVE', 'PREFER']},
{"International Alliance of Patients’ Organizations, London, United Kingdom":['PROTECT']},
{"International Consortium For Healthoutcomes Measurement Inc., Cambridge, United States":['BIGDATAHEART']},
{"International Consortium For Healthoutcomes Measurement LTD, London, United Kingdom":['BIGDATAHEART', 'EHDEN', 'PIONEER']},
{"International Federation of Associations of Pharmaceutical Physicians, Woerden, Netherlands":['PHARMATRAIN']},
{"International Health Terminology Standards Development Organisation, London, United Kingdom":['WEBRADR_2']},
{"International Prevention Research Institut-Ipri Management, Lyon, France":['ONCO_TRACK']},
{"International Primary Care Respiratory Group, Edinburgh, United Kingdom":['UBIOPRED']},
{"International Society for Pharmacoeconomics and Outcomes Research Inc, Lawrenceville, New Jersey, United States":['EUPATI']},
{"Intersystems GMBH, Darmstadt, Germany":['DOIT']},
{"Interuniversitair Micro-Electronica Centrum, Leuven, Belgium":['RAPPID']},
{"Intervet International BV, Boxmeer, Netherlands":['VAC2VAC']},
{"Ionovation GmbH, Osnabrück, Germany":['TRANSLOCATION']},
{"Iprasense, Clapiers, France":['ICONSENSUS']},
{"Ipratech SA, Mons, Belgium":['ICONSENSUS']},
{"Ipri Services, Ecully, France":['ONCO_TRACK']},
{"Ipsen Innovation SAS, Les Ulis, France":['ABIRISK', 'ADAPTSMART', 'ETRANSAFE']},
{"Iqvia Rds France, Saint-Ouen, France":['TRIALSHOME']},
{"Irish Platform For Patients Organisations Science And Industry Limited By Guarantee, Dublin, Ireland":['EFOEUPATI', 'EUPATI']},
{"Islensk Erfdagreining Ehf, Reykjavik, Iceland":['BIOVACSAFE', 'EUAIMS', 'NEWMEDS']},
{"Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy":['BEATDKD', 'PHARMACOG', 'PREMIER', 'PROTECT', 'SUMMIT']},
{"Istituto Di Ricovero E Cura A Carattere Scientifico Burlo Garofolo, Trieste, Italy":['C4C']},
{"Istituto Europeo Di Oncologia SRL, Milan, Italy":['PREFER']},
{"Istituto Giannina Gaslini, Genova, Italy":['ABIRISK', 'C4C']},
{"Istituto Nazionale Di Fisica Nucleare, Frascati, Italy":['HARMONY', 'HARMONY_PLUS']},
{"Istituto Nazionale Di Riposo E Cura  Per Anziani Inrca, Ancona, Italy":['SPRINTT']},
{"Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy":['COMBACTECDI', 'DECISION', 'EBOLAMODRAD', 'FILODIAG', 'KRONO', 'MOFINA', 'PEVIA', 'VHFMODRAD']},
{"Istituto Oncologico Veneto, Padova, Italy":['CANCERID']},
{"Istituto Ortopedico Rizzoli, Bologna, Italy":['ITCCP4']},
{"Istituto Superiore Di Sanita, Roma, Italy":['DRIVE', 'FLUCOP', 'IMMUNIVERSE', 'PEVIA', 'VAC2VAC', 'VITAL']},
{"Itä-Suomen yliopisto, Kuopio, Finland":['ARDAT', 'BEATDKD', 'BIOMAP', 'DIRECT', 'EMIF', 'NEURODERISK', 'RHAPSODY', 'SUMMIT']},
{"Ixico Technologies Limited, London, United Kingdom":['AMYPAD', 'EPAD', 'ROADMAP']},
{"Ixscient Limited, Uxbridge, United Kingdom":['IDEAFAST', 'LITMUS', 'MOBILISED']},
{"Izmir Katip Celebi Universitesi, Izmir, Turkey":['CONCEPTION']},
{"Jacobs University Bremen Ggmbh, Bremen, Germany":['TRANSLOCATION']},
{"Janssen Biologics BV, Leiden, Netherlands":['BTCURE', 'UBIOPRED']},
{"Janssen Pharmaceutica Nv, Beerse, Belgium":['3TR', 'ADAPTED', 'ADAPTSMART', 'AIMS2TRIALS', 'AMYPAD', 'ARDAT', 'C4C', 'CARE', 'CHEM21', 'COMBACTENET', 'COMBINE', 'CONCEPTION', 'DOIT', 'EBISC', 'EBISC2', 'EBODAC', 'EHDEN', 'EHR4CR', 'ELF', 'EMIF', 'EMTRAIN', 'EPAD', 'EQIPD', 'ERA4TB', 'ESCULAB', 'ETOX', 'ETRANSAFE', 'ETRIKS', 'EU2P', 'EUAIMS', 'EUPATI', 'EUPEARL', 'FAIRPLUS', 'GETREAL', 'HARMONY', 'IDEAFAST', 'IM2PACT', 'IMMUCAN', 'IMMUNEIMAGE', 'IMPRIND', 'IPIE', 'K4DD', 'MELLODDY', 'MIPDILI', 'NEURONET', 'NEWMEDS', 'ONCO_TRACK', 'OPEN_PHACTS', 'ORBITO', 'PARADIGM', 'PHAGO', 'PHARMACOG', 'PHARMALEDGER', 'PHARMATRAIN', 'PIONEER', 'PREDECT', 'PREDICTTB', 'PREFER', 'PRISM', 'RADARAD', 'RADARCNS', 'RAPPID', 'RESCEU', 'RESPIRINTM', 'RESPIRITB', 'RHAPSODY', 'ROADMAP', 'RTCURE', 'STEMBANCC', 'TRANSBIOLINE', 'TRANSLOCATION', 'TRANSQST', 'TRIALSHOME', 'ULTRADD', 'VALUEDX', 'WEBRADR']},
{"Janssen Vaccines & Prevention BV, Leiden, Netherlands":['ADVANCE', 'EBOMAN', 'EBOVAC1', 'EBOVAC2', 'EBOVAC3', 'FLUCOP', 'VITAL']},
{"Jdrf International, New York, United States":['BEATDKD', 'H2O', 'HYPORESOLVE', 'IMSAVAR', 'INNODIA', 'INNODIA_HARVEST', 'SOPHIA']},
{"Jlp Health GMBH, Vienna, Austria":['MADCOV_2']},
{"Joanneum Research Forschungsgesellschaft Mbh, Graz, Austria":['IMMUNIVERSE']},
{"Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany":['ABIRISK', 'AIMS2TRIALS', 'CARE', 'COMBACTENET', 'EUBOPEN', 'EUROPAIN', 'HARMONY', 'ORBITO', 'TRANSLOCATION']},
{"Johannes Gutenberg-Universitat Mainz, Mainz, Germany":['ORBITO']},
{"John Innes Centre, Norwich, United Kingdom":['ENABLE']},
{"Julius Clinical Research BV, Zeist, Netherlands":['COMBACTENET', 'COVIDRED', 'TRIALSHOME']},
{"Justus-Liebig-Universitaet Giessen, Giessen, Germany":['MADCOV_2']},
{"Juvabis AG, Furigen, Switzerland":['ENABLE']},
{"K.A.B.S. Laboratories Inc. - Kabs, St-Hubert, Canada":['IMPENTRI']},
{"Kaly-Cell, Plobsheim, France":['MIPDILI']},
{"Kantisto BV, Baarn, Netherlands":['ICONSENSUS']},
{"Karolinska Institutet, Stockholm, Sweden":['3TR', 'ABIRISK', 'ADVANCE', 'AETIONOMY', 'AIMS2TRIALS', 'AMYPAD', 'BIGDATAHEART', 'BIOMAP', 'BTCURE', 'C4C', 'CONCEPTION', 'EMIF', 'EMTRAIN', 'EPAD', 'EU2P', 'EUAIMS', 'EUBOPEN', 'GRAVITATEHEALTH', 'MIPDILI', 'MOPEAD', 'NECESSITY', 'NEWMEDS', 'PRECISESADS', 'RADARAD', 'RTCURE', 'SAFESCIMET', 'SUMMIT', 'UBIOPRED', 'ULTRADD']},
{"Karolinska University Hospital, Stockholm, Sweden":['PHARMATRAIN']},
{"Katholieke Universiteit Leuven, Leuven, Belgium":['3TR', 'CARDIATEAM', 'CARE', 'CONCEPTION', 'EBISC2', 'EUPEARL', 'H2O', 'IMMUCAN', 'IMMUNIVERSE', 'INNODIA', 'INNODIA_HARVEST', 'MELLODDY', 'MOBILISED', 'ORBITO', 'PHARMALEDGER', 'PRECISESADS', 'PREFER', 'PROACTIVE', 'RADARCNS', 'RAPPID', 'SOPHIA']},
{"Keosys S.A.S., Saint-Herblain, France":['QUICCONCEPT']},
{"KingS College London, London, United Kingdom":['AIMS2TRIALS', 'BIOMAP', 'BTCURE', 'EHR4CR', 'EMIF', 'EUAIMS', 'EUPEARL', 'EUROPAIN', 'H2O', 'HYPORESOLVE', 'IMIPAINCARE', 'IMMUCAN', 'INNODIA', 'INNODIA_HARVEST', 'NEWMEDS', 'NGNPET', 'PDMIND', 'PHAGO', 'PHARMATRAIN', 'PIONEER', 'QUICCONCEPT', 'RADARAD', 'RADARCNS', 'RTCURE', 'STEMBANCC']},
{"Kks-Netzwerk Ev -Netzwerk Der Koordinierungszentren Fur Klinische Studien, Berlin, Germany":['IDEAFAST', 'MACUSTAR']},
{"Klinikum Der Universitaet Regensburg, Regensburg, Germany":['BEATDKD']},
{"Klinikum Der Universitaet Zu Koeln, Cologne, Germany":['ADAPTED', 'AMYPAD', 'COMBACTECARE', 'COMBACTECDI', 'COMBACTENET', 'EBISC', 'EPAD', 'ERA4TB', 'MOPEAD', 'PRECISESADS']},
{"Klinikum Garmisch-Partenkirchen GMBH, Garmisch-Partenkirchen, Germany":['STOPFOP']},
{"Klinikum Rechts Der Isar Der Technischen Universitat Munchen, Muenchen, Germany":['ABIRISK', 'AIMS2TRIALS', 'BIOMAP', 'EUROPAIN', 'MIPDILI']},
{"Kobenhavns Universitet, Copenhagen, Denmark":['BIOMAP', 'COMPACT', 'DIRECT', 'EBOLAMODRAD', 'EFOEUPATI', 'EMIF', 'ENABLE', 'EUPATI', 'GRAVITATEHEALTH', 'IM2PACT', 'INNODIA', 'INNODIA_HARVEST', 'ORBITO', 'PHARMATRAIN', 'RESPIRINTM', 'RESPIRITB', 'RHAPSODY', 'ROADMAP', 'SAFESCIMET', 'UBIOPRED', 'VHFMODRAD']},
{"Koninklijke Nederlandse Akademie Van Wetenschappen - Knaw, Utrecht, Netherlands":['EBISC', 'EUAIMS']},
{"Kubermatic GMBH, Hamburg, Germany":['MELLODDY']},
{"Kungliga Tekniska Hoegskolan, Stockholm, Sweden":['DIRECT', 'EUBOPEN', 'ICONSENSUS', 'RAPPID']},
{"L.A Sante, Epidemiologie, Evaluation Et Recherche L.A.S.E.R., Paris, France":['GETREAL', 'GETREAL_INITIATIVE', 'PROTECT']},
{"LIFE TECHNOLOGIES GmbH, Darmstadt, Germany":['CANCERID']},
{"Labormedizinisches Zentrum Dr Rischservices AG, Buchs, Switzerland":['COVIDRED']},
{"Labormedizinosches Zentrum Dr Rischostschweiz AG, Buchs, Switzerland":['COVIDRED']},
{"Laegemiddelstyrelsen, Kobenhavn S, Denmark":['WEBRADR_2']},
{"Laeknisfraedileg myndgreining ltd, Reykjavik, Iceland":['EUAIMS']},
{"Lakemedelsverket, Uppsala, Sweden":['ORBITO']},
{"Landspitali University Hospital, Reykjavik, Iceland":['TRANSBIOLINE']},
{"Latvijas Organiskas Sintezes Instituts, Riga, Latvia":['ENABLE', 'ERA4TB']},
{"Lawrencium Legal BV, Amsterdam, Netherlands":['IMMUNEIMAGE']},
{"Lead Discovery Center GMBH, Dortmund, Germany":['ELF']},
{"Lead Molecular Design S.L., Sant Cugat del Vallès, Spain":['ETOX']},
{"Lega ltaliana Anti Fumo, Catania, Italy":['UBIOPRED']},
{"Leibniz - Institut Fur Katalyse Ev An Der Universitat Rostock, Rostock, Germany":['CHEM21']},
{"Leibniz-Institut Fur Praventionsforschung Und Epidemiologie - Bips GMBH, Bremen, Germany":['EMIF']},
{"Leo Pharma As, Ballerup, Denmark":['BIOMAP']},
{"Les Hopitaux Universitaires De Geneve, Geneva, Switzerland":['EHR4CR']},
{"Leukanet Ev, Riemerling, Germany":['HARMONY', 'HARMONY_PLUS']},
{"Leuphana Universitat Luneburg, Luneburg, Germany":['PREMIER']},
{"Lhasa Limited, Leeds, United Kingdom":['ETOX', 'ETRANSAFE', 'IPIE', 'MIPDILI']},
{"Life And Brain GMBH, Bonn, Germany":['NGNPET', 'PHAGO']},
{"Life Molecular Imaging LTD, Havant, United Kingdom":['AMYPAD']},
{"Ligue Nationale Contre Le Cancer, Paris, France":['IMMUCAN']},
{"Linkopings Universitet, Linkoping, Sweden":['COMBACTENET', 'LITMUS', 'STEMBANCC']},
{"Lionex GMBH, Braunschweig, Germany":['RAPPID']},
{"Lipotype, Dresden, Germany":['BEATDKD', 'RHAPSODY', 'SOPHIA']},
{"Liverpool John Moores University, Liverpool, United Kingdom":['ETOX', 'ETRANSAFE', 'IPIE']},
{"Liverpool School Of Tropical Medicine, Liverpool, United Kingdom":['PREDICTTB']},
{"Lixoft SAS, Orsay, France":['DDMORE', 'IDEAFAST']},
{"London School Of Economics And Political Science, London, United Kingdom":['DOIT', 'DRIVEAB', 'ROADMAP']},
{"London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom":['ADVANCE', 'BIOMAP', 'EBODAC', 'EBOVAC1', 'EBOVAC2', 'EBOVAC3', 'PERISCOPE']},
{"Lonza AG, Basel, Switzerland":['ARDAT']},
{"Lothian Health Board, Edinburgh, United Kingdom":['IABC']},
{"Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany":['COMPACT', 'EQIPD', 'EUPEARL', 'HARMONY', 'HARMONY_PLUS', 'IMMUNIVERSE', 'PROTECT', 'TRANSBIOLINE']},
{"Lunds Universitet, Lund, Sweden":['APPROACH', 'ARDAT', 'BEATDKD', 'DIRECT', 'ERA4TB', 'IMSAVAR', 'INNODIA', 'INNODIA_HARVEST', 'PIONEER', 'RHAPSODY', 'SOPHIA', 'SUMMIT', 'TRISTAN']},
{"Lunds Universitets Innovationssystem AB, Lund, Sweden":['SUMMIT']},
{"Lupus Europe, Romford Essex, United Kingdom":['3TR']},
{"Luxembourg Institute Of Health, Luxembourg, Luxembourg":['CANCERID', 'CARDIATEAM', 'IMMUCAN', 'LITMUS', 'VALUEDX']},
{"Lysarc, Pierre-Benite, France":['HARMONY', 'HARMONY_PLUS']},
{"Lysogene, Neuilly sur Seine, France":['ADAPTSMART', 'ARDAT']},
{"Lægemiddelstyrelsen, Copenhagen S, Denmark":['PROTECT']},
{"M2p-Labs GMBH, Baesweiler, Germany":['ICONSENSUS']},
{"MINISTRIA E SHENDETESISE (National Institute of Public Health of Kosovo), Pristina, Kosovo * UN resolution":['COMBACTECARE']},
{"Maat France SARL, Archamps, France":['EMIF']},
{"Manchester University Nhs Foundation Trust, Manchester, United Kingdom":['IDEAFAST', 'TRISTAN']},
{"Mango Business Solutions Limited, Stevenage, United Kingdom":['DDMORE']},
{"Martin-Luther-Universitaet Halle-Wittenberg, Halle (Saale), Germany":['SAFESCIMET']},
{"Masarykova univerzita, Brno, Czech Republic":['CONCEPTION', 'HARMONY', 'HARMONY_PLUS', 'PDMIND']},
{"Massachusetts Institute Of Technology, Cambridge, United States":['ADAPTSMART']},
{"Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany":['3TR', 'BIOVACSAFE', 'CANCERID', 'ELF', 'EUAIMS', 'ONCO_TRACK', 'PREDICTTB', 'RESOLUTE']},
{"Mcroberts BV, S Gravenhage, Netherlands":['IDEAFAST', 'MOBILISED']},
{"Mdsol Europe LTD, London, United Kingdom":['GRAVITATEHEALTH']},
{"Medibiosense LTD, Doncaster, United Kingdom":['IDEAFAST']},
{"Medical Research Council, Swindon, United Kingdom":['EPAD', 'IMPRIND']},
{"Medical Research Infrastructure Development And Health Services Fund By The Sheba Medical Center, Ramat Gan, Israel":['ABIRISK']},
{"Medical Research Network Limited, Milton Keynes, United Kingdom":['TRIALSHOME']},
{"Medicines And Healthcare Products Regulatory Agency, London, United Kingdom":['CONCEPTION', 'WEBRADR_2']},
{"Medicines and Healthcare products Regulatory Agency, London, United Kingdom":['ADVANCE', 'PHARMATRAIN']},
{"Medisapiens Oy, Helsinki, Finland":['HARMONY', 'HARMONY_PLUS']},
{"Medizinische Hochschule Hannover, Hannover, Germany":['3TR', 'ARDAT', 'COMBACTENET', 'IABC', 'IMIDIA', 'IMSAVAR', 'PRECISESADS', 'STEMBANCC']},
{"Medizinische Universitaet Wien, Vienna, Austria":['ABDIRECT', 'BEATDKD', 'BTCURE', 'COMBACTEMAGNET', 'EMTRAIN', 'EUPEARL', 'GNA_NOW', 'H2O', 'ITCCP4', 'LITMUS', 'MARCAR', 'NEURODERISK', 'PRECISESADS', 'RESPIRINTM', 'RESPIRITB', 'RTCURE']},
{"Medizinische Universitat Graz, Graz, Austria":['CANCERID', 'CONCEPTION', 'EMTRAIN', 'HYPORESOLVE', 'INNODIA', 'INNODIA_HARVEST', 'ONCO_TRACK', 'SPRINTT']},
{"Medizinische Universitat Innsbruck, Innsbruck, Austria":['ABIRISK', 'BEATDKD', 'IDEAFAST', 'IMSAVAR', 'STEMBANCC']},
{"Medtronic International Trading SARL, Tolochenaz, Switzerland":['H2O', 'HYPORESOLVE', 'SOPHIA', 'TRIALSHOME']},
{"Menarini Ricerche S.A, Pomezia, Italy":['HARMONY', 'HARMONY_PLUS']},
{"Menarini Silicon Biosystems S.A, Bologna, Italy":['CANCERID']},
{"Mendelova Univerzita V Brne, Brno, Czech Republic":['FILODIAG']},
{"Mercachem B.V., Nijmegen, Netherlands":['ELF']},
{"Mercachem Holding BV, Nijmegen, Netherlands":['ELF']},
{"Mercaleads BV, Nijmegen, Netherlands":['ELF', 'ESCULAB']},
{"Mercatorial BV, Nijmegen, Netherlands":['ELF', 'ESCULAB']},
{"Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany":['ABIRISK', 'ADAPTSMART', 'APPROACH', 'BTCURE', 'CARE', 'COMPACT', 'CONCEPTION', 'DDMORE', 'DOIT', 'EHR4CR', 'ELF', 'EMIF', 'ESCULAB', 'ETRANSAFE', 'ETRIKS', 'EUPATI', 'GETREAL', 'IMMUCAN', 'IMSAVAR', 'K4DD', 'MELLODDY', 'MIPDILI', 'MOBILISED', 'ONCO_TRACK', 'OPEN_PHACTS', 'PARADIGM', 'PHARMACOG', 'PHARMATRAIN', 'PREFER', 'PROTECT', 'QUICCONCEPT', 'SAFESCIMET', 'STEMBANCC', 'TRIALSHOME']},
{"Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States":['ADAPTSMART', 'ADVANCE', 'DOIT', 'DRIVEAB', 'EPAD', 'EUPATI', 'GETREAL', 'IMSAVAR', 'IPIE', 'NEURODERISK', 'ORBITO', 'PARADIGM', 'PHARMALEDGER', 'PREFER', 'PREMIER', 'RAPPID', 'TRANSBIOLINE', 'TRISTAN', 'UBIOPRED', 'VITAL', 'VSVEBOPLUS']},
{"Merial SAS, Lyon, France":['VAC2VAC', 'ZAPI']},
{"Metabolon GMBH, Potsdam, Germany":['SOPHIA']},
{"Metabrain Research, Maison-Alfort, France":['CARDIATEAM']},
{"Metaheps GMBH, Munich, Germany":['TRANSBIOLINE']},
{"Michigan State University, East Lansing, Michigan, United States":['IMIPAINCARE']},
{"Microbiotec SRL, Siena, Italy":['VSVEBOPLUS', 'VSVEBOVAC']},
{"Microfluidic Chipshop GMBH, Jena, Germany":['RAPPID']},
{"Microliquid SL, Arrasate-Mondragon, Spain":['DECISION']},
{"Micronit Microtechnologies BV, Enschede, Netherlands":['ICONSENSUS']},
{"Microsens Medtech Ltd, London, United Kingdom":['PREDICTTB']},
{"Mihajlovic Jovan, Novi Sad, Serbia":['VITAL']},
{"Mikrobiologicky Ustav Av Cr V.V.I, Prague 4, Czech Republic":['PERISCOPE']},
{"Mimetas BV, Leiden, Netherlands":['ADAPTED', 'ARDAT', 'IM2PACT', 'PDMITOQUANT']},
{"Mindbytes, Merksplas, Belgium":['PREFER']},
{"Mindview Symvouloi Epixeiriseon Kaierevnas Etaireia Periorismenis Efthynis, Athens, Greece":['GRAVITATEHEALTH']},
{"Ministerie Van Volksgezondheid, Welzijn En Sport, Bilthoven, Netherlands":['VAC2VAC']},
{"Ministry Of Health, Jerusalem, Israel":['CONCEPTION']},
{"Ministry of Human Resources, Medical Research Council, National Healthcare  Service Center, Budapest, Hungary":['EMTRAIN']},
{"Mitologics, Romainville, France":['RESPIRINTM', 'RESPIRITB']},
{"Mll Munchner Leukamielabor GMBH, Munich, Germany":['HARMONY', 'HARMONY_PLUS']},
{"Mlm Medical Labs GMBH, Moenchengladbach, Germany":['TRANSBIOLINE']},
{"Mmi Clinical Research Development Ireland, Dublin, Ireland":['C4C']},
{"Mmv Medicines For Malaria Venture Fondation, genevra, Switzerland":['ESCULAB']},
{"Modus Research And Innovation Limited, Dundee, United Kingdom":['ADAPTED', 'MOPEAD']},
{"Molecular Discovery LTD, London, United Kingdom":['ENABLE']},
{"Molecular Networks GMBH Computerchemie, Erlangen, Germany":['ETOX', 'ETRANSAFE', 'IPIE']},
{"Moorfields Eye Hospital Nhs Foundation Trust, London, United Kingdom":['MACUSTAR']},
{"Mrc Systems GMBH Medizintechnische Systeme, Heidelberg, Germany":['IMIPAINCARE']},
{"Msd Czech Republic Sro, Prague, Czech Republic":['RADARCNS']},
{"Muscular Dystrophy Group Of Great Britain And Northern Ireland, London, United Kingdom":['PREFER']},
{"Museum National DHistoire Naturelle, Paris, France":['PHARMACOG']},
{"Mutabilis, Paris, France":['ENABLE']},
{"Mylan Ire Healthcare Limited, Dublin, Ireland":['GRAVITATEHEALTH']},
{"Nacionalni Laboratorij Za Zdravje, Okolje In Hrano, Maribor, Slovenia":['COMBACTECDI']},
{"Nanion Technologies GMBH, München, Germany":['TRANSLOCATION']},
{"Narodowy Instytut Lekow, Warsaw , Poland":['ENABLE']},
{"National Institute For Health And Care Excellence, Manchester, United Kingdom":['ADAPTSMART', 'DOIT', 'EHDEN', 'ERA4TB', 'GETREAL', 'GETREAL_INITIATIVE', 'HARMONY', 'HARMONY_PLUS', 'NEURONET', 'ROADMAP', 'VALUEDX']},
{"National Research And Development Institute For Cryogenics And Isotopic Technologies Icsi Rm Valcea, Ramnicu Valcea, Romania":['PHARMALEDGER']},
{"Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen, Reutlingen, Germany":['MARCAR', 'NGNPET', 'SAFET', 'STEMBANCC']},
{"Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek Tno, Den Haag, Netherlands":['ORBITO']},
{"Neptunus Data Aktiebolag, Saltsjöbaden, Sweden":['EHR4CR']},
{"Netherlands Asthma Foundation, Leusden, Netherlands":['PROACTIVE', 'UBIOPRED']},
{"Neuroscience Technologies Limited, London, United Kingdom":['EUROPAIN']},
{"Neuroscience Technologies Slp, Barcelona, Spain":['EUROPAIN']},
{"Neuway Pharma GMBH, Bonn, Germany":['IM2PACT']},
{"Newcells Biotech Limited, Newcastle upon Tyne, United Kingdom":['STEMBANCC']},
{"Noldus Information Technology BV, Wageningen, Netherlands":['AIMS2TRIALS', 'EQIPD', 'EUAIMS']},
{"Nordic Bioscience A/S, Herlev, Denmark":['LITMUS']},
{"Nordic Bioscience Compound Development A/S, Herlev, Denmark":['APPROACH', 'LITMUS']},
{"Norges Parkinsonforbund, Oslo, Norway":['PDMIND']},
{"Norges teknisk-naturvitenskapelige universitet - NTNU, Trondheim, Norway":['COMPACT', 'MOBILISED']},
{"Norsk E Helse As, Oslo, Norway":['GRAVITATEHEALTH']},
{"North Bristol National Health Service Trust, Bristol, United Kingdom":['COMBACTEMAGNET', 'COMBACTENET', 'GNA_NOW']},
{"Northern Antibiotics Oy, Helsinki, Finland":['ENABLE']},
{"Northwestern University, Evanston, Illinois, United States":['RADARCNS']},
{"Nosopharm, Nimes, France":['ENABLE', 'GNA_NOW']},
{"Nottingham University Hospitals Nhs Trust, Nottingham, United Kingdom":['UBIOPRED']},
{"Novartis Pharma AG, Basel, Switzerland":['3TR', 'ABIRISK', 'ADAPTSMART', 'ADVANCE', 'AETIONOMY', 'AIMS2TRIALS', 'ARDAT', 'BIGDATAHEART', 'BIOMAP', 'C4C', 'CARE', 'CONCEPTION', 'DDMORE', 'DOIT', 'EFOEUPATI', 'EHDEN', 'EHR4CR', 'EMTRAIN', 'EPAD', 'EQIPD', 'ETOX', 'ETRANSAFE', 'EU2P', 'EUPATI', 'EUPEARL', 'FAIRPLUS', 'GETREAL', 'GRAVITATEHEALTH', 'H2O', 'HARMONY', 'HARMONY_PLUS', 'IABC', 'IM2PACT', 'IMIDIA', 'IMIPAINCARE', 'IMMUNEIMAGE', 'IMMUNIVERSE', 'IMPRIND', 'IMSAVAR', 'INNODIA', 'INNODIA_HARVEST', 'IPIE', 'LITMUS', 'MACUSTAR', 'MARCAR', 'MELLODDY', 'MOBILISED', 'NECESSITY', 'NEURODERISK', 'NEWMEDS', 'OPEN_PHACTS', 'ORBITO', 'PARADIGM', 'PHARMACOG', 'PHARMALEDGER', 'PHARMATRAIN', 'PREFER', 'PREMIER', 'PRISM', 'PROACTIVE', 'PROTECT', 'RADARAD', 'RESOLUTE', 'ROADMAP', 'SAFESCIMET', 'SAFET', 'SPRINTT', 'TRANSBIOLINE', 'TRIALSHOME', 'UBIOPRED', 'ULTRADD', 'WEBRADR', 'WEBRADR_2']},
{"Novavax Inc, Gaithersburg, United States":['RESCEU']},
{"Novo Nordisk A/S, Bagsvaerd, Denmark":['ABIRISK', 'ADAPTSMART', 'ARDAT', 'BEATDKD', 'BTCURE', 'COMPACT', 'CONCEPTION', 'DDMORE', 'DIRECT', 'DOIT', 'EBISC', 'EBISC2', 'EFOEUPATI', 'EMIF', 'EMTRAIN', 'EU2P', 'EUPATI', 'EUPEARL', 'GETREAL', 'HYPORESOLVE', 'IM2PACT', 'IMIDIA', 'INNODIA', 'INNODIA_HARVEST', 'LITMUS', 'PARADIGM', 'PHARMALEDGER', 'PHARMATRAIN', 'PROTECT', 'RHAPSODY', 'SAFESCIMET', 'SOPHIA', 'STEMBANCC', 'TRISTAN']},
{"Nuvisan Icb GMBH, Berlin, Germany":['CARE']},
{"Nv SAS Institute SA, Tervuren, Belgium":['PIONEER']},
{"Nvidia Switzerland AG, Zurich, Switzerland":['MELLODDY']},
{"Obesity Action Coalition Inc, Tampa, United States":['SOPHIA']},
{"Ocello BV, Leiden, Netherlands":['TRANSQST']},
{"Odysseus Data Services Sro, Praha, Czech Republic":['EHDEN']},
{"Okids GMBH, Wien, Austria":['C4C']},
{"Oligovax, Paris, France":['PEVIA']},
{"Oncoradiomics, Liege, Belgium":['DRAGON']},
{"One Way Liver SL, Derio, Spain":['LITMUS']},
{"Onorach LTD, Dundee, United Kingdom":['PHARMALEDGER']},
{"Ontario Institute for Cancer Research, Toronto, Ontario, Canada":['EUBOPEN']},
{"Opale, Paris, France":['CARDIATEAM']},
{"Open Evidence, Barcelona, Spain":['GRAVITATEHEALTH']},
{"Open Phacts Foundation Lbg, Cambridge, United Kingdom":['FAIRPLUS', 'OPEN_PHACTS']},
{"Openlink Group Limited, Croydon, United Kingdom":['OPEN_PHACTS']},
{"Optibrium Limited, Cambridge, United Kingdom":['ETRANSAFE']},
{"Optimata LTD, Ramat Gan, Israel":['DDMORE']},
{"Orcion BV, Asten, Netherlands":['CONCEPTION']},
{"Orebro University, Örebro, Sweden":['3TR', 'LITMUS']},
{"Orion Oyj, Espoo, Finland":['CANCERID', 'CHEM21', 'EMTRAIN', 'EQIPD', 'EU2P', 'IDEAFAST', 'MIPDILI', 'NEWMEDS', 'ORBITO', 'PHAGO', 'PHARMATRAIN', 'PIONEER', 'PREDECT', 'SAFESCIMET', 'STEMBANCC', 'TRANSQST']},
{"Orion Sante SARL, Le Plesiss Robinson, France":['IMPENTRI']},
{"Oslo Universitetssykehus Hf, Oslo, Norway":['CANCERID', 'INNODIA', 'INNODIA_HARVEST']},
{"Ospedale Pediatrico Bambino Gesu, Rome, Italy":['C4C', 'DRIVE', 'HARMONY', 'HARMONY_PLUS', 'INNODIA', 'INNODIA_HARVEST', 'ITCCP4', 'PHARMALEDGER']},
{"Ospedale San Raffaele SRL, Milano, Italy":['RADARCNS']},
{"Osterreichische Agentur Fur Gesundheit Und Ernahrungssicherheit GMBH, Vienna, Austria":['VAC2VAC']},
{"Ot Chemistry AB, Uppsala, Sweden":['ENABLE']},
{"Otsuka Novel Products GMBH, Munich, Germany":['EUPEARL']},
{"Oulun Yliopisto, Oulu, Finland":['APPROACH', 'INNODIA', 'INNODIA_HARVEST']},
{"Outcome Europe Sarl, St. Prex, Switzerland":['PROTECT']},
{"Owkin France, Paris, France":['IMMUCAN', 'MELLODDY']},
{"Owlstone Medical Limited, Cambridge, United Kingdom":['3TR', 'DRAGON']},
{"P1vital Limited, Wallingford, United Kingdom":['PRISM']},
{"P1vital Products Limited, Wallingford, United Kingdom":['PRISM']},
{"P95 CVBA, Leuven, Belgium":['ADVANCE', 'DRIVE', 'VITAL']},
{"PHARMED asbi, Brussels, Belgium":['PHARMATRAIN']},
{"PHARMO Institute N.V., Utrecht, Netherlands":['EMIF']},
{"PME Institute for Education in Pharmaceutical Medicine, Witten, Germany":['PHARMATRAIN']},
{"Paasp GMBH, Heidelberg, Germany":['EQIPD']},
{"Paia Biotech GMBH, Köln, Germany":['ICONSENSUS']},
{"Panepistimio Ioanninon, Ioannina, Greece":['GETREAL']},
{"Papworth Hospital Nhs Foundation Trust, Papworth Everard, United Kingdom":['IABC']},
{"ParkinsonS Disease Society Of Theunited Kingdom Lbg, London, United Kingdom":['IDEAFAST', 'NEURONET', 'PDMIND', 'PDMITOQUANT']},
{"Pdm E Fc Projecto Desenvolvimento Manutencao Formacao E Consultadorialda, Lisboa, Portugal":['PHARMALEDGER']},
{"Pds Computer Software Limited, Leicester, United Kingdom":['ETRANSAFE']},
{"Pelvic Pain Support Network, Poole, United Kingdom":['IMIPAINCARE']},
{"Penumologisches Forschungsinstitutan Der Lungenclinic Grosshansdorf GMBH, Grosshansdorf, Germany":['MOBILISED']},
{"Perspectum LTD, Oxford, United Kingdom":['LITMUS']},
{"Pfizer Limited, Sandwich, Kent , United Kingdom":['3TR', 'ABIRISK', 'ADAPTSMART', 'ADVANCE', 'ARDAT', 'BIOMAP', 'BTCURE', 'C4C', 'CARE', 'CHEM21', 'COMBACTECARE', 'COMBACTECDI', 'COMBACTENET', 'COMPACT', 'CONCEPTION', 'DDMORE', 'DOIT', 'DRIVEAB', 'EBISC', 'EBISC2', 'EFOEUPATI', 'EHDEN', 'EMIF', 'EPAD', 'EQIPD', 'ETOX', 'ETRIKS', 'EUAIMS', 'EUBOPEN', 'EUPATI', 'EUPEARL', 'EUROPAIN', 'GRAVITATEHEALTH', 'H2O', 'HARMONY', 'HARMONY_PLUS', 'ICONSENSUS', 'IDEAFAST', 'IM2PACT', 'IMMUNEIMAGE', 'IMMUNIVERSE', 'IPIE', 'ITCCP4', 'LITMUS', 'MOBILISED', 'NEURODERISK', 'NEWMEDS', 'ONCO_TRACK', 'OPEN_PHACTS', 'ORBITO', 'PARADIGM', 'PHARMALEDGER', 'PHARMATRAIN', 'PREFER', 'PROTECT', 'QUICCONCEPT', 'RESCEU', 'RESOLUTE', 'RTCURE', 'SAFET', 'STEMBANCC', 'SUMMIT', 'TRANSBIOLINE', 'TRIALSHOME', 'TRISTAN', 'ULTRADD', 'VAC2VAC', 'VITAL', 'WEBRADR_2']},
{"Phadia AB, Upssala, Sweden":['BTCURE']},
{"PharmaTrain Federation, Basel, Switzerland":['EMTRAIN', 'PHARMATRAIN']},
{"Pharmacoidea Fejleszto Es Szolgaltato Kft, Szeged, Hungary":['AETIONOMY', 'ARDAT', 'COMPACT', 'IM2PACT']},
{"Pharmalex Belgium, Mont Saing Guibert, Belgium":['EQIPD']},
{"Pharmamar, S.A., Colmenar Viejo, Spain":['ITCCP4']},
{"Pharmo Cooperatie Ua, Utrecht, Netherlands":['EMIF']},
{"Philipps Universitaet Marburg, Marburg, Germany":['3TR']},
{"Philips Electronics Nederland BV, Eindhoven, Netherlands":['UBIOPRED']},
{"Pinsent Masons Llp, London, United Kingdom":['PIONEER']},
{"Pintail LTD, Blackrock, Ireland":['PDMITOQUANT']},
{"Pivot Park Screening Centre BV, Oss, Netherlands":['ELF', 'ESCULAB']},
{"Pluribus One SRL, Cagliari, Italy":['IDEAFAST']},
{"Polyphor AG, Allschwil, Switzerland":['IABC']},
{"Porsolt SAS, Le Genest-Saint-Isle, France":['EQIPD']},
{"Presens Precision Sensing GMBH, Regensburg, Germany":['ICONSENSUS']},
{"Primadiag SAS, Romainville, France":['RAPIDCOVID']},
{"Prinses Maxima Centrum Voor Kinderoncologie BV, Utrecht, Netherlands":['ITCCP4']},
{"Private Universitaet Witten/Herdecke gGmbH, Witten, Germany":['PROTECT']},
{"Promptly - Software Solutions For Health Measures, Lda, Porto, Portugal":['IMIPAINCARE']},
{"Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio- Fatebenefratelli, Brescia, Italy":['EMIF', 'PHARMACOG', 'RADARCNS']},
{"Psychogenics Inc, Tarrytown, United States":['EQIPD']},
{"Psynova Neurotech LTD, Cambridge, United Kingdom":['NEWMEDS']},
{"Q-Biologicals Nv, Gent, Belgium":['PERISCOPE']},
{"Q-Linea AB, Uppsala, Sweden":['RAPPID']},
{"Qiagen GMBH, Hilden, Germany":['CANCERID']},
{"Qps Netherlands BV, Groningen, Netherlands":['ERA4TB']},
{"Qualissima, Marseille, France":['PHARMACOG']},
{"Quartz Bio S.A., Plan-les-Ouates, Switzerland":['PRECISESADS']},
{"Queen Mary University Of London, London, United Kingdom":['3TR', 'ABIRISK', 'IDEAFAST', 'IMIPAINCARE', 'NECESSITY']},
{"Quinten SAS, Paris, France":['FLUCOP']},
{"Quintiles Benefit France Inc, Levallois Perret, France":['PROTECT']},
{"Quintiles Limited, Reading, United Kingdom":['EPAD', 'PROTECT']},
{"RSC Worldwide (US) Inc., Raleigh, Wake County, North Carolina , United States":['OPEN_PHACTS']},
{"Rd-Biotech, Besançon, France":['VHFMODRAD']},
{"Reaxa Limited, Leeds, United Kingdom":['CHEM21']},
{"Redoxis AB, Lund, Sweden":['BTCURE']},
{"Redx Anti-Infectives Ltd, Manchester, United Kingdom":['ENABLE']},
{"Redx Pharma Ltd, Liverpool, United Kingdom":['ENABLE']},
{"Region Hovedstaden, Hilleroed, Denmark":['3TR', 'ABIRISK', 'ENABLE', 'EUROPAIN', 'HYPORESOLVE', 'IMIPAINCARE', 'INNODIA', 'INNODIA_HARVEST', 'RADARCNS', 'STEMBANCC']},
{"Region Stockholm, Stockholm, Sweden":['3TR', 'AMYPAD', 'C4C', 'CONCEPTION', 'EPAD', 'H2O', 'MOPEAD']},
{"Region Syddanmark, Odense, Denmark":['CONCEPTION']},
{"Rentschler Biopharma Se, Laupheim, Germany":['ICONSENSUS']},
{"Research In Advanced Medical Information And Telematics Vzw, Zwalm, Belgium":['EHR4CR']},
{"Research Triangle Institute, Research Triangle Park, United States":['LITMUS']},
{"Resoundant, Inc., Rochester, United States":['LITMUS']},
{"Rete Italiana Per Le Sperimentazioni Cliniche In Pediatria, Rome, Italy":['C4C']},
{"Revmatologicky ustav, Praha, Czech Republic":['BTCURE']},
{"Rheinisch-Westfaelische Technische Hochschule Aachen, Aachen, Germany":['ICONSENSUS']},
{"Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Germany":['OPEN_PHACTS']},
{"Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands":['ADVANCE', 'CONCEPTION', 'GRAVITATEHEALTH', 'PERISCOPE', 'PREMIER', 'RESCEU', 'VAC2VAC', 'VITAL']},
{"Rijksuniversiteit Groningen, Groningen, Netherlands":['AIMS2TRIALS', 'ELF', 'EQIPD', 'IABC', 'PRISM', 'PROTECT', 'RHAPSODY', 'ROADMAP']},
{"Rise Research Institutes Of Sweden AB, Stockholm, Sweden":['ENABLE']},
{"Robert Bosch Gesellschaft Fur Medizinische Forschung Mbh, Stuttgart, Germany":['C4C', 'MOBILISED', 'PREDECT']},
{"Roche Diagnostics Nederland BV, Almere, Netherlands":['COVIDRED']},
{"Roessingh Research And Development BV, Enschede, Netherlands":['SPRINTT']},
{"Romsoft SRL, Iasi, Romania":['PHARMALEDGER']},
{"Roslin Cell Sciences Ltd, Roslin, Midlothian, United Kingdom":['EBISC']},
{"Royal Brompton And Harefield National Health Service Trust, South Kensington, United Kingdom":['IABC', 'PROACTIVE']},
{"Royal College Of Surgeons In Ireland, Dublin, Ireland":['PDMITOQUANT']},
{"Royal Institution For The Advancement Of Learning Mcgill University, Montreal, Canada":['EUBOPEN']},
{"Royal Liverpool And Broadgreen University Hospitals Nhs Trust, Liverpool, United Kingdom":['COMBACTEMAGNET']},
{"Rsc Worldwide LTD, Cambridge, United Kingdom":['OPEN_PHACTS']},
{"Ruhr-Universitaet Bochum, Bochum, Germany":['K4DD']},
{"Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, Germany":['DRIVEAB', 'EUROPAIN', 'IM2PACT', 'IMIPAINCARE']},
{"SARL Endocells, Paris, France":['IMIDIA']},
{"SAS Alzprotect, Loos, France":['PHARMACOG']},
{"SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland":['BEATDKD', 'CARDIATEAM', 'FAIRPLUS', 'HYPORESOLVE', 'IMIDIA', 'IMMUCAN', 'OPEN_PHACTS', 'RHAPSODY', 'SOPHIA']},
{"Samfundet Folkhalsan I Svenska Finland Rf, Helsingfors, Finland":['SUMMIT']},
{"Sanofi Chimie, Gentilly, France":['CHEM21']},
{"Sanofi Pasteur SA, Lyon, France":['ADVANCE', 'BIOVACSAFE', 'COMBACTECDI', 'DRIVE', 'FLUCOP', 'PERISCOPE', 'RESCEU', 'VAC2VAC', 'VITAL']},
{"Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany":['3TR', 'BEATDKD', 'BIOMAP', 'COMPACT', 'DIRECT', 'ELF', 'EMTRAIN', 'ESCULAB', 'ETOX', 'ETRANSAFE', 'ICONSENSUS', 'IMIDIA', 'IMMUNIVERSE', 'INNODIA', 'INNODIA_HARVEST', 'K4DD', 'RHAPSODY', 'RTCURE', 'SUMMIT', 'TRISTAN']},
{"Sanofi-Aventis Groupe, Chilly-Mazarin, France":['EUPATI']},
{"Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France":['ABIRISK', 'ADAPTSMART', 'AETIONOMY', 'ARDAT', 'C4C', 'COMBACTEMAGNET', 'CONCEPTION', 'DOIT', 'DRIVEAB', 'EHDEN', 'EHR4CR', 'EPAD', 'EQIPD', 'ETRIKS', 'EU2P', 'EUPEARL', 'EUROPAIN', 'GETREAL', 'GETREAL_INITIATIVE', 'H2O', 'IDEAFAST', 'IM2PACT', 'IMMUCAN', 'IMSAVAR', 'IPIE', 'MIPDILI', 'MOBILISED', 'NEURODERISK', 'NEURONET', 'ORBITO', 'PARADIGM', 'PHAGO', 'PHARMATRAIN', 'PIONEER', 'PRECISESADS', 'PREDICTTB', 'PREFER', 'PREMIER', 'PROTECT', 'QUICCONCEPT', 'RAPPID', 'RESOLUTE', 'SAFESCIMET', 'SAFET', 'SPRINTT', 'STEMBANCC', 'TRANSBIOLINE', 'TRANSLOCATION', 'TRANSQST', 'TRIALSHOME', 'WEBRADR']},
{"Sbgneuro LTD, Thame, United Kingdom":['PRISM']},
{"SciBite Limited, Bexhill-On-Sea, United Kingdom":['OPEN_PHACTS']},
{"Scicross AB, Skovde, Sweden":['ABIRISK']},
{"Science Exchange, Inc., Palo Alto, United States":['EQIPD']},
{"Sciensano, Brussels, Belgium":['ADVANCE', 'ERA4TB', 'VAC2VAC']},
{"Scifeon Aps, Soborg, Denmark":['CARE']},
{"Sciprom SARL, St-Sulpice, Switzerland":['IMPRIND', 'RHAPSODY']},
{"Sclavo Vaccines Association, Siena, Italy":['FLUCOP', 'VSVEBOPLUS', 'VSVEBOVAC']},
{"Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna, Pisa, Italy":['IMMUNIVERSE']},
{"Semmelweis Egyetem, Budapest, Hungary":['DOIT', 'PHARMATRAIN', 'RTCURE', 'UBIOPRED']},
{"Seqirus S.r.l., Siena, Italy":['FLUCOP']},
{"Seqirus Uk Limited, Maidenhead, United Kingdom":['DRIVE']},
{"Servei De Salut De Les Illes Balears, Palma, Spain":['COMBACTEMAGNET']},
{"Servicio Andaluz De Salud, Sevilla, Spain":['3TR', 'COMBACTECARE', 'COMBACTEMAGNET', 'COMBACTENET', 'LITMUS', 'PRECISESADS', 'TRANSBIOLINE']},
{"Servicio Cántabro de Salud, Santander, Spain":['PRECISESADS']},
{"Servicio Madrileno De Salud, Madrid, Spain":['3TR', 'AIMS2TRIALS', 'C4C', 'CARE', 'COMBACTECARE', 'COMBACTEMAGNET', 'COMBACTENET', 'ENABLE', 'ERA4TB', 'GRAVITATEHEALTH', 'IABC', 'SPRINTT']},
{"Servizo Galego De Saude, Santiago de Compostela, Spain":['APPROACH', 'C4C', 'RESCEU']},
{"Sheffield Teaching Hospitals Nhs Foundation Trust, Sheffield, United Kingdom":['MOBILISED', 'TRISTAN']},
{"Shire International GMBH, Zug, Switzerland":['ADAPTSMART']},
{"Siemens Healthcare Diagnostics Products GMBH, Marburg, Germany":['CANCERID']},
{"Sierra Sensors GmbH, Hamburg, Germany":['K4DD']},
{"Signatope GMBH, Reutlingen, Germany":['TRANSBIOLINE']},
{"Simomics Limited, York, United Kingdom":['PREMIER']},
{"Simulations Plus, Inc., Lancaster, United States":['ORBITO']},
{"Siop Europe Asbl, Brussels, Belgium":['C4C']},
{"Sip Service S.R.L., Milano, Italy":['3TR']},
{"Sirius Analytical Ltd, Forest Row, United Kingdom":['ORBITO']},
{"Sivas Cumhuriyet Universitesi, Sivas, Turkey":['VHFMODRAD']},
{"Slaski Uniwersytet Medyczny W Katowicach, Katowice, Poland":['INNODIA', 'INNODIA_HARVEST']},
{"Societa Servizi Telematici SRL, Padova, Italy":['ADVANCE', 'EMIF']},
{"Societe De Pneumologie De Langue Francaise, Paris 6, France":['3TR']},
{"Societe Europeenne De Cardiologie, Biot, France":['BIGDATAHEART']},
{"Software AG, Darmstadt, Germany":['RADARAD', 'RADARCNS']},
{"Solvo Biotechnology Zrt, Szeged, Hungary":['MIPDILI']},
{"Somalogic Inc, Boulder, United States":['BIGDATAHEART', 'LITMUS']},
{"Sorbonne Universite, Paris, France":['EMIF', 'LITMUS', 'RESPIRINTM', 'RESPIRITB']},
{"Spark Therapeutics, Inc, Philadelphia, United States":['ARDAT']},
{"Spero Europe Limited, Godalming, Surrey, United Kingdom":['ENABLE']},
{"Spms - Servicos Partilhados Do Ministerio Da Saude Epe, Lisboa, Portugal":['GRAVITATEHEALTH']},
{"Spomincica Alzheimer Slovenija Slovensko Zdruzenje Za Pomoc Pri Demenci, Ljubljana, Slovenia":['MOPEAD']},
{"Springworks Therapeutics Inc, Stamford, United States":['EUPEARL']},
{"Srdc Yazilim Arastirma Ve Gelistirme Ve Danismanlik Ticaret Anonim Sirketi, Ankara, Turkey":['WEBRADR']},
{"St GeorgeS Hospital Medical School, London, United Kingdom":['BIOVACSAFE', 'COMBACTECARE', 'CONCEPTION', 'ENABLE', 'PREDICTTB']},
{"St. Anna Kinderkrebsforschung, Vienna, Austria":['ITCCP4']},
{"Starlab Barcelona SL, Barcelona, Spain":['AIMS2TRIALS']},
{"Statens Legemiddelverk, Oslo, Norway":['DOIT', 'GRAVITATEHEALTH']},
{"Statens Serum Institut, Copenhagen S, Denmark":['ADVANCE', 'BIOVACSAFE', 'COMBINE', 'EBOLAMODRAD', 'ENABLE', 'RESCEU', 'VITAL']},
{"Statens Veterinaermedicinska Anstalt, Uppsala, Sweden":['MADCOV_2']},
{"Steinbeisser Project Management Ug (Haftungsbeschrankt), Munich, Germany":['PREFER']},
{"Stellenbosch University, Stellenbosch, South Africa":['AIMS2TRIALS']},
{"Stemcell Technologies Uk LTD, Cambridge, United Kingdom":['MADCOV_2']},
{"Stichting Biomedical Primate Research Center, Rijswijk, Netherlands":['FLUCOP', 'VAC2VAC']},
{"Stichting Buro Ecnp, Utrecht, Netherlands":['AIMS2TRIALS', 'EQIPD', 'PRISM']},
{"Stichting Dtl Projects, Nijmegen, Netherlands":['OPEN_PHACTS']},
{"Stichting Entis (European Network Teratology Information Services) Foundation, Hertogenbosch, Netherlands":['CONCEPTION']},
{"Stichting European Urological Foundation, Arnhem, Netherlands":['PIONEER']},
{"Stichting Hogeschool Utrecht, Utrecht, Netherlands":['VAC2VAC']},
{"Stichting Imec Nederland, Eindhoven, Netherlands":['RADARCNS']},
{"Stichting Integraal Kankercentrum Nederland, Utrecht, Netherlands":['H2O']},
{"Stichting International Painful Bladder Foundation, Naarden, Netherlands":['IMIPAINCARE']},
{"Stichting Katholieke Universiteit, Nijmegen, Netherlands":['AIMS2TRIALS', 'AMYPAD', 'BIOMAP', 'BTCURE', 'C4C', 'COMBACTEMAGNET', 'DRIVEAB', 'ELF', 'EPAD', 'EQIPD', 'EUAIMS', 'HYPORESOLVE', 'IMMUNIVERSE', 'INNODIA', 'INNODIA_HARVEST', 'IPIE', 'MACUSTAR', 'PDMITOQUANT', 'PERISCOPE', 'PIONEER', 'PREDECT', 'PREMIER', 'PRISM', 'QUICCONCEPT', 'TRISTAN']},
{"Stichting Lareb, s Hertogenbosch, Netherlands":['CONCEPTION', 'WEBRADR', 'WEBRADR_2']},
{"Stichting Lygature, Utrecht, Netherlands":['ADAPTSMART', 'APPROACH', 'ELF', 'ESCULAB', 'FAIRPLUS', 'GNA_NOW', 'IMMUNEIMAGE', 'K4DD', 'PDMIND', 'PHARMATRAIN', 'RADARAD', 'RADARCNS', 'SAFESCIMET', 'TRIALSHOME']},
{"Stichting Maastricht Radiation Oncology Maastro Clinic, Maastricht, Netherlands":['QUICCONCEPT']},
{"Stichting Mlc Foundation, Den Haag, Netherlands":['BIGDATAHEART', 'IDEAFAST', 'TRIALSHOME']},
{"Stichting Nationaal Reumafonds, Amsterdam, Netherlands":['APPROACH']},
{"Stichting Netherlands Heart Institute, Utrecht, Netherlands":['CARDIATEAM']},
{"Stichting Sanquin Bloedvoorziening, Amsterdam, Netherlands":['COVIDRED']},
{"Stichting United Parent Projects Muscular Dystrophy, Veenendaal, Netherlands":['TRIALSHOME']},
{"Stichting Vu, Amsterdam, Netherlands":['CHEM21', 'ELF', 'ENABLE', 'ETOX', 'K4DD', 'MIPDILI', 'OPEN_PHACTS', 'PARADIGM', 'PHARMACOG', 'SAFESCIMET']},
{"Stichting Vumc, Amsterdam, Netherlands":['3TR', 'AMYPAD', 'CARDIATEAM', 'DIRECT', 'EMIF', 'EPAD', 'HARMONY', 'HARMONY_PLUS', 'IM2PACT', 'IMMUNEIMAGE', 'IMPENTRI', 'MOPEAD', 'PREDICTTB', 'PRISM', 'QUICCONCEPT', 'RADARAD', 'RADARCNS', 'RHAPSODY', 'STOPFOP']},
{"Stichting Wageningen Research, Wageningen, Netherlands":['ZAPI']},
{"Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden":['EHDEN', 'PROTECT', 'WEBRADR', 'WEBRADR_2']},
{"Stiftung Eln Foundation, Weinheim, Germany":['HARMONY', 'HARMONY_PLUS']},
{"Stiftung Tieraerztliche Hochschule Hannover, Hannover, Germany":['CARE', 'IM2PACT', 'ZAPI']},
{"Stockholms Universitet, Stockholm, Sweden":['COMPACT', 'EBOLAMODRAD', 'ONCO_TRACK', 'RAPPID']},
{"Streetlab, Paris, France":['MACUSTAR']},
{"Structural Genomics Consortium Lbg, London, United Kingdom":['EUBOPEN', 'ULTRADD']},
{"Substra, Nantes, France":['MELLODDY']},
{"Svanholm.Com Aps, Vordingborg, Denmark":['ICONSENSUS']},
{"Sveuciliste U Rijeci, Medicinski Fakultet, Rijeka, Croatia":['DRIVEAB']},
{"Swansea University, Swansea, United Kingdom":['CONCEPTION']},
{"Swiss Clinical Trial Organisation, Basel, Switzerland":['C4C']},
{"Swissmedic, Berne, Switzerland":['PHARMATRAIN']},
{"Syddansk Universitet, Odense, Denmark":['EUROPAIN', 'HYPORESOLVE', 'TRIALSHOME']},
{"Sygnature Discovery Limited, Nottingham, United Kingdom":['ELF', 'ESCULAB']},
{"Synairgen Research Ltd, Southampton, United Kingdom":['UBIOPRED']},
{"Synapse Research Management Partners SL, Barcelona, Spain":['ADVANCE', 'AMYPAD', 'DRIVE', 'EHDEN', 'EMIF', 'EPAD', 'ERA4TB', 'ETOX', 'ETRANSAFE', 'HARMONY', 'HARMONY_PLUS', 'IPIE', 'NEURONET', 'ROADMAP', 'TRANSBIOLINE', 'TRANSQST']},
{"Synaptologics BV, Amsterdam, Netherlands":['EQIPD']},
{"Synchrotron Soleil Societe Civile, GIF-sur-YVETTE CEDEX, France":['TRANSLOCATION']},
{"Syncom BV, Groningen, Netherlands":['ELF', 'ESCULAB']},
{"Synergist Services, Bruxelles, Belgium":['CONCEPTION', 'GRAVITATEHEALTH', 'PARADIGM']},
{"Synthon Biopharmaceuticals BV, Nijmegen, Netherlands":['ICONSENSUS']},
{"Synvaccine LTD, Tel Aviv, Israel":['ARDAT']},
{"Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag, Budapest, Hungary":['VITAL']},
{"Szegedi Tudomanyegyetem, Szeged, Hungary":['PRECISESADS']},
{"T-Curx GMBH, Wurzburg, Germany":['IMSAVAR']},
{"T1d Exchange Inc, Boston, United States":['SOPHIA']},
{"Takara Bio Europe AB, Göteborg, Sweden":['MIPDILI']},
{"Takeda Development Centre Europe LTD, London, United Kingdom":['3TR', 'EBISC2', 'GETREAL', 'PREFER', 'PRISM', 'PROTECT', 'ROADMAP', 'SAFET']},
{"Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland":['ADVANCE', 'ARDAT', 'CARE', 'CONCEPTION', 'COVIDRED', 'DDMORE', 'EPAD', 'EUBOPEN', 'GETREAL_INITIATIVE', 'H2O', 'HARMONY', 'IDEAFAST', 'IMMUNEIMAGE', 'LITMUS', 'MOBILISED', 'NEURONET', 'RADARAD', 'TRIALSHOME']},
{"Takis SRL, Roma, Italy":['ARDAT']},
{"Tamirna GMBH, Vienna, Austria":['TRANSBIOLINE']},
{"Tampereen Korkeakoulusaatio Sr, Tampere, Finland":['ADVANCE', 'BIOMAP', 'PIONEER']},
{"Tampereen Yliopisto, Tampere, Finland":['BIOMAP', 'PIONEER']},
{"Tandvards-Och Lakemedelsformansverket, Stockholm, Sweden":['DOIT']},
{"Taros Chemicals GMBH & Co Kg, Dortmund, Germany":['ELF', 'ESCULAB']},
{"Tartu Ulikool, Tartu, Estonia":['BIOMAP', 'C4C', 'EHDEN', 'EMIF', 'PREDECT']},
{"Tataa Biocenter AB, Göteborg, Sweden":['CANCERID']},
{"Tayside Health Board, Dundee, United Kingdom":['IABC']},
{"Team - It Research SL, Barcelona, Spain":['EUPEARL', 'H2O', 'PARADIGM', 'PREMIER', 'RESCEU']},
{"Technische Universitaet Dresden, Dresden, Germany":['3TR', 'IMIDIA', 'INNODIA', 'INNODIA_HARVEST', 'ONCO_TRACK', 'PDMIND', 'PIONEER', 'RHAPSODY']},
{"Technische Universitaet Graz, Graz, Austria":['CHEM21']},
{"Technische Universitaet Muenchen, Muenchen, Germany":['BIOMAP']},
{"Technovative Solutions LTD, Manchester, United Kingdom":['PHARMALEDGER']},
{"Teknologian Tutkimuskeskus Vtt Oy, Espoo, Finland":['EMIF', 'IDEAFAST']},
{"Tel Aviv University, Tel Aviv, Israel":['COMBACTEMAGNET', 'STEMBANCC']},
{"Terumo Bct Europe Nv, Lakewood, United States":['CANCERID']},
{"Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland":['CONCEPTION', 'DRIVE', 'SUMMIT']},
{"Teva Pharmaceutical Industries Limited, Netanya, Israel":['AIMS2TRIALS', 'CONCEPTION', 'EQIPD', 'EUPEARL', 'IMIPAINCARE', 'MOBILISED', 'PDMITOQUANT', 'TRIALSHOME']},
{"Teva Pharmaceuticals Europe B.V., Amsterdam, Netherlands":['IPIE']},
{"The Association Of The British Pharmaceutical Industry, London, United Kingdom":['DOIT', 'PARADIGM']},
{"The Brigham And WomenS Hospital Inc, Boston, United States":['STOPFOP']},
{"The Cyprus Foundation For Muscular Dystrophy Research, Nicosia, Cyprus":['PRECISESADS']},
{"The Ecancer Global Foundation, Bristol, United Kingdom":['PIONEER']},
{"The Employers Union of Innovative Pharmaceutical Companies INFARMA (Związek Pracodawców Innowacyjnych Firm Farmaceutycznych), Warsaw, Poland":['EUPATI']},
{"The European Association For The Study Of Obesity - Ireland Company Limited By Guarantee, Dublin, Ireland":['SOPHIA']},
{"The European Institute For Innovation Through Health Data, Gent, Belgium":['CONCEPTION', 'EUPEARL', 'GRAVITATEHEALTH', 'H2O']},
{"The European Medicines Agency, Canary Wharf, London, United Kingdom":['ADAPTSMART', 'ADVANCE', 'CONCEPTION', 'EU2P', 'FLUCOP', 'GETREAL', 'PREMIER', 'PROTECT', 'WEBRADR']},
{"The European Multiple Sclerosis Platform Aisbl, Brussels, Belgium":['DOIT']},
{"The Faculty Of Pharmaceutical Medicine Of The Royal Colleges Of Physicians Of The United Kingdom Lbg, London, United Kingdom":['PHARMATRAIN']},
{"The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv, Tel Aviv, Israel":['COMBACTECARE', 'COMBACTENET', 'DRIVEAB', 'MOBILISED', 'SAFET']},
{"The Governing Council Of The University Of Toronto, Toronto, Canada":['EUBOPEN', 'ULTRADD']},
{"The Health Corporation - Rambam, Haifa, Israel":['ABIRISK', 'COMBACTECARE', 'VALUEDX']},
{"The Hebrew University Of Jerusalem, Jerusalem, Israel":['STEMBANCC']},
{"The Hyve BV, Utrecht, Netherlands":['BIGDATAHEART', 'EHDEN', 'FAIRPLUS', 'H2O', 'PIONEER', 'RADARAD', 'RADARCNS', 'TRANSLOCATION']},
{"The Institute Of Cancer Research: Royal Cancer Hospital, London, United Kingdom":['ITCCP4', 'QUICCONCEPT']},
{"The International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use, Geneve, Switzerland":['WEBRADR_2']},
{"The Leeds Teaching Hospitals National Health Service Trust, Leeds, United Kingdom":['BEATDKD', 'TRISTAN']},
{"The Leona M. And Harry B. Helmsley Charitable Trust, New York, United States":['HYPORESOLVE', 'INNODIA', 'INNODIA_HARVEST']},
{"The Lymphoma Study Association, Pierre Benite, France":['HARMONY', 'HARMONY_PLUS']},
{"The Medical Cloud Company, Liege, Belgium":['DRAGON']},
{"The Medicines Company, Parsippany, United States":['COMBACTENET']},
{"The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-Upon-Tyne, United Kingdom":['CONCEPTION', 'MOBILISED']},
{"The Open University, Milton Keynes, United Kingdom":['ADVANCE', 'IM2PACT']},
{"The QueenS University Of Belfast, Belfast, United Kingdom":['3TR', 'CARDIATEAM', 'IABC']},
{"The Research Network Ltd., Sandwch, United Kingdom":['ENABLE']},
{"The Rosalind Franklin Institute, Didcot, United Kingdom":['ARDAT']},
{"The Royal College Of General Practitioners, London, United Kingdom":['ADVANCE']},
{"The Royal Institute Of International Affairs, London, United Kingdom":['DRIVEAB']},
{"The Royal National Orthopaedic Hospital National Health Service Trust, Stanmore, United Kingdom":['STOPFOP']},
{"The Royal Society Of Chemistry, Cambridge, United Kingdom":['OPEN_PHACTS']},
{"The Simons Foundation, Inc, New  York, United States":['AIMS2TRIALS']},
{"The Synergist, Bruxelles, Belgium":['CONCEPTION', 'GRAVITATEHEALTH', 'PARADIGM']},
{"The Trustees Of Boston University, Boston Ma, United States":['VALUEDX']},
{"The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom":['EQIPD', 'PIONEER']},
{"The University Court Of The University Of St Andrews, St Andrews, Fife, United Kingdom":['PREDICTTB', 'TRANSLOCATION']},
{"The University Of Birmingham, Birmingham, United Kingdom":['BIGDATAHEART', 'IMMUCAN', 'LITMUS', 'NECESSITY', 'PREFER', 'RTCURE', 'STEMBANCC']},
{"The University Of Edinburgh, Edinburgh, United Kingdom":['AIMS2TRIALS', 'AMYPAD', 'CARE', 'EBISC', 'EHR4CR', 'EPAD', 'EQIPD', 'HYPORESOLVE', 'IABC', 'IMIPAINCARE', 'MARCAR', 'PROACTIVE', 'RESCEU', 'ROADMAP', 'STEMBANCC', 'SUMMIT', 'VALUEDX']},
{"The University Of Exeter, Exeter, United Kingdom":['BEATDKD', 'DIRECT', 'EMIF', 'INNODIA', 'INNODIA_HARVEST', 'IPIE', 'PDMIND', 'PHARMACOG', 'PREMIER', 'PRISM', 'SOPHIA', 'SUMMIT']},
{"The University Of Hertfordshire Higher Education Corporation, Hatfield. Hertfordshire, United Kingdom":['EU2P']},
{"The University Of Liverpool, Liverpool, United Kingdom":['ARDAT', 'C4C', 'COMBACTEMAGNET', 'DOIT', 'DRAGON', 'GNA_NOW', 'MIPDILI', 'PREDICTTB', 'RESOLUTE', 'SAFESCIMET', 'SAFET', 'TRANSBIOLINE', 'TRANSQST', 'WEBRADR']},
{"The University Of Manchester, Manchester, United Kingdom":['3TR', 'BTCURE', 'CANCERID', 'CHEM21', 'CONCEPTION', 'EHR4CR', 'EMIF', 'EMTRAIN', 'EUPATI', 'EUPEARL', 'FAIRPLUS', 'GETREAL', 'IDEAFAST', 'NEWMEDS', 'OPEN_PHACTS', 'ORBITO', 'QUICCONCEPT', 'TRISTAN', 'UBIOPRED']},
{"The University Of North Carolina At Chapel Hill, Chapel Hill, United States":['EUBOPEN']},
{"The University Of Nottingham, Nottingham, United Kingdom":['ELF', 'K4DD', 'LITMUS', 'RADARCNS', 'TRANSBIOLINE', 'UBIOPRED']},
{"The University Of Queensland, St Lucia, Australia":['RTCURE']},
{"The University Of Sheffield, Sheffield, United Kingdom":['ARDAT', 'HYPORESOLVE', 'IM2PACT', 'MACUSTAR', 'MOBILISED', 'TRISTAN']},
{"The University Of Stirling, Stirling, United Kingdom":['EBOLAMODRAD', 'VHFMODRAD']},
{"The University Of Sussex, Brighton, United Kingdom":['PREDICTTB']},
{"The Wellcome Trust Limited, London, United Kingdom":['VALUEDX']},
{"Third-I, Vilvoorde, Belgium":['SOPHIA']},
{"Thirona BV, Nijmegen, Netherlands":['DRAGON']},
{"Thorax Research Foundation, Kolonaki, Athens Greece, Greece":['PROACTIVE']},
{"Tmf - Technologie Und Methodenplattform Fur Die Vernetzte Medizinische Forschung Ev, Berlin, Germany":['DOIT', 'EHR4CR', 'IDEAFAST']},
{"Tno Triskelion BV, Zeist, Netherlands":['ORBITO']},
{"Topmd Precision Medicine LTD, Southampton, United Kingdom":['DRAGON']},
{"TranScrip Partners LLP, Reading, United Kingdom":['COMBACTEMAGNET']},
{"Transgene SA, Illkirch-Graffenstaden, France":['IMSAVAR']},
{"Trial Nation, Copenhagen, Denmark":['H2O']},
{"Trifork Public As, Aarhus C, Denmark":['GRAVITATEHEALTH']},
{"Trinity College Dublin, Dublin, Ireland":['AIMS2TRIALS', 'BIOMAP', 'GRAVITATEHEALTH', 'PERISCOPE', 'PHARMATRAIN']},
{"Truly Labs AB, Lund, Sweden":['TRISTAN']},
{"Ttopstart BV, Bilthoven, Netherlands":['CONCEPTION', 'IMMUNEIMAGE', 'PIONEER']},
{"Twincore, Zentrum Fur Experimentelle Und Klinische Infektionsforschunggmbh, Hannover, Germany":['COMBACTENET']},
{"UCB Biopharma SRL, Brussels, Belgium":['ADAPTSMART', 'AETIONOMY', 'AIMS2TRIALS', 'BIOMAP', 'BTCURE', 'C4C', 'CONCEPTION', 'DOIT', 'EBISC', 'EBISC2', 'EFOEUPATI', 'EHDEN', 'EMIF', 'EMTRAIN', 'EPAD', 'EQIPD', 'ESCULAB', 'EUPATI', 'GETREAL_INITIATIVE', 'GRAVITATEHEALTH', 'ICONSENSUS', 'IDEAFAST', 'MIPDILI', 'NEURODERISK', 'PARADIGM', 'PDMITOQUANT', 'PHARMALEDGER', 'PRECISESADS', 'RADARCNS', 'RTCURE', 'SAFESCIMET', 'TRIALSHOME', 'WEBRADR']},
{"UCB Pharma SA, Brussels, Belgium":['ABIRISK', 'DDMORE', 'ELF', 'ETOX', 'EU2P', 'EUROPAIN', 'MARCAR', 'PHARMACOG', 'PHARMATRAIN', 'PROACTIVE', 'UBIOPRED']},
{"UNIVERSITAET zu LUEBECK, Luebeck, Germany":['CARE', 'EMIF', 'STEMBANCC']},
{"Umea Universitet, Umea, Sweden":['UBIOPRED']},
{"Umweltbundesamt, Dessau-Roßlau, Germany":['IPIE']},
{"United Kingdom Research And Innovation, Swindon, United Kingdom":['IMPRIND']},
{"Unitio Inc, Boston, United States":['HYPORESOLVE']},
{"Univercell Biosolutions SAS, Toulouse, France":['INNODIA', 'INNODIA_HARVEST', 'STEMBANCC']},
{"Universidad Autonoma De Barcelona, Bellaterra, Spain":['PHARMATRAIN']},
{"Universidad Autonoma De Madrid, Madrid, Spain":['IDEAFAST']},
{"Universidad Carlos Iii De Madrid, Getafe (Madrid), Spain":['ERA4TB', 'PREDICTTB']},
{"Universidad De Granada, Granada, Spain":['PRECISESADS']},
{"Universidad De La Rioja, Logrono, Spain":['VALUEDX']},
{"Universidad De Malaga, Malaga, Spain":['SAFET', 'TRANSBIOLINE']},
{"Universidad De Murcia, Murcia, Spain":['PHARMACOG']},
{"Universidad De Navarra, Pamplona, Spain":['DDMORE', 'HARMONY', 'HARMONY_PLUS', 'IMIPAINCARE', 'SOPHIA']},
{"Universidad De Salamanca, Salamanca, Spain":['AIMS2TRIALS', 'PERISCOPE', 'TRANSBIOLINE']},
{"Universidad De Santiago De Compostela, Santiago de Compostela, Spain":['OPEN_PHACTS']},
{"Universidad De Zaragoza, Zaragoza, Spain":['ERA4TB']},
{"Universidad Politecnica De Madrid, Madrid, Spain":['GRAVITATEHEALTH', 'PHARMALEDGER']},
{"Universidad Pompeu Fabra, Barcelona, Spain":['EMIF', 'ETOX', 'ETRANSAFE', 'IPIE', 'OPEN_PHACTS', 'PHARMATRAIN']},
{"Universidade De Aveiro, Aveiro, Portugal":['EHDEN', 'EMIF']},
{"Universidade De Coimbra, Coimbra, Portugal":['AIMS2TRIALS']},
{"Universidade De Sao Paulo, São Paulo, Brazil":['VSVEBOPLUS']},
{"Universidade Nova De Lisboa, Lisboa, Portugal":['MACUSTAR']},
{"Universita Campus Bio Medico Di Roma, Rome, Italy":['EUAIMS']},
{"Universita Cattolica Del Sacro Cuore, Milan, Italy":['GRAVITATEHEALTH', 'LITMUS', 'PHARMACOG', 'PHARMATRAIN', 'SOPHIA', 'SPRINTT', 'SUMMIT', 'UBIOPRED']},
{"Universita Commerciale Luigi Bocconi, Milan, Italy":['DOIT']},
{"Universita Degli Studi Del Piemonte Orientale Amedeo Avogadro, Vercelli, Italy":['3TR']},
{"Universita Degli Studi Di Bari Aldo Moro, Bari, Italy":['BEATDKD']},
{"Universita Degli Studi Di Bergamo, Bergamo, Italy":['RADARCNS']},
{"Universita Degli Studi Di Brescia, Brescia, Italy":['IDEAFAST']},
{"Universita Degli Studi Di Cagliari, Cagliari, Italy":['3TR', 'C4C', 'TRANSLOCATION']},
{"Universita Degli Studi Di Catania, Catania, Italy":['3TR', 'UBIOPRED']},
{"Universita Degli Studi Di Ferrara, Ferrara, Italy":['CONCEPTION', 'VITAL']},
{"Universita Degli Studi Di Firenze, Florence, Italy":['ABIRISK', 'DRAGON', 'DRIVE', 'LITMUS', 'NEURODERISK', 'SPRINTT', 'SUMMIT']},
{"Universita Degli Studi Di Foggia, Foggia , Italy":['PHARMACOG']},
{"Universita Degli Studi Di Genova, Genova, Italy":['3TR', 'PHARMACOG']},
{"Universita Degli Studi Di Milano, Milano, Italy":['EUPEARL', 'IABC', 'LITMUS', 'PRECISESADS']},
{"Universita Degli Studi Di Modena E Reggio Emilia, Modena, Italy":['IM2PACT']},
{"Universita Degli Studi Di Padova, Padova, Italy":['C4C', 'ERA4TB', 'HYPORESOLVE', 'SUMMIT']},
{"Universita Degli Studi Di Palermo, Palermo, Italy":['LITMUS']},
{"Universita Degli Studi Di Parma, Parma, Italy":['DRAGON', 'FLUCOP', 'SPRINTT']},
{"Universita Degli Studi Di Pavia, Pavia, Italy":['DDMORE', 'ERA4TB', 'SUMMIT']},
{"Universita Degli Studi Di Perugia, Perugia, Italy":['PHARMACOG']},
{"Universita Degli Studi Di Roma La Sapienza, Roma, Italy":['IMIPAINCARE']},
{"Universita Degli Studi Di Roma Tor Vergata, Rome, Italy":['C4C', 'HARMONY', 'SOPHIA', 'UBIOPRED']},
{"Universita Degli Studi Di Sassari, Sassari, Italy":['MOBILISED']},
{"Universita Degli Studi Di Siena, Siena, Italy":['BIOVACSAFE', 'FLUCOP', 'INNODIA', 'INNODIA_HARVEST', 'VSVEBOPLUS', 'VSVEBOVAC']},
{"Universita Degli Studi Di Torino, Turin, Italy":['CANCERID', 'CARDIATEAM', 'HARMONY', 'HARMONY_PLUS', 'LITMUS']},
{"Universita Degli Studi Di Udine, Udine, Italy":['NECESSITY']},
{"Universita Degli Studi Di Verona, Verona, Italy":['COMBACTEMAGNET', 'COMBACTENET', 'EU2P', 'PHARMACOG', 'VALUEDX']},
{"Universita Degli Studi Gabriele DAnnunzio Di Chieti-Pescara, Chieti, Italy":['INNODIA', 'INNODIA_HARVEST', 'PDMIND']},
{"Universita Di Pisa, Pisa, Italy":['3TR', 'EMIF', 'IMIDIA', 'INNODIA', 'INNODIA_HARVEST', 'RHAPSODY', 'SUMMIT']},
{"Universita Vita-Salute San Raffaele, Milano, Italy":['EUPEARL', 'H2O', 'INNODIA', 'INNODIA_HARVEST', 'MOBILISED', 'PIONEER', 'RADARCNS']},
{"Universitaet Augsburg, Augsburg, Germany":['RADARCNS']},
{"Universitaet Bern, Bern, Switzerland":['EQIPD', 'GETREAL', 'LITMUS', 'UBIOPRED']},
{"Universitaet Duisburg-Essen, Essen, Germany":['ELF']},
{"Universitaet Graz, Graz, Austria":['CHEM21']},
{"Universitaet Greifswald, Greifswald, Germany":['COMBACTENET', 'ORBITO']},
{"Universitaet Hamburg, Hamburg, Germany":['CARE', 'OPEN_PHACTS']},
{"Universitaet Hohenheim, Stuttgart, Germany":['ICONSENSUS']},
{"Universitaet Innsbruck, Innsbruck, Austria":['VITAL']},
{"Universitaet Leipzig, Leipzig, Germany":['CONCEPTION', 'EMIF', 'IMSAVAR', 'PHARMACOG', 'SAFET']},
{"Universitaet Stuttgart, Stuttgart, Germany":['CHEM21']},
{"Universitaet Ulm, Ulm, Germany":['AIMS2TRIALS', 'COMBACTECARE', 'COMBACTEMAGNET', 'DIRECT', 'EUAIMS', 'HARMONY', 'HARMONY_PLUS', 'INNODIA', 'INNODIA_HARVEST', 'SOPHIA']},
{"Universitaetsklinikum Aachen, Aachen, Germany":['CARDIATEAM', 'LITMUS', 'SAFET']},
{"Universitaetsklinikum Essen, Essen, Germany":['PHARMACOG', 'PHARMATRAIN']},
{"Universitaetsklinikum Freiburg, Freiburg, Germany":['BEATDKD', 'COMBACTECARE', 'COMBACTEMAGNET', 'COMBACTENET', 'PHARMATRAIN', 'RADARCNS', 'TRANSLOCATION']},
{"Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany":['BEATDKD', 'BIGDATAHEART', 'BIOMAP', 'CANCERID', 'PIONEER']},
{"Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany":['IM2PACT', 'IMSAVAR', 'LITMUS', 'PHARMALEDGER']},
{"Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany":['EQIPD', 'IM2PACT', 'LITMUS', 'ORBITO']},
{"Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts, Goettingen, Germany":['AIMS2TRIALS', 'IMPRIND', 'SPRINTT']},
{"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands":['AIMS2TRIALS', 'APPROACH', 'BIGDATAHEART', 'CARDIATEAM', 'COMBACTECARE', 'COMBACTECDI', 'COMBACTEMAGNET', 'COMBACTENET', 'CONCEPTION', 'COVIDRED', 'EUAIMS', 'GETREAL', 'GETREAL_INITIATIVE', 'IABC', 'LITMUS', 'NECESSITY', 'PREFER', 'PRISM', 'RESCEU', 'TRIALSHOME', 'VALUEDX', 'VITAL']},
{"Universitair Ziekenhuis Antwerpen, Edegem, Belgium":['COMBACTENET', 'IABC', 'LITMUS', 'QUICCONCEPT', 'RAPPID', 'VALUEDX']},
{"Universitair Ziekenhuis Gent, Gent, Belgium":['3TR', 'BIOVACSAFE']},
{"Universitat Basel, Basel, Switzerland":['3TR', 'ADVANCE', 'AIMS2TRIALS', 'EUAIMS', 'PERISCOPE', 'PHARMATRAIN', 'TRANSLOCATION']},
{"Universitat De Barcelona, Barcelona, Spain":['ENABLE', 'PHARMATRAIN']},
{"Universitat Konstanz, Konstanz, Germany":['SAFESCIMET']},
{"Universitat Politecnica De Valencia, Valencia, Spain":['ETOX']},
{"Universitat Wien, Vienna, Austria":['BIOMAP', 'COMPACT', 'ETOX', 'ETRANSAFE', 'K4DD', 'NEURODERISK', 'OPEN_PHACTS', 'PHARMATRAIN', 'RESOLUTE', 'SAFESCIMET', 'TRANSQST']},
{"Universitat Zurich, Zürich, Switzerland":['BTCURE', 'COMBACTEMAGNET', 'COMBACTENET', 'COMPACT', 'ENABLE', 'IMMUCAN', 'ITCCP4', 'MOBILISED', 'PROACTIVE', 'TRANSBIOLINE']},
{"Universitats-Kinderspital Beider Basel, Basel, Switzerland":['ADVANCE', 'PERISCOPE']},
{"Universitatsklinikum Bonn, Bonn, Germany":['ABIRISK', 'ADAPTED', 'AETIONOMY', 'EBISC', 'MACUSTAR', 'PHAGO', 'ZAPI']},
{"Universitatsklinikum Erlangen, Erlangen, Germany":['APPROACH', 'BEATDKD', 'BTCURE', 'EMIF', 'MOBILISED', 'PREFER', 'RTCURE']},
{"Universitatsklinikum Heidelberg, Heidelberg, Germany":['ARDAT', 'C4C', 'CARDIATEAM', 'TRANSQST']},
{"Universitatsklinikum Schleswig-Holstein, Lübeck, Germany":['EMIF', 'EUROPAIN', 'IDEAFAST', 'STEMBANCC']},
{"Universitatsspital Basel, Basel, Switzerland":['3TR', 'ABIRISK']},
{"Universite Catholique De Louvain, Louvain-La-Neuve, Belgium":['IMIPAINCARE', 'PRECISESADS']},
{"Universite Clermont Auvergne, Clermont-Ferrand, France":['NEURODERISK']},
{"Universite DAbomey-Calavi, Cotonou, Benin":['PEVIA']},
{"Universite DAix Marseille, Marseille, France":['AETIONOMY', 'CARDIATEAM', 'CARE', 'EBOLAMODRAD', 'KRONO', 'PHARMACOG', 'TRANSLOCATION', 'UBIOPRED', 'VHFMODRAD', 'ZAPI']},
{"Universite DAngers, Angers, France":['LITMUS']},
{"Universite De Bordeaux, Bordeaux, France":['CARE', 'EBOVAC1', 'EBOVAC2', 'EBOVAC3', 'EU2P', 'IMPRIND']},
{"Universite De Bretagne Occidentale, Brest, France":['3TR', 'NECESSITY', 'PRECISESADS']},
{"Universite De Corse Pascal Paoli, Corte, France":['KRONO']},
{"Universite De Geneve, Genève 4, Switzerland":['AMYPAD', 'COMBACTECARE', 'COMBACTEMAGNET', 'COMBACTENET', 'DIRECT', 'DRIVEAB', 'EPAD', 'IMIDIA', 'PRECISESADS', 'RAPPID', 'STEMBANCC', 'TRANSLOCATION', 'VSVEBOPLUS', 'VSVEBOVAC']},
{"Universite De Kinshasa, Kinshasa, Congo (Democratic Republic of)":['EBOVAC3']},
{"Universite De Lausanne, Lausanne, Switzerland":['HYPORESOLVE', 'IMIDIA', 'INNODIA', 'INNODIA_HARVEST', 'RHAPSODY', 'STEMBANCC']},
{"Universite De Liege, Liège, Belgium":['ENABLE']},
{"Universite De Lille Ii - Droit Et Sante, Lille, France":['DIRECT', 'PHARMACOG']},
{"Universite De Lille, Lille, France":['RHAPSODY']},
{"Universite De Lorraine, Nancy Cedex, France":['DRIVEAB', 'SAFESCIMET']},
{"Universite De Mons, Mons, Belgium":['ICONSENSUS']},
{"Universite De Montpellier, Montpellier, France":['CANCERID']},
{"Universite De Paris, Paris, France":['EBOVAC3', 'NECESSITY', 'RHAPSODY']},
{"Universite De Poitiers, Poitiers , France":['ABDIRECT', 'COMBACTECARE', 'GNA_NOW', 'IABC']},
{"Universite De Rennes I, Rennes, France":['EHR4CR', 'MIPDILI']},
{"Universite De Technologie De Compiegne, Compiegne, France":['STEMBANCC']},
{"Universite De Tours, Tours - BP12050, France":['ABIRISK']},
{"Universite Dijon Bourgogne, Dijon, France":['TRISTAN']},
{"Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg":['AETIONOMY', 'BIOMAP', 'ETRIKS', 'FAIRPLUS', 'IMMUNIVERSE', 'IMSAVAR']},
{"Universite Jean Monnet Saint-Etienne, Saint Etienne Cedex 2, France":['VITAL']},
{"Universite Louis Pasteur, Strasbourg, France":['PHARMATRAIN']},
{"Universite Lyon 1 Claude Bernard, Villeurbanne, France":['COMBACTENET', 'DRIVE', 'PHARMATRAIN']},
{"Universite Paris Descartes, Paris , France":['SPRINTT']},
{"Universite Paris Diderot - Paris 7, Paris, France":['APPROACH', 'COMBACTEMAGNET', 'COMBACTENET', 'DDMORE', 'IMIDIA', 'RHAPSODY']},
{"Universite Paris Xii Val De Marne, Creteil cedex, France":['CARE', 'EBOVAC2']},
{"Universite Paris-Saclay, Saint Aubin, France":['3TR', 'IMMUNEIMAGE', 'NECESSITY']},
{"Universite Paris-Sud, Orsay, France":['ABIRISK', 'ONCO_TRACK', 'SAFESCIMET']},
{"Universite Paul Sabatier Toulouse Iii, Toulouse, France":['EMIF', 'FAIRPLUS', 'PHARMACOG']},
{"Universiteit Antwerpen, Antwerp, Belgium":['CHEM21', 'COMBACTECARE', 'COMBACTECDI', 'COMBACTEMAGNET', 'COMBACTENET', 'DRIVEAB', 'EBOVAC3', 'EMIF', 'IABC', 'RAPPID', 'RESCEU', 'RESPIRINTM', 'RESPIRITB', 'VALUEDX']},
{"Universiteit Gent, Gent, Belgium":['3TR', 'AIMS2TRIALS', 'BIOVACSAFE', 'C4C', 'COMPACT', 'FLUCOP', 'RAPPID', 'UBIOPRED']},
{"Universiteit Hasselt, Hasselt, Belgium":['3TR']},
{"Universiteit Leiden, Leiden, Netherlands":['ADAPTED', 'COMPACT', 'DDMORE', 'ELF', 'ETRANSAFE', 'K4DD', 'MIPDILI', 'RESOLUTE', 'RESPIRINTM', 'RESPIRITB', 'SAFESCIMET', 'TRANSBIOLINE', 'TRANSQST']},
{"Universiteit Maastricht, Maastricht, Netherlands":['DRAGON', 'EMIF', 'FAIRPLUS', 'OPEN_PHACTS', 'ROADMAP', 'SOPHIA', 'SPRINTT', 'TRANSQST']},
{"Universiteit Twente, Enschede, Netherlands":['CANCERID', 'IMSAVAR', 'RAPPID']},
{"Universiteit Utrecht, Utrecht, Netherlands":['BIOVACSAFE', 'CARE', 'COMPACT', 'EU2P', 'MIPDILI', 'PROTECT', 'TRIALSHOME', 'VAC2VAC', 'ZAPI']},
{"Universitetet I Bergen, P.O. Box 7800, Bergen, Norway":['3TR', 'FLUCOP', 'UBIOPRED']},
{"Universitetet I Oslo, Oslo, Norway":['CONCEPTION', 'GRAVITATEHEALTH', 'IMSAVAR']},
{"Universitetssykehuset Nord-Norge Hf, Tromso, Norway":['GRAVITATEHEALTH']},
{"University College Cork -  National University Of Ireland, Cork, Cork, Ireland":['C4C', 'IMIPAINCARE', 'NECESSITY', 'SOPHIA']},
{"University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland":['3TR', 'BTCURE', 'MOBILISED', 'SAFET', 'SOPHIA', 'TRANSLOCATION']},
{"University College London, London, United Kingdom":['3TR', 'ABIRISK', 'AMYPAD', 'ARDAT', 'BIGDATAHEART', 'C4C', 'COMBACTEMAGNET', 'COVIDRED', 'DDMORE', 'EBISC', 'EHR4CR', 'EMIF', 'EUROPAIN', 'MACUSTAR', 'ONCO_TRACK', 'PDMITOQUANT', 'PHAGO', 'PREDICTTB', 'STEMBANCC', 'VITAL', 'WEBRADR']},
{"University Hospital Of South Manchester Nhs Foundation Trust, Wythenshaw, United Kingdom":['UBIOPRED']},
{"University Hospitals Of Leicester Nhs Trust, Leicester, United Kingdom":['3TR']},
{"University Hospitals Southampton Nhs Foundation Trust, Southampton, United Kingdom":['UBIOPRED']},
{"University Of Bath, Bath, United Kingdom":['DIRECT', 'PERISCOPE']},
{"University Of Bristol, Bristol, United Kingdom":['AIMS2TRIALS', 'BEATDKD', 'BIOMAP']},
{"University Of Dundee, Dundee, United Kingdom":['BEATDKD', 'BIOMAP', 'CARDIATEAM', 'CARE', 'DIRECT', 'EHR4CR', 'ELF', 'ERA4TB', 'ESCULAB', 'EUBOPEN', 'HYPORESOLVE', 'IABC', 'IM2PACT', 'K4DD', 'MARCAR', 'RHAPSODY', 'SOPHIA', 'SUMMIT', 'TRIALSHOME']},
{"University Of Durham, Durham, United Kingdom":['CHEM21']},
{"University Of Glasgow, Glasgow, United Kingdom":['3TR', 'AIMS2TRIALS', 'BTCURE', 'EHR4CR', 'EMIF', 'IDEAFAST', 'RTCURE']},
{"University Of Hull, Hull, United Kingdom":['BEATDKD']},
{"University Of Kwazulu-Natal, Westville, South Africa":['CONCEPTION']},
{"University Of Leeds, Leeds, United Kingdom":['APPROACH', 'BEATDKD', 'BTCURE', 'CHEM21', 'COMBACTECDI', 'ELF', 'TRISTAN']},
{"University Of Leicester, Leicester, United Kingdom":['3TR', 'EMIF', 'EPAD', 'ETOX', 'GETREAL', 'PREDICTTB']},
{"University Of Limerick, Limerick, Ireland":['IDEAFAST']},
{"University Of Michigan The Regents Of The University Of Michigan, Ann Arbor, United States":['BEATDKD']},
{"University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom":['AIMS2TRIALS', 'APPROACH', 'C4C', 'DIRECT', 'EBISC', 'EUPEARL', 'HARMONY', 'HARMONY_PLUS', 'IDEAFAST', 'LITMUS', 'MOBILISED', 'NECESSITY', 'PHARMATRAIN', 'PREFER', 'PROTECT', 'RTCURE', 'STEMBANCC', 'TRANSBIOLINE', 'TRANSLOCATION']},
{"University Of Northumbria At Newcastle, Newcastle upon Tyne, United Kingdom":['MOBILISED']},
{"University Of Sierra Leone, Freetown, Sierra Leone":['EBOVAC1', 'EBOVAC3']},
{"University Of Southampton, Southampton, United Kingdom":['3TR', 'DRAGON', 'PERISCOPE', 'UBIOPRED']},
{"University Of Strathclyde, Glasgow, United Kingdom":['DRIVEAB', 'ORBITO']},
{"University Of Surrey, Guildford, United Kingdom":['ADVANCE', 'BIOVACSAFE', 'DRIVE', 'FLUCOP', 'PHARMATRAIN', 'SAFESCIMET']},
{"University Of The West Of England, Bristol, Bristol, United Kingdom":['COMBACTEMAGNET']},
{"University Of Ulster, Coleraine, United Kingdom":['CONCEPTION']},
{"University Of York, York, United Kingdom":['CHEM21', 'HARMONY', 'IPIE', 'PREMIER']},
{"University of Cambridge, Cambridge, United Kingdom":['3TR', 'AIMS2TRIALS', 'ARDAT', 'BIGDATAHEART', 'CANCERID', 'DRAGON', 'EMIF', 'EPAD', 'EUAIMS', 'HARMONY', 'HARMONY_PLUS', 'HYPORESOLVE', 'IDEAFAST', 'IMMUNEIMAGE', 'IMMUNIVERSE', 'IMPRIND', 'INNODIA', 'INNODIA_HARVEST', 'LITMUS', 'NEWMEDS', 'PHAGO', 'QUICCONCEPT', 'RAPPID', 'STEMBANCC', 'SUMMIT']},
{"University of Helsinki, University of Helsinki, Helsinki, Finland":['BEATDKD', 'COMPACT', 'EBOLAMODRAD', 'EMIF', 'ENABLE', 'HARMONY', 'HARMONY_PLUS', 'INNODIA', 'INNODIA_HARVEST', 'LITMUS', 'PREDECT', 'PREMIER', 'SPRINTT']},
{"University of Lisboa, Faculty of Pharmacy (Faculdade de Farmácia da Universidade de Lisboa), Lisboa, Portugal":['SAFESCIMET']},
{"University of Oxford, Oxford, United Kingdom":['ADAPTSMART', 'AIMS2TRIALS', 'ARDAT', 'BEATDKD', 'BTCURE', 'COMBACTEMAGNET', 'COMBACTENET', 'COMPACT', 'DIRECT', 'EBOVAC1', 'EBOVAC2', 'EHDEN', 'ELF', 'EMIF', 'EMTRAIN', 'ENABLE', 'EPAD', 'ESCULAB', 'ETRIKS', 'EUBOPEN', 'EUPEARL', 'EUROPAIN', 'FAIRPLUS', 'FLUCOP', 'IM2PACT', 'IMIPAINCARE', 'IMPRIND', 'INNODIA', 'INNODIA_HARVEST', 'K4DD', 'LITMUS', 'PARADIGM', 'PERISCOPE', 'RADARAD', 'RESCEU', 'RESOLUTE', 'RHAPSODY', 'ROADMAP', 'STEMBANCC', 'STOPFOP', 'SUMMIT', 'TRANSQST', 'TRIALSHOME', 'ULTRADD', 'VALUEDX', 'VSVEBOVAC']},
{"University of Turku, Turku, Finland":['BEATDKD', 'EBOLAMODRAD', 'INNODIA', 'INNODIA_HARVEST', 'PERISCOPE', 'SUMMIT']},
{"Universitätsklinikum Jena, Jena, Germany":['IMIPAINCARE', 'IMSAVAR']},
{"Université Libre de Bruxelles, Bruxelles, Belgium":['INNODIA', 'INNODIA_HARVEST', 'PERISCOPE', 'RHAPSODY']},
{"Universytet Medyczny W Lodzi., Lodz, Poland":['3TR']},
{"Univerza V Ljubljani, Ljubljana, Slovenia":['ENABLE', 'INNODIA', 'INNODIA_HARVEST']},
{"Univerzita Karlova, Prague 1, Czech Republic":['ABIRISK', 'C4C', 'SPRINTT']},
{"Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia":['MOPEAD']},
{"Uniwersytet Jagiellonski, Krakow, Poland":['CARE', 'SPRINTT', 'UBIOPRED']},
{"Uniwersytet Medyczny Im Karola Marcinkowskiego W Poznaniu, Poznan, Poland":['PROTECT']},
{"Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu, Wroclaw, Poland":['CONCEPTION']},
{"Uppsala Universitet, Uppsala, Sweden":['AIMS2TRIALS', 'BIGDATAHEART', 'BTCURE', 'COMBINE', 'CONCEPTION', 'DDMORE', 'DRIVEAB', 'ENABLE', 'ERA4TB', 'IM2PACT', 'NEURODERISK', 'ONCO_TRACK', 'ORBITO', 'PREDICTTB', 'PREFER', 'SAFESCIMET']},
{"Ursula Theuretzbacher, Vienna, Austria":['COMBACTEMAGNET', 'DRIVEAB']},
{"Varsinais-Suomen Sairaanhoitopiirin Kuntayhtyma, Turku, Finland":['BEATDKD', 'RESCEU']},
{"Vaxeal Research, Evry, France":['PEVIA']},
{"Verband Forschender Arzneimittelhersteller Ev, Berlin, Germany":['DOIT', 'EUPATI', 'PARADIGM']},
{"Vereniging Samenwerkende Ouder- En Patientenorganisaties, Soest, Netherlands":['EUPATI']},
{"Vestische Caritas Kliniken GMBH, Dattien, Germany":['EMIF']},
{"Vib Vzw, Zwijnaarde - Gent, Belgium":['3TR', 'EMIF', 'HARMONY', 'HARMONY_PLUS', 'IMMUNEIMAGE', 'IMMUNIVERSE', 'IMPRIND']},
{"Vibalogics GMBH, Cuxhaven, Germany":['EBOMAN']},
{"Vifor (International) AG, St. Gallen, Switzerland":['BIGDATAHEART', 'RESOLUTE']},
{"Vifor SA, Villars-sur-Glâne, Switzerland":['EUAIMS']},
{"Viroclinics Biosciences BV, Rotterdam, Netherlands":['ZAPI']},
{"Vironova AB, Stockholm, Sweden":['MADCOV_2']},
{"Viscofan SA, Tajonar, Spain":['ARDAT']},
{"Vismederi SRL, Siena, Italy":['BIOVACSAFE']},
{"Vital Transformation, Wezembeek Oppem, Belgium":['GETREAL_INITIATIVE', 'TRIALSHOME']},
{"Vive - Det Nationale Forsknings- Og Analysecenter For Velfaerd, Copenhagen, Denmark":['COVIDRED']},
{"Vrije Universiteit Brussel, Brussel, Belgium":['IMIDIA', 'IMMUNEIMAGE']},
{"Vseobecna Fakultni Nemocnice V Praze, Praha 2, Czechia":['C4C']},
{"VyCAP BV, Deventer, Netherlands":['CANCERID']},
{"Wageningen University, Wageningen, Netherlands":['DRIVEAB']},
{"Warszawski Uniwersytet Medyczny, Warsaw, Poland":['EHR4CR']},
{"Weizmann Institute Of Science, Rehovot, Israel":['IMMUCAN', 'PIONEER', 'PREDECT']},
{"Westfaelische Wilhelms-Universitaet Muenster, Münster, Germany":['EHR4CR', 'IMIPAINCARE', 'IMMUNEIMAGE', 'QUICCONCEPT']},
{"World Vision International, Monrovia Ca, United States":['EBODAC']},
{"World Vision Of Ireland Lbg, Rathmines Park, Ireland":['EBODAC']},
{"World Vision Sierra Leone, Freetown, Sierra Leone":['EBODAC']},
{"X-Chem Inc, Waltham, MA, United States":['EUBOPEN']},
{"Xclinical GMBH, Munich, Germany":['EHR4CR']},
{"Xentech SAS, Evry, France":['ITCCP4']},
{"Yelen, Ensues La Redonne, France":['TRANSLOCATION']},
{"Zebiai Therapeutics Inc, Wilmington, United States":['EUBOPEN']},
{"Zentralinstitut Fuer Seelische Gesundheit, Mannheim, Germany":['AIMS2TRIALS', 'EUAIMS', 'NEWMEDS']},
{"Zf-Screens BV, Leiden, Netherlands":['PREDICTTB']},
{"Zoetis Belgium SA, Louvain la Neuve, Belgium":['VAC2VAC']},
{"Zorginstituut Nederland, Diemen, Netherlands":['ADAPTSMART', 'GETREAL', 'GETREAL_INITIATIVE']},
{"Zorgonderzoek Nederland Zon, Den Haag, Netherlands":['VALUEDX']},
{"charnwood technical consulting ltd, quorn, United Kingdom":['CHEM21']},
{"eClinical Forum Association, Friesenheim, France":['EHR4CR']}
]

// web links data
var web_links = [{'id': '0', 'name': '3TR', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/3tr', 'summary': 'Many patients with autoimmune, inflammatory and allergic diseases do not respond well or at all to current treatments. A major challenge for researchers is to understand which patients are most likely to respond to which treatments. The aim of 3TR is to shed new light on the factors that determine whether or not a patient is likely to respond to a given treatment. 3TR will focus on seven diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, ulcerative colitis, Crohn’s disease, asthma, and chronic obstructive pulmonary disease (COPD). Despite their diverse symptoms, these diseases have some molecular patterns in common, suggesting that patients with different diseases may share some markers that predict the likelihood of treatment response and disease progression.\nThe project will analyse data and samples from 50 000 patients who took part in 50 clinical trials. They will also carry out a new clinical study that will take samples (of diseased tissue, blood, stool and other fluids) from patients before, during and after treatment. The project will add all of its data to a centralised data management platform that will make it easier to analyse using state-of-the-art methods. The samples collected and the knowledge base will be maintained beyond the end of the project to allow further research. The project will ultimately make it easier to provide the right treatment to the right patient, thereby increasing the proportion of patients taking a treatment that works for them.\n', 'tags': 'Identification of the molecular mechanisms of non-response to treatments, relapses and remission in autoimmune, inflammatory, and allergic conditions', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Academisch Ziekenhuis Groningen, Groningen, Netherlands;Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain;Agencia Publica Empresarial Sanitaria Hospital De Poniente, El Ejido Almeria, Spain;Alacris Theranostics GMBH, Berlin, Germany;Astrazeneca AB, Södertälje, Sweden;Atrys Health, SA, Madrid, Spain;Azienda Ospedale Universita Padova, Padova, Italy;Azienda Ospedaliero-Universitaria Anna Meyer, Firenze, Italy;Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom;Centre Hospitalier Regional Et Universitaire De Brest, Brest, France;Centre Hospitalier Regional Universitaire Nancy, Nancy Cedex, France;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany;Cliniques Universitaires Saint-Luc, Brussels, Belgium;Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain;Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain;Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany;Eurice European Research And Project Office GMBH, Saarbrücken, Germany;European Federation Of Asthma &Allergy Associations Ideell Forening, Brussels, Belgium;European Lung Foundation, Lausanne, Switzerland;European Respiratory Society, Lausanne, Switzerland;F. Hoffmann-La Roche AG, Basel, Switzerland;Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy;Fundacio Centre De Regulacio Genomica, Barcelona, Spain;Fundacion Para La Investigacion Biomedica De Cordoba, Cordoba, Spain;Fundacion Para La Investigacion Biomedica Del Hospital Universitario Clinico San Carlos, Madrid, Spain;Fundacion Para La Investigacion Biosanitaria De Andalucia Oriental-Alejandro Otero, Granada, Spain;Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud, Malaga, Spain;Fundacion Publica Andaluza Progreso Y Salud, Seville , Spain;Genos Doo Za Vjestacenje I Analizu, Osijek, Croatia;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Greater Glasgow Health Board, Glasgow, United Kingdom;Hospital Clinic De Barcelona, Barcelona, Spain;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Instituto De Medicina Molecular Joao Lobo Antunes, Lisboa, Portugal;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Katholieke Universiteit Leuven, Leuven, Belgium;Lupus Europe, Romford Essex, United Kingdom;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Medizinische Hochschule Hannover, Hannover, Germany;Novartis Pharma AG, Basel, Switzerland;Orebro University, Örebro, Sweden;Owlstone Medical Limited, Cambridge, United Kingdom;Pfizer Limited, Sandwich, Kent , United Kingdom;Philipps Universitaet Marburg, Marburg, Germany;Queen Mary University Of London, London, United Kingdom;Region Hovedstaden, Hilleroed, Denmark;Region Stockholm, Stockholm, Sweden;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Servicio Andaluz De Salud, Sevilla, Spain;Servicio Madrileno De Salud, Madrid, Spain;Sip Service S.R.L., Milano, Italy;Societe De Pneumologie De Langue Francaise, Paris 6, France;Stichting Vumc, Amsterdam, Netherlands;Takeda Development Centre Europe LTD, London, United Kingdom;Technische Universitaet Dresden, Dresden, Germany;The Queen'S University Of Belfast, Belfast, United Kingdom;The University Of Manchester, Manchester, United Kingdom;Universita Degli Studi Del Piemonte Orientale Amedeo Avogadro, Vercelli, Italy;Universita Degli Studi Di Cagliari, Cagliari, Italy;Universita Degli Studi Di Catania, Catania, Italy;Universita Degli Studi Di Genova, Genova, Italy;Universita Di Pisa, Pisa, Italy;Universitair Ziekenhuis Gent, Gent, Belgium;Universitat Basel, Basel, Switzerland;Universitatsspital Basel, Basel, Switzerland;Universite De Bretagne Occidentale, Brest, France;Universite Paris-Saclay, Saint Aubin, France;Universiteit Gent, Gent, Belgium;Universiteit Hasselt, Hasselt, Belgium;Universitetet I Bergen, P.O. Box 7800, Bergen, Norway;University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland;University College London, London, United Kingdom;University Hospitals Of Leicester Nhs Trust, Leicester, United Kingdom;University Of Glasgow, Glasgow, United Kingdom;University Of Leicester, Leicester, United Kingdom;University Of Southampton, Southampton, United Kingdom;University of Cambridge, Cambridge, United Kingdom;Universytet Medyczny W Lodzi., Lodz, Poland;Vib Vzw, Zwijnaarde - Gent, Belgium", 'status': 'Ongoing'}, {'id': '0', 'name': 'ABDIRECT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ab-direct', 'summary': 'Antimicrobial resistance (AMR) is on the rise, and we urgently need new antibiotics capable of beating infections that are resistant to most existing treatments. Gepotidacin is a potential antibiotic that works differently to antibiotics in use today, and lab tests suggest it could be capable of treating many resistant infections. Currently, it is under development as a treatment for two common infections where AMR is a growing problem: urogenital gonorrhoea (which is caused by Neisseria gonorrhoeae) and acute urinary tract infections caused by Escherichia coli.\nNow, the AB-DIRECT project aims to explore the potential of gepotidacin as a treatment for infections caused by N. gonorrhoeae or E. coli elsewhere in the body. Their starting point for this will be tissue samples taken from patients who have received a single dose of gepotidacin before surgery to remove their tonsils or prostate. This will allow the scientists to assess the extent to which the antibiotic gets into these tissues and to evaluate different dosing levels. They will also carry out studies of the drug in animals. Ultimately, the data generated by AB-DIRECT will contribute to a decision on whether or not to run clinical trials of gepotidacin as a treatment for throat infections caused by N. gonorrhoeae or prostate infections caused by E. coli.\nAB-DIRECT is part of the AMR Accelerator programme.\n', 'tags': 'Antibiotic distribution and recovery in tissue', 'participants': 'Centre Hospitalier Regional Universitaire De Tours, Tours, France;Centre Hospitalier Universitaire De Poitiers, Poitiers, France;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Inserm Transfert SA, Paris, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Medizinische Universitaet Wien, Vienna, Austria;Universite De Poitiers, Poitiers , France', 'status': 'Ongoing'}, {'id': '0', 'name': 'ABIRISK', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/abirisk', 'summary': 'Biopharmaceuticals (BPs) are drugs that are biological in nature. They are widely used in the treatment of cancer, chronic viral hepatitis and inflammatory and autoimmune diseases. Unfortunately, BPs can have unwanted effects: in some patients, they can cause the immune system to produce anti-drug antibodies (ADAs), which can change the concentration of the drug in the body or even neutralise it. This can decrease the efficacy of the drug, or result in severe side effects such as allergic reactions.\nThis ADA response, also known as immunogenicity, is not very well understood. The ABIRISK project set out to find a way to predict these unwanted immune responses and thus develop safer and more effective BPs. If it were possible to predict this responses, doctors would be able to identify which patients are likely to develop an adverse reaction, and those who might be non-responsive.\nABIRISK scientists chose five lifelong diseases that are treated with BPs: multiple sclerosis (MS), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), intestinal bowel diseases (IBD) and haemophilia A (HA). To understand the mechanisms of immunogenicity, they developed standardised assays, as well as new biomarkers that would make it easier to classify patients and to set the threshold of immune response that would indicate when the efficacy of a BP was decreasing.\nLarge-scale cross-comparison of data \nThe major achievement of ABIRISK was the creation of the first large prospective cohorts in the study of BP immunogenicity. More than 700 patients, suffering from MS, RA, IBD and JIA, were recruited from more than 70 medical centres across Europe. This allowed bioassays to be cross-compared on a very large scale. For the first time ever, scientists analysed five different diseases at the same time, partially treated with the same BPs. Cross-comparison of the data allowed them to come up with best practices for measuring the immunogenicity of the therapeutic molecules, i.e. their capacity to trigger immune responses.\nStandardised assays, human standards\nAnother important outcome of the project was the standardisation of assays for testing ADA and BP concentrations, as well as the creation of human ADA standards. Until now, assays to detect antibodies used animal standards, but thanks to ABIRISK, project partner Sanofi was able to produce large quantities of human ADA standards, that will, once validated, be available to scientists worldwide through the National Institute for Biological Standards and Control (NIBSC) in the UK.\nThe availability of these ADA standards allows for the harmonisation of ADA assays for BPs and thus enables researchers and clinicians to publish data that are more consistent. The ADA assays developed by the ABIRISK consortium can help clinicians decide to keep a patient on the BP, switch to another BP with the same mode of action, or to switch to a different class of BP targeting a different part of the disease pathway.\nABIRISK researchers also discovered candidates for biomarkers that can predict early ADA development. These can be explored further by the pharma industry and academia. In cases where several different BPs are available as treatment options, the most appropriate treatment for a patient may be identified by testing for the respective immunogenicity-related biomarkers. This means that patients could receive cost-effective treatment without risking the development of potentially efficacy-limiting anti-BP immunisation.\nThe ABIRISK database\nAnother accomplishment of the project was the creation of the ABIRISK database, which brings together immunogenicity data from across Europe. The data includes patients suffering from MS, RA, JIA, IBD and HA who are being treated with various BPs, as well as cohorts of patients from dedicated studies that were part of the ABIRISK program. The database is based on the tranSMART platform, an open-source knowledge management platform for translational science.\nOther achievements:\nA better understanding of the molecular origin of immunogenicity. This has led to an improvement in the tests that evaluate the immunogenicity potential of new molecules. It also confirmed that therapeutic molecules clumped together as aggregates have higher immunogenic potential than individual molecules, with the structure being preserved.\nNew assays for HA for routine analysis. This is expected to reduce false positive ADA results and to improve the detection limit of ADAs, which will considerably improve early and reliable diagnosis of ADA in patients with HA. \nInsight into the immunogenicity of various biological drugs. Translation into clinical use depends on several other factors, such as the persistence of ADA, titres, neutralising capacity and affinity, with the results showing the incidence of ADA in the first year of treatment. \nImmunophenotyping of MS patients, revealing a signature that allows the characterisation of ADA positive and ADA negative patients. \nThe development of a common language: terms and definitions related to immunogenicity have been aligned. The paper published in 2015 is used by the industry for reports to evaluate and describe immunogenicity in clinical trials, and it is cited in health authority guidelines.\nThe ABIRISK consortium brought together a network of clinicians, academic scientists, immunologists, biologists, database experts and statisticians. This ensured that the experimental findings were transferred to biopharmaceutical product development and patient management. The consortium combined industry know-how in clinical trial organisation, data management, new technologies, assay development and validation, as well as experience in regulatory affairs, immunologists from academia, and experts in analysis, patient access and clinical experience. All of this resulted in a better understanding of the immunological events that drive anti-BP immunisation.\nWhat’s next?\nImmunogenicity is still not fully understood, and as such, these six years of collaboration between the 38 consortium partners can be considered just the beginning. During the lifetime of ABIRISK, additional immunogenicity research projects were set up between industry and academia and between different academic institutes.\nThe ABIRISK Sustainability Scientific Committee (ASSC) manages the data collected during the project, and is tasked with stimulating research based on ABIRISK. The Committee is responsible for managing authorisation to access the database, as well as access to samples in biobanks. There are also four new projects linked to ABIRISK goals, funded through various national grants, and an international immunogenicity PhD course to be held every second year at the Karolinska Institute in Stockholm. Following ABIRISK, BIOPIA was founded as a non-profit collaborative effort between a number of European laboratories with expertise in BP pharmacokinetics and immunogenicity. It is an initiative that works on BP immunogenicity awareness raising, with the aim of integrating testing of these factors in order to improve the care and health of patients.\n', 'tags': 'Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Alta Ricerca E Sviluppo In Biotecnologie Srlu, Siena, Italy;Assistance Publique Hopitaux De Paris, Paris, France;Bayer Pharma AG, Berlin, Germany;Biomonitor A/S, Copenhagen, Denmark;Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany;Centre National De La Recherche Scientifique Cnrs, Paris, France;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Drk-Blutspendedienst Baden-Wurttemberg-Hessen Ggmbh, Mannheim, Germany;Fondazione Per L Istituto Di Ricerca In Biomedicina, Bellinzona, Switzerland;Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Groupe D'Etudes Therapeutiques Desaffections Inflammatoires Digestives Association, Paris, France;Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Ipsen Innovation SAS, Les Ulis, France;Istituto Giannina Gaslini, Genova, Italy;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Karolinska Institutet, Stockholm, Sweden;Klinikum Rechts Der Isar Der Technischen Universitat Munchen, Muenchen, Germany;Medical Research Infrastructure Development And Health Services Fund By The Sheba Medical Center, Ramat Gan, Israel;Medizinische Universitat Innsbruck, Innsbruck, Austria;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Queen Mary University Of London, London, United Kingdom;Region Hovedstaden, Hilleroed, Denmark;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Scicross AB, Skovde, Sweden;The Health Corporation - Rambam, Haifa, Israel;UCB Pharma SA, Brussels, Belgium;Universita Degli Studi Di Firenze, Florence, Italy;Universitatsklinikum Bonn, Bonn, Germany;Universitatsspital Basel, Basel, Switzerland;Universite De Tours, Tours - BP12050, France;Universite Paris-Sud, Orsay, France;University College London, London, United Kingdom;Univerzita Karlova, Prague 1, Czech Republic", 'status': 'Closed'}, {'id': '0', 'name': 'ADAPTSMART', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/adapt-smart', 'summary': 'Europe faces many challenges in bringing new medicines to patients in an efficient and timely manner. The reasons for this include the high attrition rates in medicine development, a regulatory environment lagging behind rapidly evolving science, and research and development (R&D) and price/reimbursement models that are no longer financially viable.\nMedicines adaptive pathways to patients (MAPPs) refers to a concept that seeks to provide patients with timely access to beneficial medicines, starting from a small group of well-identified patients (e.g. those with no alternative treatments). As evidence accumulates on the benefits and risks of a medicine, access may be extended to other groups of patients. MAPPs relate to a flexible pathway covering the entire life cycle of a medicine, from development, through licensing, to patient access (pricing/reimbursement and healthcare delivery).\nBy bringing together representatives from key European stakeholder groups – regulatory agencies, health technology assessment (HTA) bodies, pharmaceutical companies, payers, patients and health care professionals – ADAPT-SMART created a platform where the conditions and feasibility of MAPPs implementation within the EU regulatory/legal context could be discussed openly. As a result, the project contributed to an improved understanding among stakeholders of the issues promoting early access of medicinal products to patients.\nEmbracing the lifespan approach\nThanks to ADAPT-SMART, there is now a wide acceptance among different stakeholders that medicines development should take the lifespan approach. Whereas in the past the prevailing idea was that a drug should be developed for 5 to 10 years, then launched and left out there for patients to use, this project reinforced the idea of continuous evaluation and use. The project came up with recommendations on how the system could be improved at the various decision points in the product lifespan, including before and after licencing. This means that patients who are running out of time could get access to new drugs more quickly, and that evaluation continues even after the product launch.\nOther achievements\nOther top project outputs include:\nan overview of conditions which need to be met for entering the MAPPs/adaptive pathway;\na definition of the building blocks for early access, appropriate use and the continuous evaluation of medicines;\na model for a seamless pathway for early access and continuous evaluations;\na recognition that there are no legal constraints in implementing an adaptive pathway approach for medicines development, approval and reimbursement;\na glossary of terms to be used in the debate of adaptive pathways and early access;\nrecommendations for potential future IMI research projects which will be important in progressing the implementation of MAPPs.\nFor the benefit of patients, industry and regulators\nIndustry has learned the value of interacting with regulators, HTA bodies and patient organisations throughout the drug development process. Different industry partners have also learned that it is possible to work with each other constructively in the pre-competitive space.\nRegulators such as the European Medicines Agency also benefitted from their interaction with different stakeholders, especially with HTA bodies and payers. Among other things, having a debate with these downstream decision makers could help them avoid situations where they authorise products which are later rejected for pricing and reimbursement, and never reach patients.\nADAPT-SMART also involved two patient organisations as partners in the project. They helped to set the project goals and get results that are meaningful for patients. Furthermore, the recommendations that the project brought forward acknowledge the important role patients should play in the development, approval, reimbursement and appropriate use of medicines.\nWhat’s next?\nThe most important results of the project have been published in scientific journals. Additionally, the project published a comprehensive online infographic to help stakeholders to access all the relevant documents. Finally, recommendations and conclusions brought forward by ADAPT-SMART will continue to be debated by different groups of stakeholders, and developed by different groups of researchers, including those involved in future IMI projects.\nInterview with project coordinators\n\xa0\n', 'tags': 'Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes', 'participants': "AbbVie Ltd, Maidenhead, United Kingdom;Agenzia Italiana Del Farmaco, Rome, Italy;Amgen, Brussels, Belgium;Astellas Pharma Europe LTD, Chertsey, United Kingdom;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Patients’ Forum (EPF), Brussels, Belgium;Eurordis - European Organisation For Rare Diseases Association, Paris, France;F. Hoffmann-La Roche AG, Basel, Switzerland;Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Brussels, Belgium;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Haute Autorite De Sante, Saint-Denis la Plaine , France;Institut De Recherches Internationales Servier Iris, Suresnes, France;Ipsen Innovation SAS, Les Ulis, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Lysogene, Neuilly sur Seine, France;Massachusetts Institute Of Technology, Cambridge, United States ;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;National Institute For Health And Care Excellence, Manchester, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Shire International GMBH, Zug, Switzerland;Stichting Lygature, Utrecht, Netherlands;The European Medicines Agency, Canary Wharf, London, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;University of Oxford, Oxford, United Kingdom;Zorginstituut Nederland, Diemen, Netherlands", 'status': 'Closed'}, {'id': '0', 'name': 'ADAPTED', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/adapted', 'summary': 'Alzheimer’s disease (AD) affects over 35 million people worldwide and yet there are currently no medicines which slow down the progress of the disease. The ADAPTED project aims to boost the development of new medicines by investigating an area of AD research which has previously received little attention – the APOE gene. The APOE gene is a well-known risk factor for developing the disease, but precisely how this gene contributes to the risk of developing AD is not known. People who carry the APOE4 version of the gene have a considerably higher risk of developing AD. They also tend to develop the disease much earlier in life. However, the reasons for this are not well understood and therefore APOE has largely been ignored in the quest to find treatments for AD. By bringing together leading experts in a range of state-of-the-art technologies, including three research-intensive small and medium-sized enterprises (SMEs), ADAPTED hopes to gain better insights into the causes of AD, something that will in turn lead to better treatments for patients.\n', 'tags': "Alzheimer's disease apolipoprotein pathology for treatment elucidation and development", 'participants': 'Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain;Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom;Caebi Bioinformatica Sociedad Limitada, Sevilla, Spain;Dc Biosceinces  LTD, Dundee, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Fundacio Ace, Barcelona , Spain;Janssen Pharmaceutica Nv, Beerse, Belgium;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Mimetas BV, Leiden, Netherlands;Modus Research And Innovation Limited, Dundee, United Kingdom;Universitatsklinikum Bonn, Bonn, Germany;Universiteit Leiden, Leiden, Netherlands', 'status': 'Ongoing'}, {'id': '0', 'name': 'ADVANCE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/advance', 'summary': 'Immunisation prevents two to three million deaths worldwide every year from diseases such as diphtheria, tetanus, pertussis (whooping cough) and measles. Millions more are spared the long-term health consequences of vaccine-preventable infectious diseases; the WHO estimates that due to the Global Polio Eradication Initiative, five million people are walking today who would otherwise have been paralysed by the virus.\nIn Europe, one of the greatest barriers to the wider uptake of immunisation is distrust, among some sections of the public, of immunisation programmes. This is due largely to fears surrounding vaccine safety. In fact, serious side effects are very rare. Nevertheless, as vaccines are given to healthy people, public acceptance of the risk of any adverse reaction is much lower than for medicines designed to treat sick people; the trade-off between benefit and risk is different.\nAt the same time, some vaccines have been around for so long that many people have no personal experience of the diseases prevented, and so are unaware of just how serious the illness can be.\nRestoring trust\nVaccines undergo rigorous safety testing before they are approved for public use. Currently, efforts to monitor the coverage, benefits and risks of vaccines after approval are rather fragmented.\nThe goal of ADVANCE is to review, develop and test methods, data sources and procedures which should feed into a blueprint of an efficient and sustainable pan-European framework that can rapidly deliver robust quantitative data for the assessment of the benefits and risks of vaccines that are on the market. Such a framework would allow regulators and public health authorities to make fast, informed decisions regarding vaccination strategies, and help to maintain public confidence in vaccines, particularly when questions are raised in the media about the safety of specific vaccines.\nFor example, such a framework could have more rapidly assessed and quantified the benefits and risks of the measles, mumps and rubella (MMR) vaccine, uptake of which fell in the UK in the years following the claim that it causes autism. Although that claim is now discredited and the doctor behind the claims has been struck off the medical register, uptake of the vaccine remains below the recommended threshold of 95%. A recent measles outbreak centred around the city of Swansea in south Wales (where vaccination levels were particularly low) saw over 1\xa0200 people fall ill, of which 80 were hospitalised and 1 died.\nThe good news is that pilot studies have demonstrated the feasibility of setting up the components of such a framework in Europe, although turning it into a sustainable reality will not be easy. Data on vaccine-preventable diseases, vaccination coverage and adverse reactions to vaccines exist in many places and diverse formats, such as electronic health records, disease surveillance systems, and other healthcare databases. The ADVANCE team will have to identify and profile data sources capable of yielding rapid access to information on the burden of disease, vaccine coverage, and the benefits and risks of vaccines. Another challenge for the team will be developing the tools to link up this data and analysing it, taking into account the interoperability of the data sources and associated ethical and legal issues.\nThe project will run a number-of-proof of concept studies to ensure the platform meets the needs of its users. In order to cover the most common situations, these studies should ideally cover different age groups (e.g. infants / children, adolescents and adults / the elderly), different risk groups (e.g. pregnant women, people with other underlying health problems), and different vaccination scenarios (e.g. vaccinations given annually such as the flu jab, or vaccines introduced into the routine immunisation programme).\nADVANCE will also set out the framework’s core values, covering issues such as scientific best practice, a code of conduct, and rules for interactions between the different stakeholders.\nIn all aspects of its work, ADVANCE will build on the results of, and exploit synergies with, related projects. For example, the team will work closely with IMI’s EMIF project on data frameworks, and draw on the PROTECT project’s expertise in analysing and visualising the benefits and risks of medicines.\nCollaboration is key\nIf the ADVANCE blueprint is to be adopted and implemented following the end of the project, it must be accepted by all stakeholders, including the European Centre for Disease Prevention and Control, national public health bodies, the European Medicines Agency, national regulatory agencies, health ministries, insurance companies, vaccine manufacturers, healthcare providers, and of course the general public. Collaboration between these diverse groups is very sensitive; by bringing them together around the neutral platform offered by IMI, ADVANCE is in a unique position to pave the way for a framework that will improve our ability to rapidly assess the benefits and risks of vaccines and help maintain public confidence in immunisation as a successful and effective public health tool to control infectious disease.\n', 'tags': 'Accelerated development of vaccine benefit-risk collaboration in Europe', 'participants': "Aarhus Universitet, Aarhus C, Denmark;Aarhus Universitetshospital, Aarhus, Denmark;Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain;Agenzia Di Tutela Della Salute Della Val Padana, Mantova, Italy;Agenzia Regionale Di Sanita, Firenze, Italy;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Centre for Disease Prevention and Control, Stockholm, Sweden;Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain;Fundacion Española Para La Cooperacion Internacional Salud Y Politica Social, Madrid, Spain;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Janssen Vaccines & Prevention BV, Leiden, Netherlands;Karolinska Institutet, Stockholm, Sweden;London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom;Medicines and Healthcare products Regulatory Agency, London, United Kingdom;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novartis Pharma AG, Basel, Switzerland;P95 CVBA, Leuven, Belgium;Pfizer Limited, Sandwich, Kent , United Kingdom;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Sanofi Pasteur SA, Lyon, France;Sciensano, Brussels, Belgium;Societa Servizi Telematici SRL, Padova, Italy;Statens Serum Institut, Copenhagen S, Denmark;Synapse Research Management Partners SL, Barcelona, Spain;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Tampereen Korkeakoulusaatio Sr, Tampere, Finland;The European Medicines Agency, Canary Wharf, London, United Kingdom;The Open University, Milton Keynes, United Kingdom;The Royal College Of General Practitioners, London, United Kingdom;Universitat Basel, Basel, Switzerland;Universitats-Kinderspital Beider Basel, Basel, Switzerland;University Of Surrey, Guildford, United Kingdom", 'status': 'Closed'}, {'id': '0', 'name': 'AETIONOMY', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/aetionomy', 'summary': 'Today, diseases are still defined largely based on signs and symptoms, yet while two patients may share the same diagnosis, the underlying causes of their symptoms may be very different. Naturally, this means that a treatment that works in one patient may prove ineffective in another. There is now broad acceptance that a new direction for disease classification is needed, built not on symptomatology, but derived from the mechanisms, or causes, that drive the disease.\nPrototype taxonomy and a knowledge base\nThe AETIONOMY team started by tackling the problem of how to obtain, organise, structure, integrate and interpret a broad range of data (ranging from molecular data, to information on symptoms) from the neurodegeneration community. They then ‘dissected’ the underlying mechanistic causes in order to bring structure to their classification; linking the mechanistic causes to clinical evidence in an attempt to validate them.\nThe consortium demonstrated that their prototype taxonomy can be used to identify patient subgroups in PD. They were able to perform a partial validation of a selection of candidate mechanisms for both diseases. The validation was done in-silico and by means of dedicated wet lab experiments performed by clinical research, biotech and pharmaceutical partners.\nAETIONOMY resulted in an open-access knowledge base with inventories of mechanistic hypotheses; these form the basis for the prototype taxonomies for both AD and PD. The knowledge base also contains curated clinical and relevant OMICS-data (analysis of complete genetic or molecular profiles), disease models for AD and PD, analysis and visualisation, and data from participants of a cross-sectional clinical study and additional integrated cohorts. The neurodegenerative research community now has access to the inventory of computable models, as well as a dedicated set of algorithms that can facilitate the interrogation of the mechanistic hypotheses against patient data.\nVirtual data cohorts\nAETIONOMY recruited a significant cohort of patients and controls, and coordinated the logistics of sample transfers and execution of a range of biomarker assays. The patient cohorts were profiled and characterised to a degree that allowed the consortium to perform ‘mechanism-enrichment’ procedures on patient-level biomarker data.\nTo overcome hurdles related to accessing patient data to carry out in-silico validation of disease mechanisms, the consortium developed the concept of virtual data cohorts (VDCs), which are artificial data sets that share features and characteristics of real-world study cohorts. VDCs have the potential to overcome some of the challenges inherent to translational neurodegeneration research, namely the sharing of patient-level data without compromising patient data privacy (but also other challenges, like merging heterogeneous, complex clinical data sets and more).\nThrough this conceptualisation and implementation of VDCs, the AETIONOMY project may pave the way for future data sharing and data integration of patient-level data without compromising patient privacy. The virtual patient topic was not a novel concept invented by the AETIONOMY consortium but is in line with globally emergent trends.\nCollaboration and synergies\nThe project brought together 18 partners including pharmaceutical companies, universities, and patient groups, and combined substantial expertise in neurodegenerative diseases, molecular biology, clinical research, research ethics and law, neuroimaging, data modelling and simulation, data standards, and patient engagement in research among others.\nCollaborations, beyond the original scope of the project but initiated through the identification of common goals, were key for the project’s success; in particular, collaborations with the University of Oxford and the Human Brain Project. Working with Alzheimer Europe, AETIONOMY had the valuable opportunity to network with leading European researchers in the field and to help ensure that the perspectives of people with dementia were taken into consideration.\nThe consortium is still (partially) alive\nPart of the AETIONOMY consortium is still working together; Fraunhofer SCAI (Institute for Algorithms and Scientific Computing) in Germany and the ICM (Institute for Brain and Spinal Cord) in France have collaborated since the official end of the funded period. Based on an initial workshop in Bonn on longitudinal modelling of disease progression, the collaborators decided to make the workshop a regular event that reaches out to other projects at EU level, including the IMI project RADAR-AD and the Horizon 2020 initiative, the Virtual Brain Cloud. Work in AETIONOMY has thus led to a major collaborative effort to understand the dynamics of neurodegenerative disease progression. Other collaborative efforts that have been sustained concern the topic of information extraction for model generation, where Frauenhofer SCAI have partnered with the University of Luxembourg (currently applied to the context of COVID-19).\n', 'tags': 'Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy', 'participants': "Alzheimer Europe, Luxembourg, Luxembourg;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fundacio Barcelonabeta Brain Research Center, Barcelona, Spain;Gottfried Wilhelm Leibniz Universitaet Hannover, Hannover, Germany;Institut Du Cerveau Et De La Moelle Epiniere, Paris, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Karolinska Institutet, Stockholm, Sweden;Novartis Pharma AG, Basel, Switzerland;Pharmacoidea Fejleszto Es Szolgaltato Kft, Szeged, Hungary;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;UCB Biopharma SRL, Brussels, Belgium;Universitatsklinikum Bonn, Bonn, Germany;Universite D'Aix Marseille, Marseille, France;Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg", 'status': 'Closed'}, {'id': '0', 'name': 'AIMS2TRIALS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/aims-2-trials', 'summary': 'Autism spectrum disorders (ASD) affect around 1 % of the population and are characterised by difficulties in social interactions and communication as well as repetitive behaviours. The precise symptoms and their severity vary widely from one person to another; some are only mildly afflicted and can lead relatively independent lives, while others are severely disabled and require a lot of specialist care. People with ASD often have other conditions, including epilepsy, depression, anxiety and attention deficit hyperactivity disorder (ADHD). Today, there are no drugs designed specifically to treat ASD; instead, those affected are treated with medicines designed for other conditions.\nAIMS-2-TRIALS aims to improve outcomes for people with ASD. To do this it will create a pipeline for developing, testing and implementing new treatments for ASD with stakeholder involvement at each stage. The project will set up a global clinical trial network for ASD to validate biological markers and endpoints to reliably show whether or not a treatment is effective and appropriate for ASD.\nThe project brings together experts from universities, university hospitals, pharmaceutical companies, patient groups, not-for-profit foundations, and small and medium-sized enterprises.\n', 'tags': 'Autism Innovative Medicine Studies – 2 – Trials', 'participants': "Arttic, Paris, France;Assistance Publique Hopitaux De Paris, Paris, France;Autism Speaks Inc. Non Profit Corporation, Princeton, NJ, United States ;Autisme-Europe Aisbl, Bruxelles, Belgium;Autistica, London, United Kingdom;Biosci Consulting Bvba, Maasmechelen, Belgium;Birkbeck College - University Of London, London, United Kingdom;Centre Hospitalier Regional Universitaire De Tours, Tours, France;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Demcon Advanced Mechatronics Bestb.V., Best, Netherlands;Demcon Advanced Mechatronics Enschede B.V., Enschede, Netherlands;Demcon Flex Center BV, Enschede, Netherlands;Demcon Macawi Respiratory Systems BV, Enschede, Netherlands;Demcon Production BV, Enschede, Netherlands;F. Hoffmann-La Roche AG, Basel, Switzerland;Fondazione Stella Maris, Pisa, Italy;Fundacio Clinic Per A La Recerca Biomedica, Barcelona, Spain;Fundazioa Policlinica Gipuzkoa Fundacion, Donostia / San Sebastián, Spain;Greater Glasgow Health Board, Glasgow, United Kingdom;Hospital Clinic De Barcelona, Barcelona, Spain;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Institut Pasteur, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Klinikum Rechts Der Isar Der Technischen Universitat Munchen, Muenchen, Germany;Noldus Information Technology BV, Wageningen, Netherlands;Novartis Pharma AG, Basel, Switzerland;Rijksuniversiteit Groningen, Groningen, Netherlands;Servicio Madrileno De Salud, Madrid, Spain;Starlab Barcelona SL, Barcelona, Spain;Stellenbosch University, Stellenbosch, South Africa;Stichting Buro Ecnp, Utrecht, Netherlands;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Teva Pharmaceutical Industries Limited, Netanya, Israel;The Simons Foundation, Inc, New  York, United States;The University Of Edinburgh, Edinburgh, United Kingdom;Trinity College Dublin, Dublin, Ireland;UCB Biopharma SRL, Brussels, Belgium;Universidad De Salamanca, Salamanca, Spain;Universidade De Coimbra, Coimbra, Portugal;Universitaet Ulm, Ulm, Germany;Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts, Goettingen, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitat Basel, Basel, Switzerland;Universiteit Gent, Gent, Belgium;University Of Bristol, Bristol, United Kingdom;University Of Glasgow, Glasgow, United Kingdom;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Oxford, Oxford, United Kingdom;Uppsala Universitet, Uppsala, Sweden;Zentralinstitut Fuer Seelische Gesundheit, Mannheim, Germany", 'status': 'Ongoing'}, {'id': '0', 'name': 'AMYPAD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/amypad', 'summary': 'Deposits of beta amyloid protein in the brain are a common sign of Alzheimer’s disease. AMYPAD will study the value of using positron emission tomography (PET) imaging to scan people’s brains for beta amyloid deposits. AMYPAD will carry out beta amyloid PET imaging on an unprecedented number of people who are suspected to be in the early stages of Alzheimer’s disease. The goal is to determine the clinical added value of PET imaging in diagnosis and patient monitoring, and to develop data to establish its usefulness in clinical trials. AMYPAD will work closely with IMI’s EPAD project, which is working to increase our understanding of the early stages of dementia and creating a platform to test treatments designed to prevent dementia.\n', 'tags': 'Amyloid imaging to prevent Alzheimer’s disease', 'participants': 'Alzheimer Europe, Luxembourg, Luxembourg;Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France;Fundacio Barcelonabeta Brain Research Center, Barcelona, Spain;Ge Healthcare Limited, Little Chalfont, United Kingdom;Ixico Technologies Limited, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Life Molecular Imaging LTD, Havant, United Kingdom;Region Stockholm, Stockholm, Sweden;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Stichting Vumc, Amsterdam, Netherlands;Synapse Research Management Partners SL, Barcelona, Spain;The University Of Edinburgh, Edinburgh, United Kingdom;Universite De Geneve, Genève 4, Switzerland;University College London, London, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'APPROACH', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/approach', 'summary': 'The burden of the disease is increasing yet there is no cure\nIt is estimated that 9.6% of men and 18% of women over the age of 60 worldwide experience the debilitating symptoms of osteoarthritis. As people tend to live longer, and the population of people over 60 is increasing, cases of the disease are on the rise. Direct and indirect costs of osteoarthritis in the EU are already substantial: in the UK alone, total costs for adaptive aids and devices, medicines, surgery and time off work are estimated to be equivalent to 1% of the gross national product per year. The burden will be greatest in developing countries, where life expectancy is increasing and access to arthroplasty and joint replacement is not readily available. Furthermore, although there are a wide range of devices and palliative medicines available that can relieve pain and improve quality of life, there are currently no pharmaceutical products that can halt or reverse the onset of osteoarthritis.\nDespite the large and growing burden of this disease, many pharmaceutical companies have reduced or altogether abandoned drug development. One of the problems is that there are currently no reliable ways of measuring whether a specific treatment is working or not. This is partly because the mechanisms which lead to the disease in different subgroups of patients are poorly understood. Moreover, although the current mind-set for treatment in this field is moving towards personalised medicine, there are no accepted methods of classifying the patients according to diagnosis methodology, prognosis and treatment plan. It is clear that a better understanding of the disease is urgently needed.\nComplex algorithms to hunt for disease subtypes\nBy bringing together a strong team of 25 partners from European clinical centres, basic research institutes, small and medium-sized enterprises (SMEs) and pharmaceutical companies, the APPROACH consortium will combine biomedical data of more than 10 000 patients and heathy people from 8 existing cohorts into a unified bioinformatics platform. With the help of complex algorithms, bioinformaticians will comb through this central database to identify subtypes or phenotypes of osteoarthritis. These subtypes will then be validated in a longitudinal clinical study, using existing and newly-developed biological markers. Ultimately, the identification of subtypes of this disease should lead to improved drug development and diagnostic tools, allowing osteoarthritis patients to receive better, more personalised treatment.\nThe project will focus on knee osteoarthritis – a very common form of osteoarthritis which is a major cause of impaired mobility (particularly in women) and therefore has a high clinical burden. This form of the disease is ideal for the APPROACH database because it has been extensively examined in large groups of patients and lots of standardised data, such as x-ray and MRI measurements, is available.\nValuable tools and outcomes\nAt the end of the project, APPROACH will provide valuable tools, methods and definitions that will be used to optimise future clinical trials for osteoarthritis, paving the way for personalised medicine. More specifically, the main outcomes of the project will be as follows:\nan integrated bioinformatics platform which functions as a repository for clinical data, biomarker data, images, as well as storage of bio-tissues from a broad spectrum of osteoarthritis patients;\nsubsets of patients based on well-defined subtypes or phenotypes of the disease;\nnew biological markers for osteoarthritis based on imaging, locomotion and biochemical methods;\nvalidation and optimisation of the next generation imaging methodologies, human motion analysis and biochemical methods to enable more efficient diagnosis and treatment of osteoarthritis patients.\nA big step towards more personalised medicine for patients\nBy identifying different subtypes of osteoarthritis, APPROACH will make a big step forward in helping the pharmaceutical companies develop more effective treatments for the osteoarthritis patients. Patients will reap the greatest benefits as the identification of disease subtypes will lead to improved diagnostic tools and more effective, highly personalised treatments.\n', 'tags': 'Applied public-private research enabling osteoarthritis clinical headway', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Arthritis Research UK, Chesterfield, United Kingdom;Artialis SA, Liège (Sart-Tilman), Belgium;Assistance Publique Hopitaux De Paris, Paris, France;Centre National De La Recherche Scientifique Cnrs, Paris, France;Diakonhjemmet Sykehus As, Oslo, Norway;Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Immunodiagnostic Systems Holdings PLC, Boldon, United Kingdom;Institut De Recherches Internationales Servier Iris, Suresnes, France;Lunds Universitet, Lund, Sweden;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Nordic Bioscience Compound Development A/S, Herlev, Denmark;Oulun Yliopisto, Oulu, Finland;Servizo Galego De Saude, Santiago de Compostela, Spain;Stichting Lygature, Utrecht, Netherlands;Stichting Nationaal Reumafonds, Amsterdam, Netherlands;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitatsklinikum Erlangen, Erlangen, Germany;Universite Paris Diderot - Paris 7, Paris, France;University Of Leeds, Leeds, United Kingdom;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'ARDAT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ardat', 'summary': 'Advanced therapy medicinal products (ATMPs) such as cell and gene therapies have the potential to revolutionise treatments for many serious genetic diseases as well as some cancers. However, developing ATMPs is extremely challenging; in particular it is currently very difficult to know which patients will respond well to an advanced therapy and which will experience serious side effects.\nThe aim of ARDAT is to deliver the knowledge, tools and standards needed to speed up the development of ATMPs.\nAmong other things, the project will deliver tools and knowledge that will allow researchers to study how treatments are metabolised (i.e. broken down by the body); predict which treatments are likely to trigger a harmful immune response; and identify how best to deliver the therapy (e.g. via a drip / injection).\nThey also aim to deliver tools to assess the safety and efficacy of ATMPs, and to determine how many doses a patient will need to obtain a lasting improvement in their health.\nFinally, ARDAT plans to work closely with regulators on regulatory harmonisation to accelerate ATMP product development.\nARDAT will focus on rare diseases caused by a single gene mutation. However, many of the project’s findings will be applicable to other diseases.\n', 'tags': 'Accelerating research & development for advanced therapies', 'participants': 'Asphalion SL, Barcelona, Spain;Association Genethon, Evry, France;Astellas Pharma Europe BV, Leiden, Netherlands;Bayer Aktiengesellschaft, Leverkusen, Germany;Centro De Neurociencias E Biologiacelular Associacao, Coimbra, Portugal;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Genosafe SAS, Evry, France;Institut Du Cerveau Et De La Moelle Epiniere, Paris, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Instituto De Biologia Experimental E Tecnologica, Oeiras, Portugal;Itä-Suomen yliopisto, Kuopio, Finland;Janssen Pharmaceutica Nv, Beerse, Belgium;Lonza AG, Basel, Switzerland;Lunds Universitet, Lund, Sweden;Lysogene, Neuilly sur Seine, France;Medizinische Hochschule Hannover, Hannover, Germany;Mimetas BV, Leiden, Netherlands;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Pharmacoidea Fejleszto Es Szolgaltato Kft, Szeged, Hungary;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Spark Therapeutics, Inc, Philadelphia, United States;Synvaccine LTD, Tel Aviv, Israel;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Takis SRL, Roma, Italy;The Rosalind Franklin Institute, Didcot, United Kingdom;The University Of Liverpool, Liverpool, United Kingdom;The University Of Sheffield, Sheffield, United Kingdom;Universitatsklinikum Heidelberg, Heidelberg, Germany;University College London, London, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Oxford, Oxford, United Kingdom;Viscofan SA, Tajonar, Spain', 'status': 'Ongoing'}, {'id': '0', 'name': 'BEATDKD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/beat-dkd', 'summary': 'Diabetic kidney disease (DKD) is a common complication of diabetes, and DKD is now the most common form of chronic kidney disease. There is no effective way to prevent or treat DKD, leaving many patients in extremely poor health and facing high mortality rates.\nThe BEAt-DKD project aims to deliver tools and knowledge that will facilitate the development of new, personalised treatments for DKD. Among other things, the project will identify and validate biological markers (biomarkers) to help researchers track whether a patient’s condition has worsened, and whether a treatment is working for them. They will also work to identify different sub-groups of patients that could respond differently to certain treatments.\nThe results will therefore pave the way for the development of effective personalised treatments for DKD.\n', 'tags': 'Biomarker enterprise to attack DKD', 'participants': 'Abbvie Inc, North Chicago, Illinois, United States ;Academisch Ziekenhuis Groningen, Groningen, Netherlands;Apuliabiotech Societa Consortile Ar L, Bari, Italy;Astellas Pharma Europe BV, Leiden, Netherlands;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Chu Hopitaux De Bordeaux, Talence, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy;Itä-Suomen yliopisto, Kuopio, Finland;Jdrf International, New York, United States ;Klinikum Der Universitaet Regensburg, Regensburg, Germany;Lipotype, Dresden, Germany;Lunds Universitet, Lund, Sweden;Medizinische Universitaet Wien, Vienna, Austria;Medizinische Universitat Innsbruck, Innsbruck, Austria;Novo Nordisk A/S, Bagsvaerd, Denmark;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;The Leeds Teaching Hospitals National Health Service Trust, Leeds, United Kingdom;The University Of Exeter, Exeter, United Kingdom;Universita Degli Studi Di Bari Aldo Moro, Bari, Italy;Universitaetsklinikum Freiburg, Freiburg, Germany;Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany;Universitatsklinikum Erlangen, Erlangen, Germany;University Of Bristol, Bristol, United Kingdom;University Of Dundee, Dundee, United Kingdom;University Of Hull, Hull, United Kingdom;University Of Leeds, Leeds, United Kingdom;University Of Michigan The Regents Of The University Of Michigan, Ann Arbor, United States ;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Oxford, Oxford, United Kingdom;University of Turku, Turku, Finland;Varsinais-Suomen Sairaanhoitopiirin Kuntayhtyma, Turku, Finland', 'status': 'Ongoing'}, {'id': '0', 'name': 'BIGDATAHEART', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/bigdataheart', 'summary': 'Cardiovascular disease (CVD) is a major killer in Europe, causing 3.9 million deaths (around 45% of all deaths) annually. What’s more, a third of deaths from CVD occur in the under 75s. On the economic front, CVD costs the EU around EUR 210 billion a year, with healthcare costs accounting for just over half of this figure. Three diseases – atrial fibrillation (AF), heart failure (HF) and acute coronary syndrome (ACS) are major drivers of CVD. All three are extremely complex and characterised by large differences between patients with the same diagnosis. As a result, it is hard to predict which patients will respond best to which treatments.\nThe BigData@Heart project is part of IMI’s Big Data for Better Outcome (BD4BO) Programme. It brings together some of Europe’s leading experts in CVD treatment and management, as well as epidemiologists, big data scientists, doctors, industry representatives, patient representatives, and ethics and legal experts. Between them, the partners have access to many cohorts and databases in this field. With this diverse team and resources, the project will be able to develop new definitions of diseases and outcomes; informatics platforms that link, visualise and harmonise different data sources; data science techniques; and guidelines on the cross-border use of big data resources. In the long term, the project expects to have an impact on our understanding of heart disease, the discovery of new targets for treatments, and progress towards personalised treatments for CVD.\n', 'tags': 'Big data @ heart', 'participants': 'Bayer Aktiengesellschaft, Leverkusen, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;European Heart Network Aisbl, Bruxelles, Netherlands;Fundacion Para La Investigacion Del Hospital Clinico De La Comunitat Valenciana, Fundacion Incliva, Valencia, Spain;Institut De Recherches Internationales Servier Iris, Suresnes, France;International Consortium For Healthoutcomes Measurement Inc., Cambridge, United States;International Consortium For Healthoutcomes Measurement LTD, London, United Kingdom;Karolinska Institutet, Stockholm, Sweden;Novartis Pharma AG, Basel, Switzerland;Societe Europeenne De Cardiologie, Biot, France;Somalogic Inc, Boulder, United States;Stichting Mlc Foundation, Den Haag, Netherlands;The Hyve BV, Utrecht, Netherlands;The University Of Birmingham, Birmingham, United Kingdom;Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;University College London, London, United Kingdom;University of Cambridge, Cambridge, United Kingdom;Uppsala Universitet, Uppsala, Sweden;Vifor (International) AG, St. Gallen, Switzerland', 'status': 'Ongoing'}, {'id': '0', 'name': 'BIOMAP', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/biomap', 'summary': 'Atopic dermatitis and psoriasis are serious skin diseases that affect over 300 million people globally. Atopic dermatitis causes itchy, inflamed skin that can become blistered, while psoriasis is characterised by red, scaly plaques on the skin. For many patients, the treatments available do not work well and the diseases place a huge burden on patients, their families, and healthcare systems. BIOMAP aims to shed new light on the underlying causes of both diseases, as well as the genetic and environmental factors that influence how a patient’s disease will progress and how well they will respond to a given treatment. They will do this by studying in depth data and samples from 50 000 patients as well as healthy individuals. Ultimately, BIOMAP hopes to identify new sub-types of the diseases that will allow clinicians and patients to make better, more personalised decisions on treatments. To ensure patients’ views are integrated into the project, BIOMAP has set up a Patient Advisory Group.\n', 'tags': 'Biomarkers in atopic dermatitis and psoriasis', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Ait Austrian Institute Of Technology GMBH, Wien, Austria;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany;Den Selvejende Institution Dansk Borneastma Center, Gentofte, Denmark;Eurice European Research And Project Office GMBH, Saarbrücken, Germany;HAHN-SCHICKARD-GESELLSCHAFT FUER ANGEWANDTE FORSCHUNG E.v., Villingen, Germany;Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany;Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg;Itä-Suomen yliopisto, Kuopio, Finland;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Klinikum Rechts Der Isar Der Technischen Universitat Munchen, Muenchen, Germany;Kobenhavns Universitet, Copenhagen, Denmark;Leo Pharma As, Ballerup, Denmark;London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Tampereen Korkeakoulusaatio Sr, Tampere, Finland;Tampereen Yliopisto, Tampere, Finland;Tartu Ulikool, Tartu, Estonia;Technische Universitaet Muenchen, Muenchen, Germany;Trinity College Dublin, Dublin, Ireland;UCB Biopharma SRL, Brussels, Belgium;Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany;Universitat Wien, Vienna, Austria;Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg;University Of Bristol, Bristol, United Kingdom;University Of Dundee, Dundee, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'BIOVACSAFE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/biovacsafe', 'summary': 'Vaccines are widely acknowledged to be one of the cheapest and most efficient ways to combat infectious diseases in both developed and developing countries. With billions of doses of vaccines administered globally every year, vaccine safety is a top priority for pharmaceutical companies, regulators and the public alike. The problem is that testing and monitoring new vaccines for safety is a slow, cumbersome, and extremely expensive process; the development of a new vaccine costs millions of euros, and less than 1 vaccine in 10 makes it through clinical testing.\nAs companies add new components to vaccines to make them more effective, testing them for safety becomes even more challenging. And, while severe adverse reactions to vaccines are rare, predicting who is at risk of a severe reaction is extremely difficult; this problem will be further complicated by the ageing of the population and the growing burden of chronic conditions and diseases of the immune system.A new approach to vaccine safety\nThe BIOVACSAFE project will draw on the latest life science research findings to profile, in great detail, how individuals respond to the different components of vaccines at the cellular, genetic and molecular level. This will allow the project team to develop tools that can rapidly and accurately identify warning signs that a potential vaccine may be reactogenic. The tools could be employed early on in vaccine development, before vast amounts of time and money have been spent. Meanwhile, the team will develop new ways to identify, classify and record adverse reactions to vaccines; this should also boost researchers’ ability to pick up on problems early in vaccine development. Finally, the team will probe how natural illnesses and infections, particularly diseases of the immune system, interact with vaccines. By identifying these interactions, the team hopes to find ways of preventing them occurring in the first place. Finally, the team will create databases that can be used to store information on and explore reactions to vaccines.Towards the next generation of vaccines \nBy coming up with novel ways to identify and better understand the causes of adverse reactions to vaccines at all stages of development, BIOVACSAFE will accelerate the development and introduction of a new generation of safer, more effective vaccines to combat infectious diseases, cancer and chronic diseases. As well as speeding up vaccine development, the new, more accurate tools developed by BIOVACSAFE should help to boost public confidence in vaccine safety. Furthermore, because the project includes studies of populations in both developed and developing countries, its findings should be of global relevance.An injection of health for Europe’s vaccine development sector\nBIOVACSAFE brings together for the first time three of Europe’s leading vaccine development and manufacture companies as well as top experts from academic institutions and small and medium-sized enterprises (SMEs). By sharing their expertise as well as access to data and patient groups, all project partners will see their knowledge base and their competitiveness grow. Crucially, by pooling their expertise, the BIOVACSAFE partners have a unique opportunity to make progress in this important area.\n', 'tags': 'Biomarkers for Enhanced Vaccine Immunosafety', 'participants': "Cdisc Europe Foundation Fondation, Brussels, Belgium;Chalmers Tekniska Hoegskola AB, Goeteborg, Sweden;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Department of Health, Leeds, United Kingdom;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Glaxosmithkline Vaccines SRL, Siena, Italy;Goeteborgs Universitet, Gothenburg, Sweden;ImmunArray Ltd, Rehovot, Israel;Imperial College Of Science Technology And Medicine, London, United Kingdom;Islensk Erfdagreining Ehf, Reykjavik, Iceland;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Sanofi Pasteur SA, Lyon, France;St George'S Hospital Medical School, London, United Kingdom;Statens Serum Institut, Copenhagen S, Denmark;Universita Degli Studi Di Siena, Siena, Italy;Universitair Ziekenhuis Gent, Gent, Belgium;Universiteit Gent, Gent, Belgium;Universiteit Utrecht, Utrecht, Netherlands;University Of Surrey, Guildford, United Kingdom;Vismederi SRL, Siena, Italy", 'status': 'Closed'}, {'id': '0', 'name': 'BTCURE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/btcure', 'summary': 'Key achievements\nthe pharmaceutical industry now recognises that a disease interception strategy\xa0for early treatment of people at\xa0 individuals is a realistic possibility.\nnew EULAR recognised definition of early/pre-rheumatoid arthritis\xa0\xa0“Clinically Suspect Athralgia” (CSA)\nled to initiation of first clinical studies in “at-risk population” APIPPRA & ARIAA with abatacept\ncreated opportunity to develop novel immune tolerance therapies or block early APC-T-cell events to halt progression to full disease – disrupt biologicals market\nestablished technology infrastructure established for immune monitoring\npatient registries & biobanks – identify patients suitable for early intervention\nover 200 publications – many in high impact journals\npatents\nmore than 10 new targets identified\nimproved animal models (10 SOP’s & 4 novel humanised mouse models)\nover 10 workshops - animal models, functional genomics, immune tolerance & PAD inhibitors\nimproved EFPIA reputation with academics through scientific engagement\nThe work from groups within the BTCure consortium (and others) showed\xa0that very different genetic, environmental and thus molecular events are needed to trigger different subsets of\xa0 rheumatoid arthritis (RA). The project\xa0 aimed to develop an understanding of the early process in arthritis subsets that will enable the development of\xa0precise and eventually curative treatments to be used before irreversible destruction and loss of joint function and mobility have occurred in patients.\nThe BTCure project developed diagnostic methods to discover the early forms of RA and RA-like diseases and new tools to differentiate the different forms of RA and RA-like diseases, where different molecular mechanisms are involved and where different therapies may be required.\nTo achieve these goals, samples from biobanks were\xa0analysed in vitro and models were aligned with different variants of human arthritis. In addition, new models will be established using similar molecular pathways as the relevant human arthritis subsets, leading to the understanding of the etiology and early pathology of the disease for a program aimed at early and curative treatment of RA and RA-like diseases. A major focus of these efforts was to understand and subsequently alter the adaptive immune reactions in patients from a disease-inducing mode into either a protective mode against the disease or become asymptomatic. Advances made through initial research into the pathology of this group of diseases have been successful, given enough information available on the nature and regulation of disease-inducing and disease-protective immunity. With these tools the project team was\xa0able to use new understanding of aetiology and early pathology of human disease for a program aimed at early and ultimately curative treatment of human RA and RA-like diseases. \xa0\n', 'tags': 'Be The Cure', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain;Arthrogen BV, Amsterdam, Netherlands;Astrazeneca AB, Södertälje, Sweden;Biomedcode Ellas Anonimi Eteria Epistimonikis Kai Texnologikis Erevnas Kai Emborikis Ekmetallefsis Epharmogon Iatrikis, Vari, Greece;Biomedical Sciences Research Center Alexander Fleming, Vari - Athens, Greece;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Centre Hospitalier Universitaire Montpellier, Montpellier, France;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany;Diakonhjemmet Sykehus As, Oslo, Norway;Firalis, Huningue, France;Fondazione Humanitas Per La Ricerca, Rozzano, Italy;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Idryma Iatroviologikon Ereunon Akademias Athinon, Athens, Greece;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Biologics BV, Leiden, Netherlands;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Medizinische Universitaet Wien, Vienna, Austria;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Phadia AB, Upssala, Sweden;Redoxis AB, Lund, Sweden;Revmatologicky ustav, Praha, Czech Republic;Stichting Katholieke Universiteit, Nijmegen, Netherlands;The University Of Manchester, Manchester, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universitat Zurich, Zürich, Switzerland;Universitatsklinikum Erlangen, Erlangen, Germany;University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland;University Of Glasgow, Glasgow, United Kingdom;University Of Leeds, Leeds, United Kingdom;University of Oxford, Oxford, United Kingdom;Uppsala Universitet, Uppsala, Sweden", 'status': 'Closed'}, {'id': '0', 'name': 'C4C', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/c4c', 'summary': 'Less than half of all authorised medicines commonly used in children have been properly tested in this group, and running clinical trials involving children is hard.\nThe conect4children (c4c) project aims to create a sustainable, integrated pan-European collaborative paediatric network that will speed up and facilitate the running of high quality clinical trials in children while ensuring that the voices of young patients and their families are heard. It will build the capacity for conducting multinational paediatric clinical trials for all disease areas and all phases of the clinical drug development process.\nOne focus of the project is to promote innovative trial designs that will support drug development for rare paediatric diseases and areas of high medical need. The project will also set up an education and training platform for future leaders in paediatric drug development.\nUltimately, the paediatric clinical trials network will contribute to the development of better medicines for babies, children and young people.\n', 'tags': 'conect4children - Collaborative network for European clinical trials for children', 'participants': "Aristotelio Panepistimio Thessalonikis, Thessaloniki, Greece;Arsenal.It - Centro Veneto Ricercae Innovazione Per La Sanita Digitale, Treviso Tv, Italy;Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Lisbon, Portugal;Azienda Ospedaliero-Universitaria Anna Meyer, Firenze, Italy;Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy;Azienda Sanitaria Universitaria Integrata Di Udine, Udine, Italy;Azienda Socia-Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy;Bayer Aktiengesellschaft, Leverkusen, Germany;Consorzio Per Valutazioni Biologiche E Farmacologiche, Pavia, Italy;Ecrin European Clinical Research Infrastructure Network, Paris, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Cystic Fibrosis Society, Karup, Denmark;Eurordis - European Organisation For Rare Diseases Association, Paris, France;F. Hoffmann-La Roche AG, Basel, Switzerland;Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy;Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy;Fondazione Per La Ricerca Farmacologica Gianni Benzi Onlus, Valenzano Bari, Italy;Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Gyermekgyogyaszati Klinikai Vizsgaloi Halozat, Budapest, Hungary;Helse Bergen Hf*Haukeland University Hospital, Bergen, Norway;Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä, Helsinki, Finland;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Instytut Pomnik Centrum Zdrowia Dziecka, Warszawa, Poland;Istituto Di Ricovero E Cura A Carattere Scientifico Burlo Garofolo, Trieste, Italy;Istituto Giannina Gaslini, Genova, Italy;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Mmi Clinical Research Development Ireland, Dublin, Ireland;Novartis Pharma AG, Basel, Switzerland;Okids GMBH, Wien, Austria;Ospedale Pediatrico Bambino Gesu, Rome, Italy;Pfizer Limited, Sandwich, Kent , United Kingdom;Region Stockholm, Stockholm, Sweden;Rete Italiana Per Le Sperimentazioni Cliniche In Pediatria, Rome, Italy;Robert Bosch Gesellschaft Fur Medizinische Forschung Mbh, Stuttgart, Germany;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Servicio Madrileno De Salud, Madrid, Spain;Servizo Galego De Saude, Santiago de Compostela, Spain;Siop Europe Asbl, Brussels, Belgium;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Swiss Clinical Trial Organisation, Basel, Switzerland;Tartu Ulikool, Tartu, Estonia;The University Of Liverpool, Liverpool, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universita Degli Studi Di Cagliari, Cagliari, Italy;Universita Degli Studi Di Padova, Padova, Italy;Universita Degli Studi Di Roma Tor Vergata, Rome, Italy;Universitatsklinikum Heidelberg, Heidelberg, Germany;Universiteit Gent, Gent, Belgium;University College Cork -  National University Of Ireland, Cork, Cork, Ireland;University College London, London, United Kingdom;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;Univerzita Karlova, Prague 1, Czech Republic;Vseobecna Fakultni Nemocnice V Praze, Praha 2, Czechia", 'status': 'Ongoing'}, {'id': '0', 'name': 'CANCERID', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/cancer-id', 'summary': 'Monitoring treatment response still challenging\nWith more than 3 million new cases and 1.7 million deaths each year, cancer represents the second most important cause of death and illness in Europe, after cardio-vascular disease. New, more targeted treatments are emerging and a significant proportion of cancers can be cured or at least their progression can be slowed, especially if they are detected early. However, one of the main problems for doctors and patients remains monitoring the response to treatment in real time and detecting potential tumour mutations which can lead to drug resistance.\nCancer clues hiding in the blood\nCurrently tissue biopsies are used to diagnose and monitor the disease, but doctors cannot perform these too often because they are invasive, costly, and often risky for the patient. However, cancer is a highly dynamic disease and real-time diagnostic evaluation is very much needed to determine the best personalised treatment for patients at a given time.\nNow a new solution is on the horizon. Tumours shed cells and fragments of DNA into the bloodstream and these ‘biomarkers’ can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies. Technical advances over the last two decades have enabled the extraction of these biomarkers from the blood, in a process which is called ‘liquid biopsy’. Although promising, this new method is not without challenges: looking for these biomarkers in the blood is often like looking for a needle in the haystack made up of billions of normal blood cells. Furthermore, a comprehensive evaluation, validation and head-to-head comparison of these new technologies have not yet been done. IMI’s CANCER-ID project aims to fill this gap.\nCollaborative effort needed\nBy bringing together companies and institutions in the fields of tumour biology and cancer therapy, biomarker development, clinical sciences and bioinformatics, as well as regulatory agencies and patient advocacy groups, CANCER-ID will compare, evaluate and validate the most promising non-invasive technologies for liquid biopsy. With its over 30 partners from across Europe / the world, this project will bridge the gap between research focused on these novel methods and validating the most mature technologies so they can be adopted and brought to the patients as soon as possible.\nThe project will be divided into three key phases:\nIn the pre-evaluation phase, liquid biopsy technologies will be evaluated and the criteria will be set for any of the technologies to move to the next phase.\nIn the technical evaluation phase, the technologies identified as promising will be tested on patient samples.\nIn the third stage, validated methods will be used on patients as part of clinical studies. \xa0\nLung and breast cancer as pilots\nValidating these new technologies on all cancer types would be unmanageable. That’s why the project will focus on two-types of cancer: lung and breast cancer. Between them, lung and breast cancer account for approximately 760 000 new cases of cancer per year in the EU and are responsible for more than 50% of cancer-related deaths in women. Blood-based diagnostics will be important to improve treatment and to design new clinical trials in these patients.\nMore specifically, these two types of cancer have been selected for the following reasons:\nLung cancer is the most common cause of cancer-related deaths worldwide. In the EU, lung cancer is the leading cause of cancer death among men in all countries except Sweden and women die from lung cancer more commonly than from breast cancer in a growing number of countries. Treatments with targeted drugs perform better than traditional chemotherapy. However, one obstacle is the difficulty in obtaining serial biopsies to chart tumour evolution and the emergence of drug resistance. For these reasons, CANCER-ID has selected lung cancer for development, optimisation and standardisation of the liquid biopsy biomarkers.\nBreast cancer is the most common malignancy in women. Although several therapeutic options are readily available, resistance to these therapies often significantly limits the success rate. HER2 is the most prominent molecular target in breast cancer and it defines a clear molecular subtype. In CANCER-ID, researchers will focus on breast cancer patients who failed to respond to HER2-targeted therapies. Resistance to HER2-targeted therapies represents a serious medical problem and there is an urgent need to develop novel diagnostic tests for the early detection of resistance.\nBoth patients and industry to benefit\nOnce validated and approved for use in patients, these new methods will have a significant value for patients, physicians and payers since they will prevent exposure of patients to drugs that are unlikely to be beneficial. Moreover, validated biomarker tests will be extremely important for the pharmaceutical industry as they will help reduce the very high dropout rate in clinical development by selecting the right patients for the right drugs.\n', 'tags': 'Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood', 'participants': 'ANGLE Europe Ltd, Guildford, United Kingdom;Academisch Ziekenhuis Groningen, Groningen, Netherlands;Agena Bioscience GmbH, Hamburg, Germany;Agilent Technologies Sales & Services GmbH & Co. KG, Waldbronn, Germany;Alacris Theranostics GMBH, Berlin, Germany;Arttic, Paris, France;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Clearbridge Biomedics Pte Ltd, Singapore, Singapore;Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;Gilupi GMBH, Potsdam, Germany;Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany;Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä, Helsinki, Finland;Institut Curie, Paris, France;Institut De Recherches Servier, Suresnes, France;Institut Gustave Roussy, Villejuif, France;Istituto Oncologico Veneto, Padova, Italy;LIFE TECHNOLOGIES GmbH, Darmstadt, Germany;Luxembourg Institute Of Health, Luxembourg, Luxembourg;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Medizinische Universitat Graz, Graz, Austria;Menarini Silicon Biosystems S.A, Bologna, Italy;Orion Oyj, Espoo, Finland;Oslo Universitetssykehus Hf, Oslo, Norway;Qiagen GMBH, Hilden, Germany;Siemens Healthcare Diagnostics Products GMBH, Marburg, Germany;Tataa Biocenter AB, Göteborg, Sweden;Terumo Bct Europe Nv, Lakewood, United States ;The University Of Manchester, Manchester, United Kingdom;Universita Degli Studi Di Torino, Turin, Italy;Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany;Universite De Montpellier, Montpellier, France;Universiteit Twente, Enschede, Netherlands;University of Cambridge, Cambridge, United Kingdom;VyCAP BV, Deventer, Netherlands', 'status': 'Ongoing'}, {'id': '0', 'name': 'CARDIATEAM', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/cardiateam', 'summary': 'Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is characterised by functional and structural abnormalities in the heart. Currently, the underlying causes of diabetic cardiomyopathy remain unknown, and there are no effective treatments.\nThe CARDIATEAM project aims to determine how distinct diabetic cardiomyopathy is from other forms of heart failure, and the extent to which type 2 diabetes contributes to its development and progression. The team will recruit 1 600 people with a range of cardiometabolic disorders, including people with diabetes, and follow them for 3 years. By studying this group in detail over time, the team hopes to be able to deliver biological markers that would indicate which diabetes patients are at greatest risk of developing diabetic cardiomyopathy, as well as a more detailed understanding of the disease.\nUltimately, the project results will make it easier to provide people with diabetes with more personalised approaches to managing their condition and preventing diabetic cardiomyopathy.\n', 'tags': 'Cardiomyopathy in type 2 diabetes mellitus', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Assistance Publique Hopitaux De Paris, Paris, France;Bayer Aktiengesellschaft, Leverkusen, Germany;Centre D'Etude Et De Recherche Multimodal Et Pluridisciplinaire En Imagerie Du Vivant Gie, Bron Cedex, France;Clinical Trial Center Maastricht, Maastricht, Netherlands;Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain;Fundacio Privada Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, Barcelona, Spain;Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon, Madrid, Spain;Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal, Madrid, Spain;Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany;Hospices Civils De Lyon, lyon, France;Inserm Transfert SA, Paris, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Katholieke Universiteit Leuven, Leuven, Belgium;Luxembourg Institute Of Health, Luxembourg, Luxembourg;Metabrain Research, Maison-Alfort, France;Opale, Paris, France;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;Stichting Netherlands Heart Institute, Utrecht, Netherlands;Stichting Vumc, Amsterdam, Netherlands;The Queen'S University Of Belfast, Belfast, United Kingdom;Universita Degli Studi Di Torino, Turin, Italy;Universitaetsklinikum Aachen, Aachen, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitatsklinikum Heidelberg, Heidelberg, Germany;Universite D'Aix Marseille, Marseille, France;University Of Dundee, Dundee, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'CARE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/care', 'summary': 'The goal of the CARE project is to deliver treatments for the current COVID-19 outbreak as well as future coronavirus outbreaks.\nPart of the project will focus on ‘repurposing’, in which drugs designed for other diseases are ‘repurposed’ for a new disease. Because a lot of work has already been carried out on these compounds, repurposing can deliver relatively rapid results.\nThe project also aims to deliver new drugs designed specifically to treat COVID-19 and other coronaviruses. To identify potential drugs, the project will screen 600 000 compounds across different libraries. They will also investigate antibodies capable of neutralising the virus.\nPotential drugs identified by the project will undergo a range of laboratory tests to refine their design and evaluate and improve their safety and efficacy. Compounds that make the grade will enter clinical trials, where their safety and efficacy will be tested in humans.\nThe CARE project is committed to the FAIR (findable, accessible, interoperable, reusable) principles of open science and will share its scientific results through open access platforms and peer-reviewed journals, as well as via relevant conferences and other events. The team will also work closely with other, similar projects.\nUltimately, CARE should both contribute to the world’s response to the current COVID-19 outbreak, and ensure we are better prepared for further coronavirus outbreaks in the future.\n', 'tags': 'Corona accelerated R&D in Europe', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Ai-Biopharma, Montpellier, France;Aicuris Anti-Infective Cures GMBH, Wuppertal, Germany;Astellas Pharma Europe BV, Leiden, Netherlands;Bayer Aktiengesellschaft, Leverkusen, Germany;Bill & Melinda Gates Foundation, Seattle, United States;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Centre National De La Recherche Scientifique Cnrs, Paris, France;Centrum Voor Innovatie En Stimulatie Van Medicijnontwikkeling Leuven Vzw, Leuven, Belgium;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Eidgenoessisches Departement Des Innern, Bern, Switzerland;Enyo Pharma, Lyon, France;Eurovacc Foundation, Lausanne, Switzerland;Exscientia Limited, Dundee, United Kingdom;Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La Paz, Madrid, Spain;Global Health Drug Discovery Institute, Beijing, China (People's Republic of);Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany;Inserm Transfert SA, Paris, France;Institut De Recherches Servier, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Katholieke Universiteit Leuven, Leuven, Belgium;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Nuvisan Icb GMBH, Berlin, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Scifeon Aps, Soborg, Denmark;Servicio Madrileno De Salud, Madrid, Spain;Stiftung Tieraerztliche Hochschule Hannover, Hannover, Germany;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;The University Of Edinburgh, Edinburgh, United Kingdom;UNIVERSITAET zu LUEBECK, Luebeck, Germany;Universitaet Hamburg, Hamburg, Germany;Universite D'Aix Marseille, Marseille, France;Universite De Bordeaux, Bordeaux, France;Universite Paris Xii Val De Marne, Creteil cedex, France;Universiteit Utrecht, Utrecht, Netherlands;University Of Dundee, Dundee, United Kingdom;Uniwersytet Jagiellonski, Krakow, Poland", 'status': 'Ongoing'}, {'id': '0', 'name': 'CHEM21', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/chem21', 'summary': 'The main challenge of CHEM21 was to improve the environmental footprint of drug manufacture and to identify and synthesise new catalysts which could help achieve this. With the aim of developing a portfolio of sustainable technologies for green chemical manufacture, the CHEM21 scientists had to identify reactions and methodologies that address current bottlenecks in the sustainability of processes applied to synthesising active pharmaceutical ingredients.\nMeasurable impact\nThe key project achievement was the integration of chemical, biocatalytic and synthetic chemistry methods with improved engineering methods, supported by objective green metric methods for impacts. As a result of this, the consortium developed a unified metrics toolkit that facilitates the comprehensive evaluation of the sustainability of chemical and biochemical reactions based on a series of parameters. The toolkit uses a blend of both qualitative and quantitative criteria to assess how green the chemical reaction is.\nAn early breakthrough for CHEM21 was for a more efficient method for the synthesis of flucytosine, an antifungal medication regularly used to treat fungal infections that are associated with HIV. Flucytosine is not available or registered in Africa and is too expensive to be broadly used. If the medicine could be manufactured more innovatively and cheaply, 500 000 HIV-related deaths per year in Africa could be prevented.\nPrior to CHEM21’s development of a more efficient method for making flucytosine, there wasn’t any cheap manufacturing process or supplier available. CHEM21 demonstrated that the flucytosine could be made, on an industrial scale, at a much reduced cost.\nAnother important result was the development of a new toolbox of biocatalysts (biocatalysts are enzymes used to speed up reactions). CHEM21 successfully enabled the wide usage of biocatalysis as a clean chemistry option, especially for smaller companies who did not routinely use this method before. Several new classes of enzymes were delivered with examples of improved properties, and the new access models made these rapidly available. CHEM21 scientists accelerated the development of imine reductases (IREDs), a novel class of enzyme which is now widely adopted and used by the industry in an exceptionally short time.\nUse of technologies that were previously not widely utilised within the pharmaceutical industry, such as synthetic biology, chemocatalysis and biocatalysis, led to the development of more sustainable routes, based on CHEM21 metrics, to analyse various problems in medicine production. Within the project, several flow chemistry methods were developed: fluorination, oxidation, hydrogenation, and nucleophilic displacement. All of these methodologies demonstrated cleaner reactions with better green metrics.\nCHEM21 also led the development of simple synthetic biology methods to synthesise pharmaceutically relevant molecules. For example, 2-Amino -1-butanol is a key intermediate in the production of ethambutol, a WHO essential medicine used to treat tuberculosis. Usually it is made in India through a very environment-unfriendly, dirty process, but the project succeeded in using yeast for its manufacture.\nOther achievements\nTraining – online and free education on green chemistry for current and future scientists, as well as for the wider pharmaceutical industry. Around 8 000 students graduated from this open course.\nDeveloped “Vision 2020” by reviewing the state of the art and uptake of green chemistry and biotechnology in pharmaceutical manufacture over the last 20 years.\nStudied the future needs for the type of molecules that will be the main targets in the 2020 pharmaceutical drugs portfolio.\nA green legacy\nThe biggest impact of the CHEM21 project is the changed work procedures in early stage process development in EFPIA members and the launch of the new tool that led to metric-based analysis at early stages, meaning that ‘green chemistry’ is embedded in the overall approach to chemical development. Many tools that CHEM21 produced are used by the pharmaceutical industry, with EFPIA members making follow on investments by using the CHEM21 technologies on a widespread basis. Thanks to the project, Bisy (an SME involved in enzyme production that was a spinout from project partner ACIB) significantly expanded to other areas of chemistry production. CHEM21 also provided hundreds of new cleaner catalysts with less use of critical elements, which EFPIA members are now routinely using. All of the technologies used by the project: synthetic biology, chemocatalysis and biocatalysis that are often underused by the industry; thanks to CHEM21, they got the attention they deserveand today are being used to provide greener options for medicine production.\nRead our interview with the project leaders\n', 'tags': 'Chemical manufacturing methods for the 21st century pharmaceutical industries', 'participants': 'Acib GMBH, Graz, Austria;Bayer Pharma AG, Berlin, Germany;CatScI Ltd, Wentloog, Cardiff, United Kingdom;Evolva AG, Reinach, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Leibniz - Institut Fur Katalyse Ev An Der Universitat Rostock, Rostock, Germany;Orion Oyj, Espoo, Finland;Pfizer Limited, Sandwich, Kent , United Kingdom;Reaxa Limited, Leeds, United Kingdom;Sanofi Chimie, Gentilly, France;Stichting Vu, Amsterdam, Netherlands;Technische Universitaet Graz, Graz, Austria;The University Of Manchester, Manchester, United Kingdom;Universitaet Graz, Graz, Austria;Universitaet Stuttgart, Stuttgart, Germany;Universiteit Antwerpen, Antwerp, Belgium;University Of Durham, Durham, United Kingdom;University Of Leeds, Leeds, United Kingdom;University Of York, York, United Kingdom;charnwood technical consulting ltd, quorn, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'COMBACTECARE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/combacte-care', 'summary': 'Antimicrobial resistance (AMR) represents a serious and growing threat to human and animal health worldwide. In the EU alone, AMR is responsible for some 25 000 deaths every year, and the annual treatment and social costs have been estimated at €1.5 billion. Meanwhile, new forms of resistance continue to arise and spread, leaving clinicians with few weapons to bring infections under control. Yet despite the recognised need for new antibiotics, the reality is that only two new classes of antibiotics have been brought to the market in the last three decades.\nIn many cases, where infections are already resistant to many antibiotics, the treatment of last resort is a class of antibiotics called carbapanems. Unfortunately, recent years have seen a rise in cases of infections caused by bacteria known as carbapanem-resistant enterobacteriaceae (CRE) that, as their name suggests, are resistant to carbapanems. CRE infections are most common in healthcare settings. They are extremely hard to treat (very often the only treatment options are combinations of old, toxic antibiotics) and can be fatal.\nAccording to the European Centre for Disease Prevention and Control (ECDC), cases of CRE infections have been reported in most European countries and rates of CRE infections are on the rise.\nFocus on the toughest resistant infections\nCRE infections form the focus of the COMBACTE-CARE project. Simply detecting CRE infections is challenging, as CRE bacteria are extremely diverse. With this in mind, one challenge for the COMBACTE-CARE team will contribute to both the rapid detection and characterisation of CRE infections. They will also work to deliver new knowledge on biological markers that predict which patients with the most serious healthcare-associated infections are at risk of poor outcomes.\nMore broadly, the project will analyse clinical and microbiological data to make recommendations for the development of novel antibiotics to treat resistant infections. They will also carry out research on the clinical management and outcomes of hospitalised patients (including newborn babies, children, and adults) with serious infections to identify the best available treatments.\nCOMBACTE-CARE forms part of IMI’s wider New Drugs for Bad Bugs (ND4BB) programme, and will work closely with and build on the pan-European clinical and laboratory networks (CLIN-Net and LAB-Net) set up by the COMBACTE project. COMBACTE-CARE will focus specifically on building capacity in clinical sites in south-eastern Europe, where rates of multi-drug resistance are particularly high.\nThese networks will allow the team to carry out clinical trials of a novel antibiotic combination product called Aztreonam-Avibactam (ATM-AVI). ATM-AVI is a potential option designed to tackle a sub-type of CRE infections that is especially hard to treat.\nAn urgent need\nCREs pose a growing threat to patients and health systems in Europe and beyond. By taking steps to improve the way infections are diagnosed and treated, COMBACTE-CARE is well placed to contribute to efforts to tackle these dangerous infections.\n', 'tags': 'Combatting Bacterial Resistance in Europe - Carbapenem Resistance', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Basilea Pharmaceutica International AG, Basel, Switzerland;Cardiff University, Cardiff, United Kingdom;Centre Hospitalier Universitaire De Poitiers, Poitiers, France;Centre hospitalier universitaire de Limoges, Limoges, France;Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece;Fundacion Privada Instituto De Salud Global Barcelona, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;MINISTRIA E SHENDETESISE (National Institute of Public Health of Kosovo), Pristina, Kosovo * UN resolution;Pfizer Limited, Sandwich, Kent , United Kingdom;Servicio Andaluz De Salud, Sevilla, Spain;Servicio Madrileno De Salud, Madrid, Spain;St George'S Hospital Medical School, London, United Kingdom;The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv, Tel Aviv, Israel;The Health Corporation - Rambam, Haifa, Israel;Universitaet Ulm, Ulm, Germany;Universitaetsklinikum Freiburg, Freiburg, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universite De Geneve, Genève 4, Switzerland;Universite De Poitiers, Poitiers , France;Universiteit Antwerpen, Antwerp, Belgium", 'status': 'Ongoing'}, {'id': '0', 'name': 'COMBACTECDI', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/combacte-cdi', 'summary': 'Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections, with 172 000 cases annually, many of them in the elderly, in Europe alone. Symptoms include diarrhoea and abdominal pain, and it can prove fatal. Despite its immense impact on patients and healthcare systems, researchers lack a good understanding of the epidemiology and clinical impact of CDI across Europe. The goal of the COMBACTE-CDI project is to change that, by delivering extensive data on the extent and impact of CDI across all healthcare sectors in Europe. This information is essential for the development of better methods to prevent and treat CDI.\nA large part of the project is devoted to a large epidemiology study which will quantify the burden of CDI (including incidence, distribution, recurrence, mortality, and transmission) across the whole healthcare economy. The project will also assess current practices on the management of CDI in Europe (including guidelines, testing, surveillance, treatment, and costs) and their potential impacts. Finally, the project will create a pan-European research platform capable of supporting future proof-of-concept and clinical studies of new prevention and treatment strategies for CDI.\nIn the long term, the knowledge generated by COMBACTE-CDI will aid the development of better strategies to prevent and treat this deadly infection.\n', 'tags': 'Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections', 'participants': "Academisch Ziekenhuis Leiden, Leiden, Netherlands;Biomerieux SA, Marcy L'Etoile, France;Da Volterra SAS, Paris, France;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Nacionalni Laboratorij Za Zdravje, Okolje In Hrano, Maribor, Slovenia;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi Pasteur SA, Lyon, France;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universiteit Antwerpen, Antwerp, Belgium;University Of Leeds, Leeds, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'COMBACTEMAGNET', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/combacte-magnet', 'summary': 'Antimicrobial resistance (AMR) represents a serious and growing threat to human and animal health worldwide. In the EU alone, AMR is responsible for some 25 000 deaths every year, and the annual treatment and social costs have been estimated at €1.5 billion. Meanwhile, new forms of resistance continue to arise and spread, leaving clinicians with few weapons to bring infections under control. Yet despite the recognised need for new antibiotics, the reality is that only two new classes of antibiotics have been brought to the market in the last three decades.\nCritically-ill patients in hospital intensive care units (ICUs) are particularly prone to infections of the lungs and airways, urinary tract, and intra-abdominal area. Very often, these infections are caused by so-called ‘Gram-negative’ bacteria, such as Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. These bacteria are increasingly proving resistant to antibiotics, meaning there is an urgent need for new treatment options. However, the antibiotic development pipeline is running dry.\nCOMBACTE-MAGNET – focus on intensive care patients\nThe COMBACTE-MAGNET project takes a new approach to preventing P. aeruginosa infections, especially pulmonary infections in ICU patients, and treating patients with life-threatening infections caused by MDR Gram-negative bacteria, including P. aeruginosa.\nThe project will link up with and add to the pan-European clinical and laboratory networks (CLIN-Net and LAB-Net) set up by COMBACTE, one of the first projects in IMI’s antimicrobial resistance programme New Drugs for Bad Bugs (ND4BB). COMBACTE-MAGNET will also oversee the creation of a new network called EPI-Net, which will map and connect existing surveillance systems in Europe to optimise efforts to monitor the spread of antibiotic resistance and healthcare-associated infections. EPI-Net will draw on the expertise of a range of stakeholders to develop harmonised measures for the surveillance of healthcare associated infections in Europe.\nHope for new antibacterials\nTwo novel compounds will be developed through clinical trials carried out in COMBACTE-MAGNET.\nThe first, MEDI3902 (developed by MedImmune, AstraZeneca), is a promising new anti-bacterial monoclonal antibody for the treatment of P. aeruginosa infections, especially pulmonary infections, in ICU patients. The project team will carry out Phase 2 and 3 trials in adult ICU patients; these trials, involving larger numbers of patients are designed to gather information on the safety and efficacy of the medicine. The project will also carry out a Phase 1 study of MEDI3902 in children; this study, involving only a small number of children, focuses primarily on safety and understanding how the drug is processed by the body in children.\nThe second drug, AIC499 (developed by AiCuris), a new beta-lactam antibiotic has shown to be effective against a broad range of MDR Gram-negative bacteria. COMBACTE-MAGNET will carry out Phase 1 and Phase 2 trials to assess its safety and efficacy of AIC499. If the trial results are positive, AIC499 could prove useful in the treatment of patients with life-threatening infections.\nThe clinical studies of MEDI3902 and AIC499 will be supported by additional research that will shed new light on the consequences of P. aeruginosa infections. They will also study factors that influence how different patients respond to infection.\nAn urgent need\nPatients in intensive care are already seriously ill, and infection with a multi-drug resistant bug can prove fatal. COMBACTE-MAGNET brings together leading researchers from academia and industry, and has strong ties with the other projects in IMI’s ND4BB programme as well as other relevant networks. As such it is well placed to advance the development of new, life-saving treatment options for this vulnerable group of patients.\n', 'tags': 'Combatting bacterial resistance in Europe - molecules against Gram negative infections', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Aicuris Anti-Infective Cures GMBH, Wuppertal, Germany;Assistance Publique Hopitaux De Paris, Paris, France;Astrazeneca AB, Södertälje, Sweden;Basilea Pharmaceutica International AG, Basel, Switzerland;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Centre hospitalier universitaire de Limoges, Limoges, France;Cliniques Universitaires Saint-Luc, Brussels, Belgium;Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Forum For Good Clinical Practice, Brussels, Belgium;Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Hospital Clinico Y Provincial De Barcelona, Barcelona, Spain;Inst Cardiometabolisme Nutrition Ican, Paris, France;Institut Catala De La Salut, Barcelona, Spain;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Medizinische Universitaet Wien, Vienna, Austria;North Bristol National Health Service Trust, Bristol, United Kingdom;Royal Liverpool And Broadgreen University Hospitals Nhs Trust, Liverpool, United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Servei De Salut De Les Illes Balears, Palma, Spain;Servicio Andaluz De Salud, Sevilla, Spain;Servicio Madrileno De Salud, Madrid, Spain;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Tel Aviv University, Tel Aviv, Israel;The University Of Liverpool, Liverpool, United Kingdom;TranScrip Partners LLP, Reading, United Kingdom;Universita Degli Studi Di Verona, Verona, Italy;Universitaet Ulm, Ulm, Germany;Universitaetsklinikum Freiburg, Freiburg, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitat Zurich, Zürich, Switzerland;Universite De Geneve, Genève 4, Switzerland;Universite Paris Diderot - Paris 7, Paris, France;Universiteit Antwerpen, Antwerp, Belgium;University College London, London, United Kingdom;University Of The West Of England, Bristol, Bristol, United Kingdom;University of Oxford, Oxford, United Kingdom;Ursula Theuretzbacher, Vienna, Austria", 'status': 'Ongoing'}, {'id': '0', 'name': 'COMBACTENET', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/combacte-net', 'summary': 'The AMR arms race – developing New Drugs for Bad Bugs\nAMR represents a serious and growing threat to human and animal health worldwide. According to the World Health Organization (WHO), ‘antibiotic resistance is becoming a public health emergency of yet unknown proportions’. In the EU, AMR is responsible for some 25 000 deaths every year, and the annual treatment and social costs have been estimated at some €1.5 billion. Meanwhile, new forms of resistance continue to arise and spread, leaving clinicians with few weapons to bring infections under control. Yet despite the recognised need for new antibiotics, the reality is that only two new classes of antibiotics have been brought to the market in the last three decades.\nThe reasons for this are manifold. On the scientific front, there is an urgent need for a greater understanding of how antibiotics work, how bacteria develop resistance to them, and what molecular mechanisms could be exploited to get round bacterial defence mechanisms. Running clinical trials on new antibiotics is also problematic due to regulatory requirements and the large numbers of patients required– put simply, a lot of patients have to be recruited to the major studies of efficacy performed for each clinical indication sought in order to be sure of having enough patients with the resistant bacteria under investigation and to demonstrate that the new antibiotic is not inferior to comparable antibacterial drugs. These issues mean that the costs of carrying out a clinical trial on a new antibiotic are extremely high.\nAt the same time, because some antibiotics will only be used on a very small number of patients, the costs of development often exceed the potential return on investment. In other words, antibiotic development is simply no longer a financially viable option for pharmaceutical companies, and just a handful of pharmaceutical companies remain in the field.\nIf no action is taken to address these issues, we risk leaving society in a situation where doctors will have few, if any, options to treat resistant bacterial infections. To avoid a public health emergency, the entire antibiotic research community, including researchers in universities, small and medium-sized enterprises (SMEs), and pharmaceutical companies must work together to reinvigorate research into new antibiotics. As a public-private partnership (PPP), IMI is the ideal platform to launch such an initiative.\nIn its Action Plan against the rising threats from Antimicrobial Resistance of November 2011, the European Commission called for ‘unprecedented collaborative research and development efforts to bring new antibiotics to patients’ by, among other things, launching an IMI programme ‘for research on new antibiotics aimed at improving the efficiency of research and development of new antibiotics through unprecedented open sharing of knowledge’.\nThe result is the New Drugs for Bad Bugs (ND4BB) programme, which includes the COMBACTE project.\nCOMBACTE – improving clinical trials for antibiotics\nThe COMBACTE project focuses on addressing the barriers to clinical development. A key outcome of the project will be a high quality, pan-European clinical trial network. Dubbed COMBACTE CLIN-Net, it will be capable of recruiting sufficient patients into multinational trials at all stages of development. Alongside this, the project will also establish a pan-European laboratory network (COMBACTE LAB-Net), which will deliver epidemiological information and data from microbial surveillance work to guide the selection of clinical trial sites. Crucially, the COMBACTE team aims to generate innovative trial designs to facilitate the registration of novel antibacterial agents. It will also design and validate tests to support the diagnosis of patients, identify the most appropriate treatments, and monitor the patient’s response.\nA large part of the project will be devoted to the performance of clinical trials of drugs under development in the pharmaceutical companies involved in the project. The first antibiotic to undergo clinical trials under COMBACTE is GSK1322322, which inhibits the action of a bacterial enzyme called peptide deformylase (PDF) and appears to be effective against multi-drug resistant respiratory and skin pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). Most importantly, GSK1322322 represents a new class of antibiotics with a novel mode of action. In COMBACTE, experts will run clinical trials to evaluate GSK1322322’s efficacy at treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.\nThe second compound to be tested will be MEDI4893, which is designed to prevent S. aureus disease by neutralising a specific toxin produced by the bug which is behind much of the tissue and organ damage associated with S. aureus infections. Considering the importance of S. aureus as a human pathogen and the extensive problems with antibiotic resistance, MEDI489 represents an attractive preventive measure for patients at high risk of S. aureus infections. Early clinical trials will evaluate the efficacy and safety of MEDI4893 at preventing infections in patients at risk of S. aureus surgical site infections and mechanically-ventilated patients at risk for S. aureus pneumonia. Finally, to support more broadly the clinical development of new treatments for S. aureus, the consortium will gather new data on hospital-associated infections by carrying out epidemiological surveillance among surgical and intensive care unit (ICU) patients across Europe. This will help to assess the impact of patient-related and other factors on the incidence of surgical site infections and ICU pneumonia to identify the patient subgroups that are at an increased risk of these infections.\nHope for the future\nThe challenge of antimicrobial development is so great that no organisation could take it on alone. By bringing together leading experts from universities, hospitals, and pharmaceutical companies who are skilled in microbiology, epidemiology, drug development, and clinical trial design, COMBACTE is set to give antibiotic development in Europe a major boost.\nUnique in its scale, ambition, and its potential benefits for patients, public health and pharmaceutical research in Europe, COMBACTE has the potential to become the powerhouse of antimicrobial drug development in Europe that could serve as a standard for other groups. Ultimately, the hope is that COMBACTE will provide a framework for the rapid and efficient development of new treatments as well as diagnostic tests that can be speedily commercialised for use on the patients that so urgently need them.\n', 'tags': 'Combatting Bacterial Resistance in Europe', 'participants': "Ao Documentation And Publishing Foundation, Davos, Switzerland;Astrazeneca AB, Södertälje, Sweden;CHU de Pointe-à-Pitre, Pointe-à-Pitre, France;Centre hospitalier universitaire de Limoges, Limoges, France;Cliniques Universitaires Saint-Luc, Brussels, Belgium;Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain;Da Volterra SAS, Paris, France;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Ecrin European Clinical Research Infrastructure Network, Paris, France;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece;European Forum For Good Clinical Practice, Brussels, Belgium;Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy;Fundacion Privada Instituto De Salud Global Barcelona, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany;Hospital Clinico Y Provincial De Barcelona, Barcelona, Spain;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Instituto Nacional De Saude Dr. Ricardo Jorge, Lisbon, Portugal;Janssen Pharmaceutica Nv, Beerse, Belgium;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Julius Clinical Research BV, Zeist, Netherlands;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Linkopings Universitet, Linkoping, Sweden;Medizinische Hochschule Hannover, Hannover, Germany;North Bristol National Health Service Trust, Bristol, United Kingdom;Pfizer Limited, Sandwich, Kent , United Kingdom;Servicio Andaluz De Salud, Sevilla, Spain;Servicio Madrileno De Salud, Madrid, Spain;The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv, Tel Aviv, Israel;The Medicines Company, Parsippany, United States ;Twincore, Zentrum Fur Experimentelle Und Klinische Infektionsforschunggmbh, Hannover, Germany;Universita Degli Studi Di Verona, Verona, Italy;Universitaet Greifswald, Greifswald, Germany;Universitaetsklinikum Freiburg, Freiburg, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitair Ziekenhuis Antwerpen, Edegem, Belgium;Universitat Zurich, Zürich, Switzerland;Universite De Geneve, Genève 4, Switzerland;Universite Lyon 1 Claude Bernard, Villeurbanne, France;Universite Paris Diderot - Paris 7, Paris, France;Universiteit Antwerpen, Antwerp, Belgium;University of Oxford, Oxford, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'COMBINE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/combine', 'summary': 'IMI’s Antimicrobial Resistance (AMR) Accelerator programme comprises several projects with the shared goal of progressing the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide. The COMBINE project was created to coordinate the AMR Accelerator projects and provide them with the resources they need to achieve their goals.\nThese include data management guidelines and an IT infrastructure to enable the collection, aggregation, storage, sharing and analysis of datasets generated by AMR Accelerator projects. COMBINE will also help to ensure that data adheres to ‘FAIR’ principles, i.e. it is findable, accessible, interoperable, and re-useable. Promoting communication among the projects is another COMBINE priority.\nOn the scientific front, COMBINE aims to improve the animal models used in AMR research and develop improved tools to reliably translate results in animals into results in humans. The project also aims to optimise the design and analysis of clinical trials. These tools will help all projects in the programme to deliver results that will help to accelerate the development of novel antibiotics and vaccines against AMR.\n', 'tags': 'Collaboration for prevention and treatment of MDR bacterial infections', 'participants': 'Asclepia Outsourcing Solutions Bvba, Destelbergen, Belgium;Beam Alliance, Paris, France;Biocom, Berlin, Germany;Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany;Evotec International GMBH, Hamburg, Germany;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Gritsystems As, Dragør, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;Statens Serum Institut, Copenhagen S, Denmark;Uppsala Universitet, Uppsala, Sweden', 'status': 'Ongoing'}, {'id': '0', 'name': 'COMPACT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/compact', 'summary': 'Biopharmaceuticals, medicines based on biological molecules such as proteins and nucleic acids, have already delivered effective treatments for a number of serious, often hard to treat diseases, such as Crohn’s disease and multiple sclerosis, dramatically improving patients’ quality of life.\nThe pharmaceutical industry is keen to expand its work on these novel drugs, but biopharmaceuticals still have a number of drawbacks which are hampering their broader application. For example, because these molecules tend to be complex and delicate, most biopharmaceuticals have to be injected; if they were administered orally (a more patient-friendly route), they would be destroyed by the harsh environment of the stomach. Furthermore, even once biopharmaceuticals are in the body, their large size means it is hard for them to get to their molecular targets.\nBy bringing together 14 academic groups, 7 pharmaceutical companies and 2 SMEs, the COMPACT project set out to reduce delivery and targeting bottlenecks for developing innovative biopharmaceuticals.\nBetter understanding of nanomedicines\nOne of the most significant project achievements is related to getting biopharmaceuticals from the injection site to the target that is causing the disease. For that purpose, researchers use nanocarriers, modifying their surface so that they bind to specific cells. COMPACT researchers discovered why this modification works in certain cases and not in others, which led to a better understanding of how nanomedicines work. The project also developed a novel nanoparticle to get a new type of therapeutic oligonucleotide into the lungs via inhalation.\nMore patient-friendly ways of administering drugs\nAnother important project outcome has to do with making the delivery systems for biological molecules more patient friendly. For example, insulin is a very effective treatment for diabetes but it has to be administered via injections. The COMPACT project researchers investigated whether insulin and similar biologicals could be delivered via tablets, which would be a more patient-friendly route. They showed that when insulin is taken via oral delivery, certain cell penetrating peptides can help in getting the molecules over the intestinal barrier into the blood. This represents the first important step towards the oral delivery of biological molecules.\nAdditionally, the project developed microneedles which can deliver peptides directly into the skin using a nanomedicine type of approach. These microneedles are so fine that they dissolve after they are inserted into the skin, representing a more patient-friendly alternative to traditional injections.\nImportant breakthrough in the blood-brain barrier\nAnother important achievement concerns the blood-brain barrier. The brain is a really isolated organ as there is a tight barrier between the blood and the brain cells. Getting across this barrier is a huge limitation in drug delivery. In this project, researchers identified potential new targets that can be used to get drugs into the brain. This is only at the target identification level at this stage but has led to a new IMI project which will explore those possibilities in more detail.\nDatabase, cell banks and other achievements\nOther important project achievements include:\na wide repertoire of drug delivery systems, fully characterised and tested;\nin vitro and in vivo tools to study delivery, including transgenic reporter mice;\na manually curated database containing over 1 200 entries with useful searchable information from the scientific literature on nonlipid nanoparticles and neurotrophic viruses;\ncell banks containing the most relevant cell lines and standardised protocols and a serum source to be used by all the partners throughout the consortium;\na strong network of industry and academia to further explore collaborations via bilateral agreements and European funding.\nSocio-economic benefits\nIn addition to the scientific achievements, the project generated significant socio-economic benefits. For example, during the course of the project two patents were filed: one for brain delivery and another for the nanocarrier system for lung delivery.\nIn order to build on the project achievements, a biotech company has also spun out from Oxford University. The company will look into developing exosomes –nano-sized lipid vesicles which shuttle proteins and genetic information between cells for the delivery of oligonucleotide-based therapeutics. The system is still at an early stage, but once developed, could be of great interest for pharmaceutical companies.\nFurthermore, several companies which were not part of COMPACT are now also showing interest in the delivery systems developed within the project. They are collaborating with some of the COMPACT academic partners to see if these delivery systems could be used for their therapeutics. In the long run, these new collaborations could lead to the development of a new line of therapeutics.\nFor the benefit of industry, academia, SMEs\nFor academic partners this project was a great opportunity to work with the industry, use their R&D infrastructure, and learn what kinds of problems they encounter during the drug development process. The project also contributed to training of a new generation of pharmaceutical scientists that have a better understanding of the needs and limitations of the drug development process. During the course of the project, 19 PhD students got their doctorate degrees and 5 \xa0found jobs at the companies of industry partners.\nThe pharmaceutical companies benefitted from being able to test novel nanocarrier based delivery approaches directly with academic partners. They also benefitted from the network that has been created within the project, not just with academic partners and SMEs but also with other key players in industry.\nThe SMEs in the project benefitted from access to industry knowledge and resources, getting a close-up view of the drug development process, and from being treated as an equal partner in the project.\nBenefits for patients\nBiopharmaceuticals have the potential to improve the lives of many patients with diseases and conditions that are currently hard or even impossible to treat. By finding more effective ways of administering these drugs, and improving their ability to travel through the body to where they are needed, the COMPACT project outcomes will allow more patients to benefit from biopharmaceuticals. Furthermore, designing less invasive administration routes and reducing the dose (and therefore the side effects) and frequency of administration will help to improve patient compliance with treatments.\nWhat’s next\nThe project resulted in both tangible and non-tangible assets that will be useful for further research. Among the tangible assets are the transgenic mice for analysing biodistribution of nanocarrier systems. These are already accessible to researchers through a commercial company.\nNon-tangible assets include more than 65 publications and the know-how that has been generated and will be further developed by researchers in the field, including those in follow-on IMI projects.\nInterview with project coordinators\n', 'tags': 'Collaboration on the optimisation of macromolecular pharmaceutical access to cellular targets', 'participants': 'Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Bioneer A/S, Horsholm, Denmark;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Cardiff University, Cardiff, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany;Kobenhavns Universitet, Copenhagen, Denmark;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Norges teknisk-naturvitenskapelige universitet - NTNU, Trondheim, Norway;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Pharmacoidea Fejleszto Es Szolgaltato Kft, Szeged, Hungary;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Stockholms Universitet, Stockholm, Sweden;Universitat Wien, Vienna, Austria;Universitat Zurich, Zürich, Switzerland;Universiteit Gent, Gent, Belgium;Universiteit Leiden, Leiden, Netherlands;Universiteit Utrecht, Utrecht, Netherlands;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Oxford, Oxford, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'CONCEPTION', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/conception', 'summary': 'Women who are pregnant or breastfeeding are traditionally excluded from medical research due to safety concerns. As a result of this, only 5 % of medications have adequate safety information on their use in pregnant or breastfeeding women, and this makes it very hard for doctors and women to make informed decisions about their treatment. Nonetheless, some 90 % of women are exposed to a prescription medication at some point during their pregnancy.\nThe ultimate goal of ConcePTION is to create a trusted biomedical ecosystem capable of providing evidence-based information on the safety of medications during pregnancy and breastfeeding in an efficient, systematic and ethically responsible way. The information will be provided in a form that is usable by both healthcare providers and patients alike.\nThe project will achieve this in a number of ways. Firstly, it will improve and unify existing approaches to data collection in this area by re-using existing, de-identified data generated during routine patient care. The project also aims to deliver procedures and tools for the collection of digital data and samples directly from pregnant women.\nThey will also create the first Europe-wide breast milk biobank for research purposes, and develop tools to predict which drugs are likely to be transferred to breast milk. Finally, the team will establish a web-based drug information knowledge bank.\n', 'tags': 'Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Academisch Ziekenhuis Groningen, Groningen, Netherlands;Agenzia Regionale Di Sanita, Firenze, Italy;Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy;Biobanks And Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric), Graz, Austria;Bionotus, Temse, Belgium;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Consiglio Nazionale Delle Ricerche, Roma, Italy;Covance Laboratories LTD, Harrogate, United Kingdom;Elevate BV, Utrecht, Netherlands;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Ellegaard Gottingen Minipigs As, Dalmose, Denmark;European Forum For Good Clinical Practice, Brussels, Belgium;European Institute Of Women'S Health Company Limited By Guarantee, Dublin, Ireland;Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Izmir Katip Celebi Universitesi, Izmir, Turkey;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Katholieke Universiteit Leuven, Leuven, Belgium;Masarykova univerzita, Brno, Czech Republic;Medicines And Healthcare Products Regulatory Agency, London, United Kingdom;Medizinische Universitat Graz, Graz, Austria;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Ministry Of Health, Jerusalem, Israel;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Orcion BV, Asten, Netherlands;Pfizer Limited, Sandwich, Kent , United Kingdom;Region Stockholm, Stockholm, Sweden;Region Syddanmark, Odense, Denmark;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;St George'S Hospital Medical School, London, United Kingdom;Stichting Entis (European Network Teratology Information Services) Foundation, Hertogenbosch, Netherlands;Stichting Lareb, 's Hertogenbosch, Netherlands;Swansea University, Swansea, United Kingdom;Synergist Services, Bruxelles, Belgium;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland;Teva Pharmaceutical Industries Limited, Netanya, Israel;The European Institute For Innovation Through Health Data, Gent, Belgium;The European Medicines Agency, Canary Wharf, London, United Kingdom;The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-Upon-Tyne, United Kingdom;The Synergist, Bruxelles, Belgium;The University Of Manchester, Manchester, United Kingdom;Ttopstart BV, Bilthoven, Netherlands;UCB Biopharma SRL, Brussels, Belgium;Universita Degli Studi Di Ferrara, Ferrara, Italy;Universitaet Leipzig, Leipzig, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitetet I Oslo, Oslo, Norway;University Of Kwazulu-Natal, Westville, South Africa;University Of Ulster, Coleraine, United Kingdom;Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu, Wroclaw, Poland;Uppsala Universitet, Uppsala, Sweden", 'status': 'Ongoing'}, {'id': '0', 'name': 'COVIDRED', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/covid-red', 'summary': 'Could digital technologies help to detect COVID-19 cases? The COVID-RED project thinks so – it aims to assess how wearable devices and mobile apps could pick up on potential cases before people start to feel unwell.\nIt is well known that people with COVID-19 are highly infectious in the 48 hours before they develop symptoms. A key element in COVID-RED’s plans is an Ava bracelet, a wearable device typically used by women to track their fertility. The bracelet is equipped with sensors to measure things like the user’s breathing rate, pulse and skin temperature, which could change slightly before the user actually starts to feel ill.\nThe bracelet will sync with a mobile app that will detect any unusual variation in these parameters. The app will also allow users to report any symptoms, as well as any factors that could influence the bracelet’s findings, such as having drunk alcohol or the use of medicines to reduce fever.\nBased on all this input, an algorithm would provide the user with real-time feedback on the likelihood of infection, and whether or not the user should self-isolate or seek medical advice (for a potential COVID test or for further care, for example).\nCOVID-RED will test its system on 13 000 people from the general population, plus 7 000 people from high risk groups. In parallel, a group of the same size will be equipped with just the app, but no bracelet. At the end of the study, all participants will be tested for COVID-19 antibodies.\n', 'tags': 'COVID-19 infections - remote early detection', 'participants': 'Ava AG, Zurich, Switzerland;Julius Clinical Research BV, Zeist, Netherlands;Labormedizinisches Zentrum Dr Rischservices AG, Buchs, Switzerland;Labormedizinosches Zentrum Dr Rischostschweiz AG, Buchs, Switzerland;Roche Diagnostics Nederland BV, Almere, Netherlands;Stichting Sanquin Bloedvoorziening, Amsterdam, Netherlands;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;University College London, London, United Kingdom;Vive - Det Nationale Forsknings- Og Analysecenter For Velfaerd, Copenhagen, Denmark', 'status': 'Ongoing'}, {'id': '0', 'name': 'DDMORE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ddmore', 'summary': 'Model informed-drug development (MIDD) is acknowledged as a vital approach in understanding drug-related benefits and risks. At the core of MIDD lies modelling and simulation (M&S), a technology providing the basis for informed, quantitative decision-making. M&S facilitates the continuous integration of information related to a drug or disease into constantly evolving mathematical models that are capable of describing and predicting the behaviour of systems. As such, M&S helps researchers, regulators and public health care bodies to answer the questions they face when bringing drugs to patients. The full adoption of MIDD is hindered by a lack of common tools, languages and ontologies, which often leads to inefficient reuse of data and duplication of effort by academic, industrial and regulatory stakeholders. IMI’s DDMoRe project set out to address that challenge.\nThe project’s main achievement was the development of a repository for clinical trial data models, the largest of its kind to date, which members of the modelling community can use to store and access an assortment of computational models. The repository is publicly available and contains more than 120 models so far.\nAs different models are executed in different software programmes, this may cause model structures to be very different too. In order to address this, DDMoRe also designed a set of common standards for developing, describing and storing models. These standards are now also available for everyone to use and are facilitating model sharing and communication between researchers.\nAn interoperability framework\nAdditionally, the project developed an interoperability framework in which scientists can perform a modelling exercise. The framework is free for anyone to download and enables scientists to re-run models, thereby replicating each other’s work. The framework uses new standards and connectors for many commonly used programming tools and languages. As such, the interoperability framework provides a consistent environment in which researchers can work, using modelling tools they know, while opening up their work to others through a standard language for describing models.\nTraining programme and other achievements\nOther important project achievements include:\nThe development of computer models in different therapeutic areas such as oncology and diabetes;\na training programme to support the adoption of the standards, repository and the interoperability framework;\nnew tools which enable scientists to build and evaluate models and use them for specific purposes, such as optimising clinical trials.\nFor the benefit of industry, academia and SMEs\nThanks to their participation in this project, the academic community gained access and insights into industry bottlenecks, which helped them to develop methods and models which are useful for drug development. Additionally, as part of the project, many PhD students received invaluable training and access to industry, and many of them landed jobs in the industry.\nWhen it comes to the industry, model-informed approaches have become very important in designing clinical trials and other stages of drug development. The interoperability framework, standards and model repository have already and will further enhance the way industry implements model-informed drug development projects.\nSMEs within the project benefited from expanding their customer base and gaining insights into their customers’ needs. Additionally, three SME spin-offs were created as a direct result of the project.\nWhat’s next\nBefore the project ended, the DDMoRe project partners set up a foundation, which is continuing some of the work. The foundation is now the primary caretaker of all important project outputs including the repository, the interoperability framework and the data standards.\nRead the interview with project coordinators\n', 'tags': 'Drug Disease Model Resources ', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Certara Uk Limited, London, United Kingdom;Consiglio Nazionale Delle Ricerche, Roma, Italy;Cyprotex Discovery Ltd, Macclesfield, United Kingdom;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Molecular Biology Laboratory, Heidelberg, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Freie Universitaet Berlin, Berlin, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Institut National De Recherche Eninformatique Et Automatique, LE CHESNAY Cedex, France;Lixoft SAS, Orsay, France;Mango Business Solutions Limited, Stevenage, United Kingdom;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Optimata LTD, Ramat Gan, Israel;Pfizer Limited, Sandwich, Kent , United Kingdom;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;UCB Pharma SA, Brussels, Belgium;Universidad De Navarra, Pamplona, Spain;Universita Degli Studi Di Pavia, Pavia, Italy;Universite Paris Diderot - Paris 7, Paris, France;Universiteit Leiden, Leiden, Netherlands;University College London, London, United Kingdom;Uppsala Universitet, Uppsala, Sweden', 'status': 'Closed'}, {'id': '0', 'name': 'DECISION', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/decision', 'summary': 'Since it first appeared at the end of 2019, SARS-CoV-2, the virus that causes COVID-19, has proven adept at spreading rapidly throughout entire populations. To stop the virus in its tracks, we need to be able to quickly identify people who are infected, including those with little or nothing in the way of symptoms.\nCurrently, the most reliable and safest method of testing for COVID-19 is through a PCR (polymerase chain reaction) test. However, the test alone can take several hours to run, plus samples have to be sent to a laboratory, meaning most patients have to wait at least a day to get the result. Faster tests do exist but are expensive and not always reliable.\nThe aim of DECISION is to develop an easy-to-use, low-cost, disposable test for COVID-19 that can give reliable results, on the spot, within minutes. The idea is that it can be deployed anywhere; at drive-through testing centres, airports, physician offices, hospitals, quarantine centres, and eventually, even in people’s own homes.\nDECISION’s test is based on Pulse Controlled Amplification (PCA) technology. Like a PCR test, PCA amplifies the genetic material of the virus. However, PCA is both faster and cheaper, and the device itself is portable. Ultimately, the project hopes that users will have to wait just 15 minutes to get their result.\n', 'tags': 'A minituarized disposable molecular diagnostics platform for combatting coronavirus infections', 'participants': 'Bundesministerium Der Verteidigung, Bonn, Germany;Gna Biosolutions GMBH, Martinsried, Germany;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy;Microliquid SL, Arrasate-Mondragon, Spain', 'status': 'Ongoing'}, {'id': '0', 'name': 'DIRECT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/direct', 'summary': 'Background\nType 2 diabetes patients are a diverse group, and refining how they are classified would help individualise their treatment regimens. The course of the disease and the effectiveness of different medicines vary from one patient to another. It is also not clear why some at-risk people (such as those with obesity) develop the condition while others do not. Finding biomarkers would help in both identifying who is at risk of developing the disease, and determining individual patients’ likelihood of responding well to a particular treatment.\nMain outcomes of DIRECT \nThe DIRECT consortium carried out deep phenotyping of patient groups from around Europe, in order to study extreme phenotypes of patients with very rapid or very slow glycaemic deterioration (either from prediabetes to diabetes, or through diabetes). They also sought to understand the extent to which certain therapeutic interventions result in improvement in glycaemia. They were able to perform clustering of type 2 diabetes-based and baseline characteristics, and explore the molecular signature associated with diabetes progression. It allowed them to identify processes that caused or contributed to the development of T2D and how they are linked to how the disease progresses.\nTests, clinical trials, omics \nThe project developed tests to predict who will get diabetes, whose condition will deteriorate rapidly after diagnosis, and who will respond well or badly to certain drugs. They also used machine learning to create prediction models for non-alcoholic fatty liver disease based on clinical data and omics data. They carried out analysis of plasma metabolite profiling at the beginning and again at 18 months, which gave them an objective measure of diet, as well as the link between glycaemic deterioration, cardio-metabolic health, pre-diabetics and T2D.\nThese biomarkers were tested in prospective clinical trials, paving the way for their use as new diagnostic tests as well as in the creation of personalised therapies. They enrolled approximately 2,300 pre-diabetics and 850 early T2D patients for extensive baseline and longitudinal, physiological, imaging and molecular phenotyping, and followed up at 48 and 36 months, respectively.\nDIRECT established a multi-site trial infrastructure with a web-based accessible interface to allow for recruitment centres to upload and manage clinical and case report form data for all recruited patients.\nLarge-scale analysis of whole blood transcriptome revealed a large number of associations between transcriptomic modules and measures of insulin sensitivity and glucose tolerance, pointing to a major overlap of immune and metabolic processes. In a meta-analysis in genome-wide association studies that included approximately 5,500 subjects of European ancestry from six different cohorts treated with sulphonylureas, a gene variant with glycaemic response to sulphonylureas at a genome-wide scale was identified. They also identified 25 omics features from transcriptomics, metabolomics and proteomics data linked to early diabetes remission after obesity surgery.\nLiver fat predictor\nDIRECT developed liver fat prediction models (predictliverfat.org) and identified biological features that appear to affect liver fat accumulation. Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and causes serious health complications in T2D. Early diagnosis is important, as this can help prevent irreversible damage to the liver and, ultimately, hepatocellular carcinomas. Using the baseline data from 1,514 participants, they expanded the etiological understanding and developed a diagnostic tool for NAFLD using machine learning. Multi-omic (genetic, transcriptomic, proteomic, and metabolomic) and clinical (liver enzymes and other serological biomarkers, anthropometry, and measures of beta-cell function, insulin sensitivity, and lifestyle) data were used as input.\nSulphonylurea and GLP-1R Agonist response\nIn large-scale analyses of trial and observational data, DIRECT identified novel mechanisms for why patients respond differently to two commonly used diabetes drugs: sulphonylulreas and GLP-1R Agonists. They identified genetic variants that alter response to these drugs – which provides insight into how these drugs work or are transported in the body, and importantly, have the potential to be used for targeted therapy in clinical management of diabetes in the near future.\xa0\nCentral database and biobank \nDuring the project, all data was stored in a single secure server to enable high-performance analytics. The consortium built a central biobank to enable future biomarker discovery and replication for use in other IMI projects. The database with more than 40 terabytes of data is located in Denmark, while the biobank consisting of 300,000 samples is stored in the UK.\nThe work carried out under the DIRECT project boosted the industry’s understanding of the underlying causes of T2D, and is helping it to develop tailored treatments that can be targeted to the right patients. The work carried out in DIRECT complements the efforts of other IMI diabetes projects IMIDIA and SUMMIT.\n', 'tags': 'Diabetes research on patient stratification', 'participants': "Academisch Ziekenhuis Leiden, Leiden, Netherlands;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre Hospitalier Regional Et Universitaire De Lille, Lille, France;Centre National De La Recherche Scientifique Cnrs, Paris, France;Consiglio Nazionale Delle Ricerche, Roma, Italy;Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain;Danmarks Tekniske Universitet, Kgs. Lyngby, Denmark;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany;Hospital Clinico Y Provincial De Barcelona, Barcelona, Spain;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut De Recherches Internationales Servier Iris, Suresnes, France;Itä-Suomen yliopisto, Kuopio, Finland;Kobenhavns Universitet, Copenhagen, Denmark;Kungliga Tekniska Hoegskolan, Stockholm, Sweden;Lunds Universitet, Lund, Sweden;Novo Nordisk A/S, Bagsvaerd, Denmark;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Stichting Vumc, Amsterdam, Netherlands;The University Of Exeter, Exeter, United Kingdom;Universitaet Ulm, Ulm, Germany;Universite De Geneve, Genève 4, Switzerland;Universite De Lille Ii - Droit Et Sante, Lille, France;University Of Bath, Bath, United Kingdom;University Of Dundee, Dundee, United Kingdom;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University of Oxford, Oxford, United Kingdom", 'status': 'Closed'}, {'id': '0', 'name': 'DOIT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/do-it', 'summary': 'Institutions across Europe house rich databases with detailed personal and biological information. If linked, this ‘big data’ has the potential to deliver insights that will allow healthcare systems to ensure that the patient is truly at the centre of decision-making, with outcomes that matter and resources focused on treatments that really make a difference. IMI’s Big Data for Better Outcomes (BD4BO) programme is generating knowledge, data and methodologies needed to support the transition towards more outcomes-focused, sustainable healthcare systems in Europe. Through its projects, the programme focuses on a number of key therapeutic areas, namely Alzheimer’s disease, heart disease, and certain cancers.\nThe DO>IT project was launched to provide a coordination platform for the BD4BO programme, exploiting synergies across the projects and maximising its impact on healthcare systems. Specially, DO>IT will aggregate learnings and disseminate findings from the projects; develop minimum data privacy standards; engage with key stakeholders; and recommend areas for future collaborative research.\n', 'tags': 'Big data for better outcomes, policy innovation and healthcare system transformation', 'participants': "Amgen, Brussels, Belgium;Asociacion Nacional Empresarial De La Industria Farmaceutica, Madrid, Spain;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Celgene Management SARL, Couvet, Switzerland;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Cancer Patient Coalition, Brussels, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Brussels, Belgium;Folkehelseinstituttet, Oslo, Norway;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Health Iq Limited, London, United Kingdom;Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Intersystems GMBH, Darmstadt, Germany;Janssen Pharmaceutica Nv, Beerse, Belgium;London School Of Economics And Political Science, London, United Kingdom;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;National Institute For Health And Care Excellence, Manchester, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Semmelweis Egyetem, Budapest, Hungary;Statens Legemiddelverk, Oslo, Norway;Tandvards-Och Lakemedelsformansverket, Stockholm, Sweden;The Association Of The British Pharmaceutical Industry, London, United Kingdom;The European Multiple Sclerosis Platform Aisbl, Brussels, Belgium;The University Of Liverpool, Liverpool, United Kingdom;Tmf - Technologie Und Methodenplattform Fur Die Vernetzte Medizinische Forschung Ev, Berlin, Germany;UCB Biopharma SRL, Brussels, Belgium;Universita Commerciale Luigi Bocconi, Milan, Italy;Verband Forschender Arzneimittelhersteller Ev, Berlin, Germany", 'status': 'Closed'}, {'id': '0', 'name': 'DRAGON', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/dragon', 'summary': 'Diagnosing COVID-19 and, crucially, predicting how the disease will progress in different patients, remains a challenge. The DRAGON project aims to use artificial intelligence (AI) and machine learning to develop a decision support system capable of delivering a more precise coronavirus diagnosis and more accurate predictions of patient outcomes.\nThe project will draw on new and existing data and sample collection efforts, including CT (computed tomography) scans to carry out detailed profiling of patients. They will then use AI technology to transform this information into a precision medicine approach that will help clinicians and patients with decision making around treatments.\nUnderpinning all of this will be a federated machine learning system that will allow the use of data from a range of international sources while complying with the EU’s General Data Protection Regulation (GDPR).\nA patient and public advisory group will provide advice and input throughout the project.\n', 'tags': 'Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics', 'participants': 'Biosci Consulting Bvba, Maasmechelen, Belgium;Cdisc Europe Foundation Fondation, Brussels, Belgium;Centre Hospitalier Universitaire De Liege, Liege, Belgium;Department of Health, Leeds, United Kingdom;European Lung Foundation, Lausanne, Switzerland;European Respiratory Society, Lausanne, Switzerland;Imperial College Of Science Technology And Medicine, London, United Kingdom;Oncoradiomics, Liege, Belgium;Owlstone Medical Limited, Cambridge, United Kingdom;The Medical Cloud Company, Liege, Belgium;The University Of Liverpool, Liverpool, United Kingdom;Thirona BV, Nijmegen, Netherlands;Topmd Precision Medicine LTD, Southampton, United Kingdom;Universita Degli Studi Di Firenze, Florence, Italy;Universita Degli Studi Di Parma, Parma, Italy;Universiteit Maastricht, Maastricht, Netherlands;University Of Southampton, Southampton, United Kingdom;University of Cambridge, Cambridge, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'DRIVE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/drive', 'summary': 'Influenza is a major public health issue; it is thought to infect some 60 million of the EU’s 500 million inhabitants every year. Vaccines have a major role to play in preventing the spread of the infectious disease, every year, the World Health Organization (WHO) studies the strains of flu in circulation worldwide and recommends adaptations to flu vaccines accordingly. The challenge for the entire vaccine research and healthcare community is to evaluate the effectiveness of these annual vaccines. Current efforts in this area are simply not extensive enough to assess in detail the benefits of vaccination for different groups and to guide public health measures during a flu season. One element hampering efforts to carry out more extensive vaccine effectiveness is the ability of the different stakeholders involved to work in collaboration.\nThe goal of the DRIVE project is to set up a platform, bringing together all stakeholders, to study brand-specific flu vaccine effectiveness in the EU over a five-year period. At the heart of the platform will be a governance framework that allows transparent and efficient collaboration between public and private stakeholders. To guarantee the scientific independence of the studies, the roles of all participants, including vaccine manufacturers, will be clearly defined and traceable. An Independent Scientific Committee will further minimise the risk of conflicts of interest in the design of the studies and the interpretation of their results.\n', 'tags': 'Development of Robust and Innovative Vaccine Effectiveness', 'participants': "Abbott Biologicals BV, Weesp, Netherlands;Assistance Publique Hopitaux De Paris, Paris, France;Association Internationale De Standardisation Biologique Pour L'Europe(Iabs-Eu), Lyon, France;Confederation Of Meningitis Organisations LTD, Bristol, United Kingdom;Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Istituto Superiore Di Sanita, Roma, Italy;Ospedale Pediatrico Bambino Gesu, Rome, Italy;P95 CVBA, Leuven, Belgium;Sanofi Pasteur SA, Lyon, France;Seqirus Uk Limited, Maidenhead, United Kingdom;Synapse Research Management Partners SL, Barcelona, Spain;Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland;Universita Degli Studi Di Firenze, Florence, Italy;Universite Lyon 1 Claude Bernard, Villeurbanne, France;University Of Surrey, Guildford, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'DRIVEAB', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/drive-ab', 'summary': 'The problem: investing in new antibiotics doesn’t pay off\nOne of the biggest challenges of our age is the looming threat of antimicrobial resistance (AMR). In the past few years, it has become a high-profile policy priority for governments and global institutions, thanks to many voices sounding the alarm on the implications of an antibiotics-free future. But despite the well-publicised threat, few new antibiotics are in the pipeline. The reason development has stalled has as much to do with economics as pharmacology; the pharmaceutical industry has no incentive to develop drugs that are expected to be used only rarely, assuming efforts in infection prevention and antimicrobial stewardship are successful. The purpose of DRIVE-AB was to create evidence for policymakers on new ways to stimulate drug and biotech companies to invest in new antibiotics in a way that’s consistent with efforts to responsibly limit their use.\nGetting the terminology right, predicting resistance, estimating value \nFirst off, the project partners agreed on some basic definitions. While we know that the overuse of antibiotic drugs is the reason for resistance, there’s not a whole lot of agreement on what “responsible” use looks like. DRIVE-AB project partners looked into the available literature and rated the varying definitions, ultimately settling on a description for responsible use that, they posit, should form the basis of any model that tackles the new-drugs-versus-sustainable-consumption solutions.\nThey then developed models created to predict the spread of antibiotic resistance, intended to help health systems and drug companies make decisions about where the money and effort needs to go. The project partners also described – and assigned value amounts to – the consequences for the different people affected by AMR; what is the cost to a patient, a hospital, society as a whole of untreatable infections? They did the same type of quantification in the reverse: what is it worth to society to have a new antibiotic that works?\nThe fire extinguisher analogy: buying protection from future fires\nA key finding from DRIVE-AB is that antibiotics are very valuable to society as preparedness for future drug resistance. A useful analogy is fire suppression equipment: we invest in the equipment while hoping that the actual number of fires is zero. To apply the same thinking to antibiotics calls for dramatic changes in how societies pay for them. It would require delinking revenues to the company from the number of pills sold. Antibiotics should be reimbursed based on their value to society, not the volume of patients being treated today. Those that treat Gram-negative infections, for example, are considered more valuable because these bacteria are more dangerous.\nThe outcome: a rethink of antibiotics’ true value\nThey key takeaway is that new economic models should be based on this “true value” of the new drugs. DRIVE-AB quantitatively modelled the most promising incentive systems in terms of profitability and benefit to the public, covering everything from basic science to patient treatment. They did an in-depth analysis of dozens of ideas in the policy literature, and settled on four incentives that can be considered best suited to fill the antibacterial pipeline and keep them available. The project simulated the impact of market entry rewards, which are rewards or prizes for bringing new antibiotics to the market, and found that a global reward of USD 1 billion (approx. EUR 0.9 billion), based on certain assumptions, would result in a steady supply of more innovative antibiotics.\nDRIVE-AB also recommended a long-term supply continuity model for important but rarely-used antibiotics. They recommend a country or group of countries would agree to annual payments to one or more manufacturers to ensure predictable supply, and a number of sustainable use obligations for developers.\nConflicting perspectives: seeing it from the other side\nThe project has had immense influence; anyone involved in AMR policy is never far removed from the highly networked DRIVE-AB community. The project only served to further expand and solidify this network. Its 16 public-sector partners and seven\xa0pharmaceutical companies operated as equal partners and spent three years meeting in various fora. While the motivations of the public and private partners didn’t always align, it was a great opportunity for each camp to see the issue of antimicrobial research from the other perspective. The partners were able to work together as equals to hypothesise a mutually beneficial investment environment that achieves a goal that is common to all sides. Such cross-over collaborations is one of the great potential advantages of participating a public-private funding vehicle like IMI.\nWhat’s next?\nOf the 12 policy recommendations, six are now being fully or partially implemented, say the project partners, including as part of the UK’s AMR review and an AMR report carried out by Boston Consultancy Group on behalf of the German federal government. The recommendations have also influenced the policies of the World Health Organisation, the Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EUJAMRAI), and the Global AMR R&D Hub.\nAlthough not a delinked model, the US government has recently taken an initial step to change the reimbursement pattern for new antibiotics used in the hospital, and the United Kingdom recently announced a pilot project looking at a delinked model. Legislation that could create such a model is also being considered in the United States. We can expect to see more and more policymakers adopt, or take inspiration from, the work done through the DRIVE-AB project.\n', 'tags': 'Driving re-investment in R&D and responsible antibiotic use', 'participants': 'Astellas Pharma Europe LTD, Chertsey, United Kingdom;Astrazeneca AB, Södertälje, Sweden;British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Folkehelseinstituttet, Oslo, Norway;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;London School Of Economics And Political Science, London, United Kingdom;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Pfizer Limited, Sandwich, Kent , United Kingdom;Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, Germany;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Sveuciliste U Rijeci, Medicinski Fakultet, Rijeka, Croatia;The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv, Tel Aviv, Israel;The Royal Institute Of International Affairs, London, United Kingdom;Universite De Geneve, Genève 4, Switzerland;Universite De Lorraine, Nancy Cedex, France;Universiteit Antwerpen, Antwerp, Belgium;University Of Strathclyde, Glasgow, United Kingdom;Uppsala Universitet, Uppsala, Sweden;Ursula Theuretzbacher, Vienna, Austria;Wageningen University, Wageningen, Netherlands', 'status': 'Closed'}, {'id': '0', 'name': 'EBISC', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ebisc', 'summary': 'Most adult cells can only divide to produce other cells of the same type – for example, skin cells can only make other skin cells. In contrast, embryonic stem cells are ‘pluripotent’, i.e. able to give rise to all the different kinds of cell that make up the human body. However, researchers are now able to reprogram adult cells such as blood or skin cells, to create induced pluripotent stem cells (iPSCs). Like embryonic stem cells, iPSCs are able to generate any kind of cell; as such, they offer researchers a good supply of different kinds of human cell types which can be used in research and drug development.\nWhen EBiSC began, iPSCs were still a relatively new technology. Although many human iPSC lines had been created, their quality varied enormously and few were accompanied by sufficient background \xa0data such as consent information and confirmation of cell line identity. Furthermore, access to many lines was tightly restricted, meaning demand for good quality iPSCs vastly outstripped supply.\nEBiSC, a non-profit biobank, now provides the global science community with over 800 cell lines derived from patients diagnosed with neurodegenerative, cardiovascular and eye diseases, diabetes, and muscular dystrophies, as well as healthy donors. The cell lines were created and deposited in the EBiSC catalogue by iPSC centres across Europe including a number of other large iPSC research projects (such as the IMI project StemBANCC). Moreover, the project established standardised solutions for the expansion and differentiation of cells, whilst development of a robust quality control (QC) regime means that cell lines from EBiSC contribute to improving the reliability of research results. This is important when one considers that all too often, researchers are unable to replicate the results of each other’s experiments.\nEBiSC has now distributed iPSC lines to users across the world, including USA, Australia, New Zealand, Japan and Korea, in addition to users across Europe. Collection and distribution of iPSC lines on this scale would likely not have been possible without establishment of an Information Management System, supporting EBiSC with gathering cell line data, managing cell line documentation and controlling availability across hundreds of lines. In addition to supplying iPSC lines, EBiSC also developed a training framework to support dissemination of best practice for the culture and banking of iPSC lines, this publically available resource supports users after receiving their iPSC lines, recommendation on routine QC to be performed in users’ laboratories to maintain high standards is also available. Underpinning these activities, the project set up a harmonised ethics and legal governance framework for the deposit and distribution of iPSC lines, and established harmonised donor consent forms which have been used across Europe, including other IMI projects such as PHAGO and ADAPTED.\nThese project results were only possible because of the broad collaboration between academics, the pharmaceutical industry, and SMEs. The project provided a platform for extended networking and exchanging of stem cell-related expertise across the consortium, and this allowed individual research institutions to standardise experimental procedures in alignment with the state-of-the-art quality criteria that were defined by the whole consortium.\nMore broadly, EBiSC has demonstrated that large scale, automated expansion and differentiation of iPSCs is feasible, making high-quality stem cells and their derivatives available for future applications at industrial scale in a cost efficient manner. EBiSC2 will take this to the next step, performing iPSC banking and differentiation across multiple lineages and supplying differentiated products directly to users. In the long term, EBiSC will undoubtedly help to promote Europe as an attractive place for biopharmaceutical research and development and provide a new and major resource for future medicines development which will improve the health of European citizens. It will also contribute to reductions in the use of animals in research, as the use of iPSCs replace tools and studies that use animals.\nFor the benefit of industry, academia, SMEs\nThroughout the project, scientists from multiple academic centres across Europe gained access to high-quality iPSC lines, thus reducing their reliance on poor quality cells. They also gained access to genomic data sets supporting research activities; awareness of best practice in banking, cryostorage and quality control; and access to virtual training ensuring the quality of their research. Additionally, the use of the ethical framework for the collection of biological samples suitable for iPSC generation and distribution, was translated across the academic community whilst a streamlined process for iPSC line deposition ensures that newly generated lines can be stored and distributed by a central non-profit bank.\nSMEs also benefited from access to the iPSC lines. In addition, working with pharmaceutical companies gives SMEs valuable insights into the needs of the larger companies.\xa0 For their part, the pharmaceutical companies in the project are now using the EBiSC iPSCs in their active research to study diseases and develop new treatments, for example in the neurological disease field. They also benefited from access to the state-of-the-art technology in the research institutes and SMEs in the project\nWhat’s next\nA further IMI project, EBiSC2 is now building on the work begun under EBiSC and related initiatives. EBiSC2 will extend the existing cell line collection, knowledge and infrastructure established under EBiSC ensuring the sustainability of the resource long-term.\n', 'tags': 'European Bank for induced pluripotent Stem Cells', 'participants': 'Arttic, Paris, France;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Bioneer A/S, Horsholm, Denmark;Charite - Universitaetsmedizin Berlin, Berlin, Germany;DefiniGEN Ltd, Cambridge, United Kingdom;Department of Health, Leeds, United Kingdom;Edelweiss Connect GMBH, Zeiningen, Switzerland;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Molecular Biology Laboratory, Heidelberg, Germany;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fundacio Privada Centre De Medicina Regenerativa De Barcelona, Barcelona, Spain;Fundacion Publica Andaluza Progreso Y Salud, Seville , Spain;Genome Research Limited, London, United Kingdom;Gottfried Wilhelm Leibniz Universitaet Hannover, Hannover, Germany;H. Lundbeck As, Valby, Denmark;Instituto De Salud Carlos Iii, Madrid, Spain;Janssen Pharmaceutica Nv, Beerse, Belgium;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Koninklijke Nederlandse Akademie Van Wetenschappen - Knaw, Utrecht, Netherlands;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Roslin Cell Sciences Ltd, Roslin, Midlothian, United Kingdom;The University Of Edinburgh, Edinburgh, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universitatsklinikum Bonn, Bonn, Germany;University College London, London, United Kingdom;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'EBISC2', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ebisc2', 'summary': 'Induced pluripotent stem cells (iPSCs) are key tools for early drug development and disease modelling. IPSCs are mature adult cells that have been reprogrammed to make them ‘pluripotent’, i.e. able to differentiate into any type of cell found in the human body.\nEBiSC2 aims to become a self-sustaining biobank, providing well-characterised, quality controlled iPSCs to the academic and industrial scientific communities worldwide. Building on the work of previous projects, including IMI’s EBiSC, EBiSC2 will provide access to a broad catalogue of iPSCs from diverse disease and genetic backgrounds along with comprehensive datasets. They will also offer the bulk production of iPSCs and the delivery of pre-differentiated cell populations. By supporting future iPSC-based disease research, EBiSC2 will contribute to the discovery and development of new drugs.\n', 'tags': 'EBiSC2 – A sustainable European bank for induced pluripotent stem cells', 'participants': 'Arttic, Paris, France;Bayer Aktiengesellschaft, Leverkusen, Germany;Bioneer A/S, Horsholm, Denmark;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Department of Health, Leeds, United Kingdom;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fraunhofer Uk Research Limited, Glasgow, United Kingdom;Fujifilm Cellular Dynamics Inc, Madison, United States;H. Lundbeck As, Valby, Denmark;Institut De Recherches Servier, Suresnes, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Takeda Development Centre Europe LTD, London, United Kingdom;UCB Biopharma SRL, Brussels, Belgium', 'status': 'Ongoing'}, {'id': '0', 'name': 'EBODAC', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ebodac', 'summary': 'Deployment of and compliance with vaccination regimens\nFor a vaccine to have a real impact on an outbreak, high levels of vaccination coverage are essential. In addition, for lasting protection, two doses of the vaccine may be needed. However, the stigma surrounding Ebola, coupled with a suspicion of vaccines in general, could deter many people from getting vaccinated. Strong communication campaigns are therefore needed to address these challenges.\nThe EBODAC project is developing a communication strategy and tools to promote the acceptance and uptake of new Ebola vaccines. One of the project’s most important products will be a platform, based on mobile technology, dedicated to Ebola vaccines. As well as providing local communities with information on Ebola and vaccines, the platform will send reminders to people receiving the ‘prime boost’ vaccine to return to get their second ‘booster’ dose and facilitate the tracking of vaccination coverage. EBODAC is also setting up local training programmes to make sure the communication strategy, and its tools, will be ready for deployment in the local setting.\nA part of the Ebola+ Programme\nThe IMI Ebola+ programme was launched in response to the Ebola virus disease (EVD) outbreak that started in western Africa in 2014. The comprehensive programme contributes to efforts to tackle a wide range of challenges in Ebola research, including vaccines development, clinical trials, and transport, as well as diagnostics. The programme complements work being carried out with the support of other funding bodies. In addition to Ebola, the programme will also address related diseases, such as Marburg.\nAbout Ebola and related diseases\nEbola virus disease (EVD), previously known as Ebola haemorrhagic fever, is a rare and deadly disease caused by infection with one of the Ebola virus strains. The virus spreads in the human population through direct human-to-human contact with the bodily fluids of infected patients who are showing symptoms. It has an incubation period of 2-21 days, and it usually begins with flu-like symptoms, but rapidly progresses to multiple organ failure and blood-clotting abnormalities which manifest as internal and external haemorrhages (bleeding). It is fatal in between 25% and 90% of cases. There is currently no licensed treatment against EVD, and the development of treatments and preventive measures such as vaccines is hampered by challenges including manufacturing-related hurdles, the stability of vaccines during transport and storage, vaccine deployment, and the time taken to diagnose cases of EVD.\nEbola is a member of the filovirus family of viruses, which also includes Marburg virus. Like Ebola, Marburg causes cause severe, often fatal haemorrhagic fever in humans and other primates (monkeys, gorillas and chimpanzees), and like Ebola, it is transmitted directly from one person to another. (In contrast, other viruses that cause haemorrhagic fevers are spread via intermediate hosts - for example, dengue fever is transmitted by mosquitoes.) There is no specific treatment or vaccine against Marburg haemorrhagic fever.\nThe 2014-15 Ebola epidemic was unprecedented in its scale and geographical distribution. By the middle of 2015, World Health Organization (WHO) statistics recorded over 27 000 cases and 11\xa0000 deaths from the disease, most of them in Guinea, Liberia, and Sierra Leone. The epidemic highlighted the need for research into better vaccines, diagnostics and treatments to stop future epidemics in their tracks.\n', 'tags': 'Communication strategy and tools for optimizing the impact of Ebola vaccination deployment', 'participants': 'Grameen Foundation Usa, Washington, District of Columbia, United States ;Janssen Pharmaceutica Nv, Beerse, Belgium;London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom;World Vision International, Monrovia Ca, United States;World Vision Of Ireland Lbg, Rathmines Park, Ireland;World Vision Sierra Leone, Freetown, Sierra Leone', 'status': 'Ongoing'}, {'id': '0', 'name': 'EBOLAMODRAD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ebolamodrad', 'summary': 'The problem: testing takes time, and it can be dangerous\nRapid diagnosis is imperative for controlling Ebola outbreaks. Early symptoms like fever and fatigue are the same for numerous other tropical diseases, so identifying the culprit is not easy without laboratory tests. Usually, samples need to go to specialised containment facilities to run the right tests, but due to weak infrastructure and a lack of sophisticated testing centres in the areas where Ebola outbreaks typically occur, it can take many days and up to a week to get results. There is an obvious need for a reliable, mobile and biosafe testing tool that can return results quickly and thus reduce the chances of the disease expanding further into the population. This would allow patients to be isolated straight away, and to target their close social circle for vaccination.\nA test to detect (and deactivate) Ebola\nThe first hurdle for the EbolaMoDRAD project partners was to come up with a way of handling blood samples without creating any risk for the people who are responsible for taking, working with or transporting the samples. The project partners did this by creating a vacuum collection tube filled with an inactivation liquid that deactivates the virus itself while keeping the genetic material stable for about five weeks. This eliminates the need for a glovebox-equipped lab. Diagnosis is carried out on the spot, using the lateral flow dipstick test, eliminating the need for high-spec equipment or expertise.\nThe researchers tried out different techniques for detecting the infection in the blood, such as looking out for the virus itself, or looking for immune responses that would point to an infection. Apart from the rapid lateral flow assay, one of the most promising methods is gene detection by isothermal amplification. The project pitted different methods against each other to pick the best performing method. They also developed a pipette tip extraction, a battery-operated extraction method to single out the Ebola material so that the whole process is less dependent on electricity. Using samples gathered during the 2013-2016 outbreak, the researchers were able, with the help of local NGO Emergency, to test out the efficacy of the tools in Sierra Leone.\nThe legacy: teaching the tools\nOnce the project partners had achieved their mission of developing an Ebola test that was biosafe, specific, sensitive, rapid and simple to use, they set about the practicalities of making sure the local population would be able to use the technology independently. They organised a number of well-attended workshops in order to teach local groups in west African countries the necessary skills and procedures. Specifically, the workshops covered outbreak management, diagnostics and the use of diagnostic tools and how to interpret the results. They also organised hands-on training in neighbouring but non-epidemic countries.\xa0\nAccess to more (and more varied) expertise\nThough the challenge itself was rather broad, the technical issues encountered during the project were very specific and complicated – and as such the mixed bag of expertise from the project partners was considered extremely beneficial. There were 18 partners, who knew they had to bring together whatever research and expertise was already out there, and most importantly, use the combined experience and expertise of a group to fix problems that would be next to impossible with an individual organisation.\nWhat’s next?\nThe IMI-funded VHFMoDRAD builds on the achievements of EbolaMoDRAD which aims to develop a test capable of detecting a number of diseases related to Ebola. Both projects are part of the IMI Ebola+ programme.\n', 'tags': 'Ebola virus: modern approaches for developing bedside rapid diagnostics', 'participants': "Aj Innuscreen GMBH, Berlin, Germany;Clonit SRL, Milano, Italy;Coris Bioconcept SPRL, Gembloux, Belgium;Department of Health, Leeds, United Kingdom;Emergency Life Support For Civilian War Victims Ong Onlus, Milan, Italy;Folkhalsomyndigheten, Solna, Sweden;Inserm Transfert SA, Paris, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Institut Pasteur De Dakar, Dakar, Senegal;Institut Pasteur, Paris, France;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy;Kobenhavns Universitet, Copenhagen, Denmark;Statens Serum Institut, Copenhagen S, Denmark;Stockholms Universitet, Stockholm, Sweden;The University Of Stirling, Stirling, United Kingdom;Universite D'Aix Marseille, Marseille, France;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Turku, Turku, Finland", 'status': 'Closed'}, {'id': '0', 'name': 'EBOMAN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/eboman', 'summary': 'Vaccine manufacture capability\nEbola vaccines can only be manufactured in facilities with an appropriate biosafety rating. Relatively few manufacturers have the biosafety rating required for the manufacture of Ebola vaccines, and this is slowing down the production of vaccine candidates.\nThe focus of the EBOMAN project is on accelerating the development and manufacturing of a ‘prime-boost’ Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) in development at the Janssen Pharmaceutical Companies of Johnson & Johnson. In the short term, this will ensure the delivery of sufficient quantities of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen to support the two EBOVAC projects to perform the clinical trials. In parallel, this project will create additional vaccine production capacity to allow for the rapid preparation of large quantities of vaccines.\nA part of the Ebola+ Programme\nThe IMI Ebola+ programme was launched in response to the Ebola virus disease (EVD) outbreak that started in western Africa in 2014. The comprehensive programme contributes to efforts to tackle a wide range of challenges in Ebola research, including vaccines development, clinical trials, and transport, as well as diagnostics. The programme complements work being carried out with the support of other funding bodies. In addition to Ebola, the programme will also address related diseases, such as Marburg.\nAbout Ebola and related diseases\nEbola virus disease (EVD), previously known as Ebola haemorrhagic fever, is a rare and deadly disease caused by infection with one of the Ebola virus strains. The virus spreads in the human population through direct human-to-human contact with the bodily fluids of infected patients who are showing symptoms. It has an incubation period of 2-21 days, and it usually begins with flu-like symptoms, but rapidly progresses to multiple organ failure and blood-clotting abnormalities which manifest as internal and external haemorrhages (bleeding). It is fatal in between 25% and 90% of cases. There is currently no licensed treatment against EVD, and the development of treatments and preventive measures such as vaccines is hampered by challenges including manufacturing-related hurdles, the stability of vaccines during transport and storage, vaccine deployment, and the time taken to diagnose cases of EVD.\nEbola is a member of the filovirus family of viruses, which also includes Marburg virus. Like Ebola, Marburg causes cause severe, often fatal haemorrhagic fever in humans and other primates (monkeys, gorillas and chimpanzees), and like Ebola, it is transmitted directly from one person to another. (In contrast, other viruses that cause haemorrhagic fevers are spread via intermediate hosts - for example, dengue fever is transmitted by mosquitoes.) There is no specific treatment or vaccine against Marburg haemorrhagic fever.\nThe 2014-15 Ebola epidemic was unprecedented in its scale and geographical distribution. By the middle of 2015, World Health Organization (WHO) statistics recorded over 27 000 cases and 11\xa0000 deaths from the disease, most of them in Guinea, Liberia, and Sierra Leone. The epidemic highlighted the need for research into better vaccines, diagnostics and treatments to stop future epidemics in their tracks.\n', 'tags': 'Manufacturing and development for rapid access Ebola vaccine', 'participants': 'Bavarian Nordic As, Kvistgaard, Denmark;Janssen Vaccines & Prevention BV, Leiden, Netherlands;Vibalogics GMBH, Cuxhaven, Germany', 'status': 'Closed'}, {'id': '0', 'name': 'EBOVAC1', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ebovac1', 'summary': 'Vaccine development\nThere are currently no licensed vaccines for Ebola. However, there are a number of vaccine candidates in development. EBOVAC 1 and 2 are two of three projects in the IMI Ebola+ programme that are generating the data needed to assess the safety and immunogenicity of different vaccine candidates and the level and duration of protection they actually offer against the disease.\nBetween them, the two EBOVAC projects are assessing, through clinical trials in Europe and Africa, the safety and tolerability of the ‘prime-boost’ Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) in development at the Janssen Pharmaceutical Companies of Johnson & Johnson. In a prime-boost vaccine regimen, patients are first given a dose to prime the immune system, and then a boost dose which is intended to enhance the immune response over time.\nPhase I trials will be carried out by the EBOVAC1 project. These trials will gather preliminary information on the safety and tolerability of the vaccine regimen. The immune response generated by the regimen will also be evaluated longer term.\nSubject to review of the preliminary Phase I data, the Phase II and III trials, will be carried out in parallel by the EBOVAC2 and EBOVAC1 projects respectively to speed up the clinical development of the vaccine regimen. In these trials, larger groups of people will receive the vaccine regimen, allowing the projects to gather further information on the regimen’s safety and immunogenicity, including in specific groups such as children and the elderly, and to assess its efficacy against Ebola virus.\nA part of the Ebola+ Programme\nThe IMI Ebola+ programme was launched in response to the Ebola virus disease (EVD) outbreak that started in western Africa in 2014. The comprehensive programme contributes to efforts to tackle a wide range of challenges in Ebola research, including vaccines development, clinical trials, and transport, as well as diagnostics. The programme complements work being carried out with the support of other funding bodies. In addition to Ebola, the programme will also address related diseases, such as Marburg.\nAbout Ebola and related diseases\nEbola virus disease (EVD), previously known as Ebola haemorrhagic fever, is a rare and deadly disease caused by infection with one of the Ebola virus strains. The virus spreads in the human population through direct human-to-human contact with the bodily fluids of infected patients who are showing symptoms. It has an incubation period of 2-21 days, and it usually begins with flu-like symptoms, but rapidly progresses to multiple organ failure and blood-clotting abnormalities which manifest as internal and external haemorrhages (bleeding). It is fatal in between 25% and 90% of cases. There is currently no licensed treatment against EVD, and the development of treatments and preventive measures such as vaccines is hampered by challenges including manufacturing-related hurdles, the stability of vaccines during transport and storage, vaccine deployment, and the time taken to diagnose cases of EVD.\nEbola is a member of the filovirus family of viruses, which also includes Marburg virus. Like Ebola, Marburg causes cause severe, often fatal haemorrhagic fever in humans and other primates (monkeys, gorillas and chimpanzees), and like Ebola, it is transmitted directly from one person to another. (In contrast, other viruses that cause haemorrhagic fevers are spread via intermediate hosts - for example, dengue fever is transmitted by mosquitoes.) There is no specific treatment or vaccine against Marburg haemorrhagic fever.\nThe 2014-15 Ebola epidemic was unprecedented in its scale and geographical distribution. By the middle of 2015, World Health Organization (WHO) statistics recorded over 27 000 cases and 11\xa0000 deaths from the disease, most of them in Guinea, Liberia, and Sierra Leone. The epidemic highlighted the need for research into better vaccines, diagnostics and treatments to stop future epidemics in their tracks.\n', 'tags': 'Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen', 'participants': 'Chu Hopitaux De Bordeaux, Talence, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Vaccines & Prevention BV, Leiden, Netherlands;London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom;Universite De Bordeaux, Bordeaux, France;University Of Sierra Leone, Freetown, Sierra Leone;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'EBOVAC2', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ebovac2', 'summary': 'Vaccine development\nThere are currently no licensed vaccines for Ebola. However, there are a number of vaccine candidates in development. EBOVAC 1 and 2 are two of three projects in the IMI Ebola+ programme that are generating the data needed to assess the safety and immunogenicity of different vaccine candidates and the level and duration of protection they actually offer against the disease.\nBetween them, the two EBOVAC projects are assessing, through clinical trials in Europe and Africa, the safety and tolerability of the ‘prime-boost’ Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) in development at the Janssen Pharmaceutical Companies of Johnson & Johnson. In a prime-boost vaccine regimen, patients are first given a dose to prime the immune system, and then a boost dose which is intended to enhance the immune response over time.\nPhase I trials are carried out by the EBOVAC1 project. These trials will gather preliminary information on the safety and tolerability of the vaccine regimen. The immune response generated by the regimen will also be evaluated longer term.\nSubject to review of the preliminary Phase I data, the Phase II and III trials, will be carried out in parallel by the EBOVAC2 and EBOVAC1 projects respectively to speed up the clinical development of the vaccine regimen. In these trials, larger groups of people will receive the vaccine regimen, allowing the projects to gather further information on the regimen’s safety and immunogenicity, including in specific groups such as children and the elderly, and to assess its efficacy against Ebola virus.\nA part of the Ebola+ Programme\nThe IMI Ebola+ programme was launched in response to the Ebola virus disease (EVD) outbreak that started in western Africa in 2014. The comprehensive programme contributes to efforts to tackle a wide range of challenges in Ebola research, including vaccines development, clinical trials, and transport, as well as diagnostics. The programme complements work being carried out with the support of other funding bodies. In addition to Ebola, the programme will also address related diseases, such as Marburg.\nAbout Ebola and related diseases\nEbola virus disease (EVD), previously known as Ebola haemorrhagic fever, is a rare and deadly disease caused by infection with one of the Ebola virus strains. The virus spreads in the human population through direct human-to-human contact with the bodily fluids of infected patients who are showing symptoms. It has an incubation period of 2-21 days, and it usually begins with flu-like symptoms, but rapidly progresses to multiple organ failure and blood-clotting abnormalities which manifest as internal and external haemorrhages (bleeding). It is fatal in between 25% and 90% of cases. There is currently no licensed treatment against EVD, and the development of treatments and preventive measures such as vaccines is hampered by challenges including manufacturing-related hurdles, the stability of vaccines during transport and storage, vaccine deployment, and the time taken to diagnose cases of EVD.\nEbola is a member of the filovirus family of viruses, which also includes Marburg virus. Like Ebola, Marburg causes cause severe, often fatal haemorrhagic fever in humans and other primates (monkeys, gorillas and chimpanzees), and like Ebola, it is transmitted directly from one person to another. (In contrast, other viruses that cause haemorrhagic fevers are spread via intermediate hosts - for example, dengue fever is transmitted by mosquitoes.) There is no specific treatment or vaccine against Marburg haemorrhagic fever.\nThe 2014-15 Ebola epidemic was unprecedented in its scale and geographical distribution. By the middle of 2015, World Health Organization (WHO) statistics recorded over 27 000 cases and 11\xa0000 deaths from the disease, most of them in Guinea, Liberia, and Sierra Leone. The epidemic highlighted the need for research into better vaccines, diagnostics and treatments to stop future epidemics in their tracks.\n', 'tags': 'Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II', 'participants': 'Centre Muraz, Bobo Dioulasso, Burkina Faso;Chu Hopitaux De Bordeaux, Talence, France;Inserm Transfert SA, Paris, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Vaccines & Prevention BV, Leiden, Netherlands;London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom;Universite De Bordeaux, Bordeaux, France;Universite Paris Xii Val De Marne, Creteil cedex, France;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'EBOVAC3', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ebovac3', 'summary': 'EBOVAC3 is part of the IMI Ebola+ programme, which was launched in response to the Ebola virus disease (EVD) outbreak that started in western Africa in 2014. The comprehensive programme contributes to efforts to tackle a wide range of challenges in Ebola research, including vaccines development, clinical trials, and transport, as well as diagnostics. The programme complements work being carried out with the support of other funding bodies.\nAbout Ebola and related diseases\nEbola virus disease (EVD), previously known as Ebola haemorrhagic fever, is a rare and deadly disease caused by infection with one of the Ebola virus strains. The virus spreads in the human population through direct human-to-human contact with the bodily fluids of infected patients who are showing symptoms. It has an incubation period of 2-21 days, and it usually begins with flu-like symptoms, but rapidly progresses to multiple organ failure and blood-clotting abnormalities which manifest as internal and external haemorrhages (bleeding). It is fatal in between 25% and 90% of cases. There is currently no licensed treatment against EVD, and the development of treatments and preventive measures such as vaccines is hampered by challenges including manufacturing-related hurdles, the stability of vaccines during transport and storage, vaccine deployment, and the time taken to diagnose cases of EVD.\nThe 2014-16 Ebola epidemic was unprecedented in its scale and geographical distribution. World Health Organization (WHO) statistics recorded over 28 000 cases and 11 000 deaths from the disease, most of them in Guinea, Liberia, and Sierra Leone. The epidemic highlighted the need for research into better vaccines, diagnostics and treatments to stop future epidemics in their tracks.\n', 'tags': 'Bringing a prophylactic Ebola vaccine to licensure', 'participants': 'Chu Hopitaux De Bordeaux, Talence, France;Coalition For Epidemic Preparedness Innovation, Oslo, Norway;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Vaccines & Prevention BV, Leiden, Netherlands;London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom;Universite De Bordeaux, Bordeaux, France;Universite De Kinshasa, Kinshasa, Congo (Democratic Republic of);Universite De Paris, Paris, France;Universiteit Antwerpen, Antwerp, Belgium;University Of Sierra Leone, Freetown, Sierra Leone', 'status': 'Ongoing'}, {'id': '0', 'name': 'EFOEUPATI', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/efoeupati', 'summary': 'IMI’s EUPATI project delivered a wealth of resources to support and educate patients who wish to become more involved in medical research and drug development. These include the patient expert training course, the online multilingual toolbox, and the network of national platforms. The goal of EFOEUPATI is to develop a viable business model to ensure the viability of these resources in the medium to long term. Among other things, the project will create a patient education and engagement portal that will host relevant information and resources for patients and other stakeholders. This will ultimately replace the current EUPATI website. EFOEUPATI will also strengthen the coordination and impact of the existing EUPATI national platform network by promoting collaboration and knowledge exchange.\n', 'tags': 'Ensuring the future of EUPATI beyond 2020', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Bayer Aktiengesellschaft, Leverkusen, Germany;European Aids Treatment Group Ev, Duesseldorf, Germany;European Forum For Good Clinical Practice, Brussels, Belgium;European Patients’ Forum (EPF), Brussels, Belgium;Forum Des Patients Europeens, 1040, Belgium;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Irish Platform For Patients' Organisations Science And Industry Limited By Guarantee, Dublin, Ireland;Kobenhavns Universitet, Copenhagen, Denmark;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;UCB Biopharma SRL, Brussels, Belgium", 'status': 'Ongoing'}, {'id': '0', 'name': 'EHDEN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ehden', 'summary': 'Healthcare data has the potential to transform our understanding of health, disease and outcomes, yet it is currently scattered across multiple institutions and countries, stored in different formats, and subject to different rules. This makes it very difficult to fully utilise this data to benefit patients.\xa0 The goal of EHDEN is to make the large-scale analysis of health data in Europe a reality. The project aims to do this by building a federated data network of allowing access to the data of 100 million EU citizens standardised to a common data model. At the heart of the project will be a group of trained, certified small and medium-sized enterprises (SMEs) responsible for transforming the data owned by hospitals to the common data model. The data will remain under complete control of the original data owner, thereby ensuring ethical and local data privacy rules are respected.\nEHDEN is part of IMI’s Big Data for Better Outcomes (BD4BO) programme.\n', 'tags': 'European Health Data and Evidence Network', 'participants': 'Abbvie Inc, North Chicago, Illinois, United States ;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Celgene Management SARL, Couvet, Switzerland;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Patients’ Forum (EPF), Brussels, Belgium;Forum Des Patients Europeens, 1040, Belgium;Institut De Recherches Internationales Servier Iris, Suresnes, France;International Consortium For Healthoutcomes Measurement LTD, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;National Institute For Health And Care Excellence, Manchester, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Odysseus Data Services Sro, Praha, Czech Republic;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden;Synapse Research Management Partners SL, Barcelona, Spain;Tartu Ulikool, Tartu, Estonia;The Hyve BV, Utrecht, Netherlands;UCB Biopharma SRL, Brussels, Belgium;Universidade De Aveiro, Aveiro, Portugal;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'EHR4CR', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ehr4cr', 'summary': 'Clinical trials, a necessary step in any new drug development, are expensive and complex. They are governed by strict regulations, and recruiting and retaining the right patients can be difficult. The rapid development of targeted therapies and personalised medicines is increasing the demand for efficient, patient-oriented trials with easier access to patient data. \xa0\nThe project Electronic Health Records for Clinical Research (EHR4CR) aimed to improve the design of patient-centric trials by developing a trustworthy platform that provides access to existing patient electronic health records (EHRs). The objective of the platform is to help figure out if a trial is feasible; make patient recruitment easier; automate the preloading of a patient’s EHRs into a trial data collection form; and use EHR information in the reporting of serious adverse events during a trial.\nA search platform to find the right patients \nThe main outcome of the project is the commercial platform InSite. Launched in 2016 following the completion of the project, it was developed by project partner, Custodix. It enables scientists to find suitable candidates for trials by searching millions of EHRs stored in hospitals and clinical data warehouses throughout Europe while maintaining patient privacy. Routinely used for feasibility assessment, the platform allows a clinical trial sponsor (e.g. the pharmaceutical industry), to predict the number of eligible patients for a clinical trial, and to locate the most relevant hospital sites.\nThis helps overcome one of the biggest bottlenecks in current clinical trials: slow and costly patient recruitment. The time dedicated to patient recruitment represents about 30 % of the total length of clinical trials, more than any other clinical trial activity, and almost half of all trial delays are caused by recruitment problems.\nThe InSite platform enables hospitals to efficiently identify and contact the patients who may be eligible for particular trials, saving time and money. In April 2019, the global health research network TriNetX acquired Custodix and the InSite network, making it the world’s largest platform for clinical research. The platform has increased speed, reduced cost, and improved accuracy in clinical trial design, helping the public, academia and industry in their goal to improve healthcare.\nAn independent oversight body \nThe neutral, non-profit European Institute for Innovation through Health Data (i~HD) was established in 2015 and arose in part from the EHR4CR project. It brings together research groups, hospitals and pharma companies whose mission is to find the most efficient and trustworthy ways to use and share patient data. The i~HD, which governs the InSite platform, provides independent oversight of clinical research platforms and their expanding networks of hospitals. It also tackles the challenge of scaling up innovations that rely on high-quality and interoperable health data.\nThe i~HD developed two services: DQS4H (Data Quality Service for Hospitals) assesses and improves the quality of EHR data for hospitals by measuring and improving health outcomes, thus attracting more clinical trials and conducting more research; and the QS4RP (Quality Seal for Research Platforms) is a process for the independent assessment and verification of how clinical research platforms and services handle data in accordance with information governance, security requirements and public and professional expectations.\nTargeting the global clinical trial market, projected to be worth EUR 61.2 billion by 2026, the i~HD is also taking part in two projects: EHR2EDC (From Electronic Health Records to Electronic Data Capture systems), to improve and commercialise InSite; and Trillium-II (EU/US Cooperation for Global Interoperability in Digital Health), to coordinate efforts towards an interoperable, international patient summary.\nThe Champions programme\nIn 2015, before the development of InSite, EHR4CR consortium industry partners the i~HD and Custodix developed the Champions programme, which connects 11 European hospitals. By sharing their EHR data, the hospitals were able to participate in more clinical trials which allowed them to potentially increase their research income. For their part, the industry partners gained early access to InSite, which allowed them to optimise clinical protocols through direct responses from updated hospital EHR data for ongoing trials.\nBased on the results of the EHR4CR project, the Champions programme provided the value of real-world data for clinical research and the InSite technology on a large scale. Completed in 2017, the Champions programme resulted in a European network of more than 50 hospitals, as well with the EFPIA Champion partners’ continuing collaboration.\nWhat’s next?\nThe results of EHR4CR paved the way for another IMI project called EHDEN. Building on the output of EHR4CR, as well as IMI projects EMIF and HARMONY, EHDEN aims to harmonise clinical data and develop a 21st-century ecosystem for real world health research by building a federated network of data of 100 million EU citizens standardised to a common data model.\nEHR4CR proved that the reuse of EHRs offers an opportunity for the advancement of medical research. It provides the academic community with tools and services to better plan and conduct academic trials, and facilitates comparative effectiveness research.\nThrough the programme, the pharma industry was able to improve the speed and quality of the patient recruitment process and study design by getting a better understanding of real patient populations. It also helped them conduct observational and outcomes research studies in real-world settings. The reuse of EHR data allows more efficient management of public health issues, resulting in the improvement of healthcare, the enhancement of patient safety and more evidence-based diagnosis and treatment.\n', 'tags': 'Electronic Health Records Systems for Clinical Research', 'participants': "Amgen, Brussels, Belgium;Assistance Publique Hopitaux De Paris, Paris, France;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Cdisc Europe Foundation Fondation, Brussels, Belgium;Consept Consulting SARL, Friesenheim, France;Custodix Nv, Sint-Martens-Latem, Belgium;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece;European Institute For Health Records, Lille, France;European Molecular Biology Laboratory, Heidelberg, Germany;European Platform for Patients Oganisations, Science and Industry, Leuven, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;King'S College London, London, United Kingdom;Les Hopitaux Universitaires De Geneve, Geneva, Switzerland;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Neptunus Data Aktiebolag, Saltsjöbaden, Sweden;Novartis Pharma AG, Basel, Switzerland;Research In Advanced Medical Information And Telematics Vzw, Zwalm, Belgium;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;The University Of Edinburgh, Edinburgh, United Kingdom;The University Of Manchester, Manchester, United Kingdom;Tmf - Technologie Und Methodenplattform Fur Die Vernetzte Medizinische Forschung Ev, Berlin, Germany;Universite De Rennes I, Rennes, France;University College London, London, United Kingdom;University Of Dundee, Dundee, United Kingdom;University Of Glasgow, Glasgow, United Kingdom;Warszawski Uniwersytet Medyczny, Warsaw, Poland;Westfaelische Wilhelms-Universitaet Muenster, Münster, Germany;Xclinical GMBH, Munich, Germany;eClinical Forum Association, Friesenheim, France", 'status': 'Closed'}, {'id': '0', 'name': 'ELF', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/elf', 'summary': 'The European Lead Factory set out to create a shared platform for collaborative drug discovery. Despite significant scientific advances, many medical needs remain unmet. Drug discovery is a long, complex and expensive process that starts with identifying chemical compounds or biological molecules that can modulate a drug target involved in the disease course.\nA key tool in these earlier stages of drug discovery is a technique called High Throughput Screening (HTS), in which researchers screen large collections of chemical compounds in the hunt for molecules that could be potential drugs or be used in drug development in other ways. Although pharmaceutical companies have built up large libraries of compounds over the years, access to these collections was tightly restricted to in-house use by the owners. The European Lead Factory changed that by creating the 500 000 strong Joint European Compound Library comprising compounds from pharmaceutical companies’ own collections as well as 200 000 compounds that were newly designed and synthesised by academics and SMEs. The project also set up a European Screening Centre to run high throughput screening programmes on the compound collection.\nResearchers from European universities and SMEs could apply to use the screening centre and compound collection for their own medical research and drug development programmes. In addition to a ‘hit list’ with up to 50 compounds identified through HTS, researchers who used the European Lead Factory services also received advice on experimental design, medicinal chemistry, and on setting up partnerships to further explore and develop the results. The pharmaceutical companies in the projects were also able to use the compound collection and screening centre. Underpinning the compound collection and screening centre were three specially-designed IT systems, including an honest data broker.\nThe system proved successful; by the end of the project, the team had delivered:\n72 qualified and 37 improved hit lists from crowdsourcing programmes delivered to target owners;\n30 % follow-up work on pharmaceutical partners screens (29 of 89);\nmore than 3 000 bespoke compounds synthesised in the hit validation and hit-to-lead phase of crowdsourced target programmes;\n280 bespoke assays developed to extract the most interesting hits for crowdsourced programmes.\nProject achievements\nThe creation and successful running of the compound collection and screening centre was an achievement in itself. However, on top of that, the project delivered exciting results in many therapeutic areas, including some of the world’s biggest health challenges like cancer, metabolic disorders, neurodegenerative diseases, antimicrobial resistance and neglected tropical diseases.\nELF results directly lead to further funding for new programmes, two start-ups, along with two major partnering deals with pharmaceutical companies outside the consortium (one between ScandiCure AB and Servier - for metabolic diseases) and more than 70 new scientific publications. Five patents based on ELF compounds for the treatment of multi-resistant bacterial infections, pain and cancer, were registered, and one charity-funded virtual biotech emerged (Keapstone Therapeutics, addressing Parkinson’s disease) with EUR 2.4 million in additional funding.\nELF also led to another success in transferring results to the preclinical development IMI programme, ENABLE, working on novel potential antibiotics against Gram-negative bacteria, such as Escherichia coli.\nA collaborative, scientific environment\nBy combining the experience of big pharmaceutical companies with the agility of SMEs and the innovation in academia, ELF created a highly collaborative scientific environment and unlocked untapped potential of medical innovations, benefiting all the partners involved and the general public by addressing their unmet needs.\nThe project was in particularly interesting for SMEs, who got the opportunity to translate their innovative design ideas into industry‐standard compound libraries, and access to the industrial screening capabilities without upfront costs. Out of 30 ELF project partners, 10 were SMEs. Furthermore, the ELF consortium’s activities created 150 new jobs and trained more than 190 young scientists and postdocs.\nThis pioneering project has already delivered excellent results, and the demand for ELF’s services continue to grow. Taking into account that the timeline for drug discovery is from 10 to 15 years from disease hypothesis through to drug approval, even more, tangible results are expected in the future.\nMeanwhile the ELF’s assets, processes, tools, network and experience are being further extended and expanded through the IMI2 project ESCulab (European Screening Centre; Unique Library for Attractive Biology). Partners in ESCulab are planning, among others, to develop a fee-for-service payment model, and, most importantly, to move ESCulab operations from hit generation to lead generation.\n', 'tags': 'European Lead Factory', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Arttic, Paris, France;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Bioascent Discovery Limited, Newhouse, United Kingdom;ChemAxon Kutató-Fejlesztő Korlátolt Felelősségű Társaság, Budapest, Hungary;Danmarks Tekniske Universitet, Kgs. Lyngby, Denmark;Edelris SAS, Lyon, France;H. Lundbeck As, Valby, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;Lead Discovery Center GMBH, Dortmund, Germany;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Mercachem B.V., Nijmegen, Netherlands;Mercachem Holding BV, Nijmegen, Netherlands;Mercaleads BV, Nijmegen, Netherlands;Mercatorial BV, Nijmegen, Netherlands;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Pivot Park Screening Centre BV, Oss, Netherlands;Rijksuniversiteit Groningen, Groningen, Netherlands;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Stichting Lygature, Utrecht, Netherlands;Stichting Vu, Amsterdam, Netherlands;Sygnature Discovery Limited, Nottingham, United Kingdom;Syncom BV, Groningen, Netherlands;Taros Chemicals GMBH & Co Kg, Dortmund, Germany;The University Of Nottingham, Nottingham, United Kingdom;UCB Pharma SA, Brussels, Belgium;Universitaet Duisburg-Essen, Essen, Germany;Universiteit Leiden, Leiden, Netherlands;University Of Dundee, Dundee, United Kingdom;University Of Leeds, Leeds, United Kingdom;University of Oxford, Oxford, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'EMIF', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/emif', 'summary': 'Difficulties with data\nRecent years have seen an explosion in the number of databases containing medical and research data, from Electronic Health Records (EHRs), cohort studies (in which a group of individuals are followed for a number of years), disease-specific studies, and biobanks, to name a few. Because this data is scattered across diverse platforms, it cannot be fully exploited. Linking up the data would allow scientists to significantly advance medical research and drug development.\nHowever, in practice, this is rather difficult. Not only is the data fragmented, differences in coding systems and languages, plus legal and ethical restraints, hamper efforts to combine these sources of data. Furthermore, there are often information gaps.\nThere is therefore a need for a single system that allows researchers to link data on an immense scale, including patient health records, research data, survey and administrative data, imaging, social, environmental and economic data. Such a system should also be able to bring together data from different populations; this would increase sample sizes and facilitate the study of rare or highly specific subgroups.\nA common information framework\nEMIF will develop a common information framework that will not only facilitate access to existing data sources, but ease the creation of links between sources and, where needed, collect additional information. The work will require the team to address a number of issues, including data standards, semantic interoperability, ethics, data privacy, legal issues, and the development of an IT platform that allows access to multiple data sources.\nTo guide the development of the framework, the team will initially focus on two key research issues:\nidentifying the mechanisms that make some people more susceptible to dementias (such as Alzheimer’s disease) than others;\ndetermining which individuals with obesity are most likely to develop complications such as diabetes.\nObesity and dementia are two of the greatest healthcare challenges of our time; EMIF’s work will pave the way for new diagnostic tools and treatments to help patients with these conditions. Looking to the future, additional research areas may be added to the framework through future IMI Calls for proposals.\n', 'tags': 'European Medical Information Framework', 'participants': "Aarhus Universitetshospital, Aarhus, Denmark;Agenzia Regionale Di Sanita, Firenze, Italy;Alzheimer Europe, Luxembourg, Luxembourg;Amgen, Brussels, Belgium;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Cambridge Cognition Limited, Cambridge, United Kingdom;Concentris Research Management GmbH, Fürstenfeldbruck, Germany;Custodix Nv, Sint-Martens-Latem, Belgium;Electrophoretics LTD, Cobham, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Institute For Health Records, Lille, France;European Molecular Biology Laboratory, Heidelberg, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy;Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain;Genomedics S.R.L., Firenze, Italy;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Goeteborgs Universitet, Gothenburg, Sweden;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Itä-Suomen yliopisto, Kuopio, Finland;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Kobenhavns Universitet, Copenhagen, Denmark;Leibniz-Institut Fur Praventionsforschung Und Epidemiologie - Bips GMBH, Bremen, Germany;Maat France SARL, Archamps, France;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novo Nordisk A/S, Bagsvaerd, Denmark;PHARMO Institute N.V., Utrecht, Netherlands;Pfizer Limited, Sandwich, Kent , United Kingdom;Pharmo Cooperatie Ua, Utrecht, Netherlands;Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio- Fatebenefratelli, Brescia, Italy;Societa Servizi Telematici SRL, Padova, Italy;Sorbonne Universite, Paris, France;Stichting Vumc, Amsterdam, Netherlands;Synapse Research Management Partners SL, Barcelona, Spain;Tartu Ulikool, Tartu, Estonia;Teknologian Tutkimuskeskus Vtt Oy, Espoo, Finland;The University Of Exeter, Exeter, United Kingdom;The University Of Manchester, Manchester, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;UNIVERSITAET zu LUEBECK, Luebeck, Germany;Universidad Pompeu Fabra, Barcelona, Spain;Universidade De Aveiro, Aveiro, Portugal;Universita Di Pisa, Pisa, Italy;Universitaet Leipzig, Leipzig, Germany;Universitatsklinikum Erlangen, Erlangen, Germany;Universitatsklinikum Schleswig-Holstein, Lübeck, Germany;Universite Paul Sabatier Toulouse Iii, Toulouse, France;Universiteit Antwerpen, Antwerp, Belgium;Universiteit Maastricht, Maastricht, Netherlands;University College London, London, United Kingdom;University Of Glasgow, Glasgow, United Kingdom;University Of Leicester, Leicester, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Oxford, Oxford, United Kingdom;Vestische Caritas Kliniken GMBH, Dattien, Germany;Vib Vzw, Zwijnaarde - Gent, Belgium", 'status': 'Closed'}, {'id': '0', 'name': 'EMTRAIN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/emtrain', 'summary': 'Education and training are important aspects of biomedical research and development. As the landscape and the technologies are constantly changing, it is important that the training providers also adapt quickly. By bringing together industry and academic partners, EMTRAIN established a pan-European platform for education and training, covering the entire life cycle of medicines, from basic research, clinical tests and market authorisation to follow-up research of drugs already on the market. More specifically, the project strengthened cooperation among industry and academia, enabling faster implementation of new scientific and technological developments into academic teaching, and improving the mobility of professionals across disciplines, sectors and national borders.\nThe most comprehensive on-line catalogue in Europe\nOne of the main project achievements is on-course®, a comprehensive online course catalogue which covers everything that is taught in pharmaceutical medicine and sciences across Europe and neighbouring countries. The catalogue lists more than 8 000 different courses, ranging from one-day courses to PhD programmes. Free and easy to use, it allows users to search for courses by type (master, PhD, short course), schedule (full or part-time, modular), learning type (distance, face-to-face, mixed), language, location, and scientific / therapeutic area. For each course, the catalogue provides a description, list of modules (if relevant), details of fees, contact information, and links to the course websites. It is continuously updated by course administrators and can be accessed for free. The portal is intended to become the reference platform for education and training in biomedical sciences, and will help ensure that the biomedical education and training landscape is geared towards keeping Europe at the forefront of research. It already has more than 100 000 users.\nCreating a generation of industry-aware students\nEMTRAIN also developed a workshop for PhD students to provide young researchers with a holistic understanding of medicines development and an insight into the pharmaceutical industry. This week-long workshop is creating a growing alumni network of industry-aware students, facilitating employment opportunities and strengthening cooperation between industry and academia.\nAnother project achievement is a LifeTrain, a community-based platform for life-long learning which brings together employers, course providers and students. The platform established the principles for mutually-recognised lifelong learning and developed competency profiles, assessment of competencies and recognition processes. The platform also enables students to adapt their training to industry needs, increasing their chances of employment; helps academia tailor their programmes according to real-time industry needs; and helps industry get access to professionals with specific training.\nFor the benefit of industry and academia\nBy participating in this project, the academic community learned more about how the industry works, enabling them to adapt their courses according to real-time industry needs. Thanks to this project, young PhD researchers also gained insights into career opportunities in the private sector.\nIndustry partners benefitted by gaining access to industry-aware professionals with specific training tailored to their needs. Furthermore, EMTRAIN’s framework for competency development allows better comparability of job profiles, supporting the mobility of professionals in this field. Last but not least, the on-course® catalogue gives industry easy access to continuous professional development courses which are not covered by companies’ own training activities, saving time and resources.\nFinally, the project strengthened the pan-European community of scientists in medicines development, benefitting both the industry and academia.\nWhat’s next\nEven though the project ended, most of its tools and platforms continue to operate.\nThe LifeTrain concept and framework has been taken up by one of the project partners, the European Molecular Biology Laboratory in Heidelberg. Its work continues through workshops and conferences.\nThe PhD course has been taken up by the Horizon 2020 project C-COMEND and is being further optimised as part of this project.\nThe on-course® platform continues to operate in the context of other Horizon 2020 projects (e.g. RITrain).\nRead the interview with project coordinators\n', 'tags': 'European Medicines Research Training Network', 'participants': 'Almirall SA, Barcelona, Spain;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Biobanks And Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric), Graz, Austria;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre Europeen De Recherche En Biologie Et Medecine, Illkirch, France;Esteve Pharmaceuticals, SA, Barcelona, Spain;European Molecular Biology Laboratory, Heidelberg, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Genzyme Europe B.V., Naarden, Netherlands;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany;Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Medizinische Universitaet Wien, Vienna, Austria;Medizinische Universitat Graz, Graz, Austria;Ministry of Human Resources, Medical Research Council, National Healthcare  Service Center, Budapest, Hungary;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Orion Oyj, Espoo, Finland;PharmaTrain Federation, Basel, Switzerland;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;The University Of Manchester, Manchester, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;University of Oxford, Oxford, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'ENABLE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/enable', 'summary': 'Antimicrobial resistance (AMR) is a major global public health threat. Bacteria are becoming increasingly resistant to existing antibiotics, with the rising mortality rate and extended hospitalisation for patients translating into soaring treatment and societal costs. In Europe alone, AMR causes 25 000 deaths every year; two thirds of these are due to Gram-negative bacteria such as E. coli. The clinical burden associated with AMR is estimated to cost Europe approximately €1.5 billion per year.\xa0\nIncreasingly resistant bacteria trigger the continuous need for new, effective antibiotics. Nonetheless, only two new classes of antibiotics have been brought to the market in the last 30 years and many drug developers have left the field. This mainly due to two factors: firstly, the discovery, development and delivery of new and effective antibiotics is hampered by both scientific and regulatory challenges; secondly, antibiotics have a low return on investment compared to other medicines, making it an unattractive area for drug developers.\nAccelerating the delivery of new antibiotics\nWhile there is a strong need for new medicines to treat resistant Gram-negative infections, the industrial pipeline of new drugs remains quite limited. The ENABLE project will create and manage a drug discovery platform for testing and optimising molecules that are still in the earlier stages of drug discovery but have the potential to become future drug candidates capable of treating resistant Gram-negative infections. Once up and running, the platform will be able to run several drug discovery programmes in parallel.\nResearchers in the ENABLE project who have interesting molecules that could benefit from the platform will have the opportunity to collaborate with a diverse range of experts in microbiology, pharmacology and chemistry to help advance their molecule through the drug development process until it is an attractive candidate for clinical testing.\nThe project will focus on the discovery and pre-clinical stages of drug development, as well as (potentially) phase 1 clinical trials, during which a new drug is tested in humans for the first time. Molecule owners wishing to continue with more advanced clinical trials will be able to do so outside the ENABLE project.\nMore specifically, the project is working towards:\nidentifying three antibacterial lead molecules which, following extensive testing, have been identified as having promising antimicrobial activity;\nidentifying two antibacterial clinical candidate molecules. At this stage, the final structure of the molecule is set. The candidate then undergoes more preclinical testing before being studied in humans;\nprogressing at least one compound into preclinical and phase 1 clinical studies, i.e. early clinical safety testing in humans.\nIn a nutshell, the unprecedented scientific collaboration carried out within the ENABLE project will improve early-stage antibacterial drug discovery and advance the progress of new medicines through the scientific pipelines so that they are ready for testing in patients.\nThe new antibiotics programmes run by the ENABLE platform will come from European research institutions and small and medium-sized enterprises (SMEs). There are initially seven programmes in the ENABLE portfolio. \xa0In addition, a programme arising from an alliance between GSK and Sanofi will also make use of the platform.\nThis portfolio of programmes will be expanded through open calls for additional antimicrobial programmes from the academic and SME community, to create the most promising portfolio of drug candidates to treat Gram-negative infections. The project has funding to advance a minimum of eight programmes through early testing, with the ultimate goal of obtaining at least one drug molecule for early testing in humans by 2019.\nBoosting European scientific competitiveness\nSpanning 13 countries, ENABLE brings together an initial set of 32 partners including 11 SMEs. The unique scientific collaboration stemming from ENABLE will greatly contribute to making Europe a world leader in antimicrobial drug discovery. The creation of a cooperative environment will respond to Europe’s fight against antibiotic resistance and make a sustainable impact on the future of antibacterial drug discovery.\xa0\nENABLE is the third project of IMI’s New Drugs 4 Bad Bugs (ND4BB) programme – a series of projects designed to directly address the scientific, regulatory and economic challenges associated with antibacterial drug discovery and development.\nThe need for public-private collaboration\nAMR is a multi-faceted and complex issue, and no single organisation or country can tackle it alone. A public-private partnership thus provides unique opportunities for collaboration between leading European academic researchers, SMEs and the pharmaceutical industry – working together to discover new drugs to treat Gram-negative infections.\nIt is expected that this joint effort by top experts from different fields will maximise scientific excellence and ensure that the drug discovery programmes selected in ENABLE will progress much more efficiently than if they had been pursued in isolation.\xa0\nSMEs participating in ENABLE will benefit from access to the top antimicrobial drug discovery and development expertise brought in by other partners to see their molecules further developed. ENABLE also puts into practice some principles of collaboration and open innovation through an unprecedented intellectual property (IP) agreement that was tailored to meet the needs of the project. A key aspect of the agreement is that it allows improvements made to a molecule within the project to be assigned to the original molecule owner.\xa0At the same time, agreed mechanisms to compensate those partners that contributed to the improvements were found. \xa0The project therefore represents a clear opportunity to enhance in an open and transparent way the collaborative impact of pharmaceutical research, and the IP policy could prove inspirational for R&D collaborations in other disease areas.\n', 'tags': 'European Gram-negative Antibacterial Engine', 'participants': "Abac Therapeutics, SL, Esplugues De Llobregat, Spain;Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain;Asclepia Outsourcing Solutions Bvba, Destelbergen, Belgium;Aston University, Birmingham, United Kingdom;Astrazeneca AB, Södertälje, Sweden;Basilea Pharmaceutica International AG, Basel, Switzerland;Beactica Therapeutics AB, Uppsala, Sweden;Bioresources Technology & Engineering GmbH, Giessen, Germany;Cardiff University, Cardiff, United Kingdom;Centre National De La Recherche Scientifique Cnrs, Paris, France;European Biotechnology Network aisbl, Brussels, Belgium;Evotec International GMBH, Hamburg, Germany;Forschungszentrum Borstel, Borstel, Germany;Fundacion Centro De Excelencia En Investigacion De Medicamentos Innovadores En Andalucia, Granada, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany;Helperby Therapeutics Limited, London, United Kingdom;Inspiralis Ltd, Norwich, United Kingdom;John Innes Centre, Norwich, United Kingdom;Juvabis AG, Furigen, Switzerland;Kobenhavns Universitet, Copenhagen, Denmark;Latvijas Organiskas Sintezes Instituts, Riga, Latvia;Molecular Discovery LTD, London, United Kingdom;Mutabilis, Paris, France;Narodowy Instytut Lekow, Warsaw , Poland;Northern Antibiotics Oy, Helsinki, Finland;Nosopharm, Nimes, France;Ot Chemistry AB, Uppsala, Sweden;Redx Anti-Infectives Ltd, Manchester, United Kingdom;Redx Pharma Ltd, Liverpool, United Kingdom;Region Hovedstaden, Hilleroed, Denmark;Rise Research Institutes Of Sweden AB, Stockholm, Sweden;Servicio Madrileno De Salud, Madrid, Spain;Spero Europe Limited, Godalming, Surrey, United Kingdom;St George'S Hospital Medical School, London, United Kingdom;Statens Serum Institut, Copenhagen S, Denmark;Stichting Vu, Amsterdam, Netherlands;The Research Network Ltd., Sandwch, United Kingdom;Universitat De Barcelona, Barcelona, Spain;Universitat Zurich, Zürich, Switzerland;Universite De Liege, Liège, Belgium;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Oxford, Oxford, United Kingdom;Univerza V Ljubljani, Ljubljana, Slovenia;Uppsala Universitet, Uppsala, Sweden", 'status': 'Ongoing'}, {'id': '0', 'name': 'EPAD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/epad', 'summary': 'Dementia – focus on prevention\nDementia primarily affects older people, and symptoms include memory loss, confusion, difficulties with communication and everyday tasks, and personality changes. According to the World Health Organization (WHO), an estimated 36 million people globally have dementia, and by 2050 this figure is set to rise to 115 million. A progressive disease that currently has no cure, Alzheimer’s places a huge burden on families, carers and health systems. The total annual costs of Alzheimer’s disease are estimated at around €515 billion, similar to the annual gross domestic product (GDP) of Belgium.\nConsiderable effort has gone into the search for a cure for Alzheimer’s. However, it is now well known that signs of Alzheimer’s disease can be found in the brain decades before the first symptoms appear. Researchers are therefore increasingly focusing their efforts on finding ways of stopping the disease in its tracks during this pre-symptomatic phase to prevent the disease entirely or at least delay the onset of symptoms.\nChallenges here include the difficulty of identifying people who are likely to develop Alzheimer’s dementia, our poor understanding of these earliest stages of the disease, and a lack of flexibility in the way clinical trials are carried out.\nThe EPAD project is addressing these problems in a number of ways. Firstly, it will draw on existing national and regional registers of people at risk of developing Alzheimer’s dementia to create a single, pan-European EPAD register of around 24 000 people. Of these, the 6 000 deemed to be at greatest risk of Alzheimer’s dementia will be invited to join an EPAD cohort of at risk subjects. This group will undergo standardised tests and follow-up. Finally, the project will select around 1 500 people from this EPAD cohort to take part in early stage ‘adaptive’ clinical trials of drugs designed to prevent Alzheimer’s dementia.\nTrialling adaptive trials for Alzheimer’s prevention\nIn traditional clinical trials, half of the people participating in the trial receive the drug under investigation, and half receive a placebo. Trials may last years and cost a lot of money. In adaptive clinical trials, several candidate drugs are simultaneously compared to each other and to a placebo, meaning that a greater proportion of patients benefit from a potentially active treatment. Furthermore, in an adaptive trial, researchers can adapt the trial design in response to emerging results. For example, if a candidate medicine appears to be particularly effective in only certain groups of people, that medicine can be preferentially given to those people in order to confirm the finding. Similarly, new candidate drugs can be added to the trial and medicines that prove ineffective can be dropped. In addition, adaptive trials allow researchers to test both individual drugs and combinations of different medicines.\nThis innovative trial design has already proven effective for testing new treatments for breast cancer. The EPAD project is pioneering this approach in Alzheimer’s disease. By adopting this approach, the project expects to be able to identify ineffective medicines earlier in drug development and so avoid failures in more advanced (Phase III) trials. By setting up a cohort of patients ready to enter trials and creating a pan-European network of trial sites, EPAD will also make clinical trials more efficient.\nPatients are well represented in the project; this will ensure the project responds to the needs of people with dementia and their families.\nThe EPAD project does not operate alone. Together with IMI’s EMIF-AD and AETIONOMY projects, it forms the IMI Alzheimer’s disease platform. It is also working closely with other, similar initiatives worldwide, including the US-based Global Alzheimer’s Platform.\nIn addition, all data collected from the EPAD cohort and trial will be made publicly available for analysis to help researchers everywhere improve their understanding of the early, pre-dementia phase of Alzheimer’s disease.\nUltimately, the hope is that this project will reinvigorate the development of treatments for one of the most challenging diseases facing our ageing societies.\n', 'tags': 'European prevention of Alzheimer’s dementia consortium', 'participants': 'Ac Immune SA, Lausanne, Switzerland;Alzheimer Europe, Luxembourg, Luxembourg;Amgen, Brussels, Belgium;Araclon Biotech S.L., Zaragoza, Spain;Aridhia Informatics Limited, Glasgow, United Kingdom;Assistance Publique Hopitaux De Paris, Paris, France;Berry Consultants Llp, London, United Kingdom;Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Cardiff University, Cardiff, United Kingdom;Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fundacio Barcelonabeta Brain Research Center, Barcelona, Spain;H. Lundbeck As, Valby, Denmark;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Ixico Technologies Limited, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Medical Research Council, Swindon, United Kingdom;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Quintiles Limited, Reading, United Kingdom;Region Stockholm, Stockholm, Sweden;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Stichting Vumc, Amsterdam, Netherlands;Synapse Research Management Partners SL, Barcelona, Spain;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;The University Of Edinburgh, Edinburgh, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universite De Geneve, Genève 4, Switzerland;University Of Leicester, Leicester, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'EQIPD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/eqipd', 'summary': 'Poor quality data is an issue in many research fields – all too often, results carried out in one organisation cannot be replicated elsewhere, and it is not always clear why. In medical research, consequences include poor decision-making resulting in higher failure rates and longer drug development times. There is therefore an urgent need for simple, sustainable solutions to improve data quality, and that’s where the EQIPD project comes in. Their goal is to deliver simple recommendations to facilitate data quality without impacting innovation.\nThe project team will start by analysing the variables in study design and data analysis that influence outcomes and establishing whether these are the same in academia and industry. They will then define the components of an EQIPD quality management system and work to achieve a consensus among different stakeholders on quality management recommendations for research. They will also assess the feasibility of the quality management system in prospective studies in the fields of neuroscience and safety.\nFinally, the project will set up an online educational platform that will deliver certified courses in the principles and application of data quality and rigour. This, combined with the involvement in the project of many junior scientists, will pave the way for a cultural change in approaches to data quality in the medical research and drug development field.\n', 'tags': 'European Quality In Preclinical Data', 'participants': 'Abbvie Inc, North Chicago, Illinois, United States ;Arlenda SA, Saint-Georges, Belgium;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Concentris Research Management GmbH, Fürstenfeldbruck, Germany;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut De Recherches Servier, Suresnes, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Noldus Information Technology BV, Wageningen, Netherlands;Novartis Pharma AG, Basel, Switzerland;Orion Oyj, Espoo, Finland;Paasp GMBH, Heidelberg, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Pharmalex Belgium, Mont Saing Guibert, Belgium;Porsolt SAS, Le Genest-Saint-Isle, France;Psychogenics Inc, Tarrytown, United States;Rijksuniversiteit Groningen, Groningen, Netherlands;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Science Exchange, Inc., Palo Alto, United States;Stichting Buro Ecnp, Utrecht, Netherlands;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Synaptologics BV, Amsterdam, Netherlands;Teva Pharmaceutical Industries Limited, Netanya, Israel;The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom;The University Of Edinburgh, Edinburgh, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universitaet Bern, Bern, Switzerland;Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany', 'status': 'Ongoing'}, {'id': '0', 'name': 'ERA4TB', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/era4tb', 'summary': 'Tuberculosis (TB) poses a serious threat to public health worldwide; in 2018 alone, an estimated 10 million people fell ill with the disease and 1.6 million died. The goal of the ERA4TB project is to accelerate the development of a new, more efficient treatment regimen that will help the world to meet the United Nations goal of ending the TB epidemic by 2030.\nToday, standard TB treatment consists of a regimen of four drugs and lasts at least six months; for people with drug-resistant TB, treatment lasts even longer. New drugs are added to regimens one by one, meaning that building a new, faster and safer treatment regimen takes a very long time.\nERA4TB plans to drop the sequential approach and instead adopt a parallel pathway, which will allow the project to investigate the safety and efficacy of combinations of over a dozen drug candidates at the same time. By using a standardised approach and studying multiple molecules in parallel, the project hopes to optimise and speed up the development of new drug regimens needed to stop TB in its tracks.\nThe project will achieve this by creating a world-class ‘platform’ that brings together the expertise, tools and resources needed to accelerate the development of anti-TB drug combinations. The hope is that the platform will continue to operate beyond the end of the project.\nERA4TB is part of the AMR Accelerator programme.\n', 'tags': 'European regimen accelerator for tuberculosis', 'participants': 'Bill & Melinda Gates Foundation, Seattle, United States;Bioaster Fondation De Cooperation Scientifique, Lyon, France;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Consiglio Nazionale Delle Ricerche, Roma, Italy;Critical Path Institute, Limited, Dublin, Ireland;Department of Health, Leeds, United Kingdom;Ecole Polytechnique Federale De Lausanne, Lausanne, Switzerland;Evotec International GMBH, Hamburg, Germany;Fondation Innovative Medicines For Tuberculosis (Im4tb), Lausanne, Switzerland;Forschungszentrum Borstel, Borstel, Germany;Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La Paz, Madrid, Spain;Glaxosmithkline Investigacion Y Desarrollo SL, Tres Cantos, Spain;Global Alliance For Tb Drug Development Non Profit Organisation, New York, United States;Gritsystems As, Dragør, Denmark;Imabiotech SAS, Loos, France;Institut Pasteur De Lille Fondation, Lille, France;Institut Pasteur, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Latvijas Organiskas Sintezes Instituts, Riga, Latvia;Lunds Universitet, Lund, Sweden;National Institute For Health And Care Excellence, Manchester, United Kingdom;Qps Netherlands BV, Groningen, Netherlands;Sciensano, Brussels, Belgium;Servicio Madrileno De Salud, Madrid, Spain;Synapse Research Management Partners SL, Barcelona, Spain;Universidad Carlos Iii De Madrid, Getafe (Madrid), Spain;Universidad De Zaragoza, Zaragoza, Spain;Universita Degli Studi Di Padova, Padova, Italy;Universita Degli Studi Di Pavia, Pavia, Italy;University Of Dundee, Dundee, United Kingdom;Uppsala Universitet, Uppsala, Sweden', 'status': 'Ongoing'}, {'id': '0', 'name': 'ESCULAB', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/esculab', 'summary': 'In the early stages of drug discovery, scientists screen large numbers of chemical compounds in the hunt for potential new drugs or other interesting molecules that could be used in drug development. Accessing large, high quality compound collections for this is a challenge; IMI’s European Lead Factory project, which ran from 2013 to 2018, set up a collection of over half a million compounds and a state-of-the-art high throughput screening centre that gave a massive boost to drug discovery programmes in universities, small biotechs and large companies across Europe. The aim of the ESCulab project is to build on the achievements of the European Lead Factory. This means that researchers with drug targets can apply to have their target screened free of charge against the project’s compound collection and get help developing any resulting hits further if they like. In total, ESCulab plans to run 185 new drug discovery projects during its lifetime. In the long term, the screening centre should become self-sustaining so that it can continue to provide these valuable services after the project has finished.\n', 'tags': 'European screening centre; unique library for attractive biology', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Bioascent Discovery Limited, Newhouse, United Kingdom;Edelris SAS, Lyon, France;Grunenthal GMBH, Aachen, Germany;Institut De Recherches Servier, Suresnes, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Mercaleads BV, Nijmegen, Netherlands;Mercatorial BV, Nijmegen, Netherlands;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Mmv Medicines For Malaria Venture Fondation, genevra, Switzerland;Pivot Park Screening Centre BV, Oss, Netherlands;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Stichting Lygature, Utrecht, Netherlands;Sygnature Discovery Limited, Nottingham, United Kingdom;Syncom BV, Groningen, Netherlands;Taros Chemicals GMBH & Co Kg, Dortmund, Germany;UCB Biopharma SRL, Brussels, Belgium;University Of Dundee, Dundee, United Kingdom;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'ETOX', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/etox', 'summary': 'Studies designed to predict adverse side effects in the initial phases of drug development are very important as they lower the failure rate in later phases, ensuring that companies invest resources in only the most promising drugs, and that only safe drugs reach patients. In order to improve drug safety, the pharmaceutical industry has produced vast amounts of preclinical toxicology data needed to develop compounds into drugs. After fulfilling its initial purpose, this data used to rest in individual companies’ archives, despite the fact that a lot of further knowledge could be extracted from it. However, companies used to consider this data as part of their competitive space, and so kept it to themselves.\nBy bringing together top experts in toxicology, knowledge management, bioinformatics, chemo-informatics, biostatistics and software development, the eTOX project set out to bring together this treasure trove of toxicological information into one database, so that it could be shared among companies for the first time, and probed for further insights. The result is a unique toxicology information database, eTOXsys, which now contains information from over 8 000 toxicity studies on almost 2 000 compounds, of which around a fifth are approved drugs. The studies done on these compounds amount to about 9 million data points about the toxicology of those compounds. This database is now commercially accessible and can be searched and mined, thanks to the tools that have been built by the academic part of the consortium.\nMore than 200 predictive computer-based models\nBuilding on this treasure trove of toxicology data, which has been organised and standardised, the consortium further constructed more than 200 predictive computer-based models that have the ability to give researchers an idea of the potential toxicity of future drug-like compounds. These models make their predictions by using the complex relationships between the structure of a substance, its metabolism and disposition, and its toxic effects in the body. They enable researchers to better predict potential side effects that would otherwise only be discovered in a later stage of the drug development or when the drug is already on the market.\nThese computer models have been annotated in terms of the data and methods used for developing them. The academic partners in the project also developed eTOXlab, a platform for the development and maintenance of these models.\nDeveloping a standardised language \nOne of the obstacles to extracting further insights from this wealth of toxicology data was that there was no common terminology between different researchers and companies. In order for all this toxicological data to be useful for further analysis, eTOX had to construct standardised terminology (ontologies). As part of this process, project researchers looked over more than 20 million entry lines, reducing more than 80 000 terms used in the initial data sources to under 7 000 preferred terms. These ontologies are now publicly available through the OntoBrowser tool and will be a valuable asset for future research.\nReducing the use of animals in research\nThe database and models developed within eTOX have also contributed to reducing the use of animals in research. For example, until now, pharmaceutical companies working on similar targets used to synthesise competitor compounds in order to perform laboratory studies to compare the toxicity of competitors’ compounds with their in-house candidates. Since their competitors’ toxicological data can now be found in the eTOXsys database, they no longer need to do this. According to project coordinators, there are already multiple examples of cases where information provided by eTOXsys prevented companies from running new studies on animals.\nFor the benefit of industry, academia, SMEs\nThe industry is already benefitting from the tools developed in this project, especially the eTOXsys database. For example, if a company is developing a new compound with a toxicity that is disturbing, their research teams can now go to the database to try to find a similar compound with a similar structure or a similar effect in a similar species. This is already saving time and resources, and allowing drug makers to make better-informed decisions, which could ultimately lead to safer drugs for patients. Thanks to eTOX, the industry also gained access to academic knowledge and skills, which they don’t have internally.\nThe academic partners have in turn benefited from learning to work together with the pharmaceutical companies, and having access to toxicity data from the industry that they otherwise would not have. The project also enabled them to develop new computer models for predicting the toxicity of drugs, as well as tools and technologies for sharing all this data.\nThe SMEs in the project benefitted from working with their main customers in the pharmaceutical industry, and getting to know more about who their customers are, what they want, how they think and what they do. Additionally, SMEs have gained a new business as a result of this project: eTOXsys is now commercially available and two SMEs are in charge of maintaining and managing it.\nWhat’s next?\neTOX gave rise to a successor IMI project, eTRANSAFE, which will assess the validity of the predictive value of animal data for human safety. This successor project has the potential to modify the way researchers conduct preclinical studies, and could potentially have an even bigger impact than eTOX.\nRead the interview with project coordinators\n', 'tags': 'Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Chemotargets S.L., Barcelona, Spain;Consorcio Mar Parc De Salut De Barcelona, Barcelona, Spain;Danmarks Tekniske Universitet, Kgs. Lyngby, Denmark;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Esteve Pharmaceuticals, SA, Barcelona, Spain;European Molecular Biology Laboratory, Heidelberg, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain;Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii, Madrid, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Institut De Recherches Internationales Servier Iris, Suresnes, France;Inte:Ligand Software-Entwicklungs-Und Consulting GMBH, Vienna, Austria;Janssen Pharmaceutica Nv, Beerse, Belgium;Lead Molecular Design S.L., Sant Cugat del Vallès, Spain;Lhasa Limited, Leeds, United Kingdom;Liverpool John Moores University, Liverpool, United Kingdom;Molecular Networks GMBH Computerchemie, Erlangen, Germany;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Stichting Vu, Amsterdam, Netherlands;Synapse Research Management Partners SL, Barcelona, Spain;UCB Pharma SA, Brussels, Belgium;Universidad Pompeu Fabra, Barcelona, Spain;Universitat Politecnica De Valencia, Valencia, Spain;Universitat Wien, Vienna, Austria;University Of Leicester, Leicester, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'ETRANSAFE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/etransafe', 'summary': 'Assessing the safety of potential medicines remains immensely challenging. One major difficulty is understanding how well toxicity in animal tests predicts toxicity in humans. A lot of data on toxicity exists, but it is scattered across diverse public and private sources and stored in different formats.\nThe goal of the eTRANSAFE project is to develop a powerful data integration infrastructure (the Knowledge Hub) and use this as the basis for computer-based tools for use in drug development. The infrastructure would be flexible and expandable, and would draw on the latest technologies to deliver advanced solutions for data sharing, interoperability and exploitation. An ‘honest broker’ will ensure that confidential data would remain confidential, and overarching policies and guidelines will address ethical and legal issues such as the secondary use of human data. A large part of the project will be devoted to the creation of in silico (computer-based) tools for data mining and visualisation and, crucially, the prediction of potential toxicity.\nThe project outputs will increase the efficiency of preclinical toxicity studies, most notably in the pharmaceutical industry, and this in turn will help to speed up drug development. In addition, as the tools are computer-based, their use will contribute to a reduction in the use of animals in research. Finally, the project will contribute to the FAIR (‘findable, accessible, interoperable, re-useable) data principles.\n', 'tags': 'Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management', 'participants': 'Abbvie Inc, North Chicago, Illinois, United States ;Astrazeneca AB, Södertälje, Sweden;Barcelona Supercomputing Center - Centro Nacional De Supercomputacion, Barcelona, Spain;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Certara Uk Limited, London, United Kingdom;Clarivate Analytics (Uk) Limited, London, United Kingdom;Danmarks Tekniske Universitet, Kgs. Lyngby, Denmark;Eisai Co LTD, Bunkyo Ku Tokyo, Japan;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Molecular Biology Laboratory, Heidelberg, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain;Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain;Institut De Recherches Internationales Servier Iris, Suresnes, France;Ipsen Innovation SAS, Les Ulis, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Lhasa Limited, Leeds, United Kingdom;Liverpool John Moores University, Liverpool, United Kingdom;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Molecular Networks GMBH Computerchemie, Erlangen, Germany;Novartis Pharma AG, Basel, Switzerland;Optibrium Limited, Cambridge, United Kingdom;Pds Computer Software Limited, Leicester, United Kingdom;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Synapse Research Management Partners SL, Barcelona, Spain;Universidad Pompeu Fabra, Barcelona, Spain;Universitat Wien, Vienna, Austria;Universiteit Leiden, Leiden, Netherlands', 'status': 'Ongoing'}, {'id': '0', 'name': 'ETRIKS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/etriks', 'summary': 'IMI projects generate a lot of data, particularly the ones that deal in translational research (those that ‘translate’ basic science into medical practice). Such projects depend on knowledge management (KM) capabilities that allow researchers to work with primary study data (generated themselves) and secondary study data (generated by others). Lacking a common KM platform, IMI projects were investing in individual solutions, causing wasteful and redundant overhead costs, while also risking the legacy of the data they generate. Though there are many KM platforms on the market, commercial solutions don’t suit the requirements of research projects that are publicly funded, that have multiple partners, or that wish to allow open access to datasets.\nThe consortium delivered a knowledge management software platform called eTRIKS that is now available to IMI and non-IMI researchers. They created and deployed a host of analytics applications known as eTRIKS Labs, as well as a variety of best practices, guides and standards and other documentation. The consortium’s assets are mostly available under open licenses and the application of best practices continues through the work of the eTRIKS commercial spinoff, Information Technology for Translational Medicine (ITTM), the eTRIKS Data Sciences Network and the many adopters of eTRIKS’ technologies.\neTRIKS supported over 60 projects by the end of the collaboration (with an initial goal to support 40). At the final meeting in September 2019, it was noted that several additional research groups had utilised eTRIKS’ software and best practices, bringing the known project engagements up to 70. \xa0(eTRIKS personnel have not formally tracked use of the eTRIKS project assets since the end of 2017, although some insights were gained throughout the eTRIKS extension through to end 2018 and until the project ended.)\n\xa0\nThe platform \nIn order to make an ‘open’ platform, eTRIKS translational research information platform is based on tranSMART, an open-source data warehouse designed to store large amounts of clinical data from clinical trials and basic research. eTRIKS released five major platform versions during the course of the project. The consortium split the work into different streams that covered hosting, software development, deployment, analytics, data curation, mapping, testing, as well as data standards and ethical data use.\nThe consortium also deployed and hosted the publicly-accessible open access eTRIKS Public Platform which houses about 200 curated clinical studies from a wide variety of disease areas. Those interested in using the eTRIKS platform were invited to use the public platform as a testing and training environment and were provided with a variety of support documents for helping to use the platform.\nEtriks Labs \nThe project resulted in a number of modular applications and tools that could be used to perform data analysis, exploitation and visualisation. eTRIKS Labs arose out of a desire to brand the applications and make them available to the wider research community. All eTRIKS Labs are open license. Sample apps/tools include eTRIKS Analysis Environment (eAE), a high-performance compute grid scheduler; SmartR, which provides a dynamic and interactive way of visualising and analysing data within tranSMART; SNF, a novel computational method for genomic data integration; and Patient Input Platform, a discussion game framework to assist patients and legislators in navigating the risks and benefits of consenting their individual health data.\nStandards Starter Pack\nData standards are the rules by which data are described and recorded. In order to share, exchange, and understand data, consistent standards are essential. The Standards Starter Pack was developed by the consortium to document best practices for optimising the quality and usability of data loaded to the eTRIKS platform. Intended for project leaders and data managers, it provides a review of biomedical data standards as well as guidelines on which standards platforms are best suited for specific research plans. The Standards Starter Pack documents were made available for all IMI projects to promote consistency in data handling and to raise awareness of the advantages of applying consistent standards across translational research projects.\n', 'tags': 'Delivering European Translational Information & Knowledge Management Services', 'participants': 'Association Eisbm, Vourles, France;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Biosci Consulting Bvba, Maasmechelen, Belgium;Cdisc Europe Foundation Fondation, Brussels, Belgium;Centre National De La Recherche Scientifique Cnrs, Paris, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;ID Business Solutions Limited, Guildford, United Kingdom;Imperial College Of Science Technology And Medicine, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg;University of Oxford, Oxford, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'EUAIMS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/eu-aims', 'summary': 'Autism is a spectrum of neurodevelopmental conditions. It is heterogeneous, which means that every autistic person is different and has a unique set of strengths and challenges. Some autistic people are able to live and work independently while others may have learning differences and need more or specialist support. Some co-occurring physical and mental health conditions are more common in autism, such as epilepsy, anxiety and depression.\nAutism is highly heritable, and its underlying genetic mechanisms are complex and varied. It is clear that both genetics and environmental factors influence the development of autism, but the relative contributions from and interactions between genetic and environmental factors are not yet known.\nEU-AIMS – meeting the research challenges head-on\nThe heterogeneity of autism creates a challenge for the development of effective clinical trials for medicines and non-medical interventions. For a number of reasons, prior clinical trials have been less definitive than researchers would have hoped. To address some of these reasons, EU-AIMS contributed to the development of specific tools and methods and created a European network of specialised and skilled centres for diagnosis and running of clinical studies and trials.\nAnother complicating factor for clinical trials is that autistic people can be extremely different from one another, so that no single treatment could hope to help all of them. Clinical trials working with subgroups of autistic people who share similar characteristics are more likely to find successful treatments than trials working with large, diverse groups of autistic people. The EU-AIMS project therefore aimed to learn more about the diversity of autism. This work will aid the development of personalised therapies by improving understanding of the mechanisms underpinning core features and differences in individual needs.\nEU-AIMS has considerably advanced our knowledge of the variability within the biology and behavioural characteristics of autistic people, identified areas for medical intervention and successfully demonstrated that medicines can modulate biological differences associated with autism. In order to conduct this work, the EU-AIMS project brought together over 150 leading psychiatrists, psychologists, cognitive developmental neuroscientists, basic neuroscientists, neurobiologists, geneticists and others from over 16 academic institutions, 6 industry partners, and 3 small-to-medium size enterprises (SMEs).\nIdentifying biomarkers for autism on an unprecedented scale\nA key focus of EU-AIMS was the identification of biomarkers, short for biological markers. These are any objective measures such as patterns of brain activity, a cognitive test score, or particular genetic variants that may, for example, predict how a person\xa0responds to interventions.\nBiomarkers could, for example, be used during the diagnostic process to predict whether symptoms will change during development, and/ or to select the best interventions, support or treatment for any given person. Biomarkers have the potential for supporting research into personalised profiles and thereby addressing the challenges of the diversity seen in autism.\nTo aid in the search for autism biomarkers, EU-AIMS conducted three longitudinal studies with over 1,200 participants across the lifespan, at a scale and complexity that was previously unprecedented anywhere in the world.\nData was collected from the cohorts below using the highest research standards, then analysed with newly developed methods, leading to significant progress in the understanding of the relationship of brain structure and signs of autism:\nEurosibs: a\xa0study of infants with an autistic sibling. These siblings, who have an increased genetic likelihood of developing autism, were followed up from 4 months to 3 years with the aim of better understanding early signs of autism. \nLongitudinal European Autism Project (LEAP): the largest study of its type to identify biological markers for autism from childhood to adulthood, this study included autistic and non-autistic children, adolescents and adults and volunteers with mild intellectual disabilities aged 6-30 years. \nSynaG study: this aimed to better understand the relationship between genes and symptoms in individuals with genetic syndromes associated with autism, such as variations in genes called SHANK3 and NRXN (Neurexin).\nSome of the EU-AIMS research findings from these studies include:\nBrain ‘over-connectivity’ at 14 months predicted more repetitive behaviours later in childhood. \nSix-month-old babies that show little interest in faces went on to show more social-communication difficulties later in development.\nBiological sex, whether you are genetically male or female, is associated with significant variation in the brain phenotype of autism (phenotype means a person’s observable characteristics or traits).\nDifferences in cortical connectivity and ‘shiftability’ (changes) in brain function following a one-time dose of a serotonergic or glutamatergic medication are associated with aspects of clinical symptomatology.\nLastly and importantly, researchers identified potential candidate biomarkers that could be further developed for use in clinical trials.\nAnimal and cellular studies – translating findings into humans \nAnimal models and new non-invasive techniques, such as induced pluripotent stem cells (iPSC), were used to identify causal links from genes and environmental factors to molecular changes and biological pathways. Using iPSC methods, researchers can reprogramme cells from, for example, a human hair root to stem cells so they can be turned (induced) into any cells (pluripotent) that researchers are interested in studying. In this case researchers were interested in brain cells such as neurons.\nVarious EU-AIMS animal and cellular studies have focused on conditions associated with autism that are caused by changes in a single gene, to identify associated biological and behavioural characteristics.\nA key task was to ‘translate’ findings from animal models to humans to identify comparable underlying mechanisms characteristic of autism. This can be achieved by using measures that are safe to use in humans such as high-tech magnetic resonance spectroscopy (MRS), electroencephalogram (EEG), and structural and functional magnetic resonance imaging (sMRI and fMRI). It is important to understand how mechanisms describing certain types of behaviour in animal studies relate and compare to mechanisms described in humans.\nFor example, researchers tested whether certain medicines or related pharmacological compounds were effective in rodent and cellular models, thereby identifying potential new treatments for humans based on an improved understanding of underlying biological mechanisms across animals and humans at cellular and behavioural levels.\nCreating trained networks for future research\nEU-AIMS established the first European Clinical Trials Network for autism including over 118 clinical and research sites across 37 European countries. This network provides a platform for training, research, biomarker identification and to facilitate clinical trials for medical and non-medical approaches. This network has so far supported three industry-sponsored clinical trials for autism. It will continue to accelerate information exchange, critical discourse, and collaboration between leaders of the European autism community, having a long-lasting impact on the competitiveness and quality of autism research in Europe as part of AIMS-2-TRIALS, the follow-up project that began in 2018.\nRaising standards\nEU-AIMS was the first academic/industry group to submit a proposal for potential autism biomarkers and obtain ‘qualification advice’ from the European Medicines Agency (EMA). This is key to clarifying the research standards required for identifying biomarkers for subsequent approval by the EMA. This crucial step improved understanding between regulatory authorities, academics and industry; and helps to ensure that measures used in and developed for research and clinical trials are safe and reliable. This work led to a joint publication between EU-AIMS researchers and the EMA in Nature Reviews Drug Discovery (‘Identification and validation of biomarkers for autism spectrum disorders’). The EMA quoted the work of the project when they developed new EU policies on medicine testing in autism, and as such, EU-AIMS contributed significantly to the progress in regulatory science to support the development of medical/ non-medical interventions.\nCreating a secure and sustainable central database \nEU-AIMS research efforts were underpinned by a central database to efficiently and safely store the research data collected, conduct quality control steps, pre-process and download data from each study for registered analysis projects. This anonymised and harmonised data has been made available via a custom-built infrastructure called the EU-AIMS DataSharingSystems. Institute Pasteur agreed to host the central database from the project.\n', 'tags': 'European Autism Interventions - a Multicentre Study for Developing New Medications', 'participants': "Arttic, Paris, France;Autism Speaks Inc. Non Profit Corporation, Princeton, NJ, United States ;Birkbeck College - University Of London, London, United Kingdom;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Molecular Biology Laboratory, Heidelberg, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Institut De Recherches Servier, Suresnes, France;Institut Pasteur, Paris, France;Islensk Erfdagreining Ehf, Reykjavik, Iceland;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Koninklijke Nederlandse Akademie Van Wetenschappen - Knaw, Utrecht, Netherlands;Laeknisfraedileg myndgreining ltd, Reykjavik, Iceland;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Noldus Information Technology BV, Wageningen, Netherlands;Pfizer Limited, Sandwich, Kent , United Kingdom;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Universita Campus Bio Medico Di Roma, Rome, Italy;Universitaet Ulm, Ulm, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitat Basel, Basel, Switzerland;University of Cambridge, Cambridge, United Kingdom;Vifor SA, Villars-sur-Glâne, Switzerland;Zentralinstitut Fuer Seelische Gesundheit, Mannheim, Germany", 'status': 'Closed'}, {'id': '0', 'name': 'EUPEARL', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/eu-pearl', 'summary': 'In a conventional clinical trial, typically half of the people participating in the trial receive the drug under investigation, and half receive a placebo. Trials may last years and cost a lot of money. In addition, if there are many trials in a disease area, it can be hard to find enough patients for all the trials taking place at a given time. For their part, patients struggle to find the right trial for their needs.\nEU-PEARL aims to revolutionise the way we do clinical trials by making them more efficient and patient friendly. The project team will do this by setting up adaptive clinical trial platforms which allow multiple companies to test their candidate drugs simultaneously against a shared placebo group. Furthermore, in an adaptive platform trial with a single master protocol, new treatment groups can be added at any time, and candidate drugs that prove ineffective can be dropped. This will make it easier to enrol enough patients, while patients will benefit from an increased likelihood of being allocated a promising treatment instead of the placebo.\nEU-PEARL will build the platform on a number of pillars. A clinical network of hospitals will provide the environment for the clinical trials and a place where different stakeholders can come together and interact. Patients are partners in the project and will contribute to the design of the platforms. EU-PEARL will also develop a comprehensive set of tools and methods for the planning, implementation and analysis of the trials. Finally, it will address regulatory issues as well as data governance.\nEU-PEARL will focus its efforts on four disease areas: major depressive disorder, tuberculosis, the liver disease non-alcoholic steatohepatitis (NASH), and neurofibromatosis. However, the project outputs will make it possible to set up similar trial platforms in other disease areas in the future.\n', 'tags': 'EU patient-centric clinical trial platform', 'participants': "Allergan Limited, Marlow, United Kingdom;Assistance Publique Hopitaux De Paris, Paris, France;Astrazeneca AB, Södertälje, Sweden;Berry Consultants Llp, London, United Kingdom;Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Children'S Tumor Foundation, New York, United States;Custodix Nv, Sint-Martens-Latem, Belgium;Documental Ou, Tallinn, Estonia;Eatris Eric, Amsterdam, Netherlands;Ecrin European Clinical Research Infrastructure Network, Paris, France;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Patients’ Forum (EPF), Brussels, Belgium;Euroscan International Network Ev, Koln, Germany;Forum Des Patients Europeens, 1040, Belgium;Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain;Global Alliance For Tb Drug Development Non Profit Organisation, New York, United States;Institut De Recherches Internationales Servier Iris, Suresnes, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;King'S College London, London, United Kingdom;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Medizinische Universitaet Wien, Vienna, Austria;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Otsuka Novel Products GMBH, Munich, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Springworks Therapeutics Inc, Stamford, United States;Team - It Research SL, Barcelona, Spain;Teva Pharmaceutical Industries Limited, Netanya, Israel;The European Institute For Innovation Through Health Data, Gent, Belgium;The University Of Manchester, Manchester, United Kingdom;Universita Degli Studi Di Milano, Milano, Italy;Universita Vita-Salute San Raffaele, Milano, Italy;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University of Oxford, Oxford, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'EU2P', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/eu2p', 'summary': 'The Eu2P project was set up to respond to the growing need for well-trained professionals, specialists and non-specialists, in pharmacovigilance and pharmacoepidemiology. Pharmacovigilance involves collecting and analysing information from patients and health care providers on potential adverse effect of medications that are already on the market. In pharmacoepidemiology, scientists study, predict and compare the risks and benefits of commercial or experimental medicines in populations.\nBy bringing together 7 academic, 2 regulatory and 15 industry partners, the Eu2P project developed the first pan-European, internationally recognised programmes in pharmacovigilance and pharmacoepidemiology. Through the Eu2P on-line platform, which can be accessed anytime and anywhere, it offers courses which lead to a joint master’s degree, a PhD degree, 25 joint academic certificates and over 50 short courses. Specialisations include topics such benefit assessment of medicines, medicines risk identification and quantification, and medicines risk communication. The programmes target specialists such as pharmacists, physicians, scientists and experienced professionals, but also non specialists such as journalists, lay people, and patients. More than 2 500 course registrations have already been recorded for its short courses and almost 500 people have attended Eu2P’s postgraduate programmes. About 15 % of students so far came from lower income countries (e.g. from Africa and Asia). For them, a limited number of partial grants are available.\nThe emphasis is put on ‘hands-on training’ to maximise post-training employment opportunities. The courses are delivered in English using a unique and innovative modular approach which integrates multimedia lessons, video conferences, online quizzes and assignments.\nBenefits for academia and industry\nSix European universities, part of Eu2P, are now offering Eu2P joint certificates and postgraduate programmes in pharmacovigilance and pharmaceopidemology. The establishment of these programmes raised their profile and recognition on an international level. The public partners in the project also benefited from the network and collaborations established during Eu2P.\nThanks to the project, industry employees can now get internationally recognised postgraduate certificate diplomas, master’s and PhD degrees, as well as academically recognised short courses which have been tailored to their needs.\nWhat’s next?\nAfter the project ended in June 2016, six of the universities which were part of the project and five private partners signed a memorandum of understanding to continue the project. The programmes and courses offered are now self-sustainable, and are funded through student fees. Courses are being continuously updated as the field evolves, and additional courses are planned.\nRead the interview with project coordinators\n', 'tags': 'European programme in Pharmacovigilance and Pharmacoepidemiology ', 'participants': "Agence nationale de sécurité du médicament et des produits de santé, Saint-Denis Cedex, France;Almirall SA, Barcelona, Spain;Amgen, Brussels, Belgium;Association Pour Le Developpement De L'Enseignement Et Des Recherches Aupres Des Universites, Des Centres De Recherche Et Des Entreprises D'Aquitaine, Pessac, France;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;F. Hoffmann-La Roche AG, Basel, Switzerland;Fundacio' Institut Català de Farmacologia, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Orion Oyj, Espoo, Finland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;The European Medicines Agency, Canary Wharf, London, United Kingdom;The University Of Hertfordshire Higher Education Corporation, Hatfield. Hertfordshire, United Kingdom;UCB Pharma SA, Brussels, Belgium;Universita Degli Studi Di Verona, Verona, Italy;Universite De Bordeaux, Bordeaux, France;Universiteit Utrecht, Utrecht, Netherlands", 'status': 'Closed'}, {'id': '0', 'name': 'EUBOPEN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/eubopen', 'summary': 'When developing new medicines, scientists need to understand the underlying causes of disease. To do that, they need to be able to study in detail the role of the different proteins involved in the disease. However, that requires chemical compounds capable of altering or blocking the action of individual proteins.\nThe goal of EUbOPEN is to develop high quality chemical tool compounds for 1 000 human proteins. This represents around a third of the ‘druggable’ proteins in the human body. The project will test the new tools in the areas of immunology, oncology and neuroscience.\nThe project will make the tools, plus the accompanying data and protocols, openly available to the entire research community without restrictions on use.\nBy the end of the project, the EUbOPEN team will have created the largest and most deeply characterised collection of chemical modulators of protein function that is also openly accessible. Researchers in academia and industry alike will therefore be able to use the tools to study diseases, and identify proteins that play a key role in disease development and so could be targeted by drugs. The tools will also help scientists to design drugs capable of blocking specific proteins involved in diseases.\n', 'tags': 'EUbOPEN: Enabling and unlocking biology in the OPEN', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung, Frankfurt, Germany;Diamond Light Source Limited, Didcot, United Kingdom;Eidgenoessische Technische Hochschule Zuerich, Zurich, Switzerland;European Molecular Biology Laboratory, Heidelberg, Germany;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Institut De Recherches Servier, Suresnes, France;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Karolinska Institutet, Stockholm, Sweden;Kungliga Tekniska Hoegskolan, Stockholm, Sweden;Ontario Institute for Cancer Research, Toronto, Ontario, Canada;Pfizer Limited, Sandwich, Kent , United Kingdom;Royal Institution For The Advancement Of Learning Mcgill University, Montreal, Canada;Structural Genomics Consortium Lbg, London, United Kingdom;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;The Governing Council Of The University Of Toronto, Toronto, Canada;The University Of North Carolina At Chapel Hill, Chapel Hill, United States;University Of Dundee, Dundee, United Kingdom;University of Oxford, Oxford, United Kingdom;X-Chem Inc, Waltham, MA, United States;Zebiai Therapeutics Inc, Wilmington, United States', 'status': 'Ongoing'}, {'id': '0', 'name': 'EUPATI', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/eupati', 'summary': 'While patients are keen to have access to better and safer treatments, many find it hard to understand the benefits and risks of novel therapies. With demand for healthcare rising, and a growing emphasis on both the quality and sustainability of healthcare services, there was a proven need for information resources, designed specifically for patients and the public, on how medicines research and development (R&D) and clinical trials are conducted. By bringing together major patient organisations, academic institutions and industry partners, EUPATI set out to address this major gap in public perception and knowledge.\nOne of the main project outputs is the development of the Patient Expert Training Course – a 14-month in-depth course for patient advocates on medicines R&D. Almost 100 patients from 32 countries and 58 disease areas have already graduated from the course, and more are on the way. In order to multiply the effect of this course, the project has also developed a ‘train-the-trainer programme’.\nToolbox and national platforms\nAnother important project output is the toolbox on medicines R&D which is available in eight languages on the EUPATI website. It includes articles, presentations, videos, webinars, factsheets, and much more. It already has been used by more than 500 000 people worldwide.\nThe project also established 18 national platforms which are based on the same model as EUPATI. By organising educational webinars, information days, workshops, and social media campaigns, the platforms have enabled patients on a national level to become more involved in medicines R&D, and regulatory affairs.\nGuidance documents and other achievements\nOther important project outputs include:\nguidance documents for the engagement of patient organisations in industry-led R&D, health technology assessment bodies, regulatory processes, and ethics committees;\nthe organisation of interactive annual conferences and workshops which have attracted about 1 200 participants, about 50% of them patient advocates;\nthe organisation of educational webinars on a variety of relevant topics.\nPatient voices already being heard\nThrough all these activities, EUPATI has been a catalyst for patient involvement in medicines R&D and continues to be one of the key drivers of the public debate on this topic in Europe and beyond. EUPATI fellows are engaged in regulatory committees, as speakers on medical conferences, and are participating in regulatory and ethics committees. As a result, clinical trials are changing shape, trial outcomes are being defined differently, and patient voices are being heard in regulatory discussions.\nPatients are also benefitting from a large patient network which was established as part of this project. Patient organisations are usually volunteer-driven, low-resource organisations and before EUPATI they didn’t have the capabilities to work together across different disease areas. Thanks to EUPATI, this has finally changed, and has been a game-changer in patient advocacy.\nBenefits to academia and industry\nThe academic community benefited from the project by getting a neutral platform to collaborate with the industry, regulators and patient organisations. Also, a lot of publications co-authored by academics were published in high-impact journals which contributed to increasing their reputation and visibility.\nThe industry benefited from the collaborative network that was established, and from having access to patients who are familiar with all the aspects of R&D and can help in the drug development process with their perspective.\nWhat’s next?\nEven though the project ended, thanks to a three-year sustainability plan, the main project outputs (the course, the toolbox, national platforms) continue to be maintained. \xa0Furthermore, several project partners are continuing to collaborate and initiate new projects.\nRead the interview with project coordinators\n', 'tags': "European Patients' Academy on Therapeutic Innovation", 'participants': "Amgen, Brussels, Belgium;Asociacion Nacional Empresarial De La Industria Farmaceutica, Madrid, Spain;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Central Manchester University Hospitals Nhs Foundation Trust, Manchester, United Kingdom;Chiesi Farmaceutici S.A, Parma, Italy;DIA Europe GmbH, Basel, Switzerland;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Esteve Pharmaceuticals, SA, Barcelona, Spain;European Aids Treatment Group Ev, Duesseldorf, Germany;European Forum For Good Clinical Practice, Brussels, Belgium;European Genetic Alliances' Network, Brussels, Belgium;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;European Patients’ Forum (EPF), Brussels, Belgium;Eurordis - European Organisation For Rare Diseases Association, Paris, France;F. Hoffmann-La Roche AG, Basel, Switzerland;Genetic Alliance Uk LTD, 436 Essex Road, London, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Hibernia College, Dublin, Ireland;International Society for Pharmacoeconomics and Outcomes Research Inc, Lawrenceville, New Jersey, United States ;Irish Platform For Patients' Organisations Science And Industry Limited By Guarantee, Dublin, Ireland;Janssen Pharmaceutica Nv, Beerse, Belgium;Kobenhavns Universitet, Copenhagen, Denmark;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Groupe, Chilly-Mazarin, France;The Employers' Union of Innovative Pharmaceutical Companies INFARMA (Związek Pracodawców Innowacyjnych Firm Farmaceutycznych), Warsaw, Poland;The University Of Manchester, Manchester, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Verband Forschender Arzneimittelhersteller Ev, Berlin, Germany;Vereniging Samenwerkende Ouder- En Patientenorganisaties, Soest, Netherlands", 'status': 'Closed'}, {'id': '0', 'name': 'EUROPAIN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/europain', 'summary': 'Casting the net wide, producing more than 200 publications\nChronic pain affects one in five Europeans and 7-8% of the whole population has neuropathic pain, a type of pain which results from the nerve fibres themselves being damaged, dysfunctional, or injured. Despite the prevalence and high cost to society, only 30% of people with chronic pain get an effective treatment and in the neuropathic group that figure is even lower. Even though there are a number of different products for treating pain, the last big pain drug concept was invented in 1995. New, more personalised and effective ways of treating pain are sorely needed.\nBy bringing together 12 academic institutions, 11 pharmaceutical companies and an SME, IMI’s Europain project set out to improve our understanding of the mechanisms of pain, and overcome bottlenecks in the development of analgesics (pain killers). The result was a very wide-ranging project which transformed the pain field, resulting it over 200 scientific publications. Its learnings and outputs improved both preclinical and clinical studies, as well as the ability to translate results from animal to patient studies.\nPre-clinical studies: happy rats burrow, socialise and venture into light\nIn the pre-clinical phase of pain medication studies, one of the main problems is measuring the impact of potential new drugs on laboratory animals, usually rats. In order to improve the situation, Europain scientists set out to provide something that was missing: a standardised and structured way of measuring pain in rats based on their natural behaviour. When healthy and pain-free, rats burrow, socialise and spend more time in the light. When in pain, they burrow and socialise less, and spend more time hiding in the dark. Project scientists measured these behaviours, and validated them across different laboratories in both industry and academia, performing the first multi-centre, double-blind study in a pre-clinical setting. Thanks to this work, four quantitative ways of measuring spontaneous pain behaviour in rats are now available, along with detailed protocols which other scientists can use.\nFrom animals to humans: translating results made easier\nOne of the difficulties in drug discovery is using the results of animal studies to predict what will happen in human patients. In an effort to facilitate this process, Europain scientists were able to show that a technique used to measure pain-related nerve signals, called microneurography, measures the same pain patterns in animals and humans. The European Medicines Agency (EMA) acknowledged that this technique – which involves sticking a fine needle into a nerve to measure pain – can now be used to demonstrate whether a potential drug works. Drug companies are already using the method to help them identify early on which drugs are likely to be effective.\nPreparing for a clinical study: the power of imaging\xa0\nClinical studies are lengthy and expensive, and before investing in them, pharmaceutical companies want to know if a potential drug is likely to work in patients. European scientists found that brain imaging could be used to predict early on, in limited groups of patients, whether a potential drug works. They showed that certain areas in the brain are more active when a patient is in pain, and become less active when the patient is given efficacious treatment. They further validated brain imaging as a method which can show whether a potential drug works to reduce pain (proof of mechanism). Some companies are already using this method, which has the potential to save money and ensure that more effective drugs reach patients.\nClinical studies: minimising the placebo effect\nAnother obstacle in clinical studies is the placebo effect, in which a fake treatment (such as a sugar pill) causes a patient’s condition to improve. If large, the placebo effect makes it harder to measure the real effect of a potential drug. In order to understand factors which trigger a placebo response, Europain project scientists studied how different factors in the design of the study affect the placebo response. Out of all the possible factors which could influence the patients, such as the size or the location of the study, they found that the information given to patients at the beginning of the study, likely may be the factor having the greatest impact. For example, patients who knew they were being tested for over-the-counter pain medications had a much lower placebo response than patients who knew they were being tested for morphine-like drugs. This led the scientists to conclude that researchers could be more successful in eliminating the placebo effect if they write the information in the consent forms in a more neutral way, thus lowering patients’ expectations.\nOther achievements: a new way of grouping patients\nDuring its course, Europain tackled a wide range of questions and recorded a number of other achievements. Among the most significant are the following:\nCreating a database of more than 2 300 neuropathic pain patients and 1 000 healthy volunteers – the largest of its kind in the world. The scientists further classified patients in the database into groups based on their level of sensitivity to pain rather than the type of disease which is at the origin of their pain. The EMA has acknowledged that this is a valid way of classifying patients in early clinical trials and included this new stratification in their guidelines for the development of pain drugs. This represents a paradigm shift in the field of developing treatment for neuropathic pain.\nSeveral disease-relevant animal models have been developed and validated across laboratories in industry and academia. They can now be used to study chronic pain due to diabetes, antiretroviral treatment and chemotherapy.\nA new human model for chemotherapy-induced pain has been developed and validated. Scientists also discovered that sleep deprivation is a valid model for increased sensitivity to pain in both rodents and humans.\nA discovery that people prone to catastrophising (believing that something is far worse than it actually is) have a higher risk of developing chronic pain in the aftermath of surgery. The project also found that patients who undergo endoscopic (keyhole) surgery develop chronic pain after surgery to a lesser extent than patients who undergo open surgery. This is already helping doctors personalise post-surgery follow-up treatments in some countries.\nFor the benefit of industry, academia and patients\nEuropain created unprecedented levels of cooperation in the chronic pain field, and enabled the exchange of knowledge which benefitted both industry and academia. The industry gained new tools which could make pre-clinical and clinical trials cheaper, more reliable and efficient, speeding up the development of innovative medicines. Thanks to the partnership with the industry, the academic community was able to achieve much more than it could have done on its own, raising the profile of European research in this area. Last but not least, patients will reap significant benefits: for example, the new stratification of patients according to their level of sensitivity during clinical trials could lead to the development of more personalised treatments.\nWhat happens next?\nEuropain project learnings and outputs have transformed the neuropathic pain field and triggered a lot of new research activity. A number of new projects are now building on the Europain results, and some of them involve one or several partners from the Europain team.\nRead the interview with the project coordinator\n', 'tags': 'Understanding chronic pain and improving its treatment', 'participants': "Aarhus Universitetshospital, Aarhus, Denmark;Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Astellas Pharma Europe BV, Leiden, Netherlands;Astrazeneca AB, Södertälje, Sweden;Berufsgenossenschafliches Universitaetsklinikum Bergmannsheil GMBH, Bochum, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Esteve Pharmaceuticals, SA, Barcelona, Spain;Grunenthal GMBH, Aachen, Germany;H. Lundbeck As, Valby, Denmark;Imperial College Of Science Technology And Medicine, London, United Kingdom;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;King'S College London, London, United Kingdom;Klinikum Rechts Der Isar Der Technischen Universitat Munchen, Muenchen, Germany;Neuroscience Technologies Limited, London, United Kingdom;Neuroscience Technologies Slp, Barcelona, Spain;Pfizer Limited, Sandwich, Kent , United Kingdom;Region Hovedstaden, Hilleroed, Denmark;Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, Germany;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Syddansk Universitet, Odense, Denmark;UCB Pharma SA, Brussels, Belgium;Universitatsklinikum Schleswig-Holstein, Lübeck, Germany;University College London, London, United Kingdom;University of Oxford, Oxford, United Kingdom", 'status': 'Closed'}, {'id': '0', 'name': 'FAIRPLUS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/fairplus', 'summary': 'The vast amounts of data generated in life science research have the potential to add to our understanding of disease and help advance drug development. Yet most data is hidden away in proprietary databases and stored in different formats. The goal of FAIRplus is to deliver guidelines and tools to facilitate the application of ‘FAIR’ principles to data from certain IMI projects and datasets from pharmaceutical companies. FAIR stands for ‘findable, accessible, interoperable, reusable’. The project will therefore make it easier for other researchers to find the data and integrate it into their own research. The project will also organise training courses for data scientists in academia, small and medium-sized enterprises (SMEs) and pharmaceutical companies. Ultimately, the project hopes to change the culture of data management in the life sciences sector.\n', 'tags': 'FAIRplus', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Barcelona Supercomputing Center - Centro Nacional De Supercomputacion, Barcelona, Spain;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Molecular Biology Laboratory, Heidelberg, Germany;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Heriot-Watt University, Edinburgh, United Kingdom;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Novartis Pharma AG, Basel, Switzerland;Open Phacts Foundation Lbg, Cambridge, United Kingdom;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;Stichting Lygature, Utrecht, Netherlands;The Hyve BV, Utrecht, Netherlands;The University Of Manchester, Manchester, United Kingdom;Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg;Universite Paul Sabatier Toulouse Iii, Toulouse, France;Universiteit Maastricht, Maastricht, Netherlands;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'FILODIAG', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/filodiag', 'summary': 'The problem: how to speed up PCR testing\nWith a disease like Ebola, there’s no time to lose. Typical diagnostic tests can take days to yield results, preventing health care workers from quickly determining whether a patient needs immediate treatment and isolation. If a patient has not been isolated while they await results of a blood test – not a realistic option in most cases – they have the potential to infect everyone in their social circle. On the other hand, keeping a healthy patient in a clinic risks exposing them to the disease. In the biggest Ebola outbreak that struck western Africa in 2014-2016, more than 11 000 people died. This number could have been greatly reduced had health workers had access to faster diagnostics. \xa0\nWhile fast and easy-to-use tests usually rely on immuno-diagnostic approaches, they tend not to be sensitive or specific enough to be dependable. A PCR-based test (polymerase chain reaction) is the gold standard. It’s a highly-sensitive diagnostic test that’s typically carried out in a laboratory, and involves a machine that heats up and cools down a purified sample multiple times following a particular sequence. The objective of this thermocycling is to allow the amplification of nucleic acids. While PCR tests are great for picking up tiny traces of the Ebola virus, they take time.\nFrom multiple days to mere minutes\nThe FILODIAG project partners developed and tested a thermocycler that can heat and cool the target’s nucleic acids in a fraction of the time, returning results in about 15 minutes. SME partner GNA Biosolution’s proprietary pulse controlled amplification (PCA) technology uses locally heated microcyclers (laser-heated nanoparticles) to carry out the heating and cooling cycles of the nucleic acids to be analysed. If deployed widely, in a more portable and miniaturised format, this technology has the potential to uncover unknown transmission chains and hotspots. By facilitating early detection and isolation, it could minimise the number of people exposed and enable those affected to get the best treatment possible.\nSmall consortium, big impact\nThe consortium was able to cover the entire R&D value chain with just four partners. GNA Biosolutions, a small German SME, coordinated the project. They combined their proprietary PCA technology with sample preparation techniques developed by an academic partner in the Czech Republic (University of Brno), and carried out tests with real Ebola material in a bio-safety lab in Rome (INMI, “La Spallanzani”). The partners greatly benefited from the collaboration with Emergency, an international NGO on the ground in Sierra Leone, who helped to set up and carry out a field test.\nParticularly in terms of benefits for SMEs, the connections made during the lifetime of the project helped GNA Biosolutions broaden their network, putting them in touch with prospective future partners in industry and academia. The company grew in size from about 12 people at the beginning of the project to 24 staff at the end, and they learned a great deal about coordinating an international project, encouraging the SME to embark on further future such projects. \xa0\nWhat’s next?\nThanks to the FILODIAG project, GNA Biosolutions has developed a commercial product for research use for diseases that require rapid diagnostics. A portable, shoe box-sized demonstrator with PCA for detecting Ebola is currently under development.\nThe FILODIAG project is part of the Ebola+ programme. \xa0\n', 'tags': 'Ultra-fast molecular filovirus diagnostics', 'participants': 'Emergency Life Support For Civilian War Victims Ong Onlus, Milan, Italy;Gna Biosolutions GMBH, Martinsried, Germany;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy;Mendelova Univerzita V Brne, Brno, Czech Republic', 'status': 'Closed'}, {'id': '0', 'name': 'FLUCOP', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/flucop', 'summary': 'Flu epidemics are common in the winter, and while most people infected will recover without medical intervention, certain groups are at greater risk of suffering complications that may result in hospitalisation and even death. At-risk groups include the elderly, the very young, pregnant women, and people with other underlying health problems such as lung or heart problems or a weakened immune system.\nAccording to the World Health Organization (WHO), these seasonal epidemics cause 3-5 million cases of severe illness and up to 500 000 deaths worldwide. Furthermore, flu epidemics place immense strain on health systems, and can affect economic productivity due to sick leave.\nVaccines – key to flu prevention\nThe influenza virus is spread easily and can be transmitted through coughing and by contaminating surfaces. Basic infection control measures (coughing into a tissue, regular handwashing) are important in slowing the spread of the disease. However, the WHO recommends vaccination as the most effective way to prevent the disease, especially in vulnerable people and those who care for them.\nToday’s flu vaccines do not provide protection against all strains of the virus because of\xa0 the ability of the influenza virus to change continuously as it circulates amongst human and animal populations. Therefore, every year the WHO Global Influenza Surveillance and Response System closely monitors the strains in circulation and provides advice on the emerging strains likely to be in circulation the following winter. Subsequently, in a race against time, pharmaceutical companies develop, in a matter of months, vaccines designed specifically to protect individuals from infection by those emerging strains.\nThe challenge of checking vaccines \nA major challenge in flu vaccine development is the need for standardised tests, ideally blood-tests, that rapidly and reliably indicate the level of actual protection that might be expected from a new vaccine against a given emerging strain of the virus. Public research institutions, vaccine manufacturers and other stakeholders currently use tests to measure the immune response that the vaccine generates to the virus in people. However, those tests, which have been locally developed, can vary widely from laboratory to laboratory. This prevents potentially useful comparisons, and limits their value as predictive tools – something that all stakeholders would like to increase.\nA toolbox for the entire flu vaccine community\nFLUCOP represents an unprecedented collaboration between European vaccine manufacturers, academic institutions, regulatory bodies, and public health agencies to improve the toolbox available to evaluate the ability of new influenza vaccines to stimulate the immune system in humans.The collaboration\xa0 seeks to improve current tests, develop new tests and, very importantly, to harmonise how those test are performed in different laboratories.\nIn the short term, the toolbox will ensure that results of clinical studies of flu vaccines will be comparable, even if they are carried out at different times and in different laboratories in different parts of the world. In the longer term, it will likely have an impact on the way medicines regulators approve new flu vaccines, and will improve best practice in the way flu vaccines are developed worldwide.\n', 'tags': 'Standardization and development of assays for assessment of influenza vaccines correlates of protection', 'participants': 'Abbott Biologicals BV, Weesp, Netherlands;Artemis Bio-Support B.V., Utrecht, Netherlands;Astrazeneca AB, Södertälje, Sweden;Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany;Department of Health, Leeds, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Vaccine Initiative - EEIG, Heidelberg, Germany;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Istituto Superiore Di Sanita, Roma, Italy;Janssen Vaccines & Prevention BV, Leiden, Netherlands;Quinten SAS, Paris, France;Sanofi Pasteur SA, Lyon, France;Sclavo Vaccines Association, Siena, Italy;Seqirus S.r.l., Siena, Italy;Stichting Biomedical Primate Research Center, Rijswijk, Netherlands;The European Medicines Agency, Canary Wharf, London, United Kingdom;Universita Degli Studi Di Parma, Parma, Italy;Universita Degli Studi Di Siena, Siena, Italy;Universiteit Gent, Gent, Belgium;Universitetet I Bergen, P.O. Box 7800, Bergen, Norway;University Of Surrey, Guildford, United Kingdom;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'GETREAL', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/getreal', 'summary': 'Once a new drug has been developed, it must be reviewed by both the regulators (for the decision on marketing authorisation) and health technology assessment (HTA) bodies (for the decision on access to patients). The regulators draw on data, mostly from clinical trials, to determine if a drug is safe and works well enough to be authorised for use in patients. For their part, HTA organisations assess more broadly the value of a new drug for a given healthcare system. For this, they need real-world evidence (RWE) to support the assessment of ‘relative effectiveness’: that is the extent to which a treatment does more good than harm when compared to one or more alternative treatments when provided under normal healthcare circumstances.\nHowever, while there are clear, detailed guidelines on how to carry out clinical trials and what is required to achieve marketing authorisation, there is little guidance on how to generate RWE and integrate this into drug development. This is a serious issue: even if a drug is approved as safe and effective by the regulators, insufficient evidence supporting relative effectiveness may delay, or restrict (partially or entirely) patient access to new treatments. The challenge, therefore, is to incorporate relative effectiveness research into the earlier stages of drug research and development. IMI’s GETREAL project set out to bridge that gap.\nThe project broke ground in that it brought together companies, healthcare decision-makers, patient representatives and other stakeholders to begin to work towards building a consensus on best practices in the use of RWE in drug development, as well as regulatory and reimbursement decision-making. The project developed tools, recommendations and guidance for incorporating RWE earlier in the drug development process.\nGetting to grips with RWE: the Navigator tool\nOne of the main project achievements was the launch of RWE Navigator. This online resource helps users from a broad range of research and healthcare backgrounds get to grips with the need for and the generation of RWE, and understand how this can be used to inform decision-making.\nThe RWE Navigator is designed to help users from industry define and implement a robust RWE generation plan; HTAs and regulators to better understand the analytical models used; and patients to understand concepts related to RWE and the challenges faced when using or generating RWE. It directs users to the TOOLBOX, which in turn guides them on how to define the attributes of the medicine that may drive a difference in the efficacy seen in a clinical trial setting, compared to the effectiveness when used in routine healthcare (often referred to as the efficacy-effectiveness gap). It also informs users on the specific types of analyses or study designs that can be used to generate or model RWE, including their pros and cons, and includes a comprehensive directory of resources to support users in implementing their RWE generation plans.\nPragmatic trials and the PRAGMAGIC tool\nPragmatic trials offer an opportunity to generate high-quality evidence on relative effectiveness prior to and (soon) after drug launch. However, many people are still reluctant to conduct such studies as they are very challenging to implement and there is some uncertainty regarding the acceptability of pragmatic trial data in decision-making.\nIn order to aid researchers in pragmatic clinical trial design, the GETREAL project developed an innovative online tool called PRAGMAGIC. It is a decision support tool designed to help users understand how the choices that they make when designing a pragmatic trial can impact the operational feasibility of the study, and how reflective the data generated will be of the effectiveness of the medicine in routine healthcare. The tool draws on guidance and recommendations accumulated through methods reviews, case studies and stakeholder feedback. The project hopes that the new tool will increase the understanding of the value and feasibility of conducting pragmatic trials in the future.\nDemystifying relative effectiveness assessments\nBoth network meta-analysis (NMA) and multi-criteria decision analysis (MCDA) are useful methods for assessing the relative effectiveness of medicines by using data generated from randomised controlled trials. These methods are gaining acceptance among industry, academia, HTA agencies, and regulatory bodies. However, continued efforts are required to embed these approaches in decision-making. To this end, GETREAL \xa0developed the ADDIS tool, which provides users access to clinical trial data and the software required to apply NMA and MCDA to the data. Additionally, GETREAL improved the NMA and MCDA methods further by developing a methodology to include real-world data.\nWebinars, courses and other achievements\nOther important project achievements include:\nAn interactive online course entitled ‘Real-world evidence in medicine development’. Under the supervision of leading academics from the project, the course provides students with an understanding of current techniques, opportunities and challenges for the use of real-world evidence in medicine development.\nRWE policy recommendations written by the project’s Policy Expert Group, setting out seven key themes\xa0that require further attention to advance the use of RWE and RWD in drug development.\nA network of regulators, HTA organisations, companies, academics, healthcare professionals, patients and other societal stakeholders. This network is important because the challenges faced by the pharmaceutical industry, regulators and other healthcare decision makers are all interlinked.\nGETREAL also hosted a series of webinars to support the dissemination of information and organised many cross-sector workshops and events attracting participants from academia, industry, regulatory bodies and patient organisations from across Europe.\nFor the benefit of industry, academia and SMEs\nAll of the partners in the project benefitted from the network which was created and collaboration with different stakeholders. This was a unique opportunity for the different stakeholders to share experiences and perspectives in RWE generation and use in decision-making, and all of them will benefit from a greater consensus on the issue.\nAs the funding for methodology development can be scarce, the academic partners also benefited from IMI funding, which enabled them to drive the development of innovative RWE analytical approaches, published in high-impact journals.\nLast but not least, the SME in the project was able to demonstrate their leadership in this field, and had the opportunity to work with leading academics and major pharmaceutical companies who ultimately are their key customers. Through publications and meeting attendance, they were also able to increase their company’s visibility.\nWhat’s next?\nGETREAL project partners applied for additional funding through IMI2 - Call 11 for the exploitation of project results. The follow-up project will start in June 2018 and will build on the success of GETREAL. In particular, the follow-up project will be used to continue building the research community, drive forward some of the project’s policy recommendations, and take forward the global debate regarding the opportunities for and the barriers to the use of RWE in healthcare decision-making.\nRead the interview with the project coordinator.\n', 'tags': 'Incorporating real-life clinical data into drug development', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Amgen, Brussels, Belgium;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Haute Autorite De Sante, Saint-Denis la Plaine , France;International Alliance Of Patient'Organizations, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;L.A Sante, Epidemiologie, Evaluation Et Recherche L.A.S.E.R., Paris, France;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;National Institute For Health And Care Excellence, Manchester, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Panepistimio Ioanninon, Ioannina, Greece;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Takeda Development Centre Europe LTD, London, United Kingdom;The European Medicines Agency, Canary Wharf, London, United Kingdom;The University Of Manchester, Manchester, United Kingdom;Universitaet Bern, Bern, Switzerland;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;University Of Leicester, Leicester, United Kingdom;Zorginstituut Nederland, Diemen, Netherlands", 'status': 'Closed'}, {'id': '0', 'name': 'GETREAL_INITIATIVE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/getreal-initiative', 'summary': 'IMI’s GETREAL project delivered a range of new tools and resources for incorporating real-life data earlier into drug development and decision making processes. The aim of the GETREAL Initiative is to drive the adoption of these tools and so increase the quality of real-world evidence (RWE) generation in medicines development and regulatory /health technology assessment processes. Specifically, the project will set up a think tank comprising international thought leaders to discuss, assess and give recommendations on opportunities and barriers to the generation, use and acceptability of RWE. The members will also act as ambassadors for the use of RWE, engaging with key stakeholder groups to facilitate the uptake of the project outputs. The project will also set up a number of task forces to drive the development of specific GETREAL outputs in the areas of pragmatic trials; network meta-analysis and benefit-risk assessment; and statistical approaches for enriching clinical trials with real world data. Finally, the project will create a RWE research community including researchers with expertise in RWE generation as well as regulators, health technology assessment (HTA) bodies, physicians and patients. The community will provide feedback on guidelines, recommendations and white papers produced by the project.\n', 'tags': 'The GetReal Initiative', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Amgen Limited, Cambridge, United Kingdom;Astellas Pharma Europe BV, Leiden, Netherlands;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;International Alliance Of Patient'Organizations, London, United Kingdom;L.A Sante, Epidemiologie, Evaluation Et Recherche L.A.S.E.R., Paris, France;National Institute For Health And Care Excellence, Manchester, United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;UCB Biopharma SRL, Brussels, Belgium;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Vital Transformation, Wezembeek Oppem, Belgium;Zorginstituut Nederland, Diemen, Netherlands", 'status': 'Ongoing'}, {'id': '0', 'name': 'GNA_NOW', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/gna-now', 'summary': 'Antimicrobial resistance (AMR) is a major threat to public health, causing 670 000 infections and over 33 000 deaths in Europe alone in 2015. So-called Gram-negative bacteria are particularly tough to treat, as they are encased in a tough outer membrane which effectively stops many antibiotics from getting into the bacteria and killing it. The GNA NOW project aims to address the urgent need for new antibiotics to treat Gram-negative infections by attacking the bacteria in new and different ways. The team will run three programmes in parallel, each focusing on a different drug candidate with an innovative mode of action. All drug candidates will undergo a range of tests to ensure their safety and efficacy and to understand and optimise how they work. The project hopes to complete phase 1 clinical trials for at least one candidate, and advance at least one more to the stage where it is ready to enter clinical trials.\nGNA NOW is part of the IMI AMR Accelerator Programme.\n', 'tags': 'Novel Gram-negative antibiotic now', 'participants': 'Bioaster Fondation De Cooperation Scientifique, Lyon, France;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Evotec International GMBH, Hamburg, Germany;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Medizinische Universitaet Wien, Vienna, Austria;North Bristol National Health Service Trust, Bristol, United Kingdom;Nosopharm, Nimes, France;Stichting Lygature, Utrecht, Netherlands;The University Of Liverpool, Liverpool, United Kingdom;Universite De Poitiers, Poitiers , France', 'status': 'Ongoing'}, {'id': '0', 'name': 'GRAVITATEHEALTH', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/gravitate-health', 'summary': 'Vast amounts of information on medicines is available, especially online, but it is very hard to know what is reliable or even relevant for a specific patient. And, while each medicine comes with a detailed information leaflet, patients often find these difficult to read and understand.\nThis is an issue because when patients lack important information about their treatments, they may not take them correctly and this can result in further health problems. The OECD (Organisation for Economic Cooperation and Development) estimates that poor medication adherence may contribute to around 200 000 premature deaths in Europe every year.\nThe aim of Gravitate-Health is to develop a digital health information tool called the Gravitate Lens (G-Lens). As the name suggests, the G-Lens will focus (but not conceal or filter) approved information on medicines and guide patients to understandable, trustworthy, up-to-date information that meets the patient’s needs and fits with their health context and literacy levels. The functionality of the G-Lens will be supported by an open source digital platform.\nMore broadly, the project hopes to demonstrate that by making information on medicines more accessible and understandable, patients will be more likely to take their medicines correctly, resulting in better health outcomes and quality of life.\nAll stakeholders relevant to digital health information are involved in the project, including patient representatives, regulators, ministries, digital technology experts and more.\nIn addition to the open source platform underlying the G-Lens, the project will produce a white paper with recommendations on realistic strategies on the future use of digital services like electronic product information can be used to further minimise the risks associated with incorrect adherence to advice on medicines.\n', 'tags': 'Gravitate–Health: Empowering and equipping Europeans with health information for active personal health management and adherence to treatment', 'participants': 'Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain;Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands;Akershus Universitetssykehus Hf, Lorenskog, Norway;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Beth Israel Deaconess Medical Center, Inc Non Profit Corporation, Boston Ma, United States;Datapharm Limited, Leatherhead, United Kingdom;Datawizard SRL, Roma, Italy;Echalliance Company Limited By Guarantee, Dublin, Ireland;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Forum Des Patients Europeens, 1040, Belgium;Frisq Holding AB, Stockholm, Sweden;Grunenthal GMBH, Aachen, Germany;Guardtime Ou, Tallinn, Estonia;Himss Europe GMBH, Berlin, Germany;Hl7 International Fondation, Brussels, Belgium;Karolinska Institutet, Stockholm, Sweden;Kobenhavns Universitet, Copenhagen, Denmark;Mdsol Europe LTD, London, United Kingdom;Mindview Symvouloi Epixeiriseon Kaierevnas Etaireia Periorismenis Efthynis, Athens, Greece;Mylan Ire Healthcare Limited, Dublin, Ireland;Norsk E Helse As, Oslo, Norway;Novartis Pharma AG, Basel, Switzerland;Open Evidence, Barcelona, Spain;Pfizer Limited, Sandwich, Kent , United Kingdom;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Servicio Madrileno De Salud, Madrid, Spain;Spms - Servicos Partilhados Do Ministerio Da Saude Epe, Lisboa, Portugal;Statens Legemiddelverk, Oslo, Norway;Synergist Services, Bruxelles, Belgium;The European Institute For Innovation Through Health Data, Gent, Belgium;The Synergist, Bruxelles, Belgium;Trifork Public As, Aarhus C, Denmark;Trinity College Dublin, Dublin, Ireland;UCB Biopharma SRL, Brussels, Belgium;Universidad Politecnica De Madrid, Madrid, Spain;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universitetet I Oslo, Oslo, Norway;Universitetssykehuset Nord-Norge Hf, Tromso, Norway', 'status': 'Ongoing'}, {'id': '0', 'name': 'H2O', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/h2o', 'summary': 'Today, many measures of disease (and disease outcomes) are based largely on input from clinicians. As such they do not fully capture patients’ own experiences of the disease and its impact on their lives.\nThe aim of H2O is to create ‘health outcomes observatories’ that will amplify the patient voice both in their own healthcare and in healthcare systems more broadly.\nThe health outcomes observatories will work by providing patients with digital tools, including an app, to report their health outcomes in a standardised way. Patients will always maintain control of their own data and will decide who can access it. At one level, the information will help clinicians and patients to make better decisions on their care.\nMeanwhile, the data will be anonymised and tracked so that individual patients and their clinicians can compare their progress with other patients with similar health issues. This aggregated data could also form the basis of research into new, innovative, evidence-based treatments.\nThe project will focus on setting up health outcomes observatories in four countries (Germany, Spain, the Netherlands, and Austria) covering three disease areas: diabetes, inflammatory bowel disease, and cancer. In the longer term, the project hopes that more observatories, covering a wider range of disease areas, will open up across Europe.\n', 'tags': 'H2O Health outcomes observatory', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;F. Hoffmann-La Roche AG, Basel, Switzerland;Forum Des Patients Europeens, 1040, Belgium;Institut Catala De La Salut, Barcelona, Spain;Jdrf International, New York, United States ;Katholieke Universiteit Leuven, Leuven, Belgium;King'S College London, London, United Kingdom;Medizinische Universitaet Wien, Vienna, Austria;Medtronic International Trading SARL, Tolochenaz, Switzerland;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Region Stockholm, Stockholm, Sweden;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Integraal Kankercentrum Nederland, Utrecht, Netherlands;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Team - It Research SL, Barcelona, Spain;The European Institute For Innovation Through Health Data, Gent, Belgium;The Hyve BV, Utrecht, Netherlands;Trial Nation, Copenhagen, Denmark;Universita Vita-Salute San Raffaele, Milano, Italy", 'status': 'Ongoing'}, {'id': '0', 'name': 'HARMONY', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/harmony', 'summary': 'Blood cancers, or haematologic cancers (e.g. leukaemia, lymphoma and myeloma), affect the production and function of blood cells and account for about one third of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and decision-makers alike.\nThe HARMONY project aims to use ‘big data’ to deliver information that will help to improve the care of patients with these diseases. Specifically, the project will gather together, integrate and analyse anonymous patient data from a number of high quality sources. This will help the team to define clinical endpoints and outcomes for these diseases that are recognised by all key stakeholders.\nMeanwhile the project’s data sharing platform will facilitate and improve decision making for policy makers and clinicians alike to help them to give the right treatment to the right patient at the right time. More broadly, the project will result in a pan-European network of stakeholders with expertise in this disease area.\nThe project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.\n', 'tags': 'Healthcare alliance for resourceful medicines offensive against neoplasms in hematology', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain;Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy;Amgen, Brussels, Belgium;Assistance Publique Hopitaux De Paris, Paris, France;Barts And The London Nhs Trust, London, United Kingdom;Bayer Aktiengesellschaft, Leverkusen, Germany;Bundesinstitut Fur Arzneimittel Und Medizinprodukte, Bonn, Germany;Celgene Management SARL, Couvet, Switzerland;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Alliance For Personalised Medicine Asbl, Brussels, Belgium;European Hematology Association, The Hague, Netherlands;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;European Research Initiative On Cll Ev, Köln, Germany;European Society For Blood And Marrow Transplantation, Leiden, Netherlands;Fondazione Italiana Sindromi Mielodisplastiche Ets, Alessandria, Italy;Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Barcelona, Spain;Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain;Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon, Soria, Spain;Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain;Genome Research Limited, London, United Kingdom;Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain;Gpoh Gemeinnutzige GMBH, Hannover, Germany;Group For Research On Adult Acute Lymphoblastic Leukemia, Pierre-Bénite, France;Groupe Francophone Des Myelodysplasies, Paris, France;Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany;Istituto Nazionale Di Fisica Nucleare, Frascati, Italy;Janssen Pharmaceutica Nv, Beerse, Belgium;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Leukanet Ev, Riemerling, Germany;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Lysarc, Pierre-Benite, France;Masarykova univerzita, Brno, Czech Republic;Medisapiens Oy, Helsinki, Finland;Menarini Ricerche S.A, Pomezia, Italy;Mll Munchner Leukamielabor GMBH, Munich, Germany;National Institute For Health And Care Excellence, Manchester, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Ospedale Pediatrico Bambino Gesu, Rome, Italy;Pfizer Limited, Sandwich, Kent , United Kingdom;Stichting Vumc, Amsterdam, Netherlands;Stiftung Eln Foundation, Weinheim, Germany;Synapse Research Management Partners SL, Barcelona, Spain;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;The Lymphoma Study Association, Pierre Benite, France;Universidad De Navarra, Pamplona, Spain;Universita Degli Studi Di Roma Tor Vergata, Rome, Italy;Universita Degli Studi Di Torino, Turin, Italy;Universitaet Ulm, Ulm, Germany;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University Of York, York, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Helsinki, University of Helsinki, Helsinki, Finland;Vib Vzw, Zwijnaarde - Gent, Belgium", 'status': 'Ongoing'}, {'id': '0', 'name': 'HARMONY_PLUS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/harmony-plus', 'summary': 'Haematological malignancies, also known as blood cancers, are a diverse and complex group of diseases that are difficult to diagnose and treat. Nowadays most treatments are extremely complex, and advances in patient diagnosis and treatment are slow due to the low number of patients per centre. There is therefore a need to harmonise, store, and analyse the current information on these diseases to speed up and support the decision-making process for patient access to new therapies. \nIMI’s HARMONY project is using big data to advance our understanding of the following seven blood cancers: acute lymphoblastic leukaemia (ALL); acute myeloid leukaemia (AML); chronic lymphocytic leukaemia (CLL); multiple myeloma (MM); myelodysplastic syndromes (MDS); non-Hodgkin lymphoma (NHL); and paediatric haematologic malignancies. HARMONY has set up a Big Data platform to support its work.\nThe aim of HARMONY PLUS is to build on HARMONY’s work. Firstly, it will add the following blood cancers to the list of diseases under study: chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; as well as Hodgkin’s lymphoma, Waldenström macroglobulinemia and other rare blood cancers not covered by HARMONY.\nIn addition, HARMONY PLUS will help to convert the existing HARMONY platform into an integrated services platform that could serve clinicians to improve their decision making process and support clinical trial design, among other things.\nLike HARMONY, HARMONY PLUS is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.\n', 'tags': 'Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS', 'participants': 'Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain;Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy;Bayer Aktiengesellschaft, Leverkusen, Germany;Bundesinstitut Fur Arzneimittel Und Medizinprodukte, Bonn, Germany;Celgene Management SARL, Couvet, Switzerland;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Hematology Association, The Hague, Netherlands;European Research Initiative On Cll Ev, Köln, Germany;European Society For Blood And Marrow Transplantation, Leiden, Netherlands;Fondazione Italiana Sindromi Mielodisplastiche Ets, Alessandria, Italy;Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Barcelona, Spain;Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon, Soria, Spain;Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain;Genome Research Limited, London, United Kingdom;Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain;Gpoh Gemeinnutzige GMBH, Hannover, Germany;Groupe Francophone Des Myelodysplasies, Paris, France;Istituto Nazionale Di Fisica Nucleare, Frascati, Italy;Leukanet Ev, Riemerling, Germany;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Lysarc, Pierre-Benite, France;Masarykova univerzita, Brno, Czech Republic;Medisapiens Oy, Helsinki, Finland;Menarini Ricerche S.A, Pomezia, Italy;Mll Munchner Leukamielabor GMBH, Munich, Germany;National Institute For Health And Care Excellence, Manchester, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Ospedale Pediatrico Bambino Gesu, Rome, Italy;Pfizer Limited, Sandwich, Kent , United Kingdom;Stichting Vumc, Amsterdam, Netherlands;Stiftung Eln Foundation, Weinheim, Germany;Synapse Research Management Partners SL, Barcelona, Spain;The Lymphoma Study Association, Pierre Benite, France;Universidad De Navarra, Pamplona, Spain;Universita Degli Studi Di Torino, Turin, Italy;Universitaet Ulm, Ulm, Germany;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Helsinki, University of Helsinki, Helsinki, Finland;Vib Vzw, Zwijnaarde - Gent, Belgium', 'status': 'Ongoing'}, {'id': '0', 'name': 'HYPORESOLVE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/hypo-resolve', 'summary': 'Many diabetes patients experience hypoglycaemia, when their blood sugar levels become too low. Symptoms include behavioural changes, memory loss and confusion, which can result in accidents and falls and, in the worst cases, in hospitalisation or death. Worries about hypoglycaemia represent a serious psychological burden for people with diabetes.\nDespite its seriousness, little is known about hypoglycaemia. The Hypo-RESOLVE project aims to change that by adding to our understanding of the underlying causes of the condition, as well as its predictors and consequences. They will also analyse the financial costs of hypoglycaemia. Ultimately, the hope is that the project results will pave the way for new, better treatments for people with diabetes that will help them to maintain healthy blood sugar levels.\n', 'tags': 'Hypoglycaemia - REdefining SOLutions for better liVEs', 'participants': "Abbott Diabetes Care, Alameda, United States;Centre Hospitalier Universitaire Montpellier, Montpellier, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Eurice European Research And Project Office GMBH, Saarbrücken, Germany;Federation Internationale Du Diabete, Brussels, Belgium;Jdrf International, New York, United States ;King'S College London, London, United Kingdom;Medizinische Universitat Graz, Graz, Austria;Medtronic International Trading SARL, Tolochenaz, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Region Hovedstaden, Hilleroed, Denmark;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Syddansk Universitet, Odense, Denmark;The Leona M. And Harry B. Helmsley Charitable Trust, New York, United States ;The University Of Edinburgh, Edinburgh, United Kingdom;The University Of Sheffield, Sheffield, United Kingdom;Unitio Inc, Boston, United States;Universita Degli Studi Di Padova, Padova, Italy;Universite De Lausanne, Lausanne, Switzerland;University Of Dundee, Dundee, United Kingdom;University of Cambridge, Cambridge, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'IABC', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/iabc', 'summary': 'Antimicrobial resistance (AMR) represents a serious and growing threat to human and animal health worldwide. In the EU alone, AMR is responsible for some 25 000 deaths every year, and the annual treatment and social costs have been estimated at €1.5 billion. Meanwhile, new forms of resistance continue to develop and spread, leaving clinicians with few weapons to bring infections under control. Yet despite the recognised need for new antibiotics, the reality is that only two new classes of antibiotics have been brought to the market in the last three decades.\nA vulnerable group\nPatients with cystic fibrosis (CF) and bronchiectasis (BE) are at particular risk of infection. CF is a common inherited disease that affects around 36 000 people in the EU. CF patients face regular respiratory infections; 60% of adult patients have lung infections caused by difficult to treat bacteria such as Pseudomonas aeruginosa, and respiratory failure is the cause of death for 95% of CF patients. Inhaled antibiotics have helped to both improve CF patients’ quality of life and extend their life expectancy.\nBE refers to a group of diseases in which the airways become damaged and scarred. It is more common among the elderly, affecting 3 in 1 000 among the over 75s. BE patients experience similar symptoms to CF, including regular respiratory infections, often with Pseudomonas aeruginosa. So far, no inhaled antibiotics have been approved for use in BE patients, although in practice doctors often treat BE patients with antibiotics licensed for use in CF.\nToday, the number of inhaled antibiotics available for these vulnerable patients remain limited and infections in both CF and BE patients are increasingly resistant to these life-saving medicines. The costs of carrying out clinical trials for new antibiotics for CF and BE patients are particularly high due to the relatively small number of patients affected.\nTowards new treatments for cystic fibrosis and bronchiectasis\niABC will advance the development of two inhaled antimicrobials. BAL30072 is a novel antibiotic that is effective against a range of bacterial infections. The project will develop a version of the antibiotic that can be inhaled by patients with CF and BE. Studies will probe the safety of the inhaled antibiotic and determine the ideal dose. The project will also investigate the appropriate dose of tobramycin inhalation powder (TIP) in treatment of lung infections in BE patients and how safe and effective this dose is in these patients. TIP is currently only licensed for use in CF patients.\nMore broadly, the programme will undertake a number of activities designed to facilitate future research into and clinical trials involving CF and BE.\xa0 For example, part of the project is devoted to setting up an EU-wide registry of BE patients that would align new and existing national registries and facilitate the gathering of data on BE in Europe. This will aid in the identification of research needs, make it easier to identify patients who could be included in clinical trials, and guide the development of European guidelines for the management of BE. \xa0iABC will ensure that the BE registry will remain viable after the end of the project.\nAnother project goal is to identify measures that could be used in clinical trials to assess the effectiveness of a medicine. These will include new ways of more accurately assessing lung function, DNA fingerprinting of bacteria, measurement of inflammatory biomarkers in the sputum and scoring CT (computed tomography) scans of the chest. The project will also study the nature and level of microbes found in the sputum.\nNew hope for patients\nJust a few decades ago, most CF patients died in early childhood. Thanks to antibiotics, CF patients born today can expect to reach early middle age. However, this progress is threatened by the rise of antimicrobial resistance. The iABC project represents an important contribution to efforts to counter this threat.\n', 'tags': 'Inhaled antibiotics in bronchiectasis and cystic fibrosis', 'participants': "Alaxia;Belfast Health And Social Care Trust, Belfast, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy;Fundacio Clinic Per A La Recerca Biomedica, Barcelona, Spain;Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain;Hospices Civils De Lyon, lyon, France;Institut Catala De La Salut, Barcelona, Spain;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Lothian Health Board, Edinburgh, United Kingdom;Medizinische Hochschule Hannover, Hannover, Germany;Novartis Pharma AG, Basel, Switzerland;Papworth Hospital Nhs Foundation Trust, Papworth Everard, United Kingdom;Polyphor AG, Allschwil, Switzerland;Rijksuniversiteit Groningen, Groningen, Netherlands;Royal Brompton And Harefield National Health Service Trust, South Kensington, United Kingdom;Servicio Madrileno De Salud, Madrid, Spain;Tayside Health Board, Dundee, United Kingdom;The Queen'S University Of Belfast, Belfast, United Kingdom;The University Of Edinburgh, Edinburgh, United Kingdom;Universita Degli Studi Di Milano, Milano, Italy;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitair Ziekenhuis Antwerpen, Edegem, Belgium;Universite De Poitiers, Poitiers , France;Universiteit Antwerpen, Antwerp, Belgium;University Of Dundee, Dundee, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'ICONSENSUS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/iconsensus', 'summary': 'Animal cell technology is now widely used in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies. The quality of the cell culture determines the quality of the final product. The aim of iCONSENSUS is to achieve a faster, safer and more cost-effective process for the development and manufacture of these products. Among other things, the project will develop innovative analytical, hardware, software and high-throughput tools for the development, monitoring and control of mammalian cell cultivation processes for producing biopharmaceuticals.\n', 'tags': 'Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production', 'participants': 'Bayer Aktiengesellschaft, Leverkusen, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Iprasense, Clapiers, France;Ipratech SA, Mons, Belgium;Kantisto BV, Baarn, Netherlands;Kungliga Tekniska Hoegskolan, Stockholm, Sweden;M2p-Labs GMBH, Baesweiler, Germany;Micronit Microtechnologies BV, Enschede, Netherlands;Paia Biotech GMBH, Köln, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Presens Precision Sensing GMBH, Regensburg, Germany;Rentschler Biopharma Se, Laupheim, Germany;Rheinisch-Westfaelische Technische Hochschule Aachen, Aachen, Germany;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Svanholm.Com Aps, Vordingborg, Denmark;Synthon Biopharmaceuticals BV, Nijmegen, Netherlands;UCB Biopharma SRL, Brussels, Belgium;Universitaet Hohenheim, Stuttgart, Germany;Universite De Mons, Mons, Belgium', 'status': 'Ongoing'}, {'id': '0', 'name': 'IDEAFAST', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/idea-fast', 'summary': 'Fatigue and sleep disturbances are common symptoms of many chronic diseases, and are associated with a poor quality of life and greater healthcare costs. Today, efforts to measure these symptoms, e.g. in clinical trials, are based largely on standardised paper questionnaires, which do not give very reliable results. \n\nThe aim of IDEA-FAST is to identify digital endpoints for fatigue and sleep disturbances that will provide a more sensitive, reliable measure of the severity and impact of these symptoms in a real life setting. They will do this by identifying the characteristics of fatigue and sleep disturbances and the digital endpoints that could quantify them. They will then select the digital devices and technologies that could measure and record these symptoms. They will also design a secure digital management platform to support the acquisition, storage and analysis of the data. \n\nAll of this will be validated in a pilot study involving patients with neurodegenerative diseases (Parkinson’s disease and Huntington’s disease) and immune-mediated inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren’s syndrome, and inflammatory bowel disease).\n\nIn addition to gaining new insights into the mechanisms behind fatigue and sleep disturbances, IDEA-FAST’s results should dramatically improve the efficiency of clinical trials, and so speed up the development of new treatments for these chronic diseases.\n', 'tags': 'Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Asociacion Parkinson Madrid, Madrid, Spain;Astrazeneca AB, Södertälje, Sweden;Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom;Byteflies, Antwerpen, Belgium;CHDI Foundation, Inc., New York, United States;Cambridge Cognition Limited, Cambridge, United Kingdom;Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany;Dreem, Paris, France;Ecrin European Clinical Research Infrastructure Network, Paris, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Federation Of Crohn'S And Ulcerative Colitis Associations, Bruxelles, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Faculdade De Ciencias Da Universidade De Lisboa, Lisboa, Portugal;Fciencias.Id - Associacao Para A Investigacao E Desenvolvimento De Ciencias, Lisbon, Portugal;Fundacion Para La Investigacion Biomedica Del Hospital Universitario Clinico San Carlos, Madrid, Spain;George-Huntington-Institut GMBH, Munster, Germany;Greater Glasgow Health Board, Glasgow, United Kingdom;Helse Stavanger Hf, Stavanger, Norway;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut Mines-Telecom, Paris, France;Instituto De Medicina Molecular Joao Lobo Antunes, Lisboa, Portugal;Instytut Psychiatrii I Neurologii, Warszawa, Poland;Ixscient Limited, Uxbridge, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Kks-Netzwerk Ev -Netzwerk Der Koordinierungszentren Fur Klinische Studien, Berlin, Germany;Lixoft SAS, Orsay, France;Manchester University Nhs Foundation Trust, Manchester, United Kingdom;Mcroberts BV, S Gravenhage, Netherlands;Medibiosense LTD, Doncaster, United Kingdom;Medizinische Universitat Innsbruck, Innsbruck, Austria;Orion Oyj, Espoo, Finland;Parkinson'S Disease Society Of Theunited Kingdom Lbg, London, United Kingdom;Pfizer Limited, Sandwich, Kent , United Kingdom;Pluribus One SRL, Cagliari, Italy;Queen Mary University Of London, London, United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Mlc Foundation, Den Haag, Netherlands;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Teknologian Tutkimuskeskus Vtt Oy, Espoo, Finland;The University Of Manchester, Manchester, United Kingdom;Tmf - Technologie Und Methodenplattform Fur Die Vernetzte Medizinische Forschung Ev, Berlin, Germany;UCB Biopharma SRL, Brussels, Belgium;Universidad Autonoma De Madrid, Madrid, Spain;Universita Degli Studi Di Brescia, Brescia, Italy;Universitatsklinikum Schleswig-Holstein, Lübeck, Germany;University Of Glasgow, Glasgow, United Kingdom;University Of Limerick, Limerick, Ireland;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University of Cambridge, Cambridge, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'IM2PACT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/im2pact', 'summary': "As the name suggests, the blood-brain barrier (BBB) tightly controls access to our brains, allowing nutrients and essential substances through, but blocking pathogens, for example. Getting medicines through this protective shield is a major challenge for drug developers, particularly those developing biopharmaceuticals, which are based on large molecules like proteins and antibodies. The goal of IM2PACT is to advance our understanding of the BBB to facilitate the development of more effective treatments for a range of neurological and metabolic disorders. Specifically, the project aims to develop better models of the BBB so that researchers can study it more easily; investigate the biology of the BBB in both health and disease, and the transport routes across it; and to develop innovative systems capable of delivering medicines to the brain. The project will focus on two major disease areas: neurodegenerative diseases, including Alzheimer and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease and motor neurone disease), vascular dementia, and multiple sclerosis; and metabolism-related diseases (mainly diabetes and obesity).\n", 'tags': 'Investigating mechanisms and models predictive of accessibility of therapeutics (IM2PACT) into the brain', 'participants': 'Aarhus Universitet, Aarhus C, Denmark;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Ait Austrian Institute Of Technology GMBH, Wien, Austria;Artemis Bio-Support B.V., Utrecht, Netherlands;Cardiff University, Cardiff, United Kingdom;Fujifilm Cellular Dynamics Inc, Madison, United States;H. Lundbeck As, Valby, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;Kobenhavns Universitet, Copenhagen, Denmark;Mimetas BV, Leiden, Netherlands;Neuway Pharma GMBH, Bonn, Germany;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Pharmacoidea Fejleszto Es Szolgaltato Kft, Szeged, Hungary;Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, Germany;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Vumc, Amsterdam, Netherlands;Stiftung Tieraerztliche Hochschule Hannover, Hannover, Germany;The Open University, Milton Keynes, United Kingdom;The University Of Sheffield, Sheffield, United Kingdom;Universita Degli Studi Di Modena E Reggio Emilia, Modena, Italy;Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany;Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany;University Of Dundee, Dundee, United Kingdom;University of Oxford, Oxford, United Kingdom;Uppsala Universitet, Uppsala, Sweden', 'status': 'Ongoing'}, {'id': '0', 'name': 'IMIPAINCARE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/imi-paincare', 'summary': 'Patients with a wide range of conditions may experience pain in the short or long term, and all too often, painkillers prove ineffective. Developing new analgesics is extremely challenging, and all too often, promising results in the lab do not translate into effective treatments for patients. The goal of IMI-PainCare is to develop a toolbox that will aid in the development of novel painkillers. The project comprises three sub-projects, which between them address all stages of drug development, from early-stage research to clinical practice.\nPROMPT aims to develop patient-reported outcomes that will capture in a standardised way patients’ perceptions of their pain. This information will help to show during clinical trials whether or not a treatment is actually effective at alleviating pain, for example.\nBioPain will draw on electrophysiological and imaging technologies to establish models of pain in healthy humans and rodents. This will contribute to the development of markers of pain that are relevant in both rodents and humans; this will increase researchers’ chances of translating findings in the lab into new treatments for patients.\nTRiPP focuses on pelvic pain caused by endometriosis and interstitial cystitis / bladder pain syndrome. The team hopes to identify different subgroups of patients; information that will help to deliver more personalised treatments for these debilitating conditions.\nThe IMI-PainCare consortium plans to work with regulators to validate the tools developed.\n', 'tags': 'Improving the care of patients suffering from acute or chronic pain', 'participants': "Aalborg Universitet, Aalborg OE, Denmark;Aarhus Universitet, Aarhus C, Denmark;Actual Analytics LTD, Edinburgh, United Kingdom;Assistance Publique Hopitaux De Paris, Paris, France;Bayer Aktiengesellschaft, Leverkusen, Germany;Children'S Hospital Corporation, Boston, United States;Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany;Cliniques Universitaires Saint-Luc, Brussels, Belgium;Consultech Technologieberatung GMBH, Berlin, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Endometriosis.Org LTD, London, United Kingdom;Esteve Pharmaceuticals, SA, Barcelona, Spain;European Pain Federation Efic, Aarschot, Belgium;European Society Of Anaesthesiology And Intensive Care Aisbl, Bruxelles, Belgium;European Society Of Regional Anaesthesia And Pain Therapy, Homberg, Germany;Fundacion Para La Investigacion Del Hospital Clinico De La Comunitat Valenciana, Fundacion Incliva, Valencia, Spain;Grunenthal GMBH, Aachen, Germany;Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä, Helsinki, Finland;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Instituto De Biologia Molecular E Celular-Ibmc, Porto, Portugal;King'S College London, London, United Kingdom;Michigan State University, East Lansing, Michigan, United States;Mrc Systems GMBH Medizintechnische Systeme, Heidelberg, Germany;Novartis Pharma AG, Basel, Switzerland;Pelvic Pain Support Network, Poole, United Kingdom;Promptly - Software Solutions For Health Measures, Lda, Porto, Portugal;Queen Mary University Of London, London, United Kingdom;Region Hovedstaden, Hilleroed, Denmark;Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, Germany;Stichting International Painful Bladder Foundation, Naarden, Netherlands;Teva Pharmaceutical Industries Limited, Netanya, Israel;The University Of Edinburgh, Edinburgh, United Kingdom;Universidad De Navarra, Pamplona, Spain;Universita Degli Studi Di Roma La Sapienza, Roma, Italy;Universite Catholique De Louvain, Louvain-La-Neuve, Belgium;University College Cork -  National University Of Ireland, Cork, Cork, Ireland;University of Oxford, Oxford, United Kingdom;Universitätsklinikum Jena, Jena, Germany;Westfaelische Wilhelms-Universitaet Muenster, Münster, Germany", 'status': 'Ongoing'}, {'id': '0', 'name': 'IMIDIA', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/imidia', 'summary': "Diabetes affects over 425 million people worldwide. It’s a chronic metabolic disease in which blood glucose levels are too high. It is divided into two types: type 1 diabetes (in which the body does not make enough insulin) and type 2 (where the body does not adequately respond to insulin). Over time, having too much glucose in the blood can damage the eyes, kidneys, nerves, heart and blood vessels.\nThere is currently no cure for diabetes, and treatment options are limited, even though they have somewhat improved over the recent decades thanks to knowledge about the functioning of beta cells. Type 2 diabetes is the more common kind of diabetes that develops primarily among adults. The primary cause of type 2 diabetes is probably pancreatic islet beta cell dysfunction and viability, which is caused by a mixture of genetic and environmental factors.\nThe consortium IMIDIA brought together 8 EFPIA companies, 12 academic institutions and one SME. The project sought to address the key bottlenecks in the development of beta cell focused therapies, to accelerate the path to improved diabetes management and ultimately pave the way to curing the disease.\nHuman cells rather than rodent cells \nIMIDIA researchers wanted to study the underlying molecular mechanisms and changes in human diabetic beta cells. One of the main problems in diabetes research was the lack of a human pancreatic beta cell line that could be studied in the lab. Instead, rodent beta cell lines were used in all diabetes-related research. The first major breakthrough for the IMIDIA project was the development of a human pancreatic beta cell line that behaved in the same way as beta cells in the body.\nThanks to the pharmaceutical industry’s validation of the human pancreatic beta cell line, the biotechnology SME Endocells SARL, an IMIDIA partner, patented the finding as an innovative research tool. That allowed them to further develop the cell lines, making them available to other IMI projects and for further collaboration in industry and academia. This is one of many examples of the important role that SMEs play in public-private partnership research projects, with their broad expertise in developing such tools, diagnostic equipment, database models, and applications that are core technologies of many biotechnology SMEs.\nFor the IMIDIA team, this was one of the most significant achievements. They worked on six different scientific work packages that focused on novel approaches, like imaging biomarkers, systems biology and pathway analysis. Usable human pancreatic beta cells represented a unique tool for large-scale drug discovery and provided a preclinical model for cell-replacement therapy in diabetes.\nIMIDIA’s goal was to develop patient-relevant disease models in vitro and in vivo as well as biomarkers to monitor disease progression and treatment. Researchers were also tasked with identifying novel paths for the regeneration, maintenance and protection of insulin-producing pancreatic beta cells as a means to speed up the discovery of more effective strategies to prevent and treat diabetes.\nA biobank of islets and pancreatic tissues\nOne challenge for the consortium was to define which genes are abnormally expressed in the beta cells of diabetic subjects compared to those of non-diabetic subjects. The transformed character of these genes could account for beta cell failure in diabetes. For the first time, researchers based their analysis not only on cells collected from non-diabetic and diabetic organ donors, for which the availability of clinical information is limited, but also on cells from patients undergoing pancreatic surgery.\nTo identify changes in type 2 diabetic islets, the consortium established a unique and comprehensive multicentre biobank of human islets and pancreas tissues from pre-diabetic organ donors and healthy, non-diabetic individuals.\nIdentification of disruptive genes \nComparative analysis identified 19 genes whose expression was altered in islets of both diabetic organ donors and diabetic surgery patients. Nine of these 19 genes had never previously been shown to be dysregulated in diabetic islets. The genes are not dysregulated in cells taken from people with pre-diabetes, suggesting that their altered activity levels are the consequence, rather than the cause, of beta cell failure.\nMoreover, IMIDIA scientists identified a gene that disrupts insulin secretion in individuals with a rare form of type 2 diabetes called maturity-onset diabetes of the young (MODY). The gene produces a protein called PASK (PAS kinase). Normally, when blood sugar levels are low, insulin production is close to zero. However, in people with the mutated form of PASK, insulin production at low blood sugar levels is high. The researchers believe that this may render other tissues in the body less responsive to insulin, causing problems when blood sugar levels rise. This represented the first demonstration in humans that the PASK protein plays a key role in insulin secretion, meaning that it could be used in diabetes treatment.\nDuring the course of the project, IMIDIA scientists received additional support in the order of USD 1 million (EUR 0.9 million) in funding from JDRF. JDRF is the world's largest charity and patient organisation, and supporter of research to cure, treat, and prevent type 1 diabetes. The additional support allowed IMIDIA participants to expand their research efforts into the role and survival of beta cells in diabetes, to ultimately speed up the search for a cure for diabetes.\n", 'tags': 'Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre National De La Recherche Scientifique Cnrs, Paris, France;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut De Recherches Servier, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Medizinische Hochschule Hannover, Hannover, Germany;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;SARL Endocells, Paris, France;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Technische Universitaet Dresden, Dresden, Germany;Universita Di Pisa, Pisa, Italy;Universite De Geneve, Genève 4, Switzerland;Universite De Lausanne, Lausanne, Switzerland;Universite Paris Diderot - Paris 7, Paris, France;Vrije Universiteit Brussel, Brussel, Belgium', 'status': 'Closed'}, {'id': '0', 'name': 'IMMUCAN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/immucan', 'summary': 'Some new cancer treatments harness the immune system to fight the disease. However, for most patients, they do not deliver a long-lasting response and they often cause unpleasant side effects. To address these challenges, IMMUCAN aims to study the tumour microenvironment in a bid to gain a deeper understanding of how the immune system and cancer cells interact at the molecular level.\nUsing cutting-edge technologies, the team will analyse tumour tissue, blood, stool and saliva samples as well as clinical information from some 3 000 patients with colorectal, lung, head and neck, breast, gastric and renal cancers. By comparing patients who are not going through immune therapy with patients who are, the project hopes to build up a detailed picture of the tumour and its microenvironment, and the impact of current treatments. This information could be used to further improve existing treatments and to develop new ones.\xa0 In the longer term, the project results could result in the identification of biological markers that will show which patients are most likely to respond well to immune therapies, and which patients would benefit from a combination of immune therapies and conventional treatments.\n', 'tags': 'Integrated immunoprofiling of large adaptive cancer patients cohorts', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Bayer Aktiengesellschaft, Leverkusen, Germany;Centre De Lutte Contre Le Cancer Leon Berard, Lyon, France;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Charite - Universitaetsmedizin Berlin, Berlin, Germany;De Duve Institute Aisbl, Bruxelles, Belgium;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;European Patients’ Forum (EPF), Brussels, Belgium;Forum Des Patients Europeens, 1040, Belgium;Fundacio Centre De Regulacio Genomica, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Institut Curie, Paris, France;Institut De Recherche Pierre Fabresas, Toulouse, France;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut Jules Bordet, Brussels, Belgium;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;King'S College London, London, United Kingdom;Ligue Nationale Contre Le Cancer, Paris, France;Luxembourg Institute Of Health, Luxembourg, Luxembourg;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Owkin France, Paris, France;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;The University Of Birmingham, Birmingham, United Kingdom;Universitat Zurich, Zürich, Switzerland;Weizmann Institute Of Science, Rehovot, Israel", 'status': 'Ongoing'}, {'id': '0', 'name': 'IMMUNEIMAGE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/immune-image', 'summary': 'Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The Immune-Image project aims to pioneer the use of non-invasive imaging technologies to track the activity of immune cells in the body. Ultimately, the project will make it easier to predict how patients will respond to treatment and monitor their progress during treatment.\nTo do this, the project will develop tracers capable of highlighting specific immune cells in a range of imaging types, including magnetic resonance imaging (MRI), positron emission tomography (PET), optical imaging (OI) and computed tomography (CT). They will also analyse biopsies and blood samples to build up complete immunological profiles of patients and to correlate imaging findings with pathology; this information will contribute to the development of personalised immunotherapies.\n', 'tags': 'Specific imaging of immune cell dynamics using novel tracer strategies', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Antaros Medical AB, Mölndal, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Cloudselling BV, Rijswijk, Netherlands;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;European Cancer Patient Coalition, Brussels, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain;Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain;Imaginab, Inc, Inglewood Ca, United States;Janssen Pharmaceutica Nv, Beerse, Belgium;Lawrencium Legal BV, Amsterdam, Netherlands;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Stichting Lygature, Utrecht, Netherlands;Stichting Vumc, Amsterdam, Netherlands;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Ttopstart BV, Bilthoven, Netherlands;Universite Paris-Saclay, Saint Aubin, France;University of Cambridge, Cambridge, United Kingdom;Vib Vzw, Zwijnaarde - Gent, Belgium;Vrije Universiteit Brussel, Brussel, Belgium;Westfaelische Wilhelms-Universitaet Muenster, Münster, Germany", 'status': 'Ongoing'}, {'id': '0', 'name': 'IMMUNIVERSE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/immuniverse', 'summary': 'Immune-mediated diseases are extremely diverse – patients with the same diagnosis may see the disease progress in very different ways, and respond differently to treatments. This is because the course of the disease is influenced by multiple factors, including the patient’s genes, immune system, environment, and the microbes living in their gut. Furthermore, all of these factors interact with and impact on one another. As a result, it is very hard to predict how the disease will develop in a specific patient, and which treatments will be effective.\nThe goal of ImmUniverse is to add to our understanding of two immune-mediated diseases: ulcerative colitis (in which the immune system attacks the colon), and atopic dermatitis (which affects the skin). It will use liquid biopsies to detect the immune cells circulating in the blood, and analyse how these interact with the tissues affected at the microenvironment scale. The project will follow a number of patients over time to see how the disease evolves.\nUltimately, the project’s findings should contribute to a better, more precise diagnosis for patients; and better information on how severe the disease is likely to be for each individual patient and how it will progress over time. Finally, the project will make it easier for doctors and patients to monitor how well a treatment is working.\n', 'tags': 'Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies', 'participants': "Aarhus Universitet, Aarhus C, Denmark;Aarhus Universitetshospital, Aarhus, Denmark;Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Ait Austrian Institute Of Technology GMBH, Wien, Austria;Centre Hospitalier Regional Universitaire Nancy, Nancy Cedex, France;Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Eurice European Research And Project Office GMBH, Saarbrücken, Germany;European Federation Of Asthma &Allergy Associations Ideell Forening, Brussels, Belgium;European Federation Of Crohn'S And Ulcerative Colitis Associations, Bruxelles, Belgium;European Patients’ Forum (EPF), Brussels, Belgium;Forum Des Patients Europeens, 1040, Belgium;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Humanitas Mirasole S.A, Rozzano (Mi), Italy;Humanitas University, Pieve Emanuele, Italy;Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg;Istituto Superiore Di Sanita, Roma, Italy;Joanneum Research Forschungsgesellschaft Mbh, Graz, Austria;Katholieke Universiteit Leuven, Leuven, Belgium;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna, Pisa, Italy;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg;University of Cambridge, Cambridge, United Kingdom;Vib Vzw, Zwijnaarde - Gent, Belgium", 'status': 'Ongoing'}, {'id': '0', 'name': 'IMPENTRI', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/impentri', 'summary': 'Many people with severe COVID-19 infection experience a build-up of fluid in the lungs, making it hard to breathe and, in the worst cases, contributing to the death of the patient. The body’s own immune response is partly responsible for this build-up of fluid.\nThere are signs that the generic drug imatinib, which is used to treat certain cancers including some forms of leukaemia, could address the problem. The goal of Impentri is to carry out clinical trials to get solid data on its efficacy and safety as a treatment for COVID-19 patients with a build-up of fluid on the lungs.\nThe project will run a multi-centre, randomised, double-blind clinical trial involving 100 patients in intensive care. All patients will be monitored for oxygen levels, fluid balance, length of stay and other clinical outcomes.\nThe project has already received scientific advice from the European Medicines Agency (EMA) for the treatment of acute respiratory distress syndrome. The EMA has also granted orphan drug status.\n', 'tags': 'Development of Impentri, an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)', 'participants': 'Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Exvastat LTD, Cambridge, United Kingdom;K.A.B.S. Laboratories Inc. - Kabs, St-Hubert, Canada;Orion Sante SARL, Le Plesiss Robinson, France;Stichting Vumc, Amsterdam, Netherlands', 'status': 'Ongoing'}, {'id': '0', 'name': 'IMPRIND', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/imprind', 'summary': 'Alzheimer’s and Parkinson’s diseases are neurodegenerative disorders that affect 45 million and 10 million people worldwide respectively. There is currently no cure for these diseases, which place an immense burden on carers, many of whom are family members. Both diseases are characterised by the progressive loss of brain cells. Recent evidence suggests that this loss may be due to the release and uptake by brain cells of specific aggregated proteins (misfolded proteins which clump together leading to a progressive spreading of the degeneration). If these processes could be blocked, disease progression could be halted. However, the forces driving these processes are currently poorly understood. Working to change that is the IMPRiND project, which aims to understand how these aggregated proteins are handled once inside brain cells and how they are moved from cell to cell. To do this, the project team will work collaboratively to develop standardised tools and tests to establish disease-relevant mechanisms that could be targeted by drugs in the future.\n', 'tags': 'Inhibiting misfolded protein propagation in neurodegenerative diseases', 'participants': 'AbbVie Ltd, Maidenhead, United Kingdom;Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Centre National De La Recherche Scientifique Cnrs, Paris, France;Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev, Bonn, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;H. Lundbeck As, Valby, Denmark;Idryma Iatroviologikon Ereunon Akademias Athinon, Athens, Greece;Institut De Recherches Servier, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Medical Research Council, Swindon, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Sciprom SARL, St-Sulpice, Switzerland;United Kingdom Research And Innovation, Swindon, United Kingdom;Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts, Goettingen, Germany;Universite De Bordeaux, Bordeaux, France;University of Cambridge, Cambridge, United Kingdom;University of Oxford, Oxford, United Kingdom;Vib Vzw, Zwijnaarde - Gent, Belgium', 'status': 'Ongoing'}, {'id': '0', 'name': 'IMSAVAR', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/imsavar', 'summary': 'Certain treatments for cancers and autoimmune diseases work by altering the immune system. However, a major challenge for researchers is identifying potential efficacy and safety issues with these treatments early in drug development, before they are tested in humans. Part of the problem is that the tests used early in drug development do not reflect the full complexity of the human immune system. In addition, these tests tend to be based on a healthy immune system, which is different to the immune system of someone who is ill.\nThe imSAVAR project aims to deliver a range of tools that will enhance our ability to assess the efficacy and safety of these immunomodulatory therapies. They also plan to develop new biological markers for diagnosing and predicting immune-mediated safety issues, and explore ways of mitigating them.\nIn the longer term, the project will help to deliver safer medicines for patients and also contribute to the ‘3Rs’ (i.e. the drive to replace, reduce and refine the use of animals in research).\n', 'tags': 'Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Biosci Consulting Bvba, Maasmechelen, Belgium;Bluebird Bio Inc., Cambridge Ma, United States;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany;Covance Laboratories LTD, Harrogate, United Kingdom;Dynamic42 GMBH, Jena, Germany;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg;Institut De Recherches Servier, Suresnes, France;Jdrf International, New York, United States ;Lunds Universitet, Lund, Sweden;Medizinische Hochschule Hannover, Hannover, Germany;Medizinische Universitat Innsbruck, Innsbruck, Austria;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novartis Pharma AG, Basel, Switzerland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;T-Curx GMBH, Wurzburg, Germany;Transgene SA, Illkirch-Graffenstaden, France;Universitaet Leipzig, Leipzig, Germany;Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany;Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg;Universiteit Twente, Enschede, Netherlands;Universitetet I Oslo, Oslo, Norway;Universitätsklinikum Jena, Jena, Germany', 'status': 'Ongoing'}, {'id': '0', 'name': 'INNODIA', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/innodia', 'summary': 'Type 1 diabetes affects 17 million people globally and there is no cure; instead, patients must inject themselves with insulin daily and continually check their blood sugar levels to control their condition.\nThe goal of the INNODIA project is to advance our understanding of type 1 diabetes and address the lack of tools and technologies that will allow clinicians to predict, evaluate and prevent the onset and progression of type 1 diabetes. For patients, this would mean the ability to predict the rate at which their disease will progress. The project has set up a patient advisory committee to ensure the work is in line with patients’ needs.\nThe knowledge and tools generated by the project have helped researchers to optimise the design of four clinical trials of treatments for preventing and curing this debilitating disease.\n', 'tags': 'Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes.', 'participants': "Academisch Ziekenhuis Leiden, Leiden, Netherlands;Cardiff University, Cardiff, United Kingdom;Centre Hospitalier De Luxembourg, Luxembourg, Luxembourg;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Hannoversche Kinderheilanstalt, Hannover, Germany;Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany;Imcyse SA, Sart Tilman, Belgium;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Jdrf International, New York, United States ;Katholieke Universiteit Leuven, Leuven, Belgium;King'S College London, London, United Kingdom;Kobenhavns Universitet, Copenhagen, Denmark;Lunds Universitet, Lund, Sweden;Medizinische Universitat Graz, Graz, Austria;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Oslo Universitetssykehus Hf, Oslo, Norway;Ospedale Pediatrico Bambino Gesu, Rome, Italy;Oulun Yliopisto, Oulu, Finland;Region Hovedstaden, Hilleroed, Denmark;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Slaski Uniwersytet Medyczny W Katowicach, Katowice, Poland;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Technische Universitaet Dresden, Dresden, Germany;The Leona M. And Harry B. Helmsley Charitable Trust, New York, United States ;The University Of Exeter, Exeter, United Kingdom;Univercell Biosolutions SAS, Toulouse, France;Universita Degli Studi Di Siena, Siena, Italy;Universita Degli Studi Gabriele D'Annunzio Di Chieti-Pescara, Chieti, Italy;Universita Di Pisa, Pisa, Italy;Universita Vita-Salute San Raffaele, Milano, Italy;Universitaet Ulm, Ulm, Germany;Universite De Lausanne, Lausanne, Switzerland;University of Cambridge, Cambridge, United Kingdom;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Oxford, Oxford, United Kingdom;University of Turku, Turku, Finland;Université Libre de Bruxelles, Bruxelles, Belgium;Univerza V Ljubljani, Ljubljana, Slovenia", 'status': 'Ongoing'}, {'id': '0', 'name': 'INNODIA_HARVEST', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/innodia-harvest', 'summary': 'IMI’s INNODIA project has added significantly to our understanding of type 1 diabetes (T1D). The aim of INNODIA HARVEST is to build on INNODIA’s results by carrying out additional activities that will further pave the way for new treatments to treat or even prevent T1D.\nINNODIA HARVEST plans to consolidate the INNODIA clinical network and use it to run two clinical trials of drugs designed to stop T1D. One trial is driven by academia and focuses on the pancreatic beta cells, which are responsible for producing the hormone insulin. The other trial is industry driven and focuses on the role of the immune system (as the immune system attacks the beta cells in T1D).\nElsewhere, INNODIA HARVEST will continue INNODIA’s hunt for new biomarkers that could be used to track the progress of the disease, and implement new drug discovery pipelines for novel treatments for T1D\nAs in INNODIA, people with T1D and their families will be at the heart of the project to ensure the work meets their needs.\n', 'tags': 'Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA', 'participants': "Academisch Ziekenhuis Leiden, Leiden, Netherlands;Cardiff University, Cardiff, United Kingdom;Centre Hospitalier De Luxembourg, Luxembourg, Luxembourg;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Hannoversche Kinderheilanstalt, Hannover, Germany;Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany;Imcyse SA, Sart Tilman, Belgium;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Jdrf International, New York, United States ;Katholieke Universiteit Leuven, Leuven, Belgium;King'S College London, London, United Kingdom;Kobenhavns Universitet, Copenhagen, Denmark;Lunds Universitet, Lund, Sweden;Medizinische Universitat Graz, Graz, Austria;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Oslo Universitetssykehus Hf, Oslo, Norway;Ospedale Pediatrico Bambino Gesu, Rome, Italy;Oulun Yliopisto, Oulu, Finland;Region Hovedstaden, Hilleroed, Denmark;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Slaski Uniwersytet Medyczny W Katowicach, Katowice, Poland;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Technische Universitaet Dresden, Dresden, Germany;The Leona M. And Harry B. Helmsley Charitable Trust, New York, United States ;The University Of Exeter, Exeter, United Kingdom;Univercell Biosolutions SAS, Toulouse, France;Universita Degli Studi Di Siena, Siena, Italy;Universita Degli Studi Gabriele D'Annunzio Di Chieti-Pescara, Chieti, Italy;Universita Di Pisa, Pisa, Italy;Universita Vita-Salute San Raffaele, Milano, Italy;Universitaet Ulm, Ulm, Germany;Universite De Lausanne, Lausanne, Switzerland;University of Cambridge, Cambridge, United Kingdom;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Oxford, Oxford, United Kingdom;University of Turku, Turku, Finland;Université Libre de Bruxelles, Bruxelles, Belgium;Univerza V Ljubljani, Ljubljana, Slovenia", 'status': 'Ongoing'}, {'id': '0', 'name': 'IPIE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ipie', 'summary': 'The active ingredients in medicines (known as the active pharmaceutical ingredient, or API) can be released into the environment in a variety of ways. The most common route is via the sewage system, when patients excrete them. APIs can also escape into the environment when people dispose of medicines incorrectly, and during the manufacturing process. APIs are, by definition, biologically active, and although their concentration in the environment is generally extremely low, there are concerns about the effect of these chemicals on wildlife and ecosystems in general.\nSince 2006, new medicines have had to undergo an environmental risk assessment before they are approved for use. However, current testing strategies need to be optimised to accurately predict harmful impacts on wildlife.\nFurthermore, there are over 3 000 APIs that were already in use before the new rules came into force, and just a small number of these have been subjected to environmental impact testing. As testing all of these will be a mammoth task, guidance is needed to help identify which of these ‘legacy’ APIs are most likely to pose a risk to the environment and so should be prioritised for testing.\nNew, better methodologies for assessing environmental risks\nThe goal of the iPiE project is to develop frameworks to support the environmental testing of new pharmaceuticals and to help prioritise testing of legacy APIs. The frameworks will draw on information such as existing data on the environmental impact of APIs, toxicological studies, computer models, and studies of how medicines work.\nPart of the project focuses on identifying existing methods for carrying out pharmaceutical environmental risk assessments. The project is also compiling a database that will include information on both APIs and test organisms. Another priority for the project is the development of new models for estimating exposure to APIs; this will take account of questions such as how much of an ingredient gets into the environment, how fast it is broken down, and the extent to which is accumulates in different parts of the environment. These methods will feed into the development of an exposure assessment tool that can be used to screen APIs under development and prioritise which existing APIs should undergo enhanced testing. In addition, the project plans to develop methods to predict the effects of APIs on different organisms in both terrestrial and aquatic environments. All models developed by the project will be validated experimentally.\nUser-friendly software and guidance\nAn important component of the project involves integrating the databases and methods developed into a user-friendly iPiE software system. Researchers will be able to carry out both simple searches and more advanced analyses based on scientific hypotheses. Accompanying guidance will demonstrate how the software can be used to both screen new APIs and prioritise testing of existing APIs.\nBuilding on the work of other IMI projects\nThe iPiE project will draw heavily on the work of two existing IMI projects: eTOX and Open PHACTS. The iPiE database will be modelled on the eTOX database, which contains detailed information on the toxicity to humans of many existing APIs and so includes some fields required for the iPiE database. Another part of the iPiE project entails delving into publicly-available information, and for this iPiE will use the expertise of Open PHACTS, which specialises in this area.\nA lasting impact\nThe iPiE project will make it easier for researchers to evaluate the potential impacts of new medicines in the earlier stages of development. It will also facilitate the identification of medicines that have never undergone environmental assessment yet could pose a serious risk to wildlife and the environment. Ultimately, by ensuring that APIs are developed and used in an environmentally sustainable way, the project will contribute to the health of the natural environment.\n', 'tags': 'Intelligent Assessment of Pharmaceuticals in the Environment', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Ect Oekotoxikologie GMBH, Flörsheim a.M., Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Helmholtz-Zentrum Fur Umweltforschung GMBH - Ufz, Leipzig, Germany;Janssen Pharmaceutica Nv, Beerse, Belgium;Lhasa Limited, Leeds, United Kingdom;Liverpool John Moores University, Liverpool, United Kingdom;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Molecular Networks GMBH Computerchemie, Erlangen, Germany;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Synapse Research Management Partners SL, Barcelona, Spain;Teva Pharmaceuticals Europe B.V., Amsterdam, Netherlands;The University Of Exeter, Exeter, United Kingdom;Umweltbundesamt, Dessau-Roßlau, Germany;Universidad Pompeu Fabra, Barcelona, Spain;University Of York, York, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'ITCCP4', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/itcc-p4', 'summary': 'Today, 20% of childhood cancers remain incurable and cancer kills 6\xa0000 young people in Europe every year, making it the leading cause of disease-related death in the under-19s. Moreover, two thirds of those who survive a cancer in childhood experience long-term side effects as a result of their treatment. The challenge for scientists seeking to develop new treatments is the lack of tools to study childhood cancers, which are quite different in nature to most cancers found in adults.\nThe ITCC-P4 project will develop a large-scale platform comprising 400 novel research tools based on cells and tissues from patients covering 10 common childhood cancers, including neuroblastoma, high grade glioma, and osteosarcoma. The tools will allow researchers to explore the biology of paediatric cancers, identify sub-groups of patients that might respond better to certain treatments, and carry out tests on potential drugs.\nUltimately, the platform should significantly add to our understanding of childhood cancers and speed up the development of new treatments.\n', 'tags': 'ITCC pediatric preclinical POC platform', 'participants': 'Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Alleanza Contro Il Cancro, Roma, Italy;Bayer Aktiengesellschaft, Leverkusen, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Charles River Discovery Research Services Germany GMBH, Freiburg, Germany;Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Experimentelle Pharmakologie Und Onkologie Berlin-Buch GMBH, Berlin, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Italy;Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain;Gustave Roussy Transfert, Villejuif, France;Innovative Therapies For Children With Cancer Association, Villejuif, France;Institut Curie, Paris, France;Institut Gustave Roussy, Villejuif, France;Istituto Ortopedico Rizzoli, Bologna, Italy;Medizinische Universitaet Wien, Vienna, Austria;Ospedale Pediatrico Bambino Gesu, Rome, Italy;Pfizer Limited, Sandwich, Kent , United Kingdom;Pharmamar, S.A., Colmenar Viejo, Spain;Prinses Maxima Centrum Voor Kinderoncologie BV, Utrecht, Netherlands;St. Anna Kinderkrebsforschung, Vienna, Austria;The Institute Of Cancer Research: Royal Cancer Hospital, London, United Kingdom;Universitat Zurich, Zürich, Switzerland;Xentech SAS, Evry, France', 'status': 'Ongoing'}, {'id': '0', 'name': 'K4DD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/k4dd', 'summary': 'A major difficulty for those attempting to develop new medicines is predicting whether or not a potential drug will be effective. Currently, researchers spend a lot of time studying how strongly a potential drug binds with its target. However, less attention is given to the question of how long the drug remains bound to the target.\nNevertheless, there is mounting evidence to suggest that the kinetics of the interaction between a drug and its target have a strong influence on the clinical success of a drug. For example, studies have shown that many recently marketed drugs have improved kinetic profiles. This is logical; as drugs only work when they are bound to the target, the lifetime of the drug-target complex is key to the success of a drug.\nBy bringing together a diverse group of experts from industry, academia and small and medium-sized enterprises (SMEs), K4DD set out to give a major boost to this important area of drug development. One of the main project achievements is a better understanding of binding kinetics, and exactly how small molecules interact with their targets. The project also helped raise awareness of the importance of considering the kinetic aspects of drug-target interactions throughout drug development.\nDevelopment of tests systems and new technologies\nIn order to implement target binding kinetics in the drug discovery process, researchers first had to develop test systems (assays) that specifically measure the kinetic properties of a compound. K4DD developed several assays, which have now been published and can be used on a routine basis by everyone in the scientific community. Furthermore, K4DD project scientists have already been using these systems to deepen their understanding of compound properties that trigger certain behaviour, therefore laying the foundation for a broader use.\nSMEs outside of the project have further built on these ideas by developing and commercialising several off-the-shelf kits for analysing drug-protein binding kinetics. An SME within the consortium, Sierra Sensors, also developed a molecular affinity screening machine that can be used for measuring drug-protein binding kinetics data in a high-throughput format.\nA database, a toolbox and other achievements\nOther important project achievements include:\na comprehensive database of kinetic data which is now publicly available through ChEMBL;\na toolbox of computational methods for studying molecular binding kinetics, and the computational tools that employ them;\nan improved understanding of how drug molecules bind with specific receptors that are important therapeutic targets for diseases such as Parkinson’s and cancer.\nThe project also resulted in the creation of a spin off. Called Phenaris, it will develop ToxPHACTS, a software that will combine K4DD and eTOX project outputs with the Open PHACTS discovery platform.\nFor the benefit of industry, academia and SMEs\nThe academic partners within the project benefited from getting to know how things work in industry. They also got access to industry resources such as compounds, cells and reagents, which facilitated their work in the field and enabled them to publish papers with more information and impact than they could have generated otherwise. The project also resulted in multiple PhD defences and some of the research fellows later found jobs in industry.\nThe industry benefitted from project outputs, such as assays for testing kinetics. Thanks to the K4DD project, most pharmaceutical companies, and all of the ones which were in the project, started considering the impact of binding kinetics in early drug discovery.\nThe SMEs within the project benefitted from the network that has been established. They developed promising new technologies and one SME, Sierra Sensors, has even been acquired by a larger company, a manufacturer of scientific instruments.\nNext steps\nOne of the most important project legacies is raising the awareness of target binding kinetics. Now that the project is over, this awareness raising will continue through papers that have been published and through about 30 research fellows who were trained within the project and will continue to be the ambassadors of target binding kinetics.\nThe project will also continue to have impact through assays and technologies developed within the project and through the K4DD database, which will be an invaluable asset for future research.\nRead the interview with the project coordinators\n', 'tags': 'Kinetics for Drug Discovery', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Heptares Therapeutics Limited, Welwyn Garden City, United Kingdom;Hits Ggmbh, Heidelberg, Germany;Imperial College Of Science Technology And Medicine, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Ruhr-Universitaet Bochum, Bochum, Germany;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Sierra Sensors GmbH, Hamburg, Germany;Stichting Lygature, Utrecht, Netherlands;Stichting Vu, Amsterdam, Netherlands;The University Of Nottingham, Nottingham, United Kingdom;Universitat Wien, Vienna, Austria;Universiteit Leiden, Leiden, Netherlands;University Of Dundee, Dundee, United Kingdom;University of Oxford, Oxford, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'KRONO', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/krono', 'summary': 'Currently, COVID-19 diagnostic tests need to be processed by an expert in a laboratory, and patients often have to wait at least a day for their results. The KRONO project aims to change that by delivering a simple test that can be used at a doctor’s office or a patient’s home (for example) and would deliver results in just 40 minutes.\nThe diagnostic kit is based on novel technology that can work with unprocessed samples of blood, saliva, or nose or throat swabs and can be operated by anyone with basic training in how to use the device. The software is based on algorithms trained on actual clinical data, and allows users to easily interpret the results.\nWhile the team is focusing its efforts on the current COVID-19 outbreak, they also plan to ensure the system can be easily adapted to future outbreaks of new diseases in humans as well as animals.\n', 'tags': 'Evaluation of a production ready portable, point-of-need platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection', 'participants': "B G Research LTD, Kimbolton, United Kingdom;Biogene LTD, Kimbolton, United Kingdom;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy;Universite D'Aix Marseille, Marseille, France;Universite De Corse Pascal Paoli, Corte, France", 'status': 'Ongoing'}, {'id': '0', 'name': 'LITMUS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/litmus', 'summary': 'Non-alcoholic fatty liver disease (NAFLD), which occurs when fat builds up in the liver, affects around 20-30 % of the population worldwide. In most people, NAFLD does not cause health problems. However, a small proportion (less than 10 %) of people with NAFLD will go on to develop a more serious condition called non-alcoholic steatohepatitis (NASH). The livers of people with NASH are characterised by inflammation and scarring, and they are at a greater risk of developing cirrhosis and liver cancer. The challenge for doctors is identifying which NAFLD patients will go on to develop NASH and, for those with NASH, predicting how fast the disease will progress. Currently, diagnosis requires a liver biopsy, an invasive, often painful procedure that requires a hospital stay. As a result, many patients are not diagnosed until their disease is relatively advanced. The lack of a simple diagnostic tool also hampers the development of new treatments for NAFLD and NASH.\nThe goal of the LITMUS project is therefore to develop and validate highly accurate blood tests and imaging techniques that will allow doctors and researchers to rapidly and easily diagnose the severity of patients’ disease and monitor changes in patients’ livers. The tests should also make it possible to predict which NAFLD patients are at greatest risk of developing NASH, and how fast their disease is likely to progress.\nThe impacts of the project will be twofold. For patients and doctors, the tests will ensure that patients are diagnosed earlier and more easily. For researchers, the tests will make it easier to carry out clinical studies on NAFLD/NASH, including trials of potential treatments.\n', 'tags': 'Liver Investigation: Testing Marker Utility in Steatohepatitis', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Allergan Limited, Marlow, United Kingdom;Antaros Medical AB, Mölndal, Sweden;Asociacion Centro De Investigacion Cooperativa En Biociencias, Derio, Spain;Assistance Publique Hopitaux De Paris, Paris, France;Astrazeneca AB, Södertälje, Sweden;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Consiglio Nazionale Delle Ricerche, Roma, Italy;Echosens, Paris, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Ellegaard Gottingen Minipigs As, Dalmose, Denmark;Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece;European Association For The Studyof The Liver, Zürich, Switzerland;Faculdade De Medicina Da Universidade De Lisboa, Lisbon, Portugal;Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal;Genfit, Loos, France;Gilead Sciences Inc, Foster City Ca, United States;Histoindex Pte LTD, Singapore, Singapore;Inst Cardiometabolisme Nutrition Ican, Paris, France;Intercept Pharma Europe LTD, Bristol, United Kingdom;Ixscient Limited, Uxbridge, United Kingdom;Linkopings Universitet, Linkoping, Sweden;Luxembourg Institute Of Health, Luxembourg, Luxembourg;Medizinische Universitaet Wien, Vienna, Austria;Nordic Bioscience A/S, Herlev, Denmark;Nordic Bioscience Compound Development A/S, Herlev, Denmark;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;One Way Liver SL, Derio, Spain;Orebro University, Örebro, Sweden;Perspectum LTD, Oxford, United Kingdom;Pfizer Limited, Sandwich, Kent , United Kingdom;Research Triangle Institute, Research Triangle Park, United States;Resoundant, Inc., Rochester, United States;Servicio Andaluz De Salud, Sevilla, Spain;Somalogic Inc, Boulder, United States;Sorbonne Universite, Paris, France;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;The University Of Birmingham, Birmingham, United Kingdom;The University Of Nottingham, Nottingham, United Kingdom;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universita Degli Studi Di Firenze, Florence, Italy;Universita Degli Studi Di Milano, Milano, Italy;Universita Degli Studi Di Palermo, Palermo, Italy;Universita Degli Studi Di Torino, Turin, Italy;Universitaet Bern, Bern, Switzerland;Universitaetsklinikum Aachen, Aachen, Germany;Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany;Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitair Ziekenhuis Antwerpen, Edegem, Belgium;Universite D'Angers, Angers, France;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Helsinki, University of Helsinki, Helsinki, Finland;University of Oxford, Oxford, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'MACUSTAR', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/macustar', 'summary': 'People with dry age-related macular degeneration (AMD) gradually lose their central vision, usually in both eyes. It is already a leading cause of blindness worldwide, and as the population ages, the number of cases is likely to rise. There is currently no effective treatment for dry AMD. One barrier to the development of new treatments is the lack of tests capable of determining the effectiveness of treatments under development. Put simply, current tests do not detect all of the sight problems experienced by people with earlier stages of the disease (e.g. intermediate AMD).\nThe goal of the MACUSTAR project is to develop and validate tests that are capable of accurately detecting subtle changes in the disease over time. The project will follow more than 700 AMD patients over 3 years through tests including state-of-the-art imaging techniques and vision testing, as well as patient-reported outcome measures that capture the impact of the disease on patients’ quality of life. The hope is that these methods will prove capable of detecting changes in the patients’ disease. The team also hopes to shed new light on visual impairment in intermediate AMD and its progression, as well as the risk factors that cause the disease to progress faster in some patients than others.\nBy developing and validating new methods to study disease progression in dry AMD, the overall goal of MACUSTAR is to help drug development and make clinical trials of potential treatments more efficient.\n', 'tags': 'Intermediate AMD: development of novel clinical endpoints for clinical trials in patients with a regulatory and patient access intention ', 'participants': "Aibili Associacao Para Investigacao Biomedica E Innovacao Em Luz E Imagem, Coimbra, Portugal;Bayer Aktiengesellschaft, Leverkusen, Germany;Carl Zeiss Meditec AG, Jena, Germany;Centre Hospitalier National D'Ophtalmologie Des Quinze-Vingts, Paris, France;City University Of London, London, United Kingdom;Ecrin European Clinical Research Infrastructure Network, Paris, France;F. Hoffmann-La Roche AG, Basel, Switzerland;Fondation De Cooperation Scientifique Voir Et Entendre, Paris, France;Kks-Netzwerk Ev -Netzwerk Der Koordinierungszentren Fur Klinische Studien, Berlin, Germany;Moorfields Eye Hospital Nhs Foundation Trust, London, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Streetlab, Paris, France;The University Of Sheffield, Sheffield, United Kingdom;Universidade Nova De Lisboa, Lisboa, Portugal;Universitatsklinikum Bonn, Bonn, Germany;University College London, London, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'MADCOV_2', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/mad-cov-2', 'summary': 'ACE2 (angiotensin converting enzyme 2) is a protein found on the surface of the cells of our lungs and other organs. The SARS-CoV-2 virus, which causes COVID-19, uses ACE2 to break into and infect our cells.\nThe aim of the MAD-CoV 2 project is to build on and use this knowledge to develop innovative treatments for COVID-19. It will do this via a number of approaches, including engineering human tissue to test new treatments in the lab; studying how to exploit the role of ACE2; and mapping in detail the factors that are critical for virus replication.\nThe team hopes to rapidly translate this knowledge into new, targeted drugs to fight COVID-19 as well as any future coronavirus outbreaks. The project has committed to making its data and unique tissue reagents available to the entire community for drug testing and development, supporting all other efforts.\n', 'tags': 'Modern approaches for developing antivirals against SARS-CoV 2', 'participants': 'Apeiron Biologics AG, Wien, Austria;Fundacio Institut De Bioenginyeria De Catalunya, Barcelona, Spain;Inserm Transfert SA, Paris, France;Institut Fuer Molekulare Biotechnologie GMBH, Wien, Austria;Jlp Health GMBH, Vienna, Austria;Justus-Liebig-Universitaet Giessen, Giessen, Germany;Statens Veterinaermedicinska Anstalt, Uppsala, Sweden;Stemcell Technologies Uk LTD, Cambridge, United Kingdom;Vironova AB, Stockholm, Sweden', 'status': 'Ongoing'}, {'id': '0', 'name': 'MARCAR', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/marcar', 'summary': "When it comes to the development of innovative medicines, one of the main challenges is cancer risk assessment, i.e. ensuring that the potential drug does not cause cancer. There are two ways in which drugs can induce cancer: by directly altering the structure of the DNA and causing genetic mutations (genotoxic), and by various other indirect mechanisms which are harder to identify (non-genotoxic). While genotoxic changes are quick and generally easy to detect during the early stages of the drug development process, non-genotoxic changes require more intensive studies that utilize a large number of laboratory animals (approximately 500 per drug), and carry a very significant financial burden (about €3 million per drug). Due to this long and laborious process, many developed compounds either do not reach the market, or carry drug label warnings for potential carcinogenic risk due to the observation of cancerous effects in preclinical laboratory (e.g. animal) studies.\nThe goal of the MARCAR project was to develop early biological indicators (biomarkers), for early detection of non-genotoxic carcinogenesis. This type of cancer formation is thought to be facilitated by ‘epigenetic’ changes, i.e. modifications of the DNA and proteins that surround and functionally organize the DNA in our cells. Changes in these molecules can alter the 'readability' of the DNA and so affect the activity of our genes. The MARCAR consortium set out to shed more light on these epigenetic effects, using a combination of novel and sophisticated molecular technologies. Combining their expertise in the field of biomarkers, human and rodent cancer models, imaging, molecular profiling and bioinformatics, the researchers initially focused on liver tumours, an organ that is frequently affected by non-genotoxic carcinogenesis during the preclinical safety evaluation of medicines.\nProject success: New potential epigenetic biomarkers identified\nEarly efforts in MARCAR focused on optimising methods and technologies which allow scientists to look into the relationship between drug exposure and measurable epigenetic changes in liver cells transitioning to a tumour. Once a methodology was established, the consortium partners dug deeper to determine which specific epigenetic changes were linked with tumour growth. The goal was to identify early epigenetic biomarkers which could signal that a specific drug might cause non-genotoxic changes, and ultimately create an environment in which cancer occurs. At least two classes of such potential biomarkers were identified.\nEarly in the project, MARCAR scientists discovered a promising early RNA biomarker called Meg3 that originates from a very special epigenetically-regulated region of the genome. Progressive activation of Meg3 by non-genotoxic carcinogens in mice is believed to reflect reprogramming of normal adult liver cells towards a stem cell-like pluripotent state, a change which might contribute to the development of cancer in the longer-term. This biomarker is currently being evaluated with a broader range of drugs and has the potential to explain the molecular basis of species differences in responses to non-genotoxic carcinogens, a key consideration for interpreting human relevance of animal studies.\nAnother very important clue came from looking at the DNA bases or letters that make up the genetic code. Although basic biology teaches us that there are four basic DNA bases (A, T, C and G), multiple epigenetic modifications of the C (“cytosine”) base dramatically increase the complexity of our genes. MARCAR project scientists focused on a recently discovered modified form of cytosine called 5-hydroxymethylcytosine which is epigenetic in nature because it is involved in regulating the activity of genes, i.e. switching them on and off. They were able to show that this modified base is altered in very specific patterns by exposure to drugs which are known to cause liver cancer in rodents. On this basis, the scientists postulated that 5-hydroxymethylcytosine represents a powerful early biomarker for predicting tumour growth.\nBoth of these novel biomarker discoveries have the potential to underpin the design of improved preclinical safety studies that should ultimately reduce the cost, and accelerate the development of, innovative medicines.\nMouse MRI to reduce number of animals used in testing\nIn pre-clinical trials, in order to track tumour growth in animals, scientists have to look at the tissue directly, and this means sacrificing the animal. MARCAR project scientists developed a new method which is non-invasive and thus dramatically reduces the number of animals that need to be used for mechanistic carcinogenicity studies. The method involves a special magnetic resonance imaging (MRI) technique which allows researchers to scan mice and locate tiny tumours early in the screening process that are just 1 mm in size. They can then track the subsequent growth of the tumours by rescanning the same animals instead of having to sacrifice them every time. The method holds great value in reducing the number of animals used in drug development. \xa0\nInnovation in animal models: a mouse with a human receptor\nAnother innovation focused on a well-characterised epilepsy drug, which causes cancer in mice, but not in humans. In order to shed more light on this discrepancy, MARCAR scientists inserted a human receptor for this drug into the body of a mouse, creating a ‘humanised mouse’ model. They wanted to see if the human receptor would work in the body of the mouse, and if it would lead to the formation of cancer; it did, but with a reduced incidence. Does that mean that the drug is carcinogenic for humans after all? It’s not so simple because the tumour growth still occurred in the body of a mouse. However, the use of this humanised mouse model could be useful in the further study of the mechanisms of how cancer develops.\nFor the benefit of the industry, patients and academia\nThe science, technology and models developed during the MARCAR project have the potential to strengthen the scientific rigour and strength of cancer risk assessment; improve drug safety; reduce animal use and reduce the time it takes for new innovative medicines reach patients. Furthermore, the biobank and database created during the project will be assets in future research.\nWhat next?\nNow that the project has drawn to a close, one of the priorities will be to share the knowledge gained with the global community. This will be done in a multitude of conferences and workshops. \xa0\nRead the interview with project coordinator\n", 'tags': 'Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis', 'participants': 'Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Cxr Biosciences Limited, Dundee, United Kingdom;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;H. Lundbeck As, Valby, Denmark;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Medizinische Universitaet Wien, Vienna, Austria;Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen, Reutlingen, Germany;Novartis Pharma AG, Basel, Switzerland;The University Of Edinburgh, Edinburgh, United Kingdom;UCB Pharma SA, Brussels, Belgium;University Of Dundee, Dundee, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'MELLODDY', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/melloddy', 'summary': 'The vast amounts of data generated during drug discovery are not always used optimally, meaning scientists miss out on opportunities to make new discoveries using old data. One challenge lies in the fact that much of this data is owned by companies, and making it readily available to others would affect their competitiveness.\nThe MELLODDY project aims to establish a machine learning platform that would make it possible to learn from multiple sets of proprietary data while respecting their highly confidential nature, as data and asset owners will retain control of their information throughout the project.\nThrough this innovative, blockchain-based solution, the pharmaceutical companies in the project aim to demonstrate the feasibility of this approach with an unprecedented volume of competitive data in the form of over a billion drug-development-relevant data points, and hundreds of terabytes of image data that annotate the biological effects of more than 10 million small molecules. The platform would also take a federated machine learning approach, meaning that the learning effort is not centralised but spread over different, physically separated partners.\nThe hope is that this solution will deliver insights that will advance drug development by making it easier to identify which small molecules show the most promise for further research.\n', 'tags': 'Machine learning ledger orchestration for drug discovery', 'participants': 'Amgen Research (Munich) GMBH, Munchen, Germany;Astellas Pharma Europe BV, Leiden, Netherlands;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Budapesti Muszaki Es Gazdasagtudomanyi Egyetem, Budapest, Hungary;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Iktos, Paris, France;Institut De Recherches Servier, Suresnes, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;Kubermatic GMBH, Hamburg, Germany;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Nvidia Switzerland AG, Zurich, Switzerland;Owkin France, Paris, France;Substra, Nantes, France', 'status': 'Ongoing'}, {'id': '0', 'name': 'MIPDILI', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/mip-dili', 'summary': 'Clinicians and drug manufacturers recognise two kinds of DILI. Dose-dependent DILI is usually detected early on in drug development and, as the name suggests, the risk of an adverse reaction increases with the dosage. However, some DILIs are so-called idiosyncratic reactions. These cannot be predicted in experimental systems, occur only in certain patients, and are not clearly dose dependent toxicities. Very often, idiosyncratic DILI problems are only picked up very late in drug development or even after regulatory approval. Estimates suggest that one in seven cases of liver failure are triggered by an adverse drug reaction in patients.\nThe goal of MIP-DILI was to dramatically improve the tools used to test for liver toxicity in early drug development, especially in vitro tests which measure the effect of potential drug molecules on human cell systems in a laboratory setting. By bringing together Europe’s top industrial and academic experts in the field for the first time, the project deepened our understanding of the science behind drug-induced liver injury, and then used that knowledge to overcome the many drawbacks of the laboratory tests currently used.\nLooking at existing models and developing new ones\nOne of the main project achievements was a systematic and evidence-based evaluation of both currently available and new laboratory test systems, including cultures of liver cells in one-dimensional and three dimensional configurations. MIP-DILI really took an in-depth look into how all these cell systems function and developed definitions of basic biological machinery in various in vitro test systems to see which human processes they are capable of capturing.\nThe project also developed models that capture the principal types of liver injury that these in vitro systems can detect. This is important because while some cases of DILI may be triggered by something inside the liver cells, others appear to be associated with external factors, including the immune system and viral infections. \xa0These factors also need to be taken into account in laboratory tests.\nThanks to MIP-DILI, scientists working to develop new drugs now have a more realistic and physiologically relevant set of models for looking at a defined set of chemical attacks that drugs can make on liver cells. This gives them a warning of this toxicity very early in the drug development process, so that they can focus their efforts on those molecules which can arrive safely to patients.\nOther important achievements\nIn addition to the above, the project recorded a number of other achievements, including:\nAn ability to detect a major sub-type of human DILI (called cholestasis) by a new mechanism which involves bile formation and flow. This has never been achieved before and was a breakthrough in this field of research.\nA roadmap for the evaluation of DILI test systems. Developed for the evaluation of test systems within the project, this roadmap will help future projects as well.\nDevelopment of a battery of preclinical test systems for detecting DILI, which are fit for purpose.\nDetermination of what can – and what cannot – be predicted with current DILI test systems in order to inform drug development, regulators and the public.\nNew understanding of the mechanisms of fialuridine toxicity (experimental drug for hepatitis B), including the first-ever evidence that some of the existing in vitro tests can successfully predict this toxicity.\nA roadmap to understand and assess potential DILI liabilities of new drugs during their development.\nA clearer identification of remaining knowledge gaps which need to be addressed in order to advance this field of research.\nConsiderable benefits for patients\nAlthough DILI is rare, when it happens, it is often extremely serious or even fatal for the patient concerned. Yet drugs that pose a risk of DILI still make it to the market, and DILI is a common reason for withdrawing drugs from national prescription registries. By helping researchers to detect DILI problems during drug research, before drugs are evaluated in clinical trials and approved for use, MIP-DILI will greatly contribute to the considerable efforts being made to avoid pain and suffering on the part of patients as a consequence of these adverse drug reactions.\nThe project will also help patients in therapeutic areas where there is an urgent need for new drugs. One of the biggest risks in the development of a new drug is that at a late stage, after four or five years of endeavour, that drug has to be stopped because of a problem with drug safety. The tools developed within MIP-DILI will help reduce this risk, enabling pharmaceutical companies to focus their efforts on the most promising drugs.\nFor the benefit of academia and industry\n\xa0\nAcademic partners in the project benefited from access to reference compounds with known liver toxicity, as well as from gaining a deeper insight into industry practices and needs. Additionally, the gap analysis performed within the project revealed the need for more fundamental research in some areas, which will be a fertile training ground for future PhD students and post-doctoral fellows.\nFor their part, pharmaceutical companies gained a greater understanding of the complex science behind DILI, and an appreciation that the mechanisms of DILI need to be better understood before drug toxicities, especially those associated with an immune response, can ever be predicted in patients.\nThanks to IMI, the pharmaceutical companies worked on these issues in a precompetitive space for the first time, openly sharing questions that they all have in their respective companies. There was also a tremendous benefit in working with academia to tackle these questions and find solutions which can be deployed within industry. Many of the tools and learnings developed in this project are already deployed in industry, and have resulted in both cost and time savings.\nThe SMEs in the project gained a unique opportunity to work with both industry and academia to develop their tools and test their products. Thanks to the network created within the project, they were then able to offer those products to industry customers. SMEs also participated in the project’s joint publications, which gave them visibility and increased their reputation in the wider scientific community.\nReducing the use of animals in research\nEverything about MIP-DILI has worked towards encouraging a reduction in the use of animals in preclinical research. By helping improve the value of in vitro tools in early drug discovery, MIP-DILI improved the decision making process, ensuring that only the best and most promising molecules are brought forward into further trials on animals. \xa0\nWhat’s next?\nAll the foreground and background data generated during the lifetime of the project is stored within a database, and will continue to be sustained by one of the SMEs in the project. The project’s sustainability will also be ensured through the in vitro tests which were developed within the project and are now in use in both industry and academia.\nRead the interview with project coordinators\n', 'tags': 'Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury', 'participants': 'Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany;Astrazeneca AB, Södertälje, Sweden;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Interface Europe, Bruxelles, Belgium;Janssen Pharmaceutica Nv, Beerse, Belgium;Kaly-Cell, Plobsheim, France;Karolinska Institutet, Stockholm, Sweden;Klinikum Rechts Der Isar Der Technischen Universitat Munchen, Muenchen, Germany;Lhasa Limited, Leeds, United Kingdom;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Orion Oyj, Espoo, Finland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Solvo Biotechnology Zrt, Szeged, Hungary;Stichting Vu, Amsterdam, Netherlands;Takara Bio Europe AB, Göteborg, Sweden;The University Of Liverpool, Liverpool, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universite De Rennes I, Rennes, France;Universiteit Leiden, Leiden, Netherlands;Universiteit Utrecht, Utrecht, Netherlands', 'status': 'Closed'}, {'id': '0', 'name': 'MOBILISED', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/mobilise-d', 'summary': 'Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with a greater risk of disease, cognitive decline, risk of falls and even earlier death. As the population ages, the number of people experiencing mobility issues is expected to rise. However, accurately assessing people’s mobility, especially in the real world, is far from easy. MOBILISE-D aims to develop a comprehensive system to analyse people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease (COPD), Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure. The project plans to work closely with regulators and other stakeholders to ensure that the solutions are accepted. Once validated, the MOBILISE-D results will help to improve the accurate assessment of mobility in clinical trials. They will also make it easier for clinicians to monitor patients’ mobility and thereby contribute to improved, more personalised care.\n', 'tags': 'Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement', 'participants': 'Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy;Amgen Limited, Cambridge, United Kingdom;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Centre Hospitalier Universitaire Montpellier, Montpellier, France;Christian-Albrechts-Universitaet  Zu Kiel, Kiel, Germany;Ecole Polytechnique Federale De Lausanne, Lausanne, Switzerland;Eresearch Technology Inc, Philadelphia, United States;Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany;Fundacion Privada Instituto De Salud Global Barcelona, Barcelona, Spain;Grunenthal GMBH, Aachen, Germany;Icon Clinical Research Limited, Dublin, Ireland;Imperial College Of Science Technology And Medicine, London, United Kingdom;Ixscient Limited, Uxbridge, United Kingdom;Katholieke Universiteit Leuven, Leuven, Belgium;Mcroberts BV, S Gravenhage, Netherlands;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Norges teknisk-naturvitenskapelige universitet - NTNU, Trondheim, Norway;Novartis Pharma AG, Basel, Switzerland;Penumologisches Forschungsinstitutan Der Lungenclinic Grosshansdorf GMBH, Grosshansdorf, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Robert Bosch Gesellschaft Fur Medizinische Forschung Mbh, Stuttgart, Germany;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Sheffield Teaching Hospitals Nhs Foundation Trust, Sheffield, United Kingdom;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Teva Pharmaceutical Industries Limited, Netanya, Israel;The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv, Tel Aviv, Israel;The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-Upon-Tyne, United Kingdom;The University Of Sheffield, Sheffield, United Kingdom;Universita Degli Studi Di Sassari, Sassari, Italy;Universita Vita-Salute San Raffaele, Milano, Italy;Universitat Zurich, Zürich, Switzerland;Universitatsklinikum Erlangen, Erlangen, Germany;University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University Of Northumbria At Newcastle, Newcastle upon Tyne, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'MOFINA', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/mofina', 'summary': 'The 2014-15 Ebola epidemic was unprecedented in its scale and geographical distribution. By the middle of 2015, World Health Organization (WHO) statistics recorded over 27 000 cases and 11 000 deaths from the disease, most of them in Guinea, Liberia, and Sierra Leone.\nOne of the biggest challenges in containing an Ebola outbreak is quick and efficient diagnosis. Until now, patients who were suspected of having the virus had to be taken to treatment centres far away from their communities and kept in isolation centres until tests confirmed that they were not infected. Even if they were found to be healthy and subsequently released, they were often stigmatised in their local communities, as others feared that they may have been exposed to the virus. This caused psychological stress and trauma, spreading fear in local communities, and making it harder to contain outbreaks. Some people who developed symptoms would even avoid or hide from the Ebola tracing teams as they feared being ostracised.\nIMI’s Mofina project developed a portable device, no bigger than a shoe box, which can be used for diagnosing all known Ebola virus strains as well as Marburg virus in the field. The testing is easy, safe, reliable, and can be performed by people with little training such as local health care workers, saving money and resources. All that is needed to perform the test is a simple prick of a finger. \xa0\nThe product has been validated, CE-IVD marked and is already commercially available. This is the first commercially available test that is both portable and can test for all the known Ebola virus strains. It is anticipated that potential buyers could include public health institutes, diagnostic services, WHO and non-governmental organisations tackling outbreaks.\nCooperation with key partners \nAccording to the project partners, the success of this project would not have been possible without the collaboration between the public and private partners, brought together by IMI.\nFor example, the small and medium-sized enterprise (SME) within the project, Altona Diagnostics, contributed by bringing in their diagnostic test for all the different strains of Ebola that was validated and could be used in a normal lab setting. Another private partner, Alere Technologies, brought in a molecular diagnosis platform which is already used across Africa for HIV testing in the field. It is by combining those two technologies that the project partners were able to develop a unique new test which is both portable and can test for of the known Ebola virus strains.\nFurthermore, thanks to the collaboration with the national public health institutes and other public partners, the project was able to validate the device on patient samples collected during the west African Ebola outbreak, and get it quickly approved for placement on the market.\nBenefits for industry, SMEs, and patients\nThe industry benefitted from the collaboration with SMEs and the public partners in the consortium, such as leading European public health institutions.\nThe SME in the project benefitted from getting a detailed insight into workflows in mobile laboratories during outbreaks which will help them in developing future products. They also benefitted from fostering existing scientific collaborations, and establishing new ones.\nHowever, it will be the patients who will benefit the most. The device produced by Mofina will help contain Ebola outbreaks in the future, by identifying infected patients much sooner than before.\nWhat comes next?\nThe project partners would like to develop the device further, making it possible to test for a range of other infectious diseases, which are on the list of WHO priority pathogens, such as the Zika virus, dengue and Lassa fever. \xa0\nRead the interview with the project coordinator\n', 'tags': 'Mobile Filovirus Nucleic Acid Test', 'participants': 'Alere Technologies GMBH, Jena, Germany;Altona Diagnostics GMBH, Hamburg, Germany;Bernhard-Nocht-Institut Fuer Tropenmedizin, Hamburg, Germany;Department of Health, Leeds, United Kingdom;Foundation For Innovative New Diagnostics, Geneva, Switzerland;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy', 'status': 'Closed'}, {'id': '0', 'name': 'MOPEAD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/mopead', 'summary': 'Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of dementia symptoms in the first place, and for this they need to work with people who are still in the very earliest stages of the disease. The MOPEAD project aims to identify and test different models for engaging with this important group and determine which models work best in different situations. As well as adding to our understanding of the earliest stages of dementia, the project will facilitate recruitment for clinical trials and, most importantly, ensure that patients are able to access support from early on in their disease.\n', 'tags': 'Models of patient engagement for Alzheimer’s disease', 'participants': "Alzheimer Europe, Luxembourg, Luxembourg;Asdm Consulting, Bruxelles, Belgium;Astrazeneca AB, Södertälje, Sweden;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Institute Of Women'S Health Company Limited By Guarantee, Dublin, Ireland;Fundacio Ace, Barcelona , Spain;Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain;Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain;Karolinska Institutet, Stockholm, Sweden;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Modus Research And Innovation Limited, Dundee, United Kingdom;Region Stockholm, Stockholm, Sweden;Spomincica Alzheimer Slovenija Slovensko Zdruzenje Za Pomoc Pri Demenci, Ljubljana, Slovenia;Stichting Vumc, Amsterdam, Netherlands;Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia", 'status': 'Closed'}, {'id': '0', 'name': 'NECESSITY', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/necessity', 'summary': 'Primary Sjögren’s Syndrome (pSS) is an autoimmune disease in which the immune system attacks cells in the body that secrete fluids, such as tear ducts and salivary glands. Symptoms include itchy eyes, a dry mouth, joint and muscle pain, difficulty concentrating, and disabling fatigue. Around a third of patients also experience other health problems such as arthritis, fever, vasculitis, kidney disease, and lung disease. Finally, people with pSS are at a greater risk of developing B-cell lymphomas. Although there are treatments to alleviate some symptoms of pSS, there is no cure. The aim of NECESSITY is to identify sensitive clinical endpoints that could be used in clinical trials to determine whether a new pSS medicine works or not. In addition, the project aims to identify biological markers that could be used to identify specific subgroups of patients with different types of pSS. Finally, the project plans to run an innovative clinical trial (a multi-arm, multi-stage platform trial) to validate both the newly-defined pSS endpoints and the subgroups identified. Ultimately, the project results will contribute to the development of much-needed new treatments for pSS. In addition, many of the tools and methodologies developed by the project will also be useful for other autoimmune diseases.\n', 'tags': 'New clinical endpoints in primary Sjögren’s syndrome: an interventional trial based on stratifying patients', 'participants': 'Academisch Ziekenhuis Groningen, Groningen, Netherlands;Assistance Publique Hopitaux De Paris, Paris, France;Association Francaise Gougerot-Sjogren, Courbevoie, France;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Centre Hospitalier Regional Et Universitaire De Brest, Brest, France;Ecrin European Clinical Research Infrastructure Network, Paris, France;Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece;Fundacio Clinic Per A La Recerca Biomedica, Barcelona, Spain;Fundacion Publica Andaluza Progreso Y Salud, Seville , Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Helse Stavanger Hf, Stavanger, Norway;Hopitaux Universitaires De Strasbourg, Strasbourg, France;Hospital Clinic De Barcelona, Barcelona, Spain;Innovation Acta S.R.L., Roma, Italy;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Institut Pasteur, Paris, France;Karolinska Institutet, Stockholm, Sweden;Novartis Pharma AG, Basel, Switzerland;Queen Mary University Of London, London, United Kingdom;The University Of Birmingham, Birmingham, United Kingdom;Universita Degli Studi Di Udine, Udine, Italy;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universite De Bretagne Occidentale, Brest, France;Universite De Paris, Paris, France;Universite Paris-Saclay, Saint Aubin, France;University College Cork -  National University Of Ireland, Cork, Cork, Ireland;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'NEURODERISK', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/neuroderisk', 'summary': 'In the early stages of drug development, scientists seek to identify (and weed out) compounds that could prove harmful to the brain and nervous system. However, current tests for this are not reliable, meaning that sometimes toxicities are only identified when the first human volunteers test a new drug in clinical trials. The aim of NeuroDeRisk is to deliver a comprehensive toolbox of tools and data that would make it easier for researchers to assess whether or not a compound is likely to be toxic to the brain and nervous system, long before the first tests in humans. They will focus their efforts on three of the most challenging effects: seizures, psychological / psychiatric changes, and peripheral neuropathies (in which the nerves in the extremities are damaged resulting in symptoms such as numbness, tingling and pain).\nThey will collect, organise and build on our current knowledge of the adverse effects of drugs on the nervous system. They will also develop new and improve existing tools to predict neurotoxicity, with an emphasis on approaches that are in line with the ‘3Rs’ principles to reduce, refine and replace animal use. Finally, they will organise all the tools and associated data in a comprehensive, integrated toolbox that researchers will be able to use to aid decision making during the early stages of drug development. Ultimately, the results of the project will help to make clinical trials safer for human volunteers. They will also make drug development more efficient, as scientists will not waste time studying compounds that prove to be toxic to vital organs.\n', 'tags': 'Neurotoxicity de-risking in preclinical drug discovery', 'participants': 'A. Persidis & S.A Oe, Athina, Greece;Alcediag, Montpellier, France;Astrazeneca AB, Södertälje, Sweden;Farmaceutski Fakultet Univerzitetau Beogradu, Belgrade, Serbia;Fujifilm Cellular Dynamics Inc, Madison, United States;Iceta Instituto De Ciencias, Tecnologias E Agroambiente Da Universidade Do Porto, Porto, Portugal;Inte:Ligand Software-Entwicklungs-Und Consulting GMBH, Vienna, Austria;Itä-Suomen yliopisto, Kuopio, Finland;Medizinische Universitaet Wien, Vienna, Austria;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;UCB Biopharma SRL, Brussels, Belgium;Universita Degli Studi Di Firenze, Florence, Italy;Universitat Wien, Vienna, Austria;Universite Clermont Auvergne, Clermont-Ferrand, France;Uppsala Universitet, Uppsala, Sweden', 'status': 'Ongoing'}, {'id': '0', 'name': 'NEURONET', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/neuronet', 'summary': 'IMI’s growing neurodegenerative disorders (ND) portfolio is to get a new, dynamic platform – NEURONET – that will make it easier for the many projects to exploit synergies and connect the resources and needs of the different projects. NEURONET aims to be a key enabler and mediator across the portfolio, assisting in identifying gaps, multiplying impacts, enhancing visibility and ensuring coordination with related initiatives in Europe and worldwide. The mapping of ND actions and initiatives is among NEURONET’s objectives, as is providing coordination and support to the individual IMI projects, management support to the whole programme, and the identification and dissemination of best practices and learnings. Designed to take a different approach to typical Coordination and Support Actions (CSAs), NEURONET hopes to help IMI’s ND projects to create a platform for the efficient collaboration of current and future IMI ND projects, thus helping them to make progress and deliver results that will benefit the millions of people who live with neurodegenerative diseases.\n', 'tags': 'Efficiently networking European neurodegeneration research', 'participants': "Alzheimer Europe, Luxembourg, Luxembourg;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Janssen Pharmaceutica Nv, Beerse, Belgium;National Institute For Health And Care Excellence, Manchester, United Kingdom;Parkinson'S Disease Society Of Theunited Kingdom Lbg, London, United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Synapse Research Management Partners SL, Barcelona, Spain;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland", 'status': 'Ongoing'}, {'id': '0', 'name': 'NEWMEDS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/newmeds', 'summary': 'Pressing public health concern\nSchizophrenia and depression are among the leading causes of disability in Europe, and worldwide. Schizophrenia and depression represent a tremendous health, social, and economic burden, not only for patients but also for families, other caregivers, and the wider society, making them one of the most pressing public health concerns. In the EU in 2016, the total costs of psychiatric illnesses were estimated at more than 4% of gross domestic product (GDP) – or over EUR 600 billion - with more than one in six people across the EU having a mental health issue in 2016, equivalent to about 84 million people. Schizophrenia and depression are commonly diagnosed based on patient interviews, and scientists are still trying to understand how genetic and environmental factors interact to cause them. Schizophrenia is heritable; people whose parents both have schizophrenia have a 50 % chance of developing the disease, while just 1 % of those with no family history develop the sickness. Moreover, schizophrenia is probably not just one, but several disorders that have different underlying causes, and this makes drug development difficult. Depression, like schizophrenia, is caused by genetics – close to 40 % of the risk of disease is heritable. The disorder is treatable, but about 50 % of major depression still goes untreated and long-lasting depression may become a serious health condition.\nDefining and solving bottlenecks\nNEWMEDS, the first consortium of its kind in psychiatry, set out to find new avenues for treatments for schizophrenia and depression. The team focused on a redefinition of the biology behind these diseases as ‘connectopathies’, disorders of key brain circuits in the brain, and identified and solved major bottlenecks hampering progress in the area. To start with, the consortium developed standardised, more accurate and predictive animal models, which use brain recording and behavioural tests. Such models produce highly reliable and reproducible results thus reducing the number of animals needed for drug discovery tests.\nTo tackle the lack of tools and tests that can provide early indications of the efficacy of new drugs, NEWMEDS developed positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) based tools and models to serve as early or surrogate markers to provide guidance for drug development. Thirdly, NEWMEDS examined a set of genetic risk factors - copy number variations (CNV) which are closely linked with schizophrenia - by studying them in human and animal models. This allowed them to identify which changes and mechanisms in the brain are caused by these factors, and will pave the way for the development of new treatments. Furthermore, the project examined biomarkers that can be used to stratify patients within an umbrella diagnosis, like depression, in that way allows for more targeted clinical trials and individualised treatments, matching patients to the most effective drugs.\nThose comprehensive tasks would not be have been possible without a broad public-private partnership (PPP) which allowed the sharing of ideas and resources. The project brought together 7 leading academic institutions in Europe and Israel, 2 biotech companies (SMEs), and 10 pharmaceutical companies. Through NEWMEDS, they were able to share their individual approaches to psychiatric diseases, and openly discuss technical questions and work together towards standardising technology.\nFocus on schizophrenia and depression\nSome of the most promising methods to diagnose schizophrenia or depression are biomarker tests. NEWMEDS used these new approaches to evaluate the validity of animal models of psychiatric disorders, which were previously only characterised based on behavioural measures. A major scientific breakthrough and was the demonstration that certain variations in the human genome, CNVs, have a direct effect on the brain and that they are associated with impaired intellectual and cognitive function in people with these variations. High-risk CNV will still have an impact on cognitive skills and brain structure in people who carry the genes but do not suffer from schizophrenia.\nIn addition, NEWMEDS discovered that clinical trials for antipsychotic drugs (in which patients on active treatment are compared to patients taking a placebo) could still be effective if shortened by a week or two (usually they last six weeks). The team also noticed that 71 % of the participants in schizophrenia clinical trials were male, but females had significantly less placebo response and slightly more treatment response than males.\nImportant database\nAll this was possible because five large pharmaceutical companies in the project made available clinical trial data to create the largest known database of studies on schizophrenia, including information on over 23 000 patients from 67 studies in over 25 countries. The database offers the industry and the academic community a unique opportunity for the development of tools and models that will help find targeted treatments for schizophrenia.\nFour pharmaceutical companies in NEWMEDS shared data from 39 placebo-controlled studies of 12 217 patients from antidepressant studies. The analysis of these studies identified aspects of trial design that can be optimised to increase their success. NEWMEDS also determined why some patients respond to one kind of antidepressants, and others do not, by studying data on the genetics and clinical response in over 1 800 patients. That became the largest existing resource of well-characterised patients with depression, treated with different antidepressants, providing information on who responds best to which drug.\nAchievements of the project:\xa0 \nA new approach to the biology of schizophrenia and depression and novel tools and methods to support a revamped drug discovery and development ecosystem for much needed new treatments for mental health disorders.\nA hunt for pharmacogenetics biomarkers to stratify response to antidepressant treatments did not find major stratifiers, but did lead to a simple tool for assessing the clinical utility of future biomarkers.\nEstablishment of the DupCheck tool (www.dupcheck.org) – that allows those running a clinical trial in any area of medicine to check globally if a patient is alreadyenrolled in another trial.\nScientists are trying to understand the pathology of schizophrenia and to develop the means to control so-called positive symptoms, such as hallucinations and delusions, as well as negative ones, such as social withdrawal and apathy, and cognitive deficits. During the project, it was discovered that the negative symptoms, could respond better to existing treatments than was previously thought. NEWMEDS also showed that in the future the diagnosis of brain diseases would be defined based on biological characteristics, with a more precise biological classification of patients enabling to provide tailor-made treatment of specific patients.\n', 'tags': 'Novel methods leading to new medications in depression and schizophrenia', 'participants': "Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain;Bar Ilan University, Ramat Gan, Israel;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Gabo:Mi Gesellschaft Fur Ablauforganisation:Milliarium mbH & Co. KG, Munich, Germany;H. Lundbeck As, Valby, Denmark;Institut De Recherches Servier, Suresnes, France;Islensk Erfdagreining Ehf, Reykjavik, Iceland;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Orion Oyj, Espoo, Finland;Pfizer Limited, Sandwich, Kent , United Kingdom;Psynova Neurotech LTD, Cambridge, United Kingdom;The University Of Manchester, Manchester, United Kingdom;University of Cambridge, Cambridge, United Kingdom;Zentralinstitut Fuer Seelische Gesundheit, Mannheim, Germany", 'status': 'Closed'}, {'id': '0', 'name': 'NGNPET', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ngn-pet', 'summary': 'Neuropathic pain is a chronic condition affecting around 8 % of the population. It can be triggered in various ways, including through surgery, injury, diabetes, chemotherapy, and viral infection. Existing treatments are only effective in a minority of patients. Furthermore, treatments address the symptoms, not the underlying causes of the pain, and so are not curative. In fact, the underlying causes of neuropathic pain are still poorly understood, and that’s where the NGN-PET project comes in.\nThe NGN-PET team will focus its efforts on interactions between nerve cells (neurons) and glial cells (also known as glia). There are many types of glia, and their role in the nervous system includes supporting nerve cells, insulating them, and providing them with nutrients and oxygen. Recent research has revealed that glial cells are actively involved in the development of sensory abnormalities, including pain.\nNGN-PET aims to explore neuron-glial interactions in neuropathic pain caused by chemotherapy or trauma by developing advanced neuron-glia cell cultures based on induced pluripotent stem cells (iPSCs). The outcome of the project will be a high throughput screening platform that can then be used to rapidly test potential treatments and will ultimately pave the way for the development of safe, effective pain treatments.\n', 'tags': 'Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments', 'participants': "Axxam S.A, Bresso (Milan), Italy;Esteve Pharmaceuticals, SA, Barcelona, Spain;Grunenthal GMBH, Aachen, Germany;King'S College London, London, United Kingdom;Life And Brain GMBH, Bonn, Germany;Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen, Reutlingen, Germany", 'status': 'Closed'}, {'id': '0', 'name': 'ONCO_TRACK', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/onco-track', 'summary': 'Colorectal cancer is the third most frequently occurring cancer worldwide and, at an advanced stage, one of the most common causes of death. It takes numerous forms, and not all cancers respond to the same kind of treatment. This is because tumours undergo genetic changes as they grow and spread, and these changes can vary even between patients with the same type of cancer.\xa0 To be able to predict a tumour’s response to certain drugs more accurately, IMI’s OncoTrack project set out to produce molecular fingerprints of different tumours and correlate the different fingerprints to how the tumours respond to various drugs.\nBy bringing together academic institutions, SMEs and pharmaceutical companies, OncoTrack scientists first collected tumour samples from over 100 colorectal cancer patients at different stages of the disease. They grew these tumours in tissue culture systems, as well as in special mouse strains, and proceeded to analyse them in the lab. In particular, the scientists looked for biomarkers, i.e. molecules that are typical of the different tumour sub-groups. Based on this analysis, they were able to produce molecular fingerprints for all of the tumours.\nNext, they tested how the tumours respond to different drugs and correlated various tumour fingerprints with their response to the different clinical compounds. Among other things, they discovered two biomarkers that can predict the effectiveness of two drugs commonly used to treat this disease: Cetuximab, which inhibits the receptor for the epidermal growth factor, and the chemotherapy drug 5FU.\nNew 3D models of colon cancer, and other achievements\nGrowth of tumours took place in 3D tissue culture systems and through xenografts – tissue grafted onto mice, which creates a strain of the disease adapted to mice. Analysis covered the genetic material, RNA molecules and in some cases, the proteins of the tumours. These biological models are now considered as some of the best characterised in the field, and are already being used by pharmaceutical companies in their drug discovery and development projects.\nOther important outputs generated by the project include:\na biorepository of patient-derived 3D cultures and patient-derived xenograft models;\na database which contains part of the data generated by the project, with plans to complete it in the near future.\nTwo spin outs and various patents \nThe project also resulted in two spin-out companies. One of them was created in 2014 to commercialise the technology of 3D tissue culture systems or organoids. Generated from the tumour tissue, organoids are groups of cells that grow in the culture dish, remain small, and mimic a lot of the biology of the tumour. They are potentially quite useful to pharma companies and this spin-out has been set up to commercialise this as a basis for drug testing.\nThe second company was set up in 2018. It spun out from a group at the University of Paris, and intends to commercialise OncoTrack’s technologies developed to improve diagnostic procedures.\nOne of the major goals of OncoTrack was also to find better ways to diagnose cancer, and some of the partners have refined the technologies that they have been using. Several patents have been filed as a result.\nBenefits to patients\nOncoTrack project outputs are already benefitting patients. For example, the analysis of tumour samples of more than 100 patients, which was done as part of this project, is now available to the doctors treating those patients. Furthermore, for drugs which are already used in the clinic, such mutation analysis is now becoming routine, helping doctors choose the right drug for the right patient.\nAdditionally, one of the academic partners, the Medical University in Graz, is using the 3D culture models, which were developed during the project, in an experimental setting in the clinic in order to find drugs that can potentially help patients for whom no treatment is available.\nFor the benefit of industry, academia and SMEs\nThe academic institutions in the project benefitted from access to the pharmaceutical companies’ resources, such as drugs which were tested during the project. They also got a lot more information about mechanisms of drug action then they otherwise would have. In turn, the pharmaceutical industry is benefitting from the information, materials and biological models developed during the project.\nBoth academia and industry partners gained a lot from collaborating and exchanging different viewpoints and perspectives. For example, academics have learned more about how the industry works, and the industry has benefited from academic expertise. The connections which have been established will last well into the future.\nFinally, the SMEs in the project benefitted from increased visibility and reputation, as well as new contacts with both industry and academic partners. Participating in OncoTrack accelerated their business expansion and helped them enter into new markets.\nWhat’s next?\nThe information and models created during OncoTrack are now available for future research projects. In fact, several OncoTrack partners are continuing to work together in new pan-European projects, such as the Future Health initiative. Additional new projects, funded by national or local agencies, have been initiated by some of the academic partners. \xa0\nRead the interview with project coordinators\n', 'tags': 'Methods for systematic next generation oncology biomarker development ', 'participants': "Alacris Theranostics GMBH, Berlin, Germany;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Dahlem Center For Genome Research And Medical Systems Biology GMBH, Berlin, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Experimentelle Pharmakologie Und Onkologie Berlin-Buch GMBH, Berlin, Germany;F. Hoffmann-La Roche AG, Basel, Switzerland;Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain;International Prevention Research Institut-Ipri Management, Lyon, France;Ipri Services, Ecully, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Medizinische Universitat Graz, Graz, Austria;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Stockholms Universitet, Stockholm, Sweden;Technische Universitaet Dresden, Dresden, Germany;Universite Paris-Sud, Orsay, France;University College London, London, United Kingdom;Uppsala Universitet, Uppsala, Sweden", 'status': 'Closed'}, {'id': '0', 'name': 'OPEN_PHACTS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/open-phacts', 'summary': 'Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data. Analysis and hypothesis generation for drug-discovery projects requires the assembly, overlay and comparison of data from many sources as well as the development of shared identifiers and common semantics. The alignment and integration of internal and public data and information sources requires a significant effort, and the process is repeated across companies, institutes and academic laboratories. This represents a significant waste and increases drug discovery costs. The Open PHACTS project set out to tackle that challenge.\nBy bringing together leading experts in the fields of data mining, small molecule data storage and manipulation, target bioinformatics, information handling, chemical biology and more, the project developed the Open PHACTS Discovery Platform. The platform links up about a dozen diverse and complementary drug discovery databases, allowing researchers to rapidly find and access relevant data in different domains, such as compounds, targets, diseases and tissues. It is open to all users and is freely available in the public domain. The platform significantly reduces the time needed to answer complex questions in drug discovery: what used to take days or months of research, can now be accessed with a few clicks.\nLeading the way in data standardisation\nIn order to make all this data more searchable, the project also developed standards and common identifiers. Moreover, the project was a thought incubator for the FAIR (findable, accessible, interoperable, reproducible) data principles, which are now having a wider impact on the scientific community.\nA spin off that will reduce the use of animals in research\nThe project also resulted in the creation of a spin off. Called Phenaris, it will develop ToxPHACTS, a software that will combine the eTOX project outputs with the Open PHACTS discovery platform.\nThe ToxPHACTS platform will allow toxicologists to do the very early assessment of the risk of a certain compound, even before they do the first animal experiments. The new platform will save researches money and time, and reduce the use of animals in research.\nFor the benefit of industry, academia and SMEs\nBoth industry and academia benefitted from the collaboration and the intellectual network which was created during this project.\nThe academic community also greatly benefited from getting to know how industry works, especially when it comes to data issues. Several PhD students who worked in the project found jobs in industry.\nThe SMEs within the project benefitted from close contacts with potential new customers in industry and from learning more about their needs.\nWhat’s next\nEven though the project has ended, the Open PHACTS Discovery Platform lives on thanks to the Open PHACTS Foundation, which was set up to build on the work begun in the project. The foundation was set up early in the project, in 2012, and the formal handover from project to foundation took place at the project’s closing meeting in Vienna in 2016. Meanwhile the foundation has already established itself as a leader in linking data, and is a partner in several Horizon 2020 projects.\nRead the interview with project coordinators\n', 'tags': 'The Open Pharmacological Concepts Triple Store', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Almirall SA, Barcelona, Spain;Astrazeneca AB, Södertälje, Sweden;BioSolveIT GmbH, Sankt Augustin, Germany;Connected Discovery Ltd, Walmer, Deal, United Kingdom;Consorcio Mar Parc De Salut De Barcelona, Barcelona, Spain;Danmarks Tekniske Universitet, Kgs. Lyngby, Denmark;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Esteve Pharmaceuticals, SA, Barcelona, Spain;European Molecular Biology Laboratory, Heidelberg, Germany;Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain;Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii, Madrid, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Open Phacts Foundation Lbg, Cambridge, United Kingdom;Openlink Group Limited, Croydon, United Kingdom;Pfizer Limited, Sandwich, Kent , United Kingdom;RSC Worldwide (US) Inc., Raleigh, Wake County, North Carolina , United States ;Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Germany;Rsc Worldwide LTD, Cambridge, United Kingdom;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;SciBite Limited, Bexhill-On-Sea, United Kingdom;Stichting Dtl Projects, Nijmegen, Netherlands;Stichting Vu, Amsterdam, Netherlands;The Royal Society Of Chemistry, Cambridge, United Kingdom;The University Of Manchester, Manchester, United Kingdom;Universidad De Santiago De Compostela, Santiago de Compostela, Spain;Universidad Pompeu Fabra, Barcelona, Spain;Universitaet Hamburg, Hamburg, Germany;Universitat Wien, Vienna, Austria;Universiteit Maastricht, Maastricht, Netherlands', 'status': 'Closed'}, {'id': '0', 'name': 'ORBITO', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/orbito', 'summary': 'Oral administration is the most common route for medication, which can come in the form of solid tablets, capsules, or chewable tablets, or as drinkable liquids. Solid medications, such as tablets and capsules, deliver the active ingredient to the patient after they dissolve in the gastrointestinal (GI) tract and are then absorbed into the bloodstream.\nHowever, the seemingly simple task of swallowing a pill hides a complex process which is influenced by the drug, the formulation, and GI factors like food and liquid consumption, gastric pH (acidity), and the absorptive capabilities of the digestive tract. To be able to design successful\xa0 simulation tools fundamental for the efficient development of new oral pharmaceutical dosage forms, scientists need a thorough knowledge of key aspects of GI physiology and their impact on formulation performance and subsequent drug release behaviour.\nThe main purpose of the OrBiTo project was to develop and optimise new lab-based and computational tools which could predict the performance of oral drug formulations in patients with greater accuracy than previously available tools.\nAiming to reduce and replace drug absorption studies in animals and humans currently required throughout all phases of drug development, with predictive in vitro and in silico tools, OrBiTo scientists set out to develop a framework for optimal use of tools able to predict the influence of drug form and formulation on oral drug absorption.\nTap or gas\nThe project’s main achievement is a novel understanding of the oral absorption process based on about 20 mechanistic in vivo studies that resulted in better knowledge of GI fluids and conditions, intestinal wall permeability, and drug concentrations in the GI tract, all of which form the basis for the improvement of in vitro and in silico predictive tools.\nBy further increasing our understanding of the oral drug absorption process, creating new and refined in vivo predictive tools, validating and standardising key existing tools, as well as developing a guidance for the rational use of an array of different tools, the project’s ultimate goal was to reduce the need for exposing laboratory animals and healthy volunteers to developmental drugs.\nAn illustrative and interesting discovery of OrBiTo was the impact of sparkling water on the absorption of the painkiller paracetamol when taking a standard tablet. Scientists at KU Leuven investigated the time it takes for paracetamol to reach the small intestine, from where it can be absorbed into the bloodstream. They found that a paracetamol tablet dissolves faster with sparkling water – on average, it took only 10 minutes for the drug to reach the small intestine, compared with half an hour when taken with tap water. Reaching maximum levels of paracetamol in the bloodstream took, on average, 30 minutes with sparkling water, but more than 90 minutes with tap water.\nThe study proved the important role of the stomach in oral drug absorption, since pressure events in the stomach, which occurred more frequently after intake of sparkling water, can determine the rate of drug dissolution and transfer to the small intestine. It further revealed the challenge of developing drug formulations that can withstand these real-life fluctuations in gastric physiology.\nBy magnetic resonance imaging (MRI) measurements of gastric volumes, OrBiTo researchers at Greifswald University\xa0 discovered that taking oral medicine with food, as commonly recommended, results in a slower rate of drug absorption since it follows the average six-hour long food route to the intestines. More importantly, since water empties from the stomach more rapidly than food, future medicines could be designed to follow the water, and this will result in faster drug absorption.\nOther achievements:\n15 new or refined in vitro predictive tools;\nsignificant standardisation and validation of in vitro predictive tools;\ndecision tools and best practice guidance for the rational use of this array of predictive methods;\nring studies with EFPIA partners to determine the inter-laboratory reproducibility of biorelevant dissolution testing;\na new database format for the storage of biopharmaceutics and in vivo data populated with historical data from EFPIA;\nabout 170 papers published in leading international pharmaceutics journals;\nmore than 60 examples of the implementation of OrBiTo tools, methods and best practice guides at industrial partners.\nBy taking a new approach to investigating and validating novel and existing biopharmaceutics tools, and by using active pharmaceutical ingredients, formulations and supporting data from industry partners, OrBiTo scientists were able to capture the full complexity of the GI drug absorption process. They focused on an improved insight into GI physiology and drug absorption, the development of physicochemical and in vitro tools, and\xa0 the integration of all data through the application of in silico models of drug absorption.\nOrBiTo results will contribute to:\nreducing the time and money needed for drug development (a clinical absorption study takes at least six months and a failed late-stage study could lead to delayed drug launch);\nlower manufacturing costs through in vivo relevant quality tests, and\nthe development of better products for patients with improved efficacy/safety properties through improved product designs.\nThe OrBiTo project brought together more than 150 scientists from 13 industrial and 14 academic, regulatory and technology partners, each contributing with unique expertise and best practice. That provided the opportunity for developing novel and, at the same time, practically useful solutions. The results of the project influenced similar ones outside the EU, such as Cobito, a similar type of consortium started in Japan. The OrBiTo database will be maintained and enriched by a new consortium formed of past members of OrBiTo, and with funding primarily from EFPIA. In addition, two more EU initiatives in the oral biopharmaceutics area – PEARLL and UNGAP, both with the participation of industry and academia, are to follow OrBiTo.\n', 'tags': 'Oral biopharmaceutics tools', 'participants': 'Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Certara Uk Limited, London, United Kingdom;Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Johannes Gutenberg-Universitat Mainz, Mainz, Germany;Katholieke Universiteit Leuven, Leuven, Belgium;Kobenhavns Universitet, Copenhagen, Denmark;Lakemedelsverket, Uppsala, Sweden;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek Tno, Den Haag, Netherlands;Novartis Pharma AG, Basel, Switzerland;Orion Oyj, Espoo, Finland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Simulations Plus, Inc., Lancaster, United States ;Sirius Analytical Ltd, Forest Row, United Kingdom;The University Of Manchester, Manchester, United Kingdom;Tno Triskelion BV, Zeist, Netherlands;Universitaet Greifswald, Greifswald, Germany;Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany;University Of Strathclyde, Glasgow, United Kingdom;Uppsala Universitet, Uppsala, Sweden', 'status': 'Closed'}, {'id': '0', 'name': 'PARADIGM', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/paradigm', 'summary': 'There is growing recognition that patients can and should be more involved in the medicines development process. However, many stakeholders still have questions on how to put this principle into practice – who should be involved, how, and when? The PARADIGM project aims to provide a framework for structured, effective, meaningful and ethical patient engagement and demonstrate the ‘return on engagement’ for all stakeholders. Building on existing initiatives, the consortium will develop a comprehensive set of tools and practices to support the integration of patient perspectives into drug development and enhance trust among different stakeholders.\nThe project will focus on three decision-making points in the medicines development process: research and priority setting; clinical trial design; and early dialogues with regulators and health technology assessment (HTA) bodies. Ultimately, the team hopes that the project will help patient engagement to become a reality and standard practice, helping to improve research and deliver results that are focused on patients’ needs.\n', 'tags': 'Patients active in research and dialogues for an improved generation of medicines: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes', 'participants': "Agenzia Italiana Del Farmaco, Rome, Italy;Alexion Services Europe SPRL, Brussels, Belgium;Alzheimer Europe, Luxembourg, Luxembourg;Amgen Limited, Cambridge, United Kingdom;Bayer Aktiengesellschaft, Leverkusen, Germany;Covance Laboratories LTD, Harrogate, United Kingdom;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Aids Treatment Group Ev, Duesseldorf, Germany;European Forum For Good Clinical Practice, Brussels, Belgium;European Patients’ Forum (EPF), Brussels, Belgium;Eurordis - European Organisation For Rare Diseases Association, Paris, France;F. Hoffmann-La Roche AG, Basel, Switzerland;Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Brussels, Belgium;Forum Des Patients Europeens, 1040, Belgium;Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Grunenthal GMBH, Aachen, Germany;H. Lundbeck As, Valby, Denmark;Health Technology Assessment International Society, Edmonton, Canada;Institut De Recherches Internationales Servier Iris, Suresnes, France;Instituto Aragones De  Ciencias De La Salud, Zaragoza, Spain;Janssen Pharmaceutica Nv, Beerse, Belgium;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Vu, Amsterdam, Netherlands;Synergist Services, Bruxelles, Belgium;Team - It Research SL, Barcelona, Spain;The Association Of The British Pharmaceutical Industry, London, United Kingdom;The Synergist, Bruxelles, Belgium;UCB Biopharma SRL, Brussels, Belgium;University of Oxford, Oxford, United Kingdom;Verband Forschender Arzneimittelhersteller Ev, Berlin, Germany", 'status': 'Ongoing'}, {'id': '0', 'name': 'PDMIND', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pd-mind', 'summary': 'Only 10% of compounds studied in the early stages of drug development make it into clinical trials, and of those, just 20% achieve regulatory approval. Nevertheless, the compounds that fall along the way can still prove useful in research and in some cases can be ‘repurposed’, i.e. used for the treatment of different diseases to the one for which they were originally developed. PD-MIND aims to repurpose a compound called AZD0328 as a treatment for Parkinson’s disease with mild cognitive impairment (PD-MCI). Recent trials have suggested that compounds like AZD0328 could improve cognition in people with Parkinson’s disease. Now, PD-MIND will carry out a randomised, placebo controlled study across multiple centres in different countries to see if this finding can be confirmed. Patients and other stakeholders will be involved from the start to ensure their viewpoints are taken into account in the design and execution of the trial. Repurposing drugs in this way has a number of advantages. Most notably, as a lot of work has already been carried out on the compounds, repurposing can deliver results much faster and for less money.\n', 'tags': 'Parkinson disease with mild cognition impairment treated with nicotinic agonist drug', 'participants': "Astrazeneca AB, Södertälje, Sweden;Helse Stavanger Hf, Stavanger, Norway;King'S College London, London, United Kingdom;Masarykova univerzita, Brno, Czech Republic;Norges Parkinsonforbund, Oslo, Norway;Parkinson'S Disease Society Of Theunited Kingdom Lbg, London, United Kingdom;Stichting Lygature, Utrecht, Netherlands;Technische Universitaet Dresden, Dresden, Germany;The University Of Exeter, Exeter, United Kingdom;Universita Degli Studi Gabriele D'Annunzio Di Chieti-Pescara, Chieti, Italy", 'status': 'Ongoing'}, {'id': '0', 'name': 'PDMITOQUANT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pd-mitoquant', 'summary': 'Mitochondria are the powerhouses of our cells. Mutations in the mitochondria appear to be associated with Parkinson’s disease, a neurodegenerative disease that affects around a million people in Europe. It is triggered by the death of neurons that produce a chemical called dopamine; in order to properly work, these neurons need a lot of energy.\nFocusing on mitochondria dysfunction in Parkinson’s disease, the PD-MitoQUANT project aims to identify and validate molecular drivers and mechanisms of the condition and discover innovative therapeutic targets that can be further developed by the pharmaceutical companies. Current therapies can cause adverse side effects, and cannot stop, slow or reverse disease progression. This makes the improvement of Parkinson’s disease-related treatments even more urgently needed.\n', 'tags': "PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease", 'participants': "Centre National De La Recherche Scientifique Cnrs, Paris, France;Consiglio Nazionale Delle Ricerche, Roma, Italy;Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev, Bonn, Germany;Genexplain GMBH, Wolfenbuttel, Germany;H. Lundbeck As, Valby, Denmark;Institut Du Cerveau Et De La Moelle Epiniere, Paris, France;Mimetas BV, Leiden, Netherlands;Parkinson'S Disease Society Of Theunited Kingdom Lbg, London, United Kingdom;Pintail LTD, Blackrock, Ireland;Royal College Of Surgeons In Ireland, Dublin, Ireland;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Teva Pharmaceutical Industries Limited, Netanya, Israel;UCB Biopharma SRL, Brussels, Belgium;University College London, London, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'PERISCOPE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/periscope', 'summary': 'Vaccines have helped to cut cases of pertussis (whooping cough) worldwide. However, recent years have seen a rise in cases and the disease remains a leading cause of infant mortality around the world. The PERISCOPE project is working to better understand how the currently available vaccines work, and to aid the development and licensing of the next generation of improved pertussis vaccines. The multi-disciplinary team will focus on three major areas. Firstly, they will set up a comprehensive clinical research programme to study the immune response of people of all ages to pertussis infection and vaccination. Secondly, they will establish tools (clinical and pre-clinical models) to study pertussis infection. Finally, they will develop a battery of state-of-the-art tests, to help reveal the markers of an effective and long-lasting immune response to pertussis infection. PERISCOPE will also seek to study immunisation in pregnancy to gain a better understanding of the impact of maternal antibodies on the infant’s immune responses to pertussis.\n', 'tags': 'PERtussIS COrrelates of Protection Europe', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Bill & Melinda Gates Foundation, Seattle, United States;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Department of Health, Leeds, United Kingdom;Eurice European Research And Project Office GMBH, Saarbrücken, Germany;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Institut Pasteur De Lille Fondation, Lille, France;London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom;Mikrobiologicky Ustav Av Cr V.V.I, Prague 4, Czech Republic;Q-Biologicals Nv, Gent, Belgium;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Sanofi Pasteur SA, Lyon, France;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Trinity College Dublin, Dublin, Ireland;Universidad De Salamanca, Salamanca, Spain;Universitat Basel, Basel, Switzerland;Universitats-Kinderspital Beider Basel, Basel, Switzerland;University Of Bath, Bath, United Kingdom;University Of Southampton, Southampton, United Kingdom;University of Oxford, Oxford, United Kingdom;University of Turku, Turku, Finland;Université Libre de Bruxelles, Bruxelles, Belgium', 'status': 'Ongoing'}, {'id': '0', 'name': 'PEVIA', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pevia', 'summary': 'The devastating Ebola outbreak that struck western Africa in 2014-2016 left over 11 000 dead, including many medical workers. The outbreak highlighted the urgent need for safe, effective vaccines against the highly infectious disease.\nThere are a number of promising Ebola vaccines in development, and studies suggest that they are both safe and effective. Nevertheless, their large-scale deployment could be limited by issues such as the fact that they need to be stored at extremely low temperatures (-80°C). The goal of the PEVIA project is to develop second generation Ebola vaccines based on the proteins found on the surface of the virus. The project team is using the prime-boost approach, in which one vaccine is given to prime the immune system, and a second (different) vaccine is given to boost the immune response. The project hopes that the resulting regimen will be better suited to large-scale vaccination programmes in sub-Saharan countries, most notably because it will not require storage at low temperatures. In addition, PEVIA aims to develop innovative tools and methods to facilitate the development of new vaccine candidates for Ebola and related diseases, as well as novel diagnostic tests that can be deployed in the field.\n', 'tags': 'Pan Ebola vaccine innovative approach', 'participants': "Assistance Publique Hopitaux De Paris, Paris, France;Bernhard-Nocht-Institut Fuer Tropenmedizin, Hamburg, Germany;Centre Hospitalier Regional Et Universitaire De Lille, Lille, France;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Centre National De La Recherche Scientifique Cnrs, Paris, France;Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France;Excellgene SA, Monthey, Switzerland;Heinrich-Pette Institut Leibniz Institut Fuer Experimentelle Virologie, Hamburg, Germany;Ifakara Health Institute Trust, Dar es Salaam, Tanzania (United Republic of);Institut National De La Sante Et De La Recherche Medicale, Paris, France;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy;Istituto Superiore Di Sanita, Roma, Italy;Oligovax, Paris, France;Universite D'Abomey-Calavi, Cotonou, Benin;Vaxeal Research, Evry, France", 'status': 'Ongoing'}, {'id': '0', 'name': 'PHAGO', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/phago', 'summary': 'Clumps of proteins in the brain called amyloid plaques are a hallmark of Alzheimer’s disease, and very often specialised immune cells cluster around these plaques. Recent research has shown that two genes involved in the immune system, TREM2 and CD33, appear to be involved in this immune response to Alzheimer’s disease and could therefore be targets for drugs. However, their exact role in the disease is still poorly understood. The PHAGO project aims to develop tools and methods to study the workings of these genes. The project results will therefore pave the way for the development of novel drugs that could tackle Alzheimer’s disease via this route.\n', 'tags': 'Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33', 'participants': "Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Arttic, Paris, France;Astrazeneca AB, Södertälje, Sweden;Axxam S.A, Bresso (Milan), Italy;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev, Bonn, Germany;Eisai Limited, Hatfield, United Kingdom;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Goeteborgs Universitet, Gothenburg, Sweden;H. Lundbeck As, Valby, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;King'S College London, London, United Kingdom;Life And Brain GMBH, Bonn, Germany;Orion Oyj, Espoo, Finland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Universitatsklinikum Bonn, Bonn, Germany;University College London, London, United Kingdom;University of Cambridge, Cambridge, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'PHARMACOG', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pharma-cog', 'summary': "A challenging disease\nOver 4 million Europeans suffer from Alzheimer’s disease (AD), and the cost of the disease in the EU amounted to more than 100 billion in 2008. Currently approved drugs for patients with Alzheimer's disease only treat symptoms (symptomatic approach) and their effect is limited or absent in many patients. No drugs have been approved yet that can actually slow the progression of the disease (disease modifying approach). Trials with candidate drugs take years and cost tens of millions of euros. Furthermore, a number of AD drugs which showed promise in the laboratory didn’t translate into success in the clinic, resulting in a high number of costly drug failures.\nThe Pharma-Cog project aimed to develop and validate new tools to test candidate drugs for the treatment of symptoms and disease in a faster and more sensitive way. By bringing together results from blood tests, electroencephalography (EEG) recording of brain activity, magnetic resonance imaging (MRI) scans, and behavioural tests, the scientists set out to develop a more comprehensive matrix of clues (biomarkers) that may give more accurate information on the progression of the disease and the effect of candidate drugs than current approaches. The project worked in three core areas: preclinical work with animal models; experimental medicine work involving healthy volunteers that undergo a challenge, such as sleep deprivation; and patients with mild cognitive impairment (MCI), an early sign of Alzheimer’s.\nImproving translatability between animals, healthy volunteers and patients\nIn order to find biomarkers which could help predict the effectiveness of a new drug candidate in the early stages of drug development, Pharma-Cog scientists measured the effect of known Alzheimer’s drugs in all three core areas above. By cross-checking the results, they identified and validated a matrix of biomarkers, such as\xa0EEG recordings of brain activity and MRI scans, which could help predict the effect of drugs more accurately. For example, they demonstrated that some changes in the rhythm of brain activity observed via EEG are a good marker to detect the effect of a new drug in early studies involving both human and animal models. This important discovery could help pharmaceutical companies make better decisions on which drugs are worth pursuing in clinical trials, and do this much earlier, before starting the more costly studies in patients. A French biotechnology small and medium-sized enterprise (SME) is already using some of these findings to evaluate a promising new AD drug candidate.\nImproving stratification of patients\nAn important part of the project was a study involving more than 150 patients with MCI. MCI is one of the early signs of Alzheimer’s but not all patients who have it will go on to develop the disease. In clinical studies involving MCI patients, the effect of a potential drug candidate can be masked by this variability among patients.\nBy monitoring a group of MCI patients over a longer period of time, and taking measurements such as EEG readings, MRI scans and blood tests, Pharma-Cog scientists were able to identify a set of biomarkers which signal whether a patient is likely to progress to Alzheimer’s or not. This important discovery has the potential to improve the stratification of AD patients in future clinical trials, making it more sensitive and effective.\nOther achievements\nIn addition to improving translatability between animal and human studies, and improving the stratification of patients, the project recorded a number of other achievements, including:\nReconciling the symptomatic and disease modifying approaches to AD therapy, and highlighting the need for improved symptomatic drugs despite the emphasis on disease modification.\nBuilding a large database which contains data on the effect of AD drugs on a matrix of biomarkers. As some studies are still ongoing, this database is currently open to only Pharma-Cog partners, but it will eventually be opened up to other researchers.\nDemonstration that healthy humans and animals who have been sleep-deprived for one night show some of the same changes in brain activity as AD patients, and can be used in early studies to predict the effectiveness of new drug candidates.\nThanks to Pharma-Cog, a French SME was able to validate a diagnostic kit for AD, which they had developed before the project. The kit contains inflammatory proteins which show correlation with the worsening of the disease. A patent application is pending.\nAs the European Medicines Agency was a full partner in the project, the findings could have an impact on the revision of EMA guidelines on medicines for Alzheimer’s. Discussions with the agency are still ongoing.\nStrengthening collaboration between key players in the Alzheimer’s disease field, including industry, academia and SMEs. The collaboration is continuing and could result in future projects.\nFor the benefit of industry, academia, and patients\nThe academic partners benefited from the project by gaining international visibility, strengthening their collaboration with industry and learning more about the drug development process, including the high standards of robustness and rigour of data that industry requires before further investment into novel drugs or technologies. Many publications and communications have also resulted from the project.\nThe industry also benefited from the collaboration with academia, SMEs and other industry partners. In the long term, the outputs of Pharma-Cog could help pharmaceutical companies make better decisions on which drugs are worth pursuing in clinical trials, saving them money and resources. Additionally, the stratification of patients devised in Pharma-Cog could make clinical trials more sensitive.\nBut it will be the patients who will benefit the most. Thanks to Pharma-Cog, future clinical trials may require smaller sample sizes and shorter duration, which could speed up the development of new AD drugs for the benefit of patients.\nThanks to the participation of a patient organisation, Alzheimer Europe, as a full partner in the project, Pharma-Cog also enabled patients to gain a better understanding of the drug development process and the challenges of predicting the safety and efficacy of new molecules.\nWhat’s next?\nEven though the project has officially ended, several studies are still ongoing and further publications are anticipated. Furthermore, some of the partners within the project are continuing to collaborate and apply for new projects.\nRead the interview with project coordinators\n", 'tags': 'Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development', 'participants': "Alzheimer Europe, Luxembourg, Luxembourg;Astrazeneca AB, Södertälje, Sweden;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux Marseille, Marseille, France;Centre Hospitalier Regional Et Universitaire De Lille, Lille, France;Centre National De La Recherche Scientifique Cnrs, Paris, France;Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain;Diaxonhit SA, Paris, France;Eisai Limited, Hatfield, United Kingdom;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Elliniki Etairia Nosoy Alzheimer Kai Syggenon Diatarachon Somateio, Thessaloniki, Greece;F. Hoffmann-La Roche AG, Basel, Switzerland;Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare, Napoli, Italy;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Innovative Concepts in Drug Development (ICDD-sas), Meyreuil, France;Institut De Recherches Servier, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy;Janssen Pharmaceutica Nv, Beerse, Belgium;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Museum National D'Histoire Naturelle, Paris, France;Novartis Pharma AG, Basel, Switzerland;Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio- Fatebenefratelli, Brescia, Italy;Qualissima, Marseille, France;SAS Alzprotect, Loos, France;Stichting Vu, Amsterdam, Netherlands;The University Of Exeter, Exeter, United Kingdom;UCB Pharma SA, Brussels, Belgium;Universidad De Murcia, Murcia, Spain;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universita Degli Studi Di Foggia, Foggia , Italy;Universita Degli Studi Di Genova, Genova, Italy;Universita Degli Studi Di Perugia, Perugia, Italy;Universita Degli Studi Di Verona, Verona, Italy;Universitaet Leipzig, Leipzig, Germany;Universitaetsklinikum Essen, Essen, Germany;Universite D'Aix Marseille, Marseille, France;Universite De Lille Ii - Droit Et Sante, Lille, France;Universite Paul Sabatier Toulouse Iii, Toulouse, France", 'status': 'Closed'}, {'id': '0', 'name': 'PHARMALEDGER', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pharmaledger', 'summary': 'The most famous application of blockchain technology is the bitcoin currency, yet it could also revolutionise the way other sectors work. The goal of the PharmaLedger project is to deliver a blockchain-based platform for the healthcare sector, using the supply chain, clinical trials, and health data as case studies. \n\nIn blockchain technology, data is decentralised, meaning it is stored across multiple servers. It is also immutable; this means data records (or ‘blocks’) cannot be changed or tampered with. Each new ‘block’ of data is connected to the previous one, creating the ‘blockchain’. The blocks are connected by cryptography, making the system secure.\n\nPharmaLedger aims to use these technologies to make blockchain in healthcare a reality thanks to a platform that is supported and trusted by different stakeholders and complies with existing and emerging laws and regulations. For this reason, the project brings together technical, legal, and regulatory experts as well as pharmaceutical companies and patient organisations. \n\nUltimately, the project hopes that bringing the blockchain into healthcare in this way will help to accelerate the delivery of innovation that benefits patients as well as the wider health ecosystem.\n', 'tags': 'PharmaLedger', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Arteevo Technologies LTD, Tel Aviv, Israel;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Dimokritio Panepistimio Thrakis, Komotini, Greece;Ekon Modeling Sofware Systems LTD*Ekon, Modi'in-Maccabim-Re'ut, Israel;Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece;European Forum For Good Clinical Practice, Brussels, Belgium;European Patients’ Forum (EPF), Brussels, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Forum Des Patients Europeens, 1040, Belgium;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Hospital Do Espirito Santo De Evora Epe, Evora, Portugal;Imprensa Nacional - Casa Da Moeda, S. A., Lisboa, Portugal;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;National Research And Development Institute For Cryogenics And Isotopic Technologies Icsi Rm Valcea, Ramnicu Valcea, Romania;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Onorach LTD, Dundee, United Kingdom;Ospedale Pediatrico Bambino Gesu, Rome, Italy;Pdm E Fc Projecto Desenvolvimento Manutencao Formacao E Consultadorialda, Lisboa, Portugal;Pfizer Limited, Sandwich, Kent , United Kingdom;Romsoft SRL, Iasi, Romania;Technovative Solutions LTD, Manchester, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universidad Politecnica De Madrid, Madrid, Spain;Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany", 'status': 'Ongoing'}, {'id': '0', 'name': 'PHARMATRAIN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pharmatrain', 'summary': 'Europe needs experts in the pharmaceutical industry who are able to oversee the entire medicines development process, from the identification of a molecule, through pre-clinical and clinical trials, all the way to the regulatory process and market approval. Yet \xa0education and training in these fields has been quite fragmented in Europe. The aim of PharmaTrain was to bring together all the experts who are teaching this subject and make them agree on the content that should be taught when someone wants to become a specialist in these areas. The project also wanted to ensure that post-graduate training courses that are offered across Europe have the same quality, delivering the same type of learning effect, no matter where the training is carried out.\nBy bringing together 20 university training programmes, 10 learned societies, 3 competent authorities, several partner training organisations and 15 pharmaceutical companies, PharmaTrain managed to achieve all its objectives. One of its main achievements was to create common standards and guidelines for universities who want to develop training in medicines development, regulatory affairs, clinical trials, investigator training and clinical trial management. The partners also developed a set of criteria which can be used to recognise and assess the quality of available courses in these fields, along with labels which can be awarded to programmes which meet the required standards. Thanks to this system, the project developed a network of 13 courses which are now recognised as Centres of Excellence, and evaluated more than 150 short courses.\nMore specifically, the project delivered the following outputs:\na syllabus and curricula for medicines development;\na concept for professional certification in medicines development, which has already been implemented in Italy and Japan as a pilot;\na joint postgraduate course in medicines development, which is offered by 10 cooperating regional universities, mostly in eastern Europe;\nsyllabus and learning outcomes for 26 elective modules in medicines development;\n9 e-learning compact modules which are freely available;\na good examination practice guide;\na concept for a post-graduate, on-the-job certification programme leading to a ’specialist in medicines development’;\na syllabus and curriculum for a postgraduate master of regulatory affairs;\na clinical investigator training concept.\nFor the benefit of industry, academia and patients\nFor the academic community, this project represented a unique opportunity to come together, join forces and agree on shared quality standards for training in medicines development, regulatory affairs and investigator training. It was also an opportunity to adapt their courses to the needs of the industry.\nThe industry benefited by getting employees who have a more integrated view of the needs in research and development and can be more easily integrated into companies. They have also benefitted from the network which was established during the project.\nUltimately, it will be the patients who will benefit, as the new, higher quality training standards will result in better trained medicines development professionals, which in turn will lead to better and safer medicines for patients.\nWhat’s next?\nAfter the end of the project, all the partners have agreed to donate project outcomes to the new PharmaTrain Federation, a non-profit organisation which was established to continue some of the project’s work. The federation is self-sustaining through membership fees, and among other things, it continues to asses courses offered in the medicines development field. It provides ‘PharmaTrain Recognition’ for individual courses and ‘Centre of Excellence Recognition’ for academic, commercial and non-commercial training organisations fulfilling the shared quality standards developed by the project.\nRead the interview with project coordinators\n', 'tags': 'Pharmaceutical Medicine Training Programme', 'participants': "Almirall SA, Barcelona, Spain;Amgen, Brussels, Belgium;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Cardiff University, Cardiff, United Kingdom;DIA Europe GmbH, Basel, Switzerland;Esteve Pharmaceuticals, SA, Barcelona, Spain;European Federation For Pharmaceutical Sciences, Järfälla, Stockholm, Sweden;European Forum For Good Clinical Practice, Brussels, Belgium;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Faculty Of Medicine, University Of Belgrade, Belgrade, Serbia;Fondation Health Sciences e-Training, Lausanne, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Goeteborgs Universitet, Gothenburg, Sweden;Hibernia College, Dublin, Ireland;International Federation of Associations of Pharmaceutical Physicians, Woerden, Netherlands;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska University Hospital, Stockholm, Sweden;King'S College London, London, United Kingdom;Kobenhavns Universitet, Copenhagen, Denmark;Medicines and Healthcare products Regulatory Agency, London, United Kingdom;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Orion Oyj, Espoo, Finland;PHARMED asbi, Brussels, Belgium;PME Institute for Education in Pharmaceutical Medicine, Witten, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;PharmaTrain Federation, Basel, Switzerland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Semmelweis Egyetem, Budapest, Hungary;Stichting Lygature, Utrecht, Netherlands;Swissmedic, Berne, Switzerland;The Faculty Of Pharmaceutical Medicine Of The Royal Colleges Of Physicians Of The United Kingdom Lbg, London, United Kingdom;Trinity College Dublin, Dublin, Ireland;UCB Pharma SA, Brussels, Belgium;Universidad Autonoma De Barcelona, Bellaterra, Spain;Universidad Pompeu Fabra, Barcelona, Spain;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universitaetsklinikum Essen, Essen, Germany;Universitaetsklinikum Freiburg, Freiburg, Germany;Universitat Basel, Basel, Switzerland;Universitat De Barcelona, Barcelona, Spain;Universitat Wien, Vienna, Austria;Universite Louis Pasteur, Strasbourg, France;Universite Lyon 1 Claude Bernard, Villeurbanne, France;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University Of Surrey, Guildford, United Kingdom", 'status': 'Closed'}, {'id': '0', 'name': 'PIONEER', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pioneer', 'summary': 'Prostate cancer is the second most common cancer in men, and accounts for 9 % of all cancer deaths in men. Currently, it is hard to predict which patients will respond best to different treatments, and which patients can be managed safely without undergoing treatment. The aim of PIONEER is to use big data to address key knowledge gaps related to the screening, diagnosis and treatment of prostate cancer patients. To do this, they will standardise and integrate existing ‘big data’ from sources such as clinical trials and electronic health records into a single, innovative data platform. The project will draw on this database to identify ways to improve prostate cancer outcomes and health system efficiency. The project will apply FAIR (‘findable, accessible, interoperable, and reusable’) principles to the data. Ultimately, the project results should feed back into clinical centres so that patients can benefit from the best possible care.\nPIONEER is part of IMI’s Big Data for Better Outcomes (BD4BO) programme.\n', 'tags': 'Prostate cancer diagnosis and treatment enhancement through the power of big data in Europe', 'participants': "Association Eisbm, Vourles, France;Astellas Pharma Europe BV, Leiden, Netherlands;Bayer Aktiengesellschaft, Leverkusen, Germany;Covance Laboratories LTD, Harrogate, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Alliance For Personalised Medicine Asbl, Brussels, Belgium;European Cancer Patient Coalition, Brussels, Belgium;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Goeteborgs Universitet, Gothenburg, Sweden;Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden;Imperial College Of Science Technology And Medicine, London, United Kingdom;Ims Information Solutions Medical Research Limited, London, United Kingdom;International Consortium For Healthoutcomes Measurement LTD, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;King'S College London, London, United Kingdom;Lunds Universitet, Lund, Sweden;Nv SAS Institute SA, Tervuren, Belgium;Orion Oyj, Espoo, Finland;Pinsent Masons Llp, London, United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting European Urological Foundation, Arnhem, Netherlands;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Tampereen Korkeakoulusaatio Sr, Tampere, Finland;Tampereen Yliopisto, Tampere, Finland;Technische Universitaet Dresden, Dresden, Germany;The Ecancer Global Foundation, Bristol, United Kingdom;The Hyve BV, Utrecht, Netherlands;The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom;Ttopstart BV, Bilthoven, Netherlands;Universita Vita-Salute San Raffaele, Milano, Italy;Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany;Weizmann Institute Of Science, Rehovot, Israel", 'status': 'Ongoing'}, {'id': '0', 'name': 'PRECISESADS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/precisesads', 'summary': 'Chronic inflammatory autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are found in 1-3% of the general population. They are particularly prevalent in women, with SLE affecting nine times more women than men. Symptoms of these diseases can be severe, and patients need regular check-ups. For example, symptoms of lupus include painful, swollen joints, fever, rashes, fatigue, and sensitivity to the sun. There are few treatments available for these diseases; most receive steroids, which are associated with serious side effects including an increased propensity to infections, osteoporosis, and cardiovascular disease.\nIn addition, these diseases are difficult to diagnose early enough in the disease process to prevent severe or even fatal outcomes. In some cases, it can take – six to eight years from the onset of symptoms to arrive at a diagnosis. This can also have a significant impact on the psychological well-being of the patient.\nNew and promising biological treatments are being developed for SLE, but it is not always clear which lupus patients will benefit from which treatment, plus separate disease classification means that they cannot be used to treat other autoimmune diseases which researchers believe share a similar molecular basis. In fact, the pharmaceutical companies face major problems in trying to identify tests to determine the usefulness of drugs in clinical trials.\xa0\nA new classification of inflammatory diseases\nBy establishing a Europe-wide, large-scale team, PRECISESADS will provide new data to offer a more appropriate classification of these patients. The project will analyse in great detail blood and urine samples of 2 500 people with a range of systemic autoimmune diseases, as well as patients with suspected autoimmune disease who don’t have a diagnosis because they do not fulfil current clinical criteria for any of the systemic autoimmune diseases. Through the analysis of these patients’ data, the project hopes to be able to define clusters of individuals who share similar molecular pathways for their disease and so could be treated in a targeted and personalised way. By evaluating the molecular and clinical data using the latest technology, the project will deliver new biomarkers for use in more targeted clinical trials. Clinicians can then tailor therapies according to the specific molecular pathways found in individual cases. In short, treatments will become more personalised.\nTowards targeted treatments\nA personalised approach to the treatment of autoimmune diseases would allow patients to receive an earlier and more accurate diagnosis. Since the new data will reveal the molecular mechanisms specific different groups of diseases, a tailored approach to clinical therapy can be identified and the precise molecular pathway can then be targeted. What’s more, earlier detection and more effective treatments will mean that the damaging effects of a late diagnosis can be avoided, and the patient’s disease progression can be better controlled.\xa0\nSharing data to move forward\nPRECISESADS brings together industry experience with academic and clinical expertise in the fields of genetics, metabolomics, mass spectrometry, rheumatology, and autoimmunology. The project will provide an advantage for the European pharmaceutical industry through the unique possibility of sharing new and existing data and findings on an unprecedented scale for these diseases. The expertise of the pharmaceutical industry is essential, as they have important knowledge of prior failures in this disease area and understand the urgent need to overcome the problem of the inappropriate classification of patients.\nBy pooling existing data and using cutting-edge technologies, the project will help to pave the way for more effective and earlier treatment of these debilitating and dangerous autoimmune diseases. The research being undertaken has always been seen as necessary but sufficient funding and a collaborative model has only now become possible through IMI. This is a unique research project will directly benefit from advances in technology and will ultimately deliver results at the patient’s bedside.\xa0\n', 'tags': 'Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases', 'participants': "Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain;Atrys Health, SA, Madrid, Spain;Bayer Aktiengesellschaft, Leverkusen, Germany;Centre Hospitalier Regional Et Universitaire De Brest, Brest, France;Centro Hospitalar Universitario Do Porto Epe, Porto, Portugal;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy;Fundacio Institut D'Investigacio Biomedica De Bellvitge, Hospitalet De Llobregat, Spain;Fundacion Publica Andaluza Progreso Y Salud, Seville , Spain;Institut De Recherches Internationales Servier Iris, Suresnes, France;Karolinska Institutet, Stockholm, Sweden;Katholieke Universiteit Leuven, Leuven, Belgium;Klinikum Der Universitaet Zu Koeln, Cologne, Germany;Medizinische Hochschule Hannover, Hannover, Germany;Medizinische Universitaet Wien, Vienna, Austria;Quartz Bio S.A., Plan-les-Ouates, Switzerland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Servicio Andaluz De Salud, Sevilla, Spain;Servicio Cántabro de Salud, Santander, Spain;Szegedi Tudomanyegyetem, Szeged, Hungary;The Cyprus Foundation For Muscular Dystrophy Research, Nicosia, Cyprus;UCB Biopharma SRL, Brussels, Belgium;Universidad De Granada, Granada, Spain;Universita Degli Studi Di Milano, Milano, Italy;Universite Catholique De Louvain, Louvain-La-Neuve, Belgium;Universite De Bretagne Occidentale, Brest, France;Universite De Geneve, Genève 4, Switzerland", 'status': 'Closed'}, {'id': '0', 'name': 'PREDECT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/predect', 'summary': "Laboratory tests are insufficiently predictive of cancer drugs’ activity in humans. The rate of failure to take novel drugs from the laboratory to humans, and then to registration for clinical use, has been very high. According to some estimates, between 90 and 95 per cent of drugs that went into clinical trials had no to only marginal effect on patients’ tumours. One of the reasons for that is that cancer is a very complex disease, both genetically and in terms of the tumour's interaction with the body. The models which scientists have been using in the laboratory to predict the success of a cancer drug in patients do not capture that complexity. IMI’s PREDECT project set out to change that.\nBy bringing together top researchers from nine pharmaceutical companies, eight academic institutions and three SMEs, the project developed and characterised new laboratory models which should better capture the complexity of the disease and so predict drug efficacy more reliably. This could eventually lead to a lower failure rate in the development of new cancer drugs for the benefit of patients.\nModels that capture tumour architecture\nThe most common way of investigating tumours in the laboratory is by growing cancer cells on plastic dishes. However, this method captures neither the three-dimensional architecture of tumours, nor their heterogeneity, nor the interactions between cells and their surroundings.\nIn order to better capture the three-dimensional nature of cancers, PREDECT project scientists further developed and reciprocally compared an array of spheroid models of tumour cells, as well as models generated from freshly collected tumour tissue. As an extension of this effort, the project initiated a biennial conference called ‘Goodbye Flat Biology’, under the auspices of the European Association of Cancer Research (EACR), to promote a continued dissemination of the concept that architectural aspects of cancer are very important in building good models.\nReducing use of animals in research\nOther important tumour aspects are that they are genetically diverse and that they are in constant interaction with their host. In order to capture that heterogeneity within the native microenvironment of the tumour, PREDECT project scientists developed a method to obtain very thin slices of tumours. These slices capture the complexity that is so essential for validating that a particular drug is going to work in the future.\nThe tumour slicing method developed by the project significantly reduces the use of animals and required research time. Whereas in the past 18 animals had to be used to obtain 18 tumour samples, now 18 to 20 slices can be obtained from a single tumour. For this work, PREDECT scientists won one of AstraZeneca’s awards for the use of tumour slices as an innovative in vitro platform to reduce animal use.\n‘Game-changer’ in breast cancer research\nThe project also developed a much-improved animal model to study oestrogen-receptor positive breast cancer, one of the most commonly diagnosed breast cancers. Experts wrote that this model was a ‘game-changer’, with the potential to lead to new treatments. The academic partners who developed this model now organise a course on this technique to enable other researchers to use it.\nTransfer of technology and other accomplishments\nIn addition to the successes mentioned above, other top project outputs include:\na collection of open access papers, four of which include detailed protocols on the making of new laboratory models developed within the project;\na collection of more than 30 000 images generated from a series of 16 oncology marker stainings done on all models created within the project - there are plans to make these available to the research community in the future;\ntransfer of important technology, from SMEs and academia to pharma companies, which could increase the industry’s success in the development of future drugs.\nFor the benefit of industry, academia, SMEs\nThe academic community is benefiting from gaining a deeper understanding of challenges in the development of complex cancer models, and from the new models which were created within the project. Thanks to this project, they also gained a better understanding of the thinking, constraints and needs of the industry.\nIndustry, academia and SMEs are benefitting from the transfer of technology which occurred within the project. For example, a Portuguese SME transferred their bioreactor technology to pharma companies. Thanks to this, pharma companies changed the way they work, and the SME expanded its business and gained important new customers.\nThe pharmaceutical industry is also benefitting from other technologies and models developed within the project, including tumour slices, as well as a range of 3D and animal models.\nAll project participants are also benefitting from the collaborative network which was established as part of the project.\nWhat's next?\nAlthough this project achieved significant breakthroughs, there are still many questions left unanswered. The knowledge and insights gained during the project have solidified new collaborations, and may also lead to new projects in the future.\nRead the interview with the project coordinators\n", 'tags': 'New models for preclinical evaluation of drug efficacy in common solid tumours', 'participants': 'Abbvie Inc, North Chicago, Illinois, United States ;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Biomedicum Genomics Ltd, Helsinki, Finland;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Cardiff University, Cardiff, United Kingdom;Charles River Discovery Research Services Germany GMBH, Freiburg, Germany;Ecole Polytechnique Federale De Lausanne, Lausanne, Switzerland;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;F. Hoffmann-La Roche AG, Basel, Switzerland;Institut De Recherches Servier, Suresnes, France;Instituto De Biologia Experimental E Tecnologica, Oeiras, Portugal;Janssen Pharmaceutica Nv, Beerse, Belgium;Orion Oyj, Espoo, Finland;Robert Bosch Gesellschaft Fur Medizinische Forschung Mbh, Stuttgart, Germany;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Tartu Ulikool, Tartu, Estonia;University of Helsinki, University of Helsinki, Helsinki, Finland;Weizmann Institute Of Science, Rehovot, Israel', 'status': 'Closed'}, {'id': '0', 'name': 'PREDICTTB', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/predict-tb', 'summary': 'Tuberculosis (TB) is the single biggest killer among infectious diseases, particularly in developing countries. It infects over 10 million people worldwide every year and kills 1.7 million. Treatment takes at least six months, it usually involves a combination of 4-7 drugs, and many patients struggle to take their antibiotics properly, fuelling the rise of drug-resistant strains of the disease. Despite all this, few new drugs for TB have been developed and registered since the 1970s.\nBy bringing together academic researchers with expertise in the biology, immunology and imaging of the disease, as well as industry scientists specialising in drug development, IMI’s PreDiCT-TB project set out to speed up the search for new, more effective combinations of treatments to tackle this deadly disease. In particular, the project aimed to evaluate and improve the effectiveness of preclinical laboratory models in predicting the success of drug candidates in clinical trials, which has been a major bottleneck in TB drug development.\nComparison of preclinical and clinical data\nIn order to achieve that, the project created a large database of preclinical data with many different preclinical models, from simple experiments in broth through to animal models – the largest and most diverse preclinical dataset available in TB to date. The project team also undertook a comprehensive review of published data from clinical trials, and created a large database containing 31 clinical trials with more than 15 000 participants.\nFurthermore, PreDiCT-TB scientists performed the first systematic quantitative comparisons of preclinical and clinical results in order to evaluate how effective different preclinical models are in predicting the success of drug candidates in clinical trials. The researchers took a mathematical modelling approach to integrating that information, putting it together in a way that can be used by drug developers to predict what will happen in clinical trials. Altogether, the project produced a series of tools, which drug developers can use to increase the probability of them choosing the right drug-like compounds and getting them through clinical trials successfully.\nNew biomarkers for diagnosing TB\nThe project also developed new biomarkers, which enable scientists to understand how the TB drug candidates work in preclinical and clinical trials. Currently scientists measure the effect of potential new treatments either by culturing TB bacteria from a patient-derived specimen, or by using DNA-based diagnostic tests. Growing a culture is very slow, taking up to three months before a result is available. DNA tests on the other hand are fast, but they remain positive even after the bacteria is dead, making them unsuitable for tracking the effectiveness of potential new treatments.\nA new method fine-tuned by the PreDiCT-TB project is based on measuring ribosomal RNA. The RNA is easy to detect even when there are very few organisms present, and unlike the DNA, it does not survive long after antibiotics kill the bug. The method, called the mycobacterial load assay (MBLA), offers a much faster way to diagnose tuberculosis and has the potential to improve both the speed and effectiveness of preclinical and clinical TB trials.\nReducing the use of animals in research\nPreDiCT-TB scientists have also done a lot of work to improve the design of preclinical studies and decrease the number of animals used when possible. Additionally, the project evaluated the effectiveness of different animal species in predicting the success of potential TB treatments. In some cases, this resulted in moving to the use of lower phylogenetic species such as zebrafish.\nFor example, one of the SMEs in the project developed a zebrafish high-throughput screening model. The model enables them to screen very large numbers of TB drugs, and combinations of drugs, very efficiently. The tool may become very valuable in early phases of clinical development.\nFor the benefit of industry, academia and SMEs\nThe industry benefited from the new resources and tools developed within the project, which they could not have developed on their own. They also benefited from the network of TB scientists, which will continue to exist beyond the lifetime of the project.\nThe academic community likewise benefitted from contacts with the pharmaceutical industry and SMEs, as well as from access to industry data and compounds. Thanks to this project, they learned a great deal about the drug development process and gained an understanding of how their models and skills could be used to enable better and faster drug development.\nThe SMEs in the project also benefitted from the network and resources within the project. Furthermore, contacts with the pharmaceutical industry enabled them to learn about the needs of their customers and gave them the necessary support and insights to develop and optimise important preclinical tools, such as the zebrafish high-throughput screening model.\nWhat’s next\nAll of the key resources generated by the project are, or soon will be, publicly available. The databases of preclinical data and clinical data – both of which are a key resource for the wider TB drug development community – have permanent homes that will be funded for at least the next decade.\nSome of the technologies developed within the project, such as the MBLA, have been made available to any external scientific group at a cost. Finally, a lot of the code base for many of the modelling and simulation tools that have been developed will be soon available through publicly accessible websites.\nRead the interview with project coordinators\n', 'tags': 'Model-based preclinical development of anti-tuberculosis drug combinations', 'participants': "Department of Health, Leeds, United Kingdom;Ecole Polytechnique Federale De Lausanne, Lausanne, Switzerland;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Glaxosmithkline Investigacion Y Desarrollo SL, Tres Cantos, Spain;Institut Pasteur, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Liverpool School Of Tropical Medicine, Liverpool, United Kingdom;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Microsens Medtech Ltd, London, United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;St George'S Hospital Medical School, London, United Kingdom;Stichting Vumc, Amsterdam, Netherlands;The University Court Of The University Of St Andrews, St Andrews, Fife, United Kingdom;The University Of Liverpool, Liverpool, United Kingdom;The University Of Sussex, Brighton, United Kingdom;Universidad Carlos Iii De Madrid, Getafe (Madrid), Spain;University College London, London, United Kingdom;University Of Leicester, Leicester, United Kingdom;Uppsala Universitet, Uppsala, Sweden;Zf-Screens BV, Leiden, Netherlands", 'status': 'Closed'}, {'id': '0', 'name': 'PREFER', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/prefer', 'summary': 'Patient perspective is important in all medical research and particularly in drug development. The PREFER project aims to assess when and how patient preferences on benefits and risks should be incorporated into decisions on medicinal products. While industry, regulatory authorities, health technology assessment bodies, reimbursement agencies and patient organisations all agree that patient preferences are very valuable, there is little guidance on conducting and using such studies. The goal of PREFER will be to provide a set of systematic methodologies and recommendations to assess, engage and include patient perspectives during the development, approval, and post-approval of new therapies. PREFER brings together experts from academic research institutions, pharmaceutical companies, patient organisations, a health technology assessment body, and small and medium-sized enterprises. In addition the consortium has set up stakeholder advisory groups to work closely with patients, regulators, health technology assessment (HTA) bodies and payers, to ensure that recommendations are evidence based, relevant and useful.\n', 'tags': 'Patient Preferences in benefit risk assessments during the drug life cycle', 'participants': 'AbbVie Ltd, Maidenhead, United Kingdom;Actelion Pharmaceuticals LTD, Allschwil, Switzerland;Amgen Limited, Cambridge, United Kingdom;Astellas Pharma Europe BV, Leiden, Netherlands;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Centre Federal D\'Expertise Des Soins De Sante, Brussels, Belgium;Csl Behring GMBH, Marburg, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Erasmus Universiteit Rotterdam, Rotterdam, Netherlands;European Cancer Patient Coalition, Brussels, Belgium;European Patients’ Forum (EPF), Brussels, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Forum Des Patients Europeens, 1040, Belgium;Instituto Tumori "Giovanni Paolo Ii", Bari, Italy;International Alliance Of Patient\'Organizations, London, United Kingdom;Istituto Europeo Di Oncologia SRL, Milan, Italy;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Mindbytes, Merksplas, Belgium;Muscular Dystrophy Group Of Great Britain And Northern Ireland, London, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Steinbeisser Project Management Ug (Haftungsbeschrankt), Munich, Germany;Takeda Development Centre Europe LTD, London, United Kingdom;The University Of Birmingham, Birmingham, United Kingdom;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitatsklinikum Erlangen, Erlangen, Germany;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;Uppsala Universitet, Uppsala, Sweden', 'status': 'Ongoing'}, {'id': '0', 'name': 'PREMIER', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/premier', 'summary': 'Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). However, so far just a handful of the 1900 or so active pharmaceutical ingredients (APIs) in use have been assessed.\nThe aim of PREMIER is to deliver a framework for assessing and characterising the environmental risks of APIs. This framework could be used to prioritise and screen older (‘legacy’) APIs that have never been through an ERA. It could also be used to pick up potential environmental risks in new APIs that are still under development.\nPREMIER also hopes its work will contribute to greener drug design in general, and help to make environmental data on APIs more visible and accessible to all stakeholders.\n', 'tags': 'Prioritisation and risk evaluation of medicines in the environment', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;ECOLOGIC INSTITUT gemeinnützige GmbH, Berlin, Germany;Ect Oekotoxikologie GMBH, Flörsheim a.M., Germany;Eidgenoessische Anstalt Fuer Wasserversorgung Abwasserreinigung Und Gewaesserschutz, Duebendorf, Switzerland;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Goeteborgs Universitet, Gothenburg, Sweden;Institut De Recherches Internationales Servier Iris, Suresnes, France;Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy;Leuphana Universitat Luneburg, Luneburg, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novartis Pharma AG, Basel, Switzerland;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Simomics Limited, York, United Kingdom;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Team - It Research SL, Barcelona, Spain;The European Medicines Agency, Canary Wharf, London, United Kingdom;The University Of Exeter, Exeter, United Kingdom;University Of York, York, United Kingdom;University of Helsinki, University of Helsinki, Helsinki, Finland', 'status': 'Ongoing'}, {'id': '0', 'name': 'PRISM', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/prism', 'summary': 'Social withdrawal is a common early symptom of many neurological disorders, including schizophrenia, Alzheimer’s disease, and major depressive disorder. However, the underlying, biological causes of this symptom are still poorly understood and may differ from one disease to another. The PRISM project will carry out a range of tests, including blood tests, brain scans, and measures of behaviour, on patients with these all too common diseases in a bid to determine which biological parameters correlate with specific clinical symptoms, like social withdrawal. The hope is that the project’s findings will shed new light on the causes of mental illness and their symptoms and facilitate the development of much-needed new treatments.\n', 'tags': 'Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy;Biotrial, Rennes, France;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Concentris Research Management GmbH, Fürstenfeldbruck, Germany;Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain;Drug Target Id BV, Nijmegen, Netherlands;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Europese Federatie Van Familieverenigingen Van Psychiatrisch Zieke Personen Ivzw, Leuven, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Janssen Pharmaceutica Nv, Beerse, Belgium;Novartis Pharma AG, Basel, Switzerland;P1vital Limited, Wallingford, United Kingdom;P1vital Products Limited, Wallingford, United Kingdom;Rijksuniversiteit Groningen, Groningen, Netherlands;Sbgneuro LTD, Thame, United Kingdom;Stichting Buro Ecnp, Utrecht, Netherlands;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Stichting Vumc, Amsterdam, Netherlands;Takeda Development Centre Europe LTD, London, United Kingdom;The University Of Exeter, Exeter, United Kingdom;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands', 'status': 'Closed'}, {'id': '0', 'name': 'PROACTIVE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/pro-active', 'summary': 'Chronic Obstructive Pulmonary Disease (COPD) is one of the most prevalent chronic diseases, affecting 10% of people over the age of 50. The most common symptoms of COPD are breathlessness (shortness of breath), excessive sputum production, and a chronic cough. According to the World Health Organisation, 64 million people are affected worldwide and about 3 million died from the disease. Furthermore, WHO predicts it will become the third leading cause of death worldwide by 2030.\nPatients with COPD often reduce their physical activity and their normal way of life because of unpleasant symptoms associated with the disease. Even though a lack of physical activity is one of the most common predictors of mortality, before PROactive there were no valid tests to measure the impact of the disease on physical activity levels and related dimensions (e.g. the symptoms experienced during physical activity). The commonly used lung function tests for COPD provide only limited information on the progression of the disease and the patients’ quality of life. Exercise tests, on the other hand are more an assessment of the capacity of the patient, rather than of the problems patients experience in their daily lives.\nAn innovative tool which simplifies the lives of patients\nBy following guidelines outlined by the regulatory authorities, the PROactive project developed innovative patient reported outcome (PRO) tools to measure patients’ experience of physical activity in terms of ‘amount’ of activity and ‘difficulty’. They did this in an innovative way by merging questions about patients’ experience of physical activity with information obtained through wearable physical activity monitors. This is not only an innovation but also a simplification in the PRO field which makes the life of patients easier: they have to answer only a few relevant questions and the rest is recorded via activity monitors sensitive enough to capture the activity of COPD patients. Moreover, the questionnaires were developed by patients and are therefore written in the language of patients, making them easy to use and understand.\nIn order to ensure the robustness of the new PRO tools, the consortium tested them in a heterogeneous group of more than 1000 patients in five EU languages. All the data gathered has been submitted to the European Medicines Agency for the qualification procedure of novel drug development methodologies. If accepted by the regulators, these new PRO tools would enable pharmaceutical companies and others to use them in clinical trials to assess the effectiveness of new treatments on physical activity. Such therapies could be drugs, but also non-pharmacological interventions such as rehabilitation.\nIn the meantime, the tool is already being used for research purposes by partners in the project, and at least one company outside of the consortium. Furthermore, more than 50 culturally sensitive translations are already available for use in global research.\nPutting physical activity higher on the agenda\nWhile the development of the PRO tools is the most significant project achievement, the project also contributed to the field in other ways.\nIt helped clarify the role that physical inactivity plays in COPD and put it higher on the agenda of patient organisations, researchers and clinicians. Patients are already experiencing benefits, as clinicians are increasingly recognising that tackling physical inactivity should be one of the key targets in the management of this disease.\nWhile some activity monitors are valid tools to get insight in the amount of physical activity patients engage in, this project has shown that they are not enough to capture the physical activity experience of patients suffering from COPD. They need to be combined with questions providing further insight into how patients experience physical activity.\nThe project developed a methodology for evaluating activity monitors to identify those sensitive enough to measure physical activity in patients with a chronic disease such as COPD. Three such monitors were identified and two of these extensively used. Furthermore, the project developed the know-how on processing, standardising and analysing data from activity monitors, so this data can be successfully used in clinical trials.\nIt developed several new, innovative interventions for COPD patients, such as a tele-coaching method to boost patients’ activity levels. A short term multi-centre study showed that this tele-coaching intervention significantly increases the level of physical activity in COPD patients, opening up pathways for further research.\nFor the benefit of industry, academia and patients\nPROactive’s new tools will provide drug companies with new ways of assessing the clinical benefits of novel treatments on the physical activity in COPD patients. The tools will also benefit patients by helping them evaluate the improvements or deterioration in their physical activity experience, including the effect of new treatments on this important aspect of their lives. Finally, participation in PROactive enabled academic researchers to master scientific rigour needed to develop such PRO tools, raising their profile in the field and helping them build a valuable network for future research.\nWhat happens next?\nEven though the project has officially ended, the project participants signed a memorandum of understanding to stay together and continue to develop their tools. The idea is to oversee future uses of the tools, such as translations to other languages and the development of the tools in other chronic disease areas.\xa0\nRead the interview with the project coordinators\n', 'tags': 'Physical Activity as a Crucial Patient Reported Outcome in COPD ', 'participants': 'Academisch Ziekenhuis Groningen, Groningen, Netherlands;Almirall SA, Barcelona, Spain;Astrazeneca AB, Södertälje, Sweden;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;British Lung Foundation, London, United Kingdom;Chiesi Farmaceutici S.A, Parma, Italy;Choice Healthcare solutions Ltd, Hitchin, Hertfordshire, United Kingdom;European Respiratory Society, Lausanne, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;IS GLOBAL - Barcelona Institute for Global Health, Barcelona, Spain;Katholieke Universiteit Leuven, Leuven, Belgium;Netherlands Asthma Foundation, Leusden, Netherlands;Novartis Pharma AG, Basel, Switzerland;Royal Brompton And Harefield National Health Service Trust, South Kensington, United Kingdom;The University Of Edinburgh, Edinburgh, United Kingdom;Thorax Research Foundation, Kolonaki, Athens Greece, Greece;UCB Pharma SA, Brussels, Belgium;Universitat Zurich, Zürich, Switzerland', 'status': 'Closed'}, {'id': '0', 'name': 'PROTECT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/protect', 'summary': "Read about the project's achievements in the public summary\xa0of the project's final report.\n", 'tags': 'Pharmacoepidemiological research on outcomes of therapeutics by a European consortium', 'participants': "Aarhus Universitet, Aarhus C, Denmark;Academisch Ziekenhuis Groningen, Groningen, Netherlands;Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain;Amgen, Brussels, Belgium;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Department of Health, Leeds, United Kingdom;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Fundacio' Institut Català de Farmacologia, Barcelona, Spain;Fundación Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain;Genzyme Europe B.V., Naarden, Netherlands;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut Catala De La Salut, Barcelona, Spain;Institut National De La Sante Et De La Recherche Medicale, Paris, France;International Alliance of Patients’ Organizations, London, United Kingdom;Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy;L.A Sante, Epidemiologie, Evaluation Et Recherche L.A.S.E.R., Paris, France;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Lægemiddelstyrelsen, Copenhagen S, Denmark;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Outcome Europe Sarl, St. Prex, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Private Universitaet Witten/Herdecke gGmbH, Witten, Germany;Quintiles Benefit France Inc, Levallois Perret, France;Quintiles Limited, Reading, United Kingdom;Rijksuniversiteit Groningen, Groningen, Netherlands;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden;Takeda Development Centre Europe LTD, London, United Kingdom;The European Medicines Agency, Canary Wharf, London, United Kingdom;Universiteit Utrecht, Utrecht, Netherlands;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;Uniwersytet Medyczny Im Karola Marcinkowskiego W Poznaniu, Poznan, Poland", 'status': 'Closed'}, {'id': '0', 'name': 'QUICCONCEPT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/quic-concept', 'summary': 'Background\nA good imaging biomarker shows evidence of a drug’s activity before the benefit to the patient is evident. Although imaging biomarkers are already used in cancer treatment and research, few are considered to be sufficiently reliable as to be used as a matter of routine. This project set out to get definitive evidence as to the usefulness of three different imaging biomarkers in determining whether a drug is having the effect of either forcing cell death (necrosis), encouraging tumour cells to shut themselves down and die (apoptosis), or reducing tumour cell proliferation. These three phenomena constitute the goal of many cancer drugs in development; if pharma companies could have confidence that imaging could offer reliable evidence of them, it would help them to make decisions about whether a treatment under development is worth pursuing. Likewise, if doctors could have confidence in the reliability of the biomarkers from a scan, they would be able to make crucial decisions about stopping ineffective drugs, often being administered to patients who don’t have long left to live.\nThe clinical trials\nTumours in the lung and liver were chosen as the targets for the QUIC-CONCEPT clinical trials. The reason for this is that cancer often spreads (metastasises) to these organs. Drug therapy is particularly appropriate for metastatic disease, because radiotherapy or surgery are generally less effective against metastatic tumours than primary tumours.\xa0\nThe team studied three imaging biomarkers. One was studied for its ability to indicate cell death (ADC MRI, or apparent diffusion coefficient as seen via magnetic resonance imaging); another for its ability to indicate reduced rate of cell proliferation (FLT PET, using the tracer fluorothymidine F-18 and positron emission tomography scan); and finally, one that would measure apoptosis (ICMT11 PET, another tracer material used in conjunction with a PET scan). Patients underwent scans before taking a treatment and then again a set period of time afterwards, to see if the imaging could offer reliable indications of the activity of the drug.\nIn the case of ADC MRI, which involves watching for signs that water molecules can move freely around the tumour, suggesting the drug had caused cell death; although the ADC value did increase, as expected, with treatment, the team found weak evidence that it is a reliable or effective imaging biomarker of necrosis. The fact that it disproved the assumption that it could be used as a marker for necrosis is itself a useful finding that will of particular help to drug developers. \xa0\nThe second method, which involved the injection of FLT and a PET scan, did indeed establish that this form of imaging biomarker could be used to reliably judge the effectiveness of the drug’s ability to reduce cell proliferation, as FLT uptake was found to decrease with effective treatment.\nThe study of the third imaging biomarker was ultimately unsuccessful. Apoptosis proved quite tricky to study as it occurs at a very specific time after the drug is given, otherwise the signal is weak and hard to measure. This work will make drug developers more cautious in deciding how to measure whether new drugs induce apoptosis.\xa0\xa0\nThe team also undertook comprehensive studies in tumours in rodent models, as these are often used to help design and interpret clinical trials. One important finding was that the ADC biomarker was unexpectedly found to be a weak biomarker of necrosis (cell death), but a good biomarker of cellularity. In addition, the FLT biomarker signal quickly decreased in most cases where drugs were working, but importantly the team identified some particular types of drug which could give misleading results due to the so-called ‘flare’ effect, so FLT PET should definitely be avoided in such cases.\xa0\nLegacy of the project\nAt the outset of the project the team realised that, although patient scanning is almost universally used to assess whether drugs are working, only a very small variety of types of scanning are routinely used and trusted by doctors and drug developers. This is surprising because a huge variety of types of scanning, measuring different biological processes, has been developed in universities.\xa0 The team realised that in many cases these new types of scan have not been developed in the most useful way, and they developed a new ‘roadmap’ to help get these new scanning tools into use faster. This roadmap has already been widely adopted.\nOne of the reasons previous studies on imaging biomarkers were unreliable is that each study used its own protocol, making comparison very hard. QUIC-CONCEPT introduced standardisation of the studies across the multicentre study and across animal models and cancer patients. Regarding assets, the project left behind an imaging repository, which contained over 1,200 MRI scans, 600 PET images and datasets by the end of the project lifespan. These data still being worked on to gain new insights.\nOn average, it costs about one billion euro and takes about ten years to develop a cancer drug. The benefit to industry of the results of QUIC-CONCEPT is that they will help make decisions at phase one or phase two of clinical research as to whether to continue to the more expensive later phase trials. In this respect, the project achieved its goal.\nFor cancer patients, unfortunately, time is often quite short. Anything that helps oncologists cut down on the time spent treating patients with ineffective drugs is valuable. The project outcome can ultimately help primary care practitioners understand more about what tools can reliably be used to predict prognosis, choose the optimal treatment for each patient, and to monitor treatment to determine whether drugs, doses and schedules elicit a desired or undesired biological effect.\n', 'tags': 'Quantative imaging in cancer:connecting cellular process with therapy ', 'participants': "Amgen, Brussels, Belgium;Astrazeneca AB, Södertälje, Sweden;Eidgenoessische Technische Hochschule Zuerich, Zurich, Switzerland;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;F. Hoffmann-La Roche AG, Basel, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Keosys S.A.S., Saint-Herblain, France;King'S College London, London, United Kingdom;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Katholieke Universiteit, Nijmegen, Netherlands;Stichting Maastricht Radiation Oncology Maastro Clinic, Maastricht, Netherlands;Stichting Vumc, Amsterdam, Netherlands;The Institute Of Cancer Research: Royal Cancer Hospital, London, United Kingdom;The University Of Manchester, Manchester, United Kingdom;Universitair Ziekenhuis Antwerpen, Edegem, Belgium;University of Cambridge, Cambridge, United Kingdom;Westfaelische Wilhelms-Universitaet Muenster, Münster, Germany", 'status': 'Closed'}, {'id': '0', 'name': 'RADARAD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/radar-ad', 'summary': 'People in the earliest stages of Alzheimer’s disease experience declining cognitive and functional abilities, making it harder for them to remember things and places, carry out simple calculations, use a phone/computer, drive, and adhere to medications. The goal of the RADAR-AD platform is to develop a digital platform that would draw on smartphone, wearable and home-based digital technologies to track subtle changes in the cognitive and functional abilities of people with Alzheimer’s disease. The project will adapt the existing RADAR-CNS project’s platform for Alzheimer’s disease. Among other things, the team will have to take account of the fact that many people with Alzheimer’s disease are older and so may be less familiar with technology, while their condition may make it more difficult for them to learn to handle technological devices. People with Alzheimer’s disease will be fundamentally involved in the design and development of the project so that the systems put in place are acceptable and appropriate for them. The platform will be tested in a clinical study with people with different stages of Alzheimer’s disease. Ultimately, the project results will make it easier to assess how well new dementia treatments work.\n', 'tags': 'Remote assessment of disease and relapse – Alzheimer’s disease', 'participants': "Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands;Altoida AG, Luzern, Switzerland;Alzheimer Europe, Luxembourg, Luxembourg;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Software AG, Darmstadt, Germany;Stichting Lygature, Utrecht, Netherlands;Stichting Vumc, Amsterdam, Netherlands;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;The Hyve BV, Utrecht, Netherlands;University of Oxford, Oxford, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'RADARCNS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/radar-cns', 'summary': 'The RADAR-CNS project aims to develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. The key goal of the project is to improve patients’ symptoms and quality of life and also to change how these and other chronic disorders are treated.\nEpilepsy, depression, and multiple sclerosis are distinct disorders that affect 400 million people worldwide, with different causes and symptoms, all of which can be severely detrimental to patients’ quality of life and life expectancy. For all three disorders, patients often experience periods where their symptoms are manageable, followed by periods of deterioration and acute illness (relapse). Patient surveys have repeatedly highlighted the need to predict when relapses will happen and to improve the treatments which are available to stop them from occurring. Continuous remote assessment using smartphones and wearable devices provides a complete picture of a patient’s condition at a level of detail which was previously unachievable. Moreover, it could potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.\n', 'tags': 'Remote Assessment of Disease and Relapse in Central Nervous System Disorders', 'participants': "Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain;Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain;Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain;H. Lundbeck As, Valby, Denmark;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;King'S College London, London, United Kingdom;Msd Czech Republic Sro, Prague, Czech Republic;Northwestern University, Evanston, Illinois, United States ;Ospedale San Raffaele SRL, Milano, Italy;Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio- Fatebenefratelli, Brescia, Italy;Region Hovedstaden, Hilleroed, Denmark;Software AG, Darmstadt, Germany;Stichting Imec Nederland, Eindhoven, Netherlands;Stichting Lygature, Utrecht, Netherlands;Stichting Vumc, Amsterdam, Netherlands;The Hyve BV, Utrecht, Netherlands;The University Of Nottingham, Nottingham, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universita Vita-Salute San Raffaele, Milano, Italy;Universita' Degli Studi Di Bergamo, Bergamo, Italy;Universitaet Augsburg, Augsburg, Germany;Universitaetsklinikum Freiburg, Freiburg, Germany", 'status': 'Ongoing'}, {'id': '0', 'name': 'RAPIDCOVID', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/rapid-covid', 'summary': 'While the world focuses on COVID-19, other infectious diseases with similar symptoms continue to circulate. In fact, around 5 % of people with COVID-19 and 18 % of non-COVID patients have other infections. Rapidly identifying and diagnosing not only COVID-19, but other infections such as colds and the flu, will ensure that COVID-19 patients can be quickly isolated, limiting the spread of the disease. Furthermore, rapid diagnosis of infections besides COVID-19 will ensure that all patients receive the right treatments, and reduce the unnecessary use of antibiotics.\nThe aim of RAPID-COVID is to develop a diagnostic kit capable of simultaneously detecting SARS-CoV-2 (the virus that causes COVID-19) plus 30 other common respiratory bacteria and viruses. The consortium already has a prototype technology called MPA (Multiplex Probe Amplification), and the goal of the project is to validate this and get a CE mark for both point of care (PoC) and high throughput laboratory testing.\nA number of elements set the RAPID-COVID system apart from other tests. Firstly, the tests are run on one tube, instead of multiple tubes. Secondly, it is automated, meaning users can quickly process a large number of patient samples. Finally, its compact size means it does not take up a lot of space in the lab.\nThe project partners aim to commercialise the test for EUR 9 per test. Ultimately, they hope it will allow for accurate, cost-effective and comprehensive diagnoses during the current outbreak as well as future routine diagnosis\n', 'tags': 'Robust automation and point of care identification of COVID', 'participants': 'Agencia Publica Empresarial Sanitaria Costa Del Sol, Marbella Malaga, Spain;Assistance Publique Hopitaux De Paris, Paris, France;Biosistemika, Raziskave In Razvoj Doo, Ljubljana, Slovenia;Genefirst Limited, Abingdon, United Kingdom;Primadiag SAS, Romainville, France', 'status': 'Ongoing'}, {'id': '0', 'name': 'RAPPID', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/rapp-id', 'summary': 'An important unmet need\nExcellent care for people with suspected infections involves rapid diagnosis and treatment. For instance, administering the correct antibiotic as soon as possible to patients with blood infections dramatically improves their chances of survival. On the other hand, using antibiotics when they do not benefit patients exposes them unnecessarily to side effects and potential antibiotic resistance. Despite all the advances in medicine, we still do not have the technology available that can quickly diagnose what kind of infection a patient has and what treatment they need. Even the best of the currently available diagnostic methods are too slow to help clinicians.\nThe RAPP-ID project aimed to provide an integrated solution that addresses the technological challenges to enhance clinical decision-making and improve the quality of care and clinical outcomes for patients. More specifically, it aimed to develop rapid point-of-care platforms (POCTs) for the rapid detection of bacteria, tuberculosis bacteria, fungi, and viruses as well as patients’ markers of infection (less than 2 hours in hospitals, and less than 30 min in primary care).\nGood outcomes in spite of challenges\nDeveloping diagnostic tests for infectious diseases is very challenging, and due to limited time and resources, the project fell short of developing fully-fledged rapid diagnostic tests. However, some of the innovations and technologies developed within the project could speed up the development of such tests in the future. Furthermore, the project produced other resources and tools which could be useful for the future development of POCTs.\nDefining user requirements\nMany tests have been produced in the past that are miracles of bioengineering but have not provided clinicians with what they require for optimal care. In order to understand the requirements for these tests, the RAPP-ID team put a lot of effort into drawing up user specifications which outline what diagnostic tests for different infectious diseases should even look like. These guidelines could help anyone working on diagnostic tests for infectious diseases in the future.\nPrototype of the breath sampler\nAfter the user specifications were defined, the project team set out to develop some of the technologies needed to create rapid diagnostic tests. Perhaps the biggest and most innovative achievement of the project was the development of a prototype breath sampler for influenza. Patients exhale into the instrument, which captures tiny particles in their breath, and then uses that sample to detect the presence of pathogens. During the project, the team was able to demonstrate that the instrument is able to capture airborne pathogens, and started testing it on patients in the clinic. However, the technology is still in the relatively early stages of development, and would need more time and resources to be developed into a clinically validated test. This innovation is now part of\xa0IMI2 – Call 11\xa0on the sustainability of IMI project results and might be developed further by one of the winning consortia.\nChips for diagnosing pneumonia\nAnother important project achievement was the prototype of the ventilator-associated pneumonia (VAP) test. VAP is a very serious infection in people who are in intensive care. The illness has a very high death rate and diagnostic tests that could detect these bacteria quickly are urgently needed. The RAPP-ID project developed chips which help isolate the DNA of these bacteria from aspirates of VAP patients. As the amount of DNA which can be extracted from these bacteria is very low, the DNA from these samples had to be amplified before detection. The chip was aimed to run on an instrument making it a complete diagnostic test. Although nearly there, this device-chip combination would require a further software update to run autonomously – a process which could not be fully completed within the scope of the RAPP-ID project.\nOther achievements\nIn addition to the innovations mentioned above, the project developed many other resources and innovations which are now available for future research, including a technology for the acoustic manipulation of bacteria with the help of beads, and cell lines for various bacterial strains.\nFor the benefit of industry and academia\nThe academic community benefited from the project in several ways. First of all, they made big progress in developing some of their ideas for rapid diagnostic tests. Secondly, by interacting with other academic partners and industry, they were able to expand those ideas and add certain components to their technology platforms which they could not have developed on their own. The project also resulted in about 30 scientific publications, with more to come.\nThanks to RAPP-ID, both the pharmaceutical industry and academic partners learned about the challenges involved in developing diagnostic tests and bringing them to the market. As the first IMI project of this kind, RAPP-ID was in many ways a learning experience for everyone involved and could help enhance collaboration between the medicine and diagnostic worlds, shaping better EU-funded diagnostic projects in the future.\nAll of the partners in the project, including academia, industry and SMEs, also benefitted from the collaboration and new partnerships formed within the project. Some of these collaborations are continuing and have resulted in new spin out projects.\nFuture steps\nThe findings of the RAPP-ID project inspired at least two spin out projects funded by the EU. The first focused on urinary tract infections (UTIs) and developed a chip which can detect drug-resistant, UTI-causing bacteria. The chip is similar to the one developed in RAPP-ID for VAP.\nThe second spin out project, New diagnostics for infectious diseases (ND4ID), is a Marie Skłodowska -Curie project which will enable 15 PhD students to conduct their research at industry and academic laboratories across Europe. It will run until early 2020 and involves many of the RAPP-ID project partners.\nRead the interview with project coordinators\n', 'tags': 'Development of rapid point-of-care test platforms for infectious diseases ', 'participants': 'Cardiff University, Cardiff, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Glaxosmithkline Vaccines SRL, Siena, Italy;Interuniversitair Micro-Electronica Centrum, Leuven, Belgium;Janssen Pharmaceutica Nv, Beerse, Belgium;Katholieke Universiteit Leuven, Leuven, Belgium;Kungliga Tekniska Hoegskolan, Stockholm, Sweden;Lionex GMBH, Braunschweig, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Microfluidic Chipshop GMBH, Jena, Germany;Q-Linea AB, Uppsala, Sweden;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stockholms Universitet, Stockholm, Sweden;Universitair Ziekenhuis Antwerpen, Edegem, Belgium;Universite De Geneve, Genève 4, Switzerland;Universiteit Antwerpen, Antwerp, Belgium;Universiteit Gent, Gent, Belgium;Universiteit Twente, Enschede, Netherlands;University of Cambridge, Cambridge, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'RESCEU', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/resceu', 'summary': 'Respiratory syncytial virus (RSV) is not well known outside medical circles, yet most people have probably suffered from it in childhood, as it is the most common cause of severe respiratory illness in infants and children worldwide. The elderly and people with weakened immune systems are also vulnerable to RSV infection. While most people’s symptoms are mild, it can result in pneumonia and 3.4 million cases annually require hospitalisation. There is no specific treatment or vaccine for RSV. The goal of the RESCEU project is to gather information on the scale of RSV infection in Europe and its economic impacts. It will then use this information to design best practice guidelines to improve the way RSV cases are monitored in Europe, and to shape future vaccination programmes. The team will also gather and analyse patient samples to identify biological markers associated with severe RSV infection. This information could aid in diagnosis and facilitate the development of new treatments and vaccines.\n', 'tags': 'Respiratory syncytial virus consortium in Europe', 'participants': 'Academisch Ziekenhuis Groningen, Groningen, Netherlands;Astrazeneca AB, Södertälje, Sweden;Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Imperial College Of Science Technology And Medicine, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Novavax Inc, Gaithersburg, United States ;Pfizer Limited, Sandwich, Kent , United Kingdom;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Sanofi Pasteur SA, Lyon, France;Servizo Galego De Saude, Santiago de Compostela, Spain;Statens Serum Institut, Copenhagen S, Denmark;Team - It Research SL, Barcelona, Spain;The University Of Edinburgh, Edinburgh, United Kingdom;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universiteit Antwerpen, Antwerp, Belgium;University of Oxford, Oxford, United Kingdom;Varsinais-Suomen Sairaanhoitopiirin Kuntayhtyma, Turku, Finland', 'status': 'Ongoing'}, {'id': '0', 'name': 'RESOLUTE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/resolute', 'summary': 'Transport proteins are the gate-keepers of our cells, effectively controlling the flow of nutrients and other molecules across the cell membrane. With over 400 members, solute carriers represent the largest class of transport proteins. Yet although they have been implicated in diseases ranging from Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) to schizophrenia, solute carriers have never been studied in detail.\nThe ReSOLUTE project aims to change that, by intensifying research in, and advancing our knowledge of, the solute carrier family. Specifically, the project partners plan to deliver practical research tools, protocols, databases and platforms on solute carriers. The project’s open access ethos means the results will be of benefit to researchers in universities as well as small and large biotech companies worldwide. Ultimately, the project results will aid in the identification of solute carriers that could be used as either drug targets or as pathways for enabling the transport of medicines into specific tissues.\n', 'tags': 'Research empowerment on solute carriers', 'participants': 'Axxam S.A, Bresso (Milan), Italy;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Cemm - Forschungszentrum Fuer Molekulare Medizin GMBH, Vienna, Austria;Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;The University Of Liverpool, Liverpool, United Kingdom;Universitat Wien, Vienna, Austria;Universiteit Leiden, Leiden, Netherlands;University of Oxford, Oxford, United Kingdom;Vifor (International) AG, St. Gallen, Switzerland', 'status': 'Ongoing'}, {'id': '0', 'name': 'RESPIRINTM', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/respirintm', 'summary': 'Non-tuberculous mycobacteria (NTM) cause lung diseases that look like (but are not) tuberculosis (TB), mainly in people with weakened immune systems or patients with other lung diseases such as cystic fibrosis. NTM infections are caused by bacteria such as Mycobacterium avium complex and Mycobacterium abscessus, both of which are related to the TB-causing bacteria Mycobacterium tuberculosis. Cases of NTM disease are on the rise worldwide, and in regions where TB is largely under control, NTM is much more common than TB. Although treatments exist for the most common NTM infections, they do not always work well, and the complex treatment regimen can last as long as two years. Studies have shown that there are now cases of multi-drug resistant NTM. The goal of RespiriNTM is to find new drug candidates that could be part of a new, more efficient drug regimen for NTM with a shorter treatment time. The team will focus its efforts on the respiratory pathway of the bacteria that cause the disease. They will also carry out research to identify new drug targets that could be used to attack NTM bacteria. Finally, the team will study the factors that allow NTM bacteria to survive in humans.\nRespiriNTM is part of the IMI AMR Accelerator Programme.\n', 'tags': 'Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Ffund BV, Amsterdam, Netherlands;Janssen Pharmaceutica Nv, Beerse, Belgium;Kobenhavns Universitet, Copenhagen, Denmark;Medizinische Universitaet Wien, Vienna, Austria;Mitologics, Romainville, France;Sorbonne Universite, Paris, France;Universiteit Antwerpen, Antwerp, Belgium;Universiteit Leiden, Leiden, Netherlands', 'status': 'Ongoing'}, {'id': '0', 'name': 'RESPIRITB', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/respiritb', 'summary': 'In 2017, an estimated 558 000 new cases of drug-resistant tuberculosis (TB) were diagnosed; most of these (82 %) were multidrug-resistant (MDR), meaning they are resistant to at least two of the most effective, front line antibiotics used to treat TB. MDR-TB is extremely difficult to treat; a full course of antibiotics can last up to two years, and trigger unpleasant side effects. Moreover, the drugs used are expensive, and are not always available. The goal of RespiriTB is to advance the development of new drug candidates that could be part of a new, more effective, shorter regimen to treat MDR-TB. The team is particularly interested in compounds that interfere with the TB bacterial energy metabolism. The project will carry out a range of studies on the drug candidates selected, including initial clinical studies in humans. Ultimately, the project hopes to contribute to the development of a new, more efficient combination drug regimen for MDR-TB, with a shorter treatment duration and a lower risk of further drug resistance.\nRespiriTB is part of the IMI AMR Accelerator Programme.\n', 'tags': 'Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Ffund BV, Amsterdam, Netherlands;Janssen Pharmaceutica Nv, Beerse, Belgium;Kobenhavns Universitet, Copenhagen, Denmark;Medizinische Universitaet Wien, Vienna, Austria;Mitologics, Romainville, France;Sorbonne Universite, Paris, France;Universiteit Antwerpen, Antwerp, Belgium;Universiteit Leiden, Leiden, Netherlands', 'status': 'Ongoing'}, {'id': '0', 'name': 'RHAPSODY', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/rhapsody', 'summary': 'Improving diabetes prevention and treatment is the ultimate goal of the RHAPSODY project. Type 2 diabetes affects 285 million people globally and that number is rising fast. RHAPSODY brings together experts from universities, large pharmaceutical companies and biotechs.\nTheir goal is to add to our understanding of the factors that drive the progression of pre-diabetes to diabetes, and the deterioration of the condition of people with diabetes. RHAPSODY aims to develop novel biological markers that will aid in the diagnosis of type 2 diabetes, and the identification of different sub-groups of patients.\nThis information will also help to inform clinical trial design and the development of new strategies to prevent and treat diabetes.\n', 'tags': 'Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification', 'participants': 'Academisch Ziekenhuis Groningen, Groningen, Netherlands;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino, Torino, Italy;Centre Hospitalier Regional Et Universitaire De Lille, Lille, France;Centre National De La Recherche Scientifique Cnrs, Paris, France;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut De Recherches Servier, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Itä-Suomen yliopisto, Kuopio, Finland;Janssen Pharmaceutica Nv, Beerse, Belgium;Kobenhavns Universitet, Copenhagen, Denmark;Lipotype, Dresden, Germany;Lunds Universitet, Lund, Sweden;Novo Nordisk A/S, Bagsvaerd, Denmark;Rijksuniversiteit Groningen, Groningen, Netherlands;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Sciprom SARL, St-Sulpice, Switzerland;Stichting Vumc, Amsterdam, Netherlands;Technische Universitaet Dresden, Dresden, Germany;Universita Di Pisa, Pisa, Italy;Universite De Lausanne, Lausanne, Switzerland;Universite De Lille, Lille, France;Universite De Paris, Paris, France;Universite Paris Diderot - Paris 7, Paris, France;University Of Dundee, Dundee, United Kingdom;University of Oxford, Oxford, United Kingdom;Université Libre de Bruxelles, Bruxelles, Belgium', 'status': 'Ongoing'}, {'id': '0', 'name': 'ROADMAP', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/roadmap', 'summary': 'Alzheimer’s disease is on the rise in our ageing population, and new, effective treatments are urgently needed. Currently, the safety and benefits to patients of potential treatments are assessed in strictly-controlled clinical trials. However, clinical trials do not provide information on the health benefits for patients in their daily lives in the ‘real world’. The ROADMAP project aims to deliver a series of methods and tools that will allow the scalable, transferable integration of data on patient outcomes in the real world. The tools will be developed and tested through pilot projects and will lay the foundations for a Europe-wide platform on real world evidence in Alzheimer’s disease. The project will also deliver tools for patient engagement and address the ethical, legal and social implications of adopting a real world evidence approach to Alzheimer’s disease.\nThe project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.\n', 'tags': 'Real world outcomes across the AD spectrum for better care: multi-modal data access platform', 'participants': "Aarhus Universitet, Aarhus C, Denmark;Ac Immune SA, Lausanne, Switzerland;Academisch Ziekenhuis Leiden, Leiden, Netherlands;Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands;Alzheimer Europe, Luxembourg, Luxembourg;Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom;Chu Hopitaux De Bordeaux, Talence, France;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;F. Hoffmann-La Roche AG, Basel, Switzerland;Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain;Ge Healthcare Limited, Little Chalfont, United Kingdom;Goeteborgs Universitet, Gothenburg, Sweden;H. Lundbeck As, Valby, Denmark;Ixico Technologies Limited, London, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Kobenhavns Universitet, Copenhagen, Denmark;London School Of Economics And Political Science, London, United Kingdom;National Institute For Health And Care Excellence, Manchester, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Rijksuniversiteit Groningen, Groningen, Netherlands;Synapse Research Management Partners SL, Barcelona, Spain;Takeda Development Centre Europe LTD, London, United Kingdom;The University Of Edinburgh, Edinburgh, United Kingdom;Universiteit Maastricht, Maastricht, Netherlands;University of Oxford, Oxford, United Kingdom", 'status': 'Closed'}, {'id': '0', 'name': 'RTCURE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/rtcure', 'summary': 'Rheumatoid arthritis (RA) occurs when the immune system attacks the joints. Symptoms include painful, swollen joints, stiffness, and fatigue, all of which affect patients’ quality of life. Although RA treatments exist, many patients still struggle to keep their condition under control and many experience unpleasant and sometimes serious side effects of their treatment. Furthermore, there are currently no approved drugs for the early phases of RA.\nThe RTCure project aims to develop knowledge and tools to aid in the development of treatments for people in the earliest stages of the disease as well as those at risk of developing it. As such, the team will develop and validate new methods to identify people at high risk for RA and tools to monitor the progress of the disease. They will also validate methods to monitor immune tolerance treatments; highly-targeted medicines that stop the immune system’s attacks on the joints while ensuring the immune system remains able to fight off infections.\nIn the long term, the project hopes that its findings will deliver treatments capable of preventing the disease in those at risk of RA, and curing it in people who are still in the early stages of the disease.\n', 'tags': 'Rheuma Tolerance for Cure', 'participants': "Academisch Ziekenhuis Leiden, Leiden, Netherlands;Anocca AB, Karlskrona, Sweden;Apitope International Nv, Diepenbeek, Belgium;Bristol-Myers Squibb Company Corp, Princeton, NJ, United States ;Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany;Fondazione Per L Istituto Di Ricerca In Biomedicina, Bellinzona, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;King'S College London, London, United Kingdom;Medizinische Universitaet Wien, Vienna, Austria;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Semmelweis Egyetem, Budapest, Hungary;The University Of Birmingham, Birmingham, United Kingdom;The University Of Queensland, St Lucia, Australia;UCB Biopharma SRL, Brussels, Belgium;Universitatsklinikum Erlangen, Erlangen, Germany;University Of Glasgow, Glasgow, United Kingdom;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'SAFET', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/safe-t', 'summary': "Adverse drug reactions: significant cost to society\nIt is estimated that 197 000 deaths per year in the EU are caused by adverse drug reactions and that the total cost to society in the EU is €79 million. Among the side effects most challenging to drug developers and prescribers alike are drug-induced injuries to the kidney, liver and vascular system. By bringing together pharmaceutical companies, academic centres, and SMEs, SAFE-T has made a significant contribution to detecting such adverse reactions as early and accurately as possible during drug development, through the extensive characterisation of new markers in patients’ blood and/or urine (biomarkers). As well as having great potential to improve drug safety, these biomarkers could in the future also be applied to non-drug related diseases of the liver, kidney, and vascular system.\nLetters of support from regulatory agencies\nThe project generated a vast amount of data on 105 initial biomarker candidates, of which more than 20 showed promising performance. The data on some of these biomarkers has been submitted to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and the agencies recently issued letters of support. The letters of support indicate that the new biomarkers have the potential for use in drug development, and that additional exploration and data generation is warranted.\xa0As such, the letters are designed to encourage scientists to collect additional data from nonclinical and exploratory clinical trials.\xa0\nOther achievements: biobank and database\nWhile the characterisation of the biomarkers is the most significant project achievement, SAFE-T also contributed to the field in other ways:\nThe team defined and published a scientific strategy for the qualification of biomarkers, which will help improve the efficacy of future qualification efforts.\nThe project created a biobank with serum, plasma and urine samples from more than 11 000 patients across 19 different populations. The biobank can now be used by other researchers for the qualification of additional safety biomarker candidates.\nThe project set up a database with comprehensive data on 105 new biomarkers. The database will support further research on drug-induced kidney, liver and vascular injuries.\nRead the\xa0interview with the\xa0project's coordinators\n", 'tags': 'Safer and Faster Evidence-based Translation', 'participants': 'Almirall SA, Barcelona, Spain;Amgen, Brussels, Belgium;Assistance Publique Hopitaux De Paris, Paris, France;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Consorci Institut Català De Ciències Cardiovasculars, Barcelona, Spain;EKF Diagnostics Limited, Trinity Technology and Enterprise Centre, Ireland;Edi Experimentelle Und Diagnostische Immunologie GMBH, Reutlingen, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Firalis, Huningue, France;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Interface Europe, Bruxelles, Belgium;Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen, Reutlingen, Germany;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Takeda Development Centre Europe LTD, London, United Kingdom;The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv, Tel Aviv, Israel;The University Of Liverpool, Liverpool, United Kingdom;Universidad De Malaga, Malaga, Spain;Universitaet Leipzig, Leipzig, Germany;Universitaetsklinikum Aachen, Aachen, Germany;University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland', 'status': 'Closed'}, {'id': '0', 'name': 'SAFESCIMET', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/safescimet', 'summary': 'Drug safety is an extremely important part of the drug development process. Yet, prior to the launch of IMI’s SafeSciMET project in 2010, educational and training programmes in drug safety science in Europe were scarce. IMI’s SafeSciMET project addressed this gap successfully.\nBy bringing together 16 academic institutions and 14 pharmaceutical companies, the project developed a curriculum of 20 courses which cover topics along the whole trajectory of drug safety sciences, from developing a drug candidate, through testing it in laboratory studies, and all the way to bringing it to the patient. Professionals can follow single courses in safety sciences or selected subsets of courses, and be accredited for continuing professional development. Furthermore, students successfully completing the full training programme, including a master’s thesis, get awarded with an accredited master’s degree from the University of Konstanz in Germany, one of the project partners.\nThe SafeSciMET courses are open to scientists from industry, academia and regulatory agencies, and encompass the safety, ethical, regulatory and societal aspects of drug discovery and development. About 800 students have been trained so far: about 40% of them came from the pharmaceutical industry, 35% from academia and 10% from regulatory offices.\nCourses adapted to real-life industry needs\nEach course has a course leader from industry and academia, and in addition to the theoretical knowledge, contains real-life case studies from industry partners. Thanks to this public-private collaboration, the project created a unique pan-European training network of more than 200 course leaders and teachers from both industry and academia.\nSafeSciMET training is already leading to a new generation of safety specialists with strong competences in the application of novel technologies in risk assessment. The hope is that thanks to this unique programme, they will be able to perform reliable evaluations of the safety of drug candidates and new medicines in a more effective way. This could in turn speed up biopharmaceutical innovation and may eventually lead to a cost reduction in drug development.\nFor the benefit of industry and academia\nThanks to the SafeSciMET programme, the pharmaceutical industry got access to a new breed of trained professionals who are better positioned to address challenges in drug development and safety.\nThe academic partners benefited from the pharmaceutical companies’ expertise in drug safety sciences, which helped them design courses that are more in tune with the real-life needs of the industry. As a result, students trained through this programme have been getting easier access to jobs in the industry.\nBoth industry and academic project partners are also benefiting from the pan-European network of safety science educators and experts which was established through this project.\nWhat’s next?\nDuring the course of the project, three course cycles were held. After the end of the project, the project partners managed to set up a short-term sustainability plan thanks to which a fourth course will run in 2017 and 2018. This and future course cycles are coordinated and managed by the University of Konstanz.\xa0\nRead the\xa0interview with project coordinators\n', 'tags': 'European Modular Education and Training Programme in Safety Sciences for Medicines', 'participants': 'Almirall SA, Barcelona, Spain;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;European Federation For Pharmaceutical Sciences, Järfälla, Stockholm, Sweden;F. Hoffmann-La Roche AG, Basel, Switzerland;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;H. Lundbeck As, Valby, Denmark;Hospices Civils De Lyon, lyon, France;Karolinska Institutet, Stockholm, Sweden;Kobenhavns Universitet, Copenhagen, Denmark;Martin-Luther-Universitaet Halle-Wittenberg, Halle (Saale), Germany;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Novo Nordisk A/S, Bagsvaerd, Denmark;Orion Oyj, Espoo, Finland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Lygature, Utrecht, Netherlands;Stichting Vu, Amsterdam, Netherlands;The University Of Liverpool, Liverpool, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;Universitat Konstanz, Konstanz, Germany;Universitat Wien, Vienna, Austria;Universite De Lorraine, Nancy Cedex, France;Universite Paris-Sud, Orsay, France;Universiteit Leiden, Leiden, Netherlands;University Of Surrey, Guildford, United Kingdom;University of Lisboa, Faculty of Pharmacy (Faculdade de Farmácia da Universidade de Lisboa), Lisboa, Portugal;Uppsala Universitet, Uppsala, Sweden', 'status': 'Closed'}, {'id': '0', 'name': 'SOPHIA', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/sophia', 'summary': 'Obesity affects 150 million people in Europe and 650 million worldwide. People with obesity are at a greater risk of health complications like heart disease, diabetes and cancer.\nThe aim of the SOPHIA project is to improve our ability to predict who will experience which complications, and who will respond best to different obesity treatments. Currently, this is not possible. Part of the project will focus in particular on the relationship between type 1 diabetes and weight, as a large proportion of people with type 1 diabetes is overweight or has obesity.\nSOPHIA will link up and analyse data from different cohorts of people with obesity, and carry out in-depth qualitative studies with patients to identify their perceptions and perspectives on obesity diagnosis and treatment.\nThis will hopefully deliver insights on the variables that predict the risk of complications and responses to treatment.\nPeople living with obesity will be involved in all aspects of the project via a Patient Advisory Board. Ultimately, the project results should provide the basis for treatment pathways that are accepted by patients, healthcare systems, researchers and clinicians alike.\nMore broadly, the project hopes to change the narrative around obesity, to make it more patient-centric and equitable and to underline that it is a chronic disease, not something people choose to live with.\n', 'tags': 'Stratification of obese phenotypes to optimize future obesity therapy', 'participants': "Atturos Limited, Limerick Clare, Ireland;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre Hospitalier Regional Et Universitaire De Lille, Lille, France;Consiglio Nazionale Delle Ricerche, Roma, Italy;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Fundacio Institut D'Investigacio Biomedica De Girona Doctor Josep Trueta, Salt, Spain;George Washington University Corporation, Washington Dc, United States;Goeteborgs Universitet, Gothenburg, Sweden;Jdrf International, New York, United States ;Katholieke Universiteit Leuven, Leuven, Belgium;Lipotype, Dresden, Germany;Lunds Universitet, Lund, Sweden;Medtronic International Trading SARL, Tolochenaz, Switzerland;Metabolon GMBH, Potsdam, Germany;Novo Nordisk A/S, Bagsvaerd, Denmark;Obesity Action Coalition Inc, Tampa, United States;SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland;T1d Exchange Inc, Boston, United States;The European Association For The Study Of Obesity - Ireland Company Limited By Guarantee, Dublin, Ireland;The University Of Exeter, Exeter, United Kingdom;Third-I, Vilvoorde, Belgium;Universidad De Navarra, Pamplona, Spain;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universita Degli Studi Di Roma Tor Vergata, Rome, Italy;Universitaet Ulm, Ulm, Germany;Universiteit Maastricht, Maastricht, Netherlands;University College Cork -  National University Of Ireland, Cork, Cork, Ireland;University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland;University Of Dundee, Dundee, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'SPRINTT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/sprintt', 'summary': "Europe’s population is ageing fast, with the number of over 65s set to rise from over 85 million in 2008 to 151 million in 2060. Many of these people will become frail as they age; a common feature of frailty is a loss of muscle mass and strength (known as sarcopenia), and this makes those affected more vulnerable to falls and places them at greater risk of becoming disabled. The frail are also more likely to be hospitalised or to require long-term care in a nursing home. Frailty therefore has a huge impact on older people's quality of life and represents a significant burden for health and social care systems. Frailty is not uncommon – the SHARE (Survey of Health, Ageing and Retirement in Europe) study revealed that 17% of the over 65s in Europe are frail while 42% are ‘pre-frail’. Yet despite its prevalence and its impact on both quality of life and healthcare systems, there is no formal, widely-accepted definition of frailty and no treatment to prevent its onset and progression.\nThe SPRINTT project brings together major pharmaceutical companies, leading universities and hospitals, and small and medium-sized enterprises (SMEs) with the overall goal of improving \xa0frailty care and prevention in Europe.\nThe first goal of the project is to define the specific characteristics of frailty that can be easily applied in healthcare settings. This will make possible to precisely identify people affected by frailty. At the core of SPRINTT project is \xa0a large clinical trial to assess treatment options designed to prevent the frail from becoming disabled and losing their mobility. The trial, which will involve around 1 500 patients from across Europe, will randomly allocate participants to one of two groups. The first group will receive a multi-component intervention including physical activity and nutritional advice and supplements as well as innovative technologies. Among other things, these innovative technologies will support efforts to coach participants on physical activity and diet, and help to monitor participants’ health and frailty (for example by logging falls or near-falls). The other group will take part in a general health education programme. All participants will be followed up for two years.\nThe project team will also work closely with medicines regulators to ensure its findings can be rapidly implemented in clinical practice and applied to improve the development of innovative drugs for frailty.\nUltimately, the outcomes of the SPRINTT project should result in improved treatment options and a better quality of life for the frail. This will also benefit health and social care systems. More broadly, SPRINTT’s output will demonstrate how health research and healthcare systems can be adapted to the needs of older people with long-term health problems.\nPharmaceutical industries and SMEs will also benefit from the project that will establish sound methodologies for developing innovative treatments for frailty and sarcopenia.\n", 'tags': 'Sarcopenia and physical frailty in older people: multi‐component treatment strategies', 'participants': 'Astellas Pharma Europe BV, Leiden, Netherlands;Aston University, Birmingham, United Kingdom;Biophytis SA, Paris, France;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Caretek SRL, Torino, Italy;Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France;Centre hospitalier universitaire de Limoges, Limoges, France;Diabetes Frail Limited, Droitwich, United Kingdom;Eu-Open SRL, veronella (Vr), Italy;Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Haskoli Islands, Reykjavik, Iceland;Institut De Recherches Internationales Servier Iris, Suresnes, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Istituto Nazionale Di Riposo E Cura  Per Anziani Inrca, Ancona, Italy;Medizinische Universitat Graz, Graz, Austria;Novartis Pharma AG, Basel, Switzerland;Roessingh Research And Development BV, Enschede, Netherlands;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Servicio Madrileno De Salud, Madrid, Spain;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universita Degli Studi Di Firenze, Florence, Italy;Universita Degli Studi Di Parma, Parma, Italy;Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts, Goettingen, Germany;Universite Paris Descartes, Paris , France;Universiteit Maastricht, Maastricht, Netherlands;University of Helsinki, University of Helsinki, Helsinki, Finland;Univerzita Karlova, Prague 1, Czech Republic;Uniwersytet Jagiellonski, Krakow, Poland', 'status': 'Ongoing'}, {'id': '0', 'name': 'STEMBANCC', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/stembancc', 'summary': 'The magic of iPSCs\nIPSCs are created when a normal adult cell is reprogrammed to become ‘pluripotent’, meaning it is able to give rise to all the different kinds of cells that make up the human body. As such, human iPSCs can provide scientists with a variety of human cell types that can be used in research and drug development. Research tools based on human iPSCs offer the promise of more reliable results than research tools based on animal cells. When StemBANCC started, iPSC technology was still in its infancy and many scientists struggled to access high quality, well-characterised human iPSCs for use in research.\nThe goal of StemBANCC was to make a large number of iPSC lines available for the scientific community. The cells came from people with neurodysfunctional diseases (migraine, autism, schizophrenia, and bipolar disorder), central nervous system disorders (dementias), peripheral nervous system disorders (pain), and diabetes, as well as people who had experienced adverse reactions to drugs and healthy people. By the end of the five-year project, the team had generated 491 quality controlled, well-characterised iPSC lines from 496 people. In this way, StemBANCC addressed the challenge of finding more reliable ways to translate results from early laboratory tests to human patients. The iPSC lines are now accessible to the scientific community through EBiSC and Coriell.\nRigid ethical standards\nAnother important project outcome is the strict quality control and traceability of the iPSCs. Biological material (e.g. blood and skin samples), was collected from the recruited patients and healthy individuals with their informed consent and in line with rigid ethical standards. As an example of the practical traceability system, StemBANCC has met scientific, ethical and legal requirements to protect donor privacy while also maximising the availability of data. The system tracks samples throughout reprogramming and across the various physical locations where processing occurs within the StemBANCC consortium.\nOther important project achievements include:\nnew standardised protocols to generate different types of nerve cells from iPSCs; the protocols have been reproduced in multiple labs, proving their robustness;\ntherapeutically relevant disease models in pain and Parkinson’s disease;\nnew data on disease phenotypes including pain disorders, Alzheimer’s disease, Parkinson’s disease, autism, and diabetes;\na study on the effect of drugs on a range of iPSC derived cell types, providing researchers with an important source for future work;\nthe creation of the single-point access database (operated by StemDB) with all relevant iPSC information.\nFor the benefit of industry, academia, and SMEs\nThanks to StemBANCC, the scientific community now has high quality, disease-relevant human iPSCs already that are already being used to study disease biology, and to discover and develop new drugs.\nThrough StemBANC, there has been a significant transfer of knowledge from industry to academia and SMEs on how to use iPSCs to establish disease models for translational research. Furthermore, academia obtained a deeper understanding of the critical requirements of turning basic biomedical research into medicines, while undertaking the joint projects that are globally unique, which resulted with the utilisation of complementary expertise and knowledge in academia and industry. Academics also gained best practice on working with iPSC disease models to ensure reproducibility of the results.\nFor their part, the pharmaceutical companies involved in the project have used StemBANCC to establish their own stem cells expertise, and they are now using relevant in vitro models and assays in early stage drug discovery and safety evaluation.\nSME Newcells Biotech is a spin-out company from the University of Newcastle, that is producing, reprograming and differentiating iPSC lines and creating innovative cross-species tests for specific studies. Another spin-off combines the analysis of electronic health records with stem cell studies in order to validate the data.\nWhat’s next?\nThe accessibility of iPSC lines with the donors’ disease background and the development of the disease-relevant cell types could lead pharmaceutical companies to make further investments as a means of increasing the chances of translating drug candidates into efficacious treatments for the patients. The work of StemBANCC has significantly contributed to establishing methods and platforms to de-risk drug discovery. Ultimately, the use of human cellular models will enable improvements in the selection of compounds that are efficacious and reduce the risk of toxicity. Although these benefits will take some time to materialise, StemBANCC has laid the foundations. Additionally, the generation of relevant cells and assays can in the future potentially lead to a reduction in the use of animals in drug development, thus providing one more important legacy for StemBANCC.\nRead the interview with the project coordinators\n', 'tags': 'Stem cells for biological assays of novel drugs and predictive toxicology', 'participants': "Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Astrazeneca AB, Södertälje, Sweden;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Concentris Research Management GmbH, Fürstenfeldbruck, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany;Institut National De L Environnement Et Des Risques Ineris, Verneuil En Halatte, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Janssen Pharmaceutica Nv, Beerse, Belgium;King'S College London, London, United Kingdom;Linkopings Universitet, Linkoping, Sweden;Medizinische Hochschule Hannover, Hannover, Germany;Medizinische Universitat Innsbruck, Innsbruck, Austria;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen, Reutlingen, Germany;Newcells Biotech Limited, Newcastle upon Tyne, United Kingdom;Novo Nordisk A/S, Bagsvaerd, Denmark;Orion Oyj, Espoo, Finland;Pfizer Limited, Sandwich, Kent , United Kingdom;Region Hovedstaden, Hilleroed, Denmark;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Tel Aviv University, Tel Aviv, Israel;The Hebrew University Of Jerusalem, Jerusalem, Israel;The University Of Birmingham, Birmingham, United Kingdom;The University Of Edinburgh, Edinburgh, United Kingdom;UNIVERSITAET zu LUEBECK, Luebeck, Germany;Univercell Biosolutions SAS, Toulouse, France;Universitatsklinikum Schleswig-Holstein, Lübeck, Germany;Universite De Geneve, Genève 4, Switzerland;Universite De Lausanne, Lausanne, Switzerland;Universite De Technologie De Compiegne, Compiegne, France;University College London, London, United Kingdom;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Oxford, Oxford, United Kingdom", 'status': 'Closed'}, {'id': '0', 'name': 'STOPFOP', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/stopfop', 'summary': 'Fibrodysplasia ossificans progressiva (FOP) is a rare disease in which the muscles and connective tissues (e.g. tendons and ligaments) slowly turn into bone. There is no treatment; as the disease progresses, the build-up of bone material around the joints gradually limits patients’ mobility, and can also result in difficulties eating, speaking and even breathing.\nThe aim of STOPFOP is to see if a drug called AZD0530 could be used to treat FOP. FOP is caused by a mutation in a gene that codes for a protein called ALK2 kinase. Studies in the lab have shown that AZD0530 blocks the action of ALK2 kinase, and in mice, the drug successfully stopped the formation of bone material in the soft tissues and kept the mice’s limbs moving.\nAZD0530, also known as saracatinib, has already been tested for safety in humans in healthy volunteers and as a treatment for certain cancers. Now, the STOPFOP team plans to run a clinical trial of AZD0530 in 16 adults with FOP to see if it reduces the formation of new bone. They will work with patients, FOP experts and regulatory authorities throughout the project.\n', 'tags': 'Saracatinib trial to prevent FOP', 'participants': "Astrazeneca AB, Södertälje, Sweden;Klinikum Garmisch-Partenkirchen GMBH, Garmisch-Partenkirchen, Germany;Stichting Vumc, Amsterdam, Netherlands;The Brigham And Women'S Hospital Inc, Boston, United States;The Royal National Orthopaedic Hospital National Health Service Trust, Stanmore, United Kingdom;University of Oxford, Oxford, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'SUMMIT', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/summit', 'summary': 'There are an estimated 420 million people worldwide suffering from diabetes, and that figure is set to rise to 700 million by 2025. Many diabetes patients develop devastating, chronic complications including coronary heart disease, stroke and peripheral vascular disease, as well as eye and kidney problems. These complications impose an immense burden on the quality of life of the patients and account for more than ten percent of the health care costs in Europe.\nCurrently there is a high therapeutic need for new treatments for diabetes complications beyond the existing diabetes treatments, which focus mostly on lowering blood glucose levels. Clinical trials to show the benefits of potential therapies are lengthy and costly. Therefore, the key objective of SUMMIT was to develop procedures, technologies and tools to make clinical trials to test novel medications for diabetes complications shorter and more focused.\nClues in patients’ blood\nNot all patients are at equal risk of developing diabetic complications. In order to better predict, monitor and treat the patients at risk, the scientists of the SUMMIT project searched for biological clues (biomarkers) in the patients’ blood and urine that indicate if a patient is likely to develop complications. As part of the analysis, researchers measured almost 2 000 biomarkers, and identified some important predictors for diabetes complications. For example, they discovered a panel of 14 biomarkers which can differentiate between patients who will rapidly develop end-stage renal (kidney) disease, which requires dialysis, and patients who are less likely to need dialysis in the near future. A patent has been filed for this panel of biomarkers, and could become a valuable tool for doctors and hospitals in evaluating their patients and predicting their future treatment needs.\nWhen it comes to the cardiovascular disease, the scientists also discovered a panel of six biomarkers which improve our ability to predict which patients will develop cardiovascular disease. They also found that an enzyme which softens the plaque that builds up in blood vessels is a risk factor in developing cardiovascular disease. If this enzyme is active it leads to plaque rupture, which in turn leads to a heart attack or a stroke.\nLooking for answers in the genes\nIn addition to the biomarkers, SUMMIT scientists performed large examinations of genetic variants in different individuals to see if any variants are associated with a higher risk of developing diabetes complications. These studies were performed on almost 11 000 patients for kidney disease, more than 24 000 patients for cardiovascular disease, nearly 10 000 patients for retinopathy (a common eye disorder in diabetes patients) and more than 17 000 patients for lower extremity arterial disease. The comprehensive analysis – the largest such effort undertaken to date – showed that there are no obvious genetic markers which predispose patients to developing diabetes complications. The huge collection of genetic data which was generated during this effort will be a valuable asset in further research.\nOf mice, rats and men\nIn order to improve preclinical trials, the SUMMIT team also performed a systematic review of 19 existing and newly generated animal models for diabetes complications. Such an effort had never been done before, and it helped clean up and clarify the situation in the field. A promising new rat model was developed, validated and a patent application for it has been filed.\nImaging and a new tool for predicting heart attacks and strokes\nAs part of its effort to improve imaging techniques to monitor the progress of atherosclerosis (the build-up of plaques in the blood vessels), the project has also developed a new, non-invasive ultrasound device capable of identifying patients at imminent risk of a heart attack or stroke. Although the device was developed for diabetes patients, it is now being validated for a range of other diseases. A patent application is pending and a start-up company, Mediscienta, has been created to develop this innovation commercially.\nOther achievements\nIn addition to the work on biomarkers, genetic markers, imaging and animal models, the project recorded a number of other achievements.\nScientists in the project completed a multi-centre study of diabetic cardiovascular patients, and created a database and a biobank with one of the best characterised diabetic cardiovascular patient groups in the world. Both will be an asset in future research.\nWith 1 320 study subjects, the project created the largest dataset of optical coherence tomography (OCT) measurements in diabetes patents. OCT is a technique for obtaining images of the inside of the body at much higher resolution than other imaging modalities such as MRI or ultrasound. The project also developed a method to standardise OCT measurements in multi-centre trials and clinical practice.\nThe project generated more than 100 scientific publications, with more publications still to come. It also resulted in 15 doctoral theses from different universities.\nFor the benefit of industry, academia and patients\nTools and techniques developed during this project, such as new biomarkers and imaging modalities, will improve the prediction of major diabetes complications in clinical trials. New animal models developed will make it easier to choose the right models for specific research questions in preclinical trials. All this will make drug development faster and more efficient, benefitting both the pharmaceutical industry and patients.\nThe academic community also reaped many benefits, such as access to the resources, expertise and knowledge of the pharmaceutical industry. Additionally, the project has opened up many new funding opportunities and new avenues for future collaborations between industry and academia.\nLast but not least, SUMMIT raised the profile of the European research community globally; before SUMMIT, the diabetes research field was dominated by US consortia, but now Europe is increasingly seen as the leader in the field.\nWhat happens next?\nSUMMIT generated a lot of data and opened up many avenues for future research. Two new IMI projects, BEAT-DKD and RHAPSODY, will build on the legacy of SUMMIT to further advance research in the diabetes field in coming years.\nRead the interview with project coordinators\n', 'tags': 'Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools', 'participants': 'Astrazeneca AB, Södertälje, Sweden;Biocomputing Platforms LTD Oy, Espoo, Finland;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Goeteborgs Universitet, Gothenburg, Sweden;Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany;Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy;Itä-Suomen yliopisto, Kuopio, Finland;Karolinska Institutet, Stockholm, Sweden;Lunds Universitet, Lund, Sweden;Lunds Universitets Innovationssystem AB, Lund, Sweden;Pfizer Limited, Sandwich, Kent , United Kingdom;Samfundet Folkhalsan I Svenska Finland Rf, Helsingfors, Finland;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland;The University Of Edinburgh, Edinburgh, United Kingdom;The University Of Exeter, Exeter, United Kingdom;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universita Degli Studi Di Firenze, Florence, Italy;Universita Degli Studi Di Padova, Padova, Italy;Universita Degli Studi Di Pavia, Pavia, Italy;Universita Di Pisa, Pisa, Italy;University Of Dundee, Dundee, United Kingdom;University of Cambridge, Cambridge, United Kingdom;University of Oxford, Oxford, United Kingdom;University of Turku, Turku, Finland', 'status': 'Closed'}, {'id': '0', 'name': 'TRANSBIOLINE', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/transbioline', 'summary': 'Predicting which potential medicines could be harmful to major organ systems is a major challenge during drug development. The TransBioLine project aims to develop biological markers (biomarkers) that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system. The biomarkers, which the project hopes to get through regulatory qualification, include indicators of tissue damage, biomarkers to aid patient stratification, and standardised tests for the detection of the biomarkers. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, and it will be able to provide the scientific community, industry and patients with detailed data and information across a large spectrum of advanced safety biomarkers. Ultimately, the new markers will not only improve the safety of new drugs, but will contribute to the better diagnosis and management of diseases.\n', 'tags': 'Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease', 'participants': "Abx Cro Advanced Pharmaceutical Services Forschungsgesellschaft Mbh, Oberwil, Switzerland;Assistance Publique Hopitaux De Paris, Paris, France;Charite - Universitaetsmedizin Berlin, Berlin, Germany;Eli Lilly and Company Limited, Basingstoke, United Kingdom;F. Hoffmann-La Roche AG, Basel, Switzerland;Fundacio Privada Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, Barcelona, Spain;Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg;Janssen Pharmaceutica Nv, Beerse, Belgium;Landspitali University Hospital, Reykjavik, Iceland;Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Metaheps GMBH, Munich, Germany;Mlm Medical Labs GMBH, Moenchengladbach, Germany;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Servicio Andaluz De Salud, Sevilla, Spain;Signatope GMBH, Reutlingen, Germany;Synapse Research Management Partners SL, Barcelona, Spain;Tamirna GMBH, Vienna, Austria;The University Of Liverpool, Liverpool, United Kingdom;The University Of Nottingham, Nottingham, United Kingdom;Universidad De Malaga, Malaga, Spain;Universidad De Salamanca, Salamanca, Spain;Universitat Zurich, Zürich, Switzerland;Universiteit Leiden, Leiden, Netherlands;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'TRANSLOCATION', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/translocation', 'summary': 'Outmanoeuvring multiple defences \nOur battle against bad bacteria threatens to end in a defeat. The rise of AMR, where bacteria evolve to resist our attempts to annihilate them, means new drugs are desperately needed. While researchers have no problem coming up with new molecules that can bind to lethal bacterial targets, getting the drugs inside bacterial cells is one of the biggest stumbling blocks in antibiotic drug development. Gram-negative bacteria, uniquely troublesome bugs, are protected by two different membranes; you might find a drug that gets through one of the membranes only to find that it cannot breach the other. Once you find a molecule that can cross both membranes, these bacteria have another weapon up their sleeves in the form of efflux pumps, which literally pump the drug back out of the cell.\nTricking the bacteria with “Trojan horse” antibiotics\nTRANSLOCATION discovered many features of the protective cell membranes that control the access and expulsion of compounds from bacteria. For example, several proteins contained in bacterial membranes are used by the organisms to gather food, and the research showed how bacteria might be fooled to allow entry of “Trojan Horse“ antibiotics which are designed to resemble such foods. TRANSLOCATION created new, sensitive methods to detect how much drug ends up inside the cell by means of counting molecules as they pass through single proteins. The team was able to quantify a whole range of membrane proteins at the atomic level and revealed the detailed structures of 40 different proteins involved in drug transport. They also developed new modelling approaches and a scoring function to predict permeability, which represents a loose set of “rules” about a drug’s likelihood to pass through membrane proteins.\nThe project partners also worked on creating a database, called the InfoCentre, that could link all the data that was generated from the different IMI AMR projects. Securing access to data and putting it together was very difficult, since every project tends to save data according to their own format and standards. This data gathering was part of another key feature of the project’s scope: learning from success and failure. It required a broad knowledge base, varying skill sets and a large body of data from multiple sources.\nLegacy: a wealth of protein data, and a new company \nResearchers who study molecules that can thwart the evolved protective mechanisms of bacteria will be able to use the work on proteins to help in their search for new antibiotics. The wider antibiotic research community will be able to access data from the results of all projects under the IMI AMR programme including that of TRANSLOCATION.\nThe experience gained from the development of the InfoCentre will contribute to IMI’s AMR Accelerator programme. Tools from the InfoCentre will form the basis of planned data and knowledge management systems to be used by multiple antibiotic discovery AMR Accelerator projects as they progress through to the clinic.\nThe Copenhagen-based company, GRIT42 which was founded during the TRANSLOCATION project, will help to support the day-to-day IT needs of AMR Accelerator projects and also aggregate suitable data sets. The data will be used to address complex scientific questions, such as which in-vivo models are best for testing new compounds, or how clinical trial design could be better informed by results from pre-clinical stages.\nSuch collaboration “impossible” in any other setting \nIn the area of early drug discovery, TRANSLOCATION solved a number of basic research questions from a much larger perspective compared to smaller nationwide research projects. The combination of skill sets and expertise, especially in bringing together biophysical and theoretical methods with more traditional microbiological approaches, was key to the success of TRANSLOCATION. Such close collaboration between competing pharmaceutical companies would have been impossible in any other setting. The partnership also made it easier to figure out the protocol for the collaborative relationship between the pharma companies and academic partners.\nWhat’s next? \xa0\xa0\nIn order to make sure that the expertise generated by the project remains available, the project partners took advantage of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) to set up a virtual institute. In collaboration with experts from the European Open Screen network (EU-OPENSCREEN), the platform “Translocation-transfer” is now available. It can be used as a portal for the wider scientific community to access key experimental and computational tools established in TRANSLOCATION.\nTranslocation-transfer will establish a working model for these networks to collaborate and share essential know-how on theoretical and experimental methods for determining compound transport. This can then be integrated into the EU-OPENSCREEN compound profiling workflow for antibiotic programmes. The knowledge transfer process will be carried out through a series of tasks and workshops and facilitated by the New Drugs for Bad Bugs (NDD4B) InfoCentre platform. In the longer term, once these methods have been adopted by EU-OPENSCREEN, the data generated from screening projects specifically related to compound transport quantification will be released via the European Chemical Biology Database and ChEMBL database. The publicly-available data can then be used by the scientific community to improve our understanding of how molecular features mediate compound transport in bacteria, benefiting antibiotic drug discovery overall. \xa0\n', 'tags': 'Molecular basis of the bacterial cell wall permeability', 'participants': "Assistance Publique Hopitaux De Paris, Paris, France;Astrazeneca AB, Södertälje, Sweden;Basilea Pharmaceutica International AG, Basel, Switzerland;Bruker Daltonik GMBH, Bremen, Germany;Centre National De La Recherche Scientifique Cnrs, Paris, France;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Fundacion Privada Instituto De Salud Global Barcelona, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Gritsystems As, Dragør, Denmark;Ionovation GmbH, Osnabrück, Germany;Jacobs University Bremen Ggmbh, Bremen, Germany;Janssen Pharmaceutica Nv, Beerse, Belgium;Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany;Nanion Technologies GMBH, München, Germany;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Synchrotron Soleil Societe Civile, GIF-sur-YVETTE CEDEX, France;The Hyve BV, Utrecht, Netherlands;The University Court Of The University Of St Andrews, St Andrews, Fife, United Kingdom;Universita Degli Studi Di Cagliari, Cagliari, Italy;Universitaetsklinikum Freiburg, Freiburg, Germany;Universitat Basel, Basel, Switzerland;Universite D'Aix Marseille, Marseille, France;Universite De Geneve, Genève 4, Switzerland;University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland;University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom;Yelen, Ensues La Redonne, France", 'status': 'Closed'}, {'id': '0', 'name': 'TRANSQST', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/transqst', 'summary': 'When developing a new medicine, determining whether or not it will be safe for patients to take remains a challenge, and adverse drug reactions (ADRs) remain a major issue for clinicians. Of particular concern is damage to vital organs such as the liver, kidney, cardiovascular and gastrointestinal systems. The TransQST project will gather together data (both new and existing) and develop tools that will make it easier to assess the safety profile of potential medicines. They will also work to add to our understanding of when results in animal tests can be reliably extrapolated to humans, and develop models to predict concentrations of medicines in tissues, an important element of safety assessments. Another project output will be improved methods to visualise and analyse complex datasets during decision making on drug safety.\n', 'tags': 'Translational quantitative systems toxicology to improve the understanding of the safety of medicines', 'participants': 'Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Astrazeneca AB, Södertälje, Sweden;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Certara Uk Limited, London, United Kingdom;Eli Lilly and Company Limited, Basingstoke, United Kingdom;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;European Molecular Biology Laboratory, Heidelberg, Germany;Forschungsgesellschaft Fur Arbeitsphysiologie Und Arbeitsschutz E.V., Dortmund, Germany;Fundacio Institut Mar D Investigacions Mediques Imim, Barcelona, Spain;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Institut De Recherches Internationales Servier Iris, Suresnes, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Ocello BV, Leiden, Netherlands;Orion Oyj, Espoo, Finland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Synapse Research Management Partners SL, Barcelona, Spain;The University Of Liverpool, Liverpool, United Kingdom;Universitat Wien, Vienna, Austria;Universitatsklinikum Heidelberg, Heidelberg, Germany;Universiteit Leiden, Leiden, Netherlands;Universiteit Maastricht, Maastricht, Netherlands;University of Oxford, Oxford, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'TRIALSHOME', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/trialshome', 'summary': 'In a conventional clinical trial, patients have to make regular trips to the clinic for check-ups to monitor their condition. Many patients are understandably put off by the distance to the clinic and how often they would be expected to make the trip, and many patients who initially join trials drop out for logistics reasons. Digital technologies and wearable devices mean it is now possible to assess patients remotely – while they are at home, or going about their daily lives. If used during clinical trials, they could dramatically reduce the number of times patients are expected to visit the clinic.\nTrials@Home aims to explore the potential of digital technologies for use in ‘remote decentralised clinical trials’ (RDCTs). They will develop and test methods to streamline data collection as well as patient recruitment and retention. They will also discuss RDCTs with patients as well as regulators, payers, health technology assessment bodies (HTAs) and ethics bodies, to ensure that the project outcomes can be implemented. At the heart of the project is a study in which one group of patients will have the conventional clinical trial experience with regular clinic visits; a second group of patients will participate completely remotely; and a third group will follow a partly conventional / partly RDCT approach. The project will use the results of this study to identify which approaches are best for patient satisfaction, data quality and other parameters.\nIf successful, RDCTs could make it easier to recruit and retain larger numbers of patients, including people from groups that are often under-represented in trials. Furthermore, as data collection would be more or less continuous, the results would be more reliable and more representative of the real world.\n', 'tags': 'Center of excellence – remote decentralised clinical trials', 'participants': 'Allergan Limited, Marlow, United Kingdom;Astrazeneca AB, Södertälje, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Covance Clinical And Periapproval Services, Woluwe-Saint-Lambert, Belgium;Dreem, Paris, France;Eclinicalhealth LTD, Stirling, United Kingdom;Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece;Federation Internationale Du Diabete Region Europe Aisbl, Brussels, Belgium;Fh Joanneum Gesellschaft Mbh, Graz, Austria;Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain;Iqvia Rds France, Saint-Ouen, France;Janssen Pharmaceutica Nv, Beerse, Belgium;Julius Clinical Research BV, Zeist, Netherlands;Medical Research Network Limited, Milton Keynes, United Kingdom;Medtronic International Trading SARL, Tolochenaz, Switzerland;Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Stichting Lygature, Utrecht, Netherlands;Stichting Mlc Foundation, Den Haag, Netherlands;Stichting United Parent Projects Muscular Dystrophy, Veenendaal, Netherlands;Syddansk Universitet, Odense, Denmark;Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland;Teva Pharmaceutical Industries Limited, Netanya, Israel;UCB Biopharma SRL, Brussels, Belgium;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universiteit Utrecht, Utrecht, Netherlands;University Of Dundee, Dundee, United Kingdom;University of Oxford, Oxford, United Kingdom;Vital Transformation, Wezembeek Oppem, Belgium', 'status': 'Ongoing'}, {'id': '0', 'name': 'TRICTB', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/tric-tb', 'summary': 'Tuberculosis is a major public health threat. In 2017 alone, over 10 million people developed active TB and it killed 1.7 million, making it one of the top 10 causes of death worldwide. Treatment is via a six-month course of four antibiotics. Drug resistance is a major issue in TB – in 2017, over half a million drug-resistant cases were recorded, and most of these (82 %) were multi-drug resistant (MDR); these cases are much harder to treat successfully.\nThe aim of TRIC-TB is to advance the development of two molecules that could boost the infection-fighting ability of the anti-TB drug Ethionamide. The compounds, BVL-GSK038 and BVL-GSK098, work by interfering with the systems that control gene activity in the TB bacteria. Previous studies have shown that they are able to boost the efficacy of Ethionamide three-fold.\nIf the results are confirmed in humans, this could allow doctors to reduce the dose of Ethionamide typically given to patients, something that would also reduce the side effects associated with the drug. Moreover, it appears that BVL-GSK038 and BVL-GSK098 overcome some of the mechanisms that the TB bug has developed against Ethionamide.\nTRIC-TB will carry out further research in areas such as safety, mechanism of action, and potential synergies with other drugs; if these go well, the team will carry out the first clinical studies in humans of these potential drugs.\nUltimately, the information delivered from this research will hopefully allow the new compounds to be integrated into new, improved regimens to treat TB, including MDR-TB.\nTRIC-TB is part of the IMI AMR Accelerator Programme.\n', 'tags': 'Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments', 'participants': 'BioVersys SAS, Lille, France;Bioversys AG, Basel, Switzerland;Glaxosmithkline Investigacion Y Desarrollo SL, Tres Cantos, Spain', 'status': 'Ongoing'}, {'id': '0', 'name': 'TRISTAN', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/tristan', 'summary': 'Imaging techniques such as positron emission tomography (PET), computed tomography (CT), and magnetic resonance imaging (MRI) are widely used in medicine to diagnose diseases and track how well a patient is responding to treatment. However, imaging biomarkers based on these techniques are not yet widely used in the drug discovery process, although their non-invasive nature means they offer high-resolution insights into toxicity issues early on in drug development. The TRISTAN project brings together academics, small biotechs, imaging and pharmaceutical companies with the goal of validating the use of imaging biomarkers to assess and predict the toxicity of potential medicines on the liver and lungs. It will also improve the use of imaging to avoid side-effects which arise when certain types of drugs, such as therapeutic antibodies, go to the wrong part of the body. The imaging biomarkers will help translate pre-clinical (animal) findings to healthy volunteers and patients, and clinical trial findings to real-world patients, improving the success of drug development.\n', 'tags': 'Imaging biomarkers (IBs) for safer drugs: validation of translational imaging methods in drug safety assessment', 'participants': 'Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany;Academisch Ziekenhuis Groningen, Groningen, Netherlands;Antaros Medical AB, Mölndal, Sweden;Bayer Aktiengesellschaft, Leverkusen, Germany;Bioxydyn Limited, Manchester, United Kingdom;Bruker Biospin Mri GMBH, Ettlingen, Germany;Centre National De La Recherche Scientifique Cnrs, Paris, France;Chalmers Tekniska Hoegskola AB, Goeteborg, Sweden;European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium;Ge Healthcare Limited, Little Chalfont, United Kingdom;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Lunds Universitet, Lund, Sweden;Manchester University Nhs Foundation Trust, Manchester, United Kingdom;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Novo Nordisk A/S, Bagsvaerd, Denmark;Pfizer Limited, Sandwich, Kent , United Kingdom;Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany;Sheffield Teaching Hospitals Nhs Foundation Trust, Sheffield, United Kingdom;Stichting Katholieke Universiteit, Nijmegen, Netherlands;The Leeds Teaching Hospitals National Health Service Trust, Leeds, United Kingdom;The University Of Manchester, Manchester, United Kingdom;The University Of Sheffield, Sheffield, United Kingdom;Truly Labs AB, Lund, Sweden;Universite Dijon Bourgogne, Dijon, France;University Of Leeds, Leeds, United Kingdom', 'status': 'Ongoing'}, {'id': '0', 'name': 'UBIOPRED', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/u-biopred', 'summary': 'The biggest project on severe asthma to dateAbout 300 million people worldwide suffer from asthma, with 250\xa0000 annual deaths attributed to the disease and it is estimated that the number of people with asthma will grow by more than 100 million by 2025. Despite these statistics, not many new drugs have been developed to treat this disease since the invention of corticosteroids in mid 1940s. That’s partly because corticosteroids work well for 92-97% of asthma patients and there was no strong commercial incentive to look for new drugs. However, 3-8% of patients—those with severe asthma—do not respond to corticosteroids or other existing treatments. What’s more, those patients require frequent hospital admissions and account for half of all the asthma healthcare costs.\nThe U-BIOPRED project was the biggest and most complex research project undertaken to understand severe asthma to date. It aimed to speed up the development of better treatments for patients with severe asthma by understanding the disease in more depth. More specifically, its main goal was to identify different subtypes or ‘handprints’ of severe asthma by adding complex biological markers to clinical characteristics, so that new treatments can better target the disease in different patients.\nGroundbreaking discovery of asthma subtypesThis was done in several stages: first the researchers recruited 1 025 patients with severe asthma – both adults and children. Secondly, researchers took blood, airway, breath and urine samples of those patients and analysed tens of thousands of proteins and molecules looking for common patterns. They wanted to know if patients could be divided into subtypes based on a combination of those biomolecules as well as a number of other clinical indicators.\nAnalysing all this information in 1 025 patients and looking for patterns was no small feat but thanks to bioinformatics specialists in the project, it was a success. By the end of the project, the analysis revealed that there are four to five subtypes of severe asthma among adult patients (depending on the clinical and biological markers used), a discovery which is already paving the way for the development of more effective treatments. Initial results also show that there might be several, slightly different subtypes of asthma in children, but that analysis is still on-going.\nUnprecedented cooperation and other achievementsIn addition to discovering a number of subtypes of severe asthma in adult patients, the project recorded a number of other achievements, including:\nReaching a consensus between industry and the academic partners on what constitutes severe asthma and how it differs from ‘difficult’ asthma. The consensus was published and is being taken up by others, such as the International Primary Care Respiratory Group. It will be updated in the near future to include final project results.\nBuilding a registry with data from 1 025 patients belonging to eight different groups (so-called ‘cohorts’), some of which have never been studied before. For example, the project included four different groups of children, from preschool wheezers to asthmatic school-age children. This is significant because no study has ever studied children of various ages in combination with adults before – until now they were considered young adults. The registry will be an asset in future research.\nEstablishing exemplary cooperation between all project partners, including 12 pharmaceutical companies, academia and patient groups. According to project participants, the results achieved in this project could not have been achieved by one company or academic institution alone. It was a truly collaborative effort.\nBuilding a biobank with more than 50 000 severe asthma patient samples (e.g. blood, sputum, lung tissue, urine), available for future research.\nCreating a certified rhinovirus challenge model which can mimic asthma attacks or exacerbations. Exacerbations are a key unresolved problem in severe asthma and it is difficult to recruit patients when they suffer from them. Therefore this virus could be an important asset in future research.\nNourishing exemplary patient involvement. Patients played a big role in the project, including participation in the scientific and the ethics boards. They helped in many aspects of the project, including fine-tuning research protocols and providing encouragement during difficult times. A handbook on how to successfully ensure patient participation in research was also produced.\nProducing almost 70 scientific papers which are now in various stages of preparation.\nThe data from U-BIOPRED to benefit companies, patients and academiaThe knowledge and data from U-BIOPRED is already being used extensively by the pharmaceutical companies to address a number of key bottlenecks in drug discovery which will bring immense benefits to patients:\nIdentifying and validating drug targets. As U-BIOPRED has mapped the biological processes of severe asthma in patients, companies now have a clearer view on which biological processes should be targeted with future drugs.\nDecisions on which drugs to invest in. Thanks to the U-BIOPRED data, companies can now predict whether some of the drugs which they have in the pipeline will be effective for severe asthma patients.\nGetting the right drugs to the right patients. There are already some new drugs for asthma and severe asthma which work in some patients and not in others. By using the handprints as part of clinical trials, companies and caretakers can now start predicting whether or not a certain drug will be effective in individual patients. In the long run, this will be very beneficial for patients because they won’t be unnecessarily treated by drugs which don’t work for their asthma subtype.\nThe project will also benefit the academic community as the knowledge, networks and experience gained will inform many future studies and collaborations.\nWhat happens next?Even though the official funding for the project ended, the analysis and validation of the data will continue through on-going contributions from various consortium members and other organisations such as the European Respiratory Society. In the long-term, the researchers will try to answer some of the following questions:\nHow well do different subtypes of asthma identified in this project persist over time?\nDo individual patients move between different subtypes of severe asthma?\nAre the same subtypes of severe asthma present in other populations?\nWhat are the similarities and discrepancies of handprints between severe asthma and the chronic obstructive pulmonary disease?\nSome of these research questions might be addressed in future H2020-funded studies and IMI projects.\nRead the interview with the\xa0project’s scientific coordinator, Peter Sterk\n', 'tags': 'Unbiased biomarkers for the prediction of respiratory disease outcomes', 'participants': "Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands;Aerocrine AB, Solna, Sweden;Almirall SA, Barcelona, Spain;Amc Medical Research BV, Amsterdam, Netherlands;Amgen, Brussels, Belgium;Asthma Uk Lbg, London, United Kingdom;Astrazeneca AB, Södertälje, Sweden;Biosci Consulting Bvba, Maasmechelen, Belgium;Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany;Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux Marseille, Marseille, France;Centre National De La Recherche Scientifique Cnrs, Paris, France;Chiesi Farmaceutici S.A, Parma, Italy;European Federation Of Asthma &Allergy Associations Ideell Forening, Brussels, Belgium;European Lung Foundation, Lausanne, Switzerland;F. Hoffmann-La Roche AG, Basel, Switzerland;Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Hvidovre Hospital, Hvidovre, Denmark;Imperial College Of Science Technology And Medicine, London, United Kingdom;International Primary Care Respiratory Group, Edinburgh, United Kingdom;Janssen Biologics BV, Leiden, Netherlands;Karolinska Institutet, Stockholm, Sweden;Kobenhavns Universitet, Copenhagen, Denmark;Lega ltaliana Anti Fumo, Catania, Italy;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Netherlands Asthma Foundation, Leusden, Netherlands;Nottingham University Hospitals Nhs Trust, Nottingham, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Philips Electronics Nederland BV, Eindhoven, Netherlands;Semmelweis Egyetem, Budapest, Hungary;Synairgen Research Ltd, Southampton, United Kingdom;The University Of Manchester, Manchester, United Kingdom;The University Of Nottingham, Nottingham, United Kingdom;UCB Pharma SA, Brussels, Belgium;Umea Universitet, Umea, Sweden;Universita Cattolica Del Sacro Cuore, Milan, Italy;Universita Degli Studi Di Catania, Catania, Italy;Universita Degli Studi Di Roma Tor Vergata, Rome, Italy;Universitaet Bern, Bern, Switzerland;Universite D'Aix Marseille, Marseille, France;Universiteit Gent, Gent, Belgium;Universitetet I Bergen, P.O. Box 7800, Bergen, Norway;University Hospital Of South Manchester Nhs Foundation Trust, Wythenshaw, United Kingdom;University Hospitals Southampton Nhs Foundation Trust, Southampton, United Kingdom;University Of Southampton, Southampton, United Kingdom;Uniwersytet Jagiellonski, Krakow, Poland", 'status': 'Closed'}, {'id': '0', 'name': 'ULTRADD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/ultra-dd', 'summary': 'New medicines that work via novel, previously unexploited mechanisms are known as ‘first-in-class’ treatments and developing them is extremely challenging. Firstly, the early stages of drug development often involve tests using either simple cultures of human cells or animal models of diseases. However, these are often poor mimics of how diseases actually behave in humans, and positive results in these early studies do not always translate into safe, effective treatments for patients. Furthermore, even if reliable disease models are available, tools to study them in depth may be lacking. Finally, the expertise and resources required to develop these new tools is found in a range of different organisations; industry has experience of designing new tools, the clinical community has closer contact with patients and intimate knowledge of diseases, and the academic community typically has more expertise regarding the molecular biology of diseases.\nBy bringing together representatives of these different communities to create an open, collaborative partnership, ULTRA-DD is well placed to deliver the tools, resources and knowledge that will advance research, speed up drug development, and benefit the wider research community.\nFocus on autoimmune and inflammatory diseases\nA large part of the project is dedicated to developing research tools based on high-quality samples of cells and tissues from patients with specific diseases. These tools will allow researchers to study diseases in depth. ULTRA-DD will focus on two important areas where safe, effective treatments are currently lacking: autoimmune and inflammatory diseases. Autoimmune diseases up for study in ULTRA-DD include systemic lupus erythematosus (SLE), idiopathic myositis, Sjögren’s syndrome, and systemic sclerosis. Collectively, these diseases are known as systemic inflammatory autoimmune diseases and they affect around 1% of the population in Western countries. Although their symptoms vary, they are all caused when the immune system attacks the body’s own tissues. There is currently no cure for these diseases and existing treatments are not effective in all patients and often come with unpleasant side effects.\nThe second disease category studied in ULTRA-DD is immune diseases that trigger damage to the bones and cartilage, such as fibrodysplasia ossificans progressive (FOP) and ankylosing spondylitis (AS). FOP is an extremely rare, currently-incurable condition in which bone forms in the muscles and soft tissues of the body. AS is a type of arthritis that mainly affects the spine is found in around 0.2% of the population. Again, more research is needed to find effective treatments for these devastating diseases.\nAnother part of the project is developing a suite of probes, tests and methodologies to study these disease-specific research materials in depth.\nIn addition. through project partner the Structural Genomics Consortium, ULTRA-DD will work closely with related initiatives carrying out similar work on neurological diseases and cancer.\nWide-ranging impacts\nIn order to ensure the project results are taken up and used widely, ULTRA-DD operates an open access policy. The wider scientific community will therefore have ready access to much of the knowledge, data and tools generated by the project. Ultimately, the hope is that ULTRA-DD will dramatically increase our understanding of the underlying molecular causes of the diseases under investigation and so reinvigorate drug discovery pipelines.\nFor patients, whose input is key to the success of this project, ULTRA-DD demonstrates that the entire health research and drug development community is pulling together to speed up the search for new, safer, more effective treatments.\n', 'tags': 'Unrestricted leveraging of targets for research advancement and drug discovery', 'participants': 'Bayer Aktiengesellschaft, Leverkusen, Germany;DiscoveRx Corp Ltd, Birmingham, United Kingdom;Eidgenoessische Technische Hochschule Zuerich, Zurich, Switzerland;Janssen Pharmaceutica Nv, Beerse, Belgium;Karolinska Institutet, Stockholm, Sweden;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Structural Genomics Consortium Lbg, London, United Kingdom;The Governing Council Of The University Of Toronto, Toronto, Canada;University of Oxford, Oxford, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'VAC2VAC', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/vac2vac', 'summary': 'Developing and validating alternative, non-animal testing approaches for both human and veterinary vaccines is the main goal of the VAC2VAC project. In routine vaccine production, the current quality control approach requires large numbers of laboratory animals. VAC2VAC aims to provide data to support the ‘consistency approach’ for quality control that promotes the use of in vitro, analytical, non-animal based systems. The project brings together scientists from both the human and veterinary pharmaceutical industry along with academia and regulators. Together they plan to develop and validate non-animal tests; generate vaccine specific toolkits of consistency tests; increase our scientific understanding of vaccine quality; and contribute to the regulatory acceptance and routine use of non-animal tests during vaccine quality control testing.\n', 'tags': 'Vaccine lot to vaccine lot comparison by consistency testing', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands;Association Internationale De Standardisation Biologique Pour L'Europe(Iabs-Eu), Lyon, France;Boehringer Ingelheim Vetmedica GMBH, Ingelheim am Rhein, Germany;Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany;Department of Health, Leeds, United Kingdom;European Commission - Directorate General Joint Research Centre - JRC, Brussels, Belgium;European Vaccine Initiative - EEIG, Heidelberg, Germany;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Institut Scientifique De Sante Publique, Brussels, Belgium;Intervet International BV, Boxmeer, Netherlands;Istituto Superiore Di Sanita, Roma, Italy;Merial SAS, Lyon, France;Ministerie Van Volksgezondheid, Welzijn En Sport, Bilthoven, Netherlands;Osterreichische Agentur Fur Gesundheit Und Ernahrungssicherheit GMBH, Vienna, Austria;Pfizer Limited, Sandwich, Kent , United Kingdom;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Sanofi Pasteur SA, Lyon, France;Sciensano, Brussels, Belgium;Stichting Biomedical Primate Research Center, Rijswijk, Netherlands;Stichting Hogeschool Utrecht, Utrecht, Netherlands;Universiteit Utrecht, Utrecht, Netherlands;Zoetis Belgium SA, Louvain la Neuve, Belgium", 'status': 'Ongoing'}, {'id': '0', 'name': 'VALUEDX', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/value-dx', 'summary': 'If we want to tackle anti-microbial resistance (AMR), we need to ensure that antibiotics are only used when absolutely necessary. However, data shows that in Europe, 30-50% of antibiotics are prescribed unnecessarily. Greater use of diagnostic tests could help to bring this figure down by ensuring that doctors only prescribe antibiotics when absolutely necessary. However, the wider use of diagnostic tests in healthcare is hampered by a lack of insight into their medical, technological and health economical value. In addition, our knowledge about the barriers to their use remains limited. The goal of VALUE-Dx is to generate evidence on the medical, economic, and public health value of diagnostics in treating AMR. The team, which includes six diagnostic companies, will also develop user requirement specifications of tests. The project will focus on respiratory tract infections in community care settings, as these are a common cause of inappropriate antibiotic use. However, the project’s findings are also likely to be relevant for other common infections, including urinary tract infections, blood stream infections, and respiratory tract infections acquired in hospitals. Ultimately, VALUE-Dx should help to transform medical practice by making it easier for doctors to deliver personalised, evidence-based antibiotic prescriptions thanks to the use of innovative diagnostic strategies.\n', 'tags': 'The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Accelerate Diagnostics SL, Tucson, United States;Alere International Limited, galway, Ireland;Bd Switzerland SARL, Eysins, Switzerland;Berry Consultants Llp, London, United Kingdom;Bio-Rad, Marnes-La-Coquette, France;Bioaster Fondation De Cooperation Scientifique, Lyon, France;Biomerieux SA, Marcy L'Etoile, France;European Respiratory Society, Lausanne, Switzerland;European Society Clinical Microbiology Infectious Diseases (Europaische Gesellschaft Fur Klinische Mikrobiologie Infektionskrankheiten), Basel, Switzerland;Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy;Foundation For Innovative New Diagnostics, Geneva, Switzerland;Gesundheit Osterreich GMBH, Wien, Austria;Janssen Pharmaceutica Nv, Beerse, Belgium;Luxembourg Institute Of Health, Luxembourg, Luxembourg;National Institute For Health And Care Excellence, Manchester, United Kingdom;The Health Corporation - Rambam, Haifa, Israel;The Trustees Of Boston University, Boston Ma, United States;The University Of Edinburgh, Edinburgh, United Kingdom;The Wellcome Trust Limited, London, United Kingdom;Universidad De La Rioja, Logrono, Spain;Universita Degli Studi Di Verona, Verona, Italy;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universitair Ziekenhuis Antwerpen, Edegem, Belgium;Universiteit Antwerpen, Antwerp, Belgium;University of Oxford, Oxford, United Kingdom;Zorgonderzoek Nederland Zon, Den Haag, Netherlands", 'status': 'Ongoing'}, {'id': '0', 'name': 'VHFMODRAD', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/vhfmodrad', 'summary': 'Better, faster diagnosis of viral haemorrhagic fevers like Ebola is the ultimate goal of the VHFMoDRAD project. As their name implies, viral haemorrhagic fevers are caused by viruses and a common symptoms is severe bleeding, which often results in death. Examples include Ebola and Marburg as well as dengue and yellow fever. As these diseases have many symptoms in common, it is often hard to deliver a rapid diagnosis, yet in an outbreak setting, this is essential. The aim of VHFMoDRAD is to develop rapid point-of-care (POC) diagnostic tools capable of identifying a number of viral haemorrhagic fevers. The project builds on the work of IMI’s EbolaMoDRAD project, which advanced the development of rapid diagnostics for Ebola. The new tools and methods developed by VHFMoDRAD will be validated in the field. In addition, the project plans to run training courses for professionals in the west African region. It will also transfer the production capacity for the diagnostic tools to a project partner in the region so that the tests can be produced locally. Ultimately, VHFMoDRAD will contribute to better preparedness for outbreaks of viral haemorrhagic fevers, and to capacity building in Africa.\n', 'tags': 'Viral haemorrhagic fever: modern approaches for developing bedside rapid diagnostics', 'participants': "Biotech Investissement, Besancon, France;Cepheid Europe, Maurens Scopont, France;Coris Bioconcept SPRL, Gembloux, Belgium;Department of Health, Leeds, United Kingdom;Emergency Life Support For Civilian War Victims Ong Onlus, Milan, Italy;Folkhalsomyndigheten, Solna, Sweden;Inserm Transfert SA, Paris, France;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Institut Pasteur De Dakar, Dakar, Senegal;Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy;Kobenhavns Universitet, Copenhagen, Denmark;Rd-Biotech, Besançon, France;Sivas Cumhuriyet Universitesi, Sivas, Turkey;The University Of Stirling, Stirling, United Kingdom;Universite D'Aix Marseille, Marseille, France", 'status': 'Ongoing'}, {'id': '0', 'name': 'VITAL', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/vital', 'summary': 'As people age, their immune systems become weaker, and they become more vulnerable to infectious diseases. Preventing these infections through a proper vaccination strategy is essential for promoting healthy ageing. The VITAL project will map the burden of vaccine-preventable infectious diseases in the elderly, and investigate vaccinations and immunity to infections in the ageing population. The team will also calculate the clinical and economic consequences of possible vaccination strategies in different age and risk groups, and develop educational materials for stakeholders such as healthcare providers. Ultimately, by addressing the challenge of infectious diseases in the elderly, the VITAL project will contribute to better health for the ageing populations, and a reduced burden on healthcare systems.\n', 'tags': 'Vaccines and infectious diseases in the ageing population', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Biomerieux SA, Marcy L'Etoile, France;Centre National De La Recherche Scientifique Cnrs, Paris, France;Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Brussels, Belgium;Folkehelseinstituttet, Oslo, Norway;Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain;Glaxosmithkline Biologicals SA, Rixensart, Belgium;Imperial College Of Science Technology And Medicine, London, United Kingdom;Institut National De La Sante Et De La Recherche Medicale, Paris, France;Istituto Superiore Di Sanita, Roma, Italy;Janssen Vaccines & Prevention BV, Leiden, Netherlands;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Mihajlovic Jovan, Novi Sad, Serbia;P95 CVBA, Leuven, Belgium;Pfizer Limited, Sandwich, Kent , United Kingdom;Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands;Sanofi Pasteur SA, Lyon, France;Statens Serum Institut, Copenhagen S, Denmark;Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag, Budapest, Hungary;Universita Degli Studi Di Ferrara, Ferrara, Italy;Universitaet Innsbruck, Innsbruck, Austria;Universitair Medisch Centrum Utrecht, Utrecht, Netherlands;Universite Jean Monnet Saint-Etienne, Saint Etienne Cedex 2, France;University College London, London, United Kingdom", 'status': 'Ongoing'}, {'id': '0', 'name': 'VSVEBOPLUS', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/vsv-eboplus', 'summary': 'The devastating Ebola outbreak that struck western Africa in 2014-2016 left over 11 000 dead, including many medical workers. The outbreak highlighted the urgent need for safe, effective vaccines against the highly infectious disease.\nOne vaccine that is already at an advanced stage of development is called VSV-ZEBOV (vesicular stomatitis virus – Zaire Ebola vaccine). Clinical trials of the vaccine started in Guinea, one of the most affected countries, during the outbreak. Trials have also been carried out in Europe and the US. These revealed that the vaccine is safe, generates an immune response, and offers high levels of protection against Ebola. However, researchers still have many questions about VSV-ZEBOV: How exactly does it work? How long does it offer protection against Ebola, and what influences this? And, importantly, how well does the vaccine work in children?\nThe VSV-EBOPLUS project aims to use systems biology approaches to decipher the molecular and immune signatures of responses to the vaccine in both adults and children in the short and long term. To do this, they will study blood samples taken from different groups, including adults and children who have just received the vaccine. They will also carry out yearly follow-up visits with two of the largest cohorts, in Gabon and Switzerland, for five years following vaccination.\nThe project hopes that the results will deliver novel insights into the mechanisms of action of VSV-ZEBOV, and provide signatures that can be used to accurately assess both the safety and effectiveness of vaccines.\n', 'tags': 'Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Centre de Recherches Medicales de Lambaréné, Lambaréné, Gabon;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Eidgenossisches Departement Fur Verteidigung, Bevolkerungsschutz Und Sport, Bern, Switzerland;Goeteborgs Universitet, Gothenburg, Sweden;Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States ;Microbiotec SRL, Siena, Italy;Sclavo Vaccines Association, Siena, Italy;Universidade De Sao Paulo, São Paulo, Brazil;Universita Degli Studi Di Siena, Siena, Italy;Universite De Geneve, Genève 4, Switzerland', 'status': 'Ongoing'}, {'id': '0', 'name': 'VSVEBOVAC', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/vsv-ebovac', 'summary': 'The problem: establishing efficacy of a promising Ebola vaccine\n2014-2016 saw the biggest Ebola outbreak in history. With the death toll climbing, the race was on to develop and test a vaccine that could halt its spread. One of the most promising vaccines, originally developed by the Public Health Agency of Canada, was granted permission for use in clinical trials in Africa, Europe, the United States and Canada to test its safety and efficacy. However, the number of new cases began to decline before some of the trials started. This meant that efficacy could only be evaluated in one phase three clinical trial. That left some unanswered questions: researchers had good evidence that the vaccine worked, but the exact mechanisms were still unknown. Crucially, it was unclear how long the vaccine could be expected to provide protection in those who received it.\nGetting a picture of the immune response – and side effects\nThe vaccine is based on the vesicular stomatitis virus, genetically engineered to contain a protein from the Zaire strain of the Ebola virus. Over 16, 000 volunteers have received the shot as part of controlled trials. In a study conducted in Guinea during the west African outbreak, the vaccine was shown to be up to 100 % effective using a “ring vaccination” method; this means vaccinating the patient’s close contacts as well as the contacts of those close contacts. In 2015, VSV-EBOVAC got to work using cutting-edge technologies to analyse samples taken from volunteers before and after vaccination during the early clinical trials. This gave them excellent data on the type and strength of the immune responses triggered, as well as the kind of side effects that could be expected.\nWhen a vaccine is administered it leaves its own plasma signature, which is the telltale sign in the blood of vaccine-induced immune activity. VSV-EBOVAC researchers were able to single out the rVSV∆G-ZEBOV-GP plasma signature. They now know more about how antibodies elicited by the vaccine in the body bind to viral glycoproteins, the rod-like proteins that dot the membrane of the virus. The researchers studied the neutralising properties of the antibodies, as well as their affinity and avidity, or how strongly and they bind to the virus.\nThey also made significant headway in determining the durability of immunity. They found that the antibody responses to rVSV∆G-ZEBOV-GP were shown to be going strong at least one year after immunisation, and VSV-EBOVAC’s follow-on project, VSV-EBOPLUS, later confirmed immunity up to two years (that project will soon be able to confirm if protection is conferred for up to five years). These immune responses were sustained across dose ranges and settings – as well as across gender, age and ethnicity – which is good news in countries where booster campaigns pose practical challenges.\nThey identified, too, the cytokines and chemokines that could be red flags for adverse reactions such as (self-limiting) arthritis, and showed that the occurrence of this side effect is associated with increased antibody responses over time. Another important discovery was that pre-existing antibodies against the virus didn’t affect the response to the vaccine.\nResearchers also studied the response to vaccination using transcriptomics and metabolomics, which quantify, respectively, the messenger RNAs and the metabolites in blood, allowing the identification of characteristic transcriptomic and metabolomics signatures of the rVSV∆G-ZEBOV-GP vaccine.\nFilling the translational gap, from the lab to local campaigns\nThe VSV-EBOVAC project can now provide public-health planners and workers with practical information related to how the vaccine works. It fills a translational gap between R&D in the lab and the response to the major Ebola outbreak that started in the east of the Democratic Republic of Congo in summer 2018. As part of the response to this Ebola outbreak, thousands of people were immunised with rVSV∆G-ZEBOV-GP (around 200,000 in the first year of the outbreak alone), and the data from the project has produced crucial clinical evidence that will speed up licensing. Some of the data have been published open access in important scientific journals and made available to other Ebola-related projects through the Central Ebola+ Information repository The project partners are hopeful it will help researchers studying other haemorrhagic fever disease strains establish safety and efficacy in the development of vaccines.\nSpeed and access\nThe project was made up of partners from different disciplines. The speed at which the work could be carried out was cited as one of the key benefits of working in an IMI-funded consortium. Researchers had direct access to the vaccine developer industry partner, another major advantage of IMI-funded projects, and the industry gained access to academic knowledge and skills unavailable in house. For the larger pharmaceutical industry partner, validating the most promising Ebola vaccine candidate for one of the world’s most high-profile, urgent and terrifying diseases was considered very positive for the public perception of the company. University partners also felt participation elevated their profile. As with all IMI projects, one of the key benefits is how the project allowed them to form new networks and partnerships, with SMEs working alongside academia and industry to get to know the context in which each operates, create new spin-off projects and seek funding opportunities.\nWhat’s next?\nThe vaccine has been granted “Breakthrough Therapy Designation” by the FDA, and PRIority MEdicines (PRIME) status by the European Medicines Agency, and it is being used to support the 2018 outbreak control in the Democratic Republic of Congo. VSV-EBOPLUS is the follow-on phase of VSV-EBOVAC. Also funded by IMI, this project allows the project partners to extend follow up of clinical trials of the rVSV∆G-ZEBOV-GP vaccine to five years and to conduct clinical trials in children. They are refining the plasma signature and digging much deeper into the innate immune responses, and will soon be able to confirm if vaccine-induced antibody titers remain strong at five years after immunisation.\nThe VSV-EBOVAC project is part of IMI’s Ebola+ programme.\n', 'tags': 'Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV', 'participants': 'Academisch Ziekenhuis Leiden, Leiden, Netherlands;Bioprotection Systems Corporation, Ames, United States ;Centre de Recherches Medicales de Lambaréné, Lambaréné, Gabon;Department of Health, Leeds, United Kingdom;Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany;Eidgenossisches Departement Fur Verteidigung, Bevolkerungsschutz Und Sport, Bern, Switzerland;Emory University Non Profit Corp, Atlanta, Georgia, United States ;Goeteborgs Universitet, Gothenburg, Sweden;Microbiotec SRL, Siena, Italy;Sclavo Vaccines Association, Siena, Italy;Universita Degli Studi Di Siena, Siena, Italy;Universite De Geneve, Genève 4, Switzerland;University of Oxford, Oxford, United Kingdom', 'status': 'Closed'}, {'id': '0', 'name': 'WEBRADR', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/web-radr', 'summary': 'Pharmacovigilance is the monitoring of the safety of medicines to identify new or changing risks to support the safe and effective use of medicines. This includes the monitoring and reporting of adverse drug reactions (ADRs), i.e. side effects that can be experienced during treatment. Patients experiencing ADRs and their healthcare professionals are requested to report these side effects to their national pharmacovigilance centre. However, paper-based report forms are not always available and are often perceived as inconvenient and complex. If more reports were submitted, this could facilitate the faster identification of risks.\nTo address this, IMI’s WEB-RADR project has developed a mobile app that allows users of pharmaceutical products to directly report ADRs to relevant health authorities, find out about reported side effects and opt to receive alerts on specific medicines. During the project, the app was rolled out across three EU countries – Croatia, the Netherlands, and the UK – and had about 10 000 downloads in those countries alone.\nThanks to collaboration with the World Health Organization, the app was also rolled out to support malaria programmes in two African countries: Burkina Faso and Zambia. The implementation of the app in those countries had a substantial impact, with Burkina Faso receiving more ADR reports in the first six months after the roll out than they had in all the time previously.\nA dozen additional countries around the world have also expressed interest in the app and some have already adopted it. For example, in early 2018 the United Arab Emirates also launched the app.\nThe reports received via the app have already contributed to the identification of new safety issues with various medicines, enabling regulatory authorities in relevant countries to take appropriate action.\nSocial media data mining\nThe WEB-RADR project team also explored the value of social media data for pharmacovigilance. They found that in certain circumstances it could be hugely valuable and that people are far more likely to discuss issues like medicine misuse on social media than with their doctor. To mine this wealth of data, the team developed methods to detect, extract, standardise and analyse medicine-related information reported in unstructured free text by social media users.\nThis has already led to concrete insights. For example, thanks to social media mining, the team uncovered patterns of misuse of a particular medicine by communities of students who want to improve their performance around examination time. This has provided additional information to the traditional sources, because students would normally not share this information with their doctors and pharmacists.\nWEB-RADR policy recommendations on the collection and use of data – both through the app and social media mining – have been passed on to the European Medicines Agency (EMA) for implementation in future guidance on how the pharmacovigilance legislation in the EU should be operated.\nEthical and data protection issues\nA consistent area of concern for the project was potential conflicts over data gathering and privacy regulations, as well as ethical considerations about harvesting social media data. To address this, the researchers engaged leading medical ethicists and data protection experts to assist them. That set a sound and robust framework for the analysis that they were doing, ensuring that they were both operating within the law and conducting the work in accordance with the highest ethical standards.\nBenefits for industry, academia and SMEs\nThe industry is already benefitting from the tools and resources developed within this project, especially from the guidelines on how they can use social media to monitor drug safety issues and improve their interaction with patients and carers.\nThe academic community has benefitted from the exchange of ideas and viewpoints with different stakeholders in the project, as well as from innovative research ideas and identification of new research areas. SMEs have also benefitted from the network formed within the project, and have expanded their businesses.\nFinally, patients and healthcare providers benefitted from gaining a new, user-friendly way to report adverse drug reactions and receive official, reliable and regulator-approved information on their treatments via the mobile app.\nWhat’s next?\nIn order to enable other countries in the EU and beyond to benefit from the tools developed in the project, the project partners have put in place a sustainability plan. Among other things, the project set up a management board that will support the growth of the mobile app as well as its continued development and enhancements beyond the lifetime of the project.\nIn line with IMI’s open innovation approach, the data and reference standards obtained during the course of the project will soon be published so that other researchers could build on the WEB-RADR work. Furthermore, the project’s scientific deliverables have been described in two scientific papers – as of August 2018, their publication is still pending.\nRead the interview with project coordinators.\n', 'tags': 'Recognising Adverse Drug Reactions', 'participants': "Academisch Ziekenhuis Groningen, Groningen, Netherlands;Agencija Za Lijekove I Medicinske Proizvode, Zagreb, Croatia;Amgen, Brussels, Belgium;Astrazeneca AB, Södertälje, Sweden;Bayer Pharma AG, Berlin, Germany;Department of Health, Leeds, United Kingdom;Epidemico LTD, Irishtown, Ireland;Eurordis - European Organisation For Rare Diseases Association, Paris, France;Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom;Janssen Pharmaceutica Nv, Beerse, Belgium;Novartis Pharma AG, Basel, Switzerland;Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France;Srdc Yazilim Arastirma Ve Gelistirme Ve Danismanlik Ticaret Anonim Sirketi, Ankara, Turkey;Stichting Lareb, 's Hertogenbosch, Netherlands;Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden;The European Medicines Agency, Canary Wharf, London, United Kingdom;The University Of Liverpool, Liverpool, United Kingdom;UCB Biopharma SRL, Brussels, Belgium;University College London, London, United Kingdom", 'status': 'Closed'}, {'id': '0', 'name': 'WEBRADR_2', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/web-radr-2', 'summary': 'One of the most significant outputs of IMI’s WEB-RADR project was a mobile application (app) which allows patients and healthcare professionals to report adverse drug reactions (ADRs, or side effects) directly to the relevant authorities. The WEB-RADR 2 project aims to take the app to the next level by making its functionalities available through application programming interfaces (APIs). This will allow third party organisations to embed the WEB-RADR platform’s functionality into their own systems, apps and websites. To achieve this, the team will collaborate with main organisations involved in pharmacovigilance to map the terminologies used. They will also work closely with the WEB RADR project’s networks of regulatory authorities, health charities and system providers to ensure the tools developed are what end users need.\n', 'tags': 'WEB-RADR 2', 'participants': "Abbvie Inc, North Chicago, Illinois, United States ;Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain;Agencija Za Lijekove I Medicinske Proizvode, Zagreb, Croatia;Csl Behring GMBH, Marburg, Germany;International Health Terminology Standards Development Organisation, London, United Kingdom;Laegemiddelstyrelsen, Kobenhavn S, Denmark;Medicines And Healthcare Products Regulatory Agency, London, United Kingdom;Novartis Pharma AG, Basel, Switzerland;Pfizer Limited, Sandwich, Kent , United Kingdom;Stichting Lareb, 's Hertogenbosch, Netherlands;Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden;The International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use, Geneve, Switzerland", 'status': 'Ongoing'}, {'id': '0', 'name': 'ZAPI', 'link': 'https://www.imi.europa.eu/projects-results/project-factsheets/zapi', 'summary': '25 outbreaks in 20 years\xa0\nNew infectious diseases are emerging at an increasing frequency in the EU and other regions of the world, with the potential to profoundly impact public and animal health, and strongly disrupt local and international economies. The majority of these diseases are zoonoses, meaning they originate in or are transmitted by animals. In the last 20 years, there have been 25 documented emerging diseases that moved from wild or domestic animals to human populations. It is highly probable that zoonoses that spread rapidly (many of them are insect-borne diseases) in one or several EU countries will continue or increase due to environmental and demographic changes. The EU has already been affected by many zoonoses over the past 20 years, for example, West Nile virus, chikungunya and influenza H5N1.\nToo many delays in vaccine delivery\nDue to the unpredictable nature of the zoonotic outbreaks, the rapid development of containment and control programmes is critical to the well-being of both human and animal populations. Current vaccine development platforms, however, may not be appropriate to come up with effective products that can trigger a protective response. Additionally, in most cases these platforms rely on cell lines from mammals, which may not be readily available and may not yield enough material to address outbreaks. Furthermore, long regulatory processes for product approval may delay their applications. All of this results in unacceptable delays in vaccine delivery to the populations in needs.\xa0\nCollaborative approach needed\xa0\nZoonoses clearly demonstrate that the health of the people is closely interlinked with the health of the animals and the environment – these types of diseases require a ‘One Health’ approach to research, which includes measures in the human and veterinary field. Today, no individual organisation has either the expertise or the resources available to ensure full readiness for delivering efficient control tools against future outbreaks. Therefore, close collaboration among governmental regulatory agencies, academic groups and industrial partners is a must for achieving such an ambitious objective.\nWhat does ZAPI bring to the table?\nBy bringing together more than 20 partners, including leading human and veterinary research institutions, non-governmental organisations, regulatory agencies, academic groups and manufacturers, ZAPI aims to shorten the time to respond to emerging infectious diseases by using a multidisciplinary, One Health approach. The project aims to produce both platforms for the rapid production of veterinary vaccines and antibodies to protect the human population. The project also aims to ensure fast-track registration and implementation of the control tools after the emergence of the disease.\xa0\nMore specifically, the project is working towards:\ncreating platforms that allow rapid identification and production of antibodies capable of neutralising emerging viruses;\xa0\ncreating platforms suitable for rapid increases in the production of vaccines;\nenabling the development of quality control assays that do not make use of animals;\nestablishing protocols for fast track registration of developed products.\nFocusing on three key viruses\nIt is less expensive to control new infectious diseases in animals compared to the high costs triggered when the disease spreads to people. Therefore, the focus of the project is on three pathogens which occur first in animals before moving to people.\xa0\nRift Valley fever virus causes recurrent outbreaks among ruminants (e.g. cattle, sheep and goats) and humans across the African continent, several islands of the Western Indian Ocean, and the Arabian peninsula. It is transmitted by mosquitoes. Infection can cause severe illness and/or death in animals and humans, as well as economic losses due to death and abortion among infected livestock.\nSchmallenberg virus is associated with abortions, stillbirths and malformations in ruminants in Asia, Africa and Oceania. It emerged in Europe for the first time in 2011 and is transmitted by mosquitoes. No evidence of human infection has been reported but related viruses have zoonotic potential.\nMiddle East respiratory syndrome coronavirus first emerged in the Arabian peninsula in 2012, causing severe lower respiratory tract disease in humans. Approximately 36% of the reported patients have died. Camels are likely to be a major animal source of infection in humans.\nSignificant impact while reducing animal testing\nZAPI’s innovative approaches aim to result in significant scientific and technological impact, leading to a faster response to newly emerging viruses. Furthermore, the ZAPI platform will reduce the number of animal experiments necessary for the development of vaccines, and will minimize the need for control tests in animals for the regulatory release of commercial vaccine batches.\nAchievements so far\nA year after the launch, the project is already yielding its first results. The results generated so far confirm the initial hypothesis that it should be possible to generate viral vaccines based on small subunits expressed in systems other than the classical mammalian or avian cells. Additionally, some of the project milestones have already been achieved ahead of schedule including the generation of key neutralizing antibodies against all 3 target viruses. In addition, \xa0a consensus on industrial and regulatory processes needed to deliver key vaccines and/or antibodies in quantities needed to address outbreaks was obtained; methodology to determine constraints and criteria for the selection of systems for industrial scale-up; as well as innovative advances for the design in vitro QC assays, and innovative advances in the design of vaccine candidates were developed.\xa0\n', 'tags': 'Zoonotic anticipation and preparedness initiative', 'participants': "Academisch Ziekenhuis Leiden, Leiden, Netherlands;Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain;Artemis Bio-Support B.V., Utrecht, Netherlands;Association Internationale De Standardisation Biologique Pour L'Europe (IABS-EU), Lyon, France;Astrazeneca AB, Södertälje, Sweden;Boehringer Ingelheim Vetmedica GMBH, Ingelheim am Rhein, Germany;Dyadic Nederland BV, Wageningen, Netherlands;Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands;Finovatis, Lyon, France;Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer Tiergesundheit, Greifswald-Insel Riems, Germany;Harbour Antibodies BV, Rotterdam, Netherlands;Institut De Recerca I Tecnologia Agroalimentaries, Caldes De Montbui- Barcelona, Spain;Institut Pasteur, Paris, France;Merial SAS, Lyon, France;Stichting Wageningen Research, Wageningen, Netherlands;Stiftung Tieraerztliche Hochschule Hannover, Hannover, Germany;Universitatsklinikum Bonn, Bonn, Germany;Universite D'Aix Marseille, Marseille, France;Universiteit Utrecht, Utrecht, Netherlands;Viroclinics Biosciences BV, Rotterdam, Netherlands", 'status': 'Ongoing'}]
